GenCore version 5.1.6

OM nucleic - nucleic search, using sw model

Run on: December 13, 2004, 08:20:12 ; Search time 20 Seconds
(without alignments)
3.672 Million cell updates/sec

Title: US-10-091-333-2
Perfect score: 1764
Sequence: 1 tttggccctcgaggccaaga.....ataaacatgtttgttaaaac 1764

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 0.5

Searched: 1118 seqs, 20818 residues

Total number of hits satisfying chosen parameters: 2236

Minimum DB seq length: 8
Maximum DB seq length: 50

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 156 summaries

Database : rge2.seq:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

	Result No.	Score	% Query Match	Length	DB	ID	Description
c	1	39.5	2.2	50	1	AX160404	ACCESSION:AX160404
c	2	33	1.9	38	1	AR063818	ACCESSION:AR063818
	3	21	1.2	21	1	AR063817	ACCESSION:AR063817
c	4	21	1.2	21	1	CQ802491	ACCESSION:CQ802491
c	5	21	1.2	21	1	CQ802492	ACCESSION:CQ802492
c	6	21	1.2	21	1	CQ802494	ACCESSION:CQ802494
c	7	21	1.2	21	1	CQ802495	ACCESSION:CQ802495
c	8	21	1.2	21	1	CQ802497	ACCESSION:CQ802497
c	9	21	1.2	21	1	CQ802498	ACCESSION:CQ802498
	10	20	1.1	20	1	AR411051	ACCESSION:AR411051
	11	20	1.1	20	1	AR442661	ACCESSION:AR442661
c	12	19.4	1.1	21	1	CQ802493	ACCESSION:CQ802493
c	13	19	1.1	21	1	CQ802496	ACCESSION:CQ802496
	14	18.8	1.1	24	1	AX084503	ACCESSION:AX084503
c	15	16.8	1.0	21	1	AX146066	ACCESSION:AX146066
	16	16.4	0.9	20	1	BD104599	ACCESSION:BD104599
	17	16.4	0.9	20	1	BD104602	ACCESSION:BD104602
	18	16.4	0.9	21	1	AX153990	ACCESSION:AX153990
	19	16.4	0.9	26	1	A63569	ACCESSION:A63569
c	20	16.2	0.9	21	1	AX472021	ACCESSION:AX472021
	21	16	0.9	17	1	AX266567	ACCESSION:AX266567
c	22	16	0.9	17	1	AX266568	ACCESSION:AX266568
	23	16	0.9	19	1	AR072061	ACCESSION:AR072061
c	24	16	0.9	20	1	AR230802	ACCESSION:AR230802
c	25	16	0.9	20	1	AR370189	ACCESSION:AR370189
	26	16	0.9	24	1	AX103868	ACCESSION:AX103868
	27	16	0.9	24	1	AX546921	ACCESSION:AX546921
	28	16	0.9	24	1	AX961631	ACCESSION:AX961631
	29	16	0.9	24	1	AX961678	ACCESSION:AX961678
c	30	16	0.9	26	1	AR098647	ACCESSION:AR098647
c	31	16	0.9	26	1	AR204721	ACCESSION:AR204721
	32	16	0.9	27	1	AR214918	ACCESSION:AR214918
	33	16	0.9	27	1	AX009609	ACCESSION:AX009609
c	34	15.8	0.9	19	1	AX000506	ACCESSION:AX000506
c	35	15.8	0.9	19	1	BD073339	ACCESSION:BD073339
c	36	15.8	0.9	20	1	BD225270	ACCESSION:BD225270
	37	15.8	0.9	20	1	AR181346	ACCESSION:AR181346
c	38	15.8	0.9	20	1	AR212968	ACCESSION:AR212968
	39	15.8	0.9	20	1	AR313181	ACCESSION:AR313181
c	40	15.8	0.9	20	1	AX167124	ACCESSION:AX167124
c	41	15.8	0.9	21	1	AR070809	ACCESSION:AR070809
c	42	15.8	0.9	21	1	BD244489	ACCESSION:BD244489
c	43	15.8	0.9	21	1	AR454920	ACCESSION:AR454920
c	44	15.8	0.9	27	1	E04985	ACCESSION:E04985
	45	15.8	0.9	27	1	AX104719	ACCESSION:AX104719
	46	15.8	0.9	27	1	AX355814	ACCESSION:AX355814
	47	15.8	0.9	27	1	AX547772	ACCESSION:AX547772
	48	15.8	0.9	28	1	BD234335	ACCESSION:BD234335
	49	15.4	0.9	17	1	AR067856	ACCESSION:AR067856
	50	15.4	0.9	17	1	AR164207	ACCESSION:AR164207
	51	15.4	0.9	17	1	AR164645	ACCESSION:AR164645
	52	15.4	0.9	17	1	AR168088	ACCESSION:AR168088
	53	15.4	0.9	17	1	AR192333	ACCESSION:AR192333
	54	15.4	0.9	17	1	AR232188	ACCESSION:AR232188
	55	15.4	0.9	17	1	AR236040	ACCESSION:AR236040
	56	15.4	0.9	17	1	AR326203	ACCESSION:AR326203
	57	15.4	0.9	17	1	AR337628	ACCESSION:AR337628
	58	15.4	0.9	17	1	AR473351	ACCESSION:AR473351
	59	15.4	0.9	17	1	AR492475	ACCESSION:AR492475
c	60	15.4	0.9	17	1	AX723340	ACCESSION:AX723340
	61	15.4	0.9	18	1	I72032	ACCESSION:I72032
c	62	15.4	0.9	18	1	BD104973	ACCESSION:BD104973
	63	15.4	0.9	19	1	AR179243	ACCESSION:AR179243
	64	15.4	0.9	19	1	AX129981	ACCESSION:AX129981
	65	15.4	0.9	19	1	AX129982	ACCESSION:AX129982
c	66	15.4	0.9	19	1	AX352953	ACCESSION:AX352953
c	67	15.4	0.9	19	1	AX362798	ACCESSION:AX362798
	68	15.4	0.9	19	1	BD078905	ACCESSION:BD078905
c	69	15.4	0.9	20	1	AR238868	ACCESSION:AR238868
c	70	15.4	0.9	20	1	AX278670	ACCESSION:AX278670
	71	15.4	0.9	20	1	AX487219	ACCESSION:AX487219
	72	15.4	0.9	26	1	AR174582	ACCESSION:AR174582
	73	15.4	0.9	26	1	BD248975	ACCESSION:BD248975
	74	15.4	0.9	26	1	I79495	ACCESSION:I79495
	75	15.4	0.9	26	1	AR279358	ACCESSION:AR279358
	76	15.4	0.9	26	1	AR374074	ACCESSION:AR374074
	77	15.4	0.9	26	1	AR404597	ACCESSION:AR404597
	78	15.4	0.9	26	1	AR456224	ACCESSION:AR456224
	79	15.4	0.9	26	1	BD007174	ACCESSION:BD007174
	80	15.2	0.9	20	1	AR129672	ACCESSION:AR129672
c	81	15.2	0.9	20	1	BD243920	ACCESSION:BD243920
	82	15.2	0.9	20	1	BD250365	ACCESSION:BD250365
	83	15.2	0.9	20	1	BD251839	ACCESSION:BD251839
c	84	15.2	0.9	20	1	E25765	ACCESSION:E25765
c	85	15.2	0.9	20	1	AR216026	ACCESSION:AR216026
c	86	15.2	0.9	20	1	AR243320	ACCESSION:AR243320
c	87	15.2	0.9	20	1	AR312034	ACCESSION:AR312034
c	88	15.2	0.9	20	1	AR315230	ACCESSION:AR315230
c	89	15.2	0.9	20	1	AR435671	ACCESSION:AR435671
c	90	15.2	0.9	20	1	AR453274	ACCESSION:AR453274
c	91	15.2	0.9	20	1	AR453458	ACCESSION:AR453458
	92	15.2	0.9	20	1	AR490190	ACCESSION:AR490190
	93	15.2	0.9	20	1	AX038754	ACCESSION:AX038754
c	94	15.2	0.9	20	1	AX224925	ACCESSION:AX224925
c	95	15.2	0.9	20	1	AX298814	ACCESSION:AX298814
	96	15.2	0.9	20	1	BD069139	ACCESSION:BD069139
c	97	15.2	0.9	20	1	BD106882	ACCESSION:BD106882
c	98	15.2	0.9	20	1	HUM10UVB	ACCESSION:D50140
	99	15	0.9	17	1	BD255507	ACCESSION:BD255507
	100	15	0.9	24	1	AR431312	ACCESSION:AR431312
c	101	15	0.9	25	1	I29929	ACCESSION:I29929
	102	15	0.9	25	1	BD234336	ACCESSION:BD234336
	103	15	0.9	27	1	AX711956	ACCESSION:AX711956
	104	14.8	0.8	18	1	AR134262	ACCESSION:AR134262
	105	14.8	0.8	19	1	BD261781	ACCESSION:BD261781
	106	14.8	0.8	19	1	AR404716	ACCESSION:AR404716

	107	14.8	0.8	19	1	AX025392 ACCESSION:AX025392
	108	14.8	0.8	19	1	AX130616 ACCESSION:AX130616
	109	14.8	0.8	19	1	AX130759 ACCESSION:AX130759
	110	14.8	0.8	19	1	AX131856 ACCESSION:AX131856
c	111	14.8	0.8	19	1	AX319714 ACCESSION:AX319714
c	112	14.8	0.8	19	1	AX320702 ACCESSION:AX320702
	113	14.8	0.8	19	1	AX822079 ACCESSION:AX822079
	114	14.8	0.8	26	1	AR137712 ACCESSION:AR137712
	115	14.8	0.8	26	1	BD192375 ACCESSION:BD192375
c	116	14.8	0.8	26	1	CQ828164 ACCESSION:CQ828164
	117	14.8	0.8	26	1	I79496 ACCESSION:I79496
	118	14.8	0.8	26	1	AX427154 ACCESSION:AX427154
	119	14.8	0.8	26	1	AX528804 ACCESSION:AX528804
	120	14.8	0.8	27	1	AR241865 ACCESSION:AR241865
	121	14.6	0.8	24	1	AX961625 ACCESSION:AX961625
	122	14.6	0.8	24	1	AR431313 ACCESSION:AR431313
	123	14.6	0.8	26	1	BD237566 ACCESSION:BD237566
	124	14.6	0.8	26	1	AR257336 ACCESSION:AR257336
	125	14.6	0.8	26	1	AR263647 ACCESSION:AR263647
	126	14.6	0.8	26	1	AX814950 ACCESSION:AX814950
	127	14.6	0.8	26	1	BD062456 ACCESSION:BD062456
	128	14.6	0.8	27	1	AX513052 ACCESSION:AX513052
	129	14.4	0.8	16	1	AR017827 ACCESSION:AR017827
	130	14.4	0.8	16	1	AR068061 ACCESSION:AR068061
	131	14.4	0.8	16	1	I19988 ACCESSION:I19988
	132	14.4	0.8	16	1	I30248 ACCESSION:I30248
c	133	14.4	0.8	16	1	AR435812 ACCESSION:AR435812
	134	14.4	0.8	16	1	AX938344 ACCESSION:AX938344
	135	14.4	0.8	17	1	AR039433 ACCESSION:AR039433
	136	14.4	0.8	17	1	AR192332 ACCESSION:AR192332
	137	14.4	0.8	17	1	AR192334 ACCESSION:AR192334
	138	14.4	0.8	17	1	AR195753 ACCESSION:AR195753
	139	14.4	0.8	17	1	AR286245 ACCESSION:AR286245
	140	14.4	0.8	17	1	AR326202 ACCESSION:AR326202
	141	14.4	0.8	17	1	AR326204 ACCESSION:AR326204
	142	14.4	0.8	17	1	AR328948 ACCESSION:AR328948
	143	14.4	0.8	17	1	AR328949 ACCESSION:AR328949
	144	14.4	0.8	17	1	AR398235 ACCESSION:AR398235
c	145	14.4	0.8	17	1	AX216928 ACCESSION:AX216928
c	146	14.4	0.8	17	1	AX216929 ACCESSION:AX216929
	147	14.4	0.8	17	1	AX736712 ACCESSION:AX736712
	148	14.4	0.8	17	1	AX758749 ACCESSION:AX758749
	149	14.4	0.8	18	1	AR196166 ACCESSION:AR196166
	150	14.4	0.8	18	1	AX710854 ACCESSION:AX710854
	151	14.4	0.8	18	1	BD000995 ACCESSION:BD000995
	152	14.4	0.8	18	1	BD001424 ACCESSION:BD001424
	153	14.4	0.8	18	1	BD104097 ACCESSION:BD104097
	154	14.4	0.8	19	1	E06078 ACCESSION:E06078
c	155	14.4	0.8	19	1	AX352950 ACCESSION:AX352950
c	156	14.4	0.8	19	1	AX362795 ACCESSION:AX362795

ALIGNMENTS

```
RESULT 1
AX160404/c
LOCUS       AX160404                  50 bp    DNA     linear   PAT 22-JUN-2001
DEFINITION  Sequence 3732 from Patent WO0140521.
ACCESSION   AX160404
VERSION     AX160404.1  GI:14541735
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Shimkets,R.A. and Leach,M.
  TITLE     Nucleic acids containing single nucleotide polymorphisms and
            methods of use thereof
  JOURNAL   Patent: WO 0140521-A 3732 07-JUN-2001;
            Curagen Corporation (US)
FEATURES             Location/Qualifiers
     source          1. .50
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"
     misc_feature    25. .26
                     /note="Nucleotide deleted between bases 25 and 26
                     Accession number cg43918620"
     misc_feature    26
                     /note="2 of 2 allelic variants (3731 is other entry)"

  Query Match             2.2%;  Score 39.5;  DB 1;  Length 50;
  Best Local Similarity   98.0%;  Pred. No. 0.0091;
  Matches   50;  Conservative    0;  Mismatches    0;  Indels    1;  Gaps    1;

Qy        919 CTTCAACCTGAGGGGGCCGACAGTGCCCTCCAAGACAGAGACGACTGAACT 969
              ||||||||||||||||||||||||| ||||||||||||||||||||||||||
Db         50 CTTCAACCTGAGGGGGCCGACAGTG-CCTCCAAGACAGAGACGACTGAACT 1


RESULT 2
AR063818/c
LOCUS       AR063818                  38 bp    DNA     linear   PAT 29-SEP-1999
DEFINITION  Sequence 10 from patent US 5846721.
ACCESSION   AR063818
VERSION     AR063818.1  GI:5993126
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 38)
  AUTHORS   Soares,M.Bento. and Bonaldo,Mde.Fatima.
  TITLE     Efficient and simpler method to construct normalized cDNA libraries
            with improved representations of full-length cDNAs
  JOURNAL   Patent: US 5846721-A 10 08-DEC-1998;
FEATURES             Location/Qualifiers
     source          1. .38
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             1.9%;  Score 33;  DB 1;  Length 38;
  Best Local Similarity   100.0%;  Pred. No. 0.12;
  Matches   33;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 TTTGGCCCTCGAGGCCAAGAATTCGGCACGAGG 33
              |||||||||||||||||||||||||||||||||
Db         33 TTTGGCCCTCGAGGCCAAGAATTCGGCACGAGG 1


RESULT 3
AR063817
LOCUS       AR063817                  21 bp    DNA     linear   PAT 29-SEP-1999
DEFINITION  Sequence 9 from patent US 5846721.
ACCESSION   AR063817
VERSION     AR063817.1  GI:5993125
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 21)
  AUTHORS   Soares,M.Bento. and Bonaldo,Mde.Fatima.
  TITLE     Efficient and simpler method to construct normalized cDNA libraries
            with improved representations of full-length cDNAs
  JOURNAL   Patent: US 5846721-A 9 08-DEC-1998;
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             1.2%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 13;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         12 AGGCCAAGAATTCGGCACGAG 32
```

```
                    ||||||||||||||||||||
Db          1 AGGCCAAGAATTCGGCACGAG 21


RESULT 4
CQ802491/c
LOCUS       CQ802491                  21 bp    DNA     linear   PAT 10-MAY-2004
DEFINITION  Sequence 4 from Patent WO2004035615.
ACCESSION   CQ802491
VERSION     CQ802491.1  GI:47109457
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Klippel-Giese,A., Kaufmann,J. and Schwarzer,R.
  TITLE     Factor involved in metastasis and uses thereof
  JOURNAL   Patent: WO 2004035615-A 4 29-APR-2004;
            atugen AG (DE)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="antisense oligonucleotide"
     misc_feature    1. .6
                     /note="RNA"
     misc_feature    7. .15
                     /note="DNA linked through phosphorothioate linkages"
     misc_feature    16. .21
                     /note="RNA"

  Query Match             1.2%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 13;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1559 TCGTGTACTGCAGAGTTGAGC 1579
              |||||||||||||||||||||
Db         21 TCGTGTACTGCAGAGTTGAGC 1


RESULT 5
CQ802492/c
LOCUS       CQ802492                  21 bp    DNA     linear   PAT 10-MAY-2004
DEFINITION  Sequence 5 from Patent WO2004035615.
ACCESSION   CQ802492
VERSION     CQ802492.1  GI:47109458
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Klippel-Giese,A., Kaufmann,J. and Schwarzer,R.
  TITLE     Factor involved in metastasis and uses thereof
  JOURNAL   Patent: WO 2004035615-A 5 29-APR-2004;
            atugen AG (DE)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="antisense oligonucleotide"
     misc_feature    1. .6
                     /note="RNA"
     misc_feature    7. .15
                     /note="DNA linked through phosphorothioate linkages"
     misc_feature    16. .21
                     /note="RNA"

  Query Match             1.2%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 13;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1357 TACTGGTCTGAAGGGACCAAG 1377
              |||||||||||||||||||||
Db         21 TACTGGTCTGAAGGGACCAAG 1


RESULT 6
CQ802494/c
LOCUS       CQ802494                  21 bp    DNA     linear   PAT 10-MAY-2004
DEFINITION  Sequence 7 from Patent WO2004035615.
ACCESSION   CQ802494
VERSION     CQ802494.1  GI:47109460
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Klippel-Giese,A., Kaufmann,J. and Schwarzer,R.
  TITLE     Factor involved in metastasis and uses thereof
  JOURNAL   Patent: WO 2004035615-A 7 29-APR-2004;
            atugen AG (DE)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="antisense oligonucleotide"
     misc_feature    1. .6
                     /note="RNA"
     misc_feature    7. .15
                     /note="DNA linked through phosphorothioate linkages"
     misc_feature    16. .21
                     /note="RNA"

  Query Match             1.2%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 13;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        955 AGAGACGACTGAACTTTGGG 975
              ||||||||||||||||||||
Db         21 AGAGACGACTGAACTTTGGG 1


RESULT 7
CQ802495/c
LOCUS       CQ802495                  21 bp    DNA     linear   PAT 10-MAY-2004
DEFINITION  Sequence 8 from Patent WO2004035615.
ACCESSION   CQ802495
VERSION     CQ802495.1  GI:47109461
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Klippel-Giese,A., Kaufmann,J. and Schwarzer,R.
  TITLE     Factor involved in metastasis and uses thereof
  JOURNAL   Patent: WO 2004035615-A 8 29-APR-2004;
            atugen AG (DE)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="antisense oligonucleotide"
     misc_feature    1. .6
                     /note="RNA"
     misc_feature    7. .15
                     /note="DNA linked through phosphorothioate linkages"
     misc_feature    16. .21
                     /note="RNA"

  Query Match             1.2%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 13;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;
```

```
Qy        976 GTGGAGACTAGAGGCAGGAGC 996
              |||||||||||||||||||||
Db         21 GTGGAGACTAGAGGCAGGAGC 1


RESULT 8
CQ802497/c
LOCUS       CQ802497                 21 bp    DNA     linear   PAT 10-MAY-2004
DEFINITION  Sequence 10 from Patent WO2004035615.
ACCESSION   CQ802497
VERSION     CQ802497.1  GI:47109463
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Klippel-Giese,A., Kaufmann,J. and Schwarzer,R.
  TITLE     Factor involved in metastasis and uses thereof
  JOURNAL   Patent: WO 2004035615-A 10 29-APR-2004;
            atugen AG (DE)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="antisense oligonucleotide"
     misc_feature    1. .6
                     /note="RNA"
     misc_feature    7. .15
                     /note="DNA linked through phosphorothioate linkages"
     misc_feature    16. .21
                     /note="RNA"

  Query Match             1.2%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 13;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1413 ATCGGAGCATCACTACTGACC 1433
              |||||||||||||||||||||
Db         21 ATCGGAGCATCACTACTGACC 1


RESULT 9
CQ802498/c
LOCUS       CQ802498                 21 bp    DNA     linear   PAT 10-MAY-2004
DEFINITION  Sequence 11 from Patent WO2004035615.
ACCESSION   CQ802498
VERSION     CQ802498.1  GI:47109464
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Klippel-Giese,A., Kaufmann,J. and Schwarzer,R.
  TITLE     Factor involved in metastasis and uses thereof
  JOURNAL   Patent: WO 2004035615-A 11 29-APR-2004;
            atugen AG (DE)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="antisense oligonucleotide"
     misc_feature    1. .6
                     /note="RNA"
     misc_feature    7. .15
                     /note="DNA linked through phosphorothioate linkages"
     misc_feature    16. .21
                     /note="RNA"

  Query Match             1.2%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 13;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        572 GATGCCTAGCCAGTTGGTAAG 592
              |||||||||||||||||||||
Db         21 GATGCCTAGCCAGTTGGTAAG 1


RESULT 10
AR411051
LOCUS       AR411051                 20 bp    DNA     linear   PAT 18-DEC-2003
DEFINITION  Sequence 16 from patent US 6635479.
ACCESSION   AR411051
VERSION     AR411051.1  GI:40162655
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Sutcliffe,J.G., Gautvik,K.M., De Lecea,L., Bloom,F.E.,
            Danielson,P.E., Gautvik,V.T., Kilduff,T.S. and Foye,P.E.
  TITLE     Hypothalamus-specific polypeptides
  JOURNAL   Patent: US 6635479-A 16 21-OCT-2003;
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             1.1%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 19;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         12 AGGCCAAGAATTCGGCACGA 31
              ||||||||||||||||||||
Db          1 AGGCCAAGAATTCGGCACGA 20


RESULT 11
AR442661
LOCUS       AR442661                 20 bp    DNA     linear   PAT 20-FEB-2004
DEFINITION  Sequence 10 from patent US 6670135.
ACCESSION   AR442661
VERSION     AR442661.1  GI:42669922
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Spriggs,M.K.
  TITLE     Semaphorin polypeptides
  JOURNAL   Patent: US 6670135-A 10 30-DEC-2003;
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             1.1%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 19;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          8 CTCGAGGCCAAGAATTCGGC 27
              ||||||||||||||||||||
Db          1 CTCGAGGCCAAGAATTCGGC 20


RESULT 12
CQ802493/c
LOCUS       CQ802493                 21 bp    DNA     linear   PAT 10-MAY-2004
DEFINITION  Sequence 6 from Patent WO2004035615.
ACCESSION   CQ802493
VERSION     CQ802493.1  GI:47109459
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
```

```
            artificial sequences.
REFERENCE   1
  AUTHORS   Klippel-Giese,A., Kaufmann,J. and Schwarzer,R.
  TITLE     Factor involved in metastasis and uses thereof
  JOURNAL   Patent: WO 2004035615-A 6 29-APR-2004;
            atugen AG (DE)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="antisense oligonucleotide"
     misc_feature    1. .6
                     /note="RNA"
     misc_feature    7. .15
                     /note="DNA linked through phosphorothioate linkages"
     misc_feature    16. .21
                     /note="RNA"

  Query Match             1.1%;  Score 19.4;  DB 1;  Length 21;
  Best Local Similarity   95.2%;  Pred. No. 25;
  Matches   20;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1007 ATTCCTGTGGTTGGAAAACTG 1027
              ||||| ||||||||||||||||
Db         21 ATTCCAGTGGTTGGAAAACTG 1


RESULT 13
CQ802496/c
LOCUS       CQ802496                  21 bp    DNA     linear   PAT 10-MAY-2004
DEFINITION  Sequence 9 from Patent WO2004035615.
ACCESSION   CQ802496
VERSION     CQ802496.1  GI:47109462
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Klippel-Giese,A., Kaufmann,J. and Schwarzer,R.
  TITLE     Factor involved in metastasis and uses thereof
  JOURNAL   Patent: WO 2004035615-A 9 29-APR-2004;
            atugen AG (DE)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="antisense oligonucleotide"
     misc_feature    1. .6
                     /note="RNA"
     misc_feature    7. .15
                     /note="DNA linked through phosphorothioate linkages"
     misc_feature    16. .21
                     /note="RNA"

  Query Match             1.1%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 29;
  Matches   19;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        473 TGACCCTGAGGATGAACAC 491
              |||||||||||||||||||
Db         19 TGACCCTGAGGATGAACAC 1


RESULT 14
AX084503
LOCUS       AX084503                  24 bp    RNA     linear   PAT 28-FEB-2001
DEFINITION  Sequence 45 from Patent WO0112213.
ACCESSION   AX084503
VERSION     AX084503.1  GI:13185911
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Blackshear,P.J., Lai,W.S. and Carballo-Jane,E.
  TITLE     Ttp-related zinc finger domains and methods of use
  JOURNAL   Patent: WO 0112213-A 45 22-FEB-2001;
            THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US)
FEATURES             Location/Qualifiers
     source          1. .24
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             1.1%;  Score 18.8;  DB 1;  Length 24;
  Best Local Similarity   90.9%;  Pred. No. 32;
  Matches   20;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1377 GTGTGTTTGTTGTTTGTTTTGT 1398
              || |||||||||||||||||| |
Db          3 GTTTGTTTGTTGTTTGTTTTT 24


RESULT 15
AX146066/c
LOCUS       AX146066                  21 bp    DNA     linear   PAT 31-MAY-2001
DEFINITION  Sequence 257 from Patent WO0134840.
ACCESSION   AX146066
VERSION     AX146066.1  GI:14284584
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Au,K.G., Chen,J.G., Patil,N. and Thomas,D.
  TITLE     Genetic compositions and methods
  JOURNAL   Patent: WO 0134840-A 257 17-MAY-2001;
            GLAXO GROUP LIMITED (GB) ; Affymetrix, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"
     variation       1. .21
                     /note="'n' represents a polymorphic base"

  Query Match             1.0%;  Score 16.8;  DB 1;  Length 21;
  Best Local Similarity   85.7%;  Pred. No. 69;
  Matches   18;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1549 CCTTCCCCCATCGTGTACTGC 1569
              || ||||||| |||||||| |
Db         21 CCGTCCCCCANCGTGTACTTC 1


RESULT 16
BD104599
LOCUS       BD104599                  20 bp    DNA     linear   PAT 27-AUG-2002
DEFINITION  Kit and method for determining HLA type.
ACCESSION   BD104599
VERSION     BD104599.1  GI:22650173
KEYWORDS    WO 0192572-A/703.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Inoko,H., Kagiya,T., Ichihara,T., Matsumura,Y., Moriya,S. and
            Nishida,M.
  TITLE     Kit and method for determining HLA type
  JOURNAL   Patent: WO 0192572-A 703 06-DEC-2001;
            NISSHINBO INDUSTRIES INC,SYSTEM RESEARCH INC,HIDETOSHI INOKO, TAEKO
            KAGIYA, TATSUO ICHIHARA,YOSHIYUKI MATSUMURA,SHOGO MORIYA,MICHIO
            NISHIDA
```

```
COMMENT     OS   Artificial Sequence
            PN   WO 0192572-A/703
            PD   06-DEC-2001
            PF   01-JUN-2001 WO 2001JP004662
            PR   01-JUN-2000 JP 00P   164798
            PI   HIDETOSHI INOKO,TAEKO KAGIYA,TATSUO ICHIHARA,YOSHIYUKI  PI
           MATSUMURA,
            PI   SHOGO MORIYA,MICHIO NISHIDA
            PC   C12Q1/68,C12M1/00,C12N15/09,G01N33/53
            CC   Description of Artificial Sequence:capture
            FH   Key             Location/Qualifiers
            FT   source          1. .20
            FT                   /organism='Artificial Sequence'.
FEATURES            Location/Qualifiers
     source         1. .20
                    /organism="synthetic construct"
                    /mol_type="genomic DNA"
                    /db_xref="taxon:32630"

  Query Match             0.9%;  Score 16.4;  DB 1;  Length 20;
  Best Local Similarity   94.4%;  Pred. No. 80;
  Matches   17;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        839 CCTGACGCTGAGCACTGG 856
              ||||||||||||| |||||
Db          2 CCTGACGCTGAGTACTGG 19


RESULT 17
BD104602
LOCUS       BD104602                  20 bp    DNA     linear   PAT 27-AUG-2002
DEFINITION  Kit and method for determining HLA type.
ACCESSION   BD104602
VERSION     BD104602.1  GI:22650176
KEYWORDS    WO 0192572-A/706.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Inoko,H., Kagiya,T., Ichihara,T., Matsumura,Y., Moriya,S. and
            Nishida,M.
  TITLE     Kit and method for determining HLA type
  JOURNAL   Patent: WO 0192572-A 706 06-DEC-2001;
            NISSHINBO INDUSTRIES INC,SYSTEM RESEARCH INC,HIDETOSHI INOKO, TAEKO
            KAGIYA, TATSUO ICHIHARA,YOSHIYUKI MATSUMURA,SHOGO MORIYA,MICHIO
            NISHIDA
COMMENT     OS   Artificial Sequence
            PN   WO 0192572-A/706
            PD   06-DEC-2001
            PF   01-JUN-2001 WO 2001JP004662
            PR   01-JUN-2000 JP 00P   164798
            PI   HIDETOSHI INOKO,TAEKO KAGIYA,TATSUO ICHIHARA,YOSHIYUKI  PI
           MATSUMURA,
            PI   SHOGO MORIYA,MICHIO NISHIDA
            PC   C12Q1/68,C12M1/00,C12N15/09,G01N33/53
            CC   Description of Artificial Sequence:capture
            FH   Key             Location/Qualifiers
            FT   source          1. .20
            FT                   /organism='Artificial Sequence'.
FEATURES            Location/Qualifiers
     source         1. .20
                    /organism="synthetic construct"
                    /mol_type="genomic DNA"
                    /db_xref="taxon:32630"

  Query Match             0.9%;  Score 16.4;  DB 1;  Length 20;
  Best Local Similarity   94.4%;  Pred. No. 80;
  Matches   17;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        839 CCTGACGCTGAGCACTGG 856
              |||||||| |||||||||
Db          2 CCTGACGCGGAGCACTGG 19


RESULT 18
AX153990
LOCUS       AX153990                  21 bp    DNA     linear   PAT 22-JUN-2001
DEFINITION  Sequence 88 from Patent WO0138576.
ACCESSION   AX153990
VERSION     AX153990.1  GI:14535604
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Cargill,M., Ireland,J.S. and Lander,E.S.
  TITLE     Human single nucleotide polymorphisms
  JOURNAL   Patent: WO 0138576-A 88 31-MAY-2001;
            WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US)
FEATURES            Location/Qualifiers
     source         1. .21
                    /organism="Homo sapiens"
                    /mol_type="unassigned DNA"
                    /db_xref="taxon:9606"

  Query Match             0.9%;  Score 16.4;  DB 1;  Length 21;
  Best Local Similarity   85.0%;  Pred. No. 80;
  Matches   17;  Conservative    1;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        381 GAGTCCCTGGACAGCAGCAA 400
              | || |||||:||||||||||
Db          1 GTGTACCTGGRCAGCAGCAA 20


RESULT 19
A63569
LOCUS       A63569                    26 bp    DNA     linear   PAT 12-MAR-1998
DEFINITION  Sequence 10 from Patent WO9720924.
ACCESSION   A63569
VERSION     A63569.1  GI:3717224
KEYWORDS    .
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1
  AUTHORS   Scaggiante,B. and Quadrifoglio,F.
  TITLE     A CLASS OF OLIGONUCLEOTIDES, THERAPEUTICALLY USEFUL AS ANTITUMOURAL
            AGENTS
  JOURNAL   Patent: WO 9720924-A 10 12-JUN-1997;
            SAICOM S R L (IT)
COMMENT     Other publication IT MI952539 19970604
            Other publication AU 1175497 19970627.
FEATURES            Location/Qualifiers
     source         1. .26
                    /organism="unidentified"
                    /mol_type="unassigned DNA"
                    /db_xref="taxon:32644"

  Query Match             0.9%;  Score 16.4;  DB 1;  Length 26;
  Best Local Similarity   76.9%;  Pred. No. 82;
  Matches   20;  Conservative    0;  Mismatches    6;  Indels    0;  Gaps    0;

Qy       1380 TGTTTGTTGTTTGTTTTGTATCTTGT 1405
              | ||| |||||| ||||||| | || |
Db          1 TTTTTTTTGTTTTTTTTGTTTTTTTT 26


RESULT 20
AX472021/c
LOCUS       AX472021                  21 bp    DNA     linear   PAT 09-AUG-2002
DEFINITION  Sequence 12 from Patent WO02053775.
ACCESSION   AX472021
VERSION     AX472021.1  GI:22207062
KEYWORDS    .
SOURCE      Homo sapiens (human)
```

```
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Hustert,E., Haberl,M. and Wojnowski,L.
  TITLE     Identification of the genetic determinants of the polymorphic
            cyp3a5 expression
  JOURNAL   Patent: WO 02053775-A 12 11-JUL-2002;
            EPIDAUROS BIOTECHNOLOGIE AG (DE)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             0.9%;  Score 16.2;  DB 1;  Length 21;
  Best Local Similarity   85.7%;  Pred. No. 87;
  Matches   18;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1469 AAGAGTAGGAAGGGGTGGGTG 1489
              | |||| ||||||| ||||||
Db         21 ATGAGTGGGAAGGGATGGGTG 1


RESULT 21
AX266567
LOCUS       AX266567                 17 bp    DNA     linear   PAT 26-OCT-2001
DEFINITION  Sequence 3958 from Patent WO0173002.
ACCESSION   AX266567
VERSION     AX266567.1  GI:16515366
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Kmiec,E.B., Gamper,H.B. and Rice,M.C.
  TITLE     Targeted chromosomal genomic alterations with modified single
            stranded oligonucleotides
  JOURNAL   Patent: WO 0173002-A 3958 04-OCT-2001;
            UNIVERSITY OF DELAWARE (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             0.9%;  Score 16;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 92;
  Matches   16;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1160 AAGGCTTCCAGCTGGA 1175
              ||||||||||||||||
Db          1 AAGGCTTCCAGCTGGA 16


RESULT 22
AX266568/c
LOCUS       AX266568                 17 bp    DNA     linear   PAT 26-OCT-2001
DEFINITION  Sequence 3959 from Patent WO0173002.
ACCESSION   AX266568
VERSION     AX266568.1  GI:16515367
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Kmiec,E.B., Gamper,H.B. and Rice,M.C.
  TITLE     Targeted chromosomal genomic alterations with modified single
            stranded oligonucleotides
  JOURNAL   Patent: WO 0173002-A 3959 04-OCT-2001;
            UNIVERSITY OF DELAWARE (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             0.9%;  Score 16;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 92;
  Matches   16;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1160 AAGGCTTCCAGCTGGA 1175
              ||||||||||||||||
Db         17 AAGGCTTCCAGCTGGA 2


RESULT 23
AR072061
LOCUS       AR072061                 19 bp    DNA     linear   PAT 18-FEB-2000
DEFINITION  Sequence 15 from patent US 5912326.
ACCESSION   AR072061
VERSION     AR072061.1  GI:7222949
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Chang,H.
  TITLE     Cerebellum-derived growth factors
  JOURNAL   Patent: US 5912326-A 15 15-JUN-1999;
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.9%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   100.0%;  Pred. No. 93;
  Matches   16;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         19 GAATTCGGCACGAGGG 34
              ||||||||||||||||
Db          1 GAATTCGGCACGAGGG 16


RESULT 24
AR230802/c
LOCUS       AR230802                 20 bp    DNA     linear   PAT 20-DEC-2002
DEFINITION  Sequence 62 from patent US 6451602.
ACCESSION   AR230802
VERSION     AR230802.1  GI:27271589
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Popoff,I. and Cowsert,L.M.
  TITLE     Antisense modulation of PARP expression
  JOURNAL   Patent: US 6451602-A 62 17-SEP-2002;
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             0.9%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 93;
  Matches   16;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1153 GGCCAACAAGGCTTCC 1168
              ||||||||||||||||
Db         16 GGCCAACAAGGCTTCC 1


RESULT 25
AR370189/c
```

```
LOCUS       AR370189                 20 bp    DNA     linear   PAT 12-SEP-2003
DEFINITION  Sequence 10 from patent US 6300132.
ACCESSION   AR370189
VERSION     AR370189.1  GI:34606695
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Monia,B.P. and Cowsert,L.M.
  TITLE     Antisense inhibition of telomeric repeat binding factor 2
            expression
  JOURNAL   Patent: US 6300132-A 10 09-OCT-2001;
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             0.9%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 93;
  Matches   16;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         19 GAATTCGGCACGAGGG 34
               ||||||||||||||||
Db         19 GAATTCGGCACGAGGG 4


RESULT 26
AX103868
LOCUS       AX103868                 24 bp    DNA     linear   PAT 30-APR-2001
DEFINITION  Sequence 60 from Patent WO0122972.
ACCESSION   AX103868
VERSION     AX103868.1  GI:13920065
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Krieg,A.M., Schetter,C. and Vollmer,J.C.
  TITLE     Immunostimulatory nucleic acids
  JOURNAL   Patent: WO 0122972-A 60 05-APR-2001;
            UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) ; Coley Pharmaceutical
            GmbH (DE)
FEATURES             Location/Qualifiers
     source          1. .24
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"

  Query Match             0.9%;  Score 16;  DB 1;  Length 24;
  Best Local Similarity   79.2%;  Pred. No. 95;
  Matches   19;  Conservative    0;  Mismatches    5;  Indels    0;  Gaps    0;

Qy       1386 TTGTTTGTTTTGTATCTTGTTTTT 1409
              |||||| |||  | | ||||||||
Db          1 TTGTTTTTTTGTTTTTTGTTTTT 24


RESULT 27
AX546921
LOCUS       AX546921                 24 bp    DNA     linear   PAT 01-MAR-2003
DEFINITION  Sequence 60 from Patent WO02053141.
ACCESSION   AX546921
VERSION     AX546921.1  GI:25812065
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Bratzler,R.L.
  TITLE     Inhibition of angiogenesis by nucleic acids
  JOURNAL   Patent: WO 02053141-A 60 11-JUL-2002;
            Coley Pharmaceutical Group, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .24
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Synthetic Sequence"

  Query Match             0.9%;  Score 16;  DB 1;  Length 24;
  Best Local Similarity   79.2%;  Pred. No. 95;
  Matches   19;  Conservative    0;  Mismatches    5;  Indels    0;  Gaps    0;

Qy       1386 TTGTTTGTTTTGTATCTTGTTTTT 1409
              |||||| |||  | | ||||||||
Db          1 TTGTTTTTTTGTTTTTTGTTTTT 24


RESULT 28
AX961631
LOCUS       AX961631                 24 bp    DNA     linear   PAT 14-JAN-2004
DEFINITION  Sequence 26 from Patent WO03101375.
ACCESSION   AX961631
VERSION     AX961631.1  GI:40881089
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Lopez,R.A.
  TITLE     Immunostimulatory oligonucleotides and uses thereof
  JOURNAL   Patent: WO 03101375-A 26 11-DEC-2003;
            IMMUNOTECH S.A. (AR)
FEATURES             Location/Qualifiers
     source          1. .24
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Immunostimulatory oligonucleotide"

  Query Match             0.9%;  Score 16;  DB 1;  Length 24;
  Best Local Similarity   79.2%;  Pred. No. 95;
  Matches   19;  Conservative    0;  Mismatches    5;  Indels    0;  Gaps    0;

Qy       1386 TTGTTTGTTTTGTATCTTGTTTTT 1409
              || ||| ||||  || ||||||||
Db          1 TTTTTTTTTTTTCATTTTGTTTTT 24


RESULT 29
AX961678
LOCUS       AX961678                 24 bp    DNA     linear   PAT 14-JAN-2004
DEFINITION  Sequence 73 from Patent WO03101375.
ACCESSION   AX961678
VERSION     AX961678.1  GI:40881136
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Lopez,R.A.
  TITLE     Immunostimulatory oligonucleotides and uses thereof
  JOURNAL   Patent: WO 03101375-A 73 11-DEC-2003;
            IMMUNOTECH S.A. (AR)
FEATURES             Location/Qualifiers
     source          1. .24
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Immunostimulatory oligonucleotide"

  Query Match             0.9%;  Score 16;  DB 1;  Length 24;
  Best Local Similarity   79.2%;  Pred. No. 95;
  Matches   19;  Conservative    0;  Mismatches    5;  Indels    0;  Gaps    0;
```

```
Qy       1386 TTGTTTGTTTTGTATCTTGTTTTT 1409
              || ||| |||| || ||||||||
Db          1 TTTTTTTTTTTTCATTTTGTTTTT 24


RESULT 30
AR098647/c
LOCUS       AR098647                  26 bp    DNA     linear   PAT 14-FEB-2001
DEFINITION  Sequence 5 from patent US 6077668.
ACCESSION   AR098647
VERSION     AR098647.1  GI:12808413
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 26)
  AUTHORS   Kool,E.T.
  TITLE     Highly sensitive multimeric nucleic acid probes
  JOURNAL   Patent: US 6077668-A 5 20-JUN-2000;
FEATURES             Location/Qualifiers
     source          1. .26
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.9%;  Score 16;  DB 1;  Length 26;
  Best Local Similarity   79.2%;  Pred. No. 96;
  Matches   19;  Conservative    0;  Mismatches    5;  Indels    0;  Gaps    0;

Qy       1386 TTGTTTGTTTTGTATCTTGTTTTT 1409
              || ||| |||||| | || |||||
Db         25 TTTTTTTTTTTGTTTTTTTTTTT 2


RESULT 31
AR204721/c
LOCUS       AR204721                  26 bp    DNA     linear   PAT 20-JUN-2002
DEFINITION  Sequence 5 from patent US 6368802.
ACCESSION   AR204721
VERSION     AR204721.1  GI:21502120
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 26)
  AUTHORS   Kool,E.T.
  TITLE     Circular DNA vectors for synthesis of RNA and DNA
  JOURNAL   Patent: US 6368802-A 5 09-APR-2002;
FEATURES             Location/Qualifiers
     source          1. .26
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.9%;  Score 16;  DB 1;  Length 26;
  Best Local Similarity   79.2%;  Pred. No. 96;
  Matches   19;  Conservative    0;  Mismatches    5;  Indels    0;  Gaps    0;

Qy       1386 TTGTTTGTTTTGTATCTTGTTTTT 1409
              || ||| |||||| | || |||||
Db         25 TTTTTTTTTTTGTTTTTTTTTTT 2


RESULT 32
AR214918
LOCUS       AR214918                  27 bp    DNA     linear   PAT 25-SEP-2002
DEFINITION  Sequence 18 from patent US 6410235.
ACCESSION   AR214918
VERSION     AR214918.1  GI:23312859
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 27)
  AUTHORS   Weindel,K. and Brand,J.
  TITLE     DNA detection by means of a strand reassociation complex
  JOURNAL   Patent: US 6410235-A 18 25-JUN-2002;
FEATURES             Location/Qualifiers
     source          1. .27
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             0.9%;  Score 16;  DB 1;  Length 27;
  Best Local Similarity   73.1%;  Pred. No. 97;
  Matches   19;  Conservative    1;  Mismatches    6;  Indels    0;  Gaps    0;

Qy       1386 TTGTTTGTTTTGTATCTTGTTTTTCT 1411
              || ||| |||| | | || |||||:|
Db          2 TTTTTTTTTTTTTTTTTTTTTTTYT 27


RESULT 33
AX009609
LOCUS       AX009609                  27 bp    DNA     linear   PAT 06-SEP-2000
DEFINITION  Sequence 18 from Patent EP0962536.
ACCESSION   AX009609
VERSION     AX009609.1  GI:9996841
KEYWORDS    .
SOURCE      Mycobacterium tuberculosis
  ORGANISM  Mycobacterium tuberculosis
            Bacteria; Actinobacteria; Actinobacteridae; Actinomycetales;
            Corynebacterineae; Mycobacteriaceae; Mycobacterium; Mycobacterium
            tuberculosis complex.
REFERENCE   1
  AUTHORS   Brand,J. and Weindel,K.D.
  TITLE     Dna detection by a strand reassociation complex
  JOURNAL   Patent: EP 0962536-A 18 08-DEC-1999;
            ROCHE DIAGNOSTICS GMBH (DE)
FEATURES             Location/Qualifiers
     source          1. .27
                     /organism="Mycobacterium tuberculosis"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:1773"
     misc_signal     1
                     /note="Phosphate linked to biotin via Aminolinker"
     misc_signal     27
                     /note="Y means incorporation of
                     Aminolinker-phosphoramidite subsequently estered with 3-O
                     carboxymethyl digoxigenin"

  Query Match             0.9%;  Score 16;  DB 1;  Length 27;
  Best Local Similarity   73.1%;  Pred. No. 97;
  Matches   19;  Conservative    1;  Mismatches    6;  Indels    0;  Gaps    0;

Qy       1386 TTGTTTGTTTTGTATCTTGTTTTTCT 1411
              || ||| |||| | | || |||||:|
Db          2 TTTTTTTTTTTTTTTTTTTTTTTYT 27


RESULT 34
AX000506/c
LOCUS       AX000506                  19 bp    DNA     linear   PAT 10-MAR-2000
DEFINITION  Sequence 25 from Patent WO9905283.
ACCESSION   AX000506
VERSION     AX000506.1  GI:7240910
KEYWORDS    .
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Mendez,C. and Salas,J.A.
  TITLE     BIOSYNTHESIS GENES AND TRANSFER OF 6-DESOXY-HEXOSES IN
            SACCHAROPOLYSPORA ERYTHRAEA AND IN STREPTOMYCES ANTIBIOTICUS AND
            THEIR USE
  JOURNAL   Patent: WO 9905283-A 25 04-FEB-1999;
            MENDEZ CARMEN (ES); SALAS JOSE A (ES)
FEATURES             Location/Qualifiers
     source          1. .19
```

```
                     /organism="unidentified"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32644"

  Query Match              0.9%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 1e+02;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        256 CCTCCTCTTCGCCCTCGTC 274
              || |||||||| |||||||
Db         19 CCACCTCTTCGGCCTCGTC 1


RESULT 35
BD073339/c
LOCUS       BD073339                 19 bp    DNA     linear   PAT 27-AUG-2002
DEFINITION  Gene for biosynthesis and transfer of 6-deoxyhexose in
            Saccharopolysporaerythraea and Streptomycesantibioticus.
ACCESSION   BD073339
VERSION     BD073339.1  GI:22618942
KEYWORDS    JP 2001511349-A/10.
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Fromentin,C., Michell,J., Reinal,M., Saraubay,C., Cortes,J.,
            Geyser,S., Leadlay,P., Mendez,C. and Saras,J.A.
  TITLE     Gene for biosynthesis and transfer of 6-deoxyhexose in
            Saccharopolysporaerythraea and Streptomycesantibioticus
  JOURNAL   Patent: JP 2001511349-A 10 14-AUG-2001;
            HOECHST MARION ROUSSEL
COMMENT     OS   Unidentified
            PN   JP 2001511349-A/10
            PD   14-AUG-2001
            PF   21-JUL-1998 JP 2000504257
            PR   25-JUL-1997 FR     97/09458,12-JUN-1998 FR     98/07411 PI
            CLAUDE FROMENTIN,JEANMALC MICHELL,MARYCECIL REINAL,CADIJA  PI
            SARAUBAY,
            PI   JESUS CORTES,SABINE GEYSER,PETER LEADLAY,CARMEN MENDEZ,JOSE A
            PI   SARAS
            PC   C12N15/09,C12N1/21,C12P19/62,C12Q1/68//(C12N1/21,C12R1:01), PC
              C12N15/00
            CC   Strandedness: Single;
            CC   Topology: Linear;
            CC   /desc = 'OLIGONUCLEOTIDE'
            FH   Key             Location/Qualifiers
            FT   source          1. .19
            FT                   /organism='Unidentified'.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="unidentified"
                      /mol_type="genomic DNA"
                      /db_xref="taxon:32644"

  Query Match              0.9%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 1e+02;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        256 CCTCCTCTTCGCCCTCGTC 274
              || |||||||| |||||||
Db         19 CCACCTCTTCGGCCTCGTC 1


RESULT 36
BD225270/c
LOCUS       BD225270                 20 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Remedies and diagnostic agents of glaucoma.
ACCESSION   BD225270
VERSION     BD225270.1  GI:33035040
KEYWORDS    JP 2002510508-A/25.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Stone,E.M., Sheffield,V.C., Alward,W.L.M. and Fingert,J.
  TITLE     Remedies and diagnostic agents of glaucoma
  JOURNAL   Patent: JP 2002510508-A 25 09-APR-2002;
            THE UNIVERSITY OF IOWA RESEARCH FOUNDATION
COMMENT     OS   Artificial Sequence
            PN   JP 2002510508-A/25
            PD   09-APR-2002
            PF   07-APR-1999 JP 2000542490
            PR   07-APR-1998 US     09/056285
            PI   EDWIN M STONE,VAL C SHEFFIELD,WALLACE L M ALWARD,JOHN FINGERT
            PC   C12N15/09,C12Q1/68,C12N15/00
            CC   Description of Artificial Sequence: primer
            FH   Key             Location/Qualifiers
            FT   source          1. .20
            FT                   /organism='Artificial Sequence'.
FEATURES              Location/Qualifiers
     source           1. .20
                      /organism="synthetic construct"
                      /mol_type="genomic DNA"
                      /db_xref="taxon:32630"

  Query Match              0.9%;  Score 15.8;  DB 1;  Length 20;
  Best Local Similarity   89.5%;  Pred. No. 1e+02;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        174 GGCACTCTGAGTTCATCAG 192
              || |||||||||||| |||
Db         19 GGGACTCTGAGTTCAGCAG 1


RESULT 37
AR181346
LOCUS       AR181346                 20 bp    DNA     linear   PAT 20-APR-2002
DEFINITION  Sequence 29 from patent US 6335172.
ACCESSION   AR181346
VERSION     AR181346.1  GI:20223560
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Delgado,S.Gregory., Dietrich,P.Shartzer., Fish,L.Marie.,
            Herman,R.Charles. and Sangameswaran,L.
  TITLE     Cloned tetrodotoxin-sensitive sodium channel .alpha.-subunit and a
            splice variant thereof
  JOURNAL   Patent: US 6335172-A 29 01-JAN-2002;
FEATURES              Location/Qualifiers
     source           1. .20
                      /organism="unknown"
                      /mol_type="unassigned DNA"

  Query Match              0.9%;  Score 15.8;  DB 1;  Length 20;
  Best Local Similarity   89.5%;  Pred. No. 1e+02;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        392 CAGCAGCAACAGTGGCTTC 410
              ||||||| ||||||||| |
Db          1 CAGCAGCTACAGTGGCTAC 19


RESULT 38
AR212968/c
LOCUS       AR212968                 20 bp    DNA     linear   PAT 25-SEP-2002
DEFINITION  Sequence 27 from patent US 6403307.
ACCESSION   AR212968
VERSION     AR212968.1  GI:23309853
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Stone,E.M., Sheffield,V.C., Alward,W.L.M. and Fingert,J.
```

```
  TITLE     Glaucoma therapeutics and diagnostics
  JOURNAL   Patent: US 6403307-A 27 11-JUN-2002;
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.9%;  Score 15.8;  DB 1;  Length 20;
  Best Local Similarity   89.5%;  Pred. No. 1e+02;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        174 GGCACTCTGAGTTCATCAG 192
              || |||||||||||| |||
Db         19 GGGACTCTGAGTTCAGCAG 1


RESULT 39
AR313181
LOCUS       AR313181                  20 bp    DNA     linear   PAT 12-JUN-2003
DEFINITION  Sequence 3718 from patent US 6559294.
ACCESSION   AR313181
VERSION     AR313181.1  GI:31706607
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Griffais,R., Hoiseth,S.K., Zagursky,R.J., Metcalf,B.J., Peek,J.A.,
            Sankaran,B. and Fletcher,L.D.
  TITLE     Chlamydia pneumoniae polynucleotides and uses thereof
  JOURNAL   Patent: US 6559294-A 3718 06-MAY-2003;
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             0.9%;  Score 15.8;  DB 1;  Length 20;
  Best Local Similarity   89.5%;  Pred. No. 1e+02;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        825 GGCTTCAGCCAGTCCCTGA 843
              ||| ||||||| |||||||
Db          2 GGCGTCAGCCAATCCCTGA 20


RESULT 40
AX167124/c
LOCUS       AX167124                  20 bp    DNA     linear   PAT 03-JUL-2001
DEFINITION  Sequence 11 from Patent WO0144455.
ACCESSION   AX167124
VERSION     AX167124.1  GI:14596612
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Beri,R.
  TITLE     Antisense oligonucleotides
  JOURNAL   Patent: WO 0144455-A 11 21-JUN-2001;
            AstraZeneca AB (SE)
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"
                     /note="Antisense oligonucleotide"

  Query Match             0.9%;  Score 15.8;  DB 1;  Length 20;
  Best Local Similarity   89.5%;  Pred. No. 1e+02;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        986 GAGGCAGGAGCTGAGGGAC 1004
              ||||| |||||| ||||||
Db         20 GAGGCTGGAGCTCAGGGAC 2


RESULT 41
AR070809/c
LOCUS       AR070809                  21 bp    DNA     linear   PAT 18-FEB-2000
DEFINITION  Sequence 14 from patent US 5908772.
ACCESSION   AR070809
VERSION     AR070809.1  GI:7221697
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 21)
  AUTHORS   Mitta,M., Sano,M. and Kato,I.
  TITLE     Gene encoding lacto-N-biosidase
  JOURNAL   Patent: US 5908772-A 14 01-JUN-1999;
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.9%;  Score 15.8;  DB 1;  Length 21;
  Best Local Similarity   89.5%;  Pred. No. 1e+02;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        746 CCTCGTGCTGCGCCTGGAC 764
              | ||||||||||||| ||||
Db         19 CATCGTGCTGCGCCAGGAC 1


RESULT 42
BD244489/c
LOCUS       BD244489                  21 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  New triplex forming oligonucleotides and their use in anti-HBV.
ACCESSION   BD244489
VERSION     BD244489.1  GI:33054259
KEYWORDS    JP 2002511384-A/7.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1  (bases 1 to 21)
  AUTHORS   Lu,C.
  TITLE     New triplex forming oligonucleotides and their use in anti-HBV
  JOURNAL   Patent: JP 2002511384-A 7 16-APR-2002;
            SHANGHAI INSTITUTE OF BIOCHEMISTRY CHINESE ACADEMY OF SCIENCES
COMMENT     OS   Artificial Sequence
            PN   JP 2002511384-A/7
            PD   16-APR-2002
            PF   19-OCT-1998 JP 2000516982
            PR   21-OCT-1997 CN 97 1 06667.1
            PI   CHANGDE LU
            PC   A61K31/711,A61K48/00,A61P31/20,C12N15/09,C12N15/00 CC
            Description of Artificial Sequence: Triplex forming  CC
            oligonucleotide
            CC   This oligo may or may not be 3'-monophosphorylated FH   Key
                 Location/Qualifiers
            FT   source          1. .21
            FT                   /organism='Artificial Sequence'.
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="synthetic construct"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32630"

  Query Match             0.9%;  Score 15.8;  DB 1;  Length 21;
  Best Local Similarity   89.5%;  Pred. No. 1e+02;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        256 CCTCCTCTTCGCCCTCGTC 274
              |||||||||| ||||| ||
Db         20 CCTCCTCTTCCCCCTCCTC 2
```

```
RESULT 43
AR454920/c
LOCUS       AR454920                  21 bp    DNA     linear   PAT 20-FEB-2004
DEFINITION  Sequence 7 from patent US 6682930.
ACCESSION   AR454920
VERSION     AR454920.1  GI:42688956
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 21)
  AUTHORS   Lu,C.
  TITLE     Triplex forming oligonucleotides and their use in anti-HBV
  JOURNAL   Patent: US 6682930-A 7 27-JAN-2004;
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             0.9%;  Score 15.8;  DB 1;  Length 21;
  Best Local Similarity   89.5%;  Pred. No. 1e+02;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        256 CCTCCTCTTCGCCCTCGTC 274
              ||||||||||  ||||| ||
Db         20 CCTCCTCTTCCCCCTCCTC 2


RESULT 44
E04985/c
LOCUS       E04985                    27 bp    DNA     linear   PAT 29-SEP-1997
DEFINITION  DNA sequence of 3'terminal fragment of ITR.
ACCESSION   E04985
VERSION     E04985.1  GI:2173180
KEYWORDS    JP 1993103673-A/79.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1  (bases 1 to 27)
  AUTHORS   Sengu,K.Y. and Ito,S.
  TITLE     REPLICATION OF DNA
  JOURNAL   Patent: JP 1993103673-A 79 27-APR-1993;
            ARIZONA BOARD OF REGENTS
COMMENT     OS   Artificial gene
            OC   Artificial sequence; Genes.
            PN   JP 1993103673-A/79
            PD   27-APR-1993
            PF   26-AUG-1991 JP 1991240525
            PI   SENGU KUU YUU, ITO SUMIYOSHI
            PC   C12N15/10,C12N15/11//C12Q1/68;
            CC   strandedness: Single;
            CC   topology: Linear;
            FH   Key             Location/Qualifiers
            FH
            FT   misc_feature    1. .27
            FT                   /note='3'terminal fragment of ITR'.
FEATURES             Location/Qualifiers
     source          1. .27
                     /organism="synthetic construct"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32630"

  Query Match             0.9%;  Score 15.8;  DB 1;  Length 27;
  Best Local Similarity   74.1%;  Pred. No. 1e+02;
  Matches   20;  Conservative    0;  Mismatches    7;  Indels    0;  Gaps    0;

Qy       1382 TTTGTTGTTTGTTTTGTATCTTGTTTT 1408
              ||| || ||| |||| | | || ||||
Db         27 TTTTTTTTTTTTTTTTTTTTTTTTTTT 1


RESULT 45
AX104719
LOCUS       AX104719                  27 bp    DNA     linear   PAT 30-APR-2001
DEFINITION  Sequence 911 from Patent WO0122972.
ACCESSION   AX104719
VERSION     AX104719.1  GI:13920916
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Krieg,A.M., Schetter,C. and Vollmer,J.C.
  TITLE     Immunostimulatory nucleic acids
  JOURNAL   Patent: WO 0122972-A 911 05-APR-2001;
            UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) ; Coley Pharmaceutical
            GmbH (DE)
FEATURES             Location/Qualifiers
     source          1. .27
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"

  Query Match             0.9%;  Score 15.8;  DB 1;  Length 27;
  Best Local Similarity   74.1%;  Pred. No. 1e+02;
  Matches   20;  Conservative    0;  Mismatches    7;  Indels    0;  Gaps    0;

Qy       1382 TTTGTTGTTTGTTTTGTATCTTGTTTT 1408
              ||| || ||| |||| | | || ||||
Db          1 TTTTTTTTTTTTTTTTTTTTTTTTTTT 27


RESULT 46
AX355814
LOCUS       AX355814                  27 bp    DNA     linear   PAT 06-FEB-2002
DEFINITION  Sequence 842 from Patent WO0197843.
ACCESSION   AX355814
VERSION     AX355814.1  GI:18620482
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Weiner,G. and Hartmann,G.
  TITLE     Methods for enhancing antibody-induced cell lysis and treating
            cancer
  JOURNAL   Patent: WO 0197843-A 842 27-DEC-2001;
            UNIVERSITY OF IOWA RESEARCH FOUNDATION (US)
FEATURES             Location/Qualifiers
     source          1. .27
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Synthetic oligonucleotide~phosphorothioate
                     backbone"

  Query Match             0.9%;  Score 15.8;  DB 1;  Length 27;
  Best Local Similarity   74.1%;  Pred. No. 1e+02;
  Matches   20;  Conservative    0;  Mismatches    7;  Indels    0;  Gaps    0;

Qy       1382 TTTGTTGTTTGTTTTGTATCTTGTTTT 1408
              ||| || ||| |||| | | || ||||
Db          1 TTTTTTTTTTTTTTTTTTTTTTTTTTT 27


RESULT 47
AX547772
LOCUS       AX547772                  27 bp    DNA     linear   PAT 01-MAR-2003
DEFINITION  Sequence 911 from Patent WO02053141.
ACCESSION   AX547772
VERSION     AX547772.1  GI:25812916
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
```

```
            artificial sequences.
REFERENCE   1
  AUTHORS   Bratzler,R.L.
  TITLE     Inhibition of angiogenesis by nucleic acids
  JOURNAL   Patent: WO 02053141-A 911 11-JUL-2002;
            Coley Pharmaceutical Group, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .27
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Synthetic Sequence"

  Query Match             0.9%;  Score 15.8;  DB 1;  Length 27;
  Best Local Similarity   74.1%;  Pred. No. 1e+02;
  Matches   20;  Conservative    0;  Mismatches    7;  Indels    0;  Gaps    0;

Qy       1382 TTTGTTGTTTGTTTTGTATCTTGTTTT 1408
              ||| || ||| |||| | | || ||||
Db          1 TTTTTTTTTTTTTTTTTTTTTTTTTTT 27


RESULT 48
BD234335
LOCUS       BD234335                  28 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Improved method for inserting nucleic acid into cyclic vector.
ACCESSION   BD234335
VERSION     BD234335.1  GI:33044105
KEYWORDS    JP 2002532085-A/8.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1  (bases 1 to 28)
  AUTHORS   Romantchikov,Y.
  TITLE     Improved method for inserting nucleic acid into cyclic vector
  JOURNAL   Patent: JP 2002532085-A 8 02-OCT-2002;
            YURI ROMANTCHIKOV
COMMENT     OS   Artificial Sequence
            PN   JP 2002532085-A/8
            PD   02-OCT-2002
            PF   17-DEC-1999 JP 2000588337
            PR   17-DEC-1998 US    09/213834
            PI   YURI ROMANTCHIKOV
            PC   C12N15/09,C12N1/15,C12N1/19,C12N1/21,C12N5/10,C12N15/00,C12N5/
            PC   00
            CC   Cloning Vector
            FH   Key             Location/Qualifiers
            FT   source          1. .28
            FT                   /organism='Artificial Sequence'.
FEATURES             Location/Qualifiers
     source          1. .28
                     /organism="synthetic construct"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32630"

  Query Match             0.9%;  Score 15.8;  DB 1;  Length 28;
  Best Local Similarity   74.1%;  Pred. No. 1e+02;
  Matches   20;  Conservative    0;  Mismatches    7;  Indels    0;  Gaps    0;

Qy       1383 TTGTTGTTTGTTTTGTATCTTGTTTT 1409
              | ||| ||| |||| | | || |||||
Db          2 TAGTTTTTTTTTTTTTTTTTTTTTTT 28


RESULT 49
AR067856
LOCUS       AR067856                  17 bp    DNA     linear   PAT 29-SEP-1999
DEFINITION  Sequence 6 from patent US 5851815.
ACCESSION   AR067856
VERSION     AR067856.1  GI:5999078
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Alnemri,E.S., Fernandes-Alnemri,T., Litwack,G., Armstrong,R. and
            Tomaselli,K.
  TITLE     MCH4 and MCH5, apoptotic proteases
  JOURNAL   Patent: US 5851815-A 6 22-DEC-1998;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.9%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   94.1%;  Pred. No. 1.2e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         16 CAAGAATTCGGCACGAG 32
              || ||||||||||||||
Db          1 CAGGAATTCGGCACGAG 17


RESULT 50
AR164207
LOCUS       AR164207                  17 bp    DNA     linear   PAT 17-OCT-2001
DEFINITION  Sequence 5 from patent US 6271361.
ACCESSION   AR164207
VERSION     AR164207.1  GI:16235230
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Alnemri,E.S., Fernandes-Alnemri,T. and Litwack,G.
  TITLE     Apoptotic protease Mch6, nucleic acids encoding same and methods of
            use
  JOURNAL   Patent: US 6271361-A 5 07-AUG-2001;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.9%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   94.1%;  Pred. No. 1.2e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         16 CAAGAATTCGGCACGAG 32
              || ||||||||||||||
Db          1 CAGGAATTCGGCACGAG 17


RESULT 51
AR164645
LOCUS       AR164645                  17 bp    DNA     linear   PAT 17-OCT-2001
DEFINITION  Sequence 5 from patent US 6274318.
ACCESSION   AR164645
VERSION     AR164645.1  GI:16237730
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Alnemri,E.S., Fernandes-Alnemri,T. and Litwack,G.
  TITLE     Apoptotic protease Mch6, nucleic acids encoding same and methods of
            us
  JOURNAL   Patent: US 6274318-A 5 14-AUG-2001;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.9%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   94.1%;  Pred. No. 1.2e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;
```

```
Qy          16 CAAGAATTCGGCACGAG 32
               || ||||||||||||||
Db           1 CAGGAATTCGGCACGAG 17


RESULT 52
AR168088
LOCUS       AR168088                  17 bp    DNA     linear   PAT 17-DEC-2001
DEFINITION  Sequence 6 from patent US 6287795.
ACCESSION   AR168088
VERSION     AR168088.1  GI:17903908
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Alnemri,E.S., Fernandes-Alnemri,T., Litwack,G., Armstrong,R. and
            Tomaselli,K.
  TITLE     Mch4 and Mch5, apoptotic protease, nucleic acids encoding and
            methods of use
  JOURNAL   Patent: US 6287795-A 6 11-SEP-2001;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.9%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   94.1%;  Pred. No. 1.2e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy          16 CAAGAATTCGGCACGAG 32
               || ||||||||||||||
Db           1 CAGGAATTCGGCACGAG 17


RESULT 53
AR192333
LOCUS       AR192333                  17 bp    DNA     linear   PAT 20-APR-2002
DEFINITION  Sequence 7821 from patent US 6346398.
ACCESSION   AR192333
VERSION     AR192333.1  GI:20238298
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
  TITLE     Method and reagent for the treatment of diseases or conditions
            related to levels of vascular endothelial growth factor receptor
  JOURNAL   Patent: US 6346398-A 7821 12-FEB-2002;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.9%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   94.1%;  Pred. No. 1.2e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        1382 TTTGTTGTTTGTTTTGT 1398
               |||||| ||||||||||
Db           1 TTTGTTTTTTGTTTTGT 17


RESULT 54
AR232188
LOCUS       AR232188                  17 bp    mRNA    linear   PAT 20-DEC-2002
DEFINITION  Sequence 5 from patent US 6455296.
ACCESSION   AR232188
VERSION     AR232188.1  GI:27274091
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Alnemri,E.S., Fernandes-Alnemri,T. and Litwack,G.
  TITLE     Apoptotic protease Mch6, nucleic acids encoding same and methods of
            use
  JOURNAL   Patent: US 6455296-A 5 24-SEP-2002;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="mRNA"

  Query Match             0.9%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   94.1%;  Pred. No. 1.2e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy          16 CAAGAATTCGGCACGAG 32
               || ||||||||||||||
Db           1 CAGGAATTCGGCACGAG 17


RESULT 55
AR236040
LOCUS       AR236040                  17 bp    DNA     linear   PAT 20-DEC-2002
DEFINITION  Sequence 6 from patent US 6462175.
ACCESSION   AR236040
VERSION     AR236040.1  GI:27279634
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Alnemri,E.S., Fernandes-Alnemri,T., Litwack,G., Armstrong,R. and
            Tomaselli,K.
  TITLE     Mch3, a novel apoptotic protease, nucleic acids encoding and
            methods of use
  JOURNAL   Patent: US 6462175-A 6 08-OCT-2002;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             0.9%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   94.1%;  Pred. No. 1.2e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy          16 CAAGAATTCGGCACGAG 32
               || ||||||||||||||
Db           1 CAGGAATTCGGCACGAG 17


RESULT 56
AR326203
LOCUS       AR326203                  17 bp    RNA     linear   PAT 17-AUG-2003
DEFINITION  Sequence 3605 from patent US 6566127.
ACCESSION   AR326203
VERSION     AR326203.1  GI:33712011
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
  TITLE     Method and reagent for the treatment of diseases or conditions
            related to levels of vascular endothelial growth factor receptor
  JOURNAL   Patent: US 6566127-A 3605 20-MAY-2003;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned RNA"

  Query Match             0.9%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   94.1%;  Pred. No. 1.2e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;
```

```
Qy       1382 TTTGTTGTTTGTTTTGT 1398
              ||||||  ||||||||||
Db          1 TTTGTTTTTTGTTTTGT 17


RESULT 57
AR337628
LOCUS       AR337628                  17 bp    mRNA    linear   PAT 17-AUG-2003
DEFINITION  Sequence 5 from patent US 6566505.
ACCESSION   AR337628
VERSION     AR337628.1  GI:33724059
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Alnemri,E.S., Fernandes-Alnemri,T. and Litwack,G.
  TITLE     Antibodies to Mch6 polypeptides
  JOURNAL   Patent: US 6566505-A 5 20-MAY-2003;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="mRNA"

  Query Match             0.9%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   94.1%;  Pred. No. 1.2e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         16 CAAGAATTCGGCACGAG 32
              || |||||||||||||||
Db          1 CAGGAATTCGGCACGAG 17


RESULT 58
AR473351
LOCUS       AR473351                  17 bp    DNA     linear   PAT 20-FEB-2004
DEFINITION  Sequence 6 from patent US 6686459.
ACCESSION   AR473351
VERSION     AR473351.1  GI:42708800
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Alnemri,E.S., Fernandes-Alnemri,T., Litwack,G., Armstrong,R. and
            Tomaselli,K.
  TITLE     Mch3, a novel apoptotic protease, nucleic acids encoding and
            methods of use
  JOURNAL   Patent: US 6686459-A 6 03-FEB-2004;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             0.9%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   94.1%;  Pred. No. 1.2e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         16 CAAGAATTCGGCACGAG 32
              || |||||||||||||||
Db          1 CAGGAATTCGGCACGAG 17


RESULT 59
AR492475
LOCUS       AR492475                  17 bp    DNA     linear   PAT 15-MAY-2004
DEFINITION  Sequence 6 from patent US 6716960.
ACCESSION   AR492475
VERSION     AR492475.1  GI:47261885
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Alnemri,E.S., Fernandes-Alnemri,T., Litwack,G., Armstrong,R. and
            Tomaselli,K.
  TITLE     Mch3, a novel apoptotic protease, nucleic acids encoding and
            methods of use
  JOURNAL   Patent: US 6716960-A 6 06-APR-2004;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             0.9%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   94.1%;  Pred. No. 1.2e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         16 CAAGAATTCGGCACGAG 32
              || |||||||||||||||
Db          1 CAGGAATTCGGCACGAG 17


RESULT 60
AX723340/c
LOCUS       AX723340                  17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 1027 from Patent WO03025176.
ACCESSION   AX723340
VERSION     AX723340.1  GI:30423841
KEYWORDS    .
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
  JOURNAL   Patent: WO 03025176-A 1027 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Mus musculus"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:10090"

  Query Match             0.9%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   94.1%;  Pred. No. 1.2e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1482 GGTGGGTGTCAGGGATC 1498
              |||||||  |||||||||
Db         17 GGTGGGTATCAGGGATC 1


RESULT 61
I72032
LOCUS       I72032                    18 bp    DNA     linear   PAT 03-APR-1998
DEFINITION  Sequence 68 from patent US 5683872.
ACCESSION   I72032
VERSION     I72032.1  GI:3008171
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Rudert,W.A. and Trucco,M.
  TITLE     Polymers of oligonucleotide probes as the bound ligands for use in
            reverse dot blots
  JOURNAL   Patent: US 5683872-A 68 04-NOV-1997;
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unknown"
                     /mol_type="unassigned DNA"
```

```
  Query Match             0.9%;  Score 15.4;  DB 1;  Length 18;
  Best Local Similarity   94.1%;  Pred. No. 1.2e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        839 CCTGACGCTGAGCACTG 855
              ||||||||||||| ||||
Db          2 CCTGACGCTGAGTACTG 18


RESULT 62
BD104973/c
LOCUS       BD104973                 18 bp    DNA     linear   PAT 27-AUG-2002
DEFINITION  Kit and method for determining HLA type.
ACCESSION   BD104973
VERSION     BD104973.1  GI:22650547
KEYWORDS    WO 0192572-A/1077.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Inoko,H., Kagiya,T., Ichihara,T., Matsumura,Y., Moriya,S. and
            Nishida,M.
  TITLE     Kit and method for determining HLA type
  JOURNAL   Patent: WO 0192572-A 1077 06-DEC-2001;
            NISSHINBO INDUSTRIES INC,SYSTEM RESEARCH INC,HIDETOSHI INOKO, TAEKO
            KAGIYA, TATSUO ICHIHARA,YOSHIYUKI MATSUMURA,SHOGO MORIYA,MICHIO
            NISHIDA
COMMENT     OS   Artificial Sequence
            PN   WO 0192572-A/1077
            PD   06-DEC-2001
            PF   01-JUN-2001 WO 2001JP004662
            PR   01-JUN-2000 JP 00P   164798
            PI   HIDETOSHI INOKO,TAEKO KAGIYA,TATSUO ICHIHARA,YOSHIYUKI  PI
            MATSUMURA,
            PI   SHOGO MORIYA,MICHIO NISHIDA
            PC   C12Q1/68,C12M1/00,C12N15/09,G01N33/53
            CC   Description of Artificial Sequence:primer
            FH   Key             Location/Qualifiers
            FT   source          1. .18
            FT                   /organism='Artificial Sequence'.
FEATURES              Location/Qualifiers
     source           1. .18
                      /organism="synthetic construct"
                      /mol_type="genomic DNA"
                      /db_xref="taxon:32630"

  Query Match             0.9%;  Score 15.4;  DB 1;  Length 18;
  Best Local Similarity   94.1%;  Pred. No. 1.2e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        522 GAGAGCCTGGCCCAGGC 538
              |||| ||||||||||||
Db         18 GAGACCCTGGCCCAGGC 2


RESULT 63
AR179243
LOCUS       AR179243                 19 bp    DNA     linear   PAT 20-APR-2002
DEFINITION  Sequence 31 from patent US 6326170.
ACCESSION   AR179243
VERSION     AR179243.1  GI:20220798
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Russel Burnham,M.Karl., Lonetto,M.Arthur. and Warren,P.Vernon.
  TITLE     Prokaryotic polynucleotides, polypeptides and their uses
  JOURNAL   Patent: US 6326170-A 31 04-DEC-2001;
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="unknown"
                      /mol_type="unassigned DNA"

  Query Match             0.9%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 1.2e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         19 GAATTCGGCACGAGGGG 35
              |||||||||||||| ||
Db          2 GAATTCGGCACGAGCGG 18


RESULT 64
AX129981
LOCUS       AX129981                 19 bp    DNA     linear   PAT 15-MAY-2001
DEFINITION  Sequence 1199 from Patent WO0130362.
ACCESSION   AX129981
VERSION     AX129981.1  GI:14136286
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Robbins,J.M. and Tritz,R.
  TITLE     Ribozyme therapy for the treatment of proliferative skin and eye
            diseases
  JOURNAL   Patent: WO 0130362-A 1199 03-MAY-2001;
            IMMUSOL, INC. (US)
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="Homo sapiens"
                      /mol_type="unassigned DNA"
                      /db_xref="taxon:9606"
                      /note="Cdk-we-hu ribozyme binding site"

  Query Match             0.9%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 1.2e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1001 GGACTGATTCCTGTGGT 1017
              ||| ||||||||||||
Db          2 GGAATGATTCCTGTGGT 18


RESULT 65
AX129982
LOCUS       AX129982                 19 bp    DNA     linear   PAT 15-MAY-2001
DEFINITION  Sequence 1200 from Patent WO0130362.
ACCESSION   AX129982
VERSION     AX129982.1  GI:14136287
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Robbins,J.M. and Tritz,R.
  TITLE     Ribozyme therapy for the treatment of proliferative skin and eye
            diseases
  JOURNAL   Patent: WO 0130362-A 1200 03-MAY-2001;
            IMMUSOL, INC. (US)
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="Homo sapiens"
                      /mol_type="unassigned DNA"
                      /db_xref="taxon:9606"
                      /note="Cdk-we-hu ribozyme binding site"

  Query Match             0.9%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 1.2e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1001 GGACTGATTCCTGTGGT 1017
```

```
              ||| |||||||||||||
Db          1 GGAATGATTCCTGTGGT 17


RESULT 66
AX352953/c
LOCUS       AX352953                 19 bp    DNA     linear   PAT 06-FEB-2002
DEFINITION  Sequence 159 from Patent EP1174518.
ACCESSION   AX352953
VERSION     AX352953.1  GI:18618035
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Loukachov,V.V., van Gemen,B. and Goudsmit,J.
  TITLE     Collection of binding molecules
  JOURNAL   Patent: EP 1174518-A 159 23-JAN-2002;
            Amsterdam Support Diagnostics B.V. (NL)
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="position 69"

  Query Match             0.9%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 1.2e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1646 TCCATCTAGAACTGTTT 1662
              ||||||||| |||||||
Db         18 TCCATCTAGTACTGTTT 2


RESULT 67
AX362798/c
LOCUS       AX362798                 19 bp    DNA     linear   PAT 15-FEB-2002
DEFINITION  Sequence 159 from Patent WO0208463.
ACCESSION   AX362798
VERSION     AX362798.1  GI:18694938
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Loukachov,V.V., Goudsmit,J. and van Gemen,B.
  TITLE     Collection of binding molecules
  JOURNAL   Patent: WO 0208463-A 159 31-JAN-2002;
            Amsterdam Support Diagnostics B.V. (NL)
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="position 69"

  Query Match             0.9%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 1.2e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1646 TCCATCTAGAACTGTTT 1662
              ||||||||| |||||||
Db         18 TCCATCTAGTACTGTTT 2


RESULT 68
BD078905
LOCUS       BD078905                 19 bp    DNA     linear   PAT 27-AUG-2002
DEFINITION  Novel prokaryotic polynucleotide and polypeptide and utilization
            thereof.
ACCESSION   BD078905
VERSION     BD078905.1  GI:22624508
KEYWORDS    JP 2001515707-A/21.
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Burnham,M.K.R., Lonetto,M.A. and Warren,P.V.
  TITLE     Novel prokaryotic polynucleotide and polypeptide and utilization
  JOURNAL   Patent: JP 2001515707-A 21 25-SEP-2001;
            SMITHKLINE BEECHAM CORP
COMMENT     OS   Staphylococcus aureus
            PN   JP 2001515707-A/21
            PD   25-SEP-2001
            PF   14-SEP-1998 JP 2000510454
            PR   12-SEP-1997 US    60/058710
            PI   MARTIN K R BURNHAM,MICHAEL A LONETTO,PATRICK V WARREN PC
            C12N15/09,A61K38/00,A61K45/00,A61K48/00,A61P31/04,C07H21/02, PC
            C07H21/04,
            PC
            C07K14/31,C07K16/12,C12N1/15,C12N1/19,C12N1/21,C12N5/10,C12P21/ PC
             02,
            PC   C12Q1/68//(C12N15/09,C12R1:445),C12N15/00,A61K37/02,C12N5/00,
            PC   (C12N15/00,C12R1:445)
            CC   Novel prokaryotic polynucleotide and polypeptide and  CC
                 utilization thereof
            FH   Key             Location/Qualifiers
            FT   source          1. .19
            FT                   /organism='Staphylococcus aureus'.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="unidentified"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32644"

  Query Match             0.9%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 1.2e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         19 GAATTCGGCACGAGGGG 35
              |||||||||||||| ||
Db          2 GAATTCGGCACGAGCGG 18


RESULT 69
AR238868/c
LOCUS       AR238868                 20 bp    DNA     linear   PAT 20-DEC-2002
DEFINITION  Sequence 3 from patent US 6468749.
ACCESSION   AR238868
VERSION     AR238868.1  GI:27283943
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Ulanovsky,L., Mugasimangalam,R.C., Einat,P., Zezin-Sonkin,D. and
            Gilad,S.
  TITLE     Sequence-dependent gene sorting techniques
  JOURNAL   Patent: US 6468749-A 3 22-OCT-2002;
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             0.9%;  Score 15.4;  DB 1;  Length 20;
  Best Local Similarity   94.1%;  Pred. No. 1.2e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1115 ATACCCCTCAGTACTGT 1131
              ||||| ||||||||||
Db         18 ATACCACTCAGTACTGT 2


RESULT 70
AX278670/c
```

```
LOCUS       AX278670                 20 bp    DNA     linear   PAT 02-NOV-2001
DEFINITION  Sequence 3 from Patent WO0175180.
ACCESSION   AX278670
VERSION     AX278670.1  GI:16606124
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Ulanovsky,L., Mugasimangalam,R., Einat,P., Zezin-Sonkin,D. and
            Shlomit,G.
  TITLE     Sequence-dependent gene sorting techniques
  JOURNAL   Patent: WO 0175180-A 3 11-OCT-2001;
            Qbi Enterprises Ltd. (US)
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="primer"

  Query Match             0.9%;  Score 15.4;  DB 1;  Length 20;
  Best Local Similarity   94.1%;  Pred. No. 1.2e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1115 ATACCCCTCAGTACTGT 1131
              ||||| ||||||||||
Db         18 ATACCACTCAGTACTGT 2


RESULT 71
AX487219
LOCUS       AX487219                 20 bp    DNA     linear   PAT 16-AUG-2002
DEFINITION  Sequence 4519 from Patent WO02053728.
ACCESSION   AX487219
VERSION     AX487219.1  GI:22321367
KEYWORDS    .
SOURCE      Candida albicans
  ORGANISM  Candida albicans
            Eukaryota; Fungi; Ascomycota; Saccharomycotina; Saccharomycetes;
            Saccharomycetales; mitosporic Saccharomycetales; Candida.
REFERENCE   1
  AUTHORS   Roemer,T., Jiang,B., Boone,C., Bussey,H. and Ohlsen,K.L.
  TITLE     Gene disruption methodologies for drug target discovery
  JOURNAL   Patent: WO 02053728-A 4519 11-JUL-2002;
            Elitra Pharmaceuticals, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="Candida albicans"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:5476"

  Query Match             0.9%;  Score 15.4;  DB 1;  Length 20;
  Best Local Similarity   94.1%;  Pred. No. 1.2e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1044 TGGAGGTGGGGGAATAG 1060
              |||||||||||||| |||
Db          1 TGGAGGTGGGGGAGTAG 17


RESULT 72
AR174582
LOCUS       AR174582                 26 bp    DNA     linear   PAT 17-DEC-2001
DEFINITION  Sequence 39 from patent US 6307024.
ACCESSION   AR174582
VERSION     AR174582.1  GI:17914902
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 26)
  AUTHORS   Novak,J.E., Presnell,S.R., Sprecher,C.A., Foster,D.C., Holly,R.D.,
            Gross,J.A., Johnston,J.V., Nelson,A.J., Dillon,S.R. and
            Hammond,A.K.
  TITLE     Cytokine zalpha11 Ligand
  JOURNAL   Patent: US 6307024-A 39 23-OCT-2001;
FEATURES             Location/Qualifiers
     source          1. .26
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.9%;  Score 15.4;  DB 1;  Length 26;
  Best Local Similarity   76.0%;  Pred. No. 1.2e+02;
  Matches   19;  Conservative    0;  Mismatches    6;  Indels    0;  Gaps    0;

Qy       1386 TTGTTTGTTTTGTATCTTGTTTTTC 1410
              || ||| |||| | | || ||||||
Db          2 TTTTTTTTTTTTTTTTTTTTTTTTC 26


RESULT 73
BD248975
LOCUS       BD248975                 26 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Novel cytokine ZALPHA11 ligand.
ACCESSION   BD248975
VERSION     BD248975.1  GI:33058745
KEYWORDS    JP 2002537839-A/36.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1  (bases 1 to 26)
  AUTHORS   Novak,J.E., Presnell,S.R., Sprecher,C.A., Foster,D.C., Holly,R.D.,
            Gross,J.A., Johnston,J.V., Nelson,A.J., Dillon,S.R. and
            Hammond,A.K.
  TITLE     Novel cytokine ZALPHA11 ligand
  JOURNAL   Patent: JP 2002537839-A 36 12-NOV-2002;
            ZYMOGENETICS INC
COMMENT     OS   Artificial Sequence
            PN   JP 2002537839-A/36
            PD   12-NOV-2002
            PF   09-MAR-2000 JP 2000603382
            PR   09-MAR-1999 US    09/264908,11-MAR-1999 US    09/265992 PR
            01-JUL-1999 US    60/142013
            PI   JULIA E NOVAK,SCOTT R PRESNELL,CINDY A SPRECHER,DONALD C  PI
            FOSTER,
            PI   RICHARD D HOLLY,JANE A GROSS,JANET V JOHNSTON,ANDREW J NELSON,
            PI   STACEY R DILLON,ANGELA K HAMMOND
            PC   C12N15/09,A61K38/00,A61K45/00,A61P35/00,A61P37/00,C07K14/52,
            PC   C07K14/53,
            PC   C07K14/54,C07K14/55,C07K16/24,C07K19/00,C12N1/15,C12N1/19, PC
             C12N1/21,
            PC   C12N5/10,C12P21/02,C12P21/02,G01N33/53,C12N15/00,C12N5/00, PC
             A61K37/02
            CC   Oligonucleotide primer ZC7764b
            FH   Key             Location/Qualifiers
            FT   source          1. .26
            FT                   /organism='Artificial Sequence'.
FEATURES             Location/Qualifiers
     source          1. .26
                     /organism="synthetic construct"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32630"

  Query Match             0.9%;  Score 15.4;  DB 1;  Length 26;
  Best Local Similarity   76.0%;  Pred. No. 1.2e+02;
  Matches   19;  Conservative    0;  Mismatches    6;  Indels    0;  Gaps    0;

Qy       1386 TTGTTTGTTTTGTATCTTGTTTTTC 1410
              || ||| |||| | | || ||||||
Db          2 TTTTTTTTTTTTTTTTTTTTTTTTC 26


RESULT 74
I79495
LOCUS       I79495                   26 bp    DNA     linear   PAT 10-JUN-1998
```

```
DEFINITION  Sequence 2 from patent US 5707807.
ACCESSION   I79495
VERSION     I79495.1  GI:3207785
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 26)
  AUTHORS   Kato,K.
  TITLE     Molecular indexing for expressed gene analysis
  JOURNAL   Patent: US 5707807-A 2 13-JAN-1998;
FEATURES             Location/Qualifiers
     source          1. .26
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.9%;  Score 15.4;  DB 1;  Length 26;
  Best Local Similarity   76.0%;  Pred. No. 1.2e+02;
  Matches   19;  Conservative    0;  Mismatches    6;  Indels    0;  Gaps    0;

Qy       1386 TTGTTTGTTTTGTATCTTGTTTTTC 1410
              || ||| |||| | | || ||||||
Db          2 TTTTTTTTTTTTTTTTTTTTTTTTC 26


RESULT 75
AR279358
LOCUS       AR279358                 26 bp    DNA     linear   PAT 10-APR-2003
DEFINITION  Sequence 2 from patent US 6514699.
ACCESSION   AR279358
VERSION     AR279358.1  GI:29714110
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 26)
  AUTHORS   O'Neill,R.A., Chen,J.-K., Chiesa,C. and Fry,G.
  TITLE     Multiplex polynucleotide capture methods and compositions
  JOURNAL   Patent: US 6514699-A 2 04-FEB-2003;
FEATURES             Location/Qualifiers
     source          1. .26
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             0.9%;  Score 15.4;  DB 1;  Length 26;
  Best Local Similarity   76.0%;  Pred. No. 1.2e+02;
  Matches   19;  Conservative    0;  Mismatches    6;  Indels    0;  Gaps    0;

Qy       1386 TTGTTTGTTTTGTATCTTGTTTTTC 1410
              || ||| |||| | | || ||||||
Db          2 TTTTTTTTTTTTTTTTTTTTTTTTC 26


RESULT 76
AR374074
LOCUS       AR374074                 26 bp    DNA     linear   PAT 18-DEC-2003
DEFINITION  Sequence 39 from patent US 6605272.
ACCESSION   AR374074
VERSION     AR374074.1  GI:40076646
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 26)
  AUTHORS   Novak,J.E., Presnell,S.R., Sprecher,C.A., Foster,D.C., Holly,R.D.,
            Gross,J.A., Johnston,J.V., Nelson,A.J., Dillon,S.R. and
            Hammond,A.K.
  TITLE     Methods of using zalpha11 ligand
  JOURNAL   Patent: US 6605272-A 39 12-AUG-2003;
FEATURES             Location/Qualifiers
     source          1. .26
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             0.9%;  Score 15.4;  DB 1;  Length 26;
  Best Local Similarity   76.0%;  Pred. No. 1.2e+02;
  Matches   19;  Conservative    0;  Mismatches    6;  Indels    0;  Gaps    0;

Qy       1386 TTGTTTGTTTTGTATCTTGTTTTTC 1410
              || ||| |||| | | || ||||||
Db          2 TTTTTTTTTTTTTTTTTTTTTTTTC 26


RESULT 77
AR404597
LOCUS       AR404597                 26 bp    DNA     linear   PAT 18-DEC-2003
DEFINITION  Sequence 1 from patent US 6627748.
ACCESSION   AR404597
VERSION     AR404597.1  GI:40153233
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 26)
  AUTHORS   Ju,J., Li,Z., Tong,A. and Russo,J.J.
  TITLE     Combinatorial fluorescence energy transfer tags and their
            applications for multiplex genetic analyses
  JOURNAL   Patent: US 6627748-A 1 30-SEP-2003;
FEATURES             Location/Qualifiers
     source          1. .26
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             0.9%;  Score 15.4;  DB 1;  Length 26;
  Best Local Similarity   76.0%;  Pred. No. 1.2e+02;
  Matches   19;  Conservative    0;  Mismatches    6;  Indels    0;  Gaps    0;

Qy       1386 TTGTTTGTTTTGTATCTTGTTTTTC 1410
              || ||| |||| | | || ||||||
Db          2 TTTTTTTTTTTTTTTTTTTTTTTTC 26


RESULT 78
AR456224
LOCUS       AR456224                 26 bp    DNA     linear   PAT 20-FEB-2004
DEFINITION  Sequence 39 from patent US 6686178.
ACCESSION   AR456224
VERSION     AR456224.1  GI:42691247
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 26)
  AUTHORS   Novak,J.E., Presnell,S.R., Sprecher,C.A., Foster,D.C., Holly,R.D.,
            Gross,J.A., Johnston,J.V., Nelson,A.J., Dillon,S.R. and
            Hammond,A.K.
  TITLE     Cytokine zalpha11 ligand polynucleotides
  JOURNAL   Patent: US 6686178-A 39 03-FEB-2004;
FEATURES             Location/Qualifiers
     source          1. .26
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             0.9%;  Score 15.4;  DB 1;  Length 26;
  Best Local Similarity   76.0%;  Pred. No. 1.2e+02;
  Matches   19;  Conservative    0;  Mismatches    6;  Indels    0;  Gaps    0;

Qy       1386 TTGTTTGTTTTGTATCTTGTTTTTC 1410
              || ||| |||| | | || ||||||
Db          2 TTTTTTTTTTTTTTTTTTTTTTTTC 26


RESULT 79
BD007174
LOCUS       BD007174                 26 bp    DNA     linear   PAT 31-JAN-2002
DEFINITION  Method and composition for capturing multiple polynucleotide.
```

```
ACCESSION   BD007174
VERSION     BD007174.1  GI:18635545
KEYWORDS    JP 2001503973-A/2.
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 26)
  AUTHORS   OGneill,R.A., Chen,J.C., Chiesa,C. and Fry,G.
  TITLE     Method and composition for capturing multiple polynucleotide
  JOURNAL   Patent: JP 2001503973-A 2 27-MAR-2001;
            THE PERKIN ELMAR CORP
COMMENT     OS   Unidentified
            PN   JP 2001503973-A/2
            PD   27-MAR-2001
            PF   02-OCT-1997 JP 1998516839
            PR   04-OCT-1996 US    60/027832,12-JUN-1997 US    08/873437 PI
            ROGER A O'NEILL,JAR CAIN CHEN,CLAUDIA CHIESA,GEORGE FRY PC
            C12Q1/68,C12N15/09,C12N15/00
            CC   Strandedness: Single;
            CC   Topology: Linear;
            FH   Key             Location/Qualifiers
            FT   source          1. .26
            FT                   /organism='Unidentified'.
FEATURES              Location/Qualifiers
     source           1. .26
                      /organism="unidentified"
                      /mol_type="genomic DNA"
                      /db_xref="taxon:32644"

  Query Match             0.9%;  Score 15.4;  DB 1;  Length 26;
  Best Local Similarity   76.0%;  Pred. No. 1.2e+02;
  Matches   19;  Conservative    0;  Mismatches    6;  Indels    0;  Gaps    0;

Qy       1386 TTGTTTGTTTTGTATCTTGTTTTTC 1410
              || ||| |||| | | || ||||||
Db          2 TTTTTTTTTTTTTTTTTTTTTTTTC 26


RESULT 80
AR129672
LOCUS       AR129672                 20 bp    DNA     linear   PAT 16-MAY-2001
DEFINITION  Sequence 76 from patent US 6187545.
ACCESSION   AR129672
VERSION     AR129672.1  GI:14117569
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   McKay,R., Butler,M.M., Wyatt,J. and Cowsert,L.M.
  TITLE     Antisense modulation of pepck-cytosolic expression
  JOURNAL   Patent: US 6187545-A 76 13-FEB-2001;
FEATURES              Location/Qualifiers
     source           1. .20
                      /organism="unknown"
                      /mol_type="unassigned DNA"

  Query Match             0.9%;  Score 15.2;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 1.3e+02;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        241 TCTCGTCGTCGTCCACCTCC 260
              |||||  ||| |||||||||
Db          1 TCTCGATGTCTTCCACCTCC 20


RESULT 81
BD243920/c
LOCUS       BD243920                 20 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  STE20-related protein kinases.
ACCESSION   BD243920
VERSION     BD243920.1  GI:33053690
KEYWORDS    JP 2002522009-A/82.
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Plowman,G., Martinez,R. and Whyte,D.
  TITLE     STE20-related protein kinases
  JOURNAL   Patent: JP 2002522009-A 82 23-JUL-2002;
            SUGEN INC
COMMENT     OS   Homo sapiens (human)
            PN   JP 2002522009-A/82
            PD   23-JUL-2002
            PF   13-APR-1999 JP 2000543584
            PR   14-APR-1998 US    60/081784
            PI   GREGORY PLOWMAN,RICARDO MARTINEZ,DAVID WHYTE
            PC   C12N15/09,A61K38/55,A61P9/00,A61P9/10,A61P13/12,A61P25/00, PC
             A61P35/00,
            PC   A61P37/00,C07K16/40,C12N1/15,C12N1/19,C12N1/21,C12N5/10,C12N9/
            PC   12,C12Q1/68,
            PC   C12N15/00,A61K37/64,C12N5/00
            CC   Mammalian PAK5
            FH   Key             Location/Qualifiers
            FT   source          1. .20
            FT                   /organism='Homo sapiens (human)'.
FEATURES              Location/Qualifiers
     source           1. .20
                      /organism="Homo sapiens"
                      /mol_type="genomic DNA"
                      /db_xref="taxon:9606"

  Query Match             0.9%;  Score 15.2;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 1.3e+02;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        601 GCAAAGAACTACTGCGCCTG 620
              |||||  |||||||| ||||
Db         20 GCAAATGACTACTGCACCTG 1


RESULT 82
BD250365
LOCUS       BD250365                 20 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Enzyme.
ACCESSION   BD250365
VERSION     BD250365.1  GI:33060135
KEYWORDS    JP 2002541794-A/10.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Talas,U.G., Dunlop,J. and Kelsell,D.P.
  TITLE     Enzyme
  JOURNAL   Patent: JP 2002541794-A 10 10-DEC-2002;
            QUEEN MARY AND WESTFIELD COLLEGE
COMMENT     OS   Artificial Sequence
            PN   JP 2002541794-A/10
            PD   10-DEC-2002
            PF   12-APR-2000 JP 2000611653
            PR   13-APR-1999 GB    9908458.4
            PI   ULVI GERST TALAS,JOHN DUNLOP,DAVID PETER KELSELL PC
            C12N15/09,C07K16/40,C12N1/15,C12N1/19,C12N1/21,C12N5/10,C12N9/ PC
            50,C12Q1/68,
            PC   C12Q1/68,G01N33/573,G01N33/574//C12P21/08,C12N15/00,C12N5/00
            CC   Primer
            FH   Key             Location/Qualifiers
            FT   source          1. .20
            FT                   /organism='Artificial Sequence'.
FEATURES              Location/Qualifiers
     source           1. .20
                      /organism="synthetic construct"
                      /mol_type="genomic DNA"
                      /db_xref="taxon:32630"
```

```
  Query Match             0.9%;  Score 15.2;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 1.3e+02;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1304 AGCAGCCGGAGGGAGGGGGG 1323
              | ||||||||||||| | ||
Db          1 ACCAGCCGGAGGGAGTGAGG 20


RESULT 83
BD251839
LOCUS       BD251839                 20 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Novel G protein-coupled receptor cDNA sequence.
ACCESSION   BD251839
VERSION     BD251839.1  GI:33061609
KEYWORDS    JP 2002526036-A/6.
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Liu,Q., Mcdonald,T.P. and Wang,R.
  TITLE     Novel G protein-coupled receptor cDNA sequence
  JOURNAL   Patent: JP 2002526036-A 6 20-AUG-2002;
            MERCK AND CO INC
COMMENT     OS   Homo sapiens (human)
            PN   JP 2002526036-A/6
            PD   20-AUG-2002
            PF   02-AUG-1999 JP 2000563760
            PR   06-AUG-1998 US    60/095571
            PI   QINGYUN LIU,TERRENCE P MCDONALD,RUIPING WANG
            PC   C12N15/09,A61K35/76,A61K38/00,A61K48/00,C07K14/705,C07K16/28,
            PC   C12N1/15,
            PC
            C12N1/19,C12N1/21,C12N5/10,C12P21/02,C12Q1/02,G01N33/15,G01N33/ PC
             50,
            PC   G01N33/566,C12N15/00,C12N5/00,A61K37/02
            CC   Novel G protein-coupled receptor cDNA sequence FH   Key
                 Location/Qualifiers
            FT   source          1. .20
            FT                   /organism='Homo sapiens (human)'.
FEATURES              Location/Qualifiers
     source           1. .20
                      /organism="Homo sapiens"
                      /mol_type="genomic DNA"
                      /db_xref="taxon:9606"

  Query Match             0.9%;  Score 15.2;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 1.3e+02;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1485 GGGTGTCAGGGATCACTTGG 1504
              | |||||||| | |||||||
Db          1 GCGTGTCAGGAAACACTTGG 20


RESULT 84
E25765/c
LOCUS       E25765                   20 bp    DNA     linear   PAT 18-JUN-2001
DEFINITION  Method for the type classification of hepatitis B viruses and
            primer and probe to be used therein.
ACCESSION   E25765
VERSION     E25765.1  GI:13024953
KEYWORDS    JP 1999103898-A/22.
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Masakazu,M., Kazumasa,H., Kenichi,O. and Masashi,M.
  TITLE     Method for the type classification of hepatitis B viruses and
            primer and probe to be used therein
  JOURNAL   Patent: JP 1999103898-A 22 20-APR-1999;
            SRL INC
COMMENT     OS   Unidentified
            PN   JP 1999103898-A/22
            PD   20-APR-1999
            PF   30-SEP-1997 JP 1997282784
            PR
            PI   MASAKAZU MUKAIDE,KAZUMASA HIKIJI,KENICHI OBA,MASASHI MIZOUE PC
              C12Q1/70,C12N15/09,G01N33/576,C12N15/00
            CC   Strandedness: Single;
            CC   Topology: Linear;
            FH   Key             Location/Qualifiers
            FT   source          1. .20
            FT                   /organism='Unidentified'.
FEATURES              Location/Qualifiers
     source           1. .20
                      /organism="unidentified"
                      /mol_type="genomic DNA"
                      /db_xref="taxon:32644"

  Query Match             0.9%;  Score 15.2;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 1.3e+02;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        363 CTGGAGAGCTCGGACTGCGA 382
              ||||||| | |||||||||
Db         20 CTGGAGATTTGGGACTGCGA 1


RESULT 85
AR216026/c
LOCUS       AR216026                 20 bp    DNA     linear   PAT 25-SEP-2002
DEFINITION  Sequence 73 from patent US 6410518.
ACCESSION   AR216026
VERSION     AR216026.1  GI:23314314
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Monia,B.P.
  TITLE     Antisense oligonucleotide inhibition of raf gene expression
  JOURNAL   Patent: US 6410518-A 73 25-JUN-2002;
FEATURES              Location/Qualifiers
     source           1. .20
                      /organism="unknown"
                      /mol_type="genomic DNA"

  Query Match             0.9%;  Score 15.2;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 1.3e+02;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1267 CCGGCCCAGGGTGAAGGAAG 1286
              | ||||| ||| ||||||||
Db         20 CTGGCCCTGGGAGAAGGAAG 1


RESULT 86
AR243320/c
LOCUS       AR243320                 20 bp    DNA     linear   PAT 20-DEC-2002
DEFINITION  Sequence 17 from patent US 6475783.
ACCESSION   AR243320
VERSION     AR243320.1  GI:27290516
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Lucas,S., De Smet,C. and Boon-Falleur,T.
  TITLE     Isolated nucleic acid molecule coding for tumor rejection antigen
            precursors MAGE-C1 and MAGE-C2 and uses thereof
  JOURNAL   Patent: US 6475783-A 17 05-NOV-2002;
FEATURES              Location/Qualifiers
     source           1. .20
                      /organism="unknown"
```

```
                     /mol_type="genomic DNA"

  Query Match             0.9%;  Score 15.2;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 1.3e+02;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        495 TGTGCCAACCTGATGCAGCT 514
              | ||||||||| || ||||||
Db         20 TCTGCCAACCAGAGGCAGCT 1


RESULT 87
AR312034/c
LOCUS       AR312034                 20 bp    DNA     linear   PAT 12-JUN-2003
DEFINITION  Sequence 2571 from patent US 6559294.
ACCESSION   AR312034
VERSION     AR312034.1  GI:31705460
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Griffais,R., Hoiseth,S.K., Zagursky,R.J., Metcalf,B.J., Peek,J.A.,
            Sankaran,B. and Fletcher,L.D.
  TITLE     Chlamydia pneumoniae polynucleotides and uses thereof
  JOURNAL   Patent: US 6559294-A 2571 06-MAY-2003;
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             0.9%;  Score 15.2;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 1.3e+02;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        996 CTGAGGGACTGATTCCTGTG 1015
              ||| |||| ||||||||| |
Db         20 CTGTGGGATTGATTCCTGAG 1


RESULT 88
AR315230/c
LOCUS       AR315230                 20 bp    DNA     linear   PAT 12-JUN-2003
DEFINITION  Sequence 5767 from patent US 6559294.
ACCESSION   AR315230
VERSION     AR315230.1  GI:31708656
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Griffais,R., Hoiseth,S.K., Zagursky,R.J., Metcalf,B.J., Peek,J.A.,
            Sankaran,B. and Fletcher,L.D.
  TITLE     Chlamydia pneumoniae polynucleotides and uses thereof
  JOURNAL   Patent: US 6559294-A 5767 06-MAY-2003;
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             0.9%;  Score 15.2;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 1.3e+02;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1617 CCTCCCCGGGAGGAGTGCCA 1636
              | ||||| ||||||||| ||
Db         20 CTTCCCCTGGAGGAGTGGCA 1


RESULT 89
AR435671/c
LOCUS       AR435671                 20 bp    DNA     linear   PAT 18-DEC-2003
DEFINITION  Sequence 145 from patent US 6656716.
ACCESSION   AR435671
VERSION     AR435671.1  GI:40198652
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Plowman,G., Martinez,R. and Whyte,D.
  TITLE     Polypeptide fragments of human PAK5 protein kinase
  JOURNAL   Patent: US 6656716-A 145 02-DEC-2003;
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             0.9%;  Score 15.2;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 1.3e+02;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        601 GCAAAGAACTACTGCGCCTG 620
              |||||  |||||||| ||||
Db         20 GCAAATGACTACTGCACCTG 1


RESULT 90
AR453274/c
LOCUS       AR453274                 20 bp    DNA     linear   PAT 20-FEB-2004
DEFINITION  Sequence 145 from patent US 6680170.
ACCESSION   AR453274
VERSION     AR453274.1  GI:42685528
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Plowman,G., Martinez,R. and Whyte,D.
  TITLE     Polynucleotides encoding STE20-related protein kinases and methods
            of use
  JOURNAL   Patent: US 6680170-A 145 20-JAN-2004;
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             0.9%;  Score 15.2;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 1.3e+02;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        601 GCAAAGAACTACTGCGCCTG 620
              |||||  |||||||| ||||
Db         20 GCAAATGACTACTGCACCTG 1


RESULT 91
AR453458/c
LOCUS       AR453458                 20 bp    DNA     linear   PAT 20-FEB-2004
DEFINITION  Sequence 17 from patent US 6680191.
ACCESSION   AR453458
VERSION     AR453458.1  GI:42686196
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Lucas,S. and Boon-Falleur,T.
  TITLE     Isolated nucleic acid molecules coding for tumor rejection antigen
            precursors of members of the MAGE-C and MAGE-B FAMILIES and uses
            thereof
  JOURNAL   Patent: US 6680191-A 17 20-JAN-2004;
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="genomic DNA"
```

```
  Query Match             0.9%;  Score 15.2;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 1.3e+02;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        495 TGTGCCAACCTGATGCAGCT 514
              | ||||||||  || ||||||
Db         20 TCTGCCAACCAGAGGCAGCT 1


RESULT 92
AR490190
LOCUS       AR490190                  20 bp    DNA     linear   PAT 15-MAY-2004
DEFINITION  Sequence 24 from patent US 6713065.
ACCESSION   AR490190
VERSION     AR490190.1  GI:47257371
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Baron,M.H., Farrington,S.M. and Belaoussoff,M.
  TITLE     Methods of using hedgehog proteins to modulate hematopoiesis and
            vascular growth
  JOURNAL   Patent: US 6713065-A 24 30-MAR-2004;
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             0.9%;  Score 15.2;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 1.3e+02;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        502 ACCTGATGCAGCTGCTGCAG 521
              | |||||||||||| | |||
Db          1 AGCTGATGCAGCTGATCCAG 20


RESULT 93
AX038754
LOCUS       AX038754                  20 bp    DNA     linear   PAT 16-NOV-2000
DEFINITION  Sequence 10 from Patent WO0061728.
ACCESSION   AX038754
VERSION     AX038754.1  GI:11228099
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Dunlop,J., Kelsell,D.P. and Gerst-Talas,U.
  TITLE     Enzyme
  JOURNAL   Patent: WO 0061728-A 10 19-OCT-2000;
            DUNLOP JOHN (ES) ; KELSELL DAVID PETER (GB) ; GERST TALAS ULVI (GB)
            ; QUEEN MARY & WESTFIELD COLLEGE (GB)
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Primer"

  Query Match             0.9%;  Score 15.2;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 1.3e+02;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1304 AGCAGCCGGAGGGAGGGGGG 1323
              | |||||||||||| | ||
Db          1 ACCAGCCGGAGGGAGTGAGG 20


RESULT 94
AX224925/c
LOCUS       AX224925                  20 bp    DNA     linear   PAT 10-SEP-2001
DEFINITION  Sequence 79 from Patent WO0161030.
ACCESSION   AX224925
VERSION     AX224925.1  GI:15554998
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gray,D.M. and Bollon,A.P.
  TITLE     Libraries of optimum subsequence regions of mrna and genomic dna
            for control of gene expression
  JOURNAL   Patent: WO 0161030-A 79 23-AUG-2001;
            Cytoclonal Pharmaceutics, Inc. (US) ; University of Texas at
            Dallas, Dept. of Molecular and Cell Biology (US); Lab. of
            Experimental Carcinogenesis, National Cancer Institute/NIH (US)
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             0.9%;  Score 15.2;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 1.3e+02;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        300 CGGCCGCCGCGCTCAGCCTG 319
              ||||||||||| ||| |||
Db         20 CGGCCGCCGCGTGCAGGCTG 1


RESULT 95
AX298814/c
LOCUS       AX298814                  20 bp    DNA     linear   PAT 26-NOV-2001
DEFINITION  Sequence 448 from Patent WO0183749.
ACCESSION   AX298814
VERSION     AX298814.1  GI:17128804
KEYWORDS    .
SOURCE      Mus sp.
  ORGANISM  Mus sp.
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE   1
  AUTHORS   Bachmanov,A.A., Beauchamp,G.K., Chatterjee,A., de Jong,P.J., Li,S.,
            Li,X., Ohmen,J.D., Reed,D.R., Ross,D. and Tordoff,M.G.
  TITLE     Gene and sequence variation associated with sensing carbohydrate
            compounds and other sweeteners
  JOURNAL   Patent: WO 0183749-A 448 08-NOV-2001;
            WARNER-LAMBERT COMPANY (US) ; The Monell Chemical Senses Center
            (US)
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="Mus sp."
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:10095"

  Query Match             0.9%;  Score 15.2;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 1.3e+02;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        979 GAGACTAGAGGCAGGAGCTG 998
              ||||| ||||| ||| ||||
Db         20 GAGACCAGAGGAAGGTGCTG 1


RESULT 96
BD069139
LOCUS       BD069139                  20 bp    DNA     linear   PAT 27-AUG-2002
DEFINITION  Methods for modulating hematopoiesis and vascular growth.
ACCESSION   BD069139
VERSION     BD069139.1  GI:22614742
KEYWORDS    JP 2001511650-A/24.
```

```
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Baron,M.H., Farrington,S.M. and Belaoussoff,M.
  TITLE     Methods for modulating hematopoiesis and vascular growth
  JOURNAL   Patent: JP 2001511650-A 24 14-AUG-2001;
            THE PRESIDENT AND FELLOWS OF HARVARD COLLEGE
COMMENT     OS   Unidentified
            PN   JP 2001511650-A/24
            PD   14-AUG-2001
            PF   10-FEB-1998 JP 1998535042
            PR   10-FEB-1997 US    60/037513,16-JUN-1997 US    60/049763 PI
            MARGARET H BARON,SARAH M FARRINGTON,MARIA BELAOUSSOFF PC
            C12N5/00,A61K38/18,A61K48/00
            CC   PCR Primer
            FH   Key             Location/Qualifiers
            FT   source          1. .20
            FT                   /organism='Unidentified'.
FEATURES              Location/Qualifiers
     source           1. .20
                      /organism="unidentified"
                      /mol_type="genomic DNA"
                      /db_xref="taxon:32644"

  Query Match             0.9%;  Score 15.2;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 1.3e+02;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        502 ACCTGATGCAGCTGCTGCAG 521
              | ||||||||||||  | |||
Db          1 AGCTGATGCAGCTGATCCAG 20


RESULT 97
BD106882/c
LOCUS       BD106882                 20 bp    DNA     linear   PAT 18-SEP-2002
DEFINITION  Isolated nucleic acid molecule coding for tumor rejection antigen
            precursors MAGE-C1 and MAGE-C2 and uses thereof.
ACCESSION   BD106882
VERSION     BD106882.1  GI:23201700
KEYWORDS    JP 2002503096-A/15.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Lucas,S., Smet,C.D. and Falleur,T.B.
  TITLE     Isolated nucleic acid molecule coding for tumor rejection antigen
            precursors MAGE-C1 and MAGE-C2 and uses thereof
  JOURNAL   Patent: JP 2002503096-A 15 29-JAN-2002;
            LUDWIG INSTITUTE FOR CANCER RESEARCH
COMMENT     PN   JP 2002503096-A/15
            PD   29-JAN-2002
            PF   24-APR-1998 JP 1998547266
            PR   25-APR-1997 US    08/845528
            PI   SOPHIE LUCAS,CHARLES DE SMET,THIERRY BOON FALLEUR PC
            C07H21/04,A61K38/00,A61K39/00,A61K39/12,G01N33/574,C07K5/00, PC
            C07K7/00,
            PC   C07K16/00,C07K17/00
            CC   Strandedness: Single;
            CC   Topology: Linear;
            FH   Key                 Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .20
                      /organism="synthetic construct"
                      /mol_type="genomic DNA"
                      /db_xref="taxon:32630"

  Query Match             0.9%;  Score 15.2;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 1.3e+02;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        495 TGTGCCAACCTGATGCAGCT 514
              | ||||||| || ||||||
Db         20 TCTGCCAACCAGAGGCAGCT 1


RESULT 98
HUM10UVB/c
LOCUS       HUM10UVB                 20 bp    DNA     linear   STS 29-MAY-2002
DEFINITION  A PCR primer for human chromosome 21 Sfi I linking clone STS,
            location 21q22.1, sequence tagged site.
ACCESSION   D50140
VERSION     D50140.1  GI:801744
KEYWORDS    STS.
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Tanahashi,H., Ito,T., Hattori,M., Ohira,M., Ohki,M., Tashiro,K. and
            Sakaki,Y.
  TITLE     Sixty new STSs (sequence-tagged sites) of human chromosome 21
  JOURNAL   DNA Res. 1 (2), 85-89 (1994)
  MEDLINE   96051984
   PUBMED   7584032
REFERENCE   2  (bases 1 to 20)
  AUTHORS   Sakaki,Y.
  TITLE     Direct Submission
  JOURNAL   Submitted (28-APR-1995) Yoshiyuki Sakaki, Institute of Medical
            Science, University of Tokyo, Human Genome Center; 4-6-1
            Shirokanedai Minato-ku, Tokyo 108, Japan
            (E-mail:sakaki@hgc.ims.u-tokyo.ac.jp, Tel:03-5449-5362,
            Fax:03-5449-5445)
COMMENT     Submitted (28-Apr-1995) to DDBJ by:
            Yoshiyuki Sakaki
            Human Genome Center
            Institute of Medical Science
            University of Tokyo
            4-6-1 Shirokanedai Minato-ku
            Tokyo, 108
            Japan
            Phone: 03-5449-5362
            Fax  : 03-5449-5445.
FEATURES              Location/Qualifiers
     source           1. .20
                      /organism="Homo sapiens"
                      /mol_type="genomic DNA"
                      /db_xref="taxon:9606"
                      /chromosome="21"

  Query Match             0.9%;  Score 15.2;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 1.3e+02;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1020 GAAAACTGAGGCAGCCACCT 1039
              |||| ||||||||  |||||
Db         20 GAAATCTGAGGCACACACCT 1


RESULT 99
BD255507
LOCUS       BD255507                 17 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Regulation of repressor genes using nucleic acid molecules.
ACCESSION   BD255507
VERSION     BD255507.1  GI:33065277
KEYWORDS    JP 2002541795-A/3300.
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Blatt,L., Zwick,M., Pavco,P. and Mcswiggen,J.
  TITLE     Regulation of repressor genes using nucleic acid molecules
  JOURNAL   Patent: JP 2002541795-A 3300 10-DEC-2002;
            RIBOZYME PHARMACEUTICALS INC
COMMENT     OS   Eukaryote
```

```
            PN   JP 2002541795-A/3300
            PD   10-DEC-2002
            PF   11-APR-2000 JP 2000611654
            PR   12-APR-1999 US    60/129390
            PI   LAWRENCE BLATT,MICHAEL ZWICK,PAMELA PAVCO,JAMES MCSWIGGEN PC
            C12N15/09,A61K38/00,A61K48/00,A61P43/00,A61P43/00,C12N5/10, PC
            C12P21/02,
            PC
            C12P21/02,C12P21/02//A61K31/711,(C12N5/10,C12R1:91),(C12P21/02, PC
             C12R1:91),
            PC   (C12P21/02,C12R1:91),(C12P21/02,C12R1:91),C12N15/00,C12N5/00,
            PC   A61K37/02,
            PC   (C12N5/00,C12R1:91)
            CC   Regulation of repressor genes using nucleic acid molecules FH
             Key              Location/Qualifiers
            FT   source           1. .17
            FT                    /organism='Eukaryote'.
FEATURES              Location/Qualifiers
     source           1. .17
                      /organism="unidentified"
                      /mol_type="genomic DNA"
                      /db_xref="taxon:32644"

  Query Match              0.9%;  Score 15;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 1.4e+02;
  Matches   15;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1099 TGTGCATTGGGGACA 1113
              |||||||||||||||
Db          2 TGTGCATTGGGGACA 16


RESULT 100
AR431312
LOCUS       AR431312                  24 bp    DNA     linear   PAT 18-DEC-2003
DEFINITION  Sequence 6 from patent US 6651008.
ACCESSION   AR431312
VERSION     AR431312.1  GI:40193280
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 24)
  AUTHORS   Vaisberg,E.A., Adams,C.L., Sabry,J.H. and Crompton,A.M.
  TITLE     Database system including computer code for predictive cellular
            bioinformatics
  JOURNAL   Patent: US 6651008-A 6 18-NOV-2003;
FEATURES              Location/Qualifiers
     source           1. .24
                      /organism="unknown"
                      /mol_type="genomic DNA"

  Query Match              0.9%;  Score 15;  DB 1;  Length 24;
  Best Local Similarity   78.3%;  Pred. No. 1.4e+02;
  Matches   18;  Conservative    0;  Mismatches    5;  Indels    0;  Gaps    0;

Qy       1387 TGTTTGTTTTGTATCTTGTTTTT 1409
              | ||| |||| | | ||||||||
Db          2 TTTTTTTTTTTTTTTTGTTTTT 24


RESULT 101
I29929/c
LOCUS       I29929                    25 bp    DNA     linear   PAT 06-FEB-1997
DEFINITION  Sequence 42 from patent US 5578468.
ACCESSION   I29929
VERSION     I29929.1  GI:1820720
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 25)
  AUTHORS   Pickup,D.J., Patel,D. and Antczak,J.B.
  TITLE     Site-specific RNA cleavage
  JOURNAL   Patent: US 5578468-A 42 26-NOV-1996;
FEATURES              Location/Qualifiers
     source           1. .25
                      /organism="unknown"
                      /mol_type="unassigned DNA"

  Query Match              0.9%;  Score 15;  DB 1;  Length 25;
  Best Local Similarity   78.3%;  Pred. No. 1.4e+02;
  Matches   18;  Conservative    0;  Mismatches    5;  Indels    0;  Gaps    0;

Qy       1386 TTGTTTGTTTTGTATCTTGTTTT 1408
              || ||| |||| | | |||||||
Db         24 TTTTTTTTTTTTTTTTTTGTTTT 2


RESULT 102
BD234336
LOCUS       BD234336                  25 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Improved method for inserting nucleic acid into cyclic vector.
ACCESSION   BD234336
VERSION     BD234336.1  GI:33044106
KEYWORDS    JP 2002532085-A/9.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1  (bases 1 to 25)
  AUTHORS   Romantchikov,Y.
  TITLE     Improved method for inserting nucleic acid into cyclic vector
  JOURNAL   Patent: JP 2002532085-A 9 02-OCT-2002;
            YURI ROMANTCHIKOV
COMMENT     OS   Artificial Sequence
            PN   JP 2002532085-A/9
            PD   02-OCT-2002
            PF   17-DEC-1999 JP 2000588337
            PR   17-DEC-1998 US    09/213834
            PI   YURI ROMANTCHIKOV
            PC   C12N15/09,C12N1/15,C12N1/19,C12N1/21,C12N5/10,C12N15/00,C12N5/
            PC   00
            CC   Cloning Vector
            FH   Key              Location/Qualifiers
            FT   source           1. .25
            FT                    /organism='Artificial Sequence'.
FEATURES              Location/Qualifiers
     source           1. .25
                      /organism="synthetic construct"
                      /mol_type="genomic DNA"
                      /db_xref="taxon:32630"

  Query Match              0.9%;  Score 15;  DB 1;  Length 25;
  Best Local Similarity   72.0%;  Pred. No. 1.4e+02;
  Matches   18;  Conservative    1;  Mismatches    6;  Indels    0;  Gaps    0;

Qy       1385 GTTGTTTGTTTTGTATCTTGTTTTT 1409
              :|| ||| |||| | | || |||||
Db          1 RTTTTTTTTTTTTTTTTTTTTTTTT 25


RESULT 103
AX711956
LOCUS       AX711956                  27 bp    DNA     linear   PAT 12-MAY-2003
DEFINITION  Sequence 35 from Patent WO02103060.
ACCESSION   AX711956
VERSION     AX711956.1  GI:29787747
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Tuvemo,H.T., Frisk,G.E. and Yin,H.
  TITLE     Enterovirus nucleic acids
  JOURNAL   Patent: WO 02103060-A 35 27-DEC-2002;
            Innoventus Project AB (SE)
```

```
FEATURES             Location/Qualifiers
     source          1. .27
                     /organism="synthetic construct"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32630"
                     /note="Primer"

  Query Match             0.9%;  Score 15;  DB 1;  Length 27;
  Best Local Similarity   70.4%;  Pred. No. 1.4e+02;
  Matches   19;  Conservative    1;  Mismatches    7;  Indels    0;  Gaps    0;

Qy       1384 TGTTGTTTGTTTTGTATCTTGTTTTTC 1410
              | || ||| |||| | | || |||||:
Db          1 TTTTTTTTTTTTTTTTTTTTTTTTTTV 27


RESULT 104
AR134262
LOCUS       AR134262                 18 bp    DNA     linear   PAT 16-MAY-2001
DEFINITION  Sequence 2687 from patent US 6194150.
ACCESSION   AR134262
VERSION     AR134262.1  GI:14123167
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Stinchcomb,D.T., Jarvis,T. and McSwiggen,J.
  TITLE     Nucleic acid based inhibition of CD40
  JOURNAL   Patent: US 6194150-A 2687 27-FEB-2001;
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.8%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 1.5e+02;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        505 TGATGCAGCTGCTGCAGG 522
              || ||| ||||||||||
Db          1 TGGTGCTGCTGCTGCAGG 18


RESULT 105
BD261781
LOCUS       BD261781                 19 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Controlled release formulation comprising GNRH-II.
ACCESSION   BD261781
VERSION     BD261781.1  GI:33071549
KEYWORDS    JP 2002531411-A/2.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Qi,S., Akinsanya,K. and Hayward,A.
  TITLE     Controlled release formulation comprising GNRH-II
  JOURNAL   Patent: JP 2002531411-A 2 24-SEP-2002;
            FERRING BV
COMMENT     OS   Artificial Sequence
            PN   JP 2002531411-A/2
            PD   24-SEP-2002
            PF   02-DEC-1999 JP 2000584909
            PR   03-DEC-1998 GB    9826662.0
            PI   STEVE QI,KAREN AKINSANYA,AMANDA HAYWARD
            PC   A61K38/00,A61K9/50,A61K47/34,A61P3/10,A61P13/08,A61P19/00, PC
             A61P19/10//
            PC   C07K14/59,A61K37/02
            CC   Description of Artificial Sequence: Synthetic PCR primer FH
            Key             Location/Qualifiers
            FT   source          1. .19
            FT                   /organism='Artificial Sequence'.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32630"

  Query Match             0.8%;  Score 14.8;  DB 1;  Length 19;
  Best Local Similarity   88.9%;  Pred. No. 1.5e+02;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        536 GGCGCGGCTGGGCTCTCG 553
              |||| ||| |||||||||
Db          2 GGCGGGGCGGGGCTCTCG 19


RESULT 106
AR404716
LOCUS       AR404716                 19 bp    DNA     linear   PAT 18-DEC-2003
DEFINITION  Sequence 11 from patent US 6630140.
ACCESSION   AR404716
VERSION     AR404716.1  GI:40153443
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Grunstein,M.M. and Hakonarson,H.
  TITLE     Compositions and methods for treatment of asthma
  JOURNAL   Patent: US 6630140-A 11 07-OCT-2003;
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             0.8%;  Score 14.8;  DB 1;  Length 19;
  Best Local Similarity   88.9%;  Pred. No. 1.5e+02;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        864 GTCATCAAGAAGAAGCTG 881
              | ||||||| ||||||||
Db          2 GACATCAAGGAGAAGCTG 19


RESULT 107
AX025392
LOCUS       AX025392                 19 bp    DNA     linear   PAT 16-SEP-2000
DEFINITION  Sequence 2 from Patent GB2344287.
ACCESSION   AX025392
VERSION     AX025392.1  GI:10187076
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Akinsanya,K., Hayward,A. and Qi,S.
  TITLE     Controlled release pharmaceutical formulation
  JOURNAL   Patent: GB 2344287-A 2 07-JUN-2000;
            FERRING BV (NL)
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Synthetic PCR primer"

  Query Match             0.8%;  Score 14.8;  DB 1;  Length 19;
  Best Local Similarity   88.9%;  Pred. No. 1.5e+02;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        536 GGCGCGGCTGGGCTCTCG 553
              |||| ||| |||||||||
Db          2 GGCGGGGCGGGGCTCTCG 19
```

```
RESULT 108
AX130616
LOCUS       AX130616                 19 bp    DNA     linear   PAT 15-MAY-2001
DEFINITION  Sequence 1834 from Patent WO0130362.
ACCESSION   AX130616
VERSION     AX130616.1  GI:14136921
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Robbins,J.M. and Tritz,R.
  TITLE     Ribozyme therapy for the treatment of proliferative skin and eye
            diseases
  JOURNAL   Patent: WO 0130362-A 1834 03-MAY-2001;
            IMMUSOL, INC. (US)
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"
                     /note="Cyclin D1 ribozyme binding site"

  Query Match             0.8%;  Score 14.8;  DB 1;  Length 19;
  Best Local Similarity   88.9%;  Pred. No. 1.5e+02;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        656 GCTGGACGTCTGCGTGGA 673
              |||||| ||||||| |||
Db          1 GCTGGAGGTCTGCGAGGA 18


RESULT 109
AX130759
LOCUS       AX130759                 19 bp    DNA     linear   PAT 15-MAY-2001
DEFINITION  Sequence 1977 from Patent WO0130362.
ACCESSION   AX130759
VERSION     AX130759.1  GI:14137064
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Robbins,J.M. and Tritz,R.
  TITLE     Ribozyme therapy for the treatment of proliferative skin and eye
            diseases
  JOURNAL   Patent: WO 0130362-A 1977 03-MAY-2001;
            IMMUSOL, INC. (US)
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"
                     /note="Cyclin D3 ribozyme binding site"

  Query Match             0.8%;  Score 14.8;  DB 1;  Length 19;
  Best Local Similarity   88.9%;  Pred. No. 1.5e+02;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1556 CCATCGTGTACTGCAGAG 1573
              ||| ||||| ||||||||
Db          1 CCAGCGTGTCCTGCAGAG 18


RESULT 110
AX131856
LOCUS       AX131856                 19 bp    DNA     linear   PAT 15-MAY-2001
DEFINITION  Sequence 3074 from Patent WO0130362.
ACCESSION   AX131856
VERSION     AX131856.1  GI:14138161
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Robbins,J.M. and Tritz,R.
  TITLE     Ribozyme therapy for the treatment of proliferative skin and eye
            diseases
  JOURNAL   Patent: WO 0130362-A 3074 03-MAY-2001;
            IMMUSOL, INC. (US)
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"
                     /note="Cyclin A1 ribozyme binding site"

  Query Match             0.8%;  Score 14.8;  DB 1;  Length 19;
  Best Local Similarity   88.9%;  Pred. No. 1.5e+02;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1042 GGTGGAGGTGGGGGAATA 1059
              ||||||||| |||||| |
Db          1 GGTGGAGGTTGGGGAAGA 18


RESULT 111
AX319714/c
LOCUS       AX319714                 19 bp    DNA     linear   PAT 14-DEC-2001
DEFINITION  Sequence 20 from Patent WO0183751.
ACCESSION   AX319714
VERSION     AX319714.1  GI:17901355
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Raschke,E., Wolffe,A.P. and Case,C.C.
  TITLE     Methods for binding an exogenous molecule to cellular chromatin
  JOURNAL   Patent: WO 0183751-A 20 08-NOV-2001;
            Sangamo Biosciences Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="VEGF reverse primer"

  Query Match             0.8%;  Score 14.8;  DB 1;  Length 19;
  Best Local Similarity   88.9%;  Pred. No. 1.5e+02;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1322 GGAGGTCGGAGGTCGTGG 1339
              | || ||||||||||||||
Db         19 GTAGCTCGGAGGTCGTGG 2


RESULT 112
AX320702/c
LOCUS       AX320702                 19 bp    DNA     linear   PAT 14-DEC-2001
DEFINITION  Sequence 33 from Patent WO0183793.
ACCESSION   AX320702
VERSION     AX320702.1  GI:17902349
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Wolffe,A.P. and Collingwood,T.
  TITLE     Targeted modification of chromatin structure
  JOURNAL   Patent: WO 0183793-A 33 08-NOV-2001;
            Sangamo Biosciences Inc. (US)
FEATURES             Location/Qualifiers
```

```
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="VEGF reverse primer"

  Query Match             0.8%;  Score 14.8;  DB 1;  Length 19;
  Best Local Similarity   88.9%;  Pred. No. 1.5e+02;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1322 GGAGGTCGGAGGTCGTGG 1339
              | || ||||||||||||||
Db         19 GTAGCTCGGAGGTCGTGG 2


RESULT 113
AX822079
LOCUS       AX822079                 19 bp    DNA     linear   PAT 10-DEC-2003
DEFINITION  Sequence 2 from Patent EP1340768.
ACCESSION   AX822079
VERSION     AX822079.1  GI:39725261
KEYWORDS    .
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1
  AUTHORS   Akinsanya,K., Hayward,A. and Qi,S.
  TITLE     LHRH analogues for the treatment of osteoporosis
  JOURNAL   Patent: EP 1340768-A 2 03-SEP-2003;
            . (NL)
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="unidentified"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32644"

  Query Match             0.8%;  Score 14.8;  DB 1;  Length 19;
  Best Local Similarity   88.9%;  Pred. No. 1.5e+02;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        536 GGCGCGGCTGGGCTCTCG 553
              |||| ||| |||||||||
Db          2 GGCGGGGCGGGGCTCTCG 19


RESULT 114
AR137712
LOCUS       AR137712                 26 bp    DNA     linear   PAT 16-JUN-2001
DEFINITION  Sequence 5 from patent US 6197554.
ACCESSION   AR137712
VERSION     AR137712.1  GI:14479221
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 26)
  AUTHORS   Lin,S.-L., Chuong,C.-M. and Ying,S.-Y.
  TITLE     Method for generating full-length cDNA library from single cells
  JOURNAL   Patent: US 6197554-A 5 06-MAR-2001;
FEATURES             Location/Qualifiers
     source          1. .26
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.8%;  Score 14.8;  DB 1;  Length 26;
  Best Local Similarity   73.1%;  Pred. No. 1.5e+02;
  Matches   19;  Conservative    0;  Mismatches    7;  Indels    0;  Gaps    0;

Qy       1382 TTTGTTGTTTGTTTTGTATCTTGTTT 1407
              ||| || ||| |||| | | || |||
Db          1 TTTTTTTTTTTTTTTTTTTTTTTTTT 26


RESULT 115
BD192375
LOCUS       BD192375                 26 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Reagents and methods useful for detecting diseases of the breast.
ACCESSION   BD192375
VERSION     BD192375.1  GI:33002114
KEYWORDS    JP 2002516576-A/14.
SOURCE      Mus sp.
  ORGANISM  Mus sp.
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 26)
  AUTHORS   Medel,P.A.B., Cohen,M., Colpitts,T.L., Friedman,P.N., Gordon,J.,
            Granados,E.N., Hodges,S.C., Klass,M.R., Kratochvil,J.D.,
            Russell,J.C., Scheffel,C.P., Stroupe,S.D. and Yu,H.
  TITLE     Reagents and methods useful for detecting diseases of the breast
  JOURNAL   Patent: JP 2002516576-A 14 04-JUN-2002;
            ABBOTT LABORATORIES
COMMENT     PN   JP 2002516576-A/14
            PD   04-JUN-2002
            PF   19-JUN-1998 JP 1999504891
            PR   20-JUN-1997 US    08/879354
            PI   PATRICIA A BILLING MEDEL,MAURICE COHEN,TRACEY L COLPITTS,PAULA

            PI   N FRIEDMAN,
            PI   JULIAN GORDON,EDWARD N GRANADOS,STEVEN C HODGES,MICHAEL R  PI
             KLASS,
            PI   JON D KRATOCHVIL,JOHN C RUSSELL,CHRISTI P SCHEFFEL,STEPHEN D
            PI   STROUPE,
            PI   HONG YU
            PC   C12N15/12,C07K14/47,C12Q1/68,C12N15/85,C12N5/10,C07K16/18, PC
             G01N33/574
            CC   Strandedness: Single;
            CC   Topology: Linear;
            FH   Key             Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .26
                     /organism="Mus sp."
                     /mol_type="genomic DNA"
                     /db_xref="taxon:10095"

  Query Match             0.8%;  Score 14.8;  DB 1;  Length 26;
  Best Local Similarity   73.1%;  Pred. No. 1.5e+02;
  Matches   19;  Conservative    0;  Mismatches    7;  Indels    0;  Gaps    0;

Qy       1387 TGTTTGTTTTGTATCTTGTTTTTCTG 1412
              | ||| |||| | | || ||||| ||
Db          1 TTTTTTTTTTTTTTTTTTTTTTTTTG 26


RESULT 116
CQ828164/c
LOCUS       CQ828164                 26 bp    DNA     linear   PAT 05-JUL-2004
DEFINITION  Sequence 14 from Patent WO2004053160.
ACCESSION   CQ828164
VERSION     CQ828164.1  GI:49731658
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Jimenez,M.C., Escobar,I.G., Gallego,S.C. and Cimadevilla,J.C.
  TITLE     Method to analyze polymeric nucleic acid sequence variations
  JOURNAL   Patent: WO 2004053160-A 14 24-JUN-2004;
            GENOMICA S.A.U. (ES)
FEATURES             Location/Qualifiers
     source          1. .26
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="primer"

  Query Match             0.8%;  Score 14.8;  DB 1;  Length 26;
```

```
  Best Local Similarity   73.1%;  Pred. No. 1.5e+02;
  Matches   19;  Conservative    0;  Mismatches    7;  Indels    0;  Gaps    0;

Qy       1382 TTTGTTGTTTGTTTTGTATCTTGTTT 1407
              ||| || ||| |||| | | || |||
Db         26 TTTTTTTTTTTTTTTTTTTTTTTTT 1


RESULT 117
I79496
LOCUS       I79496                   26 bp    DNA     linear   PAT 10-JUN-1998
DEFINITION  Sequence 3 from patent US 5707807.
ACCESSION   I79496
VERSION     I79496.1  GI:3207786
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 26)
  AUTHORS   Kato,K.
  TITLE     Molecular indexing for expressed gene analysis
  JOURNAL   Patent: US 5707807-A 3 13-JAN-1998;
FEATURES             Location/Qualifiers
     source          1. .26
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.8%;  Score 14.8;  DB 1;  Length 26;
  Best Local Similarity   73.1%;  Pred. No. 1.5e+02;
  Matches   19;  Conservative    0;  Mismatches    7;  Indels    0;  Gaps    0;

Qy       1387 TGTTTGTTTTGTATCTTGTTTTTCTG 1412
              | ||| |||| | | || |||||  ||
Db          1 TTTTTTTTTTTTTTTTTTTTTTTTG 26


RESULT 118
AX427154
LOCUS       AX427154                 26 bp    DNA     linear   PAT 18-JUN-2002
DEFINITION  Sequence 3 from Patent WO0210374.
ACCESSION   AX427154
VERSION     AX427154.1  GI:21530535
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Lin,S.L., Chuong,C.M. and Widelitz,R.B.
  TITLE     Gene silencing using mrna-cdna hybrids
  JOURNAL   Patent: WO 0210374-A 3 07-FEB-2002;
            UNIVERSITY OF SOUTHERN CALIFORNIA (US)
FEATURES             Location/Qualifiers
     source          1. .26
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Poly(dT)-26mer primer"

  Query Match             0.8%;  Score 14.8;  DB 1;  Length 26;
  Best Local Similarity   73.1%;  Pred. No. 1.5e+02;
  Matches   19;  Conservative    0;  Mismatches    7;  Indels    0;  Gaps    0;

Qy       1382 TTTGTTGTTTGTTTTGTATCTTGTTT 1407
              ||| || ||| |||| | | || |||
Db          1 TTTTTTTTTTTTTTTTTTTTTTTTT 26


RESULT 119
AX528804
LOCUS       AX528804                 26 bp    DNA     linear   PAT 21-NOV-2002
DEFINITION  Sequence 53 from Patent WO02059357.
ACCESSION   AX528804
VERSION     AX528804.1  GI:25172859
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Pedersen,M.L.
  TITLE     Assay and kit for analyzing gene expression
  JOURNAL   Patent: WO 02059357-A 53 01-AUG-2002;
FEATURES             Location/Qualifiers
     source          1. .26
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="synthetic construct"

  Query Match             0.8%;  Score 14.8;  DB 1;  Length 26;
  Best Local Similarity   73.1%;  Pred. No. 1.5e+02;
  Matches   19;  Conservative    0;  Mismatches    7;  Indels    0;  Gaps    0;

Qy       1382 TTTGTTGTTTGTTTTGTATCTTGTTT 1407
              ||| || ||| |||| | | || |||
Db          1 TTTTTTTTTTTTTTTTTTTTTTTTT 26


RESULT 120
AR241865
LOCUS       AR241865                 27 bp    DNA     linear   PAT 20-DEC-2002
DEFINITION  Sequence 153 from patent US 6472154.
ACCESSION   AR241865
VERSION     AR241865.1  GI:27287677
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 27)
  AUTHORS   Garner,H.R., Wren,J.D., Minna,J.D. and Fondon,J.W. III.
  TITLE     Polymorphic repeats in human genes
  JOURNAL   Patent: US 6472154-A 153 29-OCT-2002;
FEATURES             Location/Qualifiers
     source          1. .27
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             0.8%;  Score 14.8;  DB 1;  Length 27;
  Best Local Similarity   73.1%;  Pred. No. 1.5e+02;
  Matches   19;  Conservative    0;  Mismatches    7;  Indels    0;  Gaps    0;

Qy       1382 TTTGTTGTTTGTTTTGTATCTTGTTT 1407
              ||| || ||| |||| | | || |||
Db          2 TTTTTTTTTTTTTTTTTTTTTATTT 27


RESULT 121
AX961625
LOCUS       AX961625                 24 bp    DNA     linear   PAT 14-JAN-2004
DEFINITION  Sequence 20 from Patent WO03101375.
ACCESSION   AX961625
VERSION     AX961625.1  GI:40881083
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Lopez,R.A.
  TITLE     Immunostimulatory oligonucleotides and uses thereof
  JOURNAL   Patent: WO 03101375-A 20 11-DEC-2003;
            IMMUNOTECH S.A. (AR)
FEATURES             Location/Qualifiers
     source          1. .24
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Immunostimulatory oligonucleotide"
```

```
  Query Match             0.8%;  Score 14.6;  DB 1;  Length 24;
  Best Local Similarity   81.0%;  Pred. No. 1.6e+02;
  Matches   17;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1389 TTTGTTTTGTATCTTGTTTTT 1409
              ||||||||  | | || |||||
Db          4 TTTGTTTTTTTTTTTTTTTTT 24


RESULT 122
AR431313
LOCUS       AR431313                  24 bp    DNA     linear   PAT 18-DEC-2003
DEFINITION  Sequence 7 from patent US 6651008.
ACCESSION   AR431313
VERSION     AR431313.1  GI:40193281
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 24)
  AUTHORS   Vaisberg,E.A., Adams,C.L., Sabry,J.H. and Crompton,A.M.
  TITLE     Database system including computer code for predictive cellular
            bioinformatics
  JOURNAL   Patent: US 6651008-A 7 18-NOV-2003;
FEATURES             Location/Qualifiers
     source          1. .24
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             0.8%;  Score 14.6;  DB 1;  Length 24;
  Best Local Similarity   81.0%;  Pred. No. 1.6e+02;
  Matches   17;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1380 TGTTTGTTGTTTGTTTTGTAT 1400
              | ||||||  ||| |||| |||
Db          3 TTTTTGTTTTTTTTTTTCTAT 23


RESULT 123
BD237566
LOCUS       BD237566                  26 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Genes and proteins predicting and treating fit, hypertension,
            diabetes and obesity.
ACCESSION   BD237566
VERSION     BD237566.1  GI:33047336
KEYWORDS    JP 2002525115-A/1.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1  (bases 1 to 26)
  AUTHORS   Shimkets,R.A.
  TITLE     Genes and proteins predicting and treating fit, hypertension,
            diabetes and obesity
  JOURNAL   Patent: JP 2002525115-A 1 13-AUG-2002;
            CURAGEN CORP
COMMENT     OS   Artificial Sequence
            PN   JP 2002525115-A/1
            PD   13-AUG-2002
            PF   28-SEP-1999 JP 2000572365
            PR   28-SEP-1998 US    09/161939
            PI   RICHARD A SHIMKETS
            PC   C12N15/09,A01K67/027,A61K31/7088,A61K38/00,A61K39/395,A61K39/
            PC   395,
            PC   A61K39/395,A61K48/00,A61P3/04,A61P3/06,A61P9/10,A61P9/12, PC
            A61P43/00,
            PC   C07K14/47,C07K16/18,C12N9/10,C12N9/88,C12Q1/25,C12Q1/52 PC
            ,C12Q1/68,G01N33/15,
            PC   G01N33/50,C12N15/00,A61K37/02
            CC   Description of Artificial Sequence: oligo(dT)<25>V FH   Key
                 Location/Qualifiers
            FT   source          1. .26
            FT                   /organism='Artificial Sequence'.
FEATURES             Location/Qualifiers
     source          1. .26
                     /organism="synthetic construct"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32630"

  Query Match             0.8%;  Score 14.6;  DB 1;  Length 26;
  Best Local Similarity   72.0%;  Pred. No. 1.6e+02;
  Matches   18;  Conservative    1;  Mismatches    6;  Indels    0;  Gaps    0;

Qy       1386 TTGTTTGTTTTGTATCTTGTTTTTC 1410
              ||  |||  ||||  | | ||  |||||:
Db          2 TTTTTTTTTTTTTTTTTTTTTTTTV 26


RESULT 124
AR257336
LOCUS       AR257336                  26 bp    DNA     linear   PAT 20-DEC-2002
DEFINITION  Sequence 43 from patent US 6486299.
ACCESSION   AR257336
VERSION     AR257336.1  GI:27307233
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 26)
  AUTHORS   Shimkets,R.A.
  TITLE     Genes and proteins predictive and therapeutic for stroke,
            hypertension, diabetes and obesity
  JOURNAL   Patent: US 6486299-A 43 26-NOV-2002;
FEATURES             Location/Qualifiers
     source          1. .26
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             0.8%;  Score 14.6;  DB 1;  Length 26;
  Best Local Similarity   72.0%;  Pred. No. 1.6e+02;
  Matches   18;  Conservative    1;  Mismatches    6;  Indels    0;  Gaps    0;

Qy       1386 TTGTTTGTTTTGTATCTTGTTTTTC 1410
              ||  |||  ||||  | | ||  |||||:
Db          2 TTTTTTTTTTTTTTTTTTTTTTTTV 26


RESULT 125
AR263647
LOCUS       AR263647                  26 bp    DNA     linear   PAT 29-JAN-2003
DEFINITION  Sequence 6 from patent US 6331413.
ACCESSION   AR263647
VERSION     AR263647.1  GI:28075580
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 26)
  AUTHORS   Adler,D.A. and Sheppard,P.O.
  TITLE     Secreted salivary ZSIG63 Polypeptide
  JOURNAL   Patent: US 6331413-A 6 18-DEC-2001;
FEATURES             Location/Qualifiers
     source          1. .26
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             0.8%;  Score 14.6;  DB 1;  Length 26;
  Best Local Similarity   72.0%;  Pred. No. 1.6e+02;
  Matches   18;  Conservative    1;  Mismatches    6;  Indels    0;  Gaps    0;

Qy       1386 TTGTTTGTTTTGTATCTTGTTTTTC 1410
              ||  |||  ||||  | | ||  |||||:
Db          2 TTTTTTTTTTTTTTTTTTTTTTTTV 26


RESULT 126
```

```
AX814950
LOCUS       AX814950                 26 bp    DNA     linear   PAT 05-DEC-2003
DEFINITION  Sequence 36 from Patent WO03064691.
ACCESSION   AX814950
VERSION     AX814950.1  GI:39104088
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Linnarsson,S., Ernfors,P., Bauren,G., Metsis,A., Pihlak,A. and
            Montelius,A.
  TITLE     Methods and means for manipulating nucleic acid
  JOURNAL   Patent: WO 03064691-A 36 07-AUG-2003;
            Global Genomics AB (SE)
FEATURES             Location/Qualifiers
     source          1. .26
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Description of Artificial Sequence: Primer"
     misc_feature    26
                     /note="v is a, c or g"

  Query Match             0.8%;  Score 14.6;  DB 1;  Length 26;
  Best Local Similarity   72.0%;  Pred. No. 1.6e+02;
  Matches   18;  Conservative    1;  Mismatches    6;  Indels    0;  Gaps    0;

Qy       1386 TTGTTTGTTTTGTATCTTGTTTTTC 1410
             || ||| |||| | | || |||||:
Db          2 TTTTTTTTTTTTTTTTTTTTTTTTV 26


RESULT 127
BD062456
LOCUS       BD062456                 26 bp    DNA     linear   PAT 27-AUG-2002
DEFINITION  A human 2-19 protein homologue, Z219A.
ACCESSION   BD062456
VERSION     BD062456.1  GI:22608059
KEYWORDS    JP 2001507946-A/4.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1  (bases 1 to 26)
  AUTHORS   Conklin,D.C. and Blumberg,H.
  TITLE     A human 2-19 protein homologue, Z219A
  JOURNAL   Patent: JP 2001507946-A 4 19-JUN-2001;
            ZYMOGENETICS INC
COMMENT     OS   Artificial Sequence
            PN   JP 2001507946-A/4
            PD   19-JUN-2001
            PF   06-OCT-1998 JP 1999522287
            PR   06-OCT-1997 US    60/061712
            PI   DARRELL C CONKLIN,HAL BLUMBERG
            PC   C12N15/12,C12N15/62,C12N5/10,C07K14/47,C07K16/18,C12Q1/68, PC
             A01K67/027
            CC   Oligonucleotide primer ZC7231
            FH   Key             Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .26
                     /organism="synthetic construct"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32630"

  Query Match             0.8%;  Score 14.6;  DB 1;  Length 26;
  Best Local Similarity   72.0%;  Pred. No. 1.6e+02;
  Matches   18;  Conservative    1;  Mismatches    6;  Indels    0;  Gaps    0;

Qy       1386 TTGTTTGTTTTGTATCTTGTTTTTC 1410
             || ||| |||| | | || |||||:
Db          2 TTTTTTTTTTTTTTTTTTTTTTTTV 26


RESULT 128
AX513052
LOCUS       AX513052                 27 bp    DNA     linear   PAT 03-OCT-2002
DEFINITION  Sequence 42 from Patent WO02062135.
ACCESSION   AX513052
VERSION     AX513052.1  GI:23504143
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Egelrud,T. and Hansson,L.
  TITLE     Scce modified transgenic mammals and their use as models of human
            disease
  JOURNAL   Patent: WO 02062135-A 42 15-AUG-2002;
            Egelrud, Torbjorn (SE) ; Hansson, Lennart (SE)
FEATURES             Location/Qualifiers
     source          1. .27
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="5 -RACE cDNA synthesis primer."

  Query Match             0.8%;  Score 14.6;  DB 1;  Length 27;
  Best Local Similarity   72.0%;  Pred. No. 1.6e+02;
  Matches   18;  Conservative    1;  Mismatches    6;  Indels    0;  Gaps    0;

Qy       1386 TTGTTTGTTTTGTATCTTGTTTTTC 1410
             || ||| |||| | | || |||||:
Db          2 TTTTTTTTTTTTTTTTTTTTTTTTV 26


RESULT 129
AR017827
LOCUS       AR017827                 16 bp    DNA     linear   PAT 05-DEC-1998
DEFINITION  Sequence 7 from patent US 5780262.
ACCESSION   AR017827
VERSION     AR017827.1  GI:3973430
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 16)
  AUTHORS   Brent,R. and Zervos,A.S.
  TITLE     Max-interacting proteins and related molecules and methods
  JOURNAL   Patent: US 5780262-A 7 14-JUL-1998;
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.8%;  Score 14.4;  DB 1;  Length 16;
  Best Local Similarity   93.8%;  Pred. No. 1.7e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         20 AATTCGGCACGAGGGG 35
              ||||||||||||||| |
Db          1 AATTCGGCACGAGGCG 16


RESULT 130
AR068061
LOCUS       AR068061                 16 bp    DNA     linear   PAT 29-SEP-1999
DEFINITION  Sequence 7 from patent US 5852169.
ACCESSION   AR068061
VERSION     AR068061.1  GI:5999283
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 16)
  AUTHORS   Brent,R. and Zervos,A.S.
  TITLE     Max-interacting proteins and related molecules and methods
```

```
  JOURNAL    Patent: US 5852169-A 7 22-DEC-1998;
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.8%;  Score 14.4;  DB 1;  Length 16;
  Best Local Similarity   93.8%;  Pred. No. 1.7e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         20 AATTCGGCACGAGGGG 35
              ||||||||||||||| |
Db          1 AATTCGGCACGAGGCG 16


RESULT 131
I19988
LOCUS       I19988                  16 bp    DNA     linear   PAT 07-OCT-1996
DEFINITION  Sequence 7 from patent US 5512473.
ACCESSION   I19988
VERSION     I19988.1  GI:1600343
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 16)
  AUTHORS   Brent,R. and Zervos,A.S.
  TITLE     Max-interacting proteins and related molecules and methods
  JOURNAL   Patent: US 5512473-A 7 30-APR-1996;
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.8%;  Score 14.4;  DB 1;  Length 16;
  Best Local Similarity   93.8%;  Pred. No. 1.7e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         20 AATTCGGCACGAGGGG 35
              ||||||||||||||| |
Db          1 AATTCGGCACGAGGCG 16


RESULT 132
I30248
LOCUS       I30248                  16 bp    DNA     linear   PAT 06-FEB-1997
DEFINITION  Sequence 7 from patent US 5580736.
ACCESSION   I30248
VERSION     I30248.1  GI:1821039
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 16)
  AUTHORS   Brent,R., Gyuris,J. and Golemis,E.
  TITLE     Interaction trap system for isolating novel proteins
  JOURNAL   Patent: US 5580736-A 7 03-DEC-1996;
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.8%;  Score 14.4;  DB 1;  Length 16;
  Best Local Similarity   93.8%;  Pred. No. 1.7e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         20 AATTCGGCACGAGGGG 35
              ||||||||||||||| |
Db          1 AATTCGGCACGAGGCG 16


RESULT 133
AR435812/c
LOCUS       AR435812                16 bp    RNA     linear   PAT 18-DEC-2003
DEFINITION  Sequence 71 from patent US 6656731.
ACCESSION   AR435812
VERSION     AR435812.1  GI:40198896
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 16)
  AUTHORS   Eckstein,F., Ludwig,J. and Beigelman,L.
  TITLE     Nucleic acid catalysts with endonuclease activity
  JOURNAL   Patent: US 6656731-A 71 02-DEC-2003;
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="unknown"
                     /mol_type="unassigned RNA"

  Query Match             0.8%;  Score 14.4;  DB 1;  Length 16;
  Best Local Similarity   93.8%;  Pred. No. 1.7e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        663 GTCTGCGTGGAGCAGG 678
              |||||| |||||||||
Db         16 GTCTGCATGGAGCAGG 1


RESULT 134
AX938344
LOCUS       AX938344                16 bp    DNA     linear   PAT 06-JAN-2004
DEFINITION  Sequence 7 from Patent EP1362913.
ACCESSION   AX938344
VERSION     AX938344.1  GI:40713957
KEYWORDS    .
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1
  AUTHORS   Brent,R., Gyuris,J. and Golemis,E.
  TITLE     Interaction trap system for isolating proteins
  JOURNAL   Patent: EP 1362913-A 7 19-NOV-2003;
            THE GENERAL HOSPITAL CORPORATION (US)
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="unidentified"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32644"
                     /note="Unknown"

  Query Match             0.8%;  Score 14.4;  DB 1;  Length 16;
  Best Local Similarity   93.8%;  Pred. No. 1.7e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         20 AATTCGGCACGAGGGG 35
              ||||||||||||||| |
Db          1 AATTCGGCACGAGGCG 16


RESULT 135
AR039433
LOCUS       AR039433                17 bp    DNA     linear   PAT 29-SEP-1999
DEFINITION  Sequence 281 from patent US 5807743.
ACCESSION   AR039433
VERSION     AR039433.1  GI:5958796
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Stinchcomb,D.T. and McSwiggen,J.A.
  TITLE     Interleukin-2 receptor gamma-chain ribozymes
  JOURNAL   Patent: US 5807743-A 281 15-SEP-1998;
FEATURES             Location/Qualifiers
     source          1. .17
```

```
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.8%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 1.7e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        279 CCCCGAACTCCCACCC 294
              ||||||| ||||||||
Db          1 CCCCGAATTCCCACCC 16


RESULT 136
AR192332
LOCUS       AR192332                 17 bp    DNA     linear   PAT 20-APR-2002
DEFINITION  Sequence 7820 from patent US 6346398.
ACCESSION   AR192332
VERSION     AR192332.1  GI:20238297
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
  TITLE     Method and reagent for the treatment of diseases or conditions
            related to levels of vascular endothelial growth factor receptor
  JOURNAL   Patent: US 6346398-A 7820 12-FEB-2002;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.8%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 1.7e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1382 TTTGTTGTTTGTTTTG 1397
              |||||| |||||||||
Db          2 TTTGTTTTTTGTTTTG 17


RESULT 137
AR192334
LOCUS       AR192334                 17 bp    DNA     linear   PAT 20-APR-2002
DEFINITION  Sequence 7822 from patent US 6346398.
ACCESSION   AR192334
VERSION     AR192334.1  GI:20238299
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
  TITLE     Method and reagent for the treatment of diseases or conditions
            related to levels of vascular endothelial growth factor receptor
  JOURNAL   Patent: US 6346398-A 7822 12-FEB-2002;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.8%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 1.7e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1383 TTGTTGTTTGTTTTGT 1398
              ||||| ||||||||||
Db          1 TTGTTTTTTGTTTTGT 16


RESULT 138
AR195753
LOCUS       AR195753                 17 bp    DNA     linear   PAT 20-APR-2002
DEFINITION  Sequence 218 from patent US 6350934.
ACCESSION   AR195753
VERSION     AR195753.1  GI:20245190
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Zwick,M.G., Edington,B.E., McSwiggen,J.A., Merlo,P.Ann.Owens.,
            Guo,L., Skokut,T.A., Young,S.A., Folkerts,O. and Merlo,D.J.
  TITLE     Nucleic acid encoding delta-9 desaturase
  JOURNAL   Patent: US 6350934-A 218 26-FEB-2002;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.8%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 1.7e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        311 CTCAGCCTGGGGGTCG 326
              |||||||| |||||||
Db          1 CTCAGCCTCGGGGTCG 16


RESULT 139
AR286245
LOCUS       AR286245                 17 bp    RNA     linear   PAT 10-APR-2003
DEFINITION  Sequence 617 from patent US 6528640.
ACCESSION   AR286245
VERSION     AR286245.1  GI:29723841
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Beigelman,L., Burgin,A., Beaudry,A., Karpeisky,A.,
            Matulic-Adamic,J., Sweedler,D. and Zinnen,S.
  TITLE     Synthetic ribonucleic acids with RNAse activity
  JOURNAL   Patent: US 6528640-A 617 04-MAR-2003;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned RNA"

  Query Match             0.8%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 1.7e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1087 TGTGCGGGTGGCTGTG 1102
              ||||| ||||||||||
Db          2 TGTGCCGGTGGCTGTG 17


RESULT 140
AR326202
LOCUS       AR326202                 17 bp    RNA     linear   PAT 17-AUG-2003
DEFINITION  Sequence 3604 from patent US 6566127.
ACCESSION   AR326202
VERSION     AR326202.1  GI:33712010
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
  TITLE     Method and reagent for the treatment of diseases or conditions
            related to levels of vascular endothelial growth factor receptor
  JOURNAL   Patent: US 6566127-A 3604 20-MAY-2003;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
```

```
                    /mol_type="unassigned RNA"

  Query Match             0.8%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 1.7e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1382 TTTGTTGTTTGTTTTG 1397
              |||||| |||||||||
Db          2 TTTGTTTTTTGTTTTG 17


RESULT 141
AR326204
LOCUS       AR326204                  17 bp    RNA     linear   PAT 17-AUG-2003
DEFINITION  Sequence 3606 from patent US 6566127.
ACCESSION   AR326204
VERSION     AR326204.1  GI:33712012
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
  TITLE     Method and reagent for the treatment of diseases or conditions
            related to levels of vascular endothelial growth factor receptor
  JOURNAL   Patent: US 6566127-A 3606 20-MAY-2003;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned RNA"

  Query Match             0.8%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 1.7e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1383 TTGTTGTTTGTTTTGT 1398
              ||||| ||||||||||
Db          1 TTGTTTTTTGTTTTGT 16


RESULT 142
AR328948
LOCUS       AR328948                  17 bp    RNA     linear   PAT 17-AUG-2003
DEFINITION  Sequence 6350 from patent US 6566127.
ACCESSION   AR328948
VERSION     AR328948.1  GI:33714756
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
  TITLE     Method and reagent for the treatment of diseases or conditions
            related to levels of vascular endothelial growth factor receptor
  JOURNAL   Patent: US 6566127-A 6350 20-MAY-2003;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned RNA"

  Query Match             0.8%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 1.7e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        287 TCCCACCCCAGATCGG 302
              |||||||||||||| ||
Db          2 TCCCACCCCAGATTGG 17


RESULT 143
AR328949
LOCUS       AR328949                  17 bp    RNA     linear   PAT 17-AUG-2003
DEFINITION  Sequence 6351 from patent US 6566127.
ACCESSION   AR328949
VERSION     AR328949.1  GI:33714757
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
  TITLE     Method and reagent for the treatment of diseases or conditions
            related to levels of vascular endothelial growth factor receptor
  JOURNAL   Patent: US 6566127-A 6351 20-MAY-2003;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned RNA"

  Query Match             0.8%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 1.7e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        287 TCCCACCCCAGATCGG 302
              |||||||||||||| ||
Db          1 TCCCACCCCAGATTGG 16


RESULT 144
AR398235
LOCUS       AR398235                  17 bp    RNA     linear   PAT 18-DEC-2003
DEFINITION  Sequence 616 from patent US 6617438.
ACCESSION   AR398235
VERSION     AR398235.1  GI:40135883
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Beigelman,L., Burgin,A.B., Beaudry,A., Karpeisky,A.,
            Matulic-Adamic,J., Sweedler,D. and Zinnen,S.
  TITLE     Oligoribonucleotides with enzymatic activity
  JOURNAL   Patent: US 6617438-A 616 09-SEP-2003;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned RNA"

  Query Match             0.8%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 1.7e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1087 TGTGCGGGTGGCTGTG 1102
              ||||| ||||||||||
Db          2 TGTGCCGGTGGCTGTG 17


RESULT 145
AX216928/c
LOCUS       AX216928                  17 bp    RNA     linear   PAT 07-SEP-2001
DEFINITION  Sequence 2370 from Patent WO0159103.
ACCESSION   AX216928
VERSION     AX216928.1  GI:15526989
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Blatt,L., Mcswiggen,J. and Chowrira,B.M.
  TITLE     Method and reagent for the modulation and diagnosis of cd20 and
            nogo gene expression
  JOURNAL   Patent: WO 0159103-A 2370 16-AUG-2001;
            RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
            McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES             Location/Qualifiers
     source          1. .17
```

```
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"
                     /note="Nucleic Acid"

  Query Match             0.8%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 1.7e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        261 TCTTCGCCCTCGTCCT 276
              |||||| |||||||||
Db         17 TCTTCGTCCTCGTCCT 2


RESULT 146
AX216929/c
LOCUS       AX216929                  17 bp    RNA     linear   PAT 07-SEP-2001
DEFINITION  Sequence 2371 from Patent WO0159103.
ACCESSION   AX216929
VERSION     AX216929.1  GI:15526990
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Blatt,L., Mcswiggen,J. and Chowrira,B.M.
  TITLE     Method and reagent for the modulation and diagnosis of cd20 and
            nogo gene expression
  JOURNAL   Patent: WO 0159103-A 2371 16-AUG-2001;
            RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
            McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"
                     /note="Nucleic Acid"

  Query Match             0.8%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 1.7e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        261 TCTTCGCCCTCGTCCT 276
              |||||| |||||||||
Db         16 TCTTCGTCCTCGTCCT 1


RESULT 147
AX736712
LOCUS       AX736712                  17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 2302 from Patent WO03025177.
ACCESSION   AX736712
VERSION     AX736712.1  GI:30516000
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or resistance to viruses and the use
            thereof as medicaments
  JOURNAL   Patent: WO 03025177-A 2302 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             0.8%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 1.7e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1399 ATCTTGTTTTTCTGAT 1414
              ||| ||||||||||||
Db          2 ATCATGTTTTTCTGAT 17


RESULT 148
AX758749
LOCUS       AX758749                  17 bp    DNA     linear   PAT 25-JUN-2003
DEFINITION  Sequence 2070 from Patent WO03040369.
ACCESSION   AX758749
VERSION     AX758749.1  GI:32253365
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in tumoral suppression, tumoral reversion,
            apoptosis and/or viral resistance phenomena and their use as
            medicines
  JOURNAL   Patent: WO 03040369-A 2070 15-MAY-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             0.8%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 1.7e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1399 ATCTTGTTTTTCTGAT 1414
              ||| ||||||||||||
Db          2 ATCATGTTTTTCTGAT 17


RESULT 149
AR196166
LOCUS       AR196166                  18 bp    DNA     linear   PAT 20-APR-2002
DEFINITION  Sequence 631 from patent US 6350934.
ACCESSION   AR196166
VERSION     AR196166.1  GI:20245603
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Zwick,M.G., Edington,B.E., McSwiggen,J.A., Merlo,P.Ann.Owens.,
            Guo,L., Skokut,T.A., Young,S.A., Folkerts,O. and Merlo,D.J.
  TITLE     Nucleic acid encoding delta-9 desaturase
  JOURNAL   Patent: US 6350934-A 631 26-FEB-2002;
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.8%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 1.7e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        310 GCTCAGCCTGGGGGTC 325
              ||||||||| ||||||
Db          3 GCTCAGCCTCGGGGTC 18


RESULT 150
AX710854
LOCUS       AX710854                  18 bp    RNA     linear   PAT 11-APR-2003
DEFINITION  Sequence 154 from Patent EP1288296.
```

```
ACCESSION   AX710854
VERSION     AX710854.1  GI:29787235
KEYWORDS    .
SOURCE      Human herpesvirus 4 (Epstein-Barr virus)
  ORGANISM  Human herpesvirus 4
            Viruses; dsDNA viruses, no RNA stage; Herpesviridae;
            Gammaherpesvirinae; Lymphocryptovirus.
REFERENCE   1
  AUTHORS   Draper,K.G., Mcswiggen,J.A., Holecek,J.J., Dudycz,L.W.,
            Macejak,D.G. and Mamone,J.A.
  TITLE     Method and reagent for inhibiting HBV viral replication
  JOURNAL   Patent: EP 1288296-A 154 05-MAR-2003;
            RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="Human herpesvirus 4"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:10376"

  Query Match             0.8%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 1.7e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1330 GAGGTCGTGGAGGTGG 1345
              ||||||||||| ||||
Db          3 GAGGTCGTGGACGTGG 18


RESULT 151
BD000995
LOCUS       BD000995                 18 bp    RNA     linear   PAT 31-JAN-2002
DEFINITION  Method and reagent for inhibiting viral replication.
ACCESSION   BD000995
VERSION     BD000995.1  GI:18625554
KEYWORDS    JP 2000342285-A/155.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Draper,K.G., Dadyktz,L.W., Macswigen,J.A., Maysejak,D.G.,
            Holesek,J.J. and Mamone,A.J.
  TITLE     Method and reagent for inhibiting viral replication
  JOURNAL   Patent: JP 2000342285-A 155 12-DEC-2000;
            RIBOZYME PHARMACEUTICALS INC
COMMENT     OS   Artificial Sequence
            PN   JP 2000342285-A/155
            PD   12-DEC-2000
            PF   01-MAY-2000 JP 2000132616
            PR   11-MAY-1992 US    07/882689,14-MAY-1992 US    07/882712 PR
            14-MAY-1992 US    07/882713,14-MAY-1992 US    07/882714 PR
            14-MAY-1992 US    07/882823,14-MAY-1992 US    07/882824 PR
            14-MAY-1992 US    07/882886,14-MAY-1992 US    07/882888 PR
            14-MAY-1992 US    07/882889,14-MAY-1992 US    07/882921 PR
            14-MAY-1992 US    07/882922,14-MAY-1992 US    07/883823 PR
            14-MAY-1992 US    07/883849,14-MAY-1992 US    07/884073 PR
            14-MAY-1992 US    07/884074,14-MAY-1992 US    07/884333 PR
            14-MAY-1992 US    07/884422,14-MAY-1992 US    07/884431 PR
            14-MAY-1992 US    07/884436,14-MAY-1992 US    07/884521 PR
            31-JUL-1992 US    07/923738,26-AUG-1992 US    07/935854 PR
            26-AUG-1992 US    07/936086,18-SEP-1992 US    07/948359 PR
            15-OCT-1992 US    07/963322,07-DEC-1992 US    07/987129 PR
            07-DEC-1992 US    07/987130,07-DEC-1992 US    07/987133 PI
            KENNETH G DRAPER,LEC W DADYKTZ,JAMES A MACSWIGEN, PI   DENNIS G
            MAYSEJAK,
            PI   JAMES J HOLESEK,ANTHONY J MAMONE
            PC   C12N15/09,C12N5/10,C12N7/00,C12N9/22//(C12N5/10,C12R1:91), PC
             C12N15/00,
            PC   C12N5/00,(C12N5/00,C12R1:91)
            CC
            FH   Key             Location/Qualifiers
            FT   source          1. .18
            FT                   /organism='Artificial Sequence'.
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="synthetic construct"
                     /mol_type="genomic RNA"
                     /db_xref="taxon:32630"

  Query Match             0.8%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 1.7e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1330 GAGGTCGTGGAGGTGG 1345
              ||||||||||| ||||
Db          3 GAGGTCGTGGACGTGG 18


RESULT 152
BD001424
LOCUS       BD001424                 18 bp    RNA     linear   PAT 31-JAN-2002
DEFINITION  Method and reagent for inhibiting viral replication.
ACCESSION   BD001424
VERSION     BD001424.1  GI:18625983
KEYWORDS    JP 2000342286-A/155.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Draper,K.G., Dadyktz,L.W., Macswigen,J.A., Maysejak,D.G.,
            Holesek,J.J. and Mamone,A.J.
  TITLE     Method and reagent for inhibiting viral replication
  JOURNAL   Patent: JP 2000342286-A 155 12-DEC-2000;
            RIBOZYME PHARMACEUTICALS INC
COMMENT     OS   Artificial Sequence
            PN   JP 2000342286-A/155
            PD   12-DEC-2000
            PF   01-MAY-2000 JP 2000132651
            PR   11-MAY-1992 US    07/882689,14-MAY-1992 US    07/882712 PR
            14-MAY-1992 US    07/882713,14-MAY-1992 US    07/882714 PR
            14-MAY-1992 US    07/882823,14-MAY-1992 US    07/882824 PR
            14-MAY-1992 US    07/882886,14-MAY-1992 US    07/882888 PR
            14-MAY-1992 US    07/882889,14-MAY-1992 US    07/882921 PR
            14-MAY-1992 US    07/882922,14-MAY-1992 US    07/883823 PR
            14-MAY-1992 US    07/883849,14-MAY-1992 US    07/884073 PR
            14-MAY-1992 US    07/884074,14-MAY-1992 US    07/884333 PR
            14-MAY-1992 US    07/884422,14-MAY-1992 US    07/884431 PR
            14-MAY-1992 US    07/884436,14-MAY-1992 US    07/884521 PR
            31-JUL-1992 US    07/923738,26-AUG-1992 US    07/935854 PR
            26-AUG-1992 US    07/936086,18-SEP-1992 US    07/948359 PR
            15-OCT-1992 US    07/963322,07-DEC-1992 US    07/987129 PR
            07-DEC-1992 US    07/987130,07-DEC-1992 US    07/987133 PI
            KENNETH G DRAPER,LEC W DADYKTZ,JAMES A MACSWIGEN, PI   DENNIS G
            MAYSEJAK,
            PI   JAMES J HOLESEK,ANTHONY J MAMONE
            PC   C12N15/09,C12N5/10,C12N7/00//A61K38/43,A61K39/125,A61K39/13,
            PC   A61K39/135,
            PC   A61K39/145,A61K39/21,A61K39/23,A61K39/245,A61K39/29,A61K48/00,
            PC   A61P1/16,
            PC   A61P31/14,A61P31/16,A61P31/18,A61P31/22,A61P35/02,C12Q1/68, PC
              (C12N15/09,C12R1:93),C12N15/00,C12N5/00,A61K37/48,(C12N15/00, PC
             C12R1:93)
            CC
            FH   Key             Location/Qualifiers
            FT   source          1. .18
            FT                   /organism='Artificial Sequence'.
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="synthetic construct"
                     /mol_type="genomic RNA"
                     /db_xref="taxon:32630"

  Query Match             0.8%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 1.7e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1330 GAGGTCGTGGAGGTGG 1345
```

```
                 ||||||||||| ||||
Db          3 GAGGTCGTGGACGTGG 18


RESULT 153
BD104097
LOCUS       BD104097                 18 bp    DNA     linear   PAT 27-AUG-2002
DEFINITION  Kit and method for determining HLA type.
ACCESSION   BD104097
VERSION     BD104097.1  GI:22649671
KEYWORDS    WO 0192572-A/201.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Inoko,H., Kagiya,T., Ichihara,T., Matsumura,Y., Moriya,S. and
            Nishida,M.
  TITLE     Kit and method for determining HLA type
  JOURNAL   Patent: WO 0192572-A 201 06-DEC-2001;
            NISSHINBO INDUSTRIES INC,SYSTEM RESEARCH INC,HIDETOSHI INOKO, TAEKO
            KAGIYA, TATSUO ICHIHARA,YOSHIYUKI MATSUMURA,SHOGO MORIYA,MICHIO
            NISHIDA
COMMENT     OS   Artificial Sequence
            PN   WO 0192572-A/201
            PD   06-DEC-2001
            PF   01-JUN-2001 WO 2001JP004662
            PR   01-JUN-2000 JP 00P   164798
            PI   HIDETOSHI INOKO,TAEKO KAGIYA,TATSUO ICHIHARA,YOSHIYUKI  PI
            MATSUMURA,
            PI   SHOGO MORIYA,MICHIO NISHIDA
            PC   C12Q1/68,C12M1/00,C12N15/09,G01N33/53
            CC   Description of Artificial Sequence:capture
            FH   Key             Location/Qualifiers
            FT   source          1. .18
            FT                   /organism='Artificial Sequence'.
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="synthetic construct"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32630"

  Query Match             0.8%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 1.7e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        839 CCTGACGCTGAGCACT 854
              ||||||||||||| |||
Db          3 CCTGACGCTGAGTACT 18


RESULT 154
E06078
LOCUS       E06078                   19 bp    DNA     linear   PAT 29-SEP-1997
DEFINITION  Oligonucleotide specific to subtype K1 of hepatitis C virus.
ACCESSION   E06078
VERSION     E06078.1  GI:2174265
KEYWORDS    JP 1993337000-A/2.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Chayama,K. and Kumada,H.
  TITLE     METHOD FOR EXAMINING C TYPE HEPATITIS VIRUS AND PRIMER SET USED FOR
            THE SAME
  JOURNAL   Patent: JP 1993337000-A 2 21-DEC-1993;
            CHAYAMA KAZUAKI
COMMENT     OS   Artificial gene
            OC   Artificial sequence; Genes.
            OS   Hepatitis C virus
            PN   JP 1993337000-A/2
            PD   21-DEC-1993
            PF   04-JUN-1992 JP 1992168226
            PI   CHAYAMA KAZUAKI, KUMADA HIROMITSU
            PC   C12Q1/68,C12N15/10,C12N15/11,C12Q1/70;
            CC   strandedness: Single;
            CC   topology: Linear;
            CC   hypothetical: No;
            CC   anti-sense: No.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32630"

  Query Match             0.8%;  Score 14.4;  DB 1;  Length 19;
  Best Local Similarity   93.8%;  Pred. No. 1.7e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy          2 TTGGCCCTCGAGGCCA 17
              ||||||| ||||||||
Db          1 TTGGCCCCCGAGGCCA 16


RESULT 155
AX352950/c
LOCUS       AX352950                 19 bp    DNA     linear   PAT 06-FEB-2002
DEFINITION  Sequence 156 from Patent EP1174518.
ACCESSION   AX352950
VERSION     AX352950.1  GI:18618032
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Loukachov,V.V., van Gemen,B. and Goudsmit,J.
  TITLE     Collection of binding molecules
  JOURNAL   Patent: EP 1174518-A 156 23-JAN-2002;
            Amsterdam Support Diagnostics B.V. (NL)
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="position 69"

  Query Match             0.8%;  Score 14.4;  DB 1;  Length 19;
  Best Local Similarity   93.8%;  Pred. No. 1.7e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1646 TCCATCTAGAACTGTT 1661
              ||||||||| ||||||
Db         18 TCCATCTAGTACTGTT 3


RESULT 156
AX362795/c
LOCUS       AX362795                 19 bp    DNA     linear   PAT 15-FEB-2002
DEFINITION  Sequence 156 from Patent WO0208463.
ACCESSION   AX362795
VERSION     AX362795.1  GI:18694935
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Loukachov,V.V., Goudsmit,J. and van Gemen,B.
  TITLE     Collection of binding molecules
  JOURNAL   Patent: WO 0208463-A 156 31-JAN-2002;
            Amsterdam Support Diagnostics B.V. (NL)
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="position 69"
```

Query Match 0.8%; Score 14.4; DB 1; Length 19;
Best Local Similarity 93.8%; Pred. No. 1.7e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy       1646 TCCATCTAGAACTGTT 1661
              ||||||||| ||||||
Db         18 TCCATCTAGTACTGTT 3
```

Search completed: December 13, 2004, 08:20:33
Job time : 21 secs

GenCore version 5.1.6

OM nucleic - nucleic search, using sw model

Run on: December 13, 2004, 08:38:06 ; Search time 20 Seconds
(without alignments)
3.709 Million cell updates/sec

Title: US-10-091-333-2
Perfect score: 1764
Sequence: 1 tttggccctcgaggccaaga.....ataaacatgtttgttaaaac 1764

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 0.5

Searched: 1188 seqs, 21027 residues

Total number of hits satisfying chosen parameters: 2376

Minimum DB seq length: 8
Maximum DB seq length: 50

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 147 summaries

Database : rnpb2.seq:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

	Result No.	Score	% Query Match	Length	DB	ID	Description
c	1	20	1.1	20	1	US-10-368-803-11	Sequence 11, Appl
	2	20	1.1	20	1	US-10-740-773-10	Sequence 10, Appl
	3	18.8	1.1	25	1	US-10-098-263B-84584	Sequence 84584, A
	4	18	1.0	18	1	US-10-368-803-10	Sequence 10, Appl
	5	16.4	0.9	19	1	US-09-263-959-448	Sequence 448, App
	6	16.4	0.9	20	1	US-10-297-068-703	Sequence 703, App
	7	16.4	0.9	20	1	US-10-297-068-706	Sequence 706, App
	8	16.4	0.9	20	1	US-10-174-559-40	Sequence 40, Appl
	9	16.2	0.9	21	1	US-10-418-182-126	Sequence 126, App
c	10	16.2	0.9	21	1	US-10-786-720-7032	Sequence 7032, Ap
c	11	16.2	0.9	21	1	US-10-786-720-9300	Sequence 9300, Ap
	12	16	0.9	17	1	US-09-818-875-3958	Sequence 3958, Ap
c	13	16	0.9	17	1	US-09-818-875-3959	Sequence 3959, Ap
	14	16	0.9	17	1	US-10-209-787-3958	Sequence 3958, Ap
c	15	16	0.9	17	1	US-10-209-787-3959	Sequence 3959, Ap
	16	16	0.9	17	1	US-10-261-185-3958	Sequence 3958, Ap
c	17	16	0.9	17	1	US-10-261-185-3959	Sequence 3959, Ap
	18	16	0.9	17	1	US-10-681-074-3958	Sequence 3958, Ap
c	19	16	0.9	17	1	US-10-681-074-3959	Sequence 3959, Ap
c	20	16	0.9	20	1	US-10-148-355A-10	Sequence 10, Appl
	21	16	0.9	24	1	US-09-776-479-60	Sequence 60, Appl
	22	16	0.9	24	1	US-09-776-479-60	Sequence 60, Appl
	23	16	0.9	24	1	US-10-112-653-54	Sequence 54, Appl
	24	16	0.9	24	1	US-10-017-995-60	Sequence 60, Appl
	25	16	0.9	24	1	US-10-314-578-60	Sequence 60, Appl
	26	16	0.9	24	1	US-10-309-775A-26	Sequence 26, Appl
	27	16	0.9	24	1	US-10-309-775A-73	Sequence 73, Appl
c	28	16	0.9	26	1	US-09-997-931-5	Sequence 5, Appli
	29	16	0.9	27	1	US-10-102-720-18	Sequence 18, Appl
c	30	15.8	0.9	20	1	US-09-952-464A-27	Sequence 27, Appl
c	31	15.8	0.9	20	1	US-10-149-352-11	Sequence 11, Appl
	32	15.8	0.9	20	1	US-10-279-186-61	Sequence 61, Appl
c	33	15.8	0.9	20	1	US-10-181-874-35	Sequence 35, Appl
	34	15.8	0.9	20	1	US-10-289-762-3718	Sequence 3718, Ap
c	35	15.8	0.9	20	1	US-10-712-795-442	Sequence 442, App
	36	15.8	0.9	20	1	US-10-712-795-765	Sequence 765, App
	37	15.8	0.9	21	1	US-10-786-720-7030	Sequence 7030, Ap
	38	15.8	0.9	21	1	US-10-786-720-7031	Sequence 7031, Ap
	39	15.8	0.9	21	1	US-10-786-720-9298	Sequence 9298, Ap
	40	15.8	0.9	21	1	US-10-786-720-9299	Sequence 9299, Ap
	41	15.8	0.9	27	1	US-09-888-326-842	Sequence 842, App
	42	15.8	0.9	27	1	US-09-776-479-911	Sequence 911, App
	43	15.8	0.9	27	1	US-09-776-479-911	Sequence 911, App
	44	15.8	0.9	27	1	US-10-112-653-880	Sequence 880, App
	45	15.8	0.9	27	1	US-10-017-995-911	Sequence 911, App
	46	15.8	0.9	27	1	US-10-314-578-911	Sequence 911, App
	47	15.8	0.9	27	1	US-10-407-818-3	Sequence 3, Appli
	48	15.4	0.9	17	1	US-08-865-579-5	Sequence 5, Appli
	49	15.4	0.9	17	1	US-09-746-731-5	Sequence 5, Appli
	50	15.4	0.9	17	1	US-09-952-768-6	Sequence 6, Appli
	51	15.4	0.9	17	1	US-09-944-851-6	Sequence 6, Appli
c	52	15.4	0.9	17	1	US-09-969-373-2634	Sequence 2634, Ap
	53	15.4	0.9	17	1	US-10-059-749-5	Sequence 5, Appli
	54	15.4	0.9	17	1	US-10-337-060-6	Sequence 6, Appli
	55	15.4	0.9	17	1	US-10-668-955-6	Sequence 6, Appli
	56	15.4	0.9	17	1	US-10-138-674-3605	Sequence 3605, Ap
	57	15.4	0.9	17	1	US-10-287-949A-3605	Sequence 3605, Ap
c	58	15.4	0.9	18	1	US-10-297-068-1077	Sequence 1077, Ap
	59	15.4	0.9	20	1	US-09-918-187-30	Sequence 30, Appl
	60	15.4	0.9	20	1	US-10-032-585-4519	Sequence 4519, Ap
c	61	15.4	0.9	20	1	US-10-304-103-26	Sequence 26, Appl
	62	15.4	0.9	20	1	US-10-304-103-62	Sequence 62, Appl
	63	15.4	0.9	26	1	US-09-923-246-39	Sequence 39, Appl
	64	15.4	0.9	26	1	US-09-092-296-10	Sequence 10, Appl
	65	15.4	0.9	26	1	US-10-295-723-39	Sequence 39, Appl
	66	15.4	0.9	26	1	US-10-659-684-39	Sequence 39, Appl
	67	15.2	0.9	20	1	US-09-021-660A-24	Sequence 24, Appl
c	68	15.2	0.9	20	1	US-09-291-417-145	Sequence 145, App
c	69	15.2	0.9	20	1	US-10-085-108-17	Sequence 17, Appl
c	70	15.2	0.9	20	1	US-10-057-550-73	Sequence 73, Appl
	71	15.2	0.9	20	1	US-10-010-802-341	Sequence 341, App
c	72	15.2	0.9	20	1	US-10-001-076-77	Sequence 77, Appl
c	73	15.2	0.9	20	1	US-10-160-237-17	Sequence 17, Appl
c	74	15.2	0.9	20	1	US-10-144-488-25	Sequence 25, Appl
c	75	15.2	0.9	20	1	US-10-181-874-36	Sequence 36, Appl
	76	15.2	0.9	20	1	US-10-174-319-42	Sequence 42, Appl
c	77	15.2	0.9	20	1	US-10-177-554-85	Sequence 85, Appl
	78	15.2	0.9	20	1	US-10-177-554-215	Sequence 215, App
c	79	15.2	0.9	20	1	US-10-289-762-2571	Sequence 2571, Ap
c	80	15.2	0.9	20	1	US-10-289-762-5767	Sequence 5767, Ap
c	81	15.2	0.9	20	1	US-10-642-802-77	Sequence 77, Appl
c	82	15.2	0.9	20	1	US-10-272-810-41	Sequence 41, Appl
c	83	15.2	0.9	20	1	US-10-273-070-41	Sequence 41, Appl
c	84	15.2	0.9	20	1	US-10-280-183A-448	Sequence 448, App
	85	15.2	0.9	20	1	US-10-303-420-94	Sequence 94, Appl
c	86	15.2	0.9	20	1	US-10-316-515-26	Sequence 26, Appl
c	87	15.2	0.9	20	1	US-10-725-329-145	Sequence 145, App
c	88	15.2	0.9	31	1	US-09-971-353-24	Sequence 24, Appl
	89	15	0.9	17	1	US-09-848-754A-1341	Sequence 1341, Ap
	90	15	0.9	17	1	US-09-848-754A-2408	Sequence 2408, Ap
c	91	15	0.9	20	1	US-10-199-199-43	Sequence 43, Appl
	92	15	0.9	20	1	US-10-199-199-116	Sequence 116, App
	93	15	0.9	25	1	US-10-480-013-2	Sequence 2, Appli
	94	14.8	0.8	18	1	US-10-440-850-1112	Sequence 1112, Ap
c	95	14.8	0.8	19	1	US-09-844-662-20	Sequence 20, Appl
c	96	14.8	0.8	19	1	US-09-925-548-89	Sequence 89, Appl
c	97	14.8	0.8	19	1	US-09-844-508-33	Sequence 33, Appl
c	98	14.8	0.8	19	1	US-09-916-136A-10	Sequence 10, Appl
c	99	14.8	0.8	19	1	US-10-084-826-33	Sequence 33, Appl
	100	14.8	0.8	19	1	US-10-251-117-47	Sequence 47, Appl
c	101	14.8	0.8	19	1	US-10-251-117-85	Sequence 85, Appl
c	102	14.8	0.8	19	1	US-10-251-117-296	Sequence 296, App
	103	14.8	0.8	19	1	US-10-251-117-334	Sequence 334, App
	104	14.8	0.8	19	1	US-10-205-309-1	Sequence 1, Appli
c	105	14.8	0.8	19	1	US-10-205-309-14	Sequence 14, Appl
c	106	14.8	0.8	19	1	US-10-205-309-326	Sequence 326, App

	107	14.8	0.8	19	1	US-10-205-309-339	Sequence 339, App
c	108	14.8	0.8	19	1	US-10-444-925-188	Sequence 188, App
	109	14.8	0.8	19	1	US-10-206-705-66	Sequence 66, Appl
c	110	14.8	0.8	19	1	US-10-206-705-251	Sequence 251, App
	111	14.8	0.8	19	1	US-10-670-011-2	Sequence 2, Appli
c	112	14.8	0.8	19	1	US-10-670-011-98	Sequence 98, Appl
	113	14.8	0.8	26	1	US-09-099-823-14	Sequence 14, Appl
	114	14.8	0.8	26	1	US-09-920-342-3	Sequence 3, Appli
	115	14.8	0.8	26	1	US-09-949-305B-4	Sequence 4, Appli
	116	14.8	0.8	26	1	US-10-053-883-53	Sequence 53, Appl
	117	14.6	0.8	22	1	US-09-263-959-614	Sequence 614, App
	118	14.6	0.8	24	1	US-10-309-775A-20	Sequence 20, Appl
	119	14.6	0.8	26	1	US-09-922-480-6	Sequence 6, Appli
	120	14.6	0.8	26	1	US-09-923-236-6	Sequence 6, Appli
	121	14.6	0.8	26	1	US-09-922-469-6	Sequence 6, Appli
	122	14.6	0.8	26	1	US-10-039-876A-10	Sequence 10, Appl
	123	14.6	0.8	26	1	US-10-196-703-43	Sequence 43, Appl
	124	14.6	0.8	26	1	US-10-352-253A-36	Sequence 36, Appl
	125	14.6	0.8	26	1	US-10-224-289-20	Sequence 20, Appl
	126	14.6	0.8	27	1	US-10-071-214-42	Sequence 42, Appl
	127	14.4	0.8	17	1	US-09-825-805-616	Sequence 616, App
	128	14.4	0.8	17	1	US-09-961-077-218	Sequence 218, App
c	129	14.4	0.8	17	1	US-09-780-533A-2370	Sequence 2370, Ap
c	130	14.4	0.8	17	1	US-09-780-533A-2371	Sequence 2371, Ap
	131	14.4	0.8	17	1	US-10-163-552-187	Sequence 187, App
	132	14.4	0.8	17	1	US-10-156-306-6907	Sequence 6907, Ap
c	133	14.4	0.8	17	1	US-10-238-700-199	Sequence 199, App
	134	14.4	0.8	17	1	US-10-138-674-3604	Sequence 3604, Ap
	135	14.4	0.8	17	1	US-10-138-674-3606	Sequence 3606, Ap
	136	14.4	0.8	17	1	US-10-138-674-6350	Sequence 6350, Ap
	137	14.4	0.8	17	1	US-10-138-674-6351	Sequence 6351, Ap
	138	14.4	0.8	17	1	US-10-287-949A-3604	Sequence 3604, Ap
	139	14.4	0.8	17	1	US-10-287-949A-3606	Sequence 3606, Ap
	140	14.4	0.8	17	1	US-10-287-949A-6350	Sequence 6350, Ap
	141	14.4	0.8	17	1	US-10-287-949A-6351	Sequence 6351, Ap
	142	14.4	0.8	18	1	US-09-961-077-631	Sequence 631, App
	143	14.4	0.8	18	1	US-10-297-068-201	Sequence 201, App
c	144	14.4	0.8	18	1	US-10-300-683-109	Sequence 109, App
c	145	14.4	0.8	18	1	US-10-300-683-278	Sequence 278, App
c	146	14.4	0.8	18	1	US-10-300-683-466	Sequence 466, App
c	147	14.4	0.8	19	1	US-10-357-043-19	Sequence 19, Appl

ALIGNMENTS

```
RESULT 1
US-10-368-803-11/c
; Sequence 11, Application US/10368803
; Publication No. US20030219728A1
; GENERAL INFORMATION:
;  APPLICANT: Terri H. Finkel
;  APPLICANT:  Jiyi Yin
;  TITLE OF INVENTION: CELLULAR GENES REGULATED BY HIV-1
;  TITLE OF INVENTION:  INFECTION AND METHODS OF USE THEREOF
;  FILE REFERENCE: CHOP-0146
;  CURRENT APPLICATION NUMBER: US/10/368,803
;  CURRENT FILING DATE:  2003-02-19
;  PRIOR APPLICATION NUMBER: 60/358,495
;  PRIOR FILING DATE: 2002-02-19
;  NUMBER OF SEQ ID NOS: 20
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 11
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Primer
US-10-368-803-11

  Query Match             1.1%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 17;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         904 TTGAGGAGTGTTGAACTTCA 923
               ||||||||||||||||||||
Db          20 TTGAGGAGTGTTGAACTTCA 1


RESULT 2
US-10-740-773-10
; Sequence 10, Application US/10740773
; Publication No. US20040180825A1
; GENERAL INFORMATION:
;  APPLICANT: Spriggs, Melanie K.
;  TITLE OF INVENTION: NOVEL SEMAPHORIN POLYPEPTIDES
;  FILE REFERENCE: 2634-US
;  CURRENT APPLICATION NUMBER: US/10/740,773
;  CURRENT FILING DATE:  2003-12-19
;  PRIOR APPLICATION NUMBER: US/09/689,012
;  PRIOR FILING DATE: 2000-10-12
;  PRIOR APPLICATION NUMBER: PCT/US99/09831
;  PRIOR FILING DATE: 1999-05-05
;  PRIOR APPLICATION NUMBER: US 60/085,497
;  PRIOR FILING DATE: 1998-05-14
;  NUMBER OF SEQ ID NOS: 10
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 10
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: PRIMER
US-10-740-773-10

  Query Match             1.1%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 17;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy           8 CTCGAGGCCAAGAATTCGGC 27
               ||||||||||||||||||||
Db           1 CTCGAGGCCAAGAATTCGGC 20


RESULT 3
US-10-098-263B-84584
; Sequence 84584, Application US/10098263B
; Publication No. US20030104410A1
; GENERAL INFORMATION:
;  APPLICANT: Mittman, Michael
;  TITLE OF INVENTION: Human Microarray
;  FILE REFERENCE: 3118.1
;  CURRENT APPLICATION NUMBER: US/10/098,263B
;  CURRENT FILING DATE:  2003-01-08
;  PRIOR APPLICATION NUMBER: 60/276,759
;  PRIOR FILING DATE: 2001-03-16
;  NUMBER OF SEQ ID NOS: 131066
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 84584
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Homo sapien
US-10-098-263B-84584

  Query Match             1.1%;  Score 18.8;  DB 1;  Length 25;
  Best Local Similarity   90.9%;  Pred. No. 33;
  Matches   20;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         123 ACTTGTCTTAGCAGTTCTCGCT 144
               |||||||| ||| |||||||||
Db           4 ACTTGTCTGAGCTGTTCTCGCT 25


RESULT 4
US-10-368-803-10
; Sequence 10, Application US/10368803
```

```
; Publication No. US20030219728A1
; GENERAL INFORMATION:
;  APPLICANT: Terri H. Finkel
;  APPLICANT:  Jiyi Yin
;  TITLE OF INVENTION: CELLULAR GENES REGULATED BY HIV-1
;  TITLE OF INVENTION:  INFECTION AND METHODS OF USE THEREOF
;  FILE REFERENCE: CHOP-0146
;  CURRENT APPLICATION NUMBER: US/10/368,803
;  CURRENT FILING DATE:  2003-02-19
;  PRIOR APPLICATION NUMBER: 60/358,495
;  PRIOR FILING DATE: 2002-02-19
;  NUMBER OF SEQ ID NOS: 20
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 10
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Primer
US-10-368-803-10

  Query Match             1.0%;  Score 18;  DB 1;  Length 18;
  Best Local Similarity   100.0%;  Pred. No. 36;
  Matches   18;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        208 CTGTCCTCACCATGCCTA 225
              ||||||||||||||||||
Db          1 CTGTCCTCACCATGCCTA 18


RESULT 5
US-09-263-959-448
; Sequence 448, Application US/09263959
; Patent No. US20020150891A1
;  GENERAL INFORMATION:
;    APPLICANT:  Hood, Leroy E.
;    APPLICANT:  Rowen, Lee
;    APPLICANT:  Koop, Ben F.
;    TITLE OF INVENTION:  DIAGNOSTIC AND THERAPEUTIC COMPOSITIONS AND METHODS WHICH UTI
;    NUMBER OF SEQUENCES:  1279
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Seed and Berry LLP
;      STREET:  6300 Columbia Center, 701 Fifth Avenue
;      CITY:  Seattle
;      STATE:  Washington
;      COUNTRY:  US
;      ZIP:  98104-7092
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/263,959
;      FILING DATE:  05-MAR-1999
;      CLASSIFICATION:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  McMasters, David D.
;      REGISTRATION NUMBER:  33,963
;      REFERENCE/DOCKET NUMBER:  920010.426C2
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (206) 622-4900
;      TELEFAX:  (206) 682-6031
;  INFORMATION FOR SEQ ID NO:  448:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  19 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-09-263-959-448

  Query Match             0.9%;  Score 16.4;  DB 1;  Length 19;
  Best Local Similarity   94.4%;  Pred. No. 71;
  Matches   17;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1378 TGTGTTTGTTGTTTGTTT 1395
              | ||||||||||||||||
Db          1 TTTGTTTGTTGTTTGTTT 18


RESULT 6
US-10-297-068-703
; Sequence 703, Application US/10297068
; Publication No. US20030228585A1
; GENERAL INFORMATION:
;  APPLICANT: INOKO, Hidetoshi
;  APPLICANT:  KAGIYA, Taeko
;  APPLICANT:  ICHIHARA, Tatsuo
;  APPLICANT:  Matsumura, Yoshiyuki
;  APPLICANT:  MORIYA, Shogo
;  APPLICANT:  NISHIDA, Michio
;  TITLE OF INVENTION: KIT AND METHOD FOR DETERMINING HLA TYPES
;  FILE REFERENCE: 1314OP1174
;  CURRENT APPLICATION NUMBER: US/10/297,068
;  CURRENT FILING DATE:  2002-11-27
;  PRIOR APPLICATION NUMBER: JP 2000-164798
;  PRIOR FILING DATE: 2000-06-01
;  NUMBER OF SEQ ID NOS: 1298
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 703
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:capture
US-10-297-068-703

  Query Match             0.9%;  Score 16.4;  DB 1;  Length 20;
  Best Local Similarity   94.4%;  Pred. No. 74;
  Matches   17;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        839 CCTGACGCTGAGCACTGG 856
              |||||||||||| |||||
Db          2 CCTGACGCTGAGTACTGG 19


RESULT 7
US-10-297-068-706
; Sequence 706, Application US/10297068
; Publication No. US20030228585A1
; GENERAL INFORMATION:
;  APPLICANT: INOKO, Hidetoshi
;  APPLICANT:  KAGIYA, Taeko
;  APPLICANT:  ICHIHARA, Tatsuo
;  APPLICANT:  Matsumura, Yoshiyuki
;  APPLICANT:  MORIYA, Shogo
;  APPLICANT:  NISHIDA, Michio
;  TITLE OF INVENTION: KIT AND METHOD FOR DETERMINING HLA TYPES
;  FILE REFERENCE: 1314OP1174
;  CURRENT APPLICATION NUMBER: US/10/297,068
;  CURRENT FILING DATE:  2002-11-27
;  PRIOR APPLICATION NUMBER: JP 2000-164798
;  PRIOR FILING DATE: 2000-06-01
;  NUMBER OF SEQ ID NOS: 1298
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 706
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:capture
US-10-297-068-706

  Query Match             0.9%;  Score 16.4;  DB 1;  Length 20;
  Best Local Similarity   94.4%;  Pred. No. 74;
  Matches   17;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;
```

```
Qy        839 CCTGACGCTGAGCACTGG 856
              |||||||| |||||||||
Db          2 CCTGACGCGGAGCACTGG 19


RESULT 8
US-10-174-559-40
; Sequence 40, Application US/10174559
; Publication No. US20030232773A1
; GENERAL INFORMATION:
;  APPLICANT: C. Frank Bennett
;  APPLICANT:  Susan M. Freier
;  APPLICANT:  Kenneth W. Dobie
;  TITLE OF INVENTION: ANTISENSE MODULATION OF DRAK1 EXPRESSION
;  FILE REFERENCE: PTS-0006
;  CURRENT APPLICATION NUMBER: US/10/174,559
;  CURRENT FILING DATE:  2002-06-17
;  NUMBER OF SEQ ID NOS: 112
; SEQ ID NO 40
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-10-174-559-40

  Query Match             0.9%;  Score 16.4;  DB 1;  Length 20;
  Best Local Similarity   94.4%;  Pred. No. 74;
  Matches   17;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1299 CTCAGAGCAGCCGGAGGG 1316
              ||| ||||||||||||||||
Db          2 CTCCGAGCAGCCGGAGGG 19


RESULT 9
US-10-418-182-126
; Sequence 126, Application US/10418182
; Publication No. US20030228302A1
; GENERAL INFORMATION:
;  APPLICANT: Crea, Roberto
;  TITLE OF INVENTION: UNIVERSAL LIBRARIES FOR IMMUNOGLOBULINS
;  FILE REFERENCE: 1551.2001-001
;  CURRENT APPLICATION NUMBER: US/10/418,182
;  CURRENT FILING DATE:  2003-04-16
;  PRIOR APPLICATION NUMBER: 60/373,558
;  PRIOR FILING DATE: 2002-04-17
;  NUMBER OF SEQ ID NOS: 423
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 126
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: oligonucleotide
US-10-418-182-126

  Query Match             0.9%;  Score 16.2;  DB 1;  Length 21;
  Best Local Similarity   85.7%;  Pred. No. 83;
  Matches   18;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        256 CCTCCTCTTCGCCCTCGTCCT 276
              ||||||| || ||||| ||||
Db          1 CCTCCTCCTCCCCCTCCTCCT 21


RESULT 10
US-10-786-720-7032/c
; Sequence 7032, Application US/10786720
; Publication No. US20040191818A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  O'Toole, Margot
;  APPLICANT:  Liu, Wei
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
;  TITLE OF INVENTION:  DISEASES
;  FILE REFERENCE: 031896-023000 (AM101331L)
;  CURRENT APPLICATION NUMBER: US/10/786,720
;  CURRENT FILING DATE:  2004-02-26
;  NUMBER OF SEQ ID NOS: 21135
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 7032
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: RNAi-antisense strand
US-10-786-720-7032

  Query Match             0.9%;  Score 16.2;  DB 1;  Length 21;
  Best Local Similarity   85.7%;  Pred. No. 83;
  Matches   18;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        360 AGCCTGGAGAGCTCGGACTGC 380
              | |||||||| | ||||||||
Db         21 AACCTGGAGATCACGGACTGC 1


RESULT 11
US-10-786-720-9300/c
; Sequence 9300, Application US/10786720
; Publication No. US20040191818A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  O'Toole, Margot
;  APPLICANT:  Liu, Wei
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
;  TITLE OF INVENTION:  DISEASES
;  FILE REFERENCE: 031896-023000 (AM101331L)
;  CURRENT APPLICATION NUMBER: US/10/786,720
;  CURRENT FILING DATE:  2004-02-26
;  NUMBER OF SEQ ID NOS: 21135
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 9300
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: RNAi-antisense strand
US-10-786-720-9300

  Query Match             0.9%;  Score 16.2;  DB 1;  Length 21;
  Best Local Similarity   85.7%;  Pred. No. 83;
  Matches   18;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        360 AGCCTGGAGAGCTCGGACTGC 380
              | |||||||| | ||||||||
Db         21 AACCTGGAGATCACGGACTGC 1


RESULT 12
US-09-818-875-3958
; Sequence 3958, Application US/09818875
; Publication No. US20030051270A1
; GENERAL INFORMATION:
;  APPLICANT: Kmiec, Eric B.
;  APPLICANT:  Gamper, Howard B.
;  APPLICANT:  Rice, Michael C.
;  TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
;  TITLE OF INVENTION:  Stranded Oligonucleotides
;  FILE REFERENCE: Napro-4
;  CURRENT APPLICATION NUMBER: US/09/818,875
;  CURRENT FILING DATE:  2001-03-27
;  PRIOR APPLICATION NUMBER: US 60/192,176
;  PRIOR FILING DATE: 2000-03-27
;  PRIOR APPLICATION NUMBER: US 60/192,179
;  PRIOR FILING DATE: 2000-03-27
;  PRIOR APPLICATION NUMBER: US 60/208,538
;  PRIOR FILING DATE: 2000-06-01
```

```
;  PRIOR APPLICATION NUMBER: US 60/244,989
;  PRIOR FILING DATE: 2000-10-30
;  NUMBER OF SEQ ID NOS: 4385
;  SOFTWARE: Friedman macro Napro4
; SEQ ID NO 3958
;    LENGTH: 17
;    TYPE: DNA
;    ORGANISM: Homo sapiens
US-09-818-875-3958

  Query Match             0.9%;  Score 16;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 77;
  Matches   16;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1160 AAGGCTTCCAGCTGGA 1175
              ||||||||||||||||
Db          1 AAGGCTTCCAGCTGGA 16


RESULT 13
US-09-818-875-3959/c
; Sequence 3959, Application US/09818875
; Publication No. US20030051270A1
; GENERAL INFORMATION:
;  APPLICANT: Kmiec, Eric B.
;  APPLICANT:  Gamper, Howard B.
;  APPLICANT:  Rice, Michael C.
;  TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
;  TITLE OF INVENTION:  Stranded Oligonucleotides
;  FILE REFERENCE: Napro-4
;  CURRENT APPLICATION NUMBER: US/09/818,875
;  CURRENT FILING DATE:  2001-03-27
;  PRIOR APPLICATION NUMBER: US 60/192,176
;  PRIOR FILING DATE: 2000-03-27
;  PRIOR APPLICATION NUMBER: US 60/192,179
;  PRIOR FILING DATE: 2000-03-27
;  PRIOR APPLICATION NUMBER: US 60/208,538
;  PRIOR FILING DATE: 2000-06-01
;  PRIOR APPLICATION NUMBER: US 60/244,989
;  PRIOR FILING DATE: 2000-10-30
;  NUMBER OF SEQ ID NOS: 4385
;  SOFTWARE: Friedman macro Napro4
; SEQ ID NO 3959
;    LENGTH: 17
;    TYPE: DNA
;    ORGANISM: Homo sapiens
US-09-818-875-3959

  Query Match             0.9%;  Score 16;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 77;
  Matches   16;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1160 AAGGCTTCCAGCTGGA 1175
              ||||||||||||||||
Db         17 AAGGCTTCCAGCTGGA 2


RESULT 14
US-10-209-787-3958
; Sequence 3958, Application US/10209787
; Publication No. US20030217377A1
; GENERAL INFORMATION:
;  APPLICANT: Kmiec, Eric B.
;  APPLICANT:  Gamper, Howard B.
;  APPLICANT:  Rice, Michael C.
;  TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
;  TITLE OF INVENTION:  Stranded Oligonucleotides
;  FILE REFERENCE: Napro-4
;  CURRENT APPLICATION NUMBER: US/10/209,787
;  CURRENT FILING DATE:  2002-07-30
;  PRIOR APPLICATION NUMBER: US 09/818,875
;  PRIOR FILING DATE: 2001-03-27
;  PRIOR APPLICATION NUMBER: US 60/192,176
;  PRIOR FILING DATE: 2000-03-27
;  PRIOR APPLICATION NUMBER: US 60/192,179
;  PRIOR FILING DATE: 2000-03-27
;  PRIOR APPLICATION NUMBER: US 60/208,538
;  PRIOR FILING DATE: 2000-06-01
;  PRIOR APPLICATION NUMBER: US 60/244,989
;  PRIOR FILING DATE: 2000-10-30
;  NUMBER OF SEQ ID NOS: 4385
;  SOFTWARE: Friedman macro Napro4
; SEQ ID NO 3958
;    LENGTH: 17
;    TYPE: DNA
;    ORGANISM: Homo sapiens
US-10-209-787-3958

  Query Match             0.9%;  Score 16;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 77;
  Matches   16;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1160 AAGGCTTCCAGCTGGA 1175
              ||||||||||||||||
Db          1 AAGGCTTCCAGCTGGA 16


RESULT 15
US-10-209-787-3959/c
; Sequence 3959, Application US/10209787
; Publication No. US20030217377A1
; GENERAL INFORMATION:
;  APPLICANT: Kmiec, Eric B.
;  APPLICANT:  Gamper, Howard B.
;  APPLICANT:  Rice, Michael C.
;  TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
;  TITLE OF INVENTION:  Stranded Oligonucleotides
;  FILE REFERENCE: Napro-4
;  CURRENT APPLICATION NUMBER: US/10/209,787
;  CURRENT FILING DATE:  2002-07-30
;  PRIOR APPLICATION NUMBER: US 09/818,875
;  PRIOR FILING DATE: 2001-03-27
;  PRIOR APPLICATION NUMBER: US 60/192,176
;  PRIOR FILING DATE: 2000-03-27
;  PRIOR APPLICATION NUMBER: US 60/192,179
;  PRIOR FILING DATE: 2000-03-27
;  PRIOR APPLICATION NUMBER: US 60/208,538
;  PRIOR FILING DATE: 2000-06-01
;  PRIOR APPLICATION NUMBER: US 60/244,989
;  PRIOR FILING DATE: 2000-10-30
;  NUMBER OF SEQ ID NOS: 4385
;  SOFTWARE: Friedman macro Napro4
; SEQ ID NO 3959
;    LENGTH: 17
;    TYPE: DNA
;    ORGANISM: Homo sapiens
US-10-209-787-3959

  Query Match             0.9%;  Score 16;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 77;
  Matches   16;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1160 AAGGCTTCCAGCTGGA 1175
              ||||||||||||||||
Db         17 AAGGCTTCCAGCTGGA 2


RESULT 16
US-10-261-185-3958
; Sequence 3958, Application US/10261185
; Publication No. US20040014057A1
; GENERAL INFORMATION:
;  APPLICANT: Kmiec, Eric B.
;  APPLICANT:  Gamper, Howard B.
;  APPLICANT:  Rice, Michael C.
;  TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
```

```
;  TITLE OF INVENTION:  Stranded Oligonucleotides
;  FILE REFERENCE: NaPro-4CON
;  CURRENT APPLICATION NUMBER: US/10/261,185
;  CURRENT FILING DATE:  2002-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/09761
;  PRIOR FILING DATE: 2001-03-27
;  PRIOR APPLICATION NUMBER: US 60/192,176
;  PRIOR FILING DATE: 2000-03-27
;  PRIOR APPLICATION NUMBER: US 60/192,179
;  PRIOR FILING DATE: 2000-03-27
;  PRIOR APPLICATION NUMBER: US 60/208,538
;  PRIOR FILING DATE: 2000-06-01
;  PRIOR APPLICATION NUMBER: US 60/244,989
;  PRIOR FILING DATE: 2000-10-30
;  NUMBER OF SEQ ID NOS: 4385
;  SOFTWARE: Friedman macro Napro4
; SEQ ID NO 3958
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-261-185-3958

  Query Match             0.9%;  Score 16;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 77;
  Matches   16;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1160 AAGGCTTCCAGCTGGA 1175
             ||||||||||||||||
Db          1 AAGGCTTCCAGCTGGA 16


RESULT 17
US-10-261-185-3959/c
; Sequence 3959, Application US/10261185
; Publication No. US20040014057A1
; GENERAL INFORMATION:
;  APPLICANT: Kmiec, Eric B.
;  APPLICANT:  Gamper, Howard B.
;  APPLICANT:  Rice, Michael C.
;  TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
;  TITLE OF INVENTION:  Stranded Oligonucleotides
;  FILE REFERENCE: NaPro-4CON
;  CURRENT APPLICATION NUMBER: US/10/261,185
;  CURRENT FILING DATE:  2002-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/09761
;  PRIOR FILING DATE: 2001-03-27
;  PRIOR APPLICATION NUMBER: US 60/192,176
;  PRIOR FILING DATE: 2000-03-27
;  PRIOR APPLICATION NUMBER: US 60/192,179
;  PRIOR FILING DATE: 2000-03-27
;  PRIOR APPLICATION NUMBER: US 60/208,538
;  PRIOR FILING DATE: 2000-06-01
;  PRIOR APPLICATION NUMBER: US 60/244,989
;  PRIOR FILING DATE: 2000-10-30
;  NUMBER OF SEQ ID NOS: 4385
;  SOFTWARE: Friedman macro Napro4
; SEQ ID NO 3959
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-261-185-3959

  Query Match             0.9%;  Score 16;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 77;
  Matches   16;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1160 AAGGCTTCCAGCTGGA 1175
             ||||||||||||||||
Db         17 AAGGCTTCCAGCTGGA 2


RESULT 18
US-10-681-074-3958
; Sequence 3958, Application US/10681074
; Publication No. US20040175722A1
; GENERAL INFORMATION:
;  APPLICANT: KMIEC, ERIC B.
;  APPLICANT:  VAN BRABANT, ANJA
;  TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR REDUCING SCREENING IN
;  TITLE OF INVENTION:  OLIGONUCLEOTIDE-DIRECTED NUCLEIC ACID SEQUENCE ALTERATION
;  FILE REFERENCE: NaPro-18 US
;  CURRENT APPLICATION NUMBER: US/10/681,074
;  CURRENT FILING DATE:  2003-10-07
;  PRIOR APPLICATION NUMBER: US 60/453,360
;  PRIOR FILING DATE: 2003-03-07
;  PRIOR APPLICATION NUMBER: US 60/416,983
;  PRIOR FILING DATE: 2002-10-07
;  NUMBER OF SEQ ID NOS: 4375
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 3958
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-681-074-3958

  Query Match             0.9%;  Score 16;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 77;
  Matches   16;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1160 AAGGCTTCCAGCTGGA 1175
             ||||||||||||||||
Db          1 AAGGCTTCCAGCTGGA 16


RESULT 19
US-10-681-074-3959/c
; Sequence 3959, Application US/10681074
; Publication No. US20040175722A1
; GENERAL INFORMATION:
;  APPLICANT: KMIEC, ERIC B.
;  APPLICANT:  VAN BRABANT, ANJA
;  TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR REDUCING SCREENING IN
;  TITLE OF INVENTION:  OLIGONUCLEOTIDE-DIRECTED NUCLEIC ACID SEQUENCE ALTERATION
;  FILE REFERENCE: NaPro-18 US
;  CURRENT APPLICATION NUMBER: US/10/681,074
;  CURRENT FILING DATE:  2003-10-07
;  PRIOR APPLICATION NUMBER: US 60/453,360
;  PRIOR FILING DATE: 2003-03-07
;  PRIOR APPLICATION NUMBER: US 60/416,983
;  PRIOR FILING DATE: 2002-10-07
;  NUMBER OF SEQ ID NOS: 4375
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 3959
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-681-074-3959

  Query Match             0.9%;  Score 16;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 77;
  Matches   16;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1160 AAGGCTTCCAGCTGGA 1175
             ||||||||||||||||
Db         17 AAGGCTTCCAGCTGGA 2


RESULT 20
US-10-148-355A-10/c
; Sequence 10, Application US/10148355A
; Publication No. US20030207831A1
; GENERAL INFORMATION:
;  APPLICANT: Brett P. Monia
;  APPLICANT:  Lex M. Cowsert
;  APPLICANT:  ISIS PHARMACEUTICALS, INC.
;  TITLE OF INVENTION: ANTISENSE MODULATION OF TELOMERIC REPEAT BINDING FACTOR 2
```

```
;  TITLE OF INVENTION:  EXPRESSION
;  FILE REFERENCE: RTSP-0082
;  CURRENT APPLICATION NUMBER: US/10/148,355A
;  CURRENT FILING DATE:  2002-09-30
;  PRIOR APPLICATION NUMBER: 09/467,642
;  PRIOR FILING DATE: 1999-12-17
;  NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 10
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-10-148-355A-10

  Query Match             0.9%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 87;
  Matches   16;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         19 GAATTCGGCACGAGGG 34
              ||||||||||||||||
Db         19 GAATTCGGCACGAGGG 4


RESULT 21
US-09-776-479-60
; Sequence 60, Application US/09776479
; Publication No. US20030087848A1
; GENERAL INFORMATION:
;  APPLICANT: Bratzler, Robert L.
;  APPLICANT:  Petersen, Deanna M.
;  APPLICANT:  Fouron, Yves
;  TITLE OF INVENTION: Immunostimulatory Nucleic Acids for the
;  TITLE OF INVENTION:  Treatment of Asthma and Allergy
;  FILE REFERENCE: C1037/7013 (HCL/MAT)
;  CURRENT APPLICATION NUMBER: US/09/776,479
;  CURRENT FILING DATE:  2001-02-02
;  PRIOR APPLICATION NUMBER: US 60/179,991
;  PRIOR FILING DATE: 2000-02-03
;  NUMBER OF SEQ ID NOS: 1093
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 60
;   LENGTH: 24
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic Sequence
US-09-776-479-60

  Query Match             0.9%;  Score 16;  DB 1;  Length 24;
  Best Local Similarity   79.2%;  Pred. No. 1e+02;
  Matches   19;  Conservative    0;  Mismatches    5;  Indels    0;  Gaps    0;

Qy       1386 TTGTTTGTTTTGTATCTTGTTTTT 1409
              |||||| |||  | | ||||||||
Db          1 TTGTTTTTTTGTTTTTTTGTTTTT 24


RESULT 22
US-09-776-479-60
; Sequence 60, Application US/09776479
; Publication No. US20040067902A9
; GENERAL INFORMATION:
;  APPLICANT: Bratzler, Robert L.
;  APPLICANT:  Petersen, Deanna M.
;  APPLICANT:  Fouron, Yves
;  TITLE OF INVENTION: Immunostimulatory Nucleic Acids for the
;  TITLE OF INVENTION:  Treatment of Asthma and Allergy
;  FILE REFERENCE: C1037/7013 (HCL/MAT)
;  CURRENT APPLICATION NUMBER: US/09/776,479
;  CURRENT FILING DATE:  2001-02-02
;  PRIOR APPLICATION NUMBER: US 60/179,991
;  PRIOR FILING DATE: 2000-02-03
;  NUMBER OF SEQ ID NOS: 1093
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 60
;   LENGTH: 24
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic Sequence
US-09-776-479-60

  Query Match             0.9%;  Score 16;  DB 1;  Length 24;
  Best Local Similarity   79.2%;  Pred. No. 1e+02;
  Matches   19;  Conservative    0;  Mismatches    5;  Indels    0;  Gaps    0;

Qy       1386 TTGTTTGTTTTGTATCTTGTTTTT 1409
              |||||| |||  | | ||||||||
Db          1 TTGTTTTTTTGTTTTTTTGTTTTT 24


RESULT 23
US-10-112-653-54
; Sequence 54, Application US/10112653
; Publication No. US20030050268A1
; GENERAL INFORMATION:
;  APPLICANT: Krieg, Arthur M.
;  APPLICANT:  Berg, Daniel J.
;  TITLE OF INVENTION: IMMUNOSTIMULATORY NUCLEIC ACID FOR
;  TITLE OF INVENTION:  TREATMENT OF NON-ALLERGIC INFLAMMATORY DISEASES
;  FILE REFERENCE: C01039/70060(AWS)
;  CURRENT APPLICATION NUMBER: US/10/112,653
;  CURRENT FILING DATE:  2002-03-29
;  PRIOR APPLICATION NUMBER: US 60/279,642
;  PRIOR FILING DATE: 2001-03-29
;  NUMBER OF SEQ ID NOS: 1040
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 54
;   LENGTH: 24
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic Oligonucleotide
US-10-112-653-54

  Query Match             0.9%;  Score 16;  DB 1;  Length 24;
  Best Local Similarity   79.2%;  Pred. No. 1e+02;
  Matches   19;  Conservative    0;  Mismatches    5;  Indels    0;  Gaps    0;

Qy       1386 TTGTTTGTTTTGTATCTTGTTTTT 1409
              |||||| |||  | | ||||||||
Db          1 TTGTTTTTTTGTTTTTTTGTTTTT 24


RESULT 24
US-10-017-995-60
; Sequence 60, Application US/10017995
; Publication No. US20030055014A1
; GENERAL INFORMATION:
;  APPLICANT: Bratzler, Robert L.
;  TITLE OF INVENTION: Inhibition of Angiogenesis by Nucleic Acids
;  FILE REFERENCE: C1037/7025 (HCL/MAT)
;  CURRENT APPLICATION NUMBER: US/10/017,995
;  CURRENT FILING DATE:  2001-12-18
;  PRIOR APPLICATION NUMBER: US 60/255,534
;  PRIOR FILING DATE: 2000-12-14
;  NUMBER OF SEQ ID NOS: 1093
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 60
;   LENGTH: 24
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic Sequence
US-10-017-995-60
```

Query Match 0.9%; Score 16; DB 1; Length 24;
Best Local Similarity 79.2%; Pred. No. 1e+02;
Matches 19; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

Qy 1386 TTGTTTGTTTTGTATCTTGTTTTT 1409
||||||||| | | ||||||||
Db 1 TTGTTTTTTTGTTTTTTTGTTTTT 24

RESULT 25
US-10-314-578-60
; Sequence 60, Application US/10314578
; Publication No. US20030212026A1
; GENERAL INFORMATION:
; APPLICANT: Krieg, Arthur M.
; APPLICANT: Schetter, Christian
; APPLICANT: Vollmer, Jorg
; TITLE OF INVENTION: Immunostimulatory Nucleic Acids
; FILE REFERENCE: C1039/7035 (HCL/MAT)
; CURRENT APPLICATION NUMBER: US/10/314,578
; CURRENT FILING DATE: 2002-12-09
; PRIOR APPLICATION NUMBER: US 60/156,113
; PRIOR FILING DATE: 1999-09-25
; PRIOR APPLICATION NUMBER: US 60/156,135
; PRIOR FILING DATE: 1999-09-27
; PRIOR APPLICATION NUMBER: US 60/227,436
; PRIOR FILING DATE: 2000-08-23
; NUMBER OF SEQ ID NOS: 1145
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 60
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Sequence
US-10-314-578-60

Query Match 0.9%; Score 16; DB 1; Length 24;
Best Local Similarity 79.2%; Pred. No. 1e+02;
Matches 19; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

Qy 1386 TTGTTTGTTTTGTATCTTGTTTTT 1409
||||||||| | | ||||||||
Db 1 TTGTTTTTTTGTTTTTTTGTTTTT 24

RESULT 26
US-10-309-775A-26
; Sequence 26, Application US/10309775A
; Publication No. US20040006032A1
; GENERAL INFORMATION:
; APPLICANT: LOPEZ, Ricardo A.
; TITLE OF INVENTION: IMMUNOSTIMULATORY OLIGONUCLEOTIDES AND USES THEREOF
; FILE REFERENCE: 2901/0M327
; CURRENT APPLICATION NUMBER: US/10/309,775A
; CURRENT FILING DATE: 2002-12-04
; PRIOR APPLICATION NUMBER: CA 2,388,049
; PRIOR FILING DATE: 2002-05-30
; NUMBER OF SEQ ID NOS: 74
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 26
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PCR primer
US-10-309-775A-26

Query Match 0.9%; Score 16; DB 1; Length 24;
Best Local Similarity 79.2%; Pred. No. 1e+02;
Matches 19; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

Qy 1386 TTGTTTGTTTTGTATCTTGTTTTT 1409
|| ||| |||| || ||||||||
Db 1 TTTTTTTTTTTTCATTTGTTTTT 24

RESULT 27
US-10-309-775A-73
; Sequence 73, Application US/10309775A
; Publication No. US20040006032A1
; GENERAL INFORMATION:
; APPLICANT: LOPEZ, Ricardo A.
; TITLE OF INVENTION: IMMUNOSTIMULATORY OLIGONUCLEOTIDES AND USES THEREOF
; FILE REFERENCE: 2901/0M327
; CURRENT APPLICATION NUMBER: US/10/309,775A
; CURRENT FILING DATE: 2002-12-04
; PRIOR APPLICATION NUMBER: CA 2,388,049
; PRIOR FILING DATE: 2002-05-30
; NUMBER OF SEQ ID NOS: 74
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 73
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PCR primer
US-10-309-775A-73

Query Match 0.9%; Score 16; DB 1; Length 24;
Best Local Similarity 79.2%; Pred. No. 1e+02;
Matches 19; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

Qy 1386 TTGTTTGTTTTGTATCTTGTTTTT 1409
|| ||| |||| || ||||||||
Db 1 TTTTTTTTTTTTCATTTGTTTTT 24

RESULT 28
US-09-997-931-5/c
; Sequence 5, Application US/09997931
; Publication No. US20030087241A1
; GENERAL INFORMATION:
; APPLICANT: University of Rochester
; APPLICANT: Kool, Eric
; TITLE OF INVENTION: CIRCULAR DNA VECTORS FOR SYNTHESIS OF RNA AND DNA
; FILE REFERENCE: 220.00010142
; CURRENT APPLICATION NUMBER: US/09/997,931
; CURRENT FILING DATE: 2001-11-30
; PRIOR APPLICATION NUMBER: US 09/569,344
; PRIOR FILING DATE: 2000-05-11
; PRIOR APPLICATION NUMBER: US 08/805,631
; PRIOR FILING DATE: 1997-02-26
; PRIOR APPLICATION NUMBER: US 08/393,439
; PRIOR FILING DATE: 1995-02-23
; PRIOR APPLICATION NUMBER: US 08/047,860
; PRIOR FILING DATE: 1993-04-15
; NUMBER OF SEQ ID NOS: 129
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 5
; LENGTH: 26
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: circular template
US-09-997-931-5

Query Match 0.9%; Score 16; DB 1; Length 26;
Best Local Similarity 79.2%; Pred. No. 1.1e+02;
Matches 19; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

Qy 1386 TTGTTTGTTTTGTATCTTGTTTTT 1409
|| ||| |||||| | || |||||
Db 25 TTTTTTTTTTTGTTTTTTTTTTT 2

```
RESULT 29
US-10-102-720-18
; Sequence 18, Application US/10102720
; Publication No. US20030152937A1
; GENERAL INFORMATION:
;  APPLICANT: Weindel, Kurt
;  APPLICANT:  Brand, Joachim
;  TITLE OF INVENTION: DNA DETECTION BY MEANS OF A STRAND REASSOCIATION COMPLEX
;  FILE REFERENCE: 101614-00014
;  CURRENT APPLICATION NUMBER: US/10/102,720
;  CURRENT FILING DATE:  2002-03-22
;  PRIOR APPLICATION NUMBER: 09/325,554
;  PRIOR FILING DATE: 1999-06-04
;  NUMBER OF SEQ ID NOS: 18
;  SOFTWARE: Patent-In version 3.1
; SEQ ID NO 18
;   LENGTH: 27
;   TYPE: DNA
;   ORGANISM: Mycobacterium tuberculosis
;   FEATURE:
;   NAME/KEY: misc_signal
;   LOCATION: (27)..(27)
;   OTHER INFORMATION: Y means incorporation of Aminolinker-phosphoramidite subsequently
;   OTHER INFORMATION: estered with 3-O carboxymethyl digoxigenin
US-10-102-720-18

  Query Match             0.9%;  Score 16;  DB 1;  Length 27;
  Best Local Similarity   73.1%;  Pred. No. 1.1e+02;
  Matches   19;  Conservative    1;  Mismatches    6;  Indels    0;  Gaps    0;

Qy       1386 TTGTTTGTTTTGTATCTTGTTTTTCT 1411
              || ||| |||| | | || |||||:|
Db          2 TTTTTTTTTTTTTTTTTTTTTTTYT 27


RESULT 30
US-09-952-464A-27/c
; Sequence 27, Application US/09952464A
; Publication No. US20030077587A1
; GENERAL INFORMATION:
;  APPLICANT: Stone, Edwin M.
;  APPLICANT:  Sheffield, Val C.
;  APPLICANT:  Alward, Wallace L.M.
;  APPLICANT:  Fingert, John
;  TITLE OF INVENTION: GLAUCOMA THERAPEUTICS AND DIAGNOSTICS
;  FILE REFERENCE: 21087.0017U11
;  CURRENT APPLICATION NUMBER: US/09/952,464A
;  CURRENT FILING DATE:  2001-09-12
;  PRIOR APPLICATION NUMBER: 09/473,273
;  PRIOR FILING DATE: 1999-12-28
;  PRIOR APPLICATION NUMBER: 09/461,542
;  PRIOR FILING DATE: 1999-12-15
;  PRIOR APPLICATION NUMBER: 09/366,952
;  PRIOR FILING DATE: 1999-08-04
;  PRIOR APPLICATION NUMBER: 09/056,285
;  PRIOR FILING DATE: 1998-04-07
;  PRIOR APPLICATION NUMBER: 08/822,999
;  PRIOR FILING DATE: 1997-03-21
;  NUMBER OF SEQ ID NOS: 43
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 27
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence; No. US20030077587A1e =
;   OTHER INFORMATION: synthetic construct
US-09-952-464A-27

  Query Match             0.9%;  Score 15.8;  DB 1;  Length 20;
  Best Local Similarity   89.5%;  Pred. No. 94;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        174 GGCACTCTGAGTTCATCAG 192
              || |||||||||||| |||
Db         19 GGGACTCTGAGTTCAGCAG 1


RESULT 31
US-10-149-352-11/c
; Sequence 11, Application US/10149352
; Publication No. US20030105050A1
; GENERAL INFORMATION:
;  APPLICANT: Beri, Rajinder
;  TITLE OF INVENTION: ANTISENSE OLIGONUCLEOTIDES
;  FILE REFERENCE: 06275-254US1
;  CURRENT APPLICATION NUMBER: US/10/149,352
;  CURRENT FILING DATE:  2002-06-10
;  PRIOR APPLICATION NUMBER: PCT/GB00/04741
;  PRIOR FILING DATE: 2000-12-12
;  PRIOR APPLICATION NUMBER: GB 9929487.8
;  PRIOR FILING DATE: 1999-12-15
;  NUMBER OF SEQ ID NOS: 14
;  SOFTWARE: PatentIn Ver. 4.0
; SEQ ID NO 11
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Homo sapiens
;   FEATURE:
;   OTHER INFORMATION: Antisense oligonucleotide
US-10-149-352-11

  Query Match             0.9%;  Score 15.8;  DB 1;  Length 20;
  Best Local Similarity   89.5%;  Pred. No. 94;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        986 GAGGCAGGAGCTGAGGGAC 1004
              ||||| |||||| ||||||
Db         20 GAGGCTGGAGCTCAGGGAC 2


RESULT 32
US-10-279-186-61
; Sequence 61, Application US/10279186
; Publication No. US20030114407A1
; GENERAL INFORMATION:
;  APPLICANT: Brett P. Monia
;  APPLICANT:  Susan M. Freier
;  TITLE OF INVENTION: ANTISENSE MODULATION OF G PROTEIN-COUPLED RECEPTOR
;  TITLE OF INVENTION:  ETBR-LP-2 EXPRESSION
;  FILE REFERENCE: RTS-0346
;  CURRENT APPLICATION NUMBER: US/10/279,186
;  CURRENT FILING DATE:  2002-10-23
;  PRIOR APPLICATION NUMBER: US/10/003,126
;  PRIOR FILING DATE: 2001-12-06
;  NUMBER OF SEQ ID NOS: 87
; SEQ ID NO 61
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-10-279-186-61

  Query Match             0.9%;  Score 15.8;  DB 1;  Length 20;
  Best Local Similarity   89.5%;  Pred. No. 94;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        808 ACTCTCCCTTCCTCCCTGG 826
              ||||| ||||||||||||
Db          2 ACTCTGACTTCCTCCCTGG 20


RESULT 33
US-10-181-874-35/c
```

; Sequence 35, Application US/10181874
; Publication No. US20030212020A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Susan Murray
; APPLICANT: Lex M. Cowsert
; APPLICANT: Jacqueline Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF MACROPHAGE MIGRATION INHIBITORY FACTOR E
; FILE REFERENCE: RTSP-0351
; CURRENT APPLICATION NUMBER: US/10/181,874
; CURRENT FILING DATE: 2002-07-22
; PRIOR APPLICATION NUMBER: 09/489,869
; PRIOR FILING DATE: 2000-01-20
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 35
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-181-874-35

Query Match 0.9%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 94;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 621 GCCTACAGCGAGCCGTGCG 639
| || ||||||||||||||
Db 20 GGCTCCAGCGAGCCGTGCG 2

RESULT 34
US-10-289-762-3718
; Sequence 3718, Application US/10289762
; Publication No. US20040006218A1
; GENERAL INFORMATION:
; APPLICANT: Griffais, R.
; TITLE OF INVENTION: Chlamydia pneumoniae genomic sequence and polypeptides, fragments
; TITLE OF INVENTION: thereof and uses thereof, in particular for the diagnosis, preve
; TITLE OF INVENTION: and treatment of infection
; FILE REFERENCE: 9710-003-999
; CURRENT APPLICATION NUMBER: US/10/289,762
; CURRENT FILING DATE: 2003-03-27
; NUMBER OF SEQ ID NOS: 6849
; SEQ ID NO 3718
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Chlamydia pneumoniae
US-10-289-762-3718

Query Match 0.9%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 94;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 825 GGCTTCAGCCAGTCCCTGA 843
||| ||||||| |||||||
Db 2 GGCGTCAGCCAATCCCTGA 20

RESULT 35
US-10-712-795-442/c
; Sequence 442, Application US/10712795
; Publication No. US20040214325A1
; GENERAL INFORMATION:
; APPLICANT: Crooke et al.
; TITLE OF INVENTION: ANTISENSE MODULATION OF APOLIPOPROTEIN B EXPRESSION
; FILE REFERENCE: 30566/39662
; CURRENT APPLICATION NUMBER: US/10/712,795
; CURRENT FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US 60/426,234
; PRIOR FILING DATE: 2002-11-13
; PRIOR APPLICATION NUMBER: PCT/US03/15493
; PRIOR FILING DATE: 2003-05-13
; NUMBER OF SEQ ID NOS: 892
; SEQ ID NO 442
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-712-795-442

Query Match 0.9%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 94;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 574 TGCCTAGCCAGTTGGTAAG 592
||||||||||||| | |||
Db 20 TGCCTAGCCAGTTTGAAAG 2

RESULT 36
US-10-712-795-765
; Sequence 765, Application US/10712795
; Publication No. US20040214325A1
; GENERAL INFORMATION:
; APPLICANT: Crooke et al.
; TITLE OF INVENTION: ANTISENSE MODULATION OF APOLIPOPROTEIN B EXPRESSION
; FILE REFERENCE: 30566/39662
; CURRENT APPLICATION NUMBER: US/10/712,795
; CURRENT FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US 60/426,234
; PRIOR FILING DATE: 2002-11-13
; PRIOR APPLICATION NUMBER: PCT/US03/15493
; PRIOR FILING DATE: 2003-05-13
; NUMBER OF SEQ ID NOS: 892
; SEQ ID NO 765
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
US-10-712-795-765

Query Match 0.9%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 94;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 574 TGCCTAGCCAGTTGGTAAG 592
||||||||||||| | |||
Db 1 TGCCTAGCCAGTTTGAAAG 19

RESULT 37
US-10-786-720-7030
; Sequence 7030, Application US/10786720
; Publication No. US20040191818A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: O'Toole, Margot
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
; TITLE OF INVENTION: DISEASES
; FILE REFERENCE: 031896-023000 (AM101331L)
; CURRENT APPLICATION NUMBER: US/10/786,720
; CURRENT FILING DATE: 2004-02-26
; NUMBER OF SEQ ID NOS: 21135
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 7030
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-786-720-7030

Query Match 0.9%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 98;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy        362 CCTGGAGAGCTCGGACTGC 380
              |||||||| | ||||||||
Db          3 CCTGGAGATCACGGACTGC 21


RESULT 38
US-10-786-720-7031
; Sequence 7031, Application US/10786720
; Publication No. US20040191818A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  O'Toole, Margot
;  APPLICANT:  Liu, Wei
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
;  TITLE OF INVENTION:  DISEASES
;  FILE REFERENCE: 031896-023000 (AM101331L)
;  CURRENT APPLICATION NUMBER: US/10/786,720
;  CURRENT FILING DATE:  2004-02-26
;  NUMBER OF SEQ ID NOS: 21135
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 7031
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: RNAi-sense strand
US-10-786-720-7031

  Query Match             0.9%;  Score 15.8;  DB 1;  Length 21;
  Best Local Similarity   78.9%;  Pred. No. 98;
  Matches   15;  Conservative    2;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        362 CCTGGAGAGCTCGGACTGC 380
              ||:||||| | |||||:||
Db          1 CCUGGAGAUCACGGACUGC 19


RESULT 39
US-10-786-720-9298
; Sequence 9298, Application US/10786720
; Publication No. US20040191818A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  O'Toole, Margot
;  APPLICANT:  Liu, Wei
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
;  TITLE OF INVENTION:  DISEASES
;  FILE REFERENCE: 031896-023000 (AM101331L)
;  CURRENT APPLICATION NUMBER: US/10/786,720
;  CURRENT FILING DATE:  2004-02-26
;  NUMBER OF SEQ ID NOS: 21135
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 9298
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-786-720-9298

  Query Match             0.9%;  Score 15.8;  DB 1;  Length 21;
  Best Local Similarity   89.5%;  Pred. No. 98;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        362 CCTGGAGAGCTCGGACTGC 380
              |||||||| | ||||||||
Db          3 CCTGGAGATCACGGACTGC 21


RESULT 40
US-10-786-720-9299
; Sequence 9299, Application US/10786720
; Publication No. US20040191818A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  O'Toole, Margot
;  APPLICANT:  Liu, Wei
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
;  TITLE OF INVENTION:  DISEASES
;  FILE REFERENCE: 031896-023000 (AM101331L)
;  CURRENT APPLICATION NUMBER: US/10/786,720
;  CURRENT FILING DATE:  2004-02-26
;  NUMBER OF SEQ ID NOS: 21135
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 9299
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: RNAi-sense strand
US-10-786-720-9299

  Query Match             0.9%;  Score 15.8;  DB 1;  Length 21;
  Best Local Similarity   78.9%;  Pred. No. 98;
  Matches   15;  Conservative    2;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        362 CCTGGAGAGCTCGGACTGC 380
              ||:||||| | |||||:||
Db          1 CCUGGAGAUCACGGACUGC 19


RESULT 41
US-09-888-326-842
; Sequence 842, Application US/09888326
; Publication No. US20030026801A1
; GENERAL INFORMATION:
;  APPLICANT: Weiner, George
;  APPLICANT:  Hartmann, Gunther
;  TITLE OF INVENTION: Methods for Enhancing Antibody-Induced
;  TITLE OF INVENTION:  Cell Lysis and Treating Cancer
;  FILE REFERENCE: C1039/7052 (AWS)
;  CURRENT APPLICATION NUMBER: US/09/888,326
;  CURRENT FILING DATE:  2001-06-22
;  PRIOR APPLICATION NUMBER: US 60/213,346
;  PRIOR FILING DATE: 2000-06-22
;  NUMBER OF SEQ ID NOS: 848
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 842
;   LENGTH: 27
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic oligonucleotide
;   NAME/KEY: misc_feature
;   LOCATION: (0)...(0)
;   OTHER INFORMATION: phosphorothioate backbone
US-09-888-326-842

  Query Match             0.9%;  Score 15.8;  DB 1;  Length 27;
  Best Local Similarity   74.1%;  Pred. No. 1.2e+02;
  Matches   20;  Conservative    0;  Mismatches    7;  Indels    0;  Gaps    0;

Qy       1382 TTTGTTGTTTGTTTTGTATCTTGTTTT 1408
              ||| || ||| |||| | | || ||||
Db          1 TTTTTTTTTTTTTTTTTTTTTTTTTTT 27


RESULT 42
US-09-776-479-911
; Sequence 911, Application US/09776479
; Publication No. US20030087848A1
; GENERAL INFORMATION:
;  APPLICANT: Bratzler, Robert L.
;  APPLICANT:  Petersen, Deanna M.
;  APPLICANT:  Fouron, Yves
;  TITLE OF INVENTION: Immunostimulatory Nucleic Acids for the
;  TITLE OF INVENTION:  Treatment of Asthma and Allergy
;  FILE REFERENCE: C1037/7013 (HCL/MAT)
;  CURRENT APPLICATION NUMBER: US/09/776,479
;  CURRENT FILING DATE:  2001-02-02
;  PRIOR APPLICATION NUMBER: US 60/179,991
;  PRIOR FILING DATE: 2000-02-03
```

; NUMBER OF SEQ ID NOS: 1093
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 911
; LENGTH: 27
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Sequence
US-09-776-479-911

Query Match 0.9%; Score 15.8; DB 1; Length 27;
Best Local Similarity 74.1%; Pred. No. 1.2e+02;
Matches 20; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

Qy 1382 TTTGTTGTTTGTTTTGTATCTTGTTTT 1408
||| || ||| |||| | | || ||||
Db 1 TTTTTTTTTTTTTTTTTTTTTTTTTTT 27

RESULT 43
US-09-776-479-911
; Sequence 911, Application US/09776479
; Publication No. US20040067902A9
; GENERAL INFORMATION:
; APPLICANT: Bratzler, Robert L.
; APPLICANT: Petersen, Deanna M.
; APPLICANT: Fouron, Yves
; TITLE OF INVENTION: Immunostimulatory Nucleic Acids for the
; TITLE OF INVENTION: Treatment of Asthma and Allergy
; FILE REFERENCE: C1037/7013 (HCL/MAT)
; CURRENT APPLICATION NUMBER: US/09/776,479
; CURRENT FILING DATE: 2001-02-02
; PRIOR APPLICATION NUMBER: US 60/179,991
; PRIOR FILING DATE: 2000-02-03
; NUMBER OF SEQ ID NOS: 1093
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 911
; LENGTH: 27
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Sequence
US-09-776-479-911

Query Match 0.9%; Score 15.8; DB 1; Length 27;
Best Local Similarity 74.1%; Pred. No. 1.2e+02;
Matches 20; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

Qy 1382 TTTGTTGTTTGTTTTGTATCTTGTTTT 1408
||| || ||| |||| | | || ||||
Db 1 TTTTTTTTTTTTTTTTTTTTTTTTTTT 27

RESULT 44
US-10-112-653-880
; Sequence 880, Application US/10112653
; Publication No. US20030050268A1
; GENERAL INFORMATION:
; APPLICANT: Krieg, Arthur M.
; APPLICANT: Berg, Daniel J.
; TITLE OF INVENTION: IMMUNOSTIMULATORY NUCLEIC ACID FOR
; TITLE OF INVENTION: TREATMENT OF NON-ALLERGIC INFLAMMATORY DISEASES
; FILE REFERENCE: C01039/70060(AWS)
; CURRENT APPLICATION NUMBER: US/10/112,653
; CURRENT FILING DATE: 2002-03-29
; PRIOR APPLICATION NUMBER: US 60/279,642
; PRIOR FILING DATE: 2001-03-29
; NUMBER OF SEQ ID NOS: 1040
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 880
; LENGTH: 27
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Oligonucleotide
US-10-112-653-880

Query Match 0.9%; Score 15.8; DB 1; Length 27;
Best Local Similarity 74.1%; Pred. No. 1.2e+02;
Matches 20; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

Qy 1382 TTTGTTGTTTGTTTTGTATCTTGTTTT 1408
||| || ||| |||| | | || ||||
Db 1 TTTTTTTTTTTTTTTTTTTTTTTTTTT 27

RESULT 45
US-10-017-995-911
; Sequence 911, Application US/10017995
; Publication No. US20030055014A1
; GENERAL INFORMATION:
; APPLICANT: Bratzler, Robert L.
; TITLE OF INVENTION: Inhibition of Angiogenesis by Nucleic Acids
; FILE REFERENCE: C1037/7025 (HCL/MAT)
; CURRENT APPLICATION NUMBER: US/10/017,995
; CURRENT FILING DATE: 2001-12-18
; PRIOR APPLICATION NUMBER: US 60/255,534
; PRIOR FILING DATE: 2000-12-14
; NUMBER OF SEQ ID NOS: 1093
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 911
; LENGTH: 27
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Sequence
US-10-017-995-911

Query Match 0.9%; Score 15.8; DB 1; Length 27;
Best Local Similarity 74.1%; Pred. No. 1.2e+02;
Matches 20; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

Qy 1382 TTTGTTGTTTGTTTTGTATCTTGTTTT 1408
||| || ||| |||| | | || ||||
Db 1 TTTTTTTTTTTTTTTTTTTTTTTTTTT 27

RESULT 46
US-10-314-578-911
; Sequence 911, Application US/10314578
; Publication No. US20030212026A1
; GENERAL INFORMATION:
; APPLICANT: Krieg, Arthur M.
; APPLICANT: Schetter, Christian
; APPLICANT: Vollmer, Jorg
; TITLE OF INVENTION: Immunostimulatory Nucleic Acids
; FILE REFERENCE: C1039/7035 (HCL/MAT)
; CURRENT APPLICATION NUMBER: US/10/314,578
; CURRENT FILING DATE: 2002-12-09
; PRIOR APPLICATION NUMBER: US 60/156,113
; PRIOR FILING DATE: 1999-09-25
; PRIOR APPLICATION NUMBER: US 60/156,135
; PRIOR FILING DATE: 1999-09-27
; PRIOR APPLICATION NUMBER: US 60/227,436
; PRIOR FILING DATE: 2000-08-23
; NUMBER OF SEQ ID NOS: 1145
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 911
; LENGTH: 27
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Sequence
US-10-314-578-911

Query Match 0.9%; Score 15.8; DB 1; Length 27;

```
  Best Local Similarity   74.1%;  Pred. No. 1.2e+02;
  Matches   20;  Conservative    0;  Mismatches    7;  Indels    0;  Gaps    0;

Qy       1382 TTTGTTGTTTGTTTTGTATCTTGTTTT 1408
              ||| || ||| |||| | | || ||||
Db          1 TTTTTTTTTTTTTTTTTTTTTTTTTTT 27


RESULT 47
US-10-407-818-3
; Sequence 3, Application US/10407818
; Publication No. US20040198971A1
; GENERAL INFORMATION:
;  APPLICANT: RABBANI, ELAZAR
;  APPLICANT:  STAVRIANOPOULOS, JANNIS G.
;  APPLICANT:  DONEGAN, JAMES J.
;  TITLE OF INVENTION: MULTISIGNAL LABELING REAGENTS, AND PROCESSES AND USES
;  TITLE OF INVENTION:  THEREFOR
;  FILE REFERENCE: ENZ-65
;  CURRENT APPLICATION NUMBER: US/10/407,818
;  CURRENT FILING DATE:  2003-04-03
;  NUMBER OF SEQ ID NOS: 16
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 3
;    LENGTH: 27
;    TYPE: DNA
;    ORGANISM: Artificial Sequence
;    FEATURE:
;    OTHER INFORMATION: Description of Combined DNA/RNA Molecule:
;    OTHER INFORMATION: Synthetic oligonucleotide
;    FEATURE:
;    OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;    OTHER INFORMATION: oligonucleotide
US-10-407-818-3

  Query Match             0.9%;  Score 15.8;  DB 1;  Length 27;
  Best Local Similarity   59.3%;  Pred. No. 1.2e+02;
  Matches   16;  Conservative    4;  Mismatches    7;  Indels    0;  Gaps    0;

Qy       1382 TTTGTTGTTTGTTTTGTATCTTGTTTT 1408
              :|| || ||| |:|| | : || |:||
Db          1 UTTTTTUTTTTTUTTTTTUTTTTTUTT 27


RESULT 48
US-08-865-579-5
; Sequence 5, Application US/08865579
; Publication No. US20010006779A1
;  GENERAL INFORMATION:
;     APPLICANT:  Alnemri, Emad S.
;     APPLICANT:  Fernandes-Alnemri, Teresa
;     APPLICANT:  Litwack, Gerald
;     TITLE OF INVENTION:  Apoptotic Protease Mch6, Nucleic Acids
;     TITLE OF INVENTION:  Encoding Same and Methods of Use
;     NUMBER OF SEQUENCES:  87
;     CORRESPONDENCE ADDRESS:
;       ADDRESSEE:  Campbell & Flores LLP
;       STREET:  4370 La Jolla Village Drive, Suite 700
;       CITY:  San Diego
;       STATE:  California
;       COUNTRY:  United States
;       ZIP:  92122
;     COMPUTER READABLE FORM:
;       MEDIUM TYPE:  Floppy disk
;       COMPUTER:  IBM PC compatible
;       OPERATING SYSTEM:  PC-DOS/MS-DOS
;       SOFTWARE:  PatentIn Release #1.0, Version #1.25
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  US/08/865,579
;       FILING DATE:  29-MAY-1997
;       CLASSIFICATION:  435
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Campbell, Cathryn A.
;       REGISTRATION NUMBER:  31,815
;       REFERENCE/DOCKET NUMBER:  P-ID 2180
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  (619) 535-9001
;       TELEFAX:  (619) 535-9849
;   INFORMATION FOR SEQ ID NO:  5:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  17 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
;     MOLECULE TYPE:  cDNA
US-08-865-579-5

  Query Match             0.9%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   94.1%;  Pred. No. 98;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         16 CAAGAATTCGGCACGAG 32
              || ||||||||||||||
Db          1 CAGGAATTCGGCACGAG 17


RESULT 49
US-09-746-731-5
; Sequence 5, Application US/09746731
; Publication No. US20010016345A1
;   GENERAL INFORMATION:
;        APPLICANT: Alnemri, Emad S.
;                   Fernandes-Alnemri, Teresa
;                   Litwack, Gerald
;        TITLE OF INVENTION: Apoptotic Protease Mch6, Nucleic Acids
;                            Encoding Same and Methods of Use
;        NUMBER OF SEQUENCES: 87
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: Campbell & Flores LLP
;             STREET: 4370 La Jolla Village Drive, Suite 700
;             CITY: San Diego
;             STATE: California
;             COUNTRY: United States
;             ZIP: 92122
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: Floppy disk
;             COMPUTER: IBM PC compatible
;             OPERATING SYSTEM: PC-DOS/MS-DOS
;             SOFTWARE: PatentIn Release #1.0, Version #1.25
;        CURRENT APPLICATION DATA:
;             APPLICATION NUMBER: US/09/746,731
;             FILING DATE: 22-Dec-2000
;             CLASSIFICATION: <Unknown>
;        PRIOR APPLICATION DATA:
;             APPLICATION NUMBER: US/08/865,579
;             FILING DATE: 29-MAY-1997
;        ATTORNEY/AGENT INFORMATION:
;             NAME: Campbell, Cathryn A.
;             REGISTRATION NUMBER: 31,815
;             REFERENCE/DOCKET NUMBER: P-ID 2180
;        TELECOMMUNICATION INFORMATION:
;             TELEPHONE: (619) 535-9001
;             TELEFAX: (619) 535-9849
;   INFORMATION FOR SEQ ID NO: 5:
;        SEQUENCE CHARACTERISTICS:
;             LENGTH: 17 base pairs
;             TYPE: nucleic acid
;             STRANDEDNESS: single
;             TOPOLOGY: linear
;        MOLECULE TYPE: cDNA
;        SEQUENCE DESCRIPTION: SEQ ID NO: 5:
US-09-746-731-5

  Query Match             0.9%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   94.1%;  Pred. No. 98;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;
```

```
Qy          16 CAAGAATTCGGCACGAG 32
               || |||||||||||||||
Db           1 CAGGAATTCGGCACGAG 17


RESULT 50
US-09-952-768-6
; Sequence 6, Application US/09952768
; Patent No. US20020035242A1
;   GENERAL INFORMATION:
;        APPLICANT: Alnemri, Emad S.
;                   Fernandes-Alnemri, Teresa
;                   Litwack, Gerald
;                   Armstrong, Robert
;                   Tomaselli, Kevin
;        TITLE OF INVENTION: MCH4 AND MCH5, APOPTOTIC PROTEASE,
;                            NUCLEIC ACIDS ENCODING AND METHODS OF USE
;        NUMBER OF SEQUENCES: 75
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: Seed Intellectual Property Law Group
;             STREET: Suite 6300, 701 Fifth Avenue
;             CITY: Seattle
;             STATE: Washington
;             COUNTRY: USA
;             ZIP: 98104
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: Floppy disk
;             COMPUTER: IBM PC compatible
;             OPERATING SYSTEM: PC-DOS/MS-DOS
;             SOFTWARE: PatentIn Release #1.0, Version #1.30
;        CURRENT APPLICATION DATA:
;             APPLICATION NUMBER: US/09/952,768
;             FILING DATE: 10-Sep-2001
;             CLASSIFICATION: <Unknown>
;        ATTORNEY/AGENT INFORMATION:
;             NAME: Christiansen, William T.
;             REGISTRATION NUMBER: 44,614
;             REFERENCE/DOCKET NUMBER: 480140.424C4
;        TELECOMMUNICATION INFORMATION:
;             TELEPHONE: (206) 622-4900
;             TELEFAX: (206) 682-6031
;   INFORMATION FOR SEQ ID NO: 6:
;        SEQUENCE CHARACTERISTICS:
;             LENGTH: 17 base pairs
;             TYPE: nucleic acid
;             STRANDEDNESS: single
;             TOPOLOGY: linear
;        FEATURE:
;             NAME/KEY:  misc_feature
;             LOCATION:  1..17
;             OTHER INFORMATION:  /note= "SK-Zap"
;        SEQUENCE DESCRIPTION: SEQ ID NO: 6:
US-09-952-768-6

  Query Match             0.9%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   94.1%;  Pred. No. 98;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy          16 CAAGAATTCGGCACGAG 32
               || |||||||||||||||
Db           1 CAGGAATTCGGCACGAG 17


RESULT 51
US-09-944-851-6
; Sequence 6, Application US/09944851
; Patent No. US20020102648A1
;   GENERAL INFORMATION:
;        APPLICANT: Alnemri, Emad S.
;                   Fernandes-Alnemri, Teresa
;                   Litwack, Gerald
;                   Armstrong, Robert
;                   Tomaselli, Kevin
;        TITLE OF INVENTION: Mch3, A No. US20020102648A1el Apoptotic Protease,
;                            Nucleic Acids Encoding and Methods of Use
;        NUMBER OF SEQUENCES: 11
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: Campbell and Flores
;             STREET: 4370 La Jolla Village Drive, Suite 700
;             CITY: San Diego
;             STATE: California
;             COUNTRY: USA
;             ZIP: 92122
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: Floppy disk
;             COMPUTER: IBM PC compatible
;             OPERATING SYSTEM: PC-DOS/MS-DOS
;             SOFTWARE: PatentIn Release #1.0, Version #1.25
;        CURRENT APPLICATION DATA:
;             APPLICATION NUMBER: US/09/944,851
;             FILING DATE: 31-Aug-2001
;             CLASSIFICATION: <Unknown>
;        PRIOR APPLICATION DATA:
;             APPLICATION NUMBER: 08/556,627
;             FILING DATE: 13-NOV-1995
;        ATTORNEY/AGENT INFORMATION:
;             NAME: Campbell, Cathryn A.
;             REGISTRATION NUMBER: 31,815
;             REFERENCE/DOCKET NUMBER: P-ID 1813
;        TELECOMMUNICATION INFORMATION:
;             TELEPHONE: (619) 535-9001
;             TELEFAX: (619) 535-8949
;   INFORMATION FOR SEQ ID NO: 6:
;        SEQUENCE CHARACTERISTICS:
;             LENGTH: 17 base pairs
;             TYPE: nucleic acid
;             STRANDEDNESS: single
;             TOPOLOGY: linear
;        SEQUENCE DESCRIPTION: SEQ ID NO: 6:
US-09-944-851-6

  Query Match             0.9%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   94.1%;  Pred. No. 98;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy          16 CAAGAATTCGGCACGAG 32
               || |||||||||||||||
Db           1 CAGGAATTCGGCACGAG 17


RESULT 52
US-09-969-373-2634/c
; Sequence 2634, Application US/09969373
; Patent No. US20020133852A1
; GENERAL INFORMATION:
;  APPLICANT: Effertz, Roger J.
;  APPLICANT:  Hauge, Brian M.
;  TITLE OF INVENTION: Soybean SSRs and Methods of Genotyping
;  FILE REFERENCE: 38-10(52679)A
;  CURRENT APPLICATION NUMBER: US/09/969,373
;  CURRENT FILING DATE:  2001-10-02
;  PRIOR APPLICATION NUMBER: US 09/754,853
;  PRIOR FILING DATE: 2001-01-05
;  PRIOR APPLICATION NUMBER: US 09/760,427
;  PRIOR FILING DATE: 2001-01-13
;  PRIOR APPLICATION NUMBER: US 09/855,768
;  PRIOR FILING DATE: 2001-05-15
;  NUMBER OF SEQ ID NOS: 4593
; SEQ ID NO 2634
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Glycine max
US-09-969-373-2634

  Query Match             0.9%;  Score 15.4;  DB 1;  Length 17;
```

```
  Best Local Similarity   94.1%;  Pred. No. 98;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1525 TTACACCTGGCAGCTGC 1541
              ||||||  ||||||||||
Db         17 TTACACATGGCAGCTGC 1


RESULT 53
US-10-059-749-5
; Sequence 5, Application US/10059749
; Publication No. US20020183504A1
;   GENERAL INFORMATION:
;        APPLICANT: Alnemri, Emad S.
;                   Fernandes-Alnemri, Teresa
;                   Litwack, Gerald
;        TITLE OF INVENTION: Apoptotic Protease Mch6, Nucleic Acids
;                            Encoding Same and Methods of Use
;        NUMBER OF SEQUENCES: 87
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: Campbell & Flores LLP
;             STREET: 4370 La Jolla Village Drive, Suite 700
;             CITY: San Diego
;             STATE: California
;             COUNTRY: United States
;             ZIP: 92122
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: Floppy disk
;             COMPUTER: IBM PC compatible
;             OPERATING SYSTEM: PC-DOS/MS-DOS
;             SOFTWARE: PatentIn Release #1.0, Version #1.25
;        CURRENT APPLICATION DATA:
;             APPLICATION NUMBER: US/10/059,749
;             FILING DATE: 29-Jan-2002
;             CLASSIFICATION: <Unknown>
;        PRIOR APPLICATION DATA:
;             APPLICATION NUMBER: US/08/865,579
;             FILING DATE: 29-MAY-1997
;        ATTORNEY/AGENT INFORMATION:
;             NAME: Campbell, Cathryn A.
;             REGISTRATION NUMBER: 31,815
;             REFERENCE/DOCKET NUMBER: P-ID 2180
;        TELECOMMUNICATION INFORMATION:
;             TELEPHONE: (619) 535-9001
;             TELEFAX: (619) 535-9849
;   INFORMATION FOR SEQ ID NO: 5:
;        SEQUENCE CHARACTERISTICS:
;             LENGTH: 17 base pairs
;             TYPE: nucleic acid
;             STRANDEDNESS: single
;             TOPOLOGY: linear
;        MOLECULE TYPE: cDNA
;        SEQUENCE DESCRIPTION: SEQ ID NO: 5:
US-10-059-749-5

  Query Match             0.9%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   94.1%;  Pred. No. 98;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         16 CAAGAATTCGGCACGAG 32
              || ||||||||||||||
Db          1 CAGGAATTCGGCACGAG 17


RESULT 54
US-10-337-060-6
; Sequence 6, Application US/10337060
; Publication No. US20030119169A1
; GENERAL INFORMATION:
;  APPLICANT: Alnemri, Emad S.
;  APPLICANT:  Fernandez-Alnemri, Teresa
;  APPLICANT:  Litwack, Gerald
;  APPLICANT:  Armstrong, Robert
;  APPLICANT:  Tomaselli, Kevin
;  TITLE OF INVENTION: MCH3, A NOVEL APOPTOTIC PROTEASE,
;  TITLE OF INVENTION:  NUCLEIC ACIDS ENCODING AND METHODS OF USE
;  FILE REFERENCE: 480140.423D2
;  CURRENT APPLICATION NUMBER: US/10/337,060
;  CURRENT FILING DATE:  2003-01-02
;  NUMBER OF SEQ ID NOS: 17
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 6
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Primer SK-Zap
US-10-337-060-6

  Query Match             0.9%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   94.1%;  Pred. No. 98;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         16 CAAGAATTCGGCACGAG 32
              || ||||||||||||||
Db          1 CAGGAATTCGGCACGAG 17


RESULT 55
US-10-668-955-6
; Sequence 6, Application US/10668955
; Publication No. US20040054148A1
;   GENERAL INFORMATION:
;        APPLICANT: Alnemri, Emad S.
;                   Fernandes-Alnemri, Teresa
;                   Litwack, Gerald
;                   Armstrong, Robert
;                   Tomaselli, Kevin
;        TITLE OF INVENTION: MCH4 AND MCH5, APOPTOTIC PROTEASE,
;                            NUCLEIC ACIDS ENCODING AND METHODS OF USE
;        NUMBER OF SEQUENCES: 75
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: Seed Intellectual Property Law Group
;             STREET: Suite 6300, 701 Fifth Avenue
;             CITY: Seattle
;             STATE: Washington
;             COUNTRY: USA
;             ZIP: 98104
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: Floppy disk
;             COMPUTER: IBM PC compatible
;             OPERATING SYSTEM: PC-DOS/MS-DOS
;             SOFTWARE: PatentIn Release #1.0, Version #1.30
;        CURRENT APPLICATION DATA:
;             APPLICATION NUMBER: US/10/668,955
;             FILING DATE: 22-Sep-2003
;             CLASSIFICATION: <Unknown>
;        ATTORNEY/AGENT INFORMATION:
;             NAME: Laherty, Carol D.
;             REGISTRATION NUMBER: 51,909
;             REFERENCE/DOCKET NUMBER: 480140.424D1
;        TELECOMMUNICATION INFORMATION:
;             TELEPHONE: (206) 622-4900
;             TELEFAX: (206) 682-6031
;   INFORMATION FOR SEQ ID NO: 6:
;        SEQUENCE CHARACTERISTICS:
;             LENGTH: 17 base pairs
;             TYPE: nucleic acid
;             STRANDEDNESS: single
;             TOPOLOGY: linear
;        FEATURE:
;             NAME/KEY:  misc_feature
;             LOCATION:  1..17
;             OTHER INFORMATION:  /note= "SK-Zap"
;        SEQUENCE DESCRIPTION: SEQ ID NO: 6:
US-10-668-955-6
```

```
  Query Match             0.9%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   94.1%;  Pred. No. 98;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         16 CAAGAATTCGGCACGAG 32
              || |||||||||||||||
Db          1 CAGGAATTCGGCACGAG 17


RESULT 56
US-10-138-674-3605
; Sequence 3605, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/138,674
;  CURRENT FILING DATE:  2002-05-03
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3605
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Mus musculus
US-10-138-674-3605

  Query Match             0.9%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   17.6%;  Pred. No. 98;
  Matches    3;  Conservative   13;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1382 TTTGTTGTTTGTTTTGT 1398
              :::|:: :::|::::|:
Db          1 UUUGUUUUUUGUUUUGU 17


RESULT 57
US-10-287-949A-3605
; Sequence 3605, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/287,949A
;  CURRENT FILING DATE:  2003-04-11
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3605
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Mus musculus
US-10-287-949A-3605

  Query Match             0.9%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   17.6%;  Pred. No. 98;
  Matches    3;  Conservative   13;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1382 TTTGTTGTTTGTTTTGT 1398
              :::|:: :::|::::|:
Db          1 UUUGUUUUUUGUUUUGU 17


RESULT 58
US-10-297-068-1077/c
; Sequence 1077, Application US/10297068
; Publication No. US20030228585A1
; GENERAL INFORMATION:
;  APPLICANT: INOKO, Hidetoshi
;  APPLICANT:  KAGIYA, Taeko
;  APPLICANT:  ICHIHARA, Tatsuo
;  APPLICANT:  Matsumura, Yoshiyuki
;  APPLICANT:  MORIYA, Shogo
;  APPLICANT:  NISHIDA, Michio
;  TITLE OF INVENTION: KIT AND METHOD FOR DETERMINING HLA TYPES
;  FILE REFERENCE: 1314OP1174
;  CURRENT APPLICATION NUMBER: US/10/297,068
;  CURRENT FILING DATE:  2002-11-27
;  PRIOR APPLICATION NUMBER: JP 2000-164798
;  PRIOR FILING DATE: 2000-06-01
;  NUMBER OF SEQ ID NOS: 1298
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 1077
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:primer
US-10-297-068-1077

  Query Match             0.9%;  Score 15.4;  DB 1;  Length 18;
  Best Local Similarity   94.1%;  Pred. No. 1e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        522 GAGAGCCTGGCCCAGGC 538
              |||| ||||||||||||
Db         18 GAGACCCTGGCCCAGGC 2


RESULT 59
US-09-918-187-30
; Sequence 30, Application US/09918187
; Publication No. US20030083282A1
; GENERAL INFORMATION:
;  APPLICANT: Rosanne M. Crooke
;  APPLICANT:  Mark J. Graham
;  TITLE OF INVENTION: ANTISENSE MODULATION OF STEAROYL-COA DESATURASE EXPRESSION
;  FILE REFERENCE: ISPH-0590
;  CURRENT APPLICATION NUMBER: US/09/918,187
;  CURRENT FILING DATE:  2001-07-30
;  NUMBER OF SEQ ID NOS: 80
; SEQ ID NO 30
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-918-187-30

  Query Match             0.9%;  Score 15.4;  DB 1;  Length 20;
  Best Local Similarity   94.1%;  Pred. No. 1.1e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        469 TCAGTGACCCTGAGGAT 485
              |||||||||||||| ||
Db          1 TCAGTGACCCTGAGCAT 17


RESULT 60
US-10-032-585-4519
; Sequence 4519, Application US/10032585
; Publication No. US20030180953A1
; GENERAL INFORMATION:
;  APPLICANT: Terry, Roemer D.
;  APPLICANT:  Bo, Jiang
```

```
;  APPLICANT:  Charles, Boone
;  APPLICANT:  Howard, Bussey
;  TITLE OF INVENTION: Gene Disruption Methodologies for Drug Target Discovery
;  FILE REFERENCE: 10182-005-999
;  CURRENT APPLICATION NUMBER: US/10/032,585
;  CURRENT FILING DATE:  2001-12-20
;  NUMBER OF SEQ ID NOS: 8000
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 4519
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Candida albicans
US-10-032-585-4519

  Query Match             0.9%;  Score 15.4;  DB 1;  Length 20;
  Best Local Similarity   94.1%;  Pred. No. 1.1e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1044 TGGAGGTGGGGGAATAG 1060
              ||||||||||||| |||
Db          1 TGGAGGTGGGGGAGTAG 17


RESULT 61
US-10-304-103-26/c
; Sequence 26, Application US/10304103
; Publication No. US20040101853A1
; GENERAL INFORMATION:
;  APPLICANT: C. Frank Bennett
;  APPLICANT:  Kenneth W. Dobie
;  TITLE OF INVENTION: MODULATION OF STAT2 EXPRESSION
;  FILE REFERENCE: HTS-0014
;  CURRENT APPLICATION NUMBER: US/10/304,103
;  CURRENT FILING DATE:  2002-11-23
;  NUMBER OF SEQ ID NOS: 82
; SEQ ID NO 26
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-10-304-103-26

  Query Match             0.9%;  Score 15.4;  DB 1;  Length 20;
  Best Local Similarity   94.1%;  Pred. No. 1.1e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        502 ACCTGATGCAGCTGCTG 518
              ||||||||||||||||||
Db         17 ACCTGAGGCAGCTGCTG 1


RESULT 62
US-10-304-103-62
; Sequence 62, Application US/10304103
; Publication No. US20040101853A1
; GENERAL INFORMATION:
;  APPLICANT: C. Frank Bennett
;  APPLICANT:  Kenneth W. Dobie
;  TITLE OF INVENTION: MODULATION OF STAT2 EXPRESSION
;  FILE REFERENCE: HTS-0014
;  CURRENT APPLICATION NUMBER: US/10/304,103
;  CURRENT FILING DATE:  2002-11-23
;  NUMBER OF SEQ ID NOS: 82
; SEQ ID NO 62
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: H. sapiens
;   FEATURE:
US-10-304-103-62

  Query Match             0.9%;  Score 15.4;  DB 1;  Length 20;
  Best Local Similarity   94.1%;  Pred. No. 1.1e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        502 ACCTGATGCAGCTGCTG 518
              ||||||||||||||||||
Db          4 ACCTGAGGCAGCTGCTG 20


RESULT 63
US-09-923-246-39
; Sequence 39, Application US/09923246
; Patent No. US20020128446A1
; GENERAL INFORMATION:
;  APPLICANT: No. US20020128446A1ak, Julia E.
;  APPLICANT:  Presnell, Scott R.
;  APPLICANT:  Sprecher, Cindy A.
;  APPLICANT:  Foster, Donald C.
;  APPLICANT:  Holly, Richard D.
;  APPLICANT:  Gross, Jane A.
;  APPLICANT:  Johnston, Janet V.
;  APPLICANT:  Nelson, Andrew J.
;  APPLICANT:  Dillon, Stacey R.
;  APPLICANT:  Hammond, Angela K.
;  TITLE OF INVENTION: NOVEL CYTOKINE ZALPHA11 LIGAND
;  FILE REFERENCE: 99-16
;  CURRENT APPLICATION NUMBER: US/09/923,246
;  CURRENT FILING DATE:  2001-08-03
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US/09/522,217
;  PRIOR FILING DATE: EARLIER FILING DATE: 2000-03-09
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/123,904
;  PRIOR FILING DATE: EARLIER FILING DATE: 1999-03-11
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/142,013
;  PRIOR FILING DATE: EARLIER FILING DATE: 1999-07-01
;  NUMBER OF SEQ ID NOS: 115
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 39
;   LENGTH: 26
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide primer ZC7764b
US-09-923-246-39

  Query Match             0.9%;  Score 15.4;  DB 1;  Length 26;
  Best Local Similarity   76.0%;  Pred. No. 1.3e+02;
  Matches   19;  Conservative    0;  Mismatches    6;  Indels    0;  Gaps    0;

Qy       1386 TTGTTTGTTTTGTATCTTGTTTTTC 1410
              || ||| |||| | | || ||||||
Db          2 TTTTTTTTTTTTTTTTTTTTTTTTC 26


RESULT 64
US-09-092-296-10
; Sequence 10, Application US/09092296
; Publication No. US20020188114A1
;  GENERAL INFORMATION:
;     APPLICANT:  BILLING-MEDEL, PATRICIA
;     APPLICANT:  COHEN, MAURICE
;     APPLICANT:  COLPITTS, TRACEY L.
;     APPLICANT:  FRIEDMAN, PAULA N.
;     APPLICANT:  KLASS, MICHAEL R.
;     APPLICANT:  RUSSELL, JOHN C.
;     APPLICANT:  STROUPE, STEPHEN D.
;     TITLE OF INVENTION:  REAGENTS AND METHODS USEFUL
;     TITLE OF INVENTION:  FOR DETECTING DISEASES OF THE LUNG
;     NUMBER OF SEQUENCES:  20
;     CORRESPONDENCE ADDRESS:
;       ADDRESSEE:  Abbott Laboratories
;       STREET:  100 Abbott Park Road
;       CITY:  Abbott Park
;       STATE:  IL
;       COUNTRY:  USA
;       ZIP:  60064-3500
```

```
;     COMPUTER READABLE FORM:
;       MEDIUM TYPE:  Diskette
;       COMPUTER:  IBM Compatible
;       OPERATING SYSTEM:  DOS
;       SOFTWARE:  FastSEQ for Windows Version 2.0
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  US/09/092,296
;       FILING DATE:
;       CLASSIFICATION:
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  60/048,810
;       FILING DATE:  05-JUN-1997
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Becker, Cheryl L.
;       REGISTRATION NUMBER:  35,441
;       REFERENCE/DOCKET NUMBER:  6104.US.01
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  847/935-1729
;       TELEFAX:  847/938-2623
;       TELEX:
;   INFORMATION FOR SEQ ID NO:  10:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  26 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
US-09-092-296-10

  Query Match             0.9%;  Score 15.4;  DB 1;  Length 26;
  Best Local Similarity   76.0%;  Pred. No. 1.3e+02;
  Matches   19;  Conservative    0;  Mismatches    6;  Indels    0;  Gaps    0;

Qy       1386 TTGTTTGTTTTGTATCTTGTTTTTC 1410
                || ||| |||| | | || ||||||
Db          2 TTTTTTTTTTTTTTTTTTTTTTTTC 26


RESULT 65
US-10-295-723-39
; Sequence 39, Application US/10295723
; Publication No. US20030125524A1
; GENERAL INFORMATION:
;  APPLICANT: No. US20030125524A1ak, Julia E.
;  APPLICANT:  Presnell, Scott R.
;  APPLICANT:  Sprecher, Cindy A.
;  APPLICANT:  Foster, Donald C.
;  APPLICANT:  Holly, Richard D.
;  APPLICANT:  Gross, Jane A.
;  APPLICANT:  Johnston, Janet V.
;  APPLICANT:  Nelson, Andrew J.
;  APPLICANT:  Dillon, Stacey R.
;  APPLICANT:  Hammond, Angela K.
;  TITLE OF INVENTION: NOVEL CYTOKINE ZALPHA11 LIGAND
;  FILE REFERENCE: 99-16
;  CURRENT APPLICATION NUMBER: US/10/295,723
;  CURRENT FILING DATE:  2002-11-15
;  PRIOR APPLICATION NUMBER: 09/522,217
;  PRIOR FILING DATE: 2000-03-09
;  PRIOR APPLICATION NUMBER: US 60/123,547
;  PRIOR FILING DATE: 1999-03-09
;  PRIOR APPLICATION NUMBER: US 60/123,904
;  PRIOR FILING DATE: 1999-03-11
;  PRIOR APPLICATION NUMBER: US 60/142,013
;  PRIOR FILING DATE: 1999-07-01
;  NUMBER OF SEQ ID NOS: 115
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 39
;   LENGTH: 26
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide primer ZC7764b
US-10-295-723-39

  Query Match             0.9%;  Score 15.4;  DB 1;  Length 26;
  Best Local Similarity   76.0%;  Pred. No. 1.3e+02;
  Matches   19;  Conservative    0;  Mismatches    6;  Indels    0;  Gaps    0;

Qy       1386 TTGTTTGTTTTGTATCTTGTTTTTC 1410
                || ||| |||| | | || ||||||
Db          2 TTTTTTTTTTTTTTTTTTTTTTTTC 26


RESULT 66
US-10-659-684-39
; Sequence 39, Application US/10659684
; Publication No. US20040110932A1
; GENERAL INFORMATION:
;  APPLICANT: Novak, Julia E.
;  APPLICANT:  Presnell, Scott R.
;  APPLICANT:  Sprecher, Cindy A.
;  APPLICANT:  Foster, Donald C.
;  APPLICANT:  Holly, Richard D.
;  APPLICANT:  Gross, Jane A.
;  APPLICANT:  Johnston, Janet V.
;  APPLICANT:  Nelson, Andrew J.
;  APPLICANT:  Dillon, Stacey R.
;  APPLICANT:  Hammond, Angela K.
;  TITLE OF INVENTION: NOVEL CYTOKINE ZALPHA11 LIGAND
;  FILE REFERENCE: 99-16
;  CURRENT APPLICATION NUMBER: US/10/659,684
;  CURRENT FILING DATE:  2003-09-10
;  PRIOR APPLICATION NUMBER: US/09/522,217
;  PRIOR FILING DATE: 2000-03-09
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/123,547
;  PRIOR FILING DATE: EARLIER FILING DATE: 1999-03-09
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/123,904
;  PRIOR FILING DATE: EARLIER FILING DATE: 1999-03-11
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/142,013
;  PRIOR FILING DATE: EARLIER FILING DATE: 1999-07-01
;  NUMBER OF SEQ ID NOS: 115
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 39
;   LENGTH: 26
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide primer ZC7764b
US-10-659-684-39

  Query Match             0.9%;  Score 15.4;  DB 1;  Length 26;
  Best Local Similarity   76.0%;  Pred. No. 1.3e+02;
  Matches   19;  Conservative    0;  Mismatches    6;  Indels    0;  Gaps    0;

Qy       1386 TTGTTTGTTTTGTATCTTGTTTTTC 1410
                || ||| |||| | | || ||||||
Db          2 TTTTTTTTTTTTTTTTTTTTTTTTC 26


RESULT 67
US-09-021-660A-24
; Sequence 24, Application US/09021660A
; Patent No. US20010041668A1
; GENERAL INFORMATION:
;  APPLICANT: Baron, M.
;  APPLICANT:  Farrington, S.
;  APPLICANT:  Belaussoff, M.
;  TITLE OF INVENTION: METHODS FOR MODULATING HEMATOPOIESIS AND VASCULAR
;  TITLE OF INVENTION:  GROWTH
;  FILE REFERENCE: HUIP-P01-060
;  CURRENT APPLICATION NUMBER: US/09/021,660A
;  CURRENT FILING DATE:  2001-08-27
;  PRIOR APPLICATION NUMBER: 60/037,513
;  PRIOR FILING DATE: 1997-02-10
;  PRIOR APPLICATION NUMBER: 60/049,763
;  PRIOR FILING DATE: 1997-06-16
```

```
;  NUMBER OF SEQ ID NOS: 42
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 24
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Primer
US-09-021-660A-24

  Query Match             0.9%;  Score 15.2;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 1.2e+02;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        502 ACCTGATGCAGCTGCTGCAG 521
              | ||||||||||||| | |||
Db          1 AGCTGATGCAGCTGATCCAG 20


RESULT 68
US-09-291-417-145/c
; Sequence 145, Application US/09291417A
; Publication No. US20030050230A1
; GENERAL INFORMATION:
;  APPLICANT: PLOWMAN, GREGORY
;  APPLICANT: MARTINEZ, RICARDO
;  APPLICANT: WHYTE, DAVID
;  TITLE OF INVENTION: STE20-RELATED PROTEIN KINASES
;  FILE REFERENCE: 240/300
;  CURRENT APPLICATION NUMBER: US/09/291,417A
;  CURRENT FILING DATE: 1999-04-13
;  EARLIER APPLICATION NUMBER: US 60/081,784
;  EARLIER FILING DATE: 1998-04-14
;  NUMBER OF SEQ ID NOS: 147
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 145
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Mammalian (Human) PAK5
US-09-291-417-145

  Query Match             0.9%;  Score 15.2;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 1.2e+02;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        601 GCAAAGAACTACTGCGCCTG 620
              |||||  |||||||| ||||
Db         20 GCAAATGACTACTGCACCTG 1


RESULT 69
US-10-085-108-17/c
; Sequence 17, Application US/10085108
; Publication No. US20020176865A1
;   GENERAL INFORMATION:
;        APPLICANT: LUCAS, Sophie; BOON-FALLEUR, Thierry
;        TITLE OF INVENTION: ISOLATED NUCLEIC ACID MOLECULES CODING
;                            FOR
;                            TUMOR REJECTION ANTIGEN PRECURSORS OF MEMBERS OF THE MAGE-C
;                            MAGE-B FAMILIES AND USES THEREOF
;        NUMBER OF SEQUENCES: 26
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: Fulbright & Jaworski L.L.P.
;             STREET: 666 Fifth Avenue
;             CITY: New York City
;             STATE: New York
;             COUNTRY: USA
;             ZIP: 10103
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: Diskette, 3.5 inch, 360 kb storage
;             COMPUTER: IBM PS/2
;             OPERATING SYSTEM: PC-DOS
;             SOFTWARE: Wordperfect
;        CURRENT APPLICATION DATA:
;             APPLICATION NUMBER: US/10/085,108
;             FILING DATE: 01-Mar-2002
;             CLASSIFICATION: <Unknown>
;        PRIOR APPLICATION DATA:
;             APPLICATION NUMBER: 09/501,104
;             FILING DATE: 09-Feb-2000
;             APPLICATION NUMBER: 09/468,433
;             FILING DATE: December 17, 1999
;             APPLICATION NUMBER: 09/066,281
;             FILING DATE: April 24, 1998
;             APPLICATION NUMBER: 08/845,528
;             FILING DATE: April 25, 1997
;        ATTORNEY/AGENT INFORMATION:
;             NAME: Mary Anne Schofield
;             REGISTRATION NUMBER: 36,669
;             REFERENCE/DOCKET NUMBER: LUD 5611.1 JEL/MAS
;        TELECOMMUNICATION INFORMATION:
;             TELEPHONE: (212) 318-3100
;             TELEFAX: (212) 318-3400
;   INFORMATION FOR SEQ ID NO: 17:
;        SEQUENCE CHARACTERISTICS:
;             LENGTH: 20 base pairs
;             TYPE: nucleic acid
;             STRANDEDNESS: single-stranded
;             TOPOLOGY: linear
;        SEQUENCE DESCRIPTION: SEQ ID NO: 17:
US-10-085-108-17

  Query Match             0.9%;  Score 15.2;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 1.2e+02;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        495 TGTGCCAACCTGATGCAGCT 514
              | |||||||| || ||||||
Db         20 TCTGCCAACCAGAGGCAGCT 1


RESULT 70
US-10-057-550-73/c
; Sequence 73, Application US/10057550
; Publication No. US20030032607A1
; GENERAL INFORMATION:
;  APPLICANT: Monia, Brett P.
;  TITLE OF INVENTION: Antisense Oligonucleotide Modulation of raf Gene Expression
;  FILE REFERENCE:
;  CURRENT APPLICATION NUMBER: US/10/057,550
;  CURRENT FILING DATE:  2002-01-25
;  PRIOR APPLICATION NUMBER: 09/506,073
;  PRIOR FILING DATE: 2000-02-18
;  PRIOR APPLICATION NUMBER: US 09/143,214
;  PRIOR FILING DATE: 1998-08-28
;  PRIOR APPLICATION NUMBER: PCT/US98/13961
;  PRIOR FILING DATE: 1998-07-06
;  PRIOR APPLICATION NUMBER: US 08/888,982
;  PRIOR FILING DATE: 1997-07-07
;  PRIOR APPLICATION NUMBER: US 08/756,806
;  PRIOR FILING DATE: 1996-11-26
;  PRIOR APPLICATION NUMBER: PCT/US95/07111
;  PRIOR FILING DATE: 1995-05-31
;  PRIOR APPLICATION NUMBER: US 08/250,856
;  PRIOR FILING DATE: 1994-05-31
;  NUMBER OF SEQ ID NOS: 130
; SEQ ID NO 73
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: artificial sequence
;   FEATURE:
;   OTHER INFORMATION: antisense sequence
US-10-057-550-73

  Query Match             0.9%;  Score 15.2;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 1.2e+02;
```

```
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1267 CCGGCCCAGGGTGAAGGAAG 1286
              | ||||| ||| ||||||||
Db         20 CTGGCCCTGGGAGAAGGAAG 1


RESULT 71
US-10-010-802-341
; Sequence 341, Application US/10010802
; Publication No. US20030078220A1
; GENERAL INFORMATION:
;  APPLICANT: Genaissance Pharmaceuticals
;  APPLICANT:  Chew, Anne
;  APPLICANT:  Denton, R. Rex
;  APPLICANT:  Duda, Amy
;  APPLICANT:  Nandabalan, Krishnan
;  APPLICANT:  Stephens, J. Claiborne
;  APPLICANT:  Windemuth, Andreas
;  TITLE OF INVENTION: Drug Target Isogenes: Polymorphisms in the Interleukin
;  TITLE OF INVENTION:  4 Receptor Alpha Gene
;  FILE REFERENCE: MWH-0002US2 IL4R alpha
;  CURRENT APPLICATION NUMBER: US/10/010,802
;  CURRENT FILING DATE:  2001-11-09
;  PRIOR APPLICATION NUMBER: PCT/US00/19094
;  PRIOR FILING DATE: 2000-07-13
;  NUMBER OF SEQ ID NOS: 413
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 341
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-010-802-341

  Query Match             0.9%;  Score 15.2;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 1.2e+02;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        579 AGCCAGTTGGTAAGCCAGGT 598
              |||||| ||  |||||||||
Db          1 AGCCAGGTGAGAAGCCAGGT 20


RESULT 72
US-10-001-076-77/c
; Sequence 77, Application US/10001076
; Publication No. US20030096775A1
; GENERAL INFORMATION:
;  APPLICANT: Mark J. Graham
;  APPLICANT:  Andrew T. Watt
;  TITLE OF INVENTION: ANTISENSE MODULATION OF COMPLEMENT COMPONENT C3 EXPRESSION
;  FILE REFERENCE: RTS-0329
;  CURRENT APPLICATION NUMBER: US/10/001,076
;  CURRENT FILING DATE:  2001-10-23
;  NUMBER OF SEQ ID NOS: 179
; SEQ ID NO 77
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-10-001-076-77

  Query Match             0.9%;  Score 15.2;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 1.2e+02;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        667 GCGTGGAGCAGGGCAAGAGC 686
              ||| |||||||| ||| |||
Db         20 GCGAGGAGCAGGTCAACAGC 1


RESULT 73
US-10-160-237-17/c
; Sequence 17, Application US/10160237
; Publication No. US20030170256A1
;  GENERAL INFORMATION:
;       APPLICANT: LUCAS, Sophie; DE SMET, Charles; BOON-FALLEUR, Thierry
;       TITLE OF INVENTION: ISOLATED NUCLEIC ACID MOLECULE CODING
;                           FOR TUMOR REJECTION ANTIGEN PRECURSOR MAGE-C1 AND MAGE-C2
;                           AND USES THEREOF
;       NUMBER OF SEQUENCES: 20
;       CORRESPONDENCE ADDRESS:
;            ADDRESSEE: Fulbright & Jaworski L.L.P.
;            STREET: 666 Fifth Avenue
;            CITY: New York City
;            STATE: New York
;            COUNTRY: USA
;            ZIP: 10103
;       COMPUTER READABLE FORM:
;            MEDIUM TYPE: Diskette, 3.5 inch, 360 kb storage
;            COMPUTER: IBM PS/2
;            OPERATING SYSTEM: PC-DOS
;            SOFTWARE: Wordperfect
;       CURRENT APPLICATION DATA:
;            APPLICATION NUMBER: US/10/160,237
;            FILING DATE: 04-Jun-2002
;            CLASSIFICATION: <Unknown>
;       PRIOR APPLICATION DATA:
;            APPLICATION NUMBER: US/09/066,281B
;            FILING DATE: April 24, 1998
;            APPLICATION NUMBER: 08/845,528
;            FILING DATE: April 25, 1997
;       ATTORNEY/AGENT INFORMATION:
;            NAME: Mary Anne Schofield
;            REGISTRATION NUMBER: 36,669
;            REFERENCE/DOCKET NUMBER: LUD 5455.2 US - JEL/MAS
;       TELECOMMUNICATION INFORMATION:
;            TELEPHONE: (212) 318-3100
;            TELEFAX: (212) 752-5958
;   INFORMATION FOR SEQ ID NO: 17:
;       SEQUENCE CHARACTERISTICS:
;            LENGTH: 20 base pairs
;            TYPE: nucleic acid
;            STRANDEDNESS: single-stranded
;            TOPOLOGY: linear
;       SEQUENCE DESCRIPTION: SEQ ID NO: 17:
US-10-160-237-17

  Query Match             0.9%;  Score 15.2;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 1.2e+02;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        495 TGTGCCAACCTGATGCAGCT 514
              | |||||||| || ||||||
Db         20 TCTGCCAACCAGAGGCAGCT 1


RESULT 74
US-10-144-488-25/c
; Sequence 25, Application US/10144488
; Publication No. US20030212017A1
; GENERAL INFORMATION:
;  APPLICANT: Brett P. Monia
;  APPLICANT:  Susan M. Freier
;  TITLE OF INVENTION: ANTISENSE MODULATION OF FARNESYL TRANSFERASE BETA SUBUNIT EXPRESSI
;  FILE REFERENCE: RTS-0363
;  CURRENT APPLICATION NUMBER: US/10/144,488
;  CURRENT FILING DATE:  2002-05-10
;  NUMBER OF SEQ ID NOS: 80
; SEQ ID NO 25
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
```

```
US-10-144-488-25

  Query Match             0.9%;  Score 15.2;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 1.2e+02;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        879 CTGTACAGCTCGGAACAGCT 898
              ||| |||||| ||||| |||
Db         20 CTGCACAGCTTGGAACTGCT 1


RESULT 75
US-10-181-874-36/c
; Sequence 36, Application US/10181874
; Publication No. US20030212020A1
; GENERAL INFORMATION:
;  APPLICANT: Isis Pharmaceuticals, Inc.
;  APPLICANT:  Susan Murray
;  APPLICANT:  Lex M. Cowsert
;  APPLICANT:  Jacqueline Wyatt
;  TITLE OF INVENTION: ANTISENSE MODULATION OF MACROPHAGE MIGRATION INHIBITORY FACTOR E
;  FILE REFERENCE: RTSP-0351
;  CURRENT APPLICATION NUMBER: US/10/181,874
;  CURRENT FILING DATE:  2002-07-22
;  PRIOR APPLICATION NUMBER: 09/489,869
;  PRIOR FILING DATE: 2000-01-20
;  NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 36
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-10-181-874-36

  Query Match             0.9%;  Score 15.2;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 1.2e+02;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        624 TACAGCGAGCCGTGCGGCCT 643
              | ||||||||||||||  ||
Db         20 TCCAGCGAGCCGTGCGCGCT 1


RESULT 76
US-10-174-319-42
; Sequence 42, Application US/10174319
; Publication No. US20030232771A1
; GENERAL INFORMATION:
;  APPLICANT: Donna T. Ward
;  APPLICANT:  Susan M. Freier
;  APPLICANT:  Kenneth W. Dobie
;  TITLE OF INVENTION: ANTISENSE MODULATION OF MARK3 EXPRESSION
;  FILE REFERENCE: PTS-0018
;  CURRENT APPLICATION NUMBER: US/10/174,319
;  CURRENT FILING DATE:  2002-06-17
;  NUMBER OF SEQ ID NOS: 121
; SEQ ID NO 42
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-10-174-319-42

  Query Match             0.9%;  Score 15.2;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 1.2e+02;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1681 CACTGTTCATGAATACACTT 1700
              || |||||| ||| ||||||
Db          1 CAGTGTTCAGGAAAACACTT 20


RESULT 77
US-10-177-554-85/c
; Sequence 85, Application US/10177554
; Publication No. US20030235911A1
; GENERAL INFORMATION:
;  APPLICANT: Kenneth W. Dobie
;  APPLICANT:  Hong Zhang
;  TITLE OF INVENTION: ANTISENSE MODULATION OF PRL-3 EXPRESSION
;  FILE REFERENCE: RTS-0370
;  CURRENT APPLICATION NUMBER: US/10/177,554
;  CURRENT FILING DATE:  2002-06-20
;  NUMBER OF SEQ ID NOS: 239
; SEQ ID NO 85
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-10-177-554-85

  Query Match             0.9%;  Score 15.2;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 1.2e+02;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1428 CTGACCTGTTGTAGGCAGCT 1447
              |||||||||| | |||| ||
Db         20 CTGACCTGTTCTCGGCACCT 1


RESULT 78
US-10-177-554-215
; Sequence 215, Application US/10177554
; Publication No. US20030235911A1
; GENERAL INFORMATION:
;  APPLICANT: Kenneth W. Dobie
;  APPLICANT:  Hong Zhang
;  TITLE OF INVENTION: ANTISENSE MODULATION OF PRL-3 EXPRESSION
;  FILE REFERENCE: RTS-0370
;  CURRENT APPLICATION NUMBER: US/10/177,554
;  CURRENT FILING DATE:  2002-06-20
;  NUMBER OF SEQ ID NOS: 239
; SEQ ID NO 215
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: H. sapiens
;   FEATURE:
US-10-177-554-215

  Query Match             0.9%;  Score 15.2;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 1.2e+02;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1428 CTGACCTGTTGTAGGCAGCT 1447
              |||||||||| | |||| ||
Db          1 CTGACCTGTTCTCGGCACCT 20


RESULT 79
US-10-289-762-2571/c
; Sequence 2571, Application US/10289762
; Publication No. US20040006218A1
; GENERAL INFORMATION:
;  APPLICANT: Griffais, R.
;  TITLE OF INVENTION: Chlamydia pneumoniae genomic sequence and polypeptides, fragments
;  TITLE OF INVENTION:  thereof and uses thereof, in particular for the diagnosis, preve
;  TITLE OF INVENTION:  and treatment of infection
;  FILE REFERENCE: 9710-003-999
;  CURRENT APPLICATION NUMBER: US/10/289,762
;  CURRENT FILING DATE:  2003-03-27
;  NUMBER OF SEQ ID NOS: 6849
; SEQ ID NO 2571
;   LENGTH: 20
```

```
;   TYPE: DNA
;   ORGANISM: Chlamydia pneumoniae
US-10-289-762-2571

  Query Match             0.9%;  Score 15.2;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 1.2e+02;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        996 CTGAGGGACTGATTCCTGTG 1015
              ||| |||| ||||||||| |
Db         20 CTGTGGGATTGATTCCTGAG 1


RESULT 80
US-10-289-762-5767/c
; Sequence 5767, Application US/10289762
; Publication No. US20040006218A1
; GENERAL INFORMATION:
;  APPLICANT: Griffais, R.
;  TITLE OF INVENTION: Chlamydia pneumoniae genomic sequence and polypeptides, fragments
;  TITLE OF INVENTION:  thereof and uses thereof, in particular for the diagnosis, preve
;  TITLE OF INVENTION:  and treatment of infection
;  FILE REFERENCE: 9710-003-999
;  CURRENT APPLICATION NUMBER: US/10/289,762
;  CURRENT FILING DATE:  2003-03-27
;  NUMBER OF SEQ ID NOS: 6849
; SEQ ID NO 5767
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Chlamydia pneumoniae
US-10-289-762-5767

  Query Match             0.9%;  Score 15.2;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 1.2e+02;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1617 CCTCCCCGGGAGGAGTGCCA 1636
              | ||||| ||||||||| ||
Db         20 CTTCCCCTGGAGGAGTGGCA 1


RESULT 81
US-10-642-802-77/c
; Sequence 77, Application US/10642802
; Publication No. US20040043956A1
; GENERAL INFORMATION:
;  APPLICANT: Mark J. Graham
;  APPLICANT:  Andrew T. Watt
;  TITLE OF INVENTION: ANTISENSE MODULATION OF COMPLEMENT COMPONENT C3 EXPRESSION
;  FILE REFERENCE: RTS-0329
;  CURRENT APPLICATION NUMBER: US/10/642,802
;  CURRENT FILING DATE:  2003-08-18
;  PRIOR APPLICATION NUMBER: US/10/001,076
;  PRIOR FILING DATE: 2001-10-23
;  NUMBER OF SEQ ID NOS: 179
; SEQ ID NO 77
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-10-642-802-77

  Query Match             0.9%;  Score 15.2;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 1.2e+02;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        667 GCGTGGAGCAGGGCAAGAGC 686
              ||| |||||||| ||| |||
Db         20 GCGAGGAGCAGGTCAACAGC 1


RESULT 82
```

```
US-10-272-810-41/c
; Sequence 41, Application US/10272810
; Publication No. US20040077568A1
; GENERAL INFORMATION:
;  APPLICANT: Andrew T. Watt
;  TITLE OF INVENTION: ANTISENSE MODULATION OF NOTCH (DROSOPHILA) HOMOLOG 4 EXPRESSION
;  FILE REFERENCE: RTS-0263
;  CURRENT APPLICATION NUMBER: US/10/272,810
;  CURRENT FILING DATE:  2002-10-16
;  NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 41
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-10-272-810-41

  Query Match             0.9%;  Score 15.2;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 1.2e+02;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        608 ACTACTGCGCCTGGCCTACA 627
              || ||||| |||| ||||||
Db         20 ACAACTGCACCTGCCCTACA 1


RESULT 83
US-10-273-070-41/c
; Sequence 41, Application US/10273070
; Publication No. US20040077569A1
; GENERAL INFORMATION:
;  APPLICANT: Andrew T. Watt
;  TITLE OF INVENTION: ANTISENSE MODULATION OF NOTCH (DROSOPHILA) HOMOLOG 4 EXPRESSION
;  FILE REFERENCE: RTS-0231
;  CURRENT APPLICATION NUMBER: US/10/273,070
;  CURRENT FILING DATE:  2002-10-16
;  NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 41
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-10-273-070-41

  Query Match             0.9%;  Score 15.2;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 1.2e+02;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        608 ACTACTGCGCCTGGCCTACA 627
              || ||||| |||| ||||||
Db         20 ACAACTGCACCTGCCCTACA 1


RESULT 84
US-10-280-183A-448/c
; Sequence 448, Application US/10280183A
; Publication No. US20040081964A1
; GENERAL INFORMATION:
;  APPLICANT: Pfizer Inc.
;  APPLICANT:  Bachmanov, Alexander A
;  APPLICANT:  Beauchamp, Gary K.
;  APPLICANT:  Chatterjee, Aurobindo
;  APPLICANT:  De  Jong, Pieter J.
;  APPLICANT:  Li, Shanru
;  APPLICANT:  Li, Xia
;  APPLICANT:  Ohmen, Jeffrey D
;  APPLICANT:  Reed, Danielle R.
;  APPLICANT:  Ross, David
;  APPLICANT:  Tordoff, Michael G.
;  TITLE OF INVENTION: GENE AND SEQUENCE VARIATION ASSOCIATED WITH SENSING
;  TITLE OF INVENTION:  CARBOHYDRATE COMPOUNDS AND OTHER SWEETNERS
```

```
;  FILE REFERENCE: PC18306A
;  CURRENT APPLICATION NUMBER: US/10/280,183A
;  CURRENT FILING DATE:  2002-10-25
;  PRIOR APPLICATION NUMBER: 60/200,794
;  PRIOR FILING DATE: 2000-04-28
;  NUMBER OF SEQ ID NOS: 652
;  SOFTWARE: PatentIn Ver. 3.1
; SEQ ID NO 448
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Mouse
US-10-280-183A-448

  Query Match             0.9%;  Score 15.2;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 1.2e+02;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        979 GAGACTAGAGGCAGGAGCTG 998
              ||||| ||||| ||| ||||
Db         20 GAGACCAGAGGAAGGTGCTG 1


RESULT 85
US-10-303-420-94
; Sequence 94, Application US/10303420
; Publication No. US20040102398A1
; GENERAL INFORMATION:
;  APPLICANT: Brett P. Monia
;  APPLICANT:  Kenneth W. Dobie
;  TITLE OF INVENTION: MODULATION OF B7H EXPRESSION
;  FILE REFERENCE: RTS-0417
;  CURRENT APPLICATION NUMBER: US/10/303,420
;  CURRENT FILING DATE:  2002-11-23
;  NUMBER OF SEQ ID NOS: 271
; SEQ ID NO 94
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-10-303-420-94

  Query Match             0.9%;  Score 15.2;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 1.2e+02;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1116 TACCCCTCAGTACTGTAGCA 1135
              |||||||||| |||| | ||
Db          1 TACCCCTCAGCACTGGACCA 20


RESULT 86
US-10-316-515-26/c
; Sequence 26, Application US/10316515
; Publication No. US20040116365A1
; GENERAL INFORMATION:
;  APPLICANT: Alexander H. Borchers
;  APPLICANT:  Susan M. Freier
;  TITLE OF INVENTION: MODULATION OF LCK EXPRESSION
;  FILE REFERENCE: RTS-0344
;  CURRENT APPLICATION NUMBER: US/10/316,515
;  CURRENT FILING DATE:  2002-12-10
;  NUMBER OF SEQ ID NOS: 76
; SEQ ID NO 26
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-10-316-515-26

  Query Match             0.9%;  Score 15.2;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 1.2e+02;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        501 AACCTGATGCAGCTGCTGCA 520
              ||||| ||| ||| ||||||
Db         20 AACCTCATGAAGCAGCTGCA 1


RESULT 87
US-10-725-329-145/c
; Sequence 145, Application US/10725329
; Publication No. US20040224323A1
; GENERAL INFORMATION:
;  APPLICANT: PLOWMAN, GREGORY
;  APPLICANT:  MARTINEZ, RICARDO
;  APPLICANT:  WHYTE, DAVID
;  TITLE OF INVENTION: STE20-RELATED PROTEIN KINASES
;  FILE REFERENCE: 038602/0328
;  CURRENT APPLICATION NUMBER: US/10/725,329
;  CURRENT FILING DATE:  2003-12-02
;  PRIOR APPLICATION NUMBER: US/09/688,188B
;  PRIOR FILING DATE: 2000-10-16
;  PRIOR APPLICATION NUMBER: 09/291,417
;  PRIOR FILING DATE: 1999-04-14
;  PRIOR APPLICATION NUMBER: 60/081,784
;  PRIOR FILING DATE: 1998-04-14
;  NUMBER OF SEQ ID NOS: 155
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 145
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-725-329-145

  Query Match             0.9%;  Score 15.2;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 1.2e+02;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        601 GCAAAGAACTACTGCGCCTG 620
              |||||  |||||||| ||||
Db         20 GCAAATGACTACTGCACCTG 1


RESULT 88
US-09-971-353-24/c
; Sequence 24, Application US/09971353
; Publication No. US20030113723A1
; GENERAL INFORMATION:
;  APPLICANT: Bapat, Bharati
;  APPLICANT:  Rose, Melanie Anne
;  TITLE OF INVENTION: METHOD FOR EVALUATING MICROSATELLITE INSTABILITY IN A TUMOR SAMPL
;  FILE REFERENCE: 11757.54USU1
;  CURRENT APPLICATION NUMBER: US/09/971,353
;  CURRENT FILING DATE:  2001-10-04
;  PRIOR APPLICATION NUMBER: US 60/237,884
;  PRIOR FILING DATE: 2000-10-04
;  NUMBER OF SEQ ID NOS: 35
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 24
;   LENGTH: 31
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-971-353-24

  Query Match             0.9%;  Score 15.2;  DB 1;  Length 31;
  Best Local Similarity   71.4%;  Pred. No. 1.6e+02;
  Matches   20;  Conservative    0;  Mismatches    8;  Indels    0;  Gaps    0;

Qy       1386 TTGTTTGTTTTGTATCTTGTTTTTCTGA 1413
              || ||| |||| | | || ||||| | |
Db         31 TTTTTTTTTTTTTTTTTTTTTTTTTAA 4


RESULT 89
```

```
US-09-848-754A-1341
; Sequence 1341, Application US/09848754A
; Publication No. US20030073207A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
;  TITLE OF INVENTION:  Levels of Epidermal Growth Factor Receptors
;  FILE REFERENCE: MBHB00-958-I (400/018)
;  CURRENT APPLICATION NUMBER: US/09/848,754A
;  CURRENT FILING DATE:  2001-05-03
;  NUMBER OF SEQ ID NOS: 9645
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1341
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-848-754A-1341

  Query Match             0.9%;  Score 15;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 1.2e+02;
  Matches   13;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        512 GCTGCTGCAGGAGAG 526
              ||:||:|||||||||
Db          1 GCUGCUGCAGGAGAG 15


RESULT 90
US-09-848-754A-2408
; Sequence 2408, Application US/09848754A
; Publication No. US20030073207A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
;  TITLE OF INVENTION:  Levels of Epidermal Growth Factor Receptors
;  FILE REFERENCE: MBHB00-958-I (400/018)
;  CURRENT APPLICATION NUMBER: US/09/848,754A
;  CURRENT FILING DATE:  2001-05-03
;  NUMBER OF SEQ ID NOS: 9645
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2408
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-848-754A-2408

  Query Match             0.9%;  Score 15;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 1.2e+02;
  Matches   13;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        512 GCTGCTGCAGGAGAG 526
              ||:||:|||||||||
Db          3 GCUGCUGCAGGAGAG 17


RESULT 91
US-10-199-199-43/c
; Sequence 43, Application US/10199199
; Publication No. US20040014047A1
; GENERAL INFORMATION:
;  APPLICANT: Lex M. Cowsert
;  APPLICANT:  Kenneth W. Dobie
;  TITLE OF INVENTION: ANTISENSE MODULATION OF LIM DOMAIN KINASE 1 EXPRESSION
;  FILE REFERENCE: RTS-0375
;  CURRENT APPLICATION NUMBER: US/10/199,199
;  CURRENT FILING DATE:  2002-07-18
;  NUMBER OF SEQ ID NOS: 148
; SEQ ID NO 43
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-10-199-199-43

  Query Match             0.9%;  Score 15;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 1.3e+02;
  Matches   15;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        736 TCCAGCTGACCCTCG 750
              |||||||||||||||
Db         16 TCCAGCTGACCCTCG 2


RESULT 92
US-10-199-199-116
; Sequence 116, Application US/10199199
; Publication No. US20040014047A1
; GENERAL INFORMATION:
;  APPLICANT: Lex M. Cowsert
;  APPLICANT:  Kenneth W. Dobie
;  TITLE OF INVENTION: ANTISENSE MODULATION OF LIM DOMAIN KINASE 1 EXPRESSION
;  FILE REFERENCE: RTS-0375
;  CURRENT APPLICATION NUMBER: US/10/199,199
;  CURRENT FILING DATE:  2002-07-18
;  NUMBER OF SEQ ID NOS: 148
; SEQ ID NO 116
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: H. sapiens
;   FEATURE:
US-10-199-199-116

  Query Match             0.9%;  Score 15;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 1.3e+02;
  Matches   15;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        736 TCCAGCTGACCCTCG 750
              |||||||||||||||
Db          5 TCCAGCTGACCCTCG 19


RESULT 93
US-10-480-013-2
; Sequence 2, Application US/10480013
; Publication No. US20040157794A1
; GENERAL INFORMATION:
;  APPLICANT: Pohang Foundation
;  TITLE OF INVENTION: CALIX[4]ARENE-NUCLEOSIDE AND CALIX[4]ARENE-OLIGONUCLEOTIDE
;  TITLE OF INVENTION:  HYBRIDS
;  FILE REFERENCE: PCA20633/PSC
;  CURRENT APPLICATION NUMBER: US/10/480,013
;  CURRENT FILING DATE:  2003-12-04
;  NUMBER OF SEQ ID NOS: 3
;  SOFTWARE: KopatentIn 1.71
; SEQ ID NO 2
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: calix[4]arene-oligonucleotide hybrid 2
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (13)
;   OTHER INFORMATION: calix[4]arene-nucleoside of chemical formula 1
US-10-480-013-2

  Query Match             0.9%;  Score 15;  DB 1;  Length 25;
  Best Local Similarity   75.0%;  Pred. No. 1.5e+02;
  Matches   18;  Conservative    0;  Mismatches    6;  Indels    0;  Gaps    0;

Qy       1386 TTGTTTGTTTTGTATCTTGTTTTT 1409
              || ||| |||| | | || |||||
Db          2 TTTTTTTTTTTNTTTTTTTTTTT 25
```

```
RESULT 94
US-10-440-850-1112
; Sequence 1112, Application US/10440850
; Publication No. US20030207837A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Jarvis, Thale
;  APPLICANT:  McSwiggen, Jim
;  TITLE OF INVENTION: Method and Reagent for the Induction of Graft Tolerance and Rever
;  TITLE OF INVENTION:  Immune Responses
;  FILE REFERENCE: 250/130 (MBHB00-900-A)
;  CURRENT APPLICATION NUMBER: US/10/440,850
;  CURRENT FILING DATE:  2003-05-19
;  PRIOR APPLICATION NUMBER: US/09/650,012
;  PRIOR FILING DATE: 2000-08-28
;  PRIOR APPLICATION NUMBER: US 08/585,684
;  PRIOR FILING DATE: 1996-01-12
;  PRIOR APPLICATION NUMBER: US 60/000,951
;  PRIOR FILING DATE: 1995-07-07
;  PRIOR APPLICATION NUMBER: US 09/038,073
;  PRIOR FILING DATE: 1998-03-11
;  NUMBER OF SEQ ID NOS: 2285
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1112
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-440-850-1112

  Query Match             0.8%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   66.7%;  Pred. No. 1.3e+02;
  Matches   12;  Conservative    4;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        505 TGATGCAGCTGCTGCAGG 522
              :| :|| ||:||:|||||
Db          1 UGGUGCUGCUGCUGCAGG 18


RESULT 95
US-09-844-662-20/c
; Sequence 20, Application US/09844662
; Publication No. US20020064802A1
; GENERAL INFORMATION:
;  APPLICANT: Raschke, Eva
;  APPLICANT:  Wolffe, Alan P
;  APPLICANT:  Case, Casey C
;  TITLE OF INVENTION: METHODS FOR BINDING AN EXOGENOUS MOLECULE TO CELLULAR CHROMATIN
;  FILE REFERENCE: SABI-006/01US (S12-US1)
;  CURRENT APPLICATION NUMBER: US/09/844,662
;  CURRENT FILING DATE:  2001-04-27
;  PRIOR APPLICATION NUMBER: 60/200,590
;  PRIOR FILING DATE: 2000-04-28
;  NUMBER OF SEQ ID NOS: 38
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 20
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  VEGF reverse
;   OTHER INFORMATION: primer
US-09-844-662-20

  Query Match             0.8%;  Score 14.8;  DB 1;  Length 19;
  Best Local Similarity   88.9%;  Pred. No. 1.4e+02;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1322 GGAGGTCGGAGGTCGTGG 1339
              | || ||||||||||||||
Db         19 GTAGCTCGGAGGTCGTGG 2


RESULT 96
US-09-925-548-89/c
; Sequence 89, Application US/09925548
; Patent No. US20020107216A1
; GENERAL INFORMATION:
;  APPLICANT: Dedhar, Shoukat
;  APPLICANT:  Hannigan, Greg
;  APPLICANT:  Yee, Arthur
;  TITLE OF INVENTION: INTEGRIN-LINKED KINASE AND ITS USES
;  FILE REFERENCE: KINE001CIP4
;  CURRENT APPLICATION NUMBER: US/09/925,548
;  CURRENT FILING DATE:  2001-08-08
;  PRIOR APPLICATION NUMBER: 09/390,425
;  PRIOR FILING DATE: 1999-09-03
;  PRIOR APPLICATION NUMBER: 09/035,706
;  PRIOR FILING DATE: 1998-03-05
;  PRIOR APPLICATION NUMBER: 08/955,841
;  PRIOR FILING DATE: 1997-10-21
;  PRIOR APPLICATION NUMBER: 08/752,345
;  PRIOR FILING DATE: 1996-11-19
;  PRIOR APPLICATION NUMBER: 60/009,074
;  PRIOR FILING DATE: 1995-12-21
;  NUMBER OF SEQ ID NOS: 97
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 89
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-925-548-89

  Query Match             0.8%;  Score 14.8;  DB 1;  Length 19;
  Best Local Similarity   88.9%;  Pred. No. 1.4e+02;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        715 ACCCCAGCCTGGTGCCCA 732
              |||||||||||| | |||
Db         19 ACCCCAGCCTGGGGTCCA 2


RESULT 97
US-09-844-508-33/c
; Sequence 33, Application US/09844508
; Patent No. US20020115215A1
; GENERAL INFORMATION:
;  APPLICANT: WOLFFE, Alan P.
;  APPLICANT:  COLLINGWOOD, Trevor
;  TITLE OF INVENTION: TARGETED MODIFICATION OF CHROMATIN STRUCTURE
;  FILE REFERENCE: 8325-0014 / S14-US1
;  CURRENT APPLICATION NUMBER: US/09/844,508
;  CURRENT FILING DATE:  2001-04-27
;  PRIOR APPLICATION NUMBER: 60/200,590
;  PRIOR FILING DATE: 2000-04-28
;  PRIOR APPLICATION NUMBER: 60/228,523
;  PRIOR FILING DATE: 2000-08-28
;  NUMBER OF SEQ ID NOS: 49
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 33
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  VEGF reverse
;   OTHER INFORMATION: primer
US-09-844-508-33

  Query Match             0.8%;  Score 14.8;  DB 1;  Length 19;
  Best Local Similarity   88.9%;  Pred. No. 1.4e+02;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1322 GGAGGTCGGAGGTCGTGG 1339
              | || ||||||||||||||
Db         19 GTAGCTCGGAGGTCGTGG 2
```

```
RESULT 98
US-09-916-136A-10/c
; Sequence 10, Application US/09916136A
; Publication No. US20030162759A1
; GENERAL INFORMATION:
;  APPLICANT: Pharmacia Corporation
;  TITLE OF INVENTION: ALDOSTERONE BLOCKER THERAPY TO PREVENT OR TREAT INFLAMMATION-RELA
;  TITLE OF INVENTION:  DISORDERS
;  FILE REFERENCE: 3357/1US
;  CURRENT APPLICATION NUMBER: US/09/916,136A
;  CURRENT FILING DATE:  2002-12-20
;  NUMBER OF SEQ ID NOS: 35
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 10
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Reverse primer derived from rat collagen I sequence
US-09-916-136A-10

  Query Match             0.8%;  Score 14.8;  DB 1;  Length 19;
  Best Local Similarity   88.9%;  Pred. No. 1.4e+02;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        736 TCCAGCTGACCCTCGTGC 753
              |||||||||||  || |||
Db         18 TCCAGCTGACCTTCCTGC 1


RESULT 99
US-10-084-826-33/c
; Sequence 33, Application US/10084826
; Publication No. US20030049649A1
; GENERAL INFORMATION:
;  APPLICANT: WOLFFE, Alan P.
;  APPLICANT:  COLLINGWOOD, Trevor
;  TITLE OF INVENTION: TARGETED MODIFICATION OF CHROMATIN STRUCTURE
;  FILE REFERENCE: 8325-0014 / S14-US1
;  CURRENT APPLICATION NUMBER: US/10/084,826
;  CURRENT FILING DATE:  2002-02-24
;  PRIOR APPLICATION NUMBER: 09/844,508
;  PRIOR FILING DATE: 2001-04-27
;  PRIOR APPLICATION NUMBER: 60/228,523
;  PRIOR FILING DATE: 2000-08-28
;  NUMBER OF SEQ ID NOS: 49
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 33
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  VEGF reverse
;   OTHER INFORMATION: primer
US-10-084-826-33

  Query Match             0.8%;  Score 14.8;  DB 1;  Length 19;
  Best Local Similarity   88.9%;  Pred. No. 1.4e+02;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1322 GGAGGTCGGAGGTCGTGG 1339
              | || ||||||||||||||
Db         19 GTAGCTCGGAGGTCGTGG 2


RESULT 100
US-10-251-117-47
; Sequence 47, Application US/10251117
; Publication No. US20030170891A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Epidermal Growth Factor Re
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering RNA
;  FILE REFERENCE: 900/042 (MBHB02-468-A)
;  CURRENT APPLICATION NUMBER: US/10/251,117
;  CURRENT FILING DATE:  2003-02-24
;  PRIOR APPLICATION NUMBER: US 60/393,924
;  PRIOR FILING DATE: 2002-07-03
;  PRIOR APPLICATION NUMBER: US 10/163,552
;  PRIOR FILING DATE: 2002-06-06
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: US 09/916,466
;  PRIOR FILING DATE: 2001-07-25
;  PRIOR APPLICATION NUMBER: US 60/296,249
;  PRIOR FILING DATE: 2001-06-06
;  NUMBER OF SEQ ID NOS: 1213
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 47
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Target sequence/siNA sense re
US-10-251-117-47

  Query Match             0.8%;  Score 14.8;  DB 1;  Length 19;
  Best Local Similarity   55.6%;  Pred. No. 1.4e+02;
  Matches   10;  Conservative    6;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1085 TGTGTGCGGGTGGCTGTG 1102
              : :|:|| ||:|||:|:|
Db          2 UCUGUGCCGGUGGCUGUG 19


RESULT 101
US-10-251-117-85/c
; Sequence 85, Application US/10251117
; Publication No. US20030170891A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Epidermal Growth Factor Re
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering RNA
;  FILE REFERENCE: 900/042 (MBHB02-468-A)
;  CURRENT APPLICATION NUMBER: US/10/251,117
;  CURRENT FILING DATE:  2003-02-24
;  PRIOR APPLICATION NUMBER: US 60/393,924
;  PRIOR FILING DATE: 2002-07-03
;  PRIOR APPLICATION NUMBER: US 10/163,552
;  PRIOR FILING DATE: 2002-06-06
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: US 09/916,466
;  PRIOR FILING DATE: 2001-07-25
;  PRIOR APPLICATION NUMBER: US 60/296,249
;  PRIOR FILING DATE: 2001-06-06
;  NUMBER OF SEQ ID NOS: 1213
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 85
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Target sequence/siNA sense re
US-10-251-117-85

  Query Match             0.8%;  Score 14.8;  DB 1;  Length 19;
  Best Local Similarity   88.9%;  Pred. No. 1.4e+02;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        565 GCCTGCTGATGCCTAGCC 582
              ||| |||||||||  ||||
Db         19 GCCAGCTGATGCCCAGCC 2
```

```
RESULT 102
US-10-251-117-296/c
; Sequence 296, Application US/10251117
; Publication No. US20030170891A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Epidermal Growth Factor R
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering RNA
;  FILE REFERENCE: 900/042 (MBHB02-468-A)
;  CURRENT APPLICATION NUMBER: US/10/251,117
;  CURRENT FILING DATE:  2003-02-24
;  PRIOR APPLICATION NUMBER: US 60/393,924
;  PRIOR FILING DATE: 2002-07-03
;  PRIOR APPLICATION NUMBER: US 10/163,552
;  PRIOR FILING DATE: 2002-06-06
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: US 09/916,466
;  PRIOR FILING DATE: 2001-07-25
;  PRIOR APPLICATION NUMBER: US 60/296,249
;  PRIOR FILING DATE: 2001-06-06
;  NUMBER OF SEQ ID NOS: 1213
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 296
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA antisense region
US-10-251-117-296

  Query Match             0.8%;  Score 14.8;  DB 1;  Length 19;
  Best Local Similarity   88.9%;  Pred. No. 1.4e+02;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1085 TGTGTGCGGGTGGCTGTG 1102
              | ||||| ||||||||||
Db         18 TCTGTGCCGGTGGCTGTG 1


RESULT 103
US-10-251-117-334
; Sequence 334, Application US/10251117
; Publication No. US20030170891A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Epidermal Growth Factor R
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering RNA
;  FILE REFERENCE: 900/042 (MBHB02-468-A)
;  CURRENT APPLICATION NUMBER: US/10/251,117
;  CURRENT FILING DATE:  2003-02-24
;  PRIOR APPLICATION NUMBER: US 60/393,924
;  PRIOR FILING DATE: 2002-07-03
;  PRIOR APPLICATION NUMBER: US 10/163,552
;  PRIOR FILING DATE: 2002-06-06
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: US 09/916,466
;  PRIOR FILING DATE: 2001-07-25
;  PRIOR APPLICATION NUMBER: US 60/296,249
;  PRIOR FILING DATE: 2001-06-06
;  NUMBER OF SEQ ID NOS: 1213
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 334
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA antisense region
US-10-251-117-334

  Query Match             0.8%;  Score 14.8;  DB 1;  Length 19;
  Best Local Similarity   77.8%;  Pred. No. 1.4e+02;
  Matches   14;  Conservative    2;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        565 GCCTGCTGATGCCTAGCC 582
              ||| ||:||:||| ||||
Db          1 GCCAGCUGAUGCCCAGCC 18


RESULT 104
US-10-205-309-1
; Sequence 1, Application US/10205309
; Publication No. US20030190635A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Alzheimer's Disease Using
;  TITLE OF INVENTION:  Interfering RNA
;  FILE REFERENCE: 900/033
;  CURRENT APPLICATION NUMBER: US/10/205,309
;  CURRENT FILING DATE:  2002-10-25
;  NUMBER OF SEQ ID NOS: 674
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Target sequence/siNA sense re
US-10-205-309-1

  Query Match             0.8%;  Score 14.8;  DB 1;  Length 19;
  Best Local Similarity   83.3%;  Pred. No. 1.4e+02;
  Matches   15;  Conservative    1;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        708 GCACTCGACCCCAGCCTG 725
              ||||:|| |||||||| |
Db          2 GCACUCGUCCCCAGCCCG 19


RESULT 105
US-10-205-309-14/c
; Sequence 14, Application US/10205309
; Publication No. US20030190635A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Alzheimer's Disease Using
;  TITLE OF INVENTION:  Interfering RNA
;  FILE REFERENCE: 900/033
;  CURRENT APPLICATION NUMBER: US/10/205,309
;  CURRENT FILING DATE:  2002-10-25
;  NUMBER OF SEQ ID NOS: 674
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 14
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Target sequence/siNA sense r
US-10-205-309-14

  Query Match             0.8%;  Score 14.8;  DB 1;  Length 19;
  Best Local Similarity   88.9%;  Pred. No. 1.4e+02;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1582 GCAGGGGAGGGGCTGAGA 1599
              ||||||||| ||||| ||
Db         18 GCAGGGGAGAGGCTGGGA 1
```

```
RESULT 106
US-10-205-309-326/c
; Sequence 326, Application US/10205309
; Publication No. US20030190635A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Alzheimer's Disease Using
;  TITLE OF INVENTION:  Interfering RNA
;  FILE REFERENCE: 900/033
;  CURRENT APPLICATION NUMBER: US/10/205,309
;  CURRENT FILING DATE:  2002-10-25
;  NUMBER OF SEQ ID NOS: 674
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 326
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA antisense region
US-10-205-309-326

  Query Match             0.8%;  Score 14.8;  DB 1;  Length 19;
  Best Local Similarity   88.9%;  Pred. No. 1.4e+02;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        708 GCACTCGACCCCAGCCTG 725
              ||||||| |||||||| |
Db         18 GCACTCGTCCCCAGCCCG 1


RESULT 107
US-10-205-309-339
; Sequence 339, Application US/10205309
; Publication No. US20030190635A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Alzheimer's Disease Using
;  TITLE OF INVENTION:  Interfering RNA
;  FILE REFERENCE: 900/033
;  CURRENT APPLICATION NUMBER: US/10/205,309
;  CURRENT FILING DATE:  2002-10-25
;  NUMBER OF SEQ ID NOS: 674
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 339
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA antisense region
US-10-205-309-339

  Query Match             0.8%;  Score 14.8;  DB 1;  Length 19;
  Best Local Similarity   83.3%;  Pred. No. 1.4e+02;
  Matches   15;  Conservative    1;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1582 GCAGGGGAGGGGCTGAGA 1599
              ||||||||| |||:| ||
Db          2 GCAGGGGAGAGGCUGGGA 19


RESULT 108
US-10-444-925-188/c
; Sequence 188, Application US/10444925
; Publication No. US20040009946A1
; GENERAL INFORMATION:
;  APPLICANT: Lewis, Stephen Patrick
;  APPLICANT:  Klinghoffer, Richard
;  APPLICANT:  Wilson, Linda K.
;  TITLE OF INVENTION: MODULATION OF PTP1B SIGNAL TRANSDUCTION
;  TITLE OF INVENTION:  BY RNA INTERFERENCE
;  FILE REFERENCE: 200125.441
;  CURRENT APPLICATION NUMBER: US/10/444,925
;  CURRENT FILING DATE:  2003-05-23
;  NUMBER OF SEQ ID NOS: 599
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 188
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Small interfering RNA
US-10-444-925-188

  Query Match             0.8%;  Score 14.8;  DB 1;  Length 19;
  Best Local Similarity   88.9%;  Pred. No. 1.4e+02;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1033 GCCACCTAAGGTGGAGGT 1050
              ||||| ||| ||||||||
Db         19 GCCACTTAATGTGGAGGT 2


RESULT 109
US-10-206-705-66
; Sequence 66, Application US/10206705
; Publication No. US20040019001A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceutical, Inc.
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Protein Tyrosine Phosphate
;  TITLE OF INVENTION:  (PTP-1B) Gene Expression using Short Interfering RNA
;  FILE REFERENCE: 900/035 (MBHB02-738)
;  CURRENT APPLICATION NUMBER: US/10/206,705
;  CURRENT FILING DATE:  2002-07-26
;  NUMBER OF SEQ ID NOS: 388
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 66
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Target sequence/siNA sense re
US-10-206-705-66

  Query Match             0.8%;  Score 14.8;  DB 1;  Length 19;
  Best Local Similarity   83.3%;  Pred. No. 1.4e+02;
  Matches   15;  Conservative    1;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1275 GGGTGAAGGAAGAGGCAC 1292
              |||:|||||||||| | |
Db          2 GGGUGAAGGAAGAGACCC 19


RESULT 110
US-10-206-705-251/c
; Sequence 251, Application US/10206705
; Publication No. US20040019001A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceutical, Inc.
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Protein Tyrosine Phosphate
;  TITLE OF INVENTION:  (PTP-1B) Gene Expression using Short Interfering RNA
;  FILE REFERENCE: 900/035 (MBHB02-738)
;  CURRENT APPLICATION NUMBER: US/10/206,705
;  CURRENT FILING DATE:  2002-07-26
;  NUMBER OF SEQ ID NOS: 388
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 251
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA antisense region
US-10-206-705-251
```

```
  Query Match             0.8%;  Score 14.8;  DB 1;  Length 19;
  Best Local Similarity   88.9%;  Pred. No. 1.4e+02;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1275 GGGTGAAGGAAGAGGCAC 1292
              ||||||||||||||| | |
Db         18 GGGTGAAGGAAGAGACCC 1


RESULT 111
US-10-670-011-2
; Sequence 2, Application US/10670011
; Publication No. US20040209832A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Pavco, Pamela
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
;  TITLE OF INVENTION:  Growth Factor and Vascular Endothelial Growth Factor Receptor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/132 (MBHB02-742-G)
;  CURRENT APPLICATION NUMBER: US/10/670,011
;  CURRENT FILING DATE:  2003-09-23
;  PRIOR APPLICATION NUMBER: PCT/US03/05022
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: US60/363,124
;  PRIOR FILING DATE: 2002-03-11
;  PRIOR APPLICATION NUMBER: US60/386,782
;  PRIOR FILING DATE: 2002-06-06
;  PRIOR APPLICATION NUMBER: US60/393,796
;  PRIOR FILING DATE: 2002-07-03
;  PRIOR APPLICATION NUMBER: US60/399,348
;  PRIOR FILING DATE: 2002-07-29
;  PRIOR APPLICATION NUMBER: US60/406,784
;  PRIOR FILING DATE: 2002-08-29
;  PRIOR APPLICATION NUMBER: US60/408,378
;  PRIOR FILING DATE: 2002-09-05
;  PRIOR APPLICATION NUMBER: US60/409,293
;  PRIOR FILING DATE: 2002-09-09
;  PRIOR APPLICATION NUMBER: US60/440,129
;  PRIOR FILING DATE: 2003-01-15
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 427
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 2
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense re
US-10-670-011-2

  Query Match             0.8%;  Score 14.8;  DB 1;  Length 19;
  Best Local Similarity   72.2%;  Pred. No. 1.4e+02;
  Matches   13;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1320 GGGGAGGTCGGAGGTCGT 1337
              ||| || :|||||||:||:
Db          2 GGGUAGCUCGGAGGUCGU 19


RESULT 112
US-10-670-011-98/c
; Sequence 98, Application US/10670011
; Publication No. US20040209832A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Pavco, Pamela
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
;  TITLE OF INVENTION:  Growth Factor and Vascular Endothelial Growth Factor Receptor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/132 (MBHB02-742-G)
;  CURRENT APPLICATION NUMBER: US/10/670,011
;  CURRENT FILING DATE:  2003-09-23
;  PRIOR APPLICATION NUMBER: PCT/US03/05022
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: US60/363,124
;  PRIOR FILING DATE: 2002-03-11
;  PRIOR APPLICATION NUMBER: US60/386,782
;  PRIOR FILING DATE: 2002-06-06
;  PRIOR APPLICATION NUMBER: US60/393,796
;  PRIOR FILING DATE: 2002-07-03
;  PRIOR APPLICATION NUMBER: US60/399,348
;  PRIOR FILING DATE: 2002-07-29
;  PRIOR APPLICATION NUMBER: US60/406,784
;  PRIOR FILING DATE: 2002-08-29
;  PRIOR APPLICATION NUMBER: US60/408,378
;  PRIOR FILING DATE: 2002-09-05
;  PRIOR APPLICATION NUMBER: US60/409,293
;  PRIOR FILING DATE: 2002-09-09
;  PRIOR APPLICATION NUMBER: US60/440,129
;  PRIOR FILING DATE: 2003-01-15
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 427
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 98
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-670-011-98

  Query Match             0.8%;  Score 14.8;  DB 1;  Length 19;
  Best Local Similarity   88.9%;  Pred. No. 1.4e+02;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1320 GGGGAGGTCGGAGGTCGT 1337
              ||| || ||||||||||
Db         18 GGGTAGCTCGGAGGTCGT 1


RESULT 113
US-09-099-823-14
; Sequence 14, Application US/09099823
; Patent No. US20020018990A1
;  GENERAL INFORMATION:
;    APPLICANT:  BILLING-MEDEL, PATRICIA
;    APPLICANT:  COHEN, MAURICE
;    APPLICANT:  COLPITTS, TRACEY L.
;    APPLICANT:  FRIEDMAN, PAULA N.
;    APPLICANT:  GORDON, JULIAN
;    APPLICANT:  GRANADOS, EDWARD N.
;    APPLICANT:  HODGES, STEVEN C.
;    APPLICANT:  KLASS, MICHAEL R.
;    APPLICANT:  KRATOCHVIL, JON D.
;    APPLICANT:  RUSSELL, JOHN C.
;    APPLICANT:  SCHEFFEL, CHRISTI
;    APPLICANT:  STROUPE, STEPHEN D.
;    APPLICANT:  YU, HONG
;    TITLE OF INVENTION:  REAGENTS AND METHODS USEFUL
;    TITLE OF INVENTION:  FOR DETECTING DISEASES OF THE BREAST
;    NUMBER OF SEQUENCES:  27
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Abbott Laboratories
;      STREET:  100 Abbott Park Road
;      CITY:  Abbott Park
;      STATE:  IL
```

```
;       COUNTRY:  USA
;       ZIP:  60064-3500
;     COMPUTER READABLE FORM:
;       MEDIUM TYPE:  Diskette
;       COMPUTER:  IBM Compatible
;       OPERATING SYSTEM:  DOS
;       SOFTWARE:  FastSEQ for Windows Version 2.0
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  US/09/099,823
;       FILING DATE:
;       CLASSIFICATION:
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  08/879,354
;       FILING DATE:  20-JUN-1997
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Becker, Cheryl L.
;       REGISTRATION NUMBER:  35,441
;       REFERENCE/DOCKET NUMBER:  6120.US.P1
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  847/935-1729
;       TELEFAX:  847/938-2623
;       TELEX:
;  INFORMATION FOR SEQ ID NO:  14:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  26 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
US-09-099-823-14

  Query Match             0.8%;  Score 14.8;  DB 1;  Length 26;
  Best Local Similarity   73.1%;  Pred. No. 1.7e+02;
  Matches   19;  Conservative    0;  Mismatches    7;  Indels    0;  Gaps    0;

Qy       1387 TGTTTGTTTTGTATCTTGTTTTTCTG 1412
             | ||| |||| | | || ||||| ||
Db          1 TTTTTTTTTTTTTTTTTTTTTTTTTG 26


RESULT 114
US-09-920-342-3
; Sequence 3, Application US/09920342
; Patent No. US20020137709A1
; GENERAL INFORMATION:
;  APPLICANT: University of Southern California
;  APPLICANT:  Lin, Shi-Lung
;  APPLICANT:  Chuong, Cheng-Ming
;  APPLICANT:  Widelitz, Randall B.
;  TITLE OF INVENTION: GENE SILENCING USING MRNA-CDNA HYBRIDS
;  FILE REFERENCE: 13761-7024
;  CURRENT APPLICATION NUMBER: US/09/920,342
;  CURRENT FILING DATE:  2002-01-17
;  PRIOR APPLICATION NUMBER: US 60/222,479
;  PRIOR FILING DATE: 2000-08-02
;  NUMBER OF SEQ ID NOS: 15
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 3
;   LENGTH: 26
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Poly(dT)-26mer primer
US-09-920-342-3

  Query Match             0.8%;  Score 14.8;  DB 1;  Length 26;
  Best Local Similarity   73.1%;  Pred. No. 1.7e+02;
  Matches   19;  Conservative    0;  Mismatches    7;  Indels    0;  Gaps    0;

Qy       1382 TTTGTTGTTTGTTTTGTATCTTGTTT 1407
             ||| || ||| |||| | | || |||
Db          1 TTTTTTTTTTTTTTTTTTTTTTTTTT 26


RESULT 115
US-09-949-305B-4
; Sequence 4, Application US/09949305B
; Publication No. US20030022318A1
; GENERAL INFORMATION:
;  APPLICANT: Lin, Shi-Lung
;  APPLICANT:  Ying, Shao-Yao
;  TITLE OF INVENTION: Method for Thermocycling Amplification of Nucleic Acid Sequences a
;  TITLE OF INVENTION:  Generation of Related Peptides Thereof
;  FILE REFERENCE: 266/014
;  CURRENT APPLICATION NUMBER: US/09/949,305B
;  CURRENT FILING DATE:  2001-09-07
;  PRIOR APPLICATION NUMBER: 09/494,212
;  PRIOR FILING DATE: 2000-01-25
;  NUMBER OF SEQ ID NOS: 12
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 4
;   LENGTH: 26
;   TYPE: DNA
;   ORGANISM: artificial sequence
;   FEATURE:
;   OTHER INFORMATION: poly(dT) primer
US-09-949-305B-4

  Query Match             0.8%;  Score 14.8;  DB 1;  Length 26;
  Best Local Similarity   73.1%;  Pred. No. 1.7e+02;
  Matches   19;  Conservative    0;  Mismatches    7;  Indels    0;  Gaps    0;

Qy       1382 TTTGTTGTTTGTTTTGTATCTTGTTT 1407
             ||| || ||| |||| | | || |||
Db          1 TTTTTTTTTTTTTTTTTTTTTTTTTT 26


RESULT 116
US-10-053-883-53
; Sequence 53, Application US/10053883
; Publication No. US20030113737A1
; GENERAL INFORMATION:
;  APPLICANT: PEDERSEN, Morten Lorentz
;  TITLE OF INVENTION: ASSAY AND KIT FOR ANALYZING GENE EXPRESSION
;  FILE REFERENCE: PEDERSENA=1A
;  CURRENT APPLICATION NUMBER: US/10/053,883
;  CURRENT FILING DATE:  2002-01-02
;  PRIOR APPLICATION NUMBER: PA 2001 00126
;  PRIOR FILING DATE: 2001-01-24
;  PRIOR APPLICATION NUMBER: US 60/267,704
;  PRIOR FILING DATE: 2001-02-12
;  NUMBER OF SEQ ID NOS: 148
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 53
;   LENGTH: 26
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: synthetic
US-10-053-883-53

  Query Match             0.8%;  Score 14.8;  DB 1;  Length 26;
  Best Local Similarity   73.1%;  Pred. No. 1.7e+02;
  Matches   19;  Conservative    0;  Mismatches    7;  Indels    0;  Gaps    0;

Qy       1382 TTTGTTGTTTGTTTTGTATCTTGTTT 1407
             ||| || ||| |||| | | || |||
Db          1 TTTTTTTTTTTTTTTTTTTTTTTTTT 26


RESULT 117
US-09-263-959-614
; Sequence 614, Application US/09263959
; Patent No. US20020150891A1
;  GENERAL INFORMATION:
;    APPLICANT:  Hood, Leroy E.
;    APPLICANT:  Rowen, Lee
```

```
;    APPLICANT:  Koop, Ben F.
;    TITLE OF INVENTION:  DIAGNOSTIC AND THERAPEUTIC COMPOSITIONS AND METHODS WHICH UTI
;    NUMBER OF SEQUENCES:  1279
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Seed and Berry LLP
;      STREET:  6300 Columbia Center, 701 Fifth Avenue
;      CITY:  Seattle
;      STATE:  Washington
;      COUNTRY:  US
;      ZIP:  98104-7092
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/263,959
;      FILING DATE:  05-MAR-1999
;      CLASSIFICATION:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  McMasters, David D.
;      REGISTRATION NUMBER:  33,963
;      REFERENCE/DOCKET NUMBER:  920010.426C2
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (206) 622-4900
;      TELEFAX:  (206) 682-6031
;  INFORMATION FOR SEQ ID NO:  614:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  22 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-09-263-959-614

  Query Match             0.8%;  Score 14.6;  DB 1;  Length 22;
  Best Local Similarity   81.0%;  Pred. No. 1.6e+02;
  Matches   17;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1380 TGTTTGTTGTTTGTTTTGTAT 1400
              | | | ||||||||||||| |
Db          1 TTTGTTTTGTTTGTTTTGTTT 21


RESULT 118
US-10-309-775A-20
; Sequence 20, Application US/10309775A
; Publication No. US20040006032A1
; GENERAL INFORMATION:
;  APPLICANT: LOPEZ, Ricardo A.
;  TITLE OF INVENTION: IMMUNOSTIMULATORY OLIGONUCLEOTIDES AND USES THEREOF
;  FILE REFERENCE: 2901/0M327
;  CURRENT APPLICATION NUMBER: US/10/309,775A
;  CURRENT FILING DATE:  2002-12-04
;  PRIOR APPLICATION NUMBER: CA 2,388,049
;  PRIOR FILING DATE: 2002-05-30
;  NUMBER OF SEQ ID NOS: 74
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 20
;   LENGTH: 24
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: PCR primer
US-10-309-775A-20

  Query Match             0.8%;  Score 14.6;  DB 1;  Length 24;
  Best Local Similarity   81.0%;  Pred. No. 1.7e+02;
  Matches   17;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1389 TTTGTTTTGTATCTTGTTTTT 1409
              ||||||||  | |  || |||||
Db          4 TTTGTTTTTTTTTTTTTTTTT 24


RESULT 119
US-09-922-480-6
; Sequence 6, Application US/09922480
; Patent No. US20020081701A1
; GENERAL INFORMATION:
;  APPLICANT: Sheppard, Paul O.
;  APPLICANT:  Adler, David A.
;  TITLE OF INVENTION: SECRETED SALIVARY ZSIG63 POLYPEPTIDE
;  FILE REFERENCE: 97-71
;  CURRENT APPLICATION NUMBER: US/09/922,480
;  CURRENT FILING DATE:  2001-08-03
;  PRIOR APPLICATION NUMBER: US 60/124,820
;  PRIOR FILING DATE: 1999-03-17
;  NUMBER OF SEQ ID NOS: 9
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 6
;   LENGTH: 26
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide primer ZC7231
US-09-922-480-6

  Query Match             0.8%;  Score 14.6;  DB 1;  Length 26;
  Best Local Similarity   72.0%;  Pred. No. 1.8e+02;
  Matches   18;  Conservative    1;  Mismatches    6;  Indels    0;  Gaps    0;

Qy       1386 TTGTTTGTTTTGTATCTTGTTTTTC 1410
              || ||| |||| | | || |||||:
Db          2 TTTTTTTTTTTTTTTTTTTTTTTV 26


RESULT 120
US-09-923-236-6
; Sequence 6, Application US/09923236
; Patent No. US20020090677A1
; GENERAL INFORMATION:
;  APPLICANT: Sheppard, Paul O.
;  APPLICANT:  Adler, David A.
;  TITLE OF INVENTION: SECRETED SALIVARY ZSIG63 POLYPEPTIDE
;  FILE REFERENCE: 97-71
;  CURRENT APPLICATION NUMBER: US/09/923,236
;  CURRENT FILING DATE:  2001-08-03
;  PRIOR APPLICATION NUMBER: US 60/124,820
;  PRIOR FILING DATE: 1999-03-17
;  NUMBER OF SEQ ID NOS: 9
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 6
;   LENGTH: 26
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide primer ZC7231
US-09-923-236-6

  Query Match             0.8%;  Score 14.6;  DB 1;  Length 26;
  Best Local Similarity   72.0%;  Pred. No. 1.8e+02;
  Matches   18;  Conservative    1;  Mismatches    6;  Indels    0;  Gaps    0;

Qy       1386 TTGTTTGTTTTGTATCTTGTTTTTC 1410
              || ||| |||| | | || |||||:
Db          2 TTTTTTTTTTTTTTTTTTTTTTTV 26


RESULT 121
US-09-922-469-6
; Sequence 6, Application US/09922469
; Patent No. US20020173027A1
; GENERAL INFORMATION:
;  APPLICANT: Sheppard, Paul O.
;  APPLICANT:  Adler, David A.
;  TITLE OF INVENTION: SECRETED SALIVARY ZSIG63 POLYPEPTIDE
```

```
;  FILE REFERENCE: 97-71
;  CURRENT APPLICATION NUMBER: US/09/922,469
;  CURRENT FILING DATE:  2001-08-03
;  PRIOR APPLICATION NUMBER: US 60/124,820
;  PRIOR FILING DATE: 1999-03-17
;  NUMBER OF SEQ ID NOS: 9
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 6
;   LENGTH: 26
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide primer ZC7231
US-09-922-469-6

  Query Match             0.8%;  Score 14.6;  DB 1;  Length 26;
  Best Local Similarity   72.0%;  Pred. No. 1.8e+02;
  Matches   18;  Conservative    1;  Mismatches    6;  Indels    0;  Gaps    0;

Qy       1386 TTGTTTGTTTTGTATCTTGTTTTTC 1410
                || ||| |||| | | || |||||:
Db          2 TTTTTTTTTTTTTTTTTTTTTTTTV 26


RESULT 122
US-10-039-876A-10
; Sequence 10, Application US/10039876A
; Publication No. US20030032792A1
; GENERAL INFORMATION:
;  APPLICANT: Conklin, Darrell C.
;  APPLICANT:  Blumberg, Hal
;  TITLE OF INVENTION: A HUMAN 2-19 PROTEIN HOMOLOGUE, Z219A
;  FILE REFERENCE: 97-63C1
;  CURRENT APPLICATION NUMBER: US/10/039,876A
;  CURRENT FILING DATE:  2001-10-26
;  PRIOR APPLICATION NUMBER: US 60/061,712
;  PRIOR FILING DATE: 1997-10-06
;  PRIOR APPLICATION NUMBER: US 09/167,513
;  PRIOR FILING DATE: 1998-10-06
;  NUMBER OF SEQ ID NOS: 28
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 10
;   LENGTH: 26
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide primer ZC7231
US-10-039-876A-10

  Query Match             0.8%;  Score 14.6;  DB 1;  Length 26;
  Best Local Similarity   72.0%;  Pred. No. 1.8e+02;
  Matches   18;  Conservative    1;  Mismatches    6;  Indels    0;  Gaps    0;

Qy       1386 TTGTTTGTTTTGTATCTTGTTTTTC 1410
                || ||| |||| | | || |||||:
Db          2 TTTTTTTTTTTTTTTTTTTTTTTTV 26


RESULT 123
US-10-196-703-43
; Sequence 43, Application US/10196703
; Publication No. US20030055019A1
; GENERAL INFORMATION:
;  APPLICANT: Shimkets, Richard A.
;  TITLE OF INVENTION: Genes and Proteins Predictive and Therapeutic for
;  TITLE OF INVENTION:  Stroke, Hypertension, Diabetes, and Obesity
;  FILE REFERENCE: 15966-527
;  CURRENT APPLICATION NUMBER: US/10/196,703
;  CURRENT FILING DATE:  2002-07-15
;  PRIOR APPLICATION NUMBER: US/09/161,939
;  PRIOR FILING DATE: 1998-09-28
;  NUMBER OF SEQ ID NOS: 44
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 43
;   LENGTH: 26
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: oligo(dT)<25>V
US-10-196-703-43

  Query Match             0.8%;  Score 14.6;  DB 1;  Length 26;
  Best Local Similarity   72.0%;  Pred. No. 1.8e+02;
  Matches   18;  Conservative    1;  Mismatches    6;  Indels    0;  Gaps    0;

Qy       1386 TTGTTTGTTTTGTATCTTGTTTTTC 1410
                || ||| |||| | | || |||||:
Db          2 TTTTTTTTTTTTTTTTTTTTTTTTV 26


RESULT 124
US-10-352-253A-36
; Sequence 36, Application US/10352253A
; Publication No. US20030175908A1
; GENERAL INFORMATION:
;  APPLICANT: Linnarsson, Sten
;  APPLICANT:  Ernfors, Patrik
;  APPLICANT:  Bauren, Goran
;  APPLICANT:  Metsis, Ats
;  APPLICANT:  Pihlak, Arno
;  APPLICANT:  Montelius, Andreas
;  TITLE OF INVENTION: Methods And Means For Manipulating Nucleic Acid
;  FILE REFERENCE: 620-234
;  CURRENT APPLICATION NUMBER: US/10/352,253A
;  CURRENT FILING DATE:  2003-01-28
;  PRIOR APPLICATION NUMBER: US 60/352,215
;  PRIOR FILING DATE: 2002-01-29
;  NUMBER OF SEQ ID NOS: 37
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 36
;   LENGTH: 26
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:
;   OTHER INFORMATION: Primer
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (26)
;   OTHER INFORMATION: v is a, c or g
US-10-352-253A-36

  Query Match             0.8%;  Score 14.6;  DB 1;  Length 26;
  Best Local Similarity   72.0%;  Pred. No. 1.8e+02;
  Matches   18;  Conservative    1;  Mismatches    6;  Indels    0;  Gaps    0;

Qy       1386 TTGTTTGTTTTGTATCTTGTTTTTC 1410
                || ||| |||| | | || |||||:
Db          2 TTTTTTTTTTTTTTTTTTTTTTTTV 26


RESULT 125
US-10-224-289-20
; Sequence 20, Application US/10224289
; Publication No. US20030207288A1
; GENERAL INFORMATION:
;  APPLICANT: LEWIN, DAVID A.
;  APPLICANT:  STEWART, TIMOTHY A.
;  TITLE OF INVENTION: GPCR-LIKE RETINOIC ACID-INDUCED GENE 1 PROTEIN AND
;  TITLE OF INVENTION:  NUCLEIC ACID
;  FILE REFERENCE: 9800081-0085
;  CURRENT APPLICATION NUMBER: US/10/224,289
;  CURRENT FILING DATE:  2002-08-20
;  PRIOR APPLICATION NUMBER: 60/313,940
;  PRIOR FILING DATE: 2001-08-20
;  NUMBER OF SEQ ID NOS: 20
```

```
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 20
;   LENGTH: 26
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;   OTHER INFORMATION: oligonucleotide
US-10-224-289-20

  Query Match             0.8%;  Score 14.6;  DB 1;  Length 26;
  Best Local Similarity   72.0%;  Pred. No. 1.8e+02;
  Matches   18;  Conservative    1;  Mismatches    6;  Indels    0;  Gaps    0;

Qy       1386 TTGTTTGTTTTGTATCTTGTTTTTC 1410
              || ||| |||| | | || |||||:
Db          2 TTTTTTTTTTTTTTTTTTTTTTTTV 26


RESULT 126
US-10-071-214-42
; Sequence 42, Application US/10071214
; Publication No. US20030066099A1
; GENERAL INFORMATION:
;  APPLICANT: HANSSON, Lennart
;  APPLICANT:  EGELRUD, Torbjorn
;  TITLE OF INVENTION: SCCE MODIFIED TRANSGENIC MAMMALS AND THEIR USE AS MODELS OF HUMAN
;  FILE REFERENCE: HANSSON=3A
;  CURRENT APPLICATION NUMBER: US/10/071,214
;  CURRENT FILING DATE:  2002-02-11
;  PRIOR APPLICATION NUMBER: US 60/267,422
;  PRIOR FILING DATE: 2001-02-09
;  PRIOR APPLICATION NUMBER: DK PA 2001 00218
;  PRIOR FILING DATE: 2001-02-09
;  NUMBER OF SEQ ID NOS: 50
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 42
;   LENGTH: 27
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: 5'-RACE cDNA synthesis primer
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (27)..(27)
;   OTHER INFORMATION: n is a or g or c or t
US-10-071-214-42

  Query Match             0.8%;  Score 14.6;  DB 1;  Length 27;
  Best Local Similarity   72.0%;  Pred. No. 1.9e+02;
  Matches   18;  Conservative    1;  Mismatches    6;  Indels    0;  Gaps    0;

Qy       1386 TTGTTTGTTTTGTATCTTGTTTTTC 1410
              || ||| |||| | | || |||||:
Db          2 TTTTTTTTTTTTTTTTTTTTTTTTV 26


RESULT 127
US-09-825-805-616
; Sequence 616, Application US/09825805
; Publication No. US20030004122A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Beigelman, Leo
;  APPLICANT:  Beaudry, Amber
;  APPLICANT:  Karpeisky, Alex
;  APPLICANT:  Adamic, Jasenka Matulic
;  APPLICANT:  Sweedler, Dave
;  APPLICANT:  Zinnen, Shawn
;  TITLE OF INVENTION: Nucleotide Triphosphate and their Incorporation into Oligonucleot
;  FILE REFERENCE: MBHB00-831-F (400/009)
;  CURRENT APPLICATION NUMBER: US/09/825,805
;  CURRENT FILING DATE:  2001-09-27
;  PRIOR APPLICATION NUMBER: 09/578,223
;  PRIOR FILING DATE: 2000-05-23
;  PRIOR APPLICATION NUMBER: 09/476,387
;  PRIOR FILING DATE: 1999-12-30
;  PRIOR APPLICATION NUMBER: 09/474,432
;  PRIOR FILING DATE: 1999-12-29
;  PRIOR APPLICATION NUMBER: 09/301,511
;  PRIOR FILING DATE: 1999-04-28
;  PRIOR APPLICATION NUMBER: 09/186,675
;  PRIOR FILING DATE: 1998-11-04
;  PRIOR APPLICATION NUMBER: 60/083,727
;  PRIOR FILING DATE: 1998-04-29
;  PRIOR APPLICATION NUMBER: 60/064,866
;  PRIOR FILING DATE: 1997-11-05
;  NUMBER OF SEQ ID NOS: 1558
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 616
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-825-805-616

  Query Match             0.8%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   62.5%;  Pred. No. 1.5e+02;
  Matches   10;  Conservative    5;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1087 TGTGCGGGTGGCTGTG 1102
              :|:|| ||:|||:|:|
Db          2 UGUGCCGGUGGCUGUG 17


RESULT 128
US-09-961-077-218
; Sequence 218, Application US/09961077
; Publication No. US20030014775A1
;   GENERAL INFORMATION:
;        APPLICANT: Zwick, Michael G.
;                   Edington, Brent E.
;                   McSwiggen, James A.
;                   Merlo, Patricia Ann Owens
;                   Guo, Lining
;                   Skokut, Thomas A.
;                   Young, Scott A.
;                   Folkerts, Otto
;                   Merlo, Donald J.
;        TITLE OF INVENTION: COMPOSITION AND METHODS FOR
;                            MODULATION OF GENE EXPRESSION
;                            IN PLANTS
;        NUMBER OF SEQUENCES: 1263
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: Lyon & Lyon
;             STREET: 633 West Fifth Street
;                     Suite 4700
;             CITY: Los Angeles
;             STATE: California
;             COUNTRY: U.S.A.
;             ZIP: 90071-2066
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
;                          storage
;             COMPUTER: IBM Compatible
;             OPERATING SYSTEM: IBM P.C. DOS 5.0
;             SOFTWARE: Word Perfect 5.1
;        CURRENT APPLICATION DATA:
;             APPLICATION NUMBER: US/09/961,077
;             FILING DATE: 21-Sep-2001
;             CLASSIFICATION: <Unknown>
;        PRIOR APPLICATION DATA:
;             APPLICATION NUMBER: 08/679,645
;             FILING DATE: July 12, 1996
;             APPLICATION NUMBER: 60/001,135
;             FILING DATE: July 13, 1995
;             APPLICATION NUMBER: 08/300,726
```

```
;             FILING DATE: September 2, 1994
;         ATTORNEY/AGENT INFORMATION:
;             NAME: Warburg, Richard J.
;             REGISTRATION NUMBER: 32,327
;             REFERENCE/DOCKET NUMBER: 219/247
;         TELECOMMUNICATION INFORMATION:
;             TELEPHONE: (213) 489-1600
;             TELEFAX: (213) 955-0440
;             TELEX: 67-3510
;    INFORMATION FOR SEQ ID NO: 218:
;         SEQUENCE CHARACTERISTICS:
;             LENGTH: 17 base pairs
;             TYPE: nucleic acid
;             STRANDEDNESS: single
;             TOPOLOGY: linear
;         SEQUENCE DESCRIPTION: SEQ ID NO: 218:
US-09-961-077-218

  Query Match             0.8%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   75.0%;  Pred. No. 1.5e+02;
  Matches   12;  Conservative    3;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        311 CTCAGCCTGGGGGTCG 326
              |:|||||: ||||:||
Db          1 CUCAGCCUCGGGGUCG 16


RESULT 129
US-09-780-533A-2370/c
; Sequence 2370, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Blatt, Larry
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Chowrira, Bharat
;  APPLICANT:  Haeberli, Pete
;  TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
;  FILE REFERENCE: MBHB00,878-A (400/011)
;  CURRENT APPLICATION NUMBER: US/09/780,533A
;  CURRENT FILING DATE:  2001-02-09
;  PRIOR APPLICATION NUMBER: US 60/181,797
;  PRIOR FILING DATE: 2000-02-11
;  NUMBER OF SEQ ID NOS: 6679
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2370
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-780-533A-2370

  Query Match             0.8%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 1.5e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        261 TCTTCGCCCTCGTCCT 276
              |||||| |||||||||
Db         17 TCTTCGTCCTCGTCCT 2


RESULT 130
US-09-780-533A-2371/c
; Sequence 2371, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Blatt, Larry
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Chowrira, Bharat
;  APPLICANT:  Haeberli, Pete
;  TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
;  FILE REFERENCE: MBHB00,878-A (400/011)
;  CURRENT APPLICATION NUMBER: US/09/780,533A
;  CURRENT FILING DATE:  2001-02-09
;  PRIOR APPLICATION NUMBER: US 60/181,797
;  PRIOR FILING DATE: 2000-02-11
;  NUMBER OF SEQ ID NOS: 6679
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2371
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-780-533A-2371

  Query Match             0.8%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 1.5e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        261 TCTTCGCCCTCGTCCT 276
              |||||| |||||||||
Db         16 TCTTCGTCCTCGTCCT 1


RESULT 131
US-10-163-552-187
; Sequence 187, Application US/10163552
; Publication No. US20030105051A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  McSwiggen, Jim
;  TITLE OF INVENTION: Nucleic acid treatment of diseases or conditions related to levels
;  TITLE OF INVENTION:  HER2
;  FILE REFERENCE: MBHB01-1653-A (400/014)
;  CURRENT APPLICATION NUMBER: US/10/163,552
;  CURRENT FILING DATE:  2002-06-06
;  NUMBER OF SEQ ID NOS: 1997
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 187
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-163-552-187

  Query Match             0.8%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   62.5%;  Pred. No. 1.5e+02;
  Matches   10;  Conservative    5;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1087 TGTGCGGGTGGCTGTG 1102
              :|:|| ||:|||:|:|
Db          2 UGUGCCGGUGGCUGUG 17


RESULT 132
US-10-156-306-6907
; Sequence 6907, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
;  TITLE OF INVENTION:  Levels of IKK-Gamma and PKR
;  FILE REFERENCE: MBHB01-664-A (400/050)
;  CURRENT APPLICATION NUMBER: US/10/156,306
;  CURRENT FILING DATE:  2002-05-28
;  NUMBER OF SEQ ID NOS: 8013
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6907
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-156-306-6907

  Query Match             0.8%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 1.5e+02;
  Matches   14;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;
```

```
Qy        515 GCTGCAGGAGAGCCTG 530
              ||:|||||||||||| |
Db          2 GCUGCAGGAGAGCCAG 17
```

RESULT 133
US-10-238-700-199/c
; Sequence 199, Application US/10238700
; Publication No. US20030153521A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related to Level
; FILE REFERENCE: 400/057 (MBHB01-1158-A)
; CURRENT APPLICATION NUMBER: US/10/238,700
; CURRENT FILING DATE: 2002-09-18
; PRIOR APPLICATION NUMBER: PCT/US 02/16840
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/318,471
; PRIOR FILING DATE: 2001-09-10
; NUMBER OF SEQ ID NOS: 4666
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 199
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-238-700-199

Query Match 0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy        663 GTCTGCGTGGAGCAGG 678
              |||||| |||||||||
Db         16 GTCTGCATGGAGCAGG 1
```

RESULT 134
US-10-138-674-3604
; Sequence 3604, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3604
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus musculus
US-10-138-674-3604

Query Match 0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 18.8%; Pred. No. 1.5e+02;
Matches 3; Conservative 12; Mismatches 1; Indels 0; Gaps 0;

```
Qy       1382 TTTGTTGTTTGTTTTG 1397
              :::|:: :::|::::|
Db          2 UUUGUUUUUUGUUUUG 17
```

RESULT 135
US-10-138-674-3606
; Sequence 3606, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3606
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus musculus
US-10-138-674-3606

Query Match 0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 18.8%; Pred. No. 1.5e+02;
Matches 3; Conservative 12; Mismatches 1; Indels 0; Gaps 0;

```
Qy       1383 TTGTTGTTTGTTTTGT 1398
              ::|:: :::|::::|:
Db          1 UUGUUUUUUGUUUUGU 16
```

RESULT 136
US-10-138-674-6350
; Sequence 6350, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6350
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-6350

Query Match 0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 1.5e+02;
Matches 13; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

```
Qy        287 TCCCACCCCAGATCGG 302
              :|||||||||||: ||
Db          2 UCCCACCCCAGAUUGG 17
```

RESULT 137
US-10-138-674-6351
; Sequence 6351, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBHB00-876-N (400/049)

```
;  CURRENT APPLICATION NUMBER: US/10/138,674
;  CURRENT FILING DATE:  2002-05-03
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6351
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-138-674-6351

  Query Match             0.8%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 1.5e+02;
  Matches   13;  Conservative    2;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        287 TCCCACCCCAGATCGG 302
              :||||||||||: ||
Db          1 UCCCACCCCAGAUUGG 16


RESULT 138
US-10-287-949A-3604
; Sequence 3604, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/287,949A
;  CURRENT FILING DATE:  2003-04-11
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3604
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Mus musculus
US-10-287-949A-3604

  Query Match             0.8%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   18.8%;  Pred. No. 1.5e+02;
  Matches    3;  Conservative   12;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1382 TTTGTTGTTTGTTTTG 1397
              :::|:: :::|::::|
Db          2 UUUGUUUUUUGUUUUG 17


RESULT 139
US-10-287-949A-3606
; Sequence 3606, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/287,949A
;  CURRENT FILING DATE:  2003-04-11
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3606
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Mus musculus
US-10-287-949A-3606

  Query Match             0.8%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   18.8%;  Pred. No. 1.5e+02;
  Matches    3;  Conservative   12;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1383 TTGTTGTTTGTTTTGT 1398
              ::|:: :::|::::|:
Db          1 UUGUUUUUUGUUUUGU 16


RESULT 140
US-10-287-949A-6350
; Sequence 6350, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/287,949A
;  CURRENT FILING DATE:  2003-04-11
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6350
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-287-949A-6350

  Query Match             0.8%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 1.5e+02;
  Matches   13;  Conservative    2;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        287 TCCCACCCCAGATCGG 302
              :||||||||||: ||
Db          2 UCCCACCCCAGAUUGG 17


RESULT 141
US-10-287-949A-6351
; Sequence 6351, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/287,949A
;  CURRENT FILING DATE:  2003-04-11
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6351
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-287-949A-6351

  Query Match             0.8%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 1.5e+02;
  Matches   13;  Conservative    2;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        287 TCCCACCCCAGATCGG 302
              :||||||||||: ||
Db          1 UCCCACCCCAGAUUGG 16
```

```
RESULT 142
US-09-961-077-631
; Sequence 631, Application US/09961077
; Publication No. US20030014775A1
;   GENERAL INFORMATION:
;        APPLICANT: Zwick, Michael G.
;                   Edington, Brent E.
;                   McSwiggen, James A.
;                   Merlo, Patricia Ann Owens
;                   Guo, Lining
;                   Skokut, Thomas A.
;                   Young, Scott A.
;                   Folkerts, Otto
;                   Merlo, Donald J.
;        TITLE OF INVENTION: COMPOSITION AND METHODS FOR
;                            MODULATION OF GENE EXPRESSION
;                            IN PLANTS
;        NUMBER OF SEQUENCES: 1263
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: Lyon & Lyon
;             STREET: 633 West Fifth Street
;                     Suite 4700
;             CITY: Los Angeles
;             STATE: California
;             COUNTRY: U.S.A.
;             ZIP: 90071-2066
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
;                          storage
;             COMPUTER: IBM Compatible
;             OPERATING SYSTEM: IBM P.C. DOS 5.0
;             SOFTWARE: Word Perfect 5.1
;        CURRENT APPLICATION DATA:
;             APPLICATION NUMBER: US/09/961,077
;             FILING DATE: 21-Sep-2001
;             CLASSIFICATION: <Unknown>
;        PRIOR APPLICATION DATA:
;             APPLICATION NUMBER: 08/679,645
;             FILING DATE: July 12, 1996
;             APPLICATION NUMBER: 60/001,135
;             FILING DATE: July 13, 1995
;             APPLICATION NUMBER: 08/300,726
;             FILING DATE: September 2, 1994
;        ATTORNEY/AGENT INFORMATION:
;             NAME: Warburg, Richard J.
;             REGISTRATION NUMBER: 32,327
;             REFERENCE/DOCKET NUMBER: 219/247
;        TELECOMMUNICATION INFORMATION:
;             TELEPHONE: (213) 489-1600
;             TELEFAX: (213) 955-0440
;             TELEX: 67-3510
;   INFORMATION FOR SEQ ID NO: 631:
;        SEQUENCE CHARACTERISTICS:
;             LENGTH: 18 base pairs
;             TYPE: nucleic acid
;             STRANDEDNESS: single
;             TOPOLOGY: linear
;        SEQUENCE DESCRIPTION: SEQ ID NO: 631:
US-09-961-077-631

  Query Match             0.8%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   75.0%;  Pred. No. 1.5e+02;
  Matches   12;  Conservative    3;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        310 GCTCAGCCTGGGGGTC 325
              ||:|||||: ||||:|
Db          3 GCUCAGCCUCGGGGUC 18


RESULT 143
US-10-297-068-201
; Sequence 201, Application US/10297068
; Publication No. US20030228585A1
; GENERAL INFORMATION:
;  APPLICANT: INOKO, Hidetoshi
;  APPLICANT:  KAGIYA, Taeko
;  APPLICANT:  ICHIHARA, Tatsuo
;  APPLICANT:  Matsumura, Yoshiyuki
;  APPLICANT:  MORIYA, Shogo
;  APPLICANT:  NISHIDA, Michio
;  TITLE OF INVENTION: KIT AND METHOD FOR DETERMINING HLA TYPES
;  FILE REFERENCE: 1314OP1174
;  CURRENT APPLICATION NUMBER: US/10/297,068
;  CURRENT FILING DATE:  2002-11-27
;  PRIOR APPLICATION NUMBER: JP 2000-164798
;  PRIOR FILING DATE: 2000-06-01
;  NUMBER OF SEQ ID NOS: 1298
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 201
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:capture
US-10-297-068-201

  Query Match             0.8%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 1.5e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        839 CCTGACGCTGAGCACT 854
              ||||||||||| |||
Db          3 CCTGACGCTGAGTACT 18


RESULT 144
US-10-300-683-109/c
; Sequence 109, Application US/10300683
; Publication No. US20030235834A1
; GENERAL INFORMATION:
;  APPLICANT: Dunlop, Charles L.M.
;  APPLICANT:  Weisel, James M.
;  TITLE OF INVENTION: APPROACHES TO IDENTIFY CYSTIC FIBROSIS
;  FILE REFERENCE: CHARDUN.010A
;  CURRENT APPLICATION NUMBER: US/10/300,683
;  CURRENT FILING DATE:  2002-11-19
;  PRIOR APPLICATION NUMBER: 60/333,531
;  PRIOR FILING DATE: 2001-11-19
;  NUMBER OF SEQ ID NOS: 554
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 109
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Diagnostic Oligonucleotide
US-10-300-683-109

  Query Match             0.8%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 1.5e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1129 TGTAGCATGAAACAAA 1144
              ||||||||| ||||||
Db         16 TGTAGCATGTAACAAA 1


RESULT 145
US-10-300-683-278/c
; Sequence 278, Application US/10300683
; Publication No. US20030235834A1
; GENERAL INFORMATION:
;  APPLICANT: Dunlop, Charles L.M.
;  APPLICANT:  Weisel, James M.
;  TITLE OF INVENTION: APPROACHES TO IDENTIFY CYSTIC FIBROSIS
```

```
;  FILE REFERENCE: CHARDUN.010A
;  CURRENT APPLICATION NUMBER: US/10/300,683
;  CURRENT FILING DATE:  2002-11-19
;  PRIOR APPLICATION NUMBER: 60/333,531
;  PRIOR FILING DATE: 2001-11-19
;  NUMBER OF SEQ ID NOS: 554
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 278
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Diagnostic Oligonucleotide
US-10-300-683-278

  Query Match             0.8%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 1.5e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1129 TGTAGCATGAAACAAA 1144
                ||||||||| ||||||
Db         16 TGTAGCATGTAACAAA 1


RESULT 146
US-10-300-683-466/c
; Sequence 466, Application US/10300683
; Publication No. US20030235834A1
; GENERAL INFORMATION:
;  APPLICANT: Dunlop, Charles L.M.
;  APPLICANT:  Weisel, James M.
;  TITLE OF INVENTION: APPROACHES TO IDENTIFY CYSTIC FIBROSIS
;  FILE REFERENCE: CHARDUN.010A
;  CURRENT APPLICATION NUMBER: US/10/300,683
;  CURRENT FILING DATE:  2002-11-19
;  PRIOR APPLICATION NUMBER: 60/333,531
;  PRIOR FILING DATE: 2001-11-19
;  NUMBER OF SEQ ID NOS: 554
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 466
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Diagnostic Oligonucleotide
US-10-300-683-466

  Query Match             0.8%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 1.5e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1129 TGTAGCATGAAACAAA 1144
                ||||||||| ||||||
Db         16 TGTAGCATGTAACAAA 1


RESULT 147
US-10-357-043-19/c
; Sequence 19, Application US/10357043
; Publication No. US20030199012A1
; GENERAL INFORMATION:
;  APPLICANT: Ho, John L.
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR TREATMENT OF INFECTIOUS
;  TITLE OF INVENTION:  AND INFLAMMATORY DISEASES
;  FILE REFERENCE: 19603/3951
;  CURRENT APPLICATION NUMBER: US/10/357,043
;  CURRENT FILING DATE:  2003-01-31
;  PRIOR APPLICATION NUMBER: 60/353,985
;  PRIOR FILING DATE: 2002-02-01
;  NUMBER OF SEQ ID NOS: 30
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 19
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Primer
US-10-357-043-19

  Query Match             0.8%;  Score 14.4;  DB 1;  Length 19;
  Best Local Similarity   93.8%;  Pred. No. 1.6e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        449 GTTGCCCGACTTCGAG 464
                ||||||||||||||  |
Db         17 GTTGCCCGACTTCGCG 2


Search completed: December 13, 2004, 08:38:27
Job time : 21 secs
```

GenCore version 5.1.6

OM nucleic - nucleic search, using sw model

Run on: December 13, 2004, 08:35:36 ; Search time 15 Seconds
(without alignments)
3.831 Million cell updates/sec

Title: US-10-091-333-2
Perfect score: 1764
Sequence: 1 tttggccctcgaggccaaga.....ataaacatgtttgttaaaac 1764

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 0.5

Searched: 939 seqs, 16287 residues

Total number of hits satisfying chosen parameters: 1878

Minimum DB seq length: 8
Maximum DB seq length: 50

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 91 summaries

Database : rni2.seq:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

	Result No.	Score	% Query Match	Length	DB	ID	Description
c	1	33	1.9	38	1	US-08-715-941-10	Sequence 10, Appl
	2	21	1.2	21	1	US-08-715-941-9	Sequence 9, Appli
	3	20	1.1	20	1	US-09-230-896C-16	Sequence 16, Appl
	4	20	1.1	20	1	US-09-689-012-10	Sequence 10, Appl
	5	16	0.9	19	1	US-08-525-864A-15	Sequence 15, Appl
c	6	16	0.9	20	1	US-09-467-642-10	Sequence 10, Appl
c	7	16	0.9	20	1	US-09-517-467B-62	Sequence 62, Appl
c	8	16	0.9	26	1	US-08-910-632-5	Sequence 5, Appli
c	9	16	0.9	26	1	US-08-805-631A-5	Sequence 5, Appli
c	10	16	0.9	26	1	US-09-569-344-5	Sequence 5, Appli
	11	16	0.9	27	1	US-09-325-554-18	Sequence 18, Appl
	12	16	0.9	27	1	US-10-102-720-18	Sequence 18, Appl
	13	15.8	0.9	20	1	US-09-024-020B-29	Sequence 29, Appl
c	14	15.8	0.9	20	1	US-09-489-869-35	Sequence 35, Appl
	15	15.8	0.9	20	1	US-09-425-043-29	Sequence 29, Appl
c	16	15.8	0.9	20	1	US-09-056-285A-27	Sequence 27, Appl
	17	15.8	0.9	20	1	US-09-198-452A-3718	Sequence 3718, Ap
c	18	15.8	0.9	21	1	US-08-637-899-14	Sequence 14, Appl
c	19	15.8	0.9	21	1	US-09-529-812A-7	Sequence 7, Appli
c	20	15.8	0.9	27	1	US-08-208-486-79	Sequence 79, Appl
	21	15.4	0.9	17	1	US-08-665-220-6	Sequence 6, Appli
	22	15.4	0.9	17	1	US-08-618-408B-6	Sequence 6, Appli
	23	15.4	0.9	17	1	US-09-257-218-5	Sequence 5, Appli
	24	15.4	0.9	17	1	US-09-311-760-5	Sequence 5, Appli
	25	15.4	0.9	17	1	US-09-291-692-6	Sequence 6, Appli
	26	15.4	0.9	17	1	US-08-584-040-7821	Sequence 7821, Ap
	27	15.4	0.9	17	1	US-08-865-579-5	Sequence 5, Appli
	28	15.4	0.9	17	1	US-08-556-627A-6	Sequence 6, Appli
	29	15.4	0.9	17	1	US-09-371-772B-3605	Sequence 3605, Ap
	30	15.4	0.9	17	1	US-10-059-749-5	Sequence 5, Appli
	31	15.4	0.9	17	1	US-09-163-099-6	Sequence 6, Appli
	32	15.4	0.9	17	1	US-10-337-060-6	Sequence 6, Appli
	33	15.4	0.9	17	1	US-09-952-768-6	Sequence 6, Appli
	34	15.4	0.9	18	1	US-08-363-585-68	Sequence 68, Appl
	35	15.4	0.9	19	1	US-09-308-003-31	Sequence 31, Appl
	36	15.4	0.9	19	1	US-09-696-791-1199	Sequence 1199, Ap
	37	15.4	0.9	19	1	US-09-696-791-1200	Sequence 1200, Ap
c	38	15.4	0.9	20	1	US-09-357-070-8	Sequence 8, Appli
c	39	15.4	0.9	20	1	US-09-538-709-3	Sequence 3, Appli
	40	15.4	0.9	26	1	US-08-621-914A-2	Sequence 2, Appli
	41	15.4	0.9	26	1	US-08-873-437-2	Sequence 2, Appli
	42	15.4	0.9	26	1	US-09-522-217-39	Sequence 39, Appl
	43	15.4	0.9	26	1	US-09-593-312-2	Sequence 2, Appli
	44	15.4	0.9	26	1	US-09-923-246-39	Sequence 39, Appl
	45	15.4	0.9	26	1	US-09-658-077-1	Sequence 1, Appli
	46	15.4	0.9	26	1	US-10-295-723-39	Sequence 39, Appl
	47	15.2	0.9	20	1	US-09-488-671-76	Sequence 76, Appl
c	48	15.2	0.9	20	1	US-09-489-869-36	Sequence 36, Appl
c	49	15.2	0.9	20	1	US-09-506-073-73	Sequence 73, Appl
c	50	15.2	0.9	20	1	US-09-066-281B-17	Sequence 17, Appl
c	51	15.2	0.9	20	1	US-09-198-452A-2571	Sequence 2571, Ap
c	52	15.2	0.9	20	1	US-09-198-452A-5767	Sequence 5767, Ap
c	53	15.2	0.9	20	1	US-09-688-188B-145	Sequence 145, App
c	54	15.2	0.9	20	1	US-09-291-417D-145	Sequence 145, App
c	55	15.2	0.9	20	1	US-09-468-433C-17	Sequence 17, Appl
	56	15.2	0.9	20	1	US-09-021-660A-24	Sequence 24, Appl
	57	15	0.9	24	1	US-09-721-154-6	Sequence 6, Appli
c	58	15	0.9	25	1	US-08-113-646A-42	Sequence 42, Appl
	59	14.8	0.8	18	1	US-08-585-684B-2687	Sequence 2687, Ap
	60	14.8	0.8	18	1	US-09-038-073-2687	Sequence 2687, Ap
	61	14.8	0.8	19	1	US-09-261-104-11	Sequence 11, Appl
	62	14.8	0.8	19	1	US-09-696-791-1834	Sequence 1834, Ap
	63	14.8	0.8	19	1	US-09-696-791-1977	Sequence 1977, Ap
	64	14.8	0.8	19	1	US-09-696-791-3074	Sequence 3074, Ap
	65	14.8	0.8	26	1	US-08-621-914A-3	Sequence 3, Appli
	66	14.8	0.8	26	1	US-09-197-951-5	Sequence 5, Appli
	67	14.8	0.8	27	1	US-09-475-947A-153	Sequence 153, App
	68	14.6	0.8	24	1	US-09-721-154-7	Sequence 7, Appli
	69	14.6	0.8	26	1	US-09-527-345-6	Sequence 6, Appli
	70	14.6	0.8	26	1	US-09-167-513-10	Sequence 10, Appl
	71	14.6	0.8	26	1	US-09-161-939A-43	Sequence 43, Appl
	72	14.4	0.8	16	1	US-08-011-398B-7	Sequence 7, Appli
	73	14.4	0.8	16	1	US-08-370-225-7	Sequence 7, Appli
	74	14.4	0.8	16	1	US-08-464-051-7	Sequence 7, Appli
	75	14.4	0.8	16	1	US-08-461-859-7	Sequence 7, Appli
	76	14.4	0.8	16	1	US-08-462-498-7	Sequence 7, Appli
	77	14.4	0.8	16	1	US-08-879-260-10	Sequence 10, Appl
	78	14.4	0.8	16	1	US-08-554-385-7	Sequence 7, Appli
c	79	14.4	0.8	16	1	US-09-479-005A-71	Sequence 71, Appl
	80	14.4	0.8	16	1	PCT-US93-10069-7	Sequence 7, Appli
	81	14.4	0.8	17	1	US-08-758-306-281	Sequence 281, App
	82	14.4	0.8	17	1	US-08-584-040-7820	Sequence 7820, Ap
	83	14.4	0.8	17	1	US-08-584-040-7822	Sequence 7822, Ap
	84	14.4	0.8	17	1	US-08-679-645-218	Sequence 218, App
	85	14.4	0.8	17	1	US-09-474-432B-617	Sequence 617, App
	86	14.4	0.8	17	1	US-09-371-772B-3604	Sequence 3604, Ap
	87	14.4	0.8	17	1	US-09-371-772B-3606	Sequence 3606, Ap
	88	14.4	0.8	17	1	US-09-371-772B-6350	Sequence 6350, Ap
	89	14.4	0.8	17	1	US-09-371-772B-6351	Sequence 6351, Ap
	90	14.4	0.8	17	1	US-09-476-387-616	Sequence 616, App
	91	14.4	0.8	18	1	US-08-679-645-631	Sequence 631, App

ALIGNMENTS

RESULT 1
US-08-715-941-10/c
; Sequence 10, Application US/08715941
; Patent No. 5846721
; GENERAL INFORMATION:
; APPLICANT: Soares, Marcelo B.
; APPLICANT: de Fatima Bonaldo, Maria
; TITLE OF INVENTION: AN EFFICIENT AND SIMPLER METHOD TO
; TITLE OF INVENTION: CONSTRUCT NORMALIZED cDNA LIBRARIES WITH IMPROVED
; TITLE OF INVENTION: REPRESENTATIONS OF FULL-LENGTH cDNAs.

```
;    NUMBER OF SEQUENCES:  16
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Cooper & Dunham LLP
;      STREET:  1185 Avenue of the Americas
;      CITY:  New York
;      STATE:  New York
;      COUNTRY:  U.S.A.
;      ZIP:  10036
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/715,941
;      FILING DATE:  19-SEP-1996
;      CLASSIFICATION:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  White, John P.
;      REGISTRATION NUMBER:  28,678
;      REFERENCE/DOCKET NUMBER:  0575/51083
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (212) 278-0400
;      TELEFAX:  (212) 391-0526
;  INFORMATION FOR SEQ ID NO:  10:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  38 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-08-715-941-10

  Query Match             1.9%;  Score 33;  DB 1;  Length 38;
  Best Local Similarity   100.0%;  Pred. No. 0.046;
  Matches   33;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 TTTGGCCCTCGAGGCCAAGAATTCGGCACGAGG 33
              |||||||||||||||||||||||||||||||||
Db         33 TTTGGCCCTCGAGGCCAAGAATTCGGCACGAGG 1


RESULT 2
US-08-715-941-9
; Sequence 9, Application US/08715941
; Patent No. 5846721
;  GENERAL INFORMATION:
;    APPLICANT:  Soares, Marcelo B.
;    APPLICANT:  de Fatima Bonaldo, Maria
;    TITLE OF INVENTION:  AN EFFICIENT AND SIMPLER METHOD TO
;    TITLE OF INVENTION:  CONSTRUCT NORMALIZED cDNA LIBRARIES WITH IMPROVED
;    TITLE OF INVENTION:  REPRESENTATIONS OF FULL-LENGTH cDNAs.
;    NUMBER OF SEQUENCES:  16
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Cooper & Dunham LLP
;      STREET:  1185 Avenue of the Americas
;      CITY:  New York
;      STATE:  New York
;      COUNTRY:  U.S.A.
;      ZIP:  10036
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/715,941
;      FILING DATE:  19-SEP-1996
;      CLASSIFICATION:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  White, John P.
;      REGISTRATION NUMBER:  28,678
;      REFERENCE/DOCKET NUMBER:  0575/51083
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (212) 278-0400
;      TELEFAX:  (212) 391-0526
;  INFORMATION FOR SEQ ID NO:  9:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  21 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-08-715-941-9

  Query Match             1.2%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 6.8;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         12 AGGCCAAGAATTCGGCACGAG 32
              |||||||||||||||||||||
Db          1 AGGCCAAGAATTCGGCACGAG 21


RESULT 3
US-09-230-896C-16
; Sequence 16, Application US/09230896C
; Patent No. 6635479
; GENERAL INFORMATION:
;  APPLICANT: The Scripps Research Institute
;  APPLICANT:  Sutcliffe, et al.
;  TITLE OF INVENTION: Hypothalamus-Specific Polypeptides
;  FILE REFERENCE: TSRI-548.1
;  CURRENT APPLICATION NUMBER: US/09/230,896C
;  CURRENT FILING DATE:  1999-02-02
;  PRIOR APPLICATION NUMBER: 60/023,220
;  PRIOR FILING DATE: 1996-08-02
;  NUMBER OF SEQ ID NOS: 29
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 16
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: tag sequence
US-09-230-896C-16

  Query Match             1.1%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 10;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         12 AGGCCAAGAATTCGGCACGA 31
              ||||||||||||||||||||
Db          1 AGGCCAAGAATTCGGCACGA 20


RESULT 4
US-09-689-012-10
; Sequence 10, Application US/09689012
; Patent No. 6670135
; GENERAL INFORMATION:
;  APPLICANT: Spriggs, Melanie K.
;  TITLE OF INVENTION: NOVEL SEMAPHORIN POLYPEPTIDES
;  FILE REFERENCE: 2634-US
;  CURRENT APPLICATION NUMBER: US/09/689,012
;  CURRENT FILING DATE:  2000-10-12
;  PRIOR APPLICATION NUMBER: PCT/US99/09831
;  PRIOR FILING DATE: 1999-05-05
;  PRIOR APPLICATION NUMBER: US 60/085,497
;  PRIOR FILING DATE: 1998-05-14
;  NUMBER OF SEQ ID NOS: 10
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 10
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
```

```
;   FEATURE:
;   OTHER INFORMATION: PRIMER
US-09-689-012-10

  Query Match             1.1%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 10;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          8 CTCGAGGCCAAGAATTCGGC 27
              ||||||||||||||||||||
Db          1 CTCGAGGCCAAGAATTCGGC 20


RESULT 5
US-08-525-864A-15
; Sequence 15, Application US/08525864A
; Patent No. 5912326
;  GENERAL INFORMATION:
;    APPLICANT:  Chang, Han
;    TITLE OF INVENTION:  Cerebellum-derived Growth Factors, and Uses
;    TITLE OF INVENTION:  Related thereto
;    NUMBER OF SEQUENCES:  18
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  LAHIVE & COCKFIELD
;      STREET:  28 State Street
;      CITY:  Boston
;      STATE:  Massachusetts
;      COUNTRY:  USA
;      ZIP:  02109
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  AscII (text)
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/525,864A
;      FILING DATE:  8-SEP-1995
;      CLASSIFICATION:  530
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Kara, Catherine J.
;      REGISTRATION NUMBER:  41,106
;      REFERENCE/DOCKET NUMBER:  HUI-017
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (617)227-7400
;      TELEFAX:  (617)742-4214
;  INFORMATION FOR SEQ ID NO:  15:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  19 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  oligonucleotide
US-08-525-864A-15

  Query Match             0.9%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   100.0%;  Pred. No. 57;
  Matches   16;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         19 GAATTCGGCACGAGGG 34
              ||||||||||||||||
Db          1 GAATTCGGCACGAGGG 16


RESULT 6
US-09-467-642-10/c
; Sequence 10, Application US/09467642
; Patent No. 6300132
; GENERAL INFORMATION:
;  APPLICANT:  Brett P. Monia
;  APPLICANT:  Lex M. Cowsert
;  TITLE OF INVENTION:  ANTISENSE MODULATION OF TELOMERIC REPEAT BINDING FACTOR 2 EXPRES
;  FILE REFERENCE:  RTS-0106
;  CURRENT APPLICATION NUMBER: US/09/467,642
;  CURRENT FILING DATE:  1999-12-20
;  NUMBER OF SEQ ID NOS:  89
; SEQ ID NO 10
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-467-642-10

  Query Match             0.9%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 58;
  Matches   16;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         19 GAATTCGGCACGAGGG 34
              ||||||||||||||||
Db         19 GAATTCGGCACGAGGG 4


RESULT 7
US-09-517-467B-62/c
; Sequence 62, Application US/09517467B
; Patent No. 6451602
; GENERAL INFORMATION:
;  APPLICANT: Ian Popoff
;  APPLICANT:  Lex M. Cowsert
;  TITLE OF INVENTION: ANTISENSE MODULATION OF PARP EXPRESSION
;  FILE REFERENCE: RTS-0150
;  CURRENT APPLICATION NUMBER: US/09/517,467B
;  CURRENT FILING DATE:  2001-03-02
;  PRIOR APPLICATION NUMBER: 09/517,467
;  PRIOR FILING DATE: 2000-03-02
;  NUMBER OF SEQ ID NOS: 345
; SEQ ID NO 62
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-517-467B-62

  Query Match             0.9%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 58;
  Matches   16;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1153 GGCCAACAAGGCTTCC 1168
              ||||||||||||||||
Db         16 GGCCAACAAGGCTTCC 1


RESULT 8
US-08-910-632-5/c
; Sequence 5, Application US/08910632B
; Patent No. 6077668
; GENERAL INFORMATION:
;  APPLICANT: KOOL, ERIC T.
;  TITLE OF INVENTION: HIGHLY SENSITIVE MULTIMERIC NUCLEIC ACID PROBES
;  FILE REFERENCE: 220.00010130
;  CURRENT APPLICATION NUMBER: US/08/910,632B
;  CURRENT FILING DATE: 1997-08-13
;  EARLIER APPLICATION NUMBER: 08/805,631
;  EARLIER FILING DATE: 1997-02-26
;  EARLIER APPLICATION NUMBER: 08/393,439
;  EARLIER FILING DATE: 1995-02-23
;  EARLIER APPLICATION NUMBER: 08/047,860
;  EARLIER FILING DATE: 1993-04-15
;  NUMBER OF SEQ ID NOS: 83
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 5
;   LENGTH: 26
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
```

```
;   OTHER INFORMATION: synthetic AS83 DNA nanocircle
US-08-910-632-5

  Query Match             0.9%;  Score 16;  DB 1;  Length 26;
  Best Local Similarity   79.2%;  Pred. No. 64;
  Matches   19;  Conservative    0;  Mismatches    5;  Indels    0;  Gaps    0;

Qy       1386 TTGTTTGTTTTGTATCTTGTTTTT 1409
              || ||| |||||| | || |||||
Db         25 TTTTTTTTTTGTTTTTTTTTTT 2


RESULT 9
US-08-805-631A-5/c
; Sequence 5, Application US/08805631A
; Patent No. 6096880
;  GENERAL INFORMATION:
;    APPLICANT:  UNIVERSITY OF ROCHESTER
;    TITLE OF INVENTION:  CIRCULAR DNA VECTORS FOR SYNTHESIS OF RNA AND
;    TITLE OF INVENTION:  DNA
;    NUMBER OF SEQUENCES:  72
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  MUETING, RAASCH & GEBHARDT, P.A.
;      STREET:  119 No. 6096880th Fourth Street, Suite 201
;      CITY:  Minneapolis
;      STATE:  Minnesota
;      COUNTRY:  USA
;      ZIP:  55401
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/805,631A
;      FILING DATE:  26-FEB-97
;      CLASSIFICATION:  536
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/393,439
;      FILING DATE:  23-FEB-1995
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/047,860
;      FILING DATE:  15-APR-1993
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  SANDBERG, VICTORIA A.
;      REGISTRATION NUMBER:  41,287
;      REFERENCE/DOCKET NUMBER:  220.00010140
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  612-305-1226
;      TELEFAX:  612-305-1228
;  INFORMATION FOR SEQ ID NO:  5:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  26 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  circular
;    MOLECULE TYPE:  DNA (genomic)
US-08-805-631A-5

  Query Match             0.9%;  Score 16;  DB 1;  Length 26;
  Best Local Similarity   79.2%;  Pred. No. 64;
  Matches   19;  Conservative    0;  Mismatches    5;  Indels    0;  Gaps    0;

Qy       1386 TTGTTTGTTTTGTATCTTGTTTTT 1409
              || ||| |||||| | || |||||
Db         25 TTTTTTTTTTGTTTTTTTTTTT 2


RESULT 10
US-09-569-344-5/c
; Sequence 5, Application US/09569344
; Patent No. 6368802
;   GENERAL INFORMATION:
;       APPLICANT: UNIVERSITY OF ROCHESTER
;       TITLE OF INVENTION: CIRCULAR DNA VECTORS FOR SYNTHESIS OF RNA AND
;                           DNA
;       NUMBER OF SEQUENCES: 72
;       CORRESPONDENCE ADDRESS:
;            ADDRESSEE: MUETING, RAASCH & GEBHARDT, P.A.
;            STREET: 119 No. 6368802th Fourth Street, Suite 201
;            CITY: Minneapolis
;            STATE: Minnesota
;            COUNTRY: USA
;            ZIP: 55401
;       COMPUTER READABLE FORM:
;            MEDIUM TYPE: Floppy disk
;            COMPUTER: IBM PC compatible
;            OPERATING SYSTEM: PC-DOS/MS-DOS
;            SOFTWARE: PatentIn Release #1.0, Version #1.30
;       CURRENT APPLICATION DATA:
;            APPLICATION NUMBER: US/09/569,344
;            FILING DATE: 11-May-2000
;            CLASSIFICATION: <Unknown>
;       PRIOR APPLICATION DATA:
;            APPLICATION NUMBER: US 08/805,631
;            FILING DATE: 26-FEB-97
;            APPLICATION NUMBER: US 08/393,439
;            FILING DATE: 23-FEB-1995
;            APPLICATION NUMBER: US 08/047,860
;            FILING DATE: 15-APR-1993
;       ATTORNEY/AGENT INFORMATION:
;            NAME: SANDBERG, VICTORIA A.
;            REGISTRATION NUMBER: 41,287
;            REFERENCE/DOCKET NUMBER: 220.00010140
;       TELECOMMUNICATION INFORMATION:
;            TELEPHONE: 612-305-1226
;            TELEFAX: 612-305-1228
;   INFORMATION FOR SEQ ID NO: 5:
;       SEQUENCE CHARACTERISTICS:
;            LENGTH: 26 base pairs
;            TYPE: nucleic acid
;            STRANDEDNESS: single
;            TOPOLOGY: circular
;       MOLECULE TYPE: DNA (genomic)
;       SEQUENCE DESCRIPTION: SEQ ID NO: 5:
US-09-569-344-5

  Query Match             0.9%;  Score 16;  DB 1;  Length 26;
  Best Local Similarity   79.2%;  Pred. No. 64;
  Matches   19;  Conservative    0;  Mismatches    5;  Indels    0;  Gaps    0;

Qy       1386 TTGTTTGTTTTGTATCTTGTTTTT 1409
              || ||| |||||| | || |||||
Db         25 TTTTTTTTTTGTTTTTTTTTTT 2


RESULT 11
US-09-325-554-18
; Sequence 18, Application US/09325554
; Patent No. 6410235
; GENERAL INFORMATION:
;  APPLICANT: Weindel, Kurt
;  APPLICANT:  Brand, Joachim
;  TITLE OF INVENTION: DNA DETECTION BY MEANS OF A STRAND REASSOCIATION COMPLEX
;  FILE REFERENCE: 024420-00008
;  CURRENT APPLICATION NUMBER: US/09/325,554
;  CURRENT FILING DATE:  1999-06-04
;  PRIOR APPLICATION NUMBER: 198-24-900.4
;  PRIOR FILING DATE: 1998-06-04
;  NUMBER OF SEQ ID NOS: 18
;  SOFTWARE: Patent-In version 3.1
; SEQ ID NO 18
;   LENGTH: 27
;   TYPE: DNA
;   ORGANISM: Mycobacterium tuberculosis
;   FEATURE:
```

```
;   NAME/KEY: misc_signal
;   LOCATION: (27)..(27)
;   OTHER INFORMATION: Y means incorporation of Aminolinker-phosphoramidite subsequently
;   OTHER INFORMATION: estered with 3-O carboxymethyl digoxigenin
US-09-325-554-18

  Query Match              0.9%;  Score 16;  DB 1;  Length 27;
  Best Local Similarity   73.1%;  Pred. No. 65;
  Matches   19;  Conservative    1;  Mismatches    6;  Indels    0;  Gaps    0;

Qy       1386 TTGTTTGTTTTGTATCTTGTTTTTCT 1411
                 || ||| |||| | | || |||||:|
Db          2 TTTTTTTTTTTTTTTTTTTTTTTYT 27


RESULT 12
US-10-102-720-18
; Sequence 18, Application US/10102720
; Patent No. 6790623
; GENERAL INFORMATION:
;  APPLICANT: Weindel, Kurt
;  APPLICANT:  Brand, Joachim
;  TITLE OF INVENTION: DNA DETECTION BY MEANS OF A STRAND REASSOCIATION COMPLEX
;  FILE REFERENCE: 101614-00014
;  CURRENT APPLICATION NUMBER: US/10/102,720
;  CURRENT FILING DATE:  2002-03-22
;  PRIOR APPLICATION NUMBER: 09/325,554
;  PRIOR FILING DATE: 1999-06-04
;  NUMBER OF SEQ ID NOS: 18
;  SOFTWARE: Patent-In version 3.1
; SEQ ID NO 18
;   LENGTH: 27
;   TYPE: DNA
;   ORGANISM: Mycobacterium tuberculosis
;   FEATURE:
;   NAME/KEY: misc_signal
;   LOCATION: (27)..(27)
;   OTHER INFORMATION: Y means incorporation of Aminolinker-phosphoramidite subsequently
;   OTHER INFORMATION: estered with 3-O carboxymethyl digoxigenin
US-10-102-720-18

  Query Match              0.9%;  Score 16;  DB 1;  Length 27;
  Best Local Similarity   73.1%;  Pred. No. 65;
  Matches   19;  Conservative    1;  Mismatches    6;  Indels    0;  Gaps    0;

Qy       1386 TTGTTTGTTTTGTATCTTGTTTTTCT 1411
                 || ||| |||| | | || |||||:|
Db          2 TTTTTTTTTTTTTTTTTTTTTTTYT 27


RESULT 13
US-09-024-020B-29
; Sequence 29, Application US/09024020B
; Patent No. 6030810
;  GENERAL INFORMATION:
;    APPLICANT:  DELGADO, STEPHEN G.
;    APPLICANT:  DIETRICH, PAUL S.
;    APPLICANT:  FISH, LINDA M.
;    APPLICANT:  HERMAN, RONALD C.
;    APPLICANT:  SANGAMESWARAN, LAKSHMI
;    TITLE OF INVENTION:  NOVEL CLONED TETRODOTOXIN-SENSITIVE
;    TITLE OF INVENTION:  SODIUM CHANNEL I-SUBUNIT AND A SPLICE VARIANT THEREOF
;    NUMBER OF SEQUENCES:  43
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  JANET PAULINE CLARK
;      STREET:  3401 HILLVIEW AVENUE, MS A2-250
;      CITY:  PALO ALTO
;      STATE:  CA
;      COUNTRY:  U.S.A.
;      ZIP:  94304-1397
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/024,020B
;      FILING DATE:  16-FEB-1998
;      CLASSIFICATION:  536
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 60/039,447
;      FILING DATE:  26-FEB-1997
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  CLARK, JANET P.
;      REGISTRATION NUMBER:  34,799
;      REFERENCE/DOCKET NUMBER:  R0020B-REG
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (650) 852-3097
;      TELEFAX:  (650) 855-5322
;  INFORMATION FOR SEQ ID NO:  29:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  20 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-09-024-020B-29

  Query Match              0.9%;  Score 15.8;  DB 1;  Length 20;
  Best Local Similarity   89.5%;  Pred. No. 63;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        392 CAGCAGCAACAGTGGCTTC 410
                |||||| |||||||| |
Db          1 CAGCAGCTACAGTGGCTAC 19


RESULT 14
US-09-489-869-35/c
; Sequence 35, Application US/09489869A
; Patent No. 6268151
; GENERAL INFORMATION:
;  APPLICANT: Susan Murray
;  APPLICANT: Lex M. Cowsert
;  APPLICANT: Jacqueline Wyatt
;  TITLE OF INVENTION: ANTISENSE MODULATION OF MACROPHAGE MIGRATION INHIBITORY FACTOR
;  FILE REFERENCE: RTS-0110
;  CURRENT APPLICATION NUMBER: US/09/489,869A
;  CURRENT FILING DATE: 2000-01-20
;  NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 35
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-489-869-35

  Query Match              0.9%;  Score 15.8;  DB 1;  Length 20;
  Best Local Similarity   89.5%;  Pred. No. 63;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        621 GCCTACAGCGAGCCGTGCG 639
                | ||| ||||||||||||||
Db         20 GGCTCCAGCGAGCCGTGCG 2


RESULT 15
US-09-425-043-29
; Sequence 29, Application US/09425043
; Patent No. 6335172
;  GENERAL INFORMATION:
;    APPLICANT:  DELGADO, STEPHEN G.
;    APPLICANT:  DIETRICH, PAUL S.
;    APPLICANT:  FISH, LINDA M.
;    APPLICANT:  HERMAN, RONALD C.
```

```
;    APPLICANT:  SANGAMESWARAN, LAKSHMI
;    TITLE OF INVENTION:  NOVEL CLONED TETRODOTOXIN-SENSITIVE
;    TITLE OF INVENTION:  SODIUM CHANNEL I-SUBUNIT AND A SPLICE VARIANT THEREOF
;    NUMBER OF SEQUENCES:  43
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  JANET PAULINE CLARK
;      STREET:  3401 HILLVIEW AVENUE, MS A2-250
;      CITY:  PALO ALTO
;      STATE:  CA
;      COUNTRY:  U.S.A.
;      ZIP:  94304-1397
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/425,043
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 09/024,020
;      FILING DATE:  16-FEB-1998
;      APPLICATION NUMBER:  US 60/039,447
;      FILING DATE:  26-FEB-1997
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  CLARK, JANET P.
;      REGISTRATION NUMBER:  34,799
;      REFERENCE/DOCKET NUMBER:  R0020B-REG
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (650) 852-3097
;      TELEFAX:  (650) 855-5322
;  INFORMATION FOR SEQ ID NO:  29:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  20 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-09-425-043-29

  Query Match             0.9%;  Score 15.8;  DB 1;  Length 20;
  Best Local Similarity   89.5%;  Pred. No. 63;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        392 CAGCAGCAACAGTGGCTTC 410
              ||||||| ||||||||| |
Db          1 CAGCAGCTACAGTGGCTAC 19


RESULT 16
US-09-056-285A-27/c
; Sequence 27, Application US/09056285A
; Patent No. 6403307
;  GENERAL INFORMATION:
;       APPLICANT: Stone, Edwin M.
;                  Sheffield, Val C.
;                  Alward, Wallace L.M.
;                  Fingert, John
;       TITLE OF INVENTION: GLAUCOMA THERAPEUTICS AND DIAGNOSTICS
;       NUMBER OF SEQUENCES: 43
;       CORRESPONDENCE ADDRESS:
;            ADDRESSEE: FOLEY, HOAG & ELIOT LLP
;            STREET: One Post Office Square
;            CITY: Boston
;            STATE: MA
;            COUNTRY: USA
;            ZIP: 02109-2170
;       COMPUTER READABLE FORM:
;            MEDIUM TYPE: Floppy disk
;            COMPUTER: IBM PC compatible
;            OPERATING SYSTEM: PC-DOS/MS-DOS
;            SOFTWARE: PatentIn Release #1.0, Version #1.30
;       CURRENT APPLICATION DATA:
;            APPLICATION NUMBER: US/09/056,285A
;            FILING DATE: 07-Apr-1998
;       ATTORNEY/AGENT INFORMATION:
;            NAME: Arnold, Beth E.
;            REGISTRATION NUMBER: 35,430
;            REFERENCE/DOCKET NUMBER: UIA-010.28
;       TELECOMMUNICATION INFORMATION:
;            TELEPHONE: 617-832-1000
;            TELEFAX: 617-832-7000
;  INFORMATION FOR SEQ ID NO: 27:
;       SEQUENCE CHARACTERISTICS:
;            LENGTH: 20 base pairs
;            TYPE: nucleic acid
;            STRANDEDNESS: single
;            TOPOLOGY: linear
;       MOLECULE TYPE: other nucleic acid
;            DESCRIPTION: /desc = "primer"
;       SEQUENCE DESCRIPTION: SEQ ID NO: 27:
US-09-056-285A-27

  Query Match             0.9%;  Score 15.8;  DB 1;  Length 20;
  Best Local Similarity   89.5%;  Pred. No. 63;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        174 GGCACTCTGAGTTCATCAG 192
              || |||||||||||| |||
Db         19 GGGACTCTGAGTTCAGCAG 1


RESULT 17
US-09-198-452A-3718
; Sequence 3718, Application US/09198452A
; Patent No. 6559294
; GENERAL INFORMATION:
;  APPLICANT: Griffais, R.
;  TITLE OF INVENTION: Chlamydia pneumoniae genomic sequence and polypeptides, fragments
;  TITLE OF INVENTION:  thereof and uses thereof, in particular for the diagnosis, prever
;  TITLE OF INVENTION:  and treatment of infection
;  FILE REFERENCE: 9710-003-999
;  CURRENT APPLICATION NUMBER: US/09/198,452A
;  CURRENT FILING DATE:  1998-11-24
;  NUMBER OF SEQ ID NOS: 6849
; SEQ ID NO 3718
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Chlamydia pneumoniae
US-09-198-452A-3718

  Query Match             0.9%;  Score 15.8;  DB 1;  Length 20;
  Best Local Similarity   89.5%;  Pred. No. 63;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        825 GGCTTCAGCCAGTCCCTGA 843
              ||| ||||||| |||||||
Db          2 GGCGTCAGCCAATCCCTGA 20


RESULT 18
US-08-637-899-14/c
; Sequence 14, Application US/08637899
; Patent No. 5908772
;  GENERAL INFORMATION:
;    APPLICANT:  Mitta, Masanori
;    APPLICANT:  Sano, Mutsumi
;    APPLICANT:  Kato, Ikunoshin
;    TITLE OF INVENTION:  Gene Encoding Lacto-N-Biosidase
;    NUMBER OF SEQUENCES:  14
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Birch, Stewart, Kolasch and Birch
;      STREET:  P.O. Box 747
;      CITY:  Falls Church
;      STATE:  VA
```

```
;       COUNTRY:  USA
;       ZIP:  22040-0747
;     COMPUTER READABLE FORM:
;       MEDIUM TYPE:  Floppy disk
;       COMPUTER:  IBM PC compatible
;       OPERATING SYSTEM:  PC-DOS/MS-DOS
;       SOFTWARE:  PatentIn Release #1.0, Version #1.30
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  US/08/637,899
;       FILING DATE:
;       CLASSIFICATION:  435
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Weiner, Marc S
;       REGISTRATION NUMBER:  32,181
;       REFERENCE/DOCKET NUMBER:  1422-252P
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  (703) 205-8000
;       TELEFAX:  (703) 205-8050
;   INFORMATION FOR SEQ ID NO:  14:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  21 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
;     MOLECULE TYPE:  other nucleic acid (synthetic DNA)
US-08-637-899-14

  Query Match             0.9%;  Score 15.8;  DB 1;  Length 21;
  Best Local Similarity   89.5%;  Pred. No. 64;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        746 CCTCGTGCTGCGCCTGGAC 764
              | ||||||||||||| ||||
Db         19 CATCGTGCTGCGCCAGGAC 1


RESULT 19
US-09-529-812A-7/c
; Sequence 7, Application US/09529812A
; Patent No. 6682930
; GENERAL INFORMATION:
;  APPLICANT: LU, CHANGDE
;  TITLE OF INVENTION: NEW TRIPLEX FORMING OLIGONUCLEOTIDES AND THEIR USE IN
;  TITLE OF INVENTION:  ANTI-HBV
;  FILE REFERENCE: 017227/0160
;  CURRENT APPLICATION NUMBER: US/09/529,812A
;  CURRENT FILING DATE:  2000-07-24
;  PRIOR APPLICATION NUMBER: PCT/CN98/00248
;  PRIOR FILING DATE: 1998-10-19
;  PRIOR APPLICATION NUMBER: CN 97106667.1
;  PRIOR FILING DATE: 1997-10-21
;  NUMBER OF SEQ ID NOS: 18
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 7
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Triplex
;   OTHER INFORMATION: forming oligonucleotide
;   OTHER INFORMATION: This oligo may or may not be 3'-monophosphorylated
US-09-529-812A-7

  Query Match             0.9%;  Score 15.8;  DB 1;  Length 21;
  Best Local Similarity   89.5%;  Pred. No. 64;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        256 CCTCCTCTTCGCCCTCGTC 274
              |||||||||| ||||| ||
Db         20 CCTCCTCTTCCCCCTCCTC 2


RESULT 20
US-08-208-486-79/c
; Sequence 79, Application US/08208486
; Patent No. 5389531
;  GENERAL INFORMATION:
;    APPLICANT:  Ito, Junetsu
;    APPLICANT:  Yoo, Seung-Ku
;    TITLE OF INVENTION:  METHODS TO REPLICATE DNA in vitro USING
;    TITLE OF INVENTION:  PRD1-CATALYZED DNA REPLICATION SYSTEMS
;    NUMBER OF SEQUENCES:  89
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Cahill, Sutton & Thomas
;      STREET:  155 Park One, 2141 E. Highland Ave.
;      CITY:  Phoenix
;      STATE:  Arizona
;      COUNTRY:  U.S.A.
;      ZIP:  85016
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Diskette, 5.25 inch, 1.2 Mb
;      COMPUTER:  Packard Bell (IBM PC/AT compatible)
;      OPERATING SYSTEM:  MS-Dos, Version 5.0
;      SOFTWARE:  WordPerfect Version 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/208,486
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  07/869,916
;      FILING DATE:  April 14, 1992
;      APPLICATION NUMBER:  Japan 240525/91
;      FILING DATE:  August 26, 1991
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Janelle Faunce Raupp
;      REGISTRATION NUMBER:  30,485
;      REFERENCE/DOCKET NUMBER:  #3954-A-7
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (602) 956-7000
;      TELEFAX:  (602) 495-9475
;  INFORMATION FOR SEQ ID NO:  79:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  27 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  Other nucleic acid (synthetic DNA)
US-08-208-486-79

  Query Match             0.9%;  Score 15.8;  DB 1;  Length 27;
  Best Local Similarity   74.1%;  Pred. No. 71;
  Matches   20;  Conservative    0;  Mismatches    7;  Indels    0;  Gaps    0;

Qy       1382 TTTGTTGTTTGTTTTGTATCTTGTTTT 1408
              ||| || ||| |||| | | || ||||
Db         27 TTTTTTTTTTTTTTTTTTTTTTTTTTT 1


RESULT 21
US-08-665-220-6
; Sequence 6, Application US/08665220
; Patent No. 5786173
;  GENERAL INFORMATION:
;    APPLICANT:  Alnemri, Emad S.
;    APPLICANT:  Fernandes-Alnemri, Teresa
;    APPLICANT:  Litwack, Gerald
;    APPLICANT:  Armstrong, Robert
;    APPLICANT:  Tomaselli, Kevin
;    TITLE OF INVENTION:  Mch4 and Mch5, Apoptotic Proteases,
;    TITLE OF INVENTION:  Nucleic Acids Encoding and Methods of Use
;    NUMBER OF SEQUENCES:  70
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Campbell & Flores LLP
;      STREET:  4370 La Jolla Village Drive, Suite 700
;      CITY:  San Diego
;      STATE:  California
```

```
;       COUNTRY:  United States
;       ZIP:  92122
;     COMPUTER READABLE FORM:
;       MEDIUM TYPE:  Floppy disk
;       COMPUTER:  IBM PC compatible
;       OPERATING SYSTEM:  PC-DOS/MS-DOS
;       SOFTWARE:  PatentIn Release #1.0, Version #1.25
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  US/08/665,220
;       FILING DATE:  14-JUN-1996
;       CLASSIFICATION:  435
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  US 08/618,408
;       FILING DATE:  19-MAR-1996
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Campbell, Cathryn A.
;       REGISTRATION NUMBER:  31,815
;       REFERENCE/DOCKET NUMBER:  P-ID 2165
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  (619) 535-9001
;       TELEFAX:  (619) 535-8949
;   INFORMATION FOR SEQ ID NO:  6:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  17 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
;     FEATURE:
;       NAME/KEY:  misc_feature
;       LOCATION:  1..17
;       OTHER INFORMATION:  /note= "SK-Zap"
US-08-665-220-6

  Query Match             0.9%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   94.1%;  Pred. No. 70;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         16 CAAGAATTCGGCACGAG 32
              || |||||||||||||||
Db          1 CAGGAATTCGGCACGAG 17


RESULT 22
US-08-618-408B-6
; Sequence 6, Application US/08618408B
; Patent No. 5851815
;  GENERAL INFORMATION:
;    APPLICANT:  Alnemri, Emad S.
;    APPLICANT:  Fernandes-Alnemri, Teresa
;    APPLICANT:  Litwack, Gerald
;    APPLICANT:  Armstrong, Robert
;    APPLICANT:  Tomaselli, Kevin
;    TITLE OF INVENTION:  Mch4 and Mch5, No. 5851815el Apoptotic
;    TITLE OF INVENTION:  Proteases, Nucleic Acids Encoding and Methods of Use
;    NUMBER OF SEQUENCES:  63
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Campbell and Flores
;      STREET:  4370 La Jolla Village Drive, Suite 700
;      CITY:  San Diego
;      STATE:  California
;      COUNTRY:  United States
;      ZIP:  92122
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/618,408B
;      FILING DATE:  19-MAR-1996
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Campbell, Cathryn A.
;      REGISTRATION NUMBER:  31,815
;      REFERENCE/DOCKET NUMBER:  P-ID 1957
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (619) 535-9001
;      TELEFAX:  (619) 535-8949
;  INFORMATION FOR SEQ ID NO:  6:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    FEATURE:
;      NAME/KEY:  misc_feature
;      LOCATION:  1..17
;      OTHER INFORMATION:  /note= "SK-Zap"
US-08-618-408B-6

  Query Match             0.9%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   94.1%;  Pred. No. 70;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         16 CAAGAATTCGGCACGAG 32
              || |||||||||||||||
Db          1 CAGGAATTCGGCACGAG 17


RESULT 23
US-09-257-218-5
; Sequence 5, Application US/09257218
; Patent No. 6271361
;  GENERAL INFORMATION:
;    APPLICANT:  Alnemri, Emad S.
;    APPLICANT:  Fernandes-Alnemri, Teresa
;    APPLICANT:  Litwack, Gerald
;    TITLE OF INVENTION:  Apoptotic Protease Mch6, Nucleic Acids
;    TITLE OF INVENTION:  Encoding Same and Methods of Use
;    NUMBER OF SEQUENCES:  87
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Campbell & Flores LLP
;      STREET:  4370 La Jolla Village Drive, Suite 700
;      CITY:  San Diego
;      STATE:  California
;      COUNTRY:  United States
;      ZIP:  92122
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/257,218
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/865,579
;      FILING DATE:  29-MAY-1997
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Campbell, Cathryn A.
;      REGISTRATION NUMBER:  31,815
;      REFERENCE/DOCKET NUMBER:  P-ID 2180
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (619) 535-9001
;      TELEFAX:  (619) 535-9849
;  INFORMATION FOR SEQ ID NO:  5:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  cDNA
US-09-257-218-5

  Query Match             0.9%;  Score 15.4;  DB 1;  Length 17;
```

```
  Best Local Similarity   94.1%;  Pred. No. 70;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy          16 CAAGAATTCGGCACGAG 32
               || |||||||||||||||
Db           1 CAGGAATTCGGCACGAG 17


RESULT 24
US-09-311-760-5
; Sequence 5, Application US/09311760
; Patent No. 6274318
;   GENERAL INFORMATION:
;        APPLICANT: Alnemri, Emad S.
;                   Fernandes-Alnemri, Teresa
;                   Litwack, Gerald
;        TITLE OF INVENTION: Apoptotic Protease Mch6, Nucleic Acids
;                            Encoding Same and Methods of Use
;        NUMBER OF SEQUENCES: 87
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: Campbell & Flores LLP
;             STREET: 4370 La Jolla Village Drive, Suite 700
;             CITY: San Diego
;             STATE: California
;             COUNTRY: United States
;             ZIP: 92122
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: Floppy disk
;             COMPUTER: IBM PC compatible
;             OPERATING SYSTEM: PC-DOS/MS-DOS
;             SOFTWARE: PatentIn Release #1.0, Version #1.25
;        CURRENT APPLICATION DATA:
;             APPLICATION NUMBER: US/09/311,760
;             FILING DATE: 13-May-1999
;             CLASSIFICATION: <Unknown>
;        PRIOR APPLICATION DATA:
;             APPLICATION NUMBER: 08/865,579
;             FILING DATE: <Unknown>
;        ATTORNEY/AGENT INFORMATION:
;             NAME: Campbell, Cathryn A.
;             REGISTRATION NUMBER: 31,815
;             REFERENCE/DOCKET NUMBER: P-ID 2180
;        TELECOMMUNICATION INFORMATION:
;             TELEPHONE: (619) 535-9001
;             TELEFAX: (619) 535-9849
;   INFORMATION FOR SEQ ID NO: 5:
;        SEQUENCE CHARACTERISTICS:
;             LENGTH: 17 base pairs
;             TYPE: nucleic acid
;             STRANDEDNESS: single
;             TOPOLOGY: linear
;        MOLECULE TYPE: cDNA
;        SEQUENCE DESCRIPTION: SEQ ID NO: 5:
US-09-311-760-5

  Query Match             0.9%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   94.1%;  Pred. No. 70;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy          16 CAAGAATTCGGCACGAG 32
               || |||||||||||||||
Db           1 CAGGAATTCGGCACGAG 17


RESULT 25
US-09-291-692-6
; Sequence 6, Application US/09291692
; Patent No. 6287795
;  GENERAL INFORMATION:
;    APPLICANT:  Alnemri, Emad S.
;    APPLICANT:  Fernandes-Alnemri, Teresa
;    APPLICANT:  Litwack, Gerald
;    APPLICANT:  Armstrong, Robert
;    APPLICANT:  Tomaselli, Kevin
;    TITLE OF INVENTION:  MCH4 AND MCH5, APOPTOTIC PROTEASE,
;    TITLE OF INVENTION:  NUCLEIC ACIDS ENCODING AND METHODS OF USE
;    NUMBER OF SEQUENCES:  75
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  SEED and BERRY
;      STREET:  6300 Columbia Center, 701 Fifth Avenue
;      CITY:  Seattle
;      STATE:  Washington
;      COUNTRY:  USe
;      ZIP:  98104
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/291,692
;      FILING DATE:  04-13-1999
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Christiansen, william T.
;      REGISTRATION NUMBER:  44,614
;      REFERENCE/DOCKET NUMBER:  480140.424C3
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (206) 622-4900
;      TELEFAX:  (206) 682-6031
;  INFORMATION FOR SEQ ID NO:  6:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    FEATURE:
;      NAME/KEY:  misc_feature
;      LOCATION:  1..17
;      OTHER INFORMATION:  /note= "SK-Zap"
US-09-291-692-6

  Query Match             0.9%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   94.1%;  Pred. No. 70;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy          16 CAAGAATTCGGCACGAG 32
               || |||||||||||||||
Db           1 CAGGAATTCGGCACGAG 17


RESULT 26
US-08-584-040-7821
; Sequence 7821, Application US/08584040
; Patent No. 6346398
;  GENERAL INFORMATION:
;    APPLICANT:  Pavco, Pamela
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Escobedo, Jaime
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  TREATMENT OF DISEASES OR
;    TITLE OF INVENTION:  CONDITIONS RELATED TO LEVELS
;    TITLE OF INVENTION:  OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR
;    NUMBER OF SEQUENCES:  8502
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
```

```
;       MEDIUM TYPE:  storage
;       COMPUTER:  IBM Compatible
;       OPERATING SYSTEM:  IBM P.C. DOS 5.0
;       SOFTWARE:  Word Perfect 5.1
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  US/08/584,040
;       FILING DATE:  January 11, 1996
;       CLASSIFICATION:  514
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  60/005,974
;       FILING DATE:  October 26, 1995
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Warburg, Richard J.
;       REGISTRATION NUMBER:  32,327
;       REFERENCE/DOCKET NUMBER:  218/064
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  (213) 489-1600
;       TELEFAX:  (213) 955-0440
;       TELEX:  67-3510
;   INFORMATION FOR SEQ ID NO:  7821:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  17 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
US-08-584-040-7821

  Query Match             0.9%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   17.6%;  Pred. No. 70;
  Matches    3;  Conservative   13;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1382 TTTGTTGTTTGTTTTGT 1398
              :::|:: :::|::::|:
Db          1 UUUGUUUUUUGUUUUGU 17


RESULT 27
US-08-865-579-5
; Sequence 5, Application US/08865579
; Patent No. 6455296
;  GENERAL INFORMATION:
;    APPLICANT:  Alnemri, Emad S.
;    APPLICANT:  Fernandes-Alnemri, Teresa
;    APPLICANT:  Litwack, Gerald
;    TITLE OF INVENTION:  Apoptotic Protease Mch6, Nucleic Acids
;    TITLE OF INVENTION:  Encoding Same and Methods of Use
;    NUMBER OF SEQUENCES:  87
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Campbell & Flores LLP
;      STREET:  4370 La Jolla Village Drive, Suite 700
;      CITY:  San Diego
;      STATE:  California
;      COUNTRY:  United States
;      ZIP:  92122
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/865,579
;      FILING DATE:  29-MAY-1997
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Campbell, Cathryn A.
;      REGISTRATION NUMBER:  31,815
;      REFERENCE/DOCKET NUMBER:  P-ID 2180
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (619) 535-9001
;      TELEFAX:  (619) 535-9849
;  INFORMATION FOR SEQ ID NO:  5:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  cDNA
US-08-865-579-5

  Query Match             0.9%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   94.1%;  Pred. No. 70;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         16 CAAGAATTCGGCACGAG 32
              || |||||||||||||||
Db          1 CAGGAATTCGGCACGAG 17


RESULT 28
US-08-556-627A-6
; Sequence 6, Application US/08556627A
; Patent No. 6462175
;  GENERAL INFORMATION:
;    APPLICANT:  Alnemri, Emad S.
;    APPLICANT:  Fernandes-Alnemri, Teresa
;    APPLICANT:  Litwack, Gerald
;    APPLICANT:  Armstrong, Robert
;    APPLICANT:  Tomaselli, Kevin
;    TITLE OF INVENTION:  Mch3, A No. 6462175el Apoptotic Protease,
;    TITLE OF INVENTION:  Nucleic Acids Encoding and Methods of Use
;    NUMBER OF SEQUENCES:  11
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Campbell and Flores
;      STREET:  4370 La Jolla Village Drive, Suite 700
;      CITY:  San Diego
;      STATE:  California
;      COUNTRY:  USA
;      ZIP:  92122
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/556,627A
;      FILING DATE:  13-NOV-1995
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Campbell, Cathryn A.
;      REGISTRATION NUMBER:  31,815
;      REFERENCE/DOCKET NUMBER:  P-ID 1813
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (619) 535-9001
;      TELEFAX:  (619) 535-8949
;  INFORMATION FOR SEQ ID NO:  6:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-556-627A-6

  Query Match             0.9%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   94.1%;  Pred. No. 70;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         16 CAAGAATTCGGCACGAG 32
              || |||||||||||||||
Db          1 CAGGAATTCGGCACGAG 17


RESULT 29
US-09-371-772B-3605
; Sequence 3605, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
```

```
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3605
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Mus sp.
US-09-371-772B-3605

  Query Match             0.9%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   17.6%;  Pred. No. 70;
  Matches    3;  Conservative   13;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1382 TTTGTTGTTTGTTTTGT 1398
              :::|:: :::|::::|:
Db             1 UUUGUUUUUUGUUUUGU 17


RESULT 30
US-10-059-749-5
; Sequence 5, Application US/10059749
; Patent No. 6566505
;  GENERAL INFORMATION:
;       APPLICANT: Alnemri, Emad S.
;                  Fernandes-Alnemri, Teresa
;                  Litwack, Gerald
;       TITLE OF INVENTION: Apoptotic Protease Mch6, Nucleic Acids
;                           Encoding Same and Methods of Use
;       NUMBER OF SEQUENCES: 87
;       CORRESPONDENCE ADDRESS:
;            ADDRESSEE: Campbell & Flores LLP
;            STREET: 4370 La Jolla Village Drive, Suite 700
;            CITY: San Diego
;            STATE: California
;            COUNTRY: United States
;            ZIP: 92122
;       COMPUTER READABLE FORM:
;            MEDIUM TYPE: Floppy disk
;            COMPUTER: IBM PC compatible
;            OPERATING SYSTEM: PC-DOS/MS-DOS
;            SOFTWARE: PatentIn Release #1.0, Version #1.25
;       CURRENT APPLICATION DATA:
;            APPLICATION NUMBER: US/10/059,749
;            FILING DATE: 29-Jan-2002
;            CLASSIFICATION: <Unknown>
;       PRIOR APPLICATION DATA:
;            APPLICATION NUMBER: US/08/865,579
;            FILING DATE: 29-MAY-1997
;       ATTORNEY/AGENT INFORMATION:
;            NAME: Campbell, Cathryn A.
;            REGISTRATION NUMBER: 31,815
;            REFERENCE/DOCKET NUMBER: P-ID 2180
;       TELECOMMUNICATION INFORMATION:
;            TELEPHONE: (619) 535-9001
;            TELEFAX: (619) 535-9849
;   INFORMATION FOR SEQ ID NO: 5:
;       SEQUENCE CHARACTERISTICS:
;            LENGTH: 17 base pairs
;            TYPE: nucleic acid
;            STRANDEDNESS: single
;            TOPOLOGY: linear
;       MOLECULE TYPE: cDNA
;       SEQUENCE DESCRIPTION: SEQ ID NO: 5:
US-10-059-749-5

  Query Match             0.9%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   94.1%;  Pred. No. 70;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         16 CAAGAATTCGGCACGAG 32
              || |||||||||||||||
Db          1 CAGGAATTCGGCACGAG 17


RESULT 31
US-09-163-099-6
; Sequence 6, Application US/09163099
; Patent No. 6686459
;  GENERAL INFORMATION:
;    APPLICANT:  Alnemri, Emad S.
;    APPLICANT:  Fernandes-Alnemri, Teresa
;    APPLICANT:  Litwack, Gerald
;    APPLICANT:  Armstrong, Robert
;    APPLICANT:  Tomaselli, Kevin
;    TITLE OF INVENTION:  Mch3, A No. 6686459el Apoptotic Protease,
;    TITLE OF INVENTION:  Nucleic Acids Encoding and Methods of Use
;    NUMBER OF SEQUENCES:  11
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Campbell and Flores
;      STREET:  4370 La Jolla Village Drive, Suite 700
;      CITY:  San Diego
;      STATE:  California
;      COUNTRY:  USA
;      ZIP:  92122
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/163,099
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/556,627
;      FILING DATE:  13-NOV-1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Campbell, Cathryn A.
;      REGISTRATION NUMBER:  31,815
;      REFERENCE/DOCKET NUMBER:  P-ID 1813
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (619) 535-9001
;      TELEFAX:  (619) 535-8949
;  INFORMATION FOR SEQ ID NO:  6:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-09-163-099-6

  Query Match             0.9%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   94.1%;  Pred. No. 70;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         16 CAAGAATTCGGCACGAG 32
              || |||||||||||||||
Db          1 CAGGAATTCGGCACGAG 17


RESULT 32
US-10-337-060-6
; Sequence 6, Application US/10337060
```

```
; Patent No. 6716960
; GENERAL INFORMATION:
;  APPLICANT: Alnemri, Emad S.
;  APPLICANT:  Fernandez-Alnemri, Teresa
;  APPLICANT:  Litwack, Gerald
;  APPLICANT:  Armstrong, Robert
;  APPLICANT:  Tomaselli, Kevin
;  TITLE OF INVENTION: MCH3, A NOVEL APOPTOTIC PROTEASE,
;  TITLE OF INVENTION:  NUCLEIC ACIDS ENCODING AND METHODS OF USE
;  FILE REFERENCE: 480140.423D2
;  CURRENT APPLICATION NUMBER: US/10/337,060
;  CURRENT FILING DATE:  2003-01-02
;  NUMBER OF SEQ ID NOS: 17
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 6
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Primer SK-Zap
US-10-337-060-6

  Query Match             0.9%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   94.1%;  Pred. No. 70;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         16 CAAGAATTCGGCACGAG 32
              || |||||||||||||||
Db          1 CAGGAATTCGGCACGAG 17


RESULT 33
US-09-952-768-6
; Sequence 6, Application US/09952768
; Patent No. 6730779
;   GENERAL INFORMATION:
;        APPLICANT: Alnemri, Emad S.
;                   Fernandes-Alnemri, Teresa
;                   Litwack, Gerald
;                   Armstrong, Robert
;                   Tomaselli, Kevin
;        TITLE OF INVENTION: MCH4 AND MCH5, APOPTOTIC PROTEASE,
;                            NUCLEIC ACIDS ENCODING AND METHODS OF USE
;        NUMBER OF SEQUENCES: 75
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: Seed Intellectual Property Law Group
;             STREET: Suite 6300, 701 Fifth Avenue
;             CITY: Seattle
;             STATE: Washington
;             COUNTRY: USA
;             ZIP: 98104
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: Floppy disk
;             COMPUTER: IBM PC compatible
;             OPERATING SYSTEM: PC-DOS/MS-DOS
;             SOFTWARE: PatentIn Release #1.0, Version #1.30
;        CURRENT APPLICATION DATA:
;             APPLICATION NUMBER: US/09/952,768
;             FILING DATE: 10-Sep-2001
;             CLASSIFICATION: <Unknown>
;        ATTORNEY/AGENT INFORMATION:
;             NAME: Christiansen, William T.
;             REGISTRATION NUMBER: 44,614
;             REFERENCE/DOCKET NUMBER: 480140.424C4
;        TELECOMMUNICATION INFORMATION:
;             TELEPHONE: (206) 622-4900
;             TELEFAX: (206) 682-6031
;   INFORMATION FOR SEQ ID NO: 6:
;        SEQUENCE CHARACTERISTICS:
;             LENGTH: 17 base pairs
;             TYPE: nucleic acid
;             STRANDEDNESS: single
;             TOPOLOGY: linear
;        FEATURE:
;             NAME/KEY:  misc_feature
;             LOCATION:  1..17
;             OTHER INFORMATION:  /note= "SK-Zap"
;        SEQUENCE DESCRIPTION: SEQ ID NO: 6:
US-09-952-768-6

  Query Match             0.9%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   94.1%;  Pred. No. 70;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         16 CAAGAATTCGGCACGAG 32
              || |||||||||||||||
Db          1 CAGGAATTCGGCACGAG 17


RESULT 34
US-08-363-585-68
; Sequence 68, Application US/08363585
; Patent No. 5683872
;  GENERAL INFORMATION:
;    APPLICANT:  Rudert, William A.
;    APPLICANT:  Trucco, Massimo
;    TITLE OF INVENTION:  Polymers of Oligonucleotide Probes
;    TITLE OF INVENTION:  As The Bound Ligands For Use In Reverse
;    TITLE OF INVENTION:  Dot Blots
;    NUMBER OF SEQUENCES:  112
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  University of Pittsburgh
;      STREET:  Office of Intellectual Property
;      STREET:  911 William Pitt Union
;      CITY:  Pittsburgh
;      STATE:  Pennsylvania
;      COUNTRY:  USA
;      ZIP:  15260
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  5-1/4" low density diskette
;      COMPUTER:  IBM PC or compatibles
;      OPERATING SYSTEM:  MS-DOS
;      SOFTWARE:  ASCII
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/363,585
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US/07/786,228
;      FILING DATE:  31-OCT-1991
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Frederick H. Colen; Mary-Elizabeth Buckles
;      REGISTRATION NUMBER:  28,061; 31,907
;      REFERENCE/DOCKET NUMBER:  92-232
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  412/288-4164
;      TELEFAX:  412/288-3063
;      TELEX:  277871
;  INFORMATION FOR SEQ ID NO:  68:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  18 nucleotides
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  genomic DNA
;    PUBLICATION INFORMATION:
;      AUTHORS:  Kimura, A.
;      AUTHORS:  Sasazuki, T.
;      TITLE:  Eleventh International Histocompatibility
;      TITLE:  Workshop Reference Protocol for the HLA-DNA-Typing
;      TITLE:  Technique
;      JOURNAL:  HLA 1991
;      VOLUME:  1
;      PAGES:  397-419
;      DATE:  1992
;      RELEVANT RESIDUES IN SEQ ID NO:  68: 1 to 18
```

US-08-363-585-68

Query Match 0.9%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 72;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy        839 CCTGACGCTGAGCACTG 855
              ||||||||||| ||||
Db          2 CCTGACGCTGAGTACTG 18
```

RESULT 35
US-09-308-003-31
; Sequence 31, Application US/09308003
; Patent No. 6326170
; GENERAL INFORMATION:
; APPLICANT: Burnham, Martin K. R.
; APPLICANT: Lonetto, Michael A.
; APPLICANT: Warren, Patrick V.
; TITLE OF INVENTION: NOVEL PROKARYOTIC POLYNUCLEOTIDES,
; TITLE OF INVENTION: POLYPEPTIDES AND THEIR USES
; FILE REFERENCE: GM10093
; CURRENT APPLICATION NUMBER: US/09/308,003
; CURRENT FILING DATE: 1999-05-10
; EARLIER APPLICATION NUMBER: 60/058,710
; EARLIER FILING DATE: 1997-09-12
; NUMBER OF SEQ ID NOS: 52
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 31
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Staphylococcus aureus
US-09-308-003-31

Query Match 0.9%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 73;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy         19 GAATTCGGCACGAGGGG 35
              ||||||||||||| ||
Db          2 GAATTCGGCACGAGCGG 18
```

RESULT 36
US-09-696-791-1199
; Sequence 1199, Application US/09696791
; Patent No. 6770633
; GENERAL INFORMATION:
; APPLICANT: Robbins, Joan M.
; APPLICANT: Tritz, Richard
; TITLE OF INVENTION: RIBOZYME THERAPY FOR THE TREATMENT OF PROLIFERATIVE
; TITLE OF INVENTION: SKIN AND EYE DISEASES
; FILE REFERENCE: 480124.407
; CURRENT APPLICATION NUMBER: US/09/696,791
; CURRENT FILING DATE: 2000-10-25
; NUMBER OF SEQ ID NOS: 4523
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 1199
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: Cdk-we-hu ribozyme binding site
US-09-696-791-1199

Query Match 0.9%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 73;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy       1001 GGACTGATTCCTGTGGT 1017
              ||| ||||||||||||
Db          2 GGAATGATTCCTGTGGT 18
```

RESULT 37
US-09-696-791-1200
; Sequence 1200, Application US/09696791
; Patent No. 6770633
; GENERAL INFORMATION:
; APPLICANT: Robbins, Joan M.
; APPLICANT: Tritz, Richard
; TITLE OF INVENTION: RIBOZYME THERAPY FOR THE TREATMENT OF PROLIFERATIVE
; TITLE OF INVENTION: SKIN AND EYE DISEASES
; FILE REFERENCE: 480124.407
; CURRENT APPLICATION NUMBER: US/09/696,791
; CURRENT FILING DATE: 2000-10-25
; NUMBER OF SEQ ID NOS: 4523
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 1200
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: Cdk-we-hu ribozyme binding site
US-09-696-791-1200

Query Match 0.9%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 73;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy       1001 GGACTGATTCCTGTGGT 1017
              ||| ||||||||||||
Db          1 GGAATGATTCCTGTGGT 17
```

RESULT 38
US-09-357-070-8/c
; Sequence 8, Application US/09357070
; Patent No. 6046049
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Lex M. Cowsert
; TITLE OF INVENTION: ANTISENSE MODULATION OF PI3 KINASE P110 DELTA EXPRESSION
; FILE REFERENCE: RTS-0076
; CURRENT APPLICATION NUMBER: US/09/357,070
; CURRENT FILING DATE: 1999-07-19
; NUMBER OF SEQ ID NOS: 47
; SEQ ID NO 8
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-357-070-8

Query Match 0.9%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 75;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy         19 GAATTCGGCACGAGGGG 35
              ||||||||||||| ||
Db         20 GAATTCGGCACGAGCGG 4
```

RESULT 39
US-09-538-709-3/c
; Sequence 3, Application US/09538709
; Patent No. 6468749
; GENERAL INFORMATION:
; APPLICANT: Ulanovsky, et al
; TITLE OF INVENTION: SEQUENCE-DEPENDENT GENE SORTING TECHNIQUES
; FILE REFERENCE: 540579-2006
; CURRENT APPLICATION NUMBER: US/09/538,709
; CURRENT FILING DATE: 2001-06-08
; NUMBER OF SEQ ID NOS: 1311
; SOFTWARE: PatentIn version 3.0

```
; SEQ ID NO 3
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: primer
US-09-538-709-3

  Query Match             0.9%;  Score 15.4;  DB 1;  Length 20;
  Best Local Similarity   94.1%;  Pred. No. 75;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1115 ATACCCCTCAGTACTGT 1131
              ||||| ||||||||||
Db         18 ATACCACTCAGTACTGT 2


RESULT 40
US-08-621-914A-2
; Sequence 2, Application US/08621914A
; Patent No. 5707807
;  GENERAL INFORMATION:
;    APPLICANT:  KATO, KIKUYA
;    TITLE OF INVENTION:  MOLECULAR INDEXING FOR EXPRESSED GENE
;    TITLE OF INVENTION:  ANALYSIS
;    NUMBER OF SEQUENCES:  16
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  PENNIE & EDMONDS
;      STREET:  1155 AVENUE OF THE AMERICAS
;      CITY:  NEW YORK
;      STATE:  NY
;      COUNTRY:  USA
;      ZIP:  10036-2711
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/621,914A
;      FILING DATE:  26-MAR-1996
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  LAWRENCE III, STANTON T.
;      REGISTRATION NUMBER:  25,736
;      REFERENCE/DOCKET NUMBER:  7005-107-999
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (212) 790-9090
;      TELEFAX:  (212) 869-9741
;      TELEX:  66141 PENNIE
;  INFORMATION FOR SEQ ID NO:  2:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  26 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  unknown
;      TOPOLOGY:  unknown
;    MOLECULE TYPE:  other nucleic acid
US-08-621-914A-2

  Query Match             0.9%;  Score 15.4;  DB 1;  Length 26;
  Best Local Similarity   76.0%;  Pred. No. 83;
  Matches   19;  Conservative    0;  Mismatches    6;  Indels    0;  Gaps    0;

Qy       1386 TTGTTTGTTTTGTATCTTGTTTTTC 1410
              || ||| |||| | | || ||||||
Db          2 TTTTTTTTTTTTTTTTTTTTTTTTC 26


RESULT 41
US-08-873-437-2
; Sequence 2, Application US/08873437
; Patent No. 6124092
;  GENERAL INFORMATION:
;    APPLICANT:  O'Neill, Roger A.
;    APPLICANT:  Chen, Jer-Kang
;    APPLICANT:  Chiesa, Claudia
;    APPLICANT:  Fry, George
;    TITLE OF INVENTION:  Multiplex Polynucleotide Capture
;    TITLE OF INVENTION:  Methods and Compositions
;    NUMBER OF SEQUENCES:  50
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  PE Applied Biosystems
;      STREET:  850 Lincoln Centre Drive
;      CITY:  Foster City
;      STATE:  CA
;      COUNTRY:  USA
;      ZIP:  94404
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Diskette
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  DOS
;      SOFTWARE:  FastSEQ for Windows Version 2.0
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/873,437
;      FILING DATE:  12-JUN-1997
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/027,832
;      FILING DATE:  04-OCT-1996
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Bortner, Scott R
;      REGISTRATION NUMBER:  34,298
;      REFERENCE/DOCKET NUMBER:  4294
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  415-638-6245
;      TELEFAX:  415-638-6071
;  INFORMATION FOR SEQ ID NO:  2:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  26 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-873-437-2

  Query Match             0.9%;  Score 15.4;  DB 1;  Length 26;
  Best Local Similarity   76.0%;  Pred. No. 83;
  Matches   19;  Conservative    0;  Mismatches    6;  Indels    0;  Gaps    0;

Qy       1386 TTGTTTGTTTTGTATCTTGTTTTTC 1410
              || ||| |||| | | || ||||||
Db          2 TTTTTTTTTTTTTTTTTTTTTTTTC 26


RESULT 42
US-09-522-217-39
; Sequence 39, Application US/09522217
; Patent No. 6307024
; GENERAL INFORMATION:
;  APPLICANT: No. 6307024ak, Julia E.
;  APPLICANT: Presnell, Scott R.
;  APPLICANT: Sprecher, Cindy A.
;  APPLICANT: Foster, Donald C.
;  APPLICANT: Holly, Richard D.
;  APPLICANT: Gross, Jane A.
;  APPLICANT: Johnston, Janet V.
;  APPLICANT: Nelson, Andrew J.
;  APPLICANT: Dillon, Stacey R.
;  APPLICANT: Hammond, Angela K.
;  TITLE OF INVENTION: NOVEL CYTOKINE ZALPHA11 LIGAND
;  FILE REFERENCE: 99-16
;  CURRENT APPLICATION NUMBER: US/09/522,217
;  CURRENT FILING DATE: 2000-03-09
;  EARLIER APPLICATION NUMBER: US 60/123,547
;  EARLIER FILING DATE: 1999-03-09
;  EARLIER APPLICATION NUMBER: US 60/123,904
;  EARLIER FILING DATE: 1999-03-11
;  EARLIER APPLICATION NUMBER: US 60/142,013
```

```
;  EARLIER FILING DATE: 1999-07-01
;  NUMBER OF SEQ ID NOS: 115
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 39
;   LENGTH: 26
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide primer ZC7764b
US-09-522-217-39

  Query Match             0.9%;  Score 15.4;  DB 1;  Length 26;
  Best Local Similarity   76.0%;  Pred. No. 83;
  Matches   19;  Conservative    0;  Mismatches    6;  Indels    0;  Gaps    0;

Qy       1386 TTGTTTGTTTTGTATCTTGTTTTTC 1410
             || ||| |||| | | || ||||||
Db          2 TTTTTTTTTTTTTTTTTTTTTTTTC 26


RESULT 43
US-09-593-312-2
; Sequence 2, Application US/09593312
; Patent No. 6514699
;  GENERAL INFORMATION:
;    APPLICANT:  O'Neill, Roger A.
;    APPLICANT:  Chen, Jer-Kang
;    APPLICANT:  Chiesa, Claudia
;    APPLICANT:  Fry, George
;    TITLE OF INVENTION:  Multiplex Polynucleotide Capture
;    TITLE OF INVENTION:  Methods and Compositions
;    NUMBER OF SEQUENCES:  50
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  PE Applied Biosystems
;      STREET:  850 Lincoln Centre Drive
;      CITY:  Foster City
;      STATE:  CA
;      COUNTRY:  USA
;      ZIP:  94404
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Diskette
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  DOS
;      SOFTWARE:  FastSEQ for Windows Version 2.0
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/593,312
;      FILING DATE:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/873,437
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Bortner, Scott R
;      REGISTRATION NUMBER:  34,298
;      REFERENCE/DOCKET NUMBER:  4294
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  415-638-6245
;      TELEFAX:  415-638-6071
;  INFORMATION FOR SEQ ID NO:  2:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  26 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-09-593-312-2

  Query Match             0.9%;  Score 15.4;  DB 1;  Length 26;
  Best Local Similarity   76.0%;  Pred. No. 83;
  Matches   19;  Conservative    0;  Mismatches    6;  Indels    0;  Gaps    0;

Qy       1386 TTGTTTGTTTTGTATCTTGTTTTTC 1410
             || ||| |||| | | || ||||||
Db          2 TTTTTTTTTTTTTTTTTTTTTTTTC 26


RESULT 44
US-09-923-246-39
; Sequence 39, Application US/09923246
; Patent No. 6605272
; GENERAL INFORMATION:
;  APPLICANT: No. 6605272ak, Julia E.
;  APPLICANT:  Presnell, Scott R.
;  APPLICANT:  Sprecher, Cindy A.
;  APPLICANT:  Foster, Donald C.
;  APPLICANT:  Holly, Richard D.
;  APPLICANT:  Gross, Jane A.
;  APPLICANT:  Johnston, Janet V.
;  APPLICANT:  Nelson, Andrew J.
;  APPLICANT:  Dillon, Stacey R.
;  APPLICANT:  Hammond, Angela K.
;  TITLE OF INVENTION: NOVEL CYTOKINE ZALPHA11 LIGAND
;  FILE REFERENCE: 99-16
;  CURRENT APPLICATION NUMBER: US/09/923,246
;  CURRENT FILING DATE:  2001-08-03
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US/09/522,217
;  PRIOR FILING DATE: EARLIER FILING DATE: 2000-03-09
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/123,904
;  PRIOR FILING DATE: EARLIER FILING DATE: 1999-03-11
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/142,013
;  PRIOR FILING DATE: EARLIER FILING DATE: 1999-07-01
;  NUMBER OF SEQ ID NOS: 115
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 39
;   LENGTH: 26
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide primer ZC7764b
US-09-923-246-39

  Query Match             0.9%;  Score 15.4;  DB 1;  Length 26;
  Best Local Similarity   76.0%;  Pred. No. 83;
  Matches   19;  Conservative    0;  Mismatches    6;  Indels    0;  Gaps    0;

Qy       1386 TTGTTTGTTTTGTATCTTGTTTTTC 1410
             || ||| |||| | | || ||||||
Db          2 TTTTTTTTTTTTTTTTTTTTTTTTC 26


RESULT 45
US-09-658-077-1
; Sequence 1, Application US/09658077
; Patent No. 6627748
; GENERAL INFORMATION:
;  APPLICANT:  Ju, Jingyue
;  APPLICANT:  et al.
;  TITLE OF INVENTION:  Combinatorial Fluoresence Energy Transfer Tags And
;  TITLE OF INVENTION:  Their Applications For Multiplex Genetic Analyses
;  FILE REFERENCE:  0575/62238/JPW/ADM
;  CURRENT APPLICATION NUMBER: US/09/658,077
;  CURRENT FILING DATE:  2000-09-11
;  NUMBER OF SEQ ID NOS:  17
;  SOFTWARE:  PatentIn Ver. 2.1
; SEQ ID NO 1
;   LENGTH: 26
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: scaffold
US-09-658-077-1

  Query Match             0.9%;  Score 15.4;  DB 1;  Length 26;
  Best Local Similarity   76.0%;  Pred. No. 83;
  Matches   19;  Conservative    0;  Mismatches    6;  Indels    0;  Gaps    0;

Qy       1386 TTGTTTGTTTTGTATCTTGTTTTTC 1410
             || ||| |||| | | || ||||||
```

```
Db          2 TTTTTTTTTTTTTTTTTTTTTTC 26


RESULT 46
US-10-295-723-39
; Sequence 39, Application US/10295723
; Patent No. 6686178
; GENERAL INFORMATION:
;  APPLICANT: No. 6686178ak, Julia E.
;  APPLICANT:  Presnell, Scott R.
;  APPLICANT:  Sprecher, Cindy A.
;  APPLICANT:  Foster, Donald C.
;  APPLICANT:  Holly, Richard D.
;  APPLICANT:  Gross, Jane A.
;  APPLICANT:  Johnston, Janet V.
;  APPLICANT:  Nelson, Andrew J.
;  APPLICANT:  Dillon, Stacey R.
;  APPLICANT:  Hammond, Angela K.
;  TITLE OF INVENTION: NOVEL CYTOKINE ZALPHA11 LIGAND
;  FILE REFERENCE: 99-16
;  CURRENT APPLICATION NUMBER: US/10/295,723
;  CURRENT FILING DATE:  2002-11-15
;  PRIOR APPLICATION NUMBER: 09/522,217
;  PRIOR FILING DATE: 2000-03-09
;  PRIOR APPLICATION NUMBER: US 60/123,547
;  PRIOR FILING DATE: 1999-03-09
;  PRIOR APPLICATION NUMBER: US 60/123,904
;  PRIOR FILING DATE: 1999-03-11
;  PRIOR APPLICATION NUMBER: US 60/142,013
;  PRIOR FILING DATE: 1999-07-01
;  NUMBER OF SEQ ID NOS: 115
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 39
;   LENGTH: 26
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide primer ZC7764b
US-10-295-723-39

  Query Match             0.9%;  Score 15.4;  DB 1;  Length 26;
  Best Local Similarity   76.0%;  Pred. No. 83;
  Matches   19;  Conservative    0;  Mismatches    6;  Indels    0;  Gaps    0;

Qy       1386 TTGTTTGTTTTGTATCTTGTTTTTC 1410
             || ||| |||| | | || ||||||
Db          2 TTTTTTTTTTTTTTTTTTTTTTTTC 26


RESULT 47
US-09-488-671-76
; Sequence 76, Application US/09488671A
; Patent No. 6187545
; GENERAL INFORMATION:
;  APPLICANT: Robert McKay
;  APPLICANT: Madeline M. Butler
;  APPLICANT: Jacqueline Wyatt
;  APPLICANT: Lex M. Cowsert
;  TITLE OF INVENTION: ANTISENSE MODULATION OF PEPCK-CYTOSOLIC EXPRESSION
;  FILE REFERENCE: RTS-0123
;  CURRENT APPLICATION NUMBER: US/09/488,671A
;  CURRENT FILING DATE: 2000-01-21
;  NUMBER OF SEQ ID NOS: 177
; SEQ ID NO 76
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-488-671-76

  Query Match             0.9%;  Score 15.2;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 81;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        241 TCTCGTCGTCGTCCACCTCC 260
              |||||  ||| |||||||||
Db          1 TCTCGATGTCTTCCACCTCC 20


RESULT 48
US-09-489-869-36/c
; Sequence 36, Application US/09489869A
; Patent No. 6268151
; GENERAL INFORMATION:
;  APPLICANT: Susan Murray
;  APPLICANT: Lex M. Cowsert
;  APPLICANT: Jacqueline Wyatt
;  TITLE OF INVENTION: ANTISENSE MODULATION OF MACROPHAGE MIGRATION INHIBITORY FACTOR
;  FILE REFERENCE: RTS-0110
;  CURRENT APPLICATION NUMBER: US/09/489,869A
;  CURRENT FILING DATE: 2000-01-20
;  NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 36
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-489-869-36

  Query Match             0.9%;  Score 15.2;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 81;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        624 TACAGCGAGCCGTGCGGCCT 643
              | ||||||||||||||  ||
Db         20 TCCAGCGAGCCGTGCGCGCT 1


RESULT 49
US-09-506-073-73/c
; Sequence 73, Application US/09506073
; Patent No. 6410518
; GENERAL INFORMATION:
;  APPLICANT: Monia, Brett P.
;  TITLE OF INVENTION: Antisense Oligonucleotide Modulation of raf Gene Expression
;  FILE REFERENCE:
;  CURRENT APPLICATION NUMBER: US/09/506,073
;  CURRENT FILING DATE: 2000-02-18
;  EARLIER APPLICATION NUMBER: US 09/143,214
;  EARLIER FILING DATE: 1998-08-28
;  EARLIER APPLICATION NUMBER: PCT/US98/13961
;  EARLIER FILING DATE: 1998-07-06
;  EARLIER APPLICATION NUMBER: US 08/888,982
;  EARLIER FILING DATE: 1997-07-07
;  EARLIER APPLICATION NUMBER: US 08/756,806
;  EARLIER FILING DATE: 1996-11-26
;  EARLIER APPLICATION NUMBER: PCT/US95/07111
;  EARLIER FILING DATE: 1995-05-31
;  EARLIER APPLICATION NUMBER: US 08/250,856
;  EARLIER FILING DATE: 1994-05-31
;  NUMBER OF SEQ ID NOS: 130
; SEQ ID NO 73
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: artificial sequence
;   FEATURE:
;   OTHER INFORMATION: antisense sequence
US-09-506-073-73

  Query Match             0.9%;  Score 15.2;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 81;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1267 CCGGCCCAGGGTGAAGGAAG 1286
```

```
                  | ||||| ||| ||||||||
Db          20 CTGGCCCTGGGAGAAGGAAG 1


RESULT 50
US-09-066-281B-17/c
; Sequence 17, Application US/09066281B
; Patent No. 6475783
;  GENERAL INFORMATION:
;    APPLICANT:  LUCAS, Sophie; DE SMET, Charles; BOON-FALLEUR, Thierry
;    TITLE OF INVENTION:  ISOLATED NUCLEIC ACID MOLECULE CODING
;    TITLE OF INVENTION:  FOR TUMOR REJECTION ANTIGEN PRECURSOR MAGE-C1 AND MAGE-C2
;    TITLE OF INVENTION:  AND USES THEREOF
;    NUMBER OF SEQUENCES:  20
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Fulbright & Jaworski L.L.P.
;      STREET:  666 Fifth Avenue
;      CITY:  New York City
;      STATE:  New York
;      COUNTRY:  USA
;      ZIP:  10103
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Diskette, 3.5 inch, 360 kb storage
;      COMPUTER:  IBM PS/2
;      OPERATING SYSTEM:  PC-DOS
;      SOFTWARE:  Wordperfect
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/066,281B
;      FILING DATE:  April 24, 1998
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/845,528
;      FILING DATE:  April 25, 1997
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Mary Anne Schofield
;      REGISTRATION NUMBER:  36,669
;      REFERENCE/DOCKET NUMBER:  LUD 5455.2 US - JEL/MAS
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (212) 318-3100
;      TELEFAX:  (212) 752-5958
;  INFORMATION FOR SEQ ID NO:  17:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  20 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single-stranded
;      TOPOLOGY:  linear
US-09-066-281B-17

  Query Match             0.9%;  Score 15.2;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 81;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        495 TGTGCCAACCTGATGCAGCT 514
              | |||||||| || ||||||
Db         20 TCTGCCAACCAGAGGCAGCT 1


RESULT 51
US-09-198-452A-2571/c
; Sequence 2571, Application US/09198452A
; Patent No. 6559294
; GENERAL INFORMATION:
;  APPLICANT: Griffais, R.
;  TITLE OF INVENTION: Chlamydia pneumoniae genomic sequence and polypeptides, fragments
;  TITLE OF INVENTION:  thereof and uses thereof, in particular for the diagnosis, preve
;  TITLE OF INVENTION:  and treatment of infection
;  FILE REFERENCE: 9710-003-999
;  CURRENT APPLICATION NUMBER: US/09/198,452A
;  CURRENT FILING DATE:  1998-11-24
;  NUMBER OF SEQ ID NOS: 6849
; SEQ ID NO 2571
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Chlamydia pneumoniae
US-09-198-452A-2571

  Query Match             0.9%;  Score 15.2;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 81;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        996 CTGAGGGACTGATTCCTGTG 1015
              ||| |||| ||||||||| |
Db         20 CTGTGGGATTGATTCCTGAG 1


RESULT 52
US-09-198-452A-5767/c
; Sequence 5767, Application US/09198452A
; Patent No. 6559294
; GENERAL INFORMATION:
;  APPLICANT: Griffais, R.
;  TITLE OF INVENTION: Chlamydia pneumoniae genomic sequence and polypeptides, fragments
;  TITLE OF INVENTION:  thereof and uses thereof, in particular for the diagnosis, prever
;  TITLE OF INVENTION:  and treatment of infection
;  FILE REFERENCE: 9710-003-999
;  CURRENT APPLICATION NUMBER: US/09/198,452A
;  CURRENT FILING DATE:  1998-11-24
;  NUMBER OF SEQ ID NOS: 6849
; SEQ ID NO 5767
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Chlamydia pneumoniae
US-09-198-452A-5767

  Query Match             0.9%;  Score 15.2;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 81;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1617 CCTCCCCGGGAGGAGTGCCA 1636
              | ||||| ||||||||| ||
Db         20 CTTCCCCTGGAGGAGTGGCA 1


RESULT 53
US-09-688-188B-145/c
; Sequence 145, Application US/09688188B
; Patent No. 6656716
; GENERAL INFORMATION:
;  APPLICANT: PLOWMAN, GREGORY
;  APPLICANT:  MARTINEZ, RICARDO
;  APPLICANT:  WHYTE, DAVID
;  TITLE OF INVENTION: STE20-RELATED PROTEIN KINASES
;  FILE REFERENCE: 038602/0328
;  CURRENT APPLICATION NUMBER: US/09/688,188B
;  CURRENT FILING DATE:  2000-10-16
;  PRIOR APPLICATION NUMBER: 09/291,417
;  PRIOR FILING DATE: 1999-04-14
;  PRIOR APPLICATION NUMBER: 60/081,784
;  PRIOR FILING DATE: 1998-04-14
;  NUMBER OF SEQ ID NOS: 155
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 145
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-688-188B-145

  Query Match             0.9%;  Score 15.2;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 81;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        601 GCAAAGAACTACTGCGCCTG 620
              |||||  |||||||| ||||
Db         20 GCAAATGACTACTGCACCTG 1
```

```
RESULT 54
US-09-291-417D-145/c
; Sequence 145, Application US/09291417D
; Patent No. 6680170
; GENERAL INFORMATION:
;  APPLICANT: PLOWMAN, GREGORY
;  APPLICANT:  MARTINEZ, RICARDO
;  APPLICANT:  WHYTE, DAVID
;  TITLE OF INVENTION: STE20-RELATED PROTEIN KINASES
;  FILE REFERENCE: 038602/0329
;  CURRENT APPLICATION NUMBER: US/09/291,417D
;  CURRENT FILING DATE:  1999-04-13
;  PRIOR APPLICATION NUMBER: 60/081,784
;  PRIOR FILING DATE: 1998-04-14
;  NUMBER OF SEQ ID NOS: 155
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 145
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-291-417D-145

  Query Match             0.9%;  Score 15.2;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 81;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        601 GCAAAGAACTACTGCGCCTG 620
              |||||  |||||||| ||||
Db         20 GCAAATGACTACTGCACCTG 1


RESULT 55
US-09-468-433C-17/c
; Sequence 17, Application US/09468433C
; Patent No. 6680191
;  GENERAL INFORMATION:
;    APPLICANT:  LUCAS, Sophie; BOON-FALLEUR, Thierry
;    TITLE OF INVENTION:  ISOLATED NUCLEIC ACID MOLECULES CODING FOR
;    TITLE OF INVENTION:  TUMOR REJECTION ANTIGEN PRECURSORS OF MEMBERS OF THE MAGE-C AN
;    TITLE OF INVENTION:  MAGE-B FAMILIES AND USES THEREOF
;    NUMBER OF SEQUENCES:  26
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Fulbright & Jaworski L.L.P.
;      STREET:  801 Pennsylvania Avenue, NW
;      CITY:  Washington
;      STATE:  District of Columbia
;      COUNTRY:  USA
;      ZIP:  20004
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Diskette, 3.5 inch, 360 kb storage
;      COMPUTER:  IBM PS/2
;      OPERATING SYSTEM:  PC-DOS
;      SOFTWARE:  Wordperfect
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/468,433C
;      FILING DATE:  December 17, 1999
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  09/066,281
;      FILING DATE:  April 24, 1998
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/845,528
;      FILING DATE:  April 25, 1997
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Mary Anne Schofield
;      REGISTRATION NUMBER:  36,669
;      REFERENCE/DOCKET NUMBER:  LUD 5611 JEL/MAS
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (202) 662-0200
;      TELEFAX:  (202) 662-4643
;  INFORMATION FOR SEQ ID NO:  17:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  20 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single-stranded
;      TOPOLOGY:  linear
US-09-468-433C-17

  Query Match             0.9%;  Score 15.2;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 81;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        495 TGTGCCAACCTGATGCAGCT 514
              | ||||||||  || ||||||
Db         20 TCTGCCAACCAGAGGCAGCT 1


RESULT 56
US-09-021-660A-24
; Sequence 24, Application US/09021660A
; Patent No. 6713065
; GENERAL INFORMATION:
;  APPLICANT: Baron, M.
;  APPLICANT:  Farrington, S.
;  APPLICANT:  Belaussoff, M.
;  TITLE OF INVENTION: METHODS FOR MODULATING HEMATOPOIESIS AND VASCULAR
;  TITLE OF INVENTION:  GROWTH
;  FILE REFERENCE: HUIP-P01-060
;  CURRENT APPLICATION NUMBER: US/09/021,660A
;  CURRENT FILING DATE:  2001-08-27
;  PRIOR APPLICATION NUMBER: 60/037,513
;  PRIOR FILING DATE: 1997-02-10
;  PRIOR APPLICATION NUMBER: 60/049,763
;  PRIOR FILING DATE: 1997-06-16
;  NUMBER OF SEQ ID NOS: 42
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 24
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Primer
US-09-021-660A-24

  Query Match             0.9%;  Score 15.2;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 81;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        502 ACCTGATGCAGCTGCTGCAG 521
              | ||||||||||||| | |||
Db          1 AGCTGATGCAGCTGATCCAG 20


RESULT 57
US-09-721-154-6
; Sequence 6, Application US/09721154
; Patent No. 6651008
; GENERAL INFORMATION:
;  APPLICANT: Vaisberg, Eugeni
;  APPLICANT:  Adams, Cynthia
;  APPLICANT:  Sabry, James
;  APPLICANT:  Crompton, Anne
;  TITLE OF INVENTION: Database system including computer code
;  TITLE OF INVENTION:  for predictive cellular bioinformatics
;  FILE REFERENCE: CytoP007C2
;  CURRENT APPLICATION NUMBER: US/09/721,154
;  CURRENT FILING DATE:  2002-06-14
;  PRIOR APPLICATION NUMBER: 09/311,996
;  PRIOR FILING DATE: 1999-05-14
;  NUMBER OF SEQ ID NOS: 14
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 6
;   LENGTH: 24
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
```

```
;   OTHER INFORMATION: Psuedo-sequence
US-09-721-154-6

  Query Match             0.9%;  Score 15;  DB 1;  Length 24;
  Best Local Similarity   78.3%;  Pred. No. 95;
  Matches   18;  Conservative    0;  Mismatches    5;  Indels    0;  Gaps    0;

Qy       1387 TGTTTGTTTTGTATCTTGTTTTT 1409
              | ||| |||| | | ||||||||
Db          2 TTTTTTTTTTTTTTTTGTTTTT 24


RESULT 58
US-08-113-646A-42/c
; Sequence 42, Application US/08113646A
; Patent No. 5578468
;  GENERAL INFORMATION:
;    APPLICANT:  PICKUP, David J.
;    APPLICANT:  PATEL, Dhavalkumar
;    APPLICANT:  ANTCZAK, James B.
;    TITLE OF INVENTION:  SITE-SPECIFIC RNA CLEAVAGE
;    NUMBER OF SEQUENCES:  44
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  NIXON & VANDERHYE P.C.
;      STREET:  1100 NORTH GLEBE ROAD
;      CITY:  ARLINGTON
;      STATE:  VIRGINIA
;      COUNTRY:  U.S.A.
;      ZIP:  22201-4714
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/113,646A
;      FILING DATE:  31-AUG-1993
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/084,406
;      FILING DATE:  10-AUG-1987
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  WILSON, MARY J.
;      REGISTRATION NUMBER:  32,955
;      REFERENCE/DOCKET NUMBER:  1579-20
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (703) 816-4000
;      TELEFAX:  (703) 816-4100
;      TELEX:  200797 NIXN UR
;  INFORMATION FOR SEQ ID NO:  42:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  25 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  RNA (genomic)
US-08-113-646A-42

  Query Match             0.9%;  Score 15;  DB 1;  Length 25;
  Best Local Similarity   78.3%;  Pred. No. 96;
  Matches   18;  Conservative    0;  Mismatches    5;  Indels    0;  Gaps    0;

Qy       1386 TTGTTTGTTTTGTATCTTGTTTT 1408
              || ||| |||| | | |||||||
Db         24 TTTTTTTTTTTTTTTTTGTTTT 2


RESULT 59
US-08-585-684B-2687
; Sequence 2687, Application US/08585684B
; Patent No. 5877021
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Daniel T.
;    APPLICANT:  Jarvis, Thale
;    APPLICANT:  McSwiggen, James
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  INDUCTION OF GRAFT TOLERANCE
;    TITLE OF INVENTION:  AND REVERSAL OF IMMUNE RESPONSES
;    NUMBER OF SEQUENCES:  2751
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  FastSEQ Version 1.5
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/585,684B
;      FILING DATE:  January 16, 1996
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/000,951
;      FILING DATE:  July 7, 1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/078
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  2687:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  18 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-585-684B-2687

  Query Match             0.8%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   66.7%;  Pred. No. 93;
  Matches   12;  Conservative    4;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        505 TGATGCAGCTGCTGCAGG 522
              :| :|| ||:||:|||||
Db          1 UGGUGCUGCUGCUGCAGG 18


RESULT 60
US-09-038-073-2687
; Sequence 2687, Application US/09038073
; Patent No. 6194150
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Daniel T.
;    APPLICANT:  Jarvis, Thale
;    APPLICANT:  McSwiggen, James
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  INDUCTION OF GRAFT TOLERANCE
;    TITLE OF INVENTION:  AND REVERSAL OF IMMUNE RESPONSES
;    NUMBER OF SEQUENCES:  2751
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
```

```
;       MEDIUM TYPE:  storage
;       COMPUTER:  IBM Compatible
;       OPERATING SYSTEM:  IBM P.C. DOS 5.0
;       SOFTWARE:  FastSEQ Version 1.5
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  US/09/038,073
;       FILING DATE:
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  08/585,684
;       FILING DATE:
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Warburg, Richard
;       REGISTRATION NUMBER:  32,327
;       REFERENCE/DOCKET NUMBER:  218/078
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  (213) 489-1600
;       TELEFAX:  (213) 955-0440
;       TELEX:  67-3510
;   INFORMATION FOR SEQ ID NO:  2687:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  18 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
US-09-038-073-2687

  Query Match             0.8%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   66.7%;  Pred. No. 93;
  Matches   12;  Conservative    4;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        505 TGATGCAGCTGCTGCAGG 522
              :| :|| ||:||:|||||
Db          1 UGGUGCUGCUGCUGCAGG 18


RESULT 61
US-09-261-104-11
; Sequence 11, Application US/09261104
; Patent No. 6630140
; GENERAL INFORMATION:
;  APPLICANT:  GRUNSTEIN, Michael M.
;  APPLICANT:  HAKONARSON, Hakon
;  TITLE OF INVENTION:  COMPOSITIONS AND METHODS FOR TREATMENT OF ASTHMA
;  FILE REFERENCE:  7600-22U1 (207600.0065) Grunstein et
;  CURRENT APPLICATION NUMBER: US/09/261,104
;  CURRENT FILING DATE:  1999-03-03
;  PRIOR APPLICATION NUMBER:  US 60/077,398
;  PRIOR FILING DATE:  1998-03-10
;  NUMBER OF SEQ ID NOS:  16
;  SOFTWARE:  PatentIn Ver. 2.1
; SEQ ID NO 11
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Rabbit
;   OTHER INFORMATION: alpha-actin PCR primer
US-09-261-104-11

  Query Match             0.8%;  Score 14.8;  DB 1;  Length 19;
  Best Local Similarity   88.9%;  Pred. No. 95;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        864 GTCATCAAGAAGAAGCTG 881
              | ||||||| ||||||||
Db          2 GACATCAAGGAGAAGCTG 19


RESULT 62
US-09-696-791-1834
; Sequence 1834, Application US/09696791
; Patent No. 6770633
; GENERAL INFORMATION:
;  APPLICANT:  Robbins, Joan M.
;  APPLICANT:  Tritz, Richard
;  TITLE OF INVENTION:  RIBOZYME THERAPY FOR THE TREATMENT OF PROLIFERATIVE
;  TITLE OF INVENTION:  SKIN AND EYE DISEASES
;  FILE REFERENCE:  480124.407
;  CURRENT APPLICATION NUMBER: US/09/696,791
;  CURRENT FILING DATE:  2000-10-25
;  NUMBER OF SEQ ID NOS:  4523
;  SOFTWARE:  PatentIn Ver. 2.0
; SEQ ID NO 1834
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Homo sapiens
;   FEATURE:
;   OTHER INFORMATION: Cyclin D1 ribozyme binding site
US-09-696-791-1834

  Query Match             0.8%;  Score 14.8;  DB 1;  Length 19;
  Best Local Similarity   88.9%;  Pred. No. 95;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        656 GCTGGACGTCTGCGTGGA 673
              |||||| ||||||| |||
Db          1 GCTGGAGGTCTGCGAGGA 18


RESULT 63
US-09-696-791-1977
; Sequence 1977, Application US/09696791
; Patent No. 6770633
; GENERAL INFORMATION:
;  APPLICANT:  Robbins, Joan M.
;  APPLICANT:  Tritz, Richard
;  TITLE OF INVENTION:  RIBOZYME THERAPY FOR THE TREATMENT OF PROLIFERATIVE
;  TITLE OF INVENTION:  SKIN AND EYE DISEASES
;  FILE REFERENCE:  480124.407
;  CURRENT APPLICATION NUMBER: US/09/696,791
;  CURRENT FILING DATE:  2000-10-25
;  NUMBER OF SEQ ID NOS:  4523
;  SOFTWARE:  PatentIn Ver. 2.0
; SEQ ID NO 1977
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Homo sapiens
;   FEATURE:
;   OTHER INFORMATION: Cyclin D3 ribozyme binding site
US-09-696-791-1977

  Query Match             0.8%;  Score 14.8;  DB 1;  Length 19;
  Best Local Similarity   88.9%;  Pred. No. 95;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1556 CCATCGTGTACTGCAGAG 1573
              ||| ||||| ||||||||
Db          1 CCAGCGTGTCCTGCAGAG 18


RESULT 64
US-09-696-791-3074
; Sequence 3074, Application US/09696791
; Patent No. 6770633
; GENERAL INFORMATION:
;  APPLICANT:  Robbins, Joan M.
;  APPLICANT:  Tritz, Richard
;  TITLE OF INVENTION:  RIBOZYME THERAPY FOR THE TREATMENT OF PROLIFERATIVE
;  TITLE OF INVENTION:  SKIN AND EYE DISEASES
;  FILE REFERENCE:  480124.407
;  CURRENT APPLICATION NUMBER: US/09/696,791
;  CURRENT FILING DATE:  2000-10-25
;  NUMBER OF SEQ ID NOS:  4523
;  SOFTWARE:  PatentIn Ver. 2.0
; SEQ ID NO 3074
;   LENGTH: 19
```

```
;   TYPE: DNA
;   ORGANISM: Homo sapiens
;   FEATURE:
;   OTHER INFORMATION: Cyclin A1 ribozyme binding site
US-09-696-791-3074

  Query Match             0.8%;  Score 14.8;  DB 1;  Length 19;
  Best Local Similarity   88.9%;  Pred. No. 95;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1042 GGTGGAGGTGGGGGAATA 1059
              ||||||||| ||||||  |
Db          1 GGTGGAGGTTGGGGAAGA 18


RESULT 65
US-08-621-914A-3
; Sequence 3, Application US/08621914A
; Patent No. 5707807
;  GENERAL INFORMATION:
;    APPLICANT:  KATO, KIKUYA
;    TITLE OF INVENTION:  MOLECULAR INDEXING FOR EXPRESSED GENE
;    TITLE OF INVENTION:  ANALYSIS
;    NUMBER OF SEQUENCES:  16
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  PENNIE & EDMONDS
;      STREET:  1155 AVENUE OF THE AMERICAS
;      CITY:  NEW YORK
;      STATE:  NY
;      COUNTRY:  USA
;      ZIP:  10036-2711
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/621,914A
;      FILING DATE:  26-MAR-1996
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  LAWRENCE III, STANTON T.
;      REGISTRATION NUMBER:  25,736
;      REFERENCE/DOCKET NUMBER:  7005-107-999
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (212) 790-9090
;      TELEFAX:  (212) 869-9741
;      TELEX:  66141 PENNIE
;  INFORMATION FOR SEQ ID NO:  3:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  26 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  unknown
;      TOPOLOGY:  unknown
;    MOLECULE TYPE:  other nucleic acid
US-08-621-914A-3

  Query Match             0.8%;  Score 14.8;  DB 1;  Length 26;
  Best Local Similarity   73.1%;  Pred. No. 1.1e+02;
  Matches   19;  Conservative    0;  Mismatches    7;  Indels    0;  Gaps    0;

Qy       1387 TGTTTGTTTTGTATCTTGTTTTTCTG 1412
              | ||| |||| | | || ||||| ||
Db          1 TTTTTTTTTTTTTTTTTTTTTTTTG 26


RESULT 66
US-09-197-951-5
; Sequence 5, Application US/09197951
; Patent No. 6197554
;   GENERAL INFORMATION:
;        APPLICANT: LIN, SHI-LUNG
;                   CHUONG, CHENG-MING
;                   YING, SHAO-YAO
;        TITLE OF INVENTION: Method for Generating Full-Length cDNA
;                            Library from Single Cells
;        NUMBER OF SEQUENCES: 5
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: David & Raymond Patent Firm
;             STREET: 108  N. Ynez Ave.,  Suite 128
;             CITY: Monterey Park
;             STATE: CA
;             COUNTRY: USA
;             ZIP: 91754
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: Floppy disk
;             COMPUTER: IBM PC compatible
;             OPERATING SYSTEM: PC-DOS/MS-DOS
;             SOFTWARE: PatentIn Release #1.0, Version #1.30
;        CURRENT APPLICATION DATA:
;             APPLICATION NUMBER: US/09/197,951
;             FILING DATE: 20-No. 6197554-1998
;             CLASSIFICATION: <Unknown>
;        ATTORNEY/AGENT INFORMATION:
;             NAME: Chan, Raymond Y.C.
;             REGISTRATION NUMBER: 37,484
;             REFERENCE/DOCKET NUMBER: USP8462A-SL(3)
;        TELECOMMUNICATION INFORMATION:
;             TELEPHONE: (626) 571-9812
;             TELEFAX: (626) 571-9813
;   INFORMATION FOR SEQ ID NO: 5:
;        SEQUENCE CHARACTERISTICS:
;             LENGTH: 26 base pairs
;             TYPE: nucleic acid
;             STRANDEDNESS: single
;             TOPOLOGY: linear
;        MOLECULE TYPE: other nucleic acid
;             DESCRIPTION: /desc = "synthetic"
;        HYPOTHETICAL: NO
;        ANTI-SENSE: NO
;        SEQUENCE DESCRIPTION: SEQ ID NO: 5:
US-09-197-951-5

  Query Match             0.8%;  Score 14.8;  DB 1;  Length 26;
  Best Local Similarity   73.1%;  Pred. No. 1.1e+02;
  Matches   19;  Conservative    0;  Mismatches    7;  Indels    0;  Gaps    0;

Qy       1382 TTTGTTGTTTGTTTTGTATCTTGTTT 1407
              ||| || ||| |||| | | || |||
Db          1 TTTTTTTTTTTTTTTTTTTTTTTTTT 26


RESULT 67
US-09-475-947A-153
; Sequence 153, Application US/09475947A
; Patent No. 6472154
; GENERAL INFORMATION:
;  APPLICANT: Garner, Harold R.
;  APPLICANT:  Wren, Jonathan D.
;  APPLICANT:  Minna, John D.
;  TITLE OF INVENTION: Polymorphic Repeats in Human Genes
;  FILE REFERENCE: UTSD0667
;  CURRENT APPLICATION NUMBER: US/09/475,947A
;  CURRENT FILING DATE:  1999-12-31
;  NUMBER OF SEQ ID NOS: 346
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 153
;   LENGTH: 27
;   TYPE: DNA
;   ORGANISM: human
US-09-475-947A-153

  Query Match             0.8%;  Score 14.8;  DB 1;  Length 27;
  Best Local Similarity   73.1%;  Pred. No. 1.1e+02;
  Matches   19;  Conservative    0;  Mismatches    7;  Indels    0;  Gaps    0;
```

```
Qy       1382 TTTGTTGTTTGTTTTGTATCTTGTTT 1407
             ||| || ||| |||| | | || |||
Db          2 TTTTTTTTTTTTTTTTTTTTTTATTT 27


RESULT 68
US-09-721-154-7
; Sequence 7, Application US/09721154
; Patent No. 6651008
; GENERAL INFORMATION:
;  APPLICANT: Vaisberg, Eugeni
;  APPLICANT:  Adams, Cynthia
;  APPLICANT:  Sabry, James
;  APPLICANT:  Crompton, Anne
;  TITLE OF INVENTION: Database system including computer code
;  TITLE OF INVENTION:  for predictive cellular bioinformatics
;  FILE REFERENCE: CytoP007C2
;  CURRENT APPLICATION NUMBER: US/09/721,154
;  CURRENT FILING DATE:  2002-06-14
;  PRIOR APPLICATION NUMBER: 09/311,996
;  PRIOR FILING DATE: 1999-05-14
;  NUMBER OF SEQ ID NOS: 14
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 7
;   LENGTH: 24
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Psuedo-sequence
US-09-721-154-7

  Query Match             0.8%;  Score 14.6;  DB 1;  Length 24;
  Best Local Similarity   81.0%;  Pred. No. 1.1e+02;
  Matches   17;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1380 TGTTTGTTGTTTGTTTTGTAT 1400
              | |||||| ||| |||| |||
Db          3 TTTTTGTTTTTTTTTTTCTAT 23


RESULT 69
US-09-527-345-6
; Sequence 6, Application US/09527345
; Patent No. 6331413
; GENERAL INFORMATION:
;  APPLICANT:  Sheppard, Paul O.
;  APPLICANT:  Adler, David A.
;  TITLE OF INVENTION:  SECRETED SALIVARY ZSIG63 POLYPEPTIDE
;  FILE REFERENCE:  97-71
;  CURRENT APPLICATION NUMBER: US/09/527,345
;  CURRENT FILING DATE:  1999-03-17
;  PRIOR APPLICATION NUMBER:  US 60/124,820
;  PRIOR FILING DATE:  1999-03-17
;  NUMBER OF SEQ ID NOS:  9
;  SOFTWARE:  FastSEQ for Windows Version 3.0
; SEQ ID NO 6
;   LENGTH: 26
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide primer ZC7231
US-09-527-345-6

  Query Match             0.8%;  Score 14.6;  DB 1;  Length 26;
  Best Local Similarity   72.0%;  Pred. No. 1.2e+02;
  Matches   18;  Conservative    1;  Mismatches    6;  Indels    0;  Gaps    0;

Qy       1386 TTGTTTGTTTTGTATCTTGTTTTTC 1410
              || ||| |||| | | || |||||:
Db          2 TTTTTTTTTTTTTTTTTTTTTTTTV 26


RESULT 70
US-09-167-513-10
; Sequence 10, Application US/09167513
; Patent No. 6388064
; GENERAL INFORMATION:
;  APPLICANT: Conklin, Darrell C.
;  APPLICANT: Blumberg, Hal
;  TITLE OF INVENTION: A HUMAN 2-19 PROTEIN HOMOLOGUE, Z219A
;  FILE REFERENCE: 97-63
;  CURRENT APPLICATION NUMBER: US/09/167,513
;  CURRENT FILING DATE: 1998-10-06
;  EARLIER APPLICATION NUMBER: US 60/061,712
;  EARLIER FILING DATE: 1997-10-06
;  NUMBER OF SEQ ID NOS: 28
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 10
;   LENGTH: 26
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide primer ZC7231
US-09-167-513-10

  Query Match             0.8%;  Score 14.6;  DB 1;  Length 26;
  Best Local Similarity   72.0%;  Pred. No. 1.2e+02;
  Matches   18;  Conservative    1;  Mismatches    6;  Indels    0;  Gaps    0;

Qy       1386 TTGTTTGTTTTGTATCTTGTTTTTC 1410
              || ||| |||| | | || |||||:
Db          2 TTTTTTTTTTTTTTTTTTTTTTTTV 26


RESULT 71
US-09-161-939A-43
; Sequence 43, Application US/09161939A
; Patent No. 6486299
; GENERAL INFORMATION:
;  APPLICANT: Shimkets, Richard A.
;  TITLE OF INVENTION: Genes and Proteins Predictive and Therapeutic for
;  TITLE OF INVENTION:  Stroke, Hypertension, Diabetes, and Obesity
;  FILE REFERENCE: 15966-527
;  CURRENT APPLICATION NUMBER: US/09/161,939A
;  CURRENT FILING DATE:  1998-09-28
;  NUMBER OF SEQ ID NOS: 44
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 43
;   LENGTH: 26
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: oligo(dT)<25>V
US-09-161-939A-43

  Query Match             0.8%;  Score 14.6;  DB 1;  Length 26;
  Best Local Similarity   72.0%;  Pred. No. 1.2e+02;
  Matches   18;  Conservative    1;  Mismatches    6;  Indels    0;  Gaps    0;

Qy       1386 TTGTTTGTTTTGTATCTTGTTTTTC 1410
              || ||| |||| | | || |||||:
Db          2 TTTTTTTTTTTTTTTTTTTTTTTTV 26


RESULT 72
US-08-011-398B-7
; Sequence 7, Application US/08011398B
; Patent No. 5512473
;  GENERAL INFORMATION:
;     APPLICANT:  Roger Brent
;     APPLICANT:  Antonis S. Zervos
;     TITLE OF INVENTION:  MAX-INTERACTING PROTEINS AND RELATED
;     TITLE OF INVENTION:  MOLECULES AND METHODS
;     NUMBER OF SEQUENCES:  20
;     CORRESPONDENCE ADDRESS:
;       ADDRESSEE:  Fish & Richardson
```

```
;       STREET:  225 Franklin Street
;       CITY:  Boston
;       STATE:  Massachusetts
;       COUNTRY:  U.S.A.
;       ZIP:  02110-2804
;     COMPUTER READABLE FORM:
;       MEDIUM TYPE:  3.5" Diskette, 1.44  Mb
;       COMPUTER:  IBM PS/2 Model 50Z or 55SX
;       OPERATING SYSTEM:  MS-DOS (Version 5.0)
;       SOFTWARE:  WordPerfect (Version 5.1)
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  US/08/011,398B
;       FILING DATE:  29 JAN 1993
;       CLASSIFICATION:  435
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:
;       FILING DATE:
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Paul T. Clark
;       REGISTRATION NUMBER:  30,162
;       REFERENCE/DOCKET NUMBER:  00786/160001
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  (617) 542-5070
;       TELEFAX:  (617) 542-8906
;       TELEX:  200154
;   INFORMATION FOR SEQ ID NO:  7:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  16
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
US-08-011-398B-7

  Query Match             0.8%;  Score 14.4;  DB 1;  Length 16;
  Best Local Similarity   93.8%;  Pred. No. 1.1e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         20 AATTCGGCACGAGGGG 35
              ||||||||||||||| |
Db          1 AATTCGGCACGAGGCG 16


RESULT 73
US-08-370-225-7
; Sequence 7, Application US/08370225
; Patent No. 5580736
;  GENERAL INFORMATION:
;    APPLICANT:  Brent, Roger
;    APPLICANT:  Gyuris, Jeno
;    APPLICANT:  Golemis, Erica
;    TITLE OF INVENTION:  Interaction Trap System for Isolating
;    TITLE OF INVENTION:  No. 5580736el Proteins
;    NUMBER OF SEQUENCES:  33
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Fish & Richardson
;      STREET:  225 Franklin Street
;      CITY:  Boston
;      STATE:  Massachusetts
;      COUNTRY:  U.S.A.
;      ZIP:  02110-2804
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      COMPUTER:  IBM PS/2 Model 50Z or 55SX
;      OPERATING SYSTEM:  MS-DOS (Version 5.0)
;      SOFTWARE:  WordPerfect (Version 5.1)
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/370,225
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  07/969,038
;      FILING DATE:  10/30/92
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Clark, Paul T.
;      REGISTRATION NUMBER:  30,162
;      REFERENCE/DOCKET NUMBER:  00786/143001
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (617) 542-5070
;      TELEFAX:  (617) 542-8906
;      TELEX:  200154
;  INFORMATION FOR SEQ ID NO:  7:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16
;      TYPE:  nucleic acid
;      STRANDEDNESS:  double
;      TOPOLOGY:  linear
US-08-370-225-7

  Query Match             0.8%;  Score 14.4;  DB 1;  Length 16;
  Best Local Similarity   93.8%;  Pred. No. 1.1e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         20 AATTCGGCACGAGGGG 35
              ||||||||||||||| |
Db          1 AATTCGGCACGAGGCG 16


RESULT 74
US-08-464-051-7
; Sequence 7, Application US/08464051
; Patent No. 5780262
;  GENERAL INFORMATION:
;    APPLICANT:  Roger Brent
;    APPLICANT:  Antonis S. Zervos
;    TITLE OF INVENTION:  MAX-INTERACTING PROTEINS AND RELATED
;    TITLE OF INVENTION:  MOLECULES AND METHODS
;    NUMBER OF SEQUENCES:  20
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Fish & Richardson
;      STREET:  225 Franklin Street
;      CITY:  Boston
;      STATE:  Massachusetts
;      COUNTRY:  U.S.A.
;      ZIP:  02110-2804
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44  Mb
;      COMPUTER:  IBM PS/2 Model 50Z or 55SX
;      OPERATING SYSTEM:  MS-DOS (Version 5.0)
;      SOFTWARE:  WordPerfect (Version 5.1)
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/464,051
;      FILING DATE:  05 JUN 1995
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/011,398
;      FILING DATE:  29 JAN 1993
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Paul T. Clark
;      REGISTRATION NUMBER:  30,162
;      REFERENCE/DOCKET NUMBER:  00786/160002
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (617) 542-5070
;      TELEFAX:  (617) 542-8906
;      TELEX:  200154
;  INFORMATION FOR SEQ ID NO:  7:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-464-051-7

  Query Match             0.8%;  Score 14.4;  DB 1;  Length 16;
  Best Local Similarity   93.8%;  Pred. No. 1.1e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;
```

```
Qy          20 AATTCGGCACGAGGGG 35
               ||||||||||||||| |
Db           1 AATTCGGCACGAGGCG 16


RESULT 75
US-08-461-859-7
; Sequence 7, Application US/08461859
; Patent No. 5786169
;  GENERAL INFORMATION:
;    APPLICANT:  Brent, Roger
;    APPLICANT:  Gyuris, Jeno
;    APPLICANT:  Golemis, Erica
;    TITLE OF INVENTION:  Interaction Trap System for Isolating
;    TITLE OF INVENTION:  No. 5786169el Proteins
;    NUMBER OF SEQUENCES:  35
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Fish & Richardson P.C.
;      STREET:  225 Franklin Street
;      CITY:  Boston
;      STATE:  Massachusetts
;      COUNTRY:  U.S.A.
;      ZIP:  02110-2804
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      COMPUTER:  IBM PS/2 Model 50Z or 55SX
;      OPERATING SYSTEM:  MS-DOS (Version 5.0)
;      SOFTWARE:  WordPerfect (Version 5.1)
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/461,859
;      FILING DATE:  June 5, 1995
;      CLASSIFICATION:  530
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/370,225
;      FILING DATE:  January 9, 1995
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  07/969,038
;      FILING DATE:  October 30, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Lech, Karen F.
;      REGISTRATION NUMBER:  35,238
;      REFERENCE/DOCKET NUMBER:  00786/143002
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (617) 542-5070
;      TELEFAX:  (617) 542-8906
;      TELEX:  200154
;  INFORMATION FOR SEQ ID NO:  7:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-461-859-7

  Query Match             0.8%;  Score 14.4;  DB 1;  Length 16;
  Best Local Similarity   93.8%;  Pred. No. 1.1e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy          20 AATTCGGCACGAGGGG 35
               ||||||||||||||| |
Db           1 AATTCGGCACGAGGCG 16


RESULT 76
US-08-462-498-7
; Sequence 7, Application US/08462498
; Patent No. 5852169
;  GENERAL INFORMATION:
;    APPLICANT:  Roger Brent
;    APPLICANT:  Antonis S. Zervos
;    TITLE OF INVENTION:  MAX-INTERACTING PROTEINS AND RELATED
;    TITLE OF INVENTION:  MOLECULES AND METHODS
;    NUMBER OF SEQUENCES:  20
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Fish & Richardson
;      STREET:  225 Franklin Street
;      CITY:  Boston
;      STATE:  Massachusetts
;      COUNTRY:  U.S.A.
;      ZIP:  02110-2804
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44  Mb
;      COMPUTER:  IBM PS/2 Model 50Z or 55SX
;      OPERATING SYSTEM:  MS-DOS (Version 5.0)
;      SOFTWARE:  WordPerfect (Version 5.1)
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/462,498
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/011,398
;      FILING DATE:  29 JAN 1993
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Paul T. Clark
;      REGISTRATION NUMBER:  30,162
;      REFERENCE/DOCKET NUMBER:  00786/160001
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (617) 542-5070
;      TELEFAX:  (617) 542-8906
;      TELEX:  200154
;  INFORMATION FOR SEQ ID NO:  7:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-462-498-7

  Query Match             0.8%;  Score 14.4;  DB 1;  Length 16;
  Best Local Similarity   93.8%;  Pred. No. 1.1e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy          20 AATTCGGCACGAGGGG 35
               ||||||||||||||| |
Db           1 AATTCGGCACGAGGCG 16


RESULT 77
US-08-879-260-10
; Sequence 10, Application US/08879260
; Patent No. 5935851
;  GENERAL INFORMATION:
;    APPLICANT:  Murthy, Anita E.
;    APPLICANT:  Gusella, James F.
;    TITLE OF INVENTION:  TPR-Containing Genes
;    NUMBER OF SEQUENCES:  11
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C
;      STREET:  1100 New York Ave, N.W.,  Suite 600
;      CITY:  Washington
;      STATE:  D.C.
;      COUNTRY:  U.S.A.
;      ZIP:  20005
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/879,260
;      FILING DATE:  19JUN1997
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/020,204
;      FILING DATE:  20JUN1996
;    ATTORNEY/AGENT INFORMATION:
```

```
;       NAME:  Ludwig, Steven R.
;       REGISTRATION NUMBER:  36,203
;       REFERENCE/DOCKET NUMBER:  0609.4260001/JAG/SRL
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  202-371-2600
;       TELEFAX:  202-371-2540
;   INFORMATION FOR SEQ ID NO:  10:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  16 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
;     MOLECULE TYPE:  cDNA
US-08-879-260-10

  Query Match             0.8%;  Score 14.4;  DB 1;  Length 16;
  Best Local Similarity   93.8%;  Pred. No. 1.1e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         20 AATTCGGCACGAGGGG 35
               ||||||||||||||| |
Db          1 AATTCGGCACGAGGCG 16


RESULT 78
US-08-554-385-7
; Sequence 7, Application US/08554385
; Patent No. 6017692
;  GENERAL INFORMATION:
;     APPLICANT:  Roger Brent
;     APPLICANT:  Antonis S. Zervos
;     TITLE OF INVENTION:  MAX-INTERACTING PROTEINS AND RELATED
;     TITLE OF INVENTION:  MOLECULES AND METHODS
;     NUMBER OF SEQUENCES:  32
;     CORRESPONDENCE ADDRESS:
;       ADDRESSEE:  Fish & Richardson P.C.
;       STREET:  225 Franklin Street
;       CITY:  Boston
;       STATE:  Massachusetts
;       COUNTRY:  U.S.A.
;       ZIP:  02110-2804
;     COMPUTER READABLE FORM:
;       MEDIUM TYPE:  3.5" Diskette, 1.44  Mb
;       COMPUTER:  IBM PS/2 Model 50Z or 55SX
;       OPERATING SYSTEM:  MS-DOS (Version 5.0)
;       SOFTWARE:  WordPerfect (Version 5.1)
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  US/08/554,385
;       FILING DATE:  No. 6017692ember 8, 1995
;       CLASSIFICATION:  435
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:
;       FILING DATE:
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Karen F. Lech
;       REGISTRATION NUMBER:  35,238
;       REFERENCE/DOCKET NUMBER:  00786/252001
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  (617) 542-5070
;       TELEFAX:  (617) 542-8906
;       TELEX:  200154
;   INFORMATION FOR SEQ ID NO:  7:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  16
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
US-08-554-385-7

  Query Match             0.8%;  Score 14.4;  DB 1;  Length 16;
  Best Local Similarity   93.8%;  Pred. No. 1.1e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         20 AATTCGGCACGAGGGG 35
               ||||||||||||||| |
Db          1 AATTCGGCACGAGGCG 16


RESULT 79
US-09-479-005A-71/c
; Sequence 71, Application US/09479005A
; Patent No. 6656731
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  TITLE OF INVENTION: Nucleic Acid Catalysts with Endonuclease Activity
;  FILE REFERENCE: MBHB00-884-C
;  CURRENT APPLICATION NUMBER: US/09/479,005A
;  CURRENT FILING DATE:  2000-01-07
;  PRIOR APPLICATION NUMBER: US 09/444,209
;  PRIOR FILING DATE: 1999-11-19
;  PRIOR APPLICATION NUMBER: US 09/159,274
;  PRIOR FILING DATE: 1998-09-22
;  PRIOR APPLICATION NUMBER: US 60/059,473
;  PRIOR FILING DATE: 1997-09-22
;  NUMBER OF SEQ ID NOS: 1208
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 71
;   LENGTH: 16
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-479-005A-71

  Query Match             0.8%;  Score 14.4;  DB 1;  Length 16;
  Best Local Similarity   93.8%;  Pred. No. 1.1e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        663 GTCTGCGTGGAGCAGG 678
              |||||| |||||||||
Db         16 GTCTGCATGGAGCAGG 1


RESULT 80
PCT-US93-10069-7
; Sequence 7, Application PC/TUS9310069
;  GENERAL INFORMATION:
;    APPLICANT:  Brent, Roger
;    APPLICANT:  Gyuris, Jeno
;    APPLICANT:  Golemis, Erica
;    TITLE OF INVENTION:  Interaction Trap System for Isolating
;    TITLE OF INVENTION:  Novel Proteins
;    NUMBER OF SEQUENCES:  33
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Fish & Richardson
;      STREET:  225 Franklin Street
;      CITY:  Boston
;      STATE:  Massachusetts
;      COUNTRY:  U.S.A.
;      ZIP:  02110-2804
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      COMPUTER:  IBM PS/2 Model 50Z or 55SX
;      OPERATING SYSTEM:  MS-DOS (Version 5.0)
;      SOFTWARE:  WordPerfect (Version 5.1)
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  PCT/US93/10069
;      FILING DATE:  20-OCT-1993
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  07/969,038
;      FILING DATE:  10/30/92
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Clark, Paul T.
;      REGISTRATION NUMBER:  30,162
;      REFERENCE/DOCKET NUMBER:  00786/143001
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (617) 542-5070
```

```
;       TELEFAX:  (617) 542-8906
;       TELEX:  200154
;   INFORMATION FOR SEQ ID NO:  7:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  16
;       TYPE:  nucleic acid
;       STRANDEDNESS:  double
;       TOPOLOGY:  linear
PCT-US93-10069-7

  Query Match             0.8%;  Score 14.4;  DB 1;  Length 16;
  Best Local Similarity   93.8%;  Pred. No. 1.1e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         20 AATTCGGCACGAGGGG 35
              ||||||||||||||  |
Db          1 AATTCGGCACGAGGCG 16


RESULT 81
US-08-758-306-281
; Sequence 281, Application US/08758306
; Patent No. 5807743
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  McSwiggen, James A.
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  TREATMENT OF DISEASES
;    TITLE OF INVENTION:  ASSOCIATED WITH
;    TITLE OF INVENTION:  INTERLEUKIN-2 RECEPTOR
;    TITLE OF INVENTION:  GAMMA-CHAIN EXPRESSION
;    NUMBER OF SEQUENCES:  1379
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  FastSeq Version 1.5
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/758,306
;      FILING DATE:  December 3, 1996
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  212/132
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  281:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-758-306-281

  Query Match             0.8%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 1.1e+02;
  Matches   14;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         279 CCCCGAACTCCCACCC 294
               ||||||| :|||||||
Db           1 CCCCGAAUUCCCACCC 16


RESULT 82
US-08-584-040-7820
; Sequence 7820, Application US/08584040
; Patent No. 6346398
;  GENERAL INFORMATION:
;    APPLICANT:  Pavco, Pamela
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Escobedo, Jaime
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  TREATMENT OF DISEASES OR
;    TITLE OF INVENTION:  CONDITIONS RELATED TO LEVELS
;    TITLE OF INVENTION:  OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR
;    NUMBER OF SEQUENCES:  8502
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/584,040
;      FILING DATE:  January 11, 1996
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/005,974
;      FILING DATE:  October 26, 1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/064
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  7820:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-584-040-7820

  Query Match             0.8%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   18.8%;  Pred. No. 1.1e+02;
  Matches    3;  Conservative   12;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        1382 TTTGTTGTTTGTTTTG 1397
               :::|:: :::|::::|
Db           2 UUUGUUUUUUGUUUUG 17


RESULT 83
US-08-584-040-7822
; Sequence 7822, Application US/08584040
; Patent No. 6346398
;  GENERAL INFORMATION:
;    APPLICANT:  Pavco, Pamela
;    APPLICANT:  McSwiggen, James
```

```
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Escobedo, Jaime
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  TREATMENT OF DISEASES OR
;    TITLE OF INVENTION:  CONDITIONS RELATED TO LEVELS
;    TITLE OF INVENTION:  OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR
;    NUMBER OF SEQUENCES:  8502
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/584,040
;      FILING DATE:  January 11, 1996
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/005,974
;      FILING DATE:  October 26, 1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/064
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  7822:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-584-040-7822

  Query Match              0.8%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   18.8%;  Pred. No. 1.1e+02;
  Matches    3;  Conservative   12;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1383 TTGTTGTTTGTTTTGT 1398
              ::|:: :::|::::|:
Db          1 UUGUUUUUUGUUUUGU 16


RESULT 84
US-08-679-645-218
; Sequence 218, Application US/08679645
; Patent No. 6350934
;  GENERAL INFORMATION:
;    APPLICANT:  Zwick, Michael G.
;    APPLICANT:  Edington, Brent E.
;    APPLICANT:  McSwiggen, James A.
;    APPLICANT:  Merlo, Patricia Ann Owens
;    APPLICANT:  Guo, Lining
;    APPLICANT:  Skokut, Thomas A.
;    APPLICANT:  Young, Scott A.
;    APPLICANT:  Folkerts, Otto
;    APPLICANT:  Merlo, Donald J.
;    TITLE OF INVENTION:  COMPOSITION AND METHODS FOR
;    TITLE OF INVENTION:  MODULATION OF GENE EXPRESSION
;    TITLE OF INVENTION:  IN PLANTS
;    NUMBER OF SEQUENCES:  1263
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/679,645
;      FILING DATE:  July 12, 1996
;      CLASSIFICATION:  800
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/001,135
;      FILING DATE:  July 13, 1995
;      APPLICATION NUMBER:  08/300,726
;      FILING DATE:  September 2, 1994
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  219/247
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  218:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-679-645-218

  Query Match              0.8%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   75.0%;  Pred. No. 1.1e+02;
  Matches   12;  Conservative    3;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        311 CTCAGCCTGGGGGTCG 326
              |:|||||: ||||:||
Db          1 CUCAGCCUCGGGGUCG 16


RESULT 85
US-09-474-432B-617
; Sequence 617, Application US/09474432B
; Patent No. 6528640
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Beigelman, Leo
;  APPLICANT:  Burgin, Alex
;  APPLICANT:  Beaudry, Amber
;  APPLICANT:  Karpeisky, Alex
;  APPLICANT:  Adamic, Jasenka
;  APPLICANT:  Sweedler, David
;  APPLICANT:  Zinnen, Shawn
;  TITLE OF INVENTION: Nucleotide triphosphate and their incorporation into oligonucleoti
;  FILE REFERENCE: MBHB00-831-B (247/276)
;  CURRENT APPLICATION NUMBER: US/09/474,432B
;  CURRENT FILING DATE:  1999-12-19
;  PRIOR APPLICATION NUMBER: US 60/064,866
;  PRIOR FILING DATE: 1997-11-05
;  PRIOR APPLICATION NUMBER: US 60/084,727
;  PRIOR FILING DATE: 1998-04-29
;  PRIOR APPLICATION NUMBER: US 09/186,675
;  PRIOR FILING DATE: 1998-11-04
;  PRIOR APPLICATION NUMBER: US 09/301,511
;  PRIOR FILING DATE: 1999-04-28
;  NUMBER OF SEQ ID NOS: 1526
```

```
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 617
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-474-432B-617

  Query Match             0.8%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   62.5%;  Pred. No. 1.1e+02;
  Matches   10;  Conservative    5;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1087 TGTGCGGGTGGCTGTG 1102
              :|:|| ||:|||:|:|
Db          2 UGUGCCGGUGGCUGUG 17


RESULT 86
US-09-371-772B-3604
; Sequence 3604, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3604
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Mus sp.
US-09-371-772B-3604

  Query Match             0.8%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   18.8%;  Pred. No. 1.1e+02;
  Matches    3;  Conservative   12;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1382 TTTGTTGTTTGTTTTG 1397
              :::|:: :::|::::|
Db          2 UUUGUUUUUUGUUUUG 17


RESULT 87
US-09-371-772B-3606
; Sequence 3606, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3606
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Mus sp.
US-09-371-772B-3606

  Query Match             0.8%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   18.8%;  Pred. No. 1.1e+02;
  Matches    3;  Conservative   12;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1383 TTGTTGTTTGTTTTGT 1398
              ::|:: :::|::::|:
Db          1 UUGUUUUUUGUUUUGU 16


RESULT 88
US-09-371-772B-6350
; Sequence 6350, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6350
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-371-772B-6350

  Query Match             0.8%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 1.1e+02;
  Matches   13;  Conservative    2;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        287 TCCCACCCCAGATCGG 302
              :|||||||||||: ||
Db          2 UCCCACCCCAGAUUGG 17


RESULT 89
US-09-371-772B-6351
; Sequence 6351, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6351
```

```
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-371-772B-6351

  Query Match             0.8%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 1.1e+02;
  Matches   13;  Conservative    2;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        287 TCCCACCCCAGATCGG 302
              :||||||||||: ||
Db          1 UCCCACCCCAGAUUGG 16


RESULT 90
US-09-476-387-616
; Sequence 616, Application US/09476387
; Patent No. 6617438
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Beigelman, Leo
;  APPLICANT:  Beaudry, Amber
;  APPLICANT:  Karpeisky, Alex
;  APPLICANT:  Adamic, Jasenka Matulic
;  APPLICANT:  Sweedler, Dave
;  APPLICANT:  Zinnen, Shawn
;  TITLE OF INVENTION: Nucleotide Triphosphate and their Incorporation into Oligonucleot
;  FILE REFERENCE: MBHB00-831-C (249/073)
;  CURRENT APPLICATION NUMBER: US/09/476,387
;  CURRENT FILING DATE:  2001-04-04
;  PRIOR APPLICATION NUMBER: 09/474,432
;  PRIOR FILING DATE: 1999-12-29
;  PRIOR APPLICATION NUMBER: 09/301,511
;  PRIOR FILING DATE: 1999-04-28
;  PRIOR APPLICATION NUMBER: 09/186,675
;  PRIOR FILING DATE: 1998-11-04
;  PRIOR APPLICATION NUMBER: 60/083,727
;  PRIOR FILING DATE: 1998-04-29
;  PRIOR APPLICATION NUMBER: 60/064,866
;  PRIOR FILING DATE: 1997-11-05
;  NUMBER OF SEQ ID NOS: 1524
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 616
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-476-387-616

  Query Match             0.8%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   62.5%;  Pred. No. 1.1e+02;
  Matches   10;  Conservative    5;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1087 TGTGCGGGTGGCTGTG 1102
              :|:|| ||:|||:|:|
Db          2 UGUGCCGGUGGCUGUG 17


RESULT 91
US-08-679-645-631
; Sequence 631, Application US/08679645
; Patent No. 6350934
;  GENERAL INFORMATION:
;     APPLICANT:  Zwick, Michael G.
;     APPLICANT:  Edington, Brent E.
;     APPLICANT:  McSwiggen, James A.
;     APPLICANT:  Merlo, Patricia Ann Owens
;     APPLICANT:  Guo, Lining
;     APPLICANT:  Skokut, Thomas A.
;     APPLICANT:  Young, Scott A.
;     APPLICANT:  Folkerts, Otto
;     APPLICANT:  Merlo, Donald J.
;     TITLE OF INVENTION:  COMPOSITION AND METHODS FOR
;     TITLE OF INVENTION:  MODULATION OF GENE EXPRESSION
;     NUMBER OF SEQUENCES:  1263
;     CORRESPONDENCE ADDRESS:
;       ADDRESSEE:  Lyon & Lyon
;       STREET:  633 West Fifth Street
;       STREET:  Suite 4700
;       CITY:  Los Angeles
;       STATE:  California
;       COUNTRY:  U.S.A.
;       ZIP:  90071-2066
;     COMPUTER READABLE FORM:
;       MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;       MEDIUM TYPE:  storage
;       COMPUTER:  IBM Compatible
;       OPERATING SYSTEM:  IBM P.C. DOS 5.0
;       SOFTWARE:  Word Perfect 5.1
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  US/08/679,645
;       FILING DATE:  July 12, 1996
;       CLASSIFICATION:  800
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  60/001,135
;       FILING DATE:  July 13, 1995
;       APPLICATION NUMBER:  08/300,726
;       FILING DATE:  September 2, 1994
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Warburg, Richard J.
;       REGISTRATION NUMBER:  32,327
;       REFERENCE/DOCKET NUMBER:  219/247
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  (213) 489-1600
;       TELEFAX:  (213) 955-0440
;       TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  631:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  18 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
US-08-679-645-631

  Query Match             0.8%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   75.0%;  Pred. No. 1.1e+02;
  Matches   12;  Conservative    3;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        310 GCTCAGCCTGGGGGTC 325
              ||:|||||: ||||:|
Db          3 GCUCAGCCUCGGGGUC 18


Search completed: December 13, 2004, 08:35:53
Job time : 16 secs
```

OM nucleic - nucleic search, using sw model

Run on: December 13, 2004, 08:32:21 ; Search time 36 Seconds
(without alignments)
3.704 Million cell updates/sec

Title: US-10-091-333-2
Perfect score: 1764
Sequence: 1 tttggccctcgaggccaaga.....ataaacatgtttgttaaaac 1764

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 0.5

Searched: 1951 seqs, 37797 residues

Total number of hits satisfying chosen parameters: 3902

Minimum DB seq length: 8
Maximum DB seq length: 50

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 223 summaries

Database : rng2.seq:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

	Result No.	Score	% Query Match	Length	DB	ID	Description
c	1	39.5	2.2	50	1	AAI76791	Human silent SNP c
c	2	33	1.9	38	1	AAV82614	Oligonucleotide us
	3	21	1.2	21	1	AAV82613	Oligonucleotide us
	4	20	1.1	20	1	AAV18869	Primer for rat hyp
	5	20	1.1	20	1	AAZ40169	PCR primer for hum
c	6	20	1.1	20	1	ADC84458	Primer #2 used to
c	7	20	1.1	20	1	ADO59662	RTP801 gene primer
	8	20	1.1	20	1	ADO59661	RTP801 gene primer
	9	18.8	1.1	24	1	AAF77019	Part of plasmid pT
	10	18.8	1.1	25	1	ACI84593	Human microarray D
	11	18.4	1.0	24	1	ADQ58897	Yin yang-1 (YY-1)
	12	18	1.0	18	1	ADC84457	Primer #1 used to
c	13	17.8	1.0	21	1	AAH89053	Human polymorphic
	14	16.8	1.0	21	1	AAH62187	Oestrogen receptor
	15	16.4	0.9	19	1	ADH70254	Human Vbeta gene r
	16	16.4	0.9	20	1	AAA88871	Protein tyrosine p
	17	16.4	0.9	20	1	ABL31214	Human HLA genotypi
	18	16.4	0.9	20	1	ABL31217	Human HLA genotypi
	19	16.4	0.9	20	1	ABZ88246	Human oligonucleot
	20	16.4	0.9	20	1	ABD24476	AI652901-derived o
	21	16.4	0.9	20	1	ADI27548	Human DRAK1 DNA, a
	22	16.4	0.9	26	1	AAT93819	Antitumoural phosp
c	23	16.2	0.9	21	1	ABK99308	Human CYP3A5 gene
	24	16	0.9	17	1	ABA81112	LDLR mutation corr
c	25	16	0.9	17	1	ABA81113	LDLR mutation corr
	26	16	0.9	19	1	AAT87932	Primer for rat cer
c	27	16	0.9	20	1	AAS45641	Human PARP-1 antis
c	28	16	0.9	20	1	AAH20641	Human telomeric re
	29	16	0.9	24	1	AAF98935	Immunostimulatory
	30	16	0.9	24	1	ABS77576	Angiogenesis inhib
	31	16	0.9	24	1	ACD99368	Immunostimulatory
	32	16	0.9	24	1	ADB36437	Immunostimulatory
	33	16	0.9	24	1	ADG75924	Immunostimulatory
	34	16	0.9	24	1	ADG76001	Non-CpG DNA oligon
	35	16	0.9	24	1	ADG76035	Non-CpG DNA oligon
	36	16	0.9	24	1	ADG75971	Immunostimulatory
c	37	16	0.9	24	1	AAZ07017	Murine alpha-L-idu
c	38	16	0.9	26	1	AAV12482	Oligonucleotide SE
c	39	16	0.9	26	1	AAV59215	Circular template
c	40	16	0.9	26	1	AAX30018	Precircle DNA olig
c	41	16	0.9	26	1	ADC65872	DNA oligonucleotid
	42	16	0.9	27	1	AAZ43904	M. tuberculosis rp
c	43	15.8	0.9	20	1	ABZ90374	Human oligonucleot
c	44	15.8	0.9	20	1	ABD26604	AA909635-derived o
	45	15.8	0.9	20	1	AAV58430	PCR primer for PN4
	46	15.8	0.9	20	1	AAX94392	PCR primer used to
c	47	15.8	0.9	20	1	AAZ37992	Human GLC1A gene e
c	48	15.8	0.9	20	1	AAH23215	Human MMIF mRNA in
c	49	15.8	0.9	20	1	AAF90500	COL1A1 gene antise
	50	15.8	0.9	20	1	ABQ94349	Human BNO1 gene ex
	51	15.8	0.9	20	1	AAL61838	Human ETBR-LP-2 an
	52	15.8	0.9	20	1	ABZ91337	Human oligonucleot
	53	15.8	0.9	20	1	ABZ88193	Human oligonucleot
	54	15.8	0.9	20	1	ABZ99156	Human PDE4C oligon
	55	15.8	0.9	20	1	ABD32187	Human PDE4C-derive
	56	15.8	0.9	20	1	ABD24423	AI652901-derived o
	57	15.8	0.9	20	1	ABD27567	AA504431-derived o
	58	15.8	0.9	20	1	ADH18776	Human apolipoprote
c	59	15.8	0.9	20	1	ADH18453	2'-MOE gapmer anti
	60	15.8	0.9	20	1	ADJ61041	Oligonucleotide as
	61	15.8	0.9	20	1	ADO33317	Human apolipoprote
c	62	15.8	0.9	20	1	ADO32994	Antisense 2'-MOE g
c	63	15.8	0.9	21	1	AAT41783	Lacto-N-biosidase
c	64	15.8	0.9	21	1	AAX32869	HBV DR region bind
	65	15.8	0.9	21	1	AAF97567	Human gene single
	66	15.8	0.9	27	1	AAN70281	Sequence of scissi
	67	15.8	0.9	27	1	AAN70274	Sequence of scissi
	68	15.8	0.9	27	1	AAN92240	SS probe MRCO46.
	69	15.8	0.9	27	1	AAN92247	SS probe MRCO71.
c	70	15.8	0.9	27	1	AAQ40854	DNA sequence used
	71	15.8	0.9	27	1	AAF99706	Immunostimulatory
	72	15.8	0.9	27	1	ABS78427	Angiogenesis inhib
	73	15.8	0.9	27	1	ABL39406	Immunostimulatory
	74	15.8	0.9	27	1	ACH03245	Immunostimulatory
	75	15.8	0.9	27	1	ADB37208	Immunostimulatory
	76	15.8	0.9	28	1	AAA40358	pBluescriptSK+ pha
	77	15.4	0.9	17	1	AAT66995	Vector-specific pr
	78	15.4	0.9	17	1	AAT90091	Primer SK-Zap for
	79	15.4	0.9	17	1	AAX75071	Mouse flt-1 VEGF r
	80	15.4	0.9	17	1	AAH77930	PCR primer used to
	81	15.4	0.9	17	1	AAS12632	T3 PCR primer for
	82	15.4	0.9	17	1	AAD15659	Mch6 cloning prime
	83	15.4	0.9	17	1	AAH25194	Primer for DNA enc
c	84	15.4	0.9	17	1	ACC63780	Murine oligonucleo
	85	15.4	0.9	17	1	ADE52023	Mammalian ced-3 ho
	86	15.4	0.9	18	1	AAQ46560	Monomer DRB5706 fo
c	87	15.4	0.9	18	1	ABL31588	Human HLA genotypi
	88	15.4	0.9	19	1	AAX33800	S. aureus coding s
	89	15.4	0.9	19	1	AAA83614	cdk-we-hu ribozyme
	90	15.4	0.9	19	1	AAA83613	cdk-we-hu ribozyme
	91	15.4	0.9	19	1	AAH58775	Cdk-we-hu ribozyme
	92	15.4	0.9	19	1	AAH58776	Cdk-we-hu ribozyme
c	93	15.4	0.9	19	1	ABL88937	HIV-1 related bind
	94	15.4	0.9	19	1	ADF49398	Human BCL2 siNA lo
c	95	15.4	0.9	19	1	ADF49812	Human BCL2 siNA lo
c	96	15.4	0.9	20	1	AAA13146	PI3K antisense inh
c	97	15.4	0.9	20	1	ABA09745	PCR primer GPI2 us
	98	15.4	0.9	20	1	ABN89953	Real-time validati
	99	15.4	0.9	20	1	ABZ30368	Candida albicans G
c	100	15.4	0.9	20	1	ABZ99386	Human PDE4C oligon
	101	15.4	0.9	20	1	ABZ93334	Human oligonucleot
	102	15.4	0.9	20	1	ABZ77075	Human stearoyl-CoA
	103	15.4	0.9	20	1	ABD29564	AA664176-derived o
c	104	15.4	0.9	20	1	ABD32417	Human PDE4C-derive
c	105	15.4	0.9	20	1	ADJ61271	Oligonucleotide as
c	106	15.4	0.9	20	1	ADO46661	Human oligonucleot

c	107	15.4	0.9	20	1	ADP11812	Set 2 left PCR pri
	108	15.4	0.9	20	1	ADO50692	Human STAT2 antise
c	109	15.4	0.9	20	1	ADO50659	Human STAT2 antise
	110	15.4	0.9	25	1	AAX84260	PCR primer for hum
	111	15.4	0.9	26	1	AAI73048	Scaffold oligonucl
	112	15.4	0.9	26	1	AAS20672	Human zalpha11 Lig
	113	15.4	0.9	26	1	ABX93461	LS147-specific pol
	114	15.4	0.9	26	1	ADH44609	Human cDNA encodin
	115	15.4	0.9	26	1	ADI00945	Sequencing primer
	116	15.4	0.9	26	1	ADP19768	Human zalpha11 lig
	117	15.2	0.9	20	1	AAX09677	Human biallelic po
	118	15.2	0.9	20	1	AAV49804	Mouse haematopoiet
c	119	15.2	0.9	20	1	AAX55902	Hepatitis B virus
c	120	15.2	0.9	20	1	AAZ40560	Human PAK5 primer
c	121	15.2	0.9	20	1	AAV69725	MAGE-C2 specific P
c	122	15.2	0.9	20	1	AAX96441	PCR primer used to
c	123	15.2	0.9	20	1	AAX93270	PCR primer used to
	124	15.2	0.9	20	1	AAZ50781	PCR primer HG03.37
c	125	15.2	0.9	20	1	AAA52987	Candida albicans g
c	126	15.2	0.9	20	1	AAA26732	PCR primer used in
c	127	15.2	0.9	20	1	AAA11324	Human TRPC7 gene i
	128	15.2	0.9	20	1	AAC62074	Reverse primer use
c	129	15.2	0.9	20	1	AAH23216	Human MMIF mRNA in
c	130	15.2	0.9	20	1	AAD15581	Human carbonic anh
	131	15.2	0.9	20	1	AAF62920	Human PEPCK-cytoso
	132	15.2	0.9	20	1	AAC91651	Human angiotensino
c	133	15.2	0.9	20	1	AAC91840	P53 consensus bind
	134	15.2	0.9	20	1	AAF69698	Human IL4Ralpha ge
	135	15.2	0.9	20	1	AAS16424	Mouse Gli-1 transc
c	136	15.2	0.9	20	1	AAS97838	Murine SAC1 gene-s
c	137	15.2	0.9	20	1	AAD44828	Human raf kinase r
c	138	15.2	0.9	20	1	ABX95003	MAGE-C2 specific p
c	139	15.2	0.9	20	1	ADB89920	Antinsense oligonu
c	140	15.2	0.9	20	1	ADG18034	MAGE-C2 gene PCR p
c	141	15.2	0.9	20	1	ADG92990	Human FT-beta subu
c	142	15.2	0.9	20	1	ADH94264	Human gene PCR pri
	143	15.2	0.9	20	1	ABZ87187	Human oligonucleot
	144	15.2	0.9	20	1	ABZ88322	Human oligonucleot
	145	15.2	0.9	20	1	ABZ87743	Human oligonucleot
c	146	15.2	0.9	20	1	ACD42144	Human raf-associat
c	147	15.2	0.9	20	1	ADM33117	Human MAGE-C2 PCR
	148	15.2	0.9	20	1	ABD23973	Human calmodulin 2
	149	15.2	0.9	20	1	ABD23417	Human myosin X-der
	150	15.2	0.9	20	1	ABD24552	AI652764-derived o
	151	15.2	0.9	20	1	ADH67851	Human glucocortico
c	152	15.2	0.9	20	1	ADI79409	Human MAGE-C2 PCR
	153	15.2	0.9	20	1	ADI28308	Human PRL3 antisen
c	154	15.2	0.9	20	1	ADI28178	Antisense oligonuc
	155	15.2	0.9	20	1	ADI29122	Antisense oligonuc
	156	15.2	0.9	20	1	ADK97015	Primer of the inve
c	157	15.2	0.9	20	1	ADK95532	Primer of the inve
c	158	15.2	0.9	20	1	ADK97463	Primer of the inve
	159	15.2	0.9	20	1	ADK95099	Primer of the inve
c	160	15.2	0.9	20	1	ADK12219	Human complement c
c	161	15.2	0.9	20	1	ADJ25457	Human endothelial
c	162	15.2	0.9	20	1	ADK78855	Chimeric phosphoro
	163	15.2	0.9	20	1	ADL00781	Human VEGF co-regu
c	164	15.2	0.9	20	1	ADN48788	Human Notch (Droso
c	165	15.2	0.9	20	1	ADM16178	Murine SAC1 DNA PC
	166	15.2	0.9	20	1	ADN58843	Human B7H antisens
c	167	15.2	0.9	20	1	ADP48323	Human Lck DNA anti
	168	15.2	0.9	20	1	ADQ80769	Porcine IGF2 exon
	169	15	0.9	17	1	AAF03309	Hammerhead ribozym
c	170	15	0.9	20	1	ADI38744	Human LIM domain k
	171	15	0.9	20	1	ADI38817	Human LIM domain k
	172	15	0.9	24	1	ADG16131	Compound activity
c	173	15	0.9	24	1	ADO81152	Prion protein poly
	174	15	0.9	25	1	ACF79235	Calix(a)arene-olig
	175	15	0.9	27	1	ABX12469	Coxsackie B virus
	176	14.8	0.8	18	1	AAX67192	Human CD40 hairpin
	177	14.8	0.8	18	1	AAT76222	Human IL5 antisens
	178	14.8	0.8	18	1	AAX54018	Human IL-5 antisen
	179	14.8	0.8	18	1	AAA33462	Low adenosine anti
	180	14.8	0.8	18	1	AAF19584	Human IL5 polynucl
	181	14.8	0.8	18	1	ABZ95278	Human IL-5 antisen
c	182	14.8	0.8	18	1	ABZ97335	Human IL4-R oligon
	183	14.8	0.8	18	1	ABD19252	Human IL5 DNA frag
c	184	14.8	0.8	18	1	ABD30366	Human IL4-R derive
c	185	14.8	0.8	18	1	ADJ59154	Oligonucleotide as
c	186	14.8	0.8	18	1	ADO44644	Human oligonucleot
c	187	14.8	0.8	18	1	ADQ26950	Human myosin heavy
	188	14.8	0.8	19	1	AAZ22783	Rabbit alpha-actin
	189	14.8	0.8	19	1	AAA13267	PCR primer #2 used
	190	14.8	0.8	19	1	AAA84391	Cyclin D3 ribozyme
	191	14.8	0.8	19	1	AAA85488	Cyclin A1 ribozyme
	192	14.8	0.8	19	1	AAA84248	Cyclin D1 ribozyme
c	193	14.8	0.8	19	1	AAH27311	Human TSG16 PCR pr
	194	14.8	0.8	19	1	AAH59553	Cyclin D3 ribozyme
	195	14.8	0.8	19	1	AAH60650	Cyclin A1 ribozyme
	196	14.8	0.8	19	1	AAH59410	Cyclin D1 ribozyme
c	197	14.8	0.8	19	1	ABK10370	Rat Collagen I RT-
c	198	14.8	0.8	19	1	AAI67970	VEGF gene specific
c	199	14.8	0.8	19	1	AAI72105	VEGF reverse prime
c	200	14.8	0.8	19	1	ABA95113	Collagen I gene sp
c	201	14.8	0.8	19	1	ADC18709	Rat RT-PCR primer
	202	14.8	0.8	19	1	ADF71326	Protein tyrosine p
c	203	14.8	0.8	19	1	ADF71252	Protein tyrosine p
	204	14.8	0.8	19	1	ADF75525	Sense siNA that do
c	205	14.8	0.8	19	1	ADF75710	Antisense siNA tha
c	206	14.8	0.8	19	1	ADF84165	Human breakpoint c
	207	14.8	0.8	19	1	ADF83902	Human breakpoint c
	208	14.8	0.8	19	1	ADH16211	Human BACE transcr
c	209	14.8	0.8	19	1	ADH16536	Human BACE siNA lo
c	210	14.8	0.8	19	1	ADH16224	Human BACE transcr
	211	14.8	0.8	19	1	ADH16549	Human BACE siNA lo
c	212	14.8	0.8	19	1	ADL79131	Human HER2 (EGFR2)
c	213	14.8	0.8	19	1	ADL78920	Human HER2 (EGFR2)
	214	14.8	0.8	19	1	ADL78882	Human HER2 (EGFR2)
	215	14.8	0.8	19	1	ADL79169	Human HER2 (EGFR2)
c	216	14.8	0.8	19	1	ADN34242	Lower strand of cy
	217	14.8	0.8	19	1	ADN34003	Upper strand of cy
c	218	14.8	0.8	19	1	ADO14572	Human PDGFr-target
	219	14.8	0.8	19	1	ADO14883	Human PDGFr-target
c	220	14.8	0.8	19	1	ADF92112	Human cytokeratin
c	221	14.8	0.8	19	1	ADH01576	Protein tyrosine p
c	222	14.8	0.8	19	1	ADK95769	Primer of the inve
c	223	14.8	0.8	19	1	ADO52027	Rat collagen I gen

ALIGNMENTS

RESULT 1
AAI76791/c
ID AAI76791 standard; DNA; 50 BP.
XX
AC AAI76791;
XX
DT 09-NOV-2001 (first entry)
XX
DE Human silent SNP containing nucleic acid SEQ:3732.
XX
KW Human; single nucleotide polymorphism; SNP; genome; gene therapy;
KW protein therapy; vaccine; probe; diagnostic assay; detection;
KW quantitation; restorative therapy; polymorphic; ds.
XX
OS Homo sapiens.
XX
PN WO200140521-A2.
XX
PD 07-JUN-2001.
XX
PF 30-NOV-2000; 2000WO-US032758.
XX
PR 30-NOV-1999; 99US-0168138P.
PR 29-NOV-2000; 2000US-00726173.

```
XX
PA   (CURA-) CURAGEN CORP.
XX
PI   Shimkets RA,  Leach M;
XX
DR   WPI; 2001-356160/37.
XX
PT   Polymorphic nucleic acid sequences, useful in genetic testing and
PT   therapy.
XX
PS   Claim 1; Page 1193; 2653pp; English.
XX
CC   AAI73060 to AAI79867 represent isolated human polymorphic polynucleotide
CC   sequences (I), which contain single nucleotide polymorphisms (SNPs).
CC   AAM53114 to AAM53329 represent peptides related to human polymorphic
CC   polynucleotide sequences. The sequences can be used in gene and protein
CC   therapy, and in vaccine production. (I) and the polypeptides encoded by
CC   them may be used in the prevention, diagnosis and treatment of diseases
CC   associated with inappropriate expression of polymorphic polypeptides. For
CC   example, (I) may be used to treat disorders by rectifying mutations or
CC   deletions in a patient's genome that affect the activity of polypeptides
CC   by expressing inactive proteins or to supplement the patients own
CC   production of polypeptide. Additionally, (I) and its complementary
CC   sequences may also be used as DNA probes in diagnostic assays to detect
CC   and quantitate the presence of similar nucleic acids in samples, and
CC   therefore which patients may be in need of restorative therapy. The
CC   polypeptides encoded by (I) may be used as antigens in the production of
CC   antibodies specific for polymorphic polypeptides. The antibodies may also
CC   be used to down regulate expression and activity. The antibodies may also
CC   be used as diagnostic agents for detecting the presence of polymorphic
CC   polypeptides in samples
XX
SQ   Sequence 50 BP; 7 A; 14 C; 15 G; 14 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 39.5;  DB 1;  Length 50;
  Best Local Similarity   98.0%;  Pred. No. 0.012;
  Matches   50;  Conservative    0;  Mismatches    0;  Indels    1;  Gaps    1;

Qy        919 CTTCAACCTGAGGGGGCCGACAGTGCCCTCCAAGACAGAGACGACTGAACT 969
              ||||||||||||||||||||||||| |||||||||||||||||||||||||
Db         50 CTTCAACCTGAGGGGGCCGACAGTG-CCTCCAAGACAGAGACGACTGAACT 1


RESULT 2
AAV82614/c
ID   AAV82614 standard; DNA; 38 BP.
XX
AC   AAV82614;
XX
DT   10-FEB-1999  (first entry)
XX
DE   Oligonucleotide used to block 5' vector sequences of human RNA.
XX
KW   normalise; cDNA library; construct; subtractive cDNA library; primer; ss.
XX
OS   Synthetic.
XX
PN   US5846721-A.
XX
PD   08-DEC-1998.
XX
PF   19-SEP-1996;   96US-00715941.
XX
PR   19-SEP-1996;   96US-00715941.
XX
PA   (UYCO ) UNIV COLUMBIA NEW YORK.
XX
PI   Soares MB,  Bonaldo MDF;
XX
DR   WPI; 1999-059042/05.
XX
PT   Method of normalising cDNA libraries - and construction of subtractive
PT   cDNA libraries.
XX
PS   Disclosure; Col 13; 28pp; English.
XX
CC   The present oligonucleotide was used to block 5' vector sequences of all
CC   human organ library RNAs, in the method of the invention. The
CC   specification describes methods to normalise a cDNA library, and to
CC   construct a subtractive cDNA library
XX
SQ   Sequence 38 BP; 6 A; 14 C; 9 G; 9 T; 0 U; 0 Other;

  Query Match             1.9%;  Score 33;  DB 1;  Length 38;
  Best Local Similarity   100.0%;  Pred. No. 0.17;
  Matches   33;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 TTTGGCCCTCGAGGCCAAGAATTCGGCACGAGG 33
              |||||||||||||||||||||||||||||||||
Db         33 TTTGGCCCTCGAGGCCAAGAATTCGGCACGAGG 1


RESULT 3
AAV82613
ID   AAV82613 standard; DNA; 21 BP.
XX
AC   AAV82613;
XX
DT   10-FEB-1999  (first entry)
XX
DE   Oligonucleotide used to block 3' vector sequences of human RNA.
XX
KW   normalise; cDNA library; construct; subtractive cDNA library; primer; ss.
XX
OS   Synthetic.
XX
PN   US5846721-A.
XX
PD   08-DEC-1998.
XX
PF   19-SEP-1996;   96US-00715941.
XX
PR   19-SEP-1996;   96US-00715941.
XX
PA   (UYCO ) UNIV COLUMBIA NEW YORK.
XX
PI   Soares MB,  Bonaldo MDF;
XX
DR   WPI; 1999-059042/05.
XX
PT   Method of normalising cDNA libraries - and construction of subtractive
PT   cDNA libraries.
XX
PS   Disclosure; Col 13; 28pp; English.
XX
CC   The present oligonucleotide was used to block 3' vector sequences of all
CC   human organ library RNAs, in the method of the invention. The
CC   specification describes methods to normalise a cDNA library, and to
CC   construct a subtractive cDNA library
XX
SQ   Sequence 21 BP; 7 A; 5 C; 7 G; 2 T; 0 U; 0 Other;

  Query Match             1.2%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 22;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         12 AGGCCAAGAATTCGGCACGAG 32
              |||||||||||||||||||||
Db          1 AGGCCAAGAATTCGGCACGAG 21


RESULT 4
AAV18869
ID   AAV18869 standard; DNA; 20 BP.
XX
AC   AAV18869;
```

XX
DT 09-JUL-1998 (first entry)
XX
DE Primer for rat hypocretin 35 cDNA.
XX
KW Rat; hypocretin 35; H35; treatment; neurological disease;
KW homeostatic dysfunction; PCR primer;
KW homeostatic regulatory hormone production; ss.
XX
OS Synthetic.
OS Rattus rattus.
XX
PN WO9805352-A1.
XX
PD 12-FEB-1998.
XX
PF 01-AUG-1997; 97WO-US013657.
XX
PR 02-AUG-1996; 96US-0023220P.
XX
PA (SCRI) SCRIPPS RES INST.
XX
PI Sutcliffe JG, Gautvik KM, De Lecea L, Bloom FE, Danielson PE;
PI Gautvik VT, Kilduff TS, Foye PE;
XX
DR WPI; 1998-145352/13.
XX
PT Nucleic acid encoding hypocretin of rat and mouse - useful for diagnosis
PT and treatment of neurological disease, homeostatic dysfunction etc., also
PT sequence for calmodulin kinase-like protein.
XX
PS Example 1; Page 71; 111pp; English.
XX
CC The present sequence is a primer for the cDNA encoding rat hypocretin 35
CC (H35), which is involved in lowering body temperature and reducing food
CC intake. Modulation of the H35 receptor can be used in the treatment of
CC neurological disease or homeostatic dysfunction, or to control
CC homeostatic regulatory hormone production. Hypocretin proteins can be
CC used to raise antibodies (Ab), to identify specific agonists or
CC antagonists, in therapy, to detect Ab and to isolate cognate receptors.
CC Oligonucleotides based on H35 cDNA can be used to detect the hypocretin
CC gene or its RNA transcript, and as antisense agents for inhibiting gene
CC expression. H35 cDNA can also be used for recombinant protein production.
CC The Ab can be used to detect or quantify hypocretin proteins and as a
CC therapeutic inhibitor
XX
SQ Sequence 20 BP; 7 A; 5 C; 6 G; 2 T; 0 U; 0 Other;

Query Match 1.1%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 34;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          12 AGGCCAAGAATTCGGCACGA 31
               ||||||||||||||||||||
Db           1 AGGCCAAGAATTCGGCACGA 20
```

RESULT 5
AAZ40169
ID AAZ40169 standard; DNA; 20 BP.
XX
AC AAZ40169;
XX
DT 18-FEB-2000 (first entry)
XX
DE PCR primer for human semaphorin, DCSema, coding sequence.
XX
KW Semaphorin; DCSema; human; inflammatory disease; VESPR; interleukin-12;
KW IL-12; immune response; aggressive micrometastasising tumour; therapy;
KW immune suppression; autoimmune disorder; semaphorin receptor;
KW immune regulation; viral infection; PCR primer; ss.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN WO9958676-A2.
XX
PD 18-NOV-1999.
XX
PF 05-MAY-1999; 99WO-US009831.
XX
PR 14-MAY-1998; 98US-0085497P.
XX
PA (IMMV) IMMUNEX CORP.
XX
PI Spriggs MK;
XX
DR WPI; 2000-053100/04.
XX
PT Novel neurologic regulator polypeptide for treating inflammatory
PT diseases, autoimmune disorders, etc.,.
XX
PS Example 1; Page 20; 41pp; English.
XX
CC This sequence represents a PCR primer for DNA encoding the human
CC semaphorin protein, designated DCSema, of the invention. DCSema is used
CC for treating inflammatory diseases. DCSema ligands bind with VESPR to
CC enhance or promote interleukin-12 (IL-12) production which induces an
CC immune response against aggressive micrometastasising tumours. They are
CC associated with immune suppression of mature dendritic cells and
CC therefore can be used for treating autoimmune disorders. They can be
CC employed to measure biological activity of any semaphorin receptor in
CC terms of its binding affinity for semaphorin ligand and also for
CC detecting semaphorin receptor by in vitro assays. DCSema polypeptides are
CC used as reagents in quality assurance studies (to monitor shelf life and
CC stability of semaphorin receptor under different conditions). They are
CC also used as a research tool for studying the role of this ligand and its
CC receptor in immune regulation and are also used as carriers for
CC delivering diagnostic or therapeutic agents to cells expressing
CC semaphorin receptor. They are shown to play a role as immune regulators
CC in viral infection
XX
SQ Sequence 20 BP; 5 A; 6 C; 6 G; 3 T; 0 U; 0 Other;

Query Match 1.1%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 34;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy           8 CTCGAGGCCAAGAATTCGGC 27
               ||||||||||||||||||||
Db           1 CTCGAGGCCAAGAATTCGGC 20
```

RESULT 6
ADC84458/c
ID ADC84458 standard; DNA; 20 BP.
XX
AC ADC84458;
XX
DT 01-JAN-2004 (first entry)
XX
DE Primer #2 used to to generate DA2 cDNA.
XX
KW HALP protein; anti-apoptotic activity; chronic inflammatory disease;
KW leukemia; myocardial infarction; stroke; traumatic brain injury;
KW muscular degenerative diseases; aging; tumor induced-cachexia;
KW rheumatoid arthritis; system lupus erythematosus; hair loss;
KW antiinflammatory; cytostatic; cardiant; cerebroprotective;
KW immunomodulator; antirheumatic; antiarthritic; immunosuppressive;
KW dermatological; anti-HIV; ss; primer.
XX
OS Synthetic.
XX
PN WO2003070906-A2.
XX
PD 28-AUG-2003.

```
XX
PF   19-FEB-2003; 2003WO-US004945.
XX
PR   19-FEB-2002; 2002US-0358495P.
XX
PA   (CHIL-) CHILDRENS HOSPITAL PHILADELPHIA.
XX
PI   Finkel TH,  Yin J;
XX
DR   WPI; 2003-679875/64.
XX
PT   New HALP protein and nucleic acids having anti-apoptotic activity in HIV-
PT   1 infected cells, useful for treating HIV infection and AIDS, or
PT   disorders associated with inordinate cellular apoptosis, e.g. leukemia,
PT   stroke or brain injury.
XX
PS   Example 2; Page 28; 92pp; English.
XX
CC   A nucleic acid molecule encoding HALP protein having anti-apoptotic
CC   activity in HIV-1 infected cells, is new. The agent is selected from
CC   HALP, CD4, DF2, DF3, CC8 and molecule selected from those given in the
CC   specification. The disorder may be acute and chronic inflammatory
CC   disease, leukemia, myocardial infarction, stroke, traumatic brain injury,
CC   neural and muscular degenerative diseases, aging, tumor induced-cachexia,
CC   rheumatoid arthritis, system lupus erythematosus, or hair loss. The
CC   method is considered antiinflammatory, cytostatic, cardiant,
CC   cerebroprotective, immunomodulator, antirheumatic, antiarthritic,
CC   immunosuppressive, dermatological and anti-HIV. HALP, CD4, DF2, DF3, and
CC   CC8 are useful for maintaining cell viability in a subject having a
CC   disorder characterized by inordinate cellular apoptosis, such as acute
CC   and chronic inflammatory disease, leukemia, myocardial infarction,
CC   stroke, traumatic brain injury, neural and muscular degenerative
CC   diseases, aging, tumor induced-cachexia, rheumatoid arthritis, system
CC   lupus erythematosus, or hair loss. The HALP nucleic acids are
CC   particularly useful for the development of therapeutic agents for
CC   treating HIV infection and AIDS. The present sequence represents a primer
CC   used in the method of invention.
XX
SQ   Sequence 20 BP; 7 A; 6 C; 2 G; 5 T; 0 U; 0 Other;

  Query Match             1.1%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 34;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        904 TTGAGGAGTGTTGAACTTCA 923
              ||||||||||||||||||||
Db         20 TTGAGGAGTGTTGAACTTCA 1


RESULT 7
ADO59662/c
ID   ADO59662 standard; DNA; 20 BP.
XX
AC   ADO59662;
XX
DT   26-AUG-2004  (first entry)
XX
DE   RTP801 gene primer #2.
XX
KW   ss; primer; cytostatic; gene therapy; KIT tyrosine kinase inhibitor;
KW   tumor; gene expression; cancer.
XX
OS   Homo sapiens.
XX
PN   WO2004045545-A2.
XX
PD   03-JUN-2004.
XX
PF   18-NOV-2003; 2003WO-US036820.
XX
PR   18-NOV-2002; 2002US-0427326P.
XX
PA   (FOXC-) FOX CHASE CANCER CENT.
XX
PI   Eisenberg B,  Von Mehren M,  Frolov A,  Godwin A;
XX
DR   WPI; 2004-420529/39.
XX
PT   Assessing the biological activity of a KIT tyrosine kinase inhibitor
PT   against a tumor for preparing a composition for treating tumor by
PT   detecting in a sample the expression level of a gene that correlates with
PT   the activity of the inhibitor.
XX
PS   Example 5; SEQ ID NO 14; 77pp; English.
XX
CC   The invention relates to a method of assessing the biological activity of
CC   a KIT tyrosine kinase inhibitor against a tumor by detecting in a
CC   biological sample of the tumor the level of expression of a gene which
CC   correlates with the biological activity of the KIT tyrosine kinase
CC   inhibitor, where the biological sample has been exposed to the KIT
CC   tyrosine kinase inhibitor. The method is useful in assessing the
CC   biological activity of a KIT tyrosine kinase inhibitor against a tumor
CC   for preparing a composition for treating cancer. This sequence
CC   corresponds to a PCR primer used in the method of the invention.
XX
SQ   Sequence 20 BP; 5 A; 4 C; 6 G; 5 T; 0 U; 0 Other;

  Query Match             1.1%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 34;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        852 ACTGGCTTCCGAGTCATCAA 871
              ||||||||||||||||||||
Db         20 ACTGGCTTCCGAGTCATCAA 1


RESULT 8
ADO59661
ID   ADO59661 standard; DNA; 20 BP.
XX
AC   ADO59661;
XX
DT   26-AUG-2004  (first entry)
XX
DE   RTP801 gene primer #1.
XX
KW   ss; primer; cytostatic; gene therapy; KIT tyrosine kinase inhibitor;
KW   tumor; gene expression; cancer.
XX
OS   Homo sapiens.
XX
PN   WO2004045545-A2.
XX
PD   03-JUN-2004.
XX
PF   18-NOV-2003; 2003WO-US036820.
XX
PR   18-NOV-2002; 2002US-0427326P.
XX
PA   (FOXC-) FOX CHASE CANCER CENT.
XX
PI   Eisenberg B,  Von Mehren M,  Frolov A,  Godwin A;
XX
DR   WPI; 2004-420529/39.
XX
PT   Assessing the biological activity of a KIT tyrosine kinase inhibitor
PT   against a tumor for preparing a composition for treating tumor by
PT   detecting in a sample the expression level of a gene that correlates with
PT   the activity of the inhibitor.
XX
PS   Example 5; SEQ ID NO 13; 77pp; English.
XX
CC   The invention relates to a method of assessing the biological activity of
CC   a KIT tyrosine kinase inhibitor against a tumor by detecting in a
CC   biological sample of the tumor the level of expression of a gene which
CC   correlates with the biological activity of the KIT tyrosine kinase
```

```
CC   inhibitor, where the biological sample has been exposed to the KIT
CC   tyrosine kinase inhibitor. The method is useful in assessing the
CC   biological activity of a KIT tyrosine kinase inhibitor against a tumor
CC   for preparing a composition for treating cancer. This sequence
CC   corresponds to a PCR primer used in the method of the invention.
XX
SQ   Sequence 20 BP; 5 A; 5 C; 6 G; 4 T; 0 U; 0 Other;

  Query Match             1.1%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 34;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        422 AGACACGGCTTACCTGGATG 441
              ||||||||||||||||||||
Db          1 AGACACGGCTTACCTGGATG 20


RESULT 9
AAF77019
ID   AAF77019 standard; RNA; 24 BP.
XX
AC   AAF77019;
XX
DT   14-MAY-2001  (first entry)
XX
DE   Part of plasmid pTNF 1309-1332.
XX
KW   AU-rich element; ARE: zinc finger; tristetraprolin; TTP; TNF alpha;
KW   tumour necrosis factor; ss.
XX
OS   Unidentified.
XX
PN   WO200112213-A2.
XX
PD   22-FEB-2001.
XX
PF   14-AUG-2000; 2000WO-US022199.
XX
PR   13-AUG-1999;   99US-0148810P.
XX
PA   (USSH ) US DEPT HEALTH & HUMAN SERVICES.
XX
PI   Blackshear PJ,  Lai WS,  Carballo-Jane E;
XX
DR   WPI; 2001-202827/20.
XX
PT   Stimulating degradation of mRNA containing AU-rich elements, especially
PT   tumor necrosis factor-alpha mRNA, by contacting with tandem zinc finger
PT   polypeptide containing tristetraprolin zinc finger domains, useful for
PT   treating Crohn's disease.
XX
PS   Example 4; Page 90; 133pp; English.
XX
CC   The present invention relates to stimulating degradation of an mRNA
CC   molecule having an AU-rich element (ARE), comprises contacting the mRNA
CC   molecule with a tandem zinc finger (TZF) polypeptide consisting of the
CC   tristetraprolin (TTP) zinc finger domain or comprising a TTP-like zinc
CC   finger domain, therefore stimulating degradation of the mRNA molecule.
CC   The invention is useful for stimulating the degradation of mRNA within a
CC   cytosolic extract or a cell, where the mRNA preferably encodes tumour
CC   necrosis factor-alpha (TNF-alpha) and administration of TZF polypeptide
CC   or nucleic acid encoding the polypeptide inhibits, prevents or treats TNF
CC   -alpha-related diseases or condition in a patient
XX
SQ   Sequence 24 BP; 0 A; 0 C; 5 G; 0 T; 19 U; 0 Other;

  Query Match             1.1%;  Score 18.8;  DB 1;  Length 24;
  Best Local Similarity   22.7%;  Pred. No. 54;
  Matches    5;  Conservative   15;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1377 GTGTGTTTGTTGTTTGTTTTGT 1398
              |: :|:::|::|:::|:::: :
Db          3 GUUUGUUUGUUGUUUGUUUUU 24


RESULT 10
ACI84593
ID   ACI84593 standard; DNA; 25 BP.
XX
AC   ACI84593;
XX
DT   14-OCT-2003  (first entry)
XX
DE   Human microarray DNA oligonucleotide SEQ ID NO 84584.
XX
KW   EST; ss; probe; expressed sequence tag; microarray; gene expression;
KW   genetic variation; biallelic marker; polymorphism; human;
KW   cross-species comparison.
XX
OS   Homo sapiens.
XX
PN   US2003104410-A1.
XX
PD   05-JUN-2003.
XX
PF   15-MAR-2002; 2002US-00098263.
XX
PR   16-MAR-2001; 2001US-0276759P.
XX
PA   (AFFY-) AFFYMETRIX INC.
XX
PI   Mittmann MP;
XX
DR   WPI; 2003-567953/53.
XX
PT   New array of nucleic acid probes, useful for in situ hybridization, in
PT   Southern, Northern or dot-blot hybridization to identify or detect the
PT   sequence or specific mutations of any gene.
XX
PS   Claim 1; SEQ ID NO 84584; 9pp; English.
XX
CC   The invention discloses a microarray comprising a plurality of nucleic
CC   acid probes including one of 2,018,500 fully defined sequences, or its
CC   perfect match, perfect mismatch, antisense match or antisense mismatch.
CC   Also disclosed is a method of gene expression analysis. The array is used
CC   in monitoring gene expression levels by hybridisation to a DNA library,
CC   in analysis of genetic variation or in hybridisation of tag-labelled
CC   compounds. The nucleic acid probes are specifically designed for analysis
CC   of at least one target sequence. The method of analysis comprises
CC   hybridising at least one or more nucleic acids to at least two or more
CC   nucleic acid probes and detecting the hybridisation. The nucleic acid
CC   probes are attached to a solid support. The analysis comprises monitoring
CC   gene expression levels, identifying biallelic markers or polymorphisms,
CC   or family members of a gene and a cross-species comparison. Each of the
CC   nucleic acids further comprises a tag sequence. The array of nucleic acid
CC   probes is useful in in situ hybridisation, in Southern, Northern or dot-
CC   blot hybridisation to identify or detect the sequence or specific
CC   mutations of any gene, in mapping the 5' termini of mRNA molecules by
CC   primer extensions or in screening cDNA or genomic libraries or subclones
CC   for additional subclones containing segments of DNA that have been
CC   isolated and previously sequenced. The sequence presented is one of the
CC   nucleic acid probes incorporated in the microarray. Note: The sequence
CC   data for this patent can also be obtained in electronic format directly
CC   from USPTO at seqdata.uspto.goc/sequence.html
XX
SQ   Sequence 25 BP; 4 A; 7 C; 5 G; 9 T; 0 U; 0 Other;

  Query Match             1.1%;  Score 18.8;  DB 1;  Length 25;
  Best Local Similarity   90.9%;  Pred. No. 54;
  Matches   20;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        123 ACTTGTCTTAGCAGTTCTCGCT 144
              |||||||| ||| |||||||||
Db          4 ACTTGTCTGAGCTGTTCTCGCT 25
```

```
RESULT 11
ADQ58897
ID   ADQ58897 standard; DNA; 24 BP.
XX
AC   ADQ58897;
XX
DT   23-SEP-2004  (first entry)
XX
DE   Yin yang-1 (YY-1) associated primer #5.
XX
KW   antidiabetic; immunosuppressive; cytostatic; Yin Yang-1;
KW   transcription factor; type 1 diabetes; transgenic; diabetes;
KW   multifunctional transcription factor; type 2 diabetes;
KW   autoimmune disease; cancer; mineral metabolism disorder;
KW   lipid metabolism disorder; rat; YY-1; PCR; primer; ss.
XX
OS   Rattus norvegicus.
XX
PN   WO2004056857-A2.
XX
PD   08-JUL-2004.
XX
PF   19-DEC-2003; 2003WO-EP014762.
XX
PR   20-DEC-2002; 2002DE-01061650.
XX
PA   (UYGR ) UNIV GREIFSWALD.
XX
PI   Kloeting I,  Kloeting N;
XX
DR   WPI; 2004-507695/48.
XX
PT   New variant of the Yin Yang-1 transcription factor, useful for treating
PT   e.g. diabetes and autoimmune disease, also for diagnosing predisposition
PT   and in screening for therapeutic agents.
XX
PS   Disclosure; Fig 11; 193pp; German.
XX
CC   The invention describes a protein variant of the Yin Yang-1 transcription
CC   factor (I), having a 411 amino acid (aa) sequence (4) reproduced. Also
CC   described are: protein (Ia) that is a homologue of (4) and includes Arg a
CC   position 303 and Lys at position 311; peptide (II) that is a fragment of
CC   (I) or (Ia) and includes the positions 303 and 311 of (4); nucleic acid
CC   (III) that encodes (I), (Ia) or (II); an antibody (Ab) directed against
CC   (I) or (Ia); methods for determining a tendency to develop type 1
CC   diabetes; transgenic non-human mammal (A) in which the germ and somatic
CC   cells contain a nucleic acid (or segment) encoding a 411 aa sequence (2),
CC   or sequences with at least 95, best 99% homology, where the homologue
CC   includes 303Met and 311Arg; and use of (A) to screen for compounds (B)
CC   that are protective against diabetes. The methods are useful for
CC   modulating activity of the YY1 (Yin Yang-1) multifunctional transcription
CC   factor. (I), or its homologues and peptides, also nucleic acids encoding
CC   them and antisense oligonucleotides, are useful for treatment of type 1
CC   and 2 diabetes, autoimmune diseases, cancer and disorders of mineral and
CC   lipid metabolism. Detecting mutations in the human analogue of (4) is
CC   used to determine a predisposition for these diseases. Transgenic animals
CC   that contain the sequence encoding (4), or its homologues, are used to
CC   screen for agents protective against diabetes. This sequence represents a
CC   primer associated with the isolation and analysis of yin yang-1
CC   transcription factor.
XX
SQ   Sequence 24 BP; 0 A; 11 C; 4 G; 9 T; 0 U; 0 Other;

  Query Match             1.0%;  Score 18.4;  DB 1;  Length 24;
  Best Local Similarity   95.0%;  Pred. No. 63;
  Matches   19;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        243 TCGTCGTCGTCCACCTCCTC 262
              ||||||||||||  |||||||
Db          5 TCGTCGTCGTCCTCCTCCTC 24
```

RESULT 12

```
ADC84457
ID   ADC84457 standard; DNA; 18 BP.
XX
AC   ADC84457;
XX
DT   01-JAN-2004  (first entry)
XX
DE   Primer #1 used to to generate DA2 cDNA.
XX
KW   HALP protein; anti-apoptotic activity; chronic inflammatory disease;
KW   leukemia; myocardial infarction; stroke; traumatic brain injury;
KW   muscular degenerative diseases; aging; tumor induced-cachexia;
KW   rheumatoid arthritis; system lupus erythematosus; hair loss;
KW   antiinflammatory; cytostatic; cardiant; cerebroprotective;
KW   immunomodulator; antirheumatic; antiarthritic; immunosuppressive;
KW   dermatological; anti-HIV; ss; primer.
XX
OS   Synthetic.
XX
PN   WO2003070906-A2.
XX
PD   28-AUG-2003.
XX
PF   19-FEB-2003; 2003WO-US004945.
XX
PR   19-FEB-2002; 2002US-0358495P.
XX
PA   (CHIL-) CHILDRENS HOSPITAL PHILADELPHIA.
XX
PI   Finkel TH,  Yin J;
XX
DR   WPI; 2003-679875/64.
XX
PT   New HALP protein and nucleic acids having anti-apoptotic activity in HIV-
PT   1 infected cells, useful for treating HIV infection and AIDS, or
PT   disorders associated with inordinate cellular apoptosis, e.g. leukemia,
PT   stroke or brain injury.
XX
PS   Example 2; Page 28; 92pp; English.
XX
CC   A nucleic acid molecule encoding HALP protein having anti-apoptotic
CC   activity in HIV-1 infected cells, is new. The agent is selected from
CC   HALP, CD4, DF2, DF3, CC8 and molecule selected from those given in the
CC   specification. The disorder may be acute and chronic inflammatory
CC   disease, leukemia, myocardial infarction, stroke, traumatic brain injury,
CC   neural and muscular degenerative diseases, aging, tumor induced-cachexia,
CC   rheumatoid arthritis, system lupus erythematosus, or hair loss. The
CC   method is considered antiinflammatory, cytostatic, cardiant,
CC   cerebroprotective, immunomodulator, antirheumatic, antiarthritic,
CC   immunosuppressive, dermatological and anti-HIV. HALP, CD4, DF2, DF3, and
CC   CC8 are useful for maintaining cell viability in a subject having a
CC   disorder characterized by inordinate cellular apoptosis, such as acute
CC   and chronic inflammatory disease, leukemia, myocardial infarction,
CC   stroke, traumatic brain injury, neural and muscular degenerative
CC   diseases, aging, tumor induced-cachexia, rheumatoid arthritis, system
CC   lupus erythematosus, or hair loss. The HALP nucleic acids are
CC   particularly useful for the development of therapeutic agents for
CC   treating HIV infection and AIDS. The present sequence represents a primer
CC   used in the method of invention.
XX
SQ   Sequence 18 BP; 3 A; 8 C; 2 G; 5 T; 0 U; 0 Other;

  Query Match             1.0%;  Score 18;  DB 1;  Length 18;
  Best Local Similarity   100.0%;  Pred. No. 75;
  Matches   18;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        208 CTGTCCTCACCATGCCTA 225
              ||||||||||||||||||
Db          1 CTGTCCTCACCATGCCTA 18
```

RESULT 13
AAH89053/c

```
ID   AAH89053 standard; DNA; 21 BP.
XX
AC   AAH89053;
XX
DT   09-SEP-2004  (revised)
DT   27-FEB-2002  (first entry)
XX
DE   Human polymorphic oligonucleotide AC000159 fragment #7.
XX
KW   Human; single nucleotide polymorphic; SNP; forensic science;
KW   paternity testing; phenotypic trait; genetic mapping; animal breeding;
KW   plant breeding; ds.
XX
OS   Homo sapiens.
OS   Unidentified.
XX
FH   Key             Location/Qualifiers
FT   variation       11
FT                   /*tag=  a
FT                   /standard_name= "single nucleotide polymorphism"
XX
PN   WO200134840-A2.
XX
PD   17-MAY-2001.
XX
PF   10-NOV-2000; 2000WO-US030766.
XX
PR   10-NOV-1999;   99US-0164596P.
XX
PA   (GLAX ) GLAXO GROUP LTD.
PA   (AFFY-) AFFYMETRIX INC.
XX
PI   Au K,  Chen J,  Patil N,  Thomas D;
XX
DR   WPI; 2001-335945/35.
XX
PT   New polymorphic sites derived from the human genome are useful to
PT   determine sites correlating with phenotypic traits, particularly disease,
PT   and also in forensics and paternity testing.
XX
PS   Claim 79; Page 12; 43pp; English.
XX
CC   The present invention relates to human oligonucleotides comprising a
CC   single nucleotide polymorphic site (SNP: AAH88797-AAH89219). The present
CC   sequence is one such oligonucleotide. The oligonucleotides can be used in
CC   forensics, paternity testing, correlation of polymorphisms with
CC   phenotypic traits, genetic mapping of phenotypic traits and marker
CC   assisted breeding of animals and crop plants
CC
CC   Revised record issued on 09-SEP-2004 : Correction to Feature Table Key
XX
SQ   Sequence 21 BP; 6 A; 3 C; 10 G; 2 T; 0 U; 0 Other;

  Query Match             1.0%;  Score 17.8;  DB 1;  Length 21;
  Best Local Similarity   90.5%;  Pred. No. 81;
  Matches   19;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1549 CCTTCCCCCATCGTGTACTGC 1569
              || |||||||||||||||| |
Db         21 CCGTCCCCCATCGTGTACTTC 1


RESULT 14
AAH62187
ID   AAH62187 standard; DNA; 21 BP.
XX
AC   AAH62187;
XX
DT   09-SEP-2004  (revised)
DT   12-SEP-2001  (first entry)
XX
DE   Oestrogen receptor 1 polymorphism containing DNA fragment #88.
XX
KW   Single nucleotide polymorphism; SNP; human; cancer; inflammation;
KW   heart disease; paternity testing; forensic science; ds.
XX
OS   Homo sapiens.
OS   Unidentified.
XX
FH   Key             Location/Qualifiers
FT   variation       11
FT                   /*tag=  a
FT                   /standard_name= "single nucleotide polymorphism"
XX
PN   WO200138576-A2.
XX
PD   31-MAY-2001.
XX
PF   17-NOV-2000; 2000WO-US031639.
XX
PR   24-NOV-1999;   99US-0167334P.
XX
PA   (WHED ) WHITEHEAD INST BIOMEDICAL RES.
XX
PI   Cargill M,  Ireland JS,  Lander ES;
XX
DR   WPI; 2001-367705/38.
XX
PT   New nucleic acid segments of the human genome, particularly from genes
PT   including polymorphic sites,for phenotype correlation, forensics,
PT   paternity testing, medicine and genetic analysis.
XX
PS   Claim 1; Page 37; 80pp; English.
XX
CC   DNA sequences AAH62100 - AAH62688 represent segments of human genes which
CC   contain single nucleotide polymorphisms (SNPs). A method is included in
CC   the invention for analysing a nucleic acid sample, which consists of
CC   determining the base occupying any one of the polymorphic sites given in
CC   the SNP containing sequences. The nucleotide sequences can be used in the
CC   diagnosis or monitoring of diseases, such as cancer, inflammation, heart
CC   diseases, diseases of the cardiovascular system, and infection by
CC   microorganisms. The oligonucleotides are also useful in the manufacture
CC   of a medicament for the treatment or prophylaxis of the diseases, and as
CC   a pharmaceutical. SNP containing oligonucleotides are useful in
CC   applications such as phenotype correlation, forensics, paternity testing,
CC   medicine and genetic analysis
CC
CC   Revised record issued on 09-SEP-2004 : Correction to Feature Table Key
XX
SQ   Sequence 21 BP; 6 A; 5 C; 7 G; 3 T; 0 U; 0 Other;

  Query Match             1.0%;  Score 16.8;  DB 1;  Length 21;
  Best Local Similarity   90.0%;  Pred. No. 1.2e+02;
  Matches   18;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       381 GAGTCCCTGGACAGCAGCAA 400
             | || ||||||||||||||||
Db         1 GTGTACCTGGACAGCAGCAA 20


RESULT 15
ADH70254
ID   ADH70254 standard; DNA; 19 BP.
XX
AC   ADH70254;
XX
DT   25-MAR-2004  (first entry)
XX
DE   Human Vbeta gene repeat sequence #44.
XX
KW   human; T-cell associated disease; Vbeta; autoimmune disease;
KW   degenerative nervous system disease; graft versus host disease;
KW   hypersensitivity disease; infectious disease; neoplastic disease;
KW   Addison's disease; atrophic gastritis;
KW   degenerative nervous system disease; multiple sclerosis;
KW   Alzheimer's disease; hypersensitivity disease; type I hypersensitivity;
```

```
KW   allergy; type II hypersensitivity; Goodpasture's syndrome;
KW   type IV hypersensitivity; leprosy; infectious disease; viral infection;
KW   HIV; fungal infection; Candida; parasitic infection; schistosome;
KW   filaria; bacterial infection; Mycobacterium; neoplastic disease;
KW   lymphoproliferative disease; leukaemia; lymphoma; cancer; brain cancer;
KW   breast cancer; ds.
XX
OS   Homo sapiens.
XX
PN   US2002150891-A1.
XX
PD   17-OCT-2002.
XX
PF   05-MAR-1999;   99US-00263959.
XX
PR   19-SEP-1994;   94US-00309335.
PR   19-SEP-1995;   95US-00531241.
XX
PA   (HOOD/) HOOD L E.
PA   (ROWE/) ROWEN L.
XX
PI   Hood LE,  Rowen L;
XX
DR   WPI; 2004-059052/06.
XX
PT   Kit for diagnozing and treating T-cell associated diseases e.g.
PT   autoimmune, degenerative nervous system and infectious disease, comprises
PT   nucleic acid primers specifically priming and allowing amplification of a
PT   Vbeta gene.
XX
PS   Disclosure; SEQ ID NO 448; 164pp; English.
XX
CC   The invention relates to a kit for diagnosing and treating T-cell
CC   associated diseases which comprises a panel of nucleic acid primers
CC   specifically priming and allowing amplification of each Vbeta gene,
CC   VbetaRNA or cDNA. The kit is useful for diagnosing organ transplant
CC   rejection and diagnosing and treating T-cell associated diseases
CC   including autoimmune diseases, degenerative nervous system diseases,
CC   graft versus host disease, hypersensitivity diseases, infectious diseases
CC   and neoplastic diseases. Autoimmune diseases include Addison's disease,
CC   atrophic gastritis. Degenerative nervous system diseases include multiple
CC   sclerosis and Alzheimer's disease. Hypersensitivity diseases include Type
CC   I hypersensitivities such as contact with allergens that lead to
CC   allergies, Type II hypersensitivities such as those present in
CC   Goodpasture's syndrome and Type IV hypersensitivities such as those
CC   manifested in leprosy. Infectious diseases include viral infections
CC   caused by viruses such as HIV, fungal infections such as those caused by
CC   the yeast genus Candida, parasitic infections such as those caused by
CC   schistosomes, filaria and bacterial infections such as those caused by
CC   Mycobacterium. Neoplastic diseases include lymphoproliferative diseases
CC   such as leukaemias, lymphomas and cancers such as cancer of the brain,
CC   breast. The present sequence represents a Vbeta gene repeat sequence.
XX
SQ   Sequence 19 BP; 0 A; 0 C; 5 G; 14 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 16.4;  DB 1;  Length 19;
  Best Local Similarity   94.4%;  Pred. No. 1.4e+02;
  Matches   17;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1378 TGTGTTTGTTGTTTGTTT 1395
              | ||||||||||||||||
Db          1 TTTGTTTGTTGTTTGTTT 18


RESULT 16
AAA88871
ID   AAA88871 standard; DNA; 20 BP.
XX
AC   AAA88871;
XX
DT   19-FEB-2001  (first entry)
XX
DE   Protein tyrosine phosphatase PCR primer betaseq2.
XX
KW   Vascular-endothelial protein tyrosine phosphatase; VE-PTP; mouse; Tie-2;
KW   receptor-type tyrosine kinase; antiangiogenic; antitumour;
KW   antimetastatic; tumour; metastasis; angiogenesis; therapy; PCR primer;
KW   ss.
XX
OS   Mus musculus.
XX
PN   EP1046715-A1.
XX
PD   25-OCT-2000.
XX
PF   23-APR-1999;   99EP-00108074.
XX
PR   23-APR-1999;   99EP-00108074.
XX
PA   (PLAC ) MAX PLANCK GES FOERDERUNG WISSENSCHAFTEN.
XX
PI   Fachinger G,  Risau B,  Deutsch U;
XX
DR   WPI; 2000-648932/63.
XX
PT   Monitoring or modulating Tie-2 tyrosine kinase activity, useful e.g. for
PT   regulating tumor growth, using vascular-endothelial protein tyrosine
PT   phosphatase.
XX
PS   Example 2; Page 4; 60pp; English.
XX
CC   The present sequence is that of primer betaseq2, which was used with
CC   primer betarev (see AAA99972) in the PCR amplification of a 416 bp
CC   fragment of mouse vascular-endothelial protein tyrosine phosphatase (VE-
CC   PTP) cDNA (see AAA88865). PCR analysis was used to examine VE-PTP
CC   expression in mouse tissues and during mouse embryonic development. In
CC   adult mouse, VE-PTP was strongly expressed in brain as well as in lung
CC   and heart. In embryonic development, VE-PTP increased from day E11 to day
CC   E17. VE-PTP polypeptides, nucleic acids and ligands are used in claimed
CC   methods for detecting and modulating receptor tyrosine kinase Tie-2
CC   activity. This allows the monitoring or modulation of angiogenesis,
CC   induction or inhibition of vascular growth or remodelling and blood
CC   vessel maturation, and inhibition of tumour growth or metastasis
XX
SQ   Sequence 20 BP; 1 A; 11 C; 2 G; 6 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 16.4;  DB 1;  Length 20;
  Best Local Similarity   94.4%;  Pred. No. 1.4e+02;
  Matches   17;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        809 CTCTCCCTTCCTCCCTGG 826
              |||||||||||| |||||
Db          3 CTCTCCCTTCCTACCTGG 20


RESULT 17
ABL31214
ID   ABL31214 standard; DNA; 20 BP.
XX
AC   ABL31214;
XX
DT   21-MAR-2002  (first entry)
XX
DE   Human HLA genotyping oligonucleotide SEQ ID NO 703.
XX
KW   Human; human leukocyte antigen; HLA; genotype; polymorphism;
KW   immunogenetic; transplantation; genetic disease; ss.
XX
OS   Homo sapiens.
XX
PN   WO200192572-A1.
XX
PD   06-DEC-2001.
XX
PF   01-JUN-2001; 2001WO-JP004662.
XX
```

PR 01-JUN-2000; 2000JP-00164798.
XX
PA (NISN) NISSHINBO IND INC.
PA (SYST-) SYSTEM RES INC.
XX
PI Inoko H, Kagiya T, Ichihara T, Matsumura Y, Moriya S, Nishida M;
XX
DR WPI; 2002-122074/16.
XX
PT Human leukocyte antigen (HLA) typing, useful for judging HLA genotypes of
PT individuals e.g. by determining immunogenetic differences when
PT transplanting between them.
XX
PS Claim 10; Page 226; 345pp; Japanese.
XX
CC The invention relates to a typing kit for judging human leukocyte antigen
CC (HLA) genotype of a sample by hybridising a substrate on which 10-24 base
CC oligonucleotides (ABL30512-ABL31809) originating in the sequences of
CC genes e.g. belonging to HLA class I antigens on human genome and
CC containing gene polymorphisms as alloantigens have been immobilised as
CC primers for amplification of cleaved nucleic acids relating to gene
CC polymorphisms. The method is useful for judging HLA genotypes of
CC individuals by determining immunogenetic differences before transplanting
CC between them, providing genetic information to decide compatibility of
CC organ and tissue for transplantation e.g. of bone marrow, kidney, liver,
CC pancreas, Langerhans islet in pancreas and cornea, susceptibility
CC diagnosis of genetic diseases and identifying individuals
XX
SQ Sequence 20 BP; 4 A; 5 C; 7 G; 4 T; 0 U; 0 Other;

Query Match 0.9%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 839 CCTGACGCTGAGCACTGG 856
||||||||||| |||||
Db 2 CCTGACGCTGAGTACTGG 19

RESULT 18
ABL31217
ID ABL31217 standard; DNA; 20 BP.
XX
AC ABL31217;
XX
DT 21-MAR-2002 (first entry)
XX
DE Human HLA genotyping oligonucleotide SEQ ID NO 706.
XX
KW Human; human leukocyte antigen; HLA; genotype; polymorphism;
KW immunogenetic; transplantation; genetic disease; ss.
XX
OS Homo sapiens.
XX
PN WO200192572-A1.
XX
PD 06-DEC-2001.
XX
PF 01-JUN-2001; 2001WO-JP004662.
XX
PR 01-JUN-2000; 2000JP-00164798.
XX
PA (NISN) NISSHINBO IND INC.
PA (SYST-) SYSTEM RES INC.
XX
PI Inoko H, Kagiya T, Ichihara T, Matsumura Y, Moriya S, Nishida M;
XX
DR WPI; 2002-122074/16.
XX
PT Human leukocyte antigen (HLA) typing, useful for judging HLA genotypes of
PT individuals e.g. by determining immunogenetic differences when
PT transplanting between them.
XX
PS Claim 10; Page 227; 345pp; Japanese.
XX
CC The invention relates to a typing kit for judging human leukocyte antigen
CC (HLA) genotype of a sample by hybridising a substrate on which 10-24 base
CC oligonucleotides (ABL30512-ABL31809) originating in the sequences of
CC genes e.g. belonging to HLA class I antigens on human genome and
CC containing gene polymorphisms as alloantigens have been immobilised as
CC primers for amplification of cleaved nucleic acids relating to gene
CC polymorphisms. The method is useful for judging HLA genotypes of
CC individuals by determining immunogenetic differences before transplanting
CC between them, providing genetic information to decide compatibility of
CC organ and tissue for transplantation e.g. of bone marrow, kidney, liver,
CC pancreas, Langerhans islet in pancreas and cornea, susceptibility
CC diagnosis of genetic diseases and identifying individuals
XX
SQ Sequence 20 BP; 4 A; 6 C; 8 G; 2 T; 0 U; 0 Other;

Query Match 0.9%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 839 CCTGACGCTGAGCACTGG 856
|||||||| |||||||||
Db 2 CCTGACGCGGAGCACTGG 19

RESULT 19
ABZ88246
ID ABZ88246 standard; DNA; 20 BP.
XX
AC ABZ88246;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-229219/22.
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 3488; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an

```
CC   antiinflammatory steroid and ubiquinone. A composition of the invention
CC   has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC   immunosuppressive, and cytostatic activity. The composition may have a
CC   use in antisense gene therapy. The composition is useful for treating or
CC   preventing a respiratory, lung or malignant disease or condition, also
CC   for enhancing the prophylactic or therapeutic respiratory effect of an
CC   antiinflammatory steroid in a subject, for reducing or depleting levels
CC   of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC   receptor, producing bronchodilation, increasing levels of ubiquinone or
CC   lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC   lung inflammation, lung allergies, or a respiratory disease or condition.
CC   Note: The sequence data for this patent is not represented in the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 20 BP; 1 A; 10 C; 4 G; 5 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 16.4;  DB 1;  Length 20;
  Best Local Similarity   94.4%;  Pred. No. 1.4e+02;
  Matches   17;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        817 TCCTCCCTGGCTTCAGCC 834
              ||||||||||||| |||||
Db          2 TCCTCCCTGGCTGCAGCC 19


RESULT 20
ABD24476
ID   ABD24476 standard; DNA; 20 BP.
XX
AC   ABD24476;
XX
DT   29-JUL-2004  (first entry)
XX
DE   AI652901-derived oligonucleotide SEQ ID 3488.
XX
KW   Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
KW   respiratory tract inflammation; adenosine sensitivity; lung; cancer;
KW   surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
KW   analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
KW   beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
KW   respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
KW   emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
KW   pulmonary transplantation rejection; ss; primer.
XX
OS   Homo sapiens.
XX
PN   WO200285309-A2.
XX
PD   31-OCT-2002.
XX
PF   23-APR-2002; 2002WO-US013143.
XX
PR   24-APR-2001; 2001US-0286036P.
XX
PA   (EPIG-) EPIGENESIS PHARM INC.
XX
PI   Nyce JW,  Li Y,  Sandrasagra A,  Katz E,  Pabalan J,  Aguilar D;
PI   Miller S,  Tang L,  Shahabuddin S;
XX
DR   WPI; 2003-093058/08.
XX
PT   Pharmaceutical composition for treating asthma, has antisense
PT   oligonucleotide containing less percentage of adenosine, targeted to
PT   nucleic acids associated with lung airway or lung dysfunction, and
PT   bronchodilating agent.
XX
PS   Claim 15; SEQ ID NO 3488; 763pp; English.
XX
CC   This invention describes a novel composition (a) a first active agent,
CC   comprising oligonucleotides, effective for alleviating
CC   bronchoconstriction, respiratory tract inflammation, allergies and
CC   reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
CC   surfactant depletion or hyposecretion, when administered to a mammal. The
CC   oligonucleotides are derived from a gene encoding or regulating
CC   expression of a target polypeptide associated with lung airway or lung
CC   dysfunction or cancer and can be anti-sense to the corresponding mRNA.
CC   The invention also describes a kit, that comprises: (a) a delivery
CC   device, in separate containers, (b) the oligonucleotides, (c)
CC   instructions for adding a carrier and for use of the kit. The composition
CC   of the invention has antiallergic, antiinflammatory, antiasthmatic,
CC   analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
CC   beta-adrenergic agonist. The composition is useful for preventing or
CC   treating a respiratory, lung or malignant disease. The administered
CC   composition comprises oligo and is administered to reduce the production
CC   or availability, or to increase the degradation of the target mRNA or to
CC   reduce the amount of target polypeptide present in the lungs. The
CC   pulmonary obstruction, and/or bronchoconstriction and/or lung
CC   inflammation, allergies and/or surfactant hypoproduction are associated
CC   with a disease or condition such as pulmonary vasoconstriction,
CC   inflammation, allergies, asthma, impeded respiration, respiratory
CC   distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
CC   hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
CC   transplantation rejection, pulmonary infections, bronchitis or cancer.
CC   The reduced adenosine content of the anti-sense oligos corresponding to
CC   thymidines present in the target RNA serves to prevent the breakdown of
CC   the oligonucleotides into products that free adenosine into the system
CC   e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
CC   prevent any unwanted effects due to it
XX
SQ   Sequence 20 BP; 1 A; 10 C; 4 G; 5 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 16.4;  DB 1;  Length 20;
  Best Local Similarity   94.4%;  Pred. No. 1.4e+02;
  Matches   17;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        817 TCCTCCCTGGCTTCAGCC 834
              ||||||||||||| |||||
Db          2 TCCTCCCTGGCTGCAGCC 19


RESULT 21
ADI27548
ID   ADI27548 standard; DNA; 20 BP.
XX
AC   ADI27548;
XX
DT   22-APR-2004  (first entry)
XX
DE   Human DRAK1 DNA, antisense oligonucleotide #26.
XX
KW   Antisense therapy; human;
KW   death-associated protein kinase-related apoptosis-inducing;
KW   protein kinase 1; DRAK1; hyperproliferative disorder; cancer;
KW   neurological disorder; infection; inflammation; tumour formation;
KW   cytostatic; antiinflammatory; neuroprotective; antimicrobial;
KW   phosphorothioate; ss.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "This oligonucleotide has a phosphorothioate
FT                   backbone and 2'-methyoxyethyl (2'-MOE) wings at the 5'
FT                   and 3' ends, which are 5 nucleotides in length at each
FT                   end. All cytidine residues are 5-methylcytidines"
XX
PN   US2003232773-A1.
XX
PD   18-DEC-2003.
XX
PF   17-JUN-2002; 2002US-00174559.
XX
PR   17-JUN-2002; 2002US-00174559.
```

```
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Bennett CF,  Freier SM,  Dobie KW;
XX
DR   WPI; 2004-061310/06.
XX
PT   New antisense compound targeted to a nucleic acid molecule encoding death
PT   -associated protein kinase-related apoptosis-inducing protein kinase 1
PT   (DRAK1), useful for modulating expression of DRAK1 or for treating
PT   cancer.
XX
PS   Example 15; SEQ ID NO 40; 56pp; English.
XX
CC   The present invention relates to antisense compounds targeted to a
CC   nucleic acid encoding death-associated protein kinase-related apoptosis-
CC   inducing protein kinase 1 (DRAK1). The antisense compound comprises an
CC   antisense oligonucleotide that specifically hybridises with the nucleic
CC   acid and inhibits the expression of DRAK1. The antisense oligonucleotide
CC   is a chimeric oligonucleotide. The antisense oligonucleotide comprises at
CC   least one modified internucleoside linkage, preferably a phosphorothioate
CC   linkage. It also comprises at least one modified sugar moiety, preferably
CC   a 2'-O-methoxyethyl (2'-MOE) sugar moiety. The antisense oligonucleotide
CC   further comprises at least one modified nucleobase, preferably a 5-
CC   methylcytosine. The antisense oligonucleotides are useful for the
CC   treatment of diseases such as hyperproliferative disorders, preferably
CC   cancer, and neurological disorders. The antisense compound can also be
CC   used as prophylaxis, e.g. to prevent or delay infection, inflammation or
CC   tumour formation. The present sequence represents an antisense
CC   oligonucleotide used in the examples of the present invention.
XX
SQ   Sequence 20 BP; 4 A; 6 C; 8 G; 2 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 16.4;  DB 1;  Length 20;
  Best Local Similarity   94.4%;  Pred. No. 1.4e+02;
  Matches   17;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1299 CTCAGAGCAGCCGGAGGG 1316
              ||| ||||||||||||||
Db          2 CTCCGAGCAGCCGGAGGG 19


RESULT 22
AAT93819
ID   AAT93819 standard; DNA; 26 BP.
XX
AC   AAT93819;
XX
DT   25-MAR-2003  (revised)
DT   24-FEB-1998  (first entry)
XX
DE   Antitumoural phosphodiester oligonucleotide 9 with cytotoxic activity.
XX
KW   Phosphodiester; selective binding; cell viability; growth;
KW   tumoural cell line; cytotoxic activity; tumour cell; lymphoma;
KW   lymphoblastic tumour; ss.
XX
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base    1. .26
FT                    /*tag=  a
FT                    /note= "phosphodiester oligonucleotide"
XX
PN   WO9720924-A1.
XX
PD   12-JUN-1997.
XX
PF   04-DEC-1996;   96WO-EP005388.
XX
PR   04-DEC-1995;   95IT-MI002539.
XX
PA   (SAIC-) SAICOM SRL.
XX
PI   Scaggiante B,  Quadrifoglio F;
XX
DR   WPI; 1997-319771/29.
XX
PT   New phospho:di:esteric oligo:nucleotide(s) - which exert a specific and
PT   selective cytotoxic effect on tumour cells, for treating both solid and
PT   liquid tumours.
XX
PS   Claim 10; Page 5; 38pp; English.
XX
CC   Novel phosphodiesteric oligonucleotides AAT93811-27 are based on the
CC   generic formula, in the 3'-5' or 5'-3' direction: (GaTa')a''-(GbTb')b''-
CC   (GcTc')c''-(GdTd')d''-(GeTe')e''-(GfTf')f''- (G-gTg')g''-N', where: N and
CC   N' = T or G, equal or different from each other; x = 0-8, equal or
CC   different from each other; a, b, c, d, e, f, and g = 0-10, equal or
CC   different from each other; a', b', c', d', e', f', and g' = 0-30, equal
CC   or different from each other; a'', b'', c'', d'', e'', f'', and g'' = 1-
CC   16, equal or different from each other; The oligonucleotides are believed
CC   to selectively bind and sequester some proteins which are essential to
CC   the viability and growth of tumoural cell line. They have specific and
CC   selective cytotoxic activity against tumour cells, and can be used for
CC   treating tumours of the liquid type, in particular of lymphoblastic
CC   origin, and of solid type, in particular lymphomas. The present
CC   phosphodiester oligonucleotide, at a concentration of 15 micromolar,
CC   reduced growth of CCRF-CEM tumoural cells by 76%, which is detectable 48
CC   hours after administration. (Updated on 25-MAR-2003 to correct PR field.)
XX
SQ   Sequence 26 BP; 0 A; 0 C; 2 G; 24 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 16.4;  DB 1;  Length 26;
  Best Local Similarity   76.9%;  Pred. No. 1.4e+02;
  Matches   20;  Conservative    0;  Mismatches    6;  Indels    0;  Gaps    0;

Qy       1380 TGTTTGTTGTTTGTTTTGTATCTTGT 1405
                | ||| |||||| |||||| | || |
Db          1 TTTTTTTGTTTTTTTTGTTTTTTTT 26


RESULT 23
ABK99308/c
ID   ABK99308 standard; DNA; 21 BP.
XX
AC   ABK99308;
XX
DT   21-OCT-2002  (first entry)
XX
DE   Human CYP3A5 gene PCR primer #12.
XX
KW   Human; CYP3A5; polymorphism; cancer; cardiovascular disease; diabetes;
KW   AIDS; African American; forensic marker; pharmacological; cytostatic;
KW   antidiabetic; anti-HIV; gene therapy; PCR; primer; ss.
XX
OS   Homo sapiens.
XX
PN   WO200253775-A2.
XX
PD   11-JUL-2002.
XX
PF   21-DEC-2001; 2001WO-EP015290.
XX
PR   28-DEC-2000; 2000EP-00128627.
PR   28-DEC-2000; 2000US-0258684P.
PR   29-DEC-2000; 2000US-0258952P.
PR   16-JAN-2001; 2001EP-00100172.
PR   18-JAN-2001; 2001US-0262859P.
PR   16-AUG-2001; 2001EP-00118884.
PR   16-AUG-2001; 2001US-0312825P.
XX
PA   (EPID-) EPIDAUROS BIOTECHNOLOGIE AG.
XX
PI   Wojnowski L,  Haberl M,  Hustert E;
XX
```

DR WPI; 2002-583628/62.
XX
PT Novel CYP3A5 polynucleotide useful for diagnosis and treatment of cancer,
PT cardiovascular diseases, diabetes and AIDS, and for identifying
PT polymorphisms.
XX
PS Example 1; Page 46; 138pp; English.
XX
CC The present invention relates to a new CYP3A5 polynucleotide encoding a
CC polypeptide, where the polynucleotide is capable of hybridising to a
CC CYP3A5 gene. The invention is useful in an in vitro method for
CC identifying a polymorphism. The invention is also useful for useful for
CC diagnosing a disorder related to the presence of a molecular variant of a
CC CYP3A5 or susceptibility to such a disorder, where the disorder is
CC cancer, or diseases including cardiovascular diseases, diabetes and AIDS.
CC The invention can further be used for the preparation of a diagnostic
CC composition for diagnosing a disease in a subject having a genome
CC comprising a variant allele of the CYP3A5 gene, where the subject is an
CC African American. The molecules of the invention are as forensic markers
CC and in pharmacological studies. The present nucleic acid sequence
CC represents a PCR primer that was used in the methods of the invention to
CC screen for polymorphisms in the human CYP3A5 gene
XX
SQ Sequence 21 BP; 4 A; 12 C; 0 G; 5 T; 0 U; 0 Other;

Query Match 0.9%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 1.5e+02;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1469 AAGAGTAGGAAGGGGTGGGTG 1489
| |||| ||||||| ||||||
Db 21 ATGAGTGGGAAGGGATGGGTG 1

RESULT 24
ABA81112
ID ABA81112 standard; DNA; 17 BP.
XX
AC ABA81112;
XX
DT 24-JAN-2002 (first entry)
XX
DE LDLR mutation correcting oligonucleotide SEQ ID NO: 3958.
XX
KW Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;
KW retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;
KW cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
KW adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
KW haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE;
KW mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
KW familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;
KW UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
KW Alzheimer's disease; cytostatic; antisickling; antianaemic; haemostatic;
KW antilipemic; ss.
XX
OS Homo sapiens.
XX
PN WO200173002-A2.
XX
PD 04-OCT-2001.
XX
PF 27-MAR-2001; 2001WO-US009761.
XX
PR 27-MAR-2000; 2000US-0192176P.
PR 27-MAR-2000; 2000US-0192179P.
PR 01-JUN-2000; 2000US-0208538P.
PR 30-OCT-2000; 2000US-0244989P.
XX
PA (UYDE) UNIV DELAWARE.
XX
PI Kmiec EB, Gamper HB, Rice MC;
XX
DR WPI; 2001-639230/73.
XX
PT Oligonucleotide for targeted alterations of genetic sequences and for
PT treating cystic fibrosis, comprises at least one mismatch and chemical
PT modification.
XX
PS Claim 7; Page 257; 294pp; English.
XX
CC The present invention provides single-stranded oligonucleotides which can
CC be used for the targeted alteration of genomic sequences, where the
CC oligonucleotide has at least one mismatch compared with the genomic
CC sequence to be altered. In particular, these sequences are directed at
CC the following genes: adenosine deaminase, p53, beta-globin,
CC retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A
CC (CDKN2A), APC, Factor V, Factor VIII, Factor IX, haemoglobin alpha locus
CC 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,
CC apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase
CC (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and
CC presenilin-2 (PSEN2). These can be used in the gene therapy of diseases
CC such as cancer, adenosine deaminase deficiency, cystic fibrosis,
CC haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia,
CC Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
CC various syndromes. The present sequence is one of the gene correcting
CC oligonucleotides of the invention
XX
SQ Sequence 17 BP; 4 A; 5 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 0.9%; Score 16; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1160 AAGGCTTCCAGCTGGA 1175
||||||||||||||||
Db 1 AAGGCTTCCAGCTGGA 16

RESULT 25
ABA81113/c
ID ABA81113 standard; DNA; 17 BP.
XX
AC ABA81113;
XX
DT 24-JAN-2002 (first entry)
XX
DE LDLR mutation correcting oligonucleotide SEQ ID NO: 3959.
XX
KW Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;
KW retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;
KW cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
KW adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
KW haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE;
KW mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
KW familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;
KW UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
KW Alzheimer's disease; cytostatic; antisickling; antianaemic; haemostatic;
KW antilipemic; ss.
XX
OS Homo sapiens.
XX
PN WO200173002-A2.
XX
PD 04-OCT-2001.
XX
PF 27-MAR-2001; 2001WO-US009761.
XX
PR 27-MAR-2000; 2000US-0192176P.
PR 27-MAR-2000; 2000US-0192179P.
PR 01-JUN-2000; 2000US-0208538P.
PR 30-OCT-2000; 2000US-0244989P.
XX
PA (UYDE) UNIV DELAWARE.
XX
PI Kmiec EB, Gamper HB, Rice MC;
XX

```
DR   WPI; 2001-639230/73.
XX
PT   Oligonucleotide for targeted alterations of genetic sequences and for
PT   treating cystic fibrosis, comprises at least one mismatch and chemical
PT   modification.
XX
PS   Claim 7; Page 257; 294pp; English.
XX
CC   The present invention provides single-stranded oligonucleotides which can
CC   be used for the targeted alteration of genomic sequences, where the
CC   oligonucleotide has at least one mismatch compared with the genomic
CC   sequence to be altered. In particular, these sequences are directed at
CC   the following genes: adenosine deaminase, p53, beta-globin,
CC   retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A
CC   (CDKN2A), APC, Factor V, Factor VIII, Factor IX, haemoglobin alpha locus
CC   1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,
CC   apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase
CC   (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and
CC   presenilin-2 (PSEN2). These can be used in the gene therapy of diseases
CC   such as cancer, adenosine deaminase deficiency, cystic fibrosis,
CC   haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia,
CC   Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
CC   various syndromes. The present sequence is one of the gene correcting
CC   oligonucleotides of the invention
XX
SQ   Sequence 17 BP; 3 A; 5 C; 5 G; 4 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 16;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+02;
  Matches   16;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1160 AAGGCTTCCAGCTGGA 1175
              ||||||||||||||||
Db         17 AAGGCTTCCAGCTGGA 2


RESULT 26
AAT87932
ID   AAT87932 standard; cDNA; 19 BP.
XX
AC   AAT87932;
XX
DT   18-DEC-1997  (first entry)
XX
DE   Primer for rat cerebellum derived growth factor 1 cDNA.
XX
KW   Rat; cerebellum derived growth factor; CDGF1; screening; binding;
KW   modulation; erbB type receptor; identification; indication; risk;
KW   proliferation; differentiation; induction; neuron; hyperplasia;
KW   stem cell culture; intracerebral graft; alleviation; repair;
KW   behavioural defect; nervous system; central; peripheral; nerve;
KW   prothesis; damage; entubulation; cell survival; treatment; injury;
KW   trauma; ischaemia; ischemia; stroke; infection; disorder; inflammation;
KW   neurodegeneration; disease; Parkinson's; Huntingdon's;
KW   amylotrophic lateral sclerosis; sensory; retina;
KW   spinocerebellar degeneration; multiple sclerosis; neoplasia;
KW   amalignant glioma; medulloblastoma; neuroectodermal tumour; primer;
KW   polymerase chain reaction; PCR; amplification; ss.
XX
OS   Synthetic.
XX
PN   WO9709425-A1.
XX
PD   13-MAR-1997.
XX
PF   09-SEP-1996;   96WO-US014484.
XX
PR   08-SEP-1995;   95US-00525864.
XX
PA   (HARD ) HARVARD COLLEGE.
PA   (STRD ) UNIV LELAND S STANFORD.
XX
PI   Chang H;
XX
DR   WPI; 1997-192900/17.
XX
PT   Rat and human cerebellum-derived growth factors - used in the treatment
PT   of neuronal injury and proliferative disorders.
XX
PS   Example; Page 57; 94pp; English.
XX
CC   The present sequence is a primer for the PCR amplification of rat
CC   cerebellum derived growth factor 1 (CDGF1) cDNA. CDGF can be used to
CC   screen for modulators of CDGF binding to erbB type receptors.
CC   Identification of a modification or mutation in a CDGF gene, or aberrant
CC   expression of a CDGF gene or levels of soluble CDGF may be used to
CC   indicate the risk of unwanted cell proliferation or differentiation. CDGF
CC   may be used to induce neuronal differentiation in stem cell culture, and
CC   maintain the integrity of a terminally differentiated neuronal cell
CC   culture, e.g. useful for intracerebral grafting to alleviate behavioural
CC   defects. CDGF may also be used in nerve protheses to repair central and
CC   peripheral nerve damage, especially where a crushed or severed axon is
CC   entubulated by a prosthetic. CDGF may also be used to enhance neuronal
CC   cell survival in the central or peripheral nervous system, to treat
CC   neurological conditions associated with nervous system injury, e.g.
CC   traumatic, chemical or vasal injury and deficits such as ischaemia
CC   resulting from stroke, infectious/inflammatory and tumour induced injury,
CC   chronic neurodegenerative disease including Parkinson's and Huntingdon's,
CC   amylotrophic lateral sclerosis, spinocerebellar degeneration, chronic
CC   immunological disease of the nervous system including multiple sclerosis,
CC   disorders of the sensory neurons and degenerative diseases of the retina.
CC   CDGF may also be used to treat neoplastic or hyperplastic
CC   transformations, particularly of the central nervous system, e.g.
CC   amalignant gliomas, medulloblastomas and neuroectodermal tumours
XX
SQ   Sequence 19 BP; 5 A; 4 C; 8 G; 2 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+02;
  Matches   16;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         19 GAATTCGGCACGAGGG 34
              ||||||||||||||||
Db          1 GAATTCGGCACGAGGG 16


RESULT 27
AAS45641/c
ID   AAS45641 standard; DNA; 20 BP.
XX
AC   AAS45641;
XX
DT   18-DEC-2001  (first entry)
XX
DE   Human PARP-1 antisense inhibitor ISIS #126002.
XX
KW   Human; ss; PARP; Poly (ADP-ribose) polymerase; antisense oligonucleotide;
KW   cytostatic; nootropic; neuroprotective; antiinflammatory; antidiabetic;
KW   immunosuppressant; hyperproliferative disorder; cancer; cellular injury;
KW   oxidative stress; neurological disorder; parkinsonism; apoptosis;
KW   meningitis-associated intracranial complication; ischaemia; probe;
KW   inflammatory disorder; autoimmune disorder; arthritis; diabetes.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate backbone"
FT   modified_base   1. .20
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "All cytidine residues are 5-methyl cytidine"
FT   modified_base   1. .5
FT                   /*tag=  c
```

```
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl nucleotides"
FT   modified_base   16. .20
FT                   /*tag=  d
FT                   /mod_base= OTHER
FT                   /note= "2' methoxyethyl nucleotides"
XX
PN   WO200164955-A1.
XX
PD   07-SEP-2001.
XX
PF   01-MAR-2001; 2001WO-US006572.
XX
PR   02-MAR-2000; 2000US-00517467.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Popoff I,  Cowsert LM;
XX
DR   WPI; 2001-602570/68.
XX
PT   Antisense compound useful for treating hyperproliferative, neurological,
PT   inflammatory and autoimmune disorders and diabetes inhibits human PARP.
XX
PS   Example 15; Page 83; 168pp; English.
XX
CC   The invention relates to antisense oligonucleotides targeted to human
CC   PARP nucleic acid and inhibiting expression of human PARP. PARP (Poly
CC   (ADP-ribose) polymerase plays an important role in chromatin
CC   decondensation, DNA replication, DNA repair, gene expression, malignant
CC   transformation, cellular differentiation and apoptosis. The antisense
CC   oligonucleotide inhibitors are useful for inhibiting the expression of
CC   PARP in human cells or tissues. They are also useful for treating a human
CC   with a disease associated with PARP especially hyperproliferative
CC   disorders (e.g. cancer), cellular injury resulting from oxidative stress,
CC   neurological (e.g parkinsonism, meningitis-associated intracranial
CC   complications and ischaemia) , inflammatory and autoimmune disorders (e.g
CC   arthritis) and diabetes. The present sequence is an antisense
CC   oligonucleotide of the invention
XX
SQ   Sequence 20 BP; 2 A; 6 C; 7 G; 5 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+02;
  Matches   16;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1153 GGCCAACAAGGCTTCC 1168
              ||||||||||||||||
Db         16 GGCCAACAAGGCTTCC 1


RESULT 28
AAH20641/c
ID   AAH20641 standard; DNA; 20 BP.
XX
AC   AAH20641;
XX
DT   13-AUG-2001  (first entry)
XX
DE   Human telomeric repeat binding factor 2 oligonucleotide 111369.
XX
KW   Antisense; phosphorothioate; human; telomeric repeat binding factor 2;
KW   inhibitor; premature aging; hyperproliferative disorder; cancer;
KW   cytostatic; ss.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "phosphorothioate backbone"
FT   modified_base   1. .3
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "2-O-methoxyethyl"
FT   modified_base   13. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "2-O-methoxyethyl"
XX
PN   WO200143752-A1.
XX
PD   21-JUN-2001.
XX
PF   14-DEC-2000; 2000WO-US033954.
XX
PR   17-DEC-1999;   99US-00467642.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP,  Cowsert LM;
XX
DR   WPI; 2001-398071/42.
XX
PT   Antisense compounds targeted to nucleic acid encoding telomeric repeat
PT   binding factor 2 useful for treating conditions such as premature aging
PT   and diseases such as cancer.
XX
PS   Example 15; Page 79; 108pp; English.
XX
CC   This invention describes a novel antisense compound (I) 8-30 nucleobases
CC   in length targeted to a polynucleotide encoding human telomeric repeat
CC   binding factor 2 (II) which specifically hybridizes with, and inhibits
CC   the expression of (II). (I) is useful for treating a human having a
CC   disease or condition associated with (II) such as premature aging or a
CC   hyperproliferative disorder especially cancer, by inhibiting the
CC   expression of (II) in human cells or tissues. (I) is useful for
CC   diagnostics, therapeutics, prophylaxis and as research reagents and kits.
CC   The products of the invention have cytostatic activity. This sequence
CC   represents an antisense oligonucleotide used to illustrate the method of
CC   the invention
XX
SQ   Sequence 20 BP; 2 A; 9 C; 4 G; 5 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+02;
  Matches   16;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         19 GAATTCGGCACGAGGG 34
              ||||||||||||||||
Db         19 GAATTCGGCACGAGGG 4


RESULT 29
AAF98935
ID   AAF98935 standard; DNA; 24 BP.
XX
AC   AAF98935;
XX
DT   12-JUN-2001  (first entry)
XX
DE   Immunostimulatory nucleic acid #51.
XX
KW   Vaccine; cytostatic; virucidal; bactericidal; fungicidal; anti-parasitic;
KW   immunostimulatory; tumour; viral infection; bacterial infection;
KW   fungal infection; parasitic infection; cancer; asthma;
KW   infectious disease; allergy; immune deficiency; phosphorothioate; ss.
XX
OS   Synthetic.
XX
PN   WO200122972-A2.
XX
PD   05-APR-2001.
XX
PF   25-SEP-2000; 2000WO-US026383.
```

XX
PR 25-SEP-1999; 99US-0156113P.
PR 27-SEP-1999; 99US-0156135P.
PR 23-AUG-2000; 2000US-0227436P.
XX
PA (IOWA) UNIV IOWA RES FOUND.
PA (COLE-) COLEY PHARM GMBH.
XX
PI Krieg AM, Schetter C, Vollmer J;
XX
DR WPI; 2001-273485/28.
XX
PT Vaccinating against tumors, infectious diseases, allergies and asthma
PT using immunostimulatory Py-rich and TG nucleic acids.
XX
PS Disclosure; Page 39; 338pp; English.
XX
CC The present invention relates to a method for stimulating an immune
CC response. The method comprises administering an immunostimulatory nucleic
CC acid to a non-rodent subject in sufficient quantity to stimulate an
CC immune response. The present sequence is one such immunostimulatory
CC nucleic acid. The immunostimulatory nucleic acids can be pyrimidine rich
CC (py-rich) or thymidine (T) rich. The method is used to vaccinate subjects
CC against tumour antigens, viral antigens (e.g. herpesviridae, retroviridae
CC and/or orthomyxoviridae), bacterial antigens (e.g. toxoplasma,
CC haemophilus, campylobacter, clostridium, Escherichia coli and/or
CC staphylococcus), fungal antigens and/or parasitic antigens. The method is
CC also useful for preventing cancer, asthma, infectious disease, allergy or
CC immune deficiency. The present sequence can also be used to redirect a
CC Th2 to a Th1 immune response and to activate immune cells. Note: the
CC present sequence may have a phosphorothioate backbone
XX
SQ Sequence 24 BP; 0 A; 0 C; 3 G; 21 T; 0 U; 0 Other;

Query Match 0.9%; Score 16; DB 1; Length 24;
Best Local Similarity 79.2%; Pred. No. 1.6e+02;
Matches 19; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

Qy 1386 TTGTTTGTTTTGTATCTTGTTTTT 1409
||||||||| | | ||||||||
Db 1 TTGTTTTTTTGTTTTTTTGTTTTT 24

RESULT 30
ABS77576
ID ABS77576 standard; DNA; 24 BP.
XX
AC ABS77576;
XX
DT 13-DEC-2002 (first entry)
XX
DE Angiogenesis inhibitory oligonucleotide #60.
XX
KW Angiogenesis inhibitor; ss; angiogenesis; solid tumour growth;
KW tumour metastasis; precancerous lesion; rheumatoid arthritis; psoriasis;
KW diabetic retinopathy; retinopathy of prematurity; macular degeneration;
KW corneal graft rejection; neovascular glaucoma; retrolental fibroplasia;
KW rubeosis; Osler-Webber Syndrome; myocardial angiogenesis;
KW plaque neovascularisation; telangiectasia; haemophiliac joint;
KW angiofibroma; wound granulation; intestinal adhesion; atherosclerosis;
KW scleroderma; hypertrophic scar.
XX
OS Synthetic.
XX
PN WO200253141-A2.
XX
PD 11-JUL-2002.
XX
PF 14-DEC-2001; 2001WO-US048458.
XX
PR 14-DEC-2000; 2000US-0255534P.
XX
PA (COLE-) COLEY PHARM GROUP INC.
XX
PI Bratzler RL;
XX
DR WPI; 2002-566690/60.
XX
PT Inhibiting angiogenesis in a subject, involves administering at least one
PT antiangiogenic nucleic acid molecule to the subject.
XX
PS Claim 2; Page 20; 276pp; English.
XX
CC The invention relates to inhibiting angiogenesis in a subject, comprising
CC administering at least one antiangiogenic nucleic acid molecule. Also
CC included is a kit comprising a first container housing the antiangiogenic
CC nucleic acids, and instructions for administering them to a subject
CC having a condition characterised by unwanted angiogenesis. The method is
CC useful for inhibiting angiogenesis associated with solid tumour growth,
CC tumour metastasis, precancerous lesion, rheumatoid arthritis, psoriasis,
CC diabetic retinopathy, retinopathy of prematurity, macular degeneration,
CC corneal graft rejection, neovascular glaucoma, retrolental fibroplasia,
CC rubeosis, Osler-Webber Syndrome, myocardial angiogenesis, plaque
CC neovascularisation, telangiectasia, haemophiliac joints, angiofibroma,
CC wound granulation, intestinal adhesions, atherosclerosis, scleroderma and
CC hypertrophic scars. The present sequence is an antiangiogenic nucleic
CC acid of the invention
XX
SQ Sequence 24 BP; 0 A; 0 C; 3 G; 21 T; 0 U; 0 Other;

Query Match 0.9%; Score 16; DB 1; Length 24;
Best Local Similarity 79.2%; Pred. No. 1.6e+02;
Matches 19; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

Qy 1386 TTGTTTGTTTTGTATCTTGTTTTT 1409
||||||||| | | ||||||||
Db 1 TTGTTTTTTTGTTTTTTTGTTTTT 24

RESULT 31
ACD99368
ID ACD99368 standard; DNA; 24 BP.
XX
AC ACD99368;
XX
DT 25-SEP-2003 (first entry)
XX
DE Immunostimulatory nucleic acid #54.
XX
KW Immunostimulatory; antiinflammatory; dermatological; antipsoriatic;
KW antiulcer; gene therapy; vaccine; non-allergic inflammatory disease;
KW psoriasis; eczema; allergic contact dermatitis; latex dermatitis;
KW inflammatory bowel disease; ulcerative colitis; Crohn's disease; ss.
XX
OS Synthetic.
XX
PN US2003050268-A1.
XX
PD 13-MAR-2003.
XX
PF 29-MAR-2002; 2002US-00112653.
XX
PR 29-MAR-2001; 2001US-0279642P.
XX
PA (KRIE/) KRIEG A M.
PA (BERG/) BERG D J.
XX
PI Krieg AM, Berg DJ;
XX
DR WPI; 2003-521815/49.
XX
PT Treating non-allergic inflammatory diseases, such as psoriasis, eczema,
PT allergic contact dermatitis, latex dermatitis or inflammatory bowel
PT disease by administering an immunostimulatory nucleic acid.
XX
PS Disclosure; Page 10; 229pp; English.

```
XX
CC   The invention describes a method of treating non-allergic inflammatory
CC   disease comprising administering to a subject having or at risk of
CC   developing a non-allergic inflammatory disease an immunostimulatory
CC   nucleic acid for prevention or treatment of the disease. The method is
CC   useful for treating non-allergic inflammatory diseases, such as
CC   psoriasis, eczema, allergic contact dermatitis, latex dermatitis or
CC   inflammatory bowel disease e.g., ulcerative colitis or Crohn's disease.
CC   This sequence represents an immunostimulatory nucleic acid
XX
SQ   Sequence 24 BP; 0 A; 0 C; 3 G; 21 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 16;  DB 1;  Length 24;
  Best Local Similarity   79.2%;  Pred. No. 1.6e+02;
  Matches   19;  Conservative    0;  Mismatches    5;  Indels    0;  Gaps    0;

Qy       1386 TTGTTTGTTTTGTATCTTGTTTTT 1409
             |||||| |||  | | ||||||||
Db          1 TTGTTTTTTTGTTTTTTTGTTTTT 24


RESULT 32
ADB36437
ID   ADB36437 standard; DNA; 24 BP.
XX
AC   ADB36437;
XX
DT   04-DEC-2003  (first entry)
XX
DE   Immunostimulatory nucleic acid #51.
XX
KW   ds; allergy; asthma; poly-G nucleic acid; aerosol formulation;
KW   hypo-responsive subject; immunostimulatory.
XX
OS   Synthetic.
XX
PN   US2003087848-A1.
XX
PD   08-MAY-2003.
XX
PF   02-FEB-2001; 2001US-00776479.
XX
PR   03-FEB-2000; 2000US-0179991P.
XX
PA   (BRAT/) BRATZLER R L.
PA   (PETE/) PETERSEN D M.
PA   (FOUR/) FOURON Y.
XX
PI   Bratzler RL,  Petersen DM,  Fouron Y;
XX
DR   WPI; 2003-657977/62.
XX
PT   Treating and/or preventing allergy or asthma using an immunostimulatory
PT   nucleic acid alone or in combination with an asthma/allergy medicament.
XX
PS   Disclosure; Page 6; 221pp; English.
XX
CC   The invention relates to a method of treating or preventing allergy or
CC   asthma which comprises administering to a subject a poly-G nucleic acid
CC   in an aerosol formulation. The methods and compositions of the present
CC   invention are useful for diagnosing and/or treating asthma and allergy
CC   especially in a hypo-responsive subject. The present sequence represents
CC   an immunostimulatory nucleic acid of the invention.
XX
SQ   Sequence 24 BP; 0 A; 0 C; 3 G; 21 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 16;  DB 1;  Length 24;
  Best Local Similarity   79.2%;  Pred. No. 1.6e+02;
  Matches   19;  Conservative    0;  Mismatches    5;  Indels    0;  Gaps    0;

Qy       1386 TTGTTTGTTTTGTATCTTGTTTTT 1409
             |||||| |||  | | ||||||||
Db          1 TTGTTTTTTTGTTTTTTTGTTTTT 24


RESULT 33
ADG75924
ID   ADG75924 standard; DNA; 24 BP.
XX
AC   ADG75924;
XX
DT   11-MAR-2004  (first entry)
XX
DE   Immunostimulatory non-CpG oligonucleotide IMT 179 SeqID 26.
XX
KW   ss; non-CpG; immunostimulatory; non-palindromic; immune response;
KW   proliferation; differentiation; cytokine; antibody production; B-cell;
KW   plasmacytoid dendritic cell; immunomodulator; gene therapy;
KW   chronic myelogenous leukaemia; melanoma; Kaposi's sarcoma;
KW   renal cell carcinoma.
XX
OS   Synthetic.
XX
PN   WO2003101375-A2.
XX
PD   11-DEC-2003.
XX
PF   30-MAY-2003; 2003WO-EP005691.
XX
PR   30-MAY-2002; 2002CA-02388049.
XX
PA   (IMMU-) IMMUNOTECH SA.
XX
PI   Lopez RA;
XX
DR   WPI; 2004-053333/05.
XX
PT   New immunostimulatory oligonucleotide comprising non-palindromic nucleic
PT   acid sequence motif, useful for inducing B-cell activation, treating,
PT   preventing or ameliorating immune system disorder or tumoral disease e.g.
PT   melanoma.
XX
PS   Claim 14; SEQ ID NO 26; 139pp; English.
XX
CC   This invention relates to novel immunostimulatory oligonucleotides that
CC   contain a non-palindromic sequence motif. Specifically, it refers to DNA
CC   oligonucleotides (without a CpG motif), which can stimulate an immune
CC   response in animals of the order of primate, including humans. The immune
CC   response is characterised by the proliferation, differentiation, cytokine
CC   and antibody production in B-cells, as well as cell differentiation and
CC   cytokine production in plasmacytoid dendritic cells. The present
CC   invention describes immunomodulator compositions that also comprise an
CC   antigen selected from, for example, viruses, bacteria, parasites, tumour
CC   cells and glycolipids. As such, these DNA oligos can be used in gene
CC   therapy for inducing B-cell activation, treating, preventing or
CC   ameliorating an immune system disorder or a tumoural disease including
CC   chronic myelogenous leukaemia, melanoma, Kaposi's sarcoma, and renal cell
CC   carcinoma. This oligonucleotide sequence is an immunostimulatory non-CpG
CC   variant DNA oligo, used in an exemplification of the invention.
XX
SQ   Sequence 24 BP; 1 A; 1 C; 1 G; 21 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 16;  DB 1;  Length 24;
  Best Local Similarity   79.2%;  Pred. No. 1.6e+02;
  Matches   19;  Conservative    0;  Mismatches    5;  Indels    0;  Gaps    0;

Qy       1386 TTGTTTGTTTTGTATCTTGTTTTT 1409
             || ||| ||||  || ||||||||
Db          1 TTTTTTTTTTTTCATTTGTTTTT 24


RESULT 34
ADG76001
ID   ADG76001 standard; DNA; 24 BP.
XX
AC   ADG76001;
```

XX
DT 11-MAR-2004 (first entry)
XX
DE Non-CpG DNA oligonucleotide 2.
XX
KW ss; non-CpG; immunostimulatory; non-palindromic; immune response;
KW proliferation; differentiation; cytokine; antibody production; B-cell;
KW plasmacytoid dendritic cell; immunomodulator; gene therapy;
KW chronic myelogenous leukaemia; melanoma; Kaposi's sarcoma;
KW renal cell carcinoma.
XX
OS Synthetic.
XX
PN WO2003101375-A2.
XX
PD 11-DEC-2003.
XX
PF 30-MAY-2003; 2003WO-EP005691.
XX
PR 30-MAY-2002; 2002CA-02388049.
XX
PA (IMMU-) IMMUNOTECH SA.
XX
PI Lopez RA;
XX
DR WPI; 2004-053333/05.
XX
PT New immunostimulatory oligonucleotide comprising non-palindromic nucleic
PT acid sequence motif, useful for inducing B-cell activation, treating,
PT preventing or ameliorating immune system disorder or tumoral disease e.g.
PT melanoma.
XX
PS Example 17; Page 80; 139pp; English.
XX
CC This invention relates to novel immunostimulatory oligonucleotides that
CC contain a non-palindromic sequence motif. Specifically, it refers to DNA
CC oligonucleotides (without a CpG motif), which can stimulate an immune
CC response in animals of the order of primate, including humans. The immune
CC response is characterised by the proliferation, differentiation, cytokine
CC and antibody production in B-cells, as well as cell differentiation and
CC cytokine production in plasmacytoid dendritic cells. The present
CC invention describes immunomodulator compositions that also comprise an
CC antigen selected from, for example, viruses, bacteria, parasites, tumour
CC cells and glycolipids. As such, these DNA oligos can be used in gene
CC therapy for inducing B-cell activation, treating, preventing or
CC ameliorating an immune system disorder or a tumoural disease including
CC chronic myelogenous leukaemia, melanoma, Kaposi's sarcoma, and renal cell
CC carcinoma. This oligonucleotide sequence is a non-CpG DNA oligo of the
CC invention.
XX
SQ Sequence 24 BP; 0 A; 0 C; 3 G; 21 T; 0 U; 0 Other;

Query Match 0.9%; Score 16; DB 1; Length 24;
Best Local Similarity 79.2%; Pred. No. 1.6e+02;
Matches 19; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

```
Qy       1386 TTGTTTGTTTTGTATCTTGTTTTT 1409
              |||||| |||  | | ||||||||
Db          1 TTGTTTTTTTGTTTTTTGTTTTT 24
```

RESULT 35
ADG76035
ID ADG76035 standard; DNA; 24 BP.
XX
AC ADG76035;
XX
DT 11-MAR-2004 (first entry)
XX
DE Non-CpG DNA oligonucleotide 36.
XX
KW ss; non-CpG; immunostimulatory; non-palindromic; immune response;
KW proliferation; differentiation; cytokine; antibody production; B-cell;
KW plasmacytoid dendritic cell; immunomodulator; gene therapy;
KW chronic myelogenous leukaemia; melanoma; Kaposi's sarcoma;
KW renal cell carcinoma.
XX
OS Synthetic.
XX
PN WO2003101375-A2.
XX
PD 11-DEC-2003.
XX
PF 30-MAY-2003; 2003WO-EP005691.
XX
PR 30-MAY-2002; 2002CA-02388049.
XX
PA (IMMU-) IMMUNOTECH SA.
XX
PI Lopez RA;
XX
DR WPI; 2004-053333/05.
XX
PT New immunostimulatory oligonucleotide comprising non-palindromic nucleic
PT acid sequence motif, useful for inducing B-cell activation, treating,
PT preventing or ameliorating immune system disorder or tumoral disease e.g.
PT melanoma.
XX
PS Example 17; Page 81; 139pp; English.
XX
CC This invention relates to novel immunostimulatory oligonucleotides that
CC contain a non-palindromic sequence motif. Specifically, it refers to DNA
CC oligonucleotides (without a CpG motif), which can stimulate an immune
CC response in animals of the order of primate, including humans. The immune
CC response is characterised by the proliferation, differentiation, cytokine
CC and antibody production in B-cells, as well as cell differentiation and
CC cytokine production in plasmacytoid dendritic cells. The present
CC invention describes immunomodulator compositions that also comprise an
CC antigen selected from, for example, viruses, bacteria, parasites, tumour
CC cells and glycolipids. As such, these DNA oligos can be used in gene
CC therapy for inducing B-cell activation, treating, preventing or
CC ameliorating an immune system disorder or a tumoural disease including
CC chronic myelogenous leukaemia, melanoma, Kaposi's sarcoma, and renal cell
CC carcinoma. This oligonucleotide sequence is a non-CpG DNA oligo of the
CC invention.
XX
SQ Sequence 24 BP; 0 A; 0 C; 3 G; 21 T; 0 U; 0 Other;

Query Match 0.9%; Score 16; DB 1; Length 24;
Best Local Similarity 79.2%; Pred. No. 1.6e+02;
Matches 19; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

```
Qy       1386 TTGTTTGTTTTGTATCTTGTTTTT 1409
              |||||| |||  | | ||||||||
Db          1 TTGTTTTTTTGTTTTTTGTTTTT 24
```

RESULT 36
ADG75971
ID ADG75971 standard; DNA; 24 BP.
XX
AC ADG75971;
XX
DT 11-MAR-2004 (first entry)
XX
DE Immunostimulatory non-CpG phosphorothioate DNA oligo IMT179 SeqID73.
XX
KW ss; non-CpG; immunostimulatory; non-palindromic; immune response;
KW proliferation; differentiation; cytokine; antibody production; B-cell;
KW plasmacytoid dendritic cell; immunomodulator; gene therapy;
KW chronic myelogenous leukaemia; melanoma; Kaposi's sarcoma;
KW renal cell carcinoma.
XX
OS Synthetic.
XX
PN WO2003101375-A2.

XX
PD 11-DEC-2003.
XX
PF 30-MAY-2003; 2003WO-EP005691.
XX
PR 30-MAY-2002; 2002CA-02388049.
XX
PA (IMMU-) IMMUNOTECH SA.
XX
PI Lopez RA;
XX
DR WPI; 2004-053333/05.
XX
PT New immunostimulatory oligonucleotide comprising non-palindromic nucleic
PT acid sequence motif, useful for inducing B-cell activation, treating,
PT preventing or ameliorating immune system disorder or tumoral disease e.g.
PT melanoma.
XX
PS Example 5; SEQ ID NO 73; 139pp; English.
XX
CC This invention relates to novel immunostimulatory oligonucleotides that
CC contain a non-palindromic sequence motif. Specifically, it refers to DNA
CC oligonucleotides (without a CpG motif), which can stimulate an immune
CC response in animals of the order of primate, including humans. The immune
CC response is characterised by the proliferation, differentiation, cytokine
CC and antibody production in B-cells, as well as cell differentiation and
CC cytokine production in plasmacytoid dendritic cells. The present
CC invention describes immunomodulator compositions that also comprise an
CC antigen selected from, for example, viruses, bacteria, parasites, tumour
CC cells and glycolipids. As such, these DNA oligos can be used in gene
CC therapy for inducing B-cell activation, treating, preventing or
CC ameliorating an immune system disorder or a tumoural disease including
CC chronic myelogenous leukaemia, melanoma, Kaposi's sarcoma, and renal cell
CC carcinoma. This oligonucleotide sequence is an immunostimulatory
CC phosphorothioate non-CpG variant DNA oligo, used to determine the effect
CC of oligo size on B cell proliferation and IL6 secretion in an
CC exemplification of the invention.
XX
SQ Sequence 24 BP; 1 A; 1 C; 1 G; 21 T; 0 U; 0 Other;

Query Match 0.9%; Score 16; DB 1; Length 24;
Best Local Similarity 79.2%; Pred. No. 1.6e+02;
Matches 19; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

```
Qy       1386 TTGTTTGTTTTGTATCTTGTTTTT 1409
              || ||| ||||  || ||||||||
Db          1 TTTTTTTTTTTCATTTTGTTTTT 24
```

RESULT 37
AAZ07017/c
ID AAZ07017 standard; DNA; 24 BP.
XX
AC AAZ07017;
XX
DT 09-NOV-1999 (first entry)
XX
DE Murine alpha-L-iduronidase genomic DNA oligonucleotide #3.
XX
KW Murine; mouse; alpha-L-iduronidase; IDUA; hepatic sulphate transporter;
KW SAT-1; mucopolysaccharidosis type I; MPS I; transgenic mouse;
KW cell-specific targeting system; tissue-specific targeting system;
KW lysosomal disorder; ss.
XX
OS Mus sp.
XX
PN CA2205710-A.
XX
PD 20-NOV-1997.
XX
PF 20-MAY-1997; 97CA-02205710.
XX
PR 20-MAY-1996; 96US-0017156P.
XX
PA (UYBR-) UNIV BRITISH COLUMBIA.
PA (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI Jirik F, Clarke LA;
XX
DR WPI; 1999-494691/42.
XX
PT New transgenic mouse, useful for modeling lysosomal disorders and testing
PT cell- or tissue-specific targeting systems.
XX
PS Example 3; Page 12; 20pp; English.
XX
CC The present invention describes a mouse (I), homozygous for a disruption
CC in the alpha-L-iduronidase (IDUA) gene but with normal expression of the
CC hepatic sulphate transporter SAT-1 gene. (I) is used to evaluate
CC therapeutic agents for use in treating mucopolysaccharidosis Type I (MPS
CC I) by administering the agent to (I) and evaluating the mouse for
CC pathology associated with iduronidase deficiency. (I) may also be used to
CC evaluate the ability of a targeting system to deliver a therapeutic agent
CC to a specific tissue or organ in the mouse using the same techniques.
CC Targeting systems which may be tested using this regime include a target-
CC specific label, a viral expression vector or a liposome coupled to
CC iduronidase. (I) may also be used as a general model for studying the
CC pathology of MPS I. The SAT-1 gene overlaps with the IDUA gene but in (I)
CC the expression of the SAT-1 gene is unaffected. Therefore any
CC pathological effects observed in (I) are due solely to the disruption of
CC the IDUA gene. The present sequence represents a IDUA genomic DNA
CC oligonucleotide used in the exemplification of the present invention
XX
SQ Sequence 24 BP; 20 A; 4 C; 0 G; 0 T; 0 U; 0 Other;

Query Match 0.9%; Score 16; DB 1; Length 24;
Best Local Similarity 79.2%; Pred. No. 1.6e+02;
Matches 19; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

```
Qy       1384 TGTTGTTTGTTTTGTATCTTGTTT 1407
              |||| | | |||||| | ||||||
Db         24 TGTTTTGTTTTTTGTTTTTTGTTT 1
```

RESULT 38
AAV12482/c
ID AAV12482 standard; DNA; 26 BP.
XX
AC AAV12482;
XX
DT 15-MAY-1998 (first entry)
XX
DE Oligonucleotide SEQ ID NO:5 from US5174320 Example 2.
XX
KW Synthesis; selection; amplification; circular oligonucleotide;
KW rolling circle synthesis; diagnosis; therapeutic agent; ss.
XX
OS Synthetic.
XX
PN US5714320-A.
XX
PD 03-FEB-1998.
XX
PF 23-FEB-1995; 95US-00393439.
XX
PR 15-APR-1993; 93US-00047860.
XX
PA (UYRP) UNIV ROCHESTER.
XX
PI Kool ET;
XX
DR WPI; 1998-144278/13.
XX
PT Rolling circle synthesis of oligo:nucleotide(s) - using primed circular
PT template to produce oligonucleotide multimer for cleavage.
XX

```
PS   Example 2; Col 45; 38pp; English.
XX
CC   The present sequence represents an oligonucleotide used in an example of
CC   the present invention. The present invention describes a method for
CC   synthesising a selected oligonucleotide (I) having well defined ends. The
CC   method comprises: (a) annealing a primer to a single-stranded (ss)
CC   circular template to yield a primed circular template, where the template
CC   comprises: (i) at least one nucleotide sequence complementary to (I); and
CC   (ii) at least one nucleotide effective to produce a cleavage site in the
CC   oligonucleotide multimer; (b) combining the primed circular template with
CC   at least two types of nucleotide triphosphates and a polymerase enzyme
CC   without the addition of auxiliary proteins to yield a ss oligonucleotide
CC   multimer complementary to the circular oligonucleotide template,
CC   comprising multiple copies of (I); and (c) cleaving the oligonucleotide
CC   multimer at the cleavage site to produce (I) having well defined ends.
CC   The method is used for the large-scale synthesis of DNA and RNA oligomers
CC   for use, e.g. as probes and diagnostic agents and/or therapeutic agents
XX
SQ   Sequence 26 BP; 24 A; 2 C; 0 G; 0 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 16;  DB 1;  Length 26;
  Best Local Similarity   79.2%;  Pred. No. 1.6e+02;
  Matches   19;  Conservative    0;  Mismatches    5;  Indels    0;  Gaps    0;

Qy       1386 TTGTTTGTTTTGTATCTTGTTTTT 1409
              || ||| |||||| | || |||||
Db         25 TTTTTTTTTTTGTTTTTTTTTTT 2


RESULT 39
AAV59215/c
ID   AAV59215 standard; DNA; 26 BP.
XX
AC   AAV59215;
XX
DT   14-DEC-1998  (first entry)
XX
DE   Circular template for linear oligomer dT12.
XX
KW   ss; circular; cyclic; RNA oligonucleotide; probe; standard; diagnostic;
KW   therapeutic agent.
XX
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   misc_binding    1
FT                   /*tag=  a
FT                   /note= "Position 1 optionally bound to position 26"
FT   misc_binding    26
FT                   /*tag=  b
FT                   /note= "Position 26 optionally bound to position 1"
XX
PN   WO9838300-A1.
XX
PD   03-SEP-1998.
XX
PF   26-FEB-1998;   98WO-US003784.
XX
PR   26-FEB-1997;   97US-00805631.
XX
PA   (UYRP ) UNIV ROCHESTER.
XX
PI   Kool ET;
XX
DR   WPI; 1998-481202/41.
XX
PT   Synthesis of oligo:nucleotide(s) - using a single-stranded circular
PT   oligo:nucleotide template ribonucleotide tri:phosphate(s) and a
PT   polymerase to form multimer(s) which can be cleaved.
XX
PS   Example 2; Page 36; 100pp; English.
XX
CC   The circular template was used for the synthesis of the oligomer dT12 in
CC   an example of the method of the invention for synthesising an RNA
CC   oligonucleotide, comprising combining a single-stranded circular
CC   oligonucleotide template comprising at least one copy of a nucleotide
CC   sequence complementary to the sequence of the desired RNA oligonucleotide
CC   with at least 2 types of ribonucleotide triphosphate and a polymerase
CC   enzyme to yield a single-stranded RNA oligonucleotide multimer
CC   complementary to the circular oligonucleotide template, where the RNA
CC   oligonucleotide multimer comprises multiple copies of the desired RNA
CC   oligonucleotide. The methods can be used for producing RNA
CC   oligonucleotides having a specific sequence and well defined ends. The
CC   RNA oligonucleotides produced can be used as probes, standards and
CC   diagnostic or therapeutic agents. They can be used for modifying the
CC   structure or function of a target molecule. They can also be used to
CC   cleave disease-associated RNA, DNA or protein
XX
SQ   Sequence 26 BP; 24 A; 2 C; 0 G; 0 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 16;  DB 1;  Length 26;
  Best Local Similarity   79.2%;  Pred. No. 1.6e+02;
  Matches   19;  Conservative    0;  Mismatches    5;  Indels    0;  Gaps    0;

Qy       1386 TTGTTTGTTTTGTATCTTGTTTTT 1409
              || ||| |||||| | || |||||
Db         25 TTTTTTTTTTTGTTTTTTTTTTT 2


RESULT 40
AAX30018/c
ID   AAX30018 standard; DNA; 26 BP.
XX
AC   AAX30018;
XX
DT   16-JUN-1999  (first entry)
XX
DE   Precircle DNA oligonucleotide SEQ ID NO:5.
XX
KW   Multimer; probe; diagnosis; synthesis; detection; polymerase; ss.
XX
OS   Synthetic.
XX
PN   WO9909216-A2.
XX
PD   25-FEB-1999.
XX
PF   13-AUG-1998;   98WO-US016776.
XX
PR   13-AUG-1997;   97US-00910632.
XX
PA   (UYRP ) UNIV ROCHESTER.
XX
PI   Kool ET;
XX
DR   WPI; 1999-181062/15.
XX
PT   New detectably labelled oligonucleotide multimer, comprising multiple
PT   contiguous copies of a repeated oligonucleotide - useful for detecting
PT   target molecules in diagnosis and medicinal applications.
XX
PS   Example 2; Page 41; 103pp; English.
XX
CC   The present invention describes a detectably labelled oligonucleotide
CC   multimer, comprising multiple contiguous copies of a repeated
CC   oligonucleotides. The detectably labelled oligonucleotide multimer is
CC   useful for detecting a target molecule. Oligonucleotide multimers may be
CC   produced in sufficient quantity to be useful for diagnostic and medical
CC   applications. The multimers are useful for affinity labelling of
CC   proteins, and for signal amplification in highly sensitive affinity
CC   capture and sequence identification applications. The method provides a
CC   faster, cheaper and simpler way for large-scale production of DNA and RNA
CC   oligomers and multimers. The incorporation of labels enables the
CC   oligonucleotide multimers to be useful in diagnostics and medicine. The
CC   present sequence represents an oligonucleotide used in an example from
CC   the present invention
```

```
XX
SQ   Sequence 26 BP; 24 A; 2 C; 0 G; 0 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 16;  DB 1;  Length 26;
  Best Local Similarity   79.2%;  Pred. No. 1.6e+02;
  Matches   19;  Conservative    0;  Mismatches    5;  Indels    0;  Gaps    0;

Qy       1386 TTGTTTGTTTTGTATCTTGTTTTT 1409
              || ||| |||||| | || |||||
Db         25 TTTTTTTTTTTGTTTTTTTTTTTT 2


RESULT 41
ADC65872/c
ID   ADC65872 standard; DNA; 26 BP.
XX
AC   ADC65872;
XX
DT   18-DEC-2003  (first entry)
XX
DE   DNA oligonucleotide #5.
XX
KW   RNA oligonucleotide synthesis; ribonucleotide triphosphate; polymerase;
KW   electroporation; calcium phosphate treatment; lipid-mediated delivery;
KW   cation-mediated delivery; bacterial infection; viral infection;
KW   drug resistant infection; double stranded DNA oligomer; ss.
XX
OS   Synthetic.
XX
PN   US2003087241-A1.
XX
PD   08-MAY-2003.
XX
PF   30-NOV-2001; 2001US-00997931.
XX
PR   15-APR-1993;   93US-00047860.
PR   23-FEB-1995;   95US-00393439.
PR   26-FEB-1997;   97US-00805631.
PR   11-MAY-2000; 2000US-00569344.
XX
PA   (UYRP ) UNIV ROCHESTER.
XX
PI   Kool ET;
XX
DR   WPI; 2003-755141/71.
XX
PT   Synthesizing RNA oligonucleotide involves combining single-stranded
PT   circular oligonucleotide, ribonucleotide triphosphate and polymerase
PT   enzyme to yield desired RNA complementary to circular oligonucleotide
PT   template.
XX
PS   Example 2; SEQ ID NO 5; 78pp; English.
XX
CC   The invention relates to a method for synthesising an RNA
CC   oligonucleotide, comprising combining a single-stranded circular
CC   oligonucleotide template with at least two types of ribonucleotide
CC   triphosphate and a polymerase enzyme to yield a single-stranded RNA
CC   oligonucleotide multimer complementary to the circular oligonucleotide
CC   template, where the RNA oligonucleotide multimer comprises multiple
CC   copies of the desired RNA oligonucleotide. The method is useful for
CC   synthesising an RNA oligonucleotide with well-defined ends. The circular
CC   oligonucleotide is introduced into the cell using direct injection,
CC   electroporation, calcium phosphate treatment, lipid-mediated delivery, or
CC   cation-mediated delivery. The method is useful for treating bacterial
CC   and/or viral infections in mammals, particularly drug resistant
CC   infections, and for producing double stranded DNA oligomers. The method
CC   is performed in the absence of an oligonucleotide primer, or without the
CC   addition of auxiliary proteins. This sequence represents an
CC   oligonucleotide used in the method of the invention.
XX
SQ   Sequence 26 BP; 24 A; 2 C; 0 G; 0 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 16;  DB 1;  Length 26;
  Best Local Similarity   79.2%;  Pred. No. 1.6e+02;
  Matches   19;  Conservative    0;  Mismatches    5;  Indels    0;  Gaps    0;

Qy       1386 TTGTTTGTTTTGTATCTTGTTTTT 1409
              || ||| |||||| | || |||||
Db         25 TTTTTTTTTTTGTTTTTTTTTTTT 2


RESULT 42
AAZ43904
ID   AAZ43904 standard; DNA; 27 BP.
XX
AC   AAZ43904;
XX
DT   10-MAR-2000  (first entry)
XX
DE   M. tuberculosis rpo-beta primer 17.
XX
KW   RNA polymerase; rpo-beta; detection; diagnostic; trap probe; primer; ss.
XX
OS   Mycobacterium tuberculosis.
XX
PN   EP962536-A1.
XX
PD   08-DEC-1999.
XX
PF   29-MAY-1999;   99EP-00110458.
XX
PR   04-JUN-1998;   98DE-01024900.
XX
PA   (HOFF ) ROCHE DIAGNOSTICS GMBH.
XX
PI   Weindel K,  Brand J;
XX
DR   WPI; 2000-055287/05.
XX
PT   Selective detection of nucleic acids by amplification with labeled
PT   primers and detection with a trap probe.
XX
PS   Example 1c; Page 19; 27pp; German.
XX
CC   This invention describes a novel method for the selective detection of
CC   nucleic acids which comprises amplification of the nucleic acid with the
CC   help of labeled primers and detection with a trap probe. The methods and
CC   reagents are used for the detection of a marker primer and at least 2
CC   immobilized (or immobilizable) trap probes with the corresponding nucleic
CC   acid sequence of interest for mutation analysis. The method can be used
CC   to detect a specific sequence in a sample of one or more nucleic acids by
CC   using several sets of primers and trap probes (i.e. in an array). The
CC   methods are useful in molecular biology and diagnostic applications,
CC   especially for simultaneous detection of multi-pathogens, typing of
CC   organisms, analyzing genetic diversity and sequencing of genes or
CC   genomes. This sequence represents a primer used in the method of the
CC   invention
XX
SQ   Sequence 27 BP; 0 A; 0 C; 0 G; 26 T; 0 U; 1 Other;

  Query Match             0.9%;  Score 16;  DB 1;  Length 27;
  Best Local Similarity   73.1%;  Pred. No. 1.6e+02;
  Matches   19;  Conservative    1;  Mismatches    6;  Indels    0;  Gaps    0;

Qy       1386 TTGTTTGTTTTGTATCTTGTTTTTCT 1411
              || ||| |||| | | || |||||:|
Db          2 TTTTTTTTTTTTTTTTTTTTTTTYT 27


RESULT 43
ABZ90374/c
ID   ABZ90374 standard; DNA; 20 BP.
XX
AC   ABZ90374;
XX
DT   17-OCT-2003  (first entry)
```

XX
DE Human oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-229219/22.
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 5616; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 17 A; 3 C; 0 G; 0 T; 0 U; 0 Other;

```
  Query Match             0.9%;  Score 15.8;  DB 1;  Length 20;
  Best Local Similarity   89.5%;  Pred. No. 1.8e+02;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1382 TTTGTTGTTTGTTTTGTAT 1400
              |||||| |||||||||| |
Db         20 TTTGTTTTTTGTTTTGTTT 2
```

RESULT 44
ABD26604/c
ID ABD26604 standard; DNA; 20 BP.
XX
AC ABD26604;
XX
DT 29-JUL-2004 (first entry)

XX
DE AA909635-derived oligonucleotide SEQ ID 5616.
XX
KW Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
KW surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
KW pulmonary transplantation rejection; ss; primer.
XX
OS Homo sapiens.
XX
PN WO200285309-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013143.
XX
PR 24-APR-2001; 2001US-0286036P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-093058/08.
XX
PT Pharmaceutical composition for treating asthma, has antisense
PT oligonucleotide containing less percentage of adenosine, targeted to
PT nucleic acids associated with lung airway or lung dysfunction, and
PT bronchodilating agent.
XX
PS Claim 15; SEQ ID NO 5616; 763pp; English.
XX
CC This invention describes a novel composition (a) a first active agent,
CC comprising oligonucleotides, effective for alleviating
CC bronchoconstriction, respiratory tract inflammation, allergies and
CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
CC surfactant depletion or hyposecretion, when administered to a mammal. The
CC oligonucleotides are derived from a gene encoding or regulating
CC expression of a target polypeptide associated with lung airway or lung
CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
CC The invention also describes a kit, that comprises: (a) a delivery
CC device, in separate containers, (b) the oligonucleotides, (c)
CC instructions for adding a carrier and for use of the kit. The composition
CC of the invention has antiallergic, antiinflammatory, antiasthmatic,
CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
CC beta-adrenergic agonist. The composition is useful for preventing or
CC treating a respiratory, lung or malignant disease. The administered
CC composition comprises oligo and is administered to reduce the production
CC or availability, or to increase the degradation of the target mRNA or to
CC reduce the amount of target polypeptide present in the lungs. The
CC pulmonary obstruction, and/or bronchoconstriction and/or lung
CC inflammation, allergies and/or surfactant hypoproduction are associated
CC with a disease or condition such as pulmonary vasoconstriction,
CC inflammation, allergies, asthma, impeded respiration, respiratory
CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
CC transplantation rejection, pulmonary infections, bronchitis or cancer.
CC The reduced adenosine content of the anti-sense oligos corresponding to
CC thymidines present in the target RNA serves to prevent the breakdown of
CC the oligonucleotides into products that free adenosine into the system
CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
CC prevent any unwanted effects due to it
XX
SQ Sequence 20 BP; 17 A; 3 C; 0 G; 0 T; 0 U; 0 Other;

```
  Query Match             0.9%;  Score 15.8;  DB 1;  Length 20;
  Best Local Similarity   89.5%;  Pred. No. 1.8e+02;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;
```

```
Qy       1382 TTTGTTGTTTGTTTTGTAT 1400
              |||||| |||||||||| |
Db         20 TTTGTTTTTTGTTTTGTTT 2
```

RESULT 45
AAV58430
ID AAV58430 standard; cDNA; 20 BP.
XX
AC AAV58430;
XX
DT 01-DEC-1998 (first entry)
XX
DE PCR primer for PN4 sodium channel clone.
XX
KW Tetrodotoxin-sensitive sodium channel; rat; PN4 sodium channel; stroke;
KW nervous system disorder; epilepsy; brain injury; diabetic neuropathy;
KW AIDS-associated neuropathy; therapy; PCR primer; ss.
XX
OS Synthetic.
OS Rattus sp.
XX
PN WO9838302-A2.
XX
PD 03-SEP-1998.
XX
PF 20-FEB-1998; 98WO-EP000997.
XX
PR 26-FEB-1997; 97US-0039447P.
XX
PA (HOFF) HOFFMANN LA ROCHE & CO AG F.
XX
PI Delgado SG, Dietrich PS, Fish LM, Herman RC, Sangameswaran L;
XX
DR WPI; 1998-481204/41.
XX
PT New rat tetrodotoxin-sensitive sodium channel alpha subunit and DNA - for
PT detecting inhibitors which alleviate pain, and treating nervous system
PT disorders, e.g. epilepsy, stroke, diabetic and AIDS neuropathy.
XX
PS Example 2; Page 20; 87pp; English.
XX
CC This sequence represents a primer for the isolated rat PN4 sodium channel
CC cDNA clone of the invention. The clone sequence was isolated from a
CC peripheral nerve from a rat dorsal ganglia. The PN4 sodium channel
CC sequences are tetrodotoxin-sensitive sodium channels. The protein is used
CC in assays for detecting inhibitors of tetrodotoxin-sensitive sodium
CC channels, which alleviate pain. The probes can be used to detect and
CC isolate the DNA or protein in tissues. The antibodies can also be used to
CC isolate the protein. The protein is used as a therapeutic target for
CC compounds to treat disorders of the nervous system, such as epilepsy,
CC stroke and brain injury, diabetic neuropathy, and AIDS-associated
CC neuropathy, etc
XX
SQ Sequence 20 BP; 6 A; 6 C; 5 G; 3 T; 0 U; 0 Other;

  Query Match   0.9%; Score 15.8; DB 1; Length 20;
  Best Local Similarity   89.5%; Pred. No. 1.8e+02;
  Matches   17; Conservative   0; Mismatches   2; Indels   0; Gaps   0;

```
Qy        392 CAGCAGCAACAGTGGCTTC 410
              ||||||| |||||||||| |
Db          1 CAGCAGCTACAGTGGCTAC 19
```

RESULT 46
AAX94392
ID AAX94392 standard; DNA; 20 BP.
XX
AC AAX94392;
XX
DT 13-SEP-1999 (first entry)
XX
DE PCR primer used to amplify an ORF of Chlamydia pneumoniae.
XX
KW Respiratory disease; pneumonia; bronchitis; heart disease; sarcoidosis;
KW sinusitis; purulent otitis media; erythema nodosum; pharyngitis; vaccine;
KW neutralising epitope; PCR primer; ss.
XX
OS Synthetic.
OS Chlamydophila pneumoniae.
XX
PN WO9927105-A2.
XX
PD 03-JUN-1999.
XX
PF 20-NOV-1998; 98WO-IB001890.
XX
PR 21-NOV-1997; 97FR-00014673.
PR 04-NOV-1998; 98US-0107078P.
XX
PA (GEST) GENSET.
XX
PI Griffais R;
XX
DR WPI; 1999-357842/30.
XX
PT Genome sequence of Chlamydia pneumoniae.
XX
PS Page 1666; Disclosure; 1912pp; English.
XX
CC AAX91991-X97517 represent PCR primers used to amplify open reading frames
CC and other nucleic acid sequences from the genome of Chlamydia pneumoniae
CC (see AAX91990). C. pneumoniae causes respiratory disease such as
CC pneumonia and bronchitis and is thought to be a contributing factor in
CC heart disease, sarcoidosis, sinusitis, purulent otitis media, erythema
CC nodosum or pharyngitis. The polypeptides encoded by the open reading
CC frames of the C. pneumoniae genome (see AAY34584- AAY35879) can be used
CC in immunogenic compositions as vaccines. Vectors containing C. pneumoniae
CC nucleotides sequences can also be used as immunogenic compositions,
CC especially where the vector directs the expression of a neutralising
CC epitope of C. pneumoniae
XX
SQ Sequence 20 BP; 5 A; 7 C; 5 G; 3 T; 0 U; 0 Other;

  Query Match   0.9%; Score 15.8; DB 1; Length 20;
  Best Local Similarity   89.5%; Pred. No. 1.8e+02;
  Matches   17; Conservative   0; Mismatches   2; Indels   0; Gaps   0;

```
Qy        825 GGCTTCAGCCAGTCCCTGA 843
              ||| ||||||| |||||||
Db          2 GGCGTCAGCCAATCCCTGA 20
```

RESULT 47
AAZ37992/c
ID AAZ37992 standard; DNA; 20 BP.
XX
AC AAZ37992;
XX
DT 07-FEB-2000 (first entry)
XX
DE Human GLC1A gene exon 1 specific reverse primer.
XX
KW Glaucoma; PCR amplification; primary open wide angle glaucoma;
KW GLC1A gene; human; PCR primer; ss.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN WO9951779-A2.
XX
PD 14-OCT-1999.
XX
PF 07-APR-1999; 99WO-US007671.
XX

```
PR   07-APR-1998;   98US-00056285.
XX
PA   (IOWA ) UNIV IOWA RES FOUND.
XX
PI   Stone EM,  Sheffield VC,  Alward WLM,  Fingert J;
XX
DR   WPI; 2000-022956/02.
XX
PT   Determination of a predisposition to glaucoma by analysing mutations in
PT   the GLC1A gene.
XX
PS   Claim 1; Page 131; 137pp; English.
XX
CC   The invention relates to a method for the determination of a
CC   predisposition to glaucoma. The method comprises amplifying a GLC1A gene
CC   with a primer pair selected from the sequences shown in AAZ37981-Z38008.
CC   The primers are used to determine whether a subject has or has the
CC   potential to develop primary open wide angle glaucoma. Sequences AAZ37981
CC   -Z38008 represent primer pairs specific for human GLC1A gene exon
CC   sequences. These primers were used for the GLC1A assay to identify
CC   patients having a predisposition to glaucoma
XX
SQ   Sequence 20 BP; 4 A; 8 C; 4 G; 4 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 15.8;  DB 1;  Length 20;
  Best Local Similarity   89.5%;  Pred. No. 1.8e+02;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        174 GGCACTCTGAGTTCATCAG 192
              || |||||||||||| |||
Db         19 GGGACTCTGAGTTCAGCAG 1


RESULT 48
AAH23215/c
ID   AAH23215 standard; DNA; 20 BP.
XX
AC   AAH23215;
XX
DT   17-SEP-2001  (first entry)
XX
DE   Human MMIF mRNA inhibiting antisense oligo ISIS #112366.
XX
KW   Macrophage migration inhibitory factor; MMIF; antisense; neurological;
KW   hyperproliferation; nootropic; antihormonal; immunosuppresive; human;
KW   antiinflammatory; cytostatic; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO200153317-A1.
XX
PD   26-JUL-2001.
XX
PF   16-JAN-2001; 2001WO-US001475.
XX
PR   20-JAN-2000; 2000US-00489869.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Murray SF,  Cowsert LM,  Wyatt JR;
XX
DR   WPI; 2001-451899/48.
XX
PT   New antisense compound(s) are useful to inhibit a nucleic acid molecule
PT   encoding macrophage migration inhibitory factor.
XX
PS   Claim 3; Page 83; 105pp; English.
XX
CC   The invention relates to antisense oligonucleotides 8-30 nucleotides in
CC   length targeted to a nucleic acid molecule encoding macrophage migration
CC   inhibitory factor (MMIF), where the antisense compound specifically
CC   hybridizes with and inhibits the expression of MMIF. The antisense
CC   nucleotides are useful for the treatment of a disease or condition
CC   associated with MMIF such as neurological, hormonal, immune, inflammatory
CC   or hyperproliferative disorder. Sequences AAH23191-268 represent chimeric
CC   antisense phosphorothioate oligonucleotides used for inhibition of human
CC   MMIF mRNA expression
XX
SQ   Sequence 20 BP; 2 A; 8 C; 8 G; 2 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 15.8;  DB 1;  Length 20;
  Best Local Similarity   89.5%;  Pred. No. 1.8e+02;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        621 GCCTACAGCGAGCCGTGCG 639
              | || ||||||||||||||
Db         20 GGCTCCAGCGAGCCGTGCG 2


RESULT 49
AAF90500/c
ID   AAF90500 standard; DNA; 20 BP.
XX
AC   AAF90500;
XX
DT   22-AUG-2001  (first entry)
XX
DE   COL1A1 gene antisense oligonucleotide 9.
XX
KW   COL1A1 gene; collagen; procollagen; human; antisense; vulnerary;
KW   dermatological; scar; keloid; scleroderma; cirrhosis; fibrosis; therapy;
KW   ss.
XX
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base    1. .20
FT                    /*tag=  a
FT                    /note= "phosphorothioate linkage"
XX
PN   WO200144455-A2.
XX
PD   21-JUN-2001.
XX
PF   12-DEC-2000; 2000WO-GB004741.
XX
PR   15-DEC-1999;   99GB-00029487.
XX
PA   (ASTR ) ASTRAZENECA AB.
PA   (ASTR ) ASTRAZENECA UK LTD.
XX
PI   Beri R;
XX
DR   WPI; 2001-398145/42.
XX
PT   Novel antisense DNA oligonucleotide useful for inhibiting the expression
PT   of wild type COL1A1 gene, for treating, reducing the risk of, and
PT   preventing collagen disorders.
XX
PS   Claim 10; Page 8; 30pp; English.
XX
CC   The present sequence is that of 1 of 12 claimed antisense
CC   oligonucleotides (ASOs, see AAF90492-503) of the invention. These ASOs
CC   are complementary to regions of the human gene (see AAF90491) for the pro
CC   -alpha-1 chain of type I procollagen. They are capable of inhibiting the
CC   expression of type I procollagen pro-alpha-1 chain in a cell that
CC   expresses it. The ASO, or a pharmaceutical composition including it, is
CC   used in a claimed method of treating, or reducing a risk of, a collagen
CC   disorder. Such disorders may include those caused by overproduction of
CC   collagen fibres, such as liver cirrhosis, kidney, liver and heart
CC   fibrosis, scleroderma, hypertrophic scars and keloids. The present ASO,
CC   when administered to human WI-26 cells, inhibited type I collagen
CC   production by 50%
XX
SQ   Sequence 20 BP; 2 A; 9 C; 5 G; 4 T; 0 U; 0 Other;
```

```
  Query Match             0.9%;  Score 15.8;  DB 1;  Length 20;
  Best Local Similarity   89.5%;  Pred. No. 1.8e+02;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        986 GAGGCAGGAGCTGAGGGAC 1004
              ||||| |||||| ||||||
Db         20 GAGGCTGGAGCTCAGGGAC 2


RESULT 50
ABQ94349
ID   ABQ94349 standard; DNA; 20 BP.
XX
AC   ABQ94349;
XX
DT   01-NOV-2002  (first entry)
XX
DE   Human BNO1 gene exon 9 primer 2.
XX
KW   Human; BNO1; F-box; FBXO; chromosome 16q24.3; SCF ubiquitin-E3 ligase;
KW   protein ubiquitination; proteasome targeting; breast; prostate; liver;
KW   ovarian; immune disease; inflammatory disease; AIDS;
KW   acquired immunodeficiency syndrome; asthma; Crohn's disease;
KW   multiple sclerosis; neurological disorder; Parkinson's disease;
KW   Alzheimer's disease; cytostatic; immunomodulator; neuroprotective;
KW   gene therapy; diagnosis; prognosis; mutation analysis; SSCP;
KW   single-strand conformation polymorphism; PCR; primer; ss.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "Labelled with HEX"
XX
PN   WO200261081-A1.
XX
PD   08-AUG-2002.
XX
PF   31-JAN-2002; 2002WO-AU000096.
XX
PR   31-JAN-2001; 2001AU-00002783.
XX
PA   (BION-) BIONOMICS LTD.
XX
PI   Callen DF,  Powell JA,  Kremmidiotis G,  Gardner AE,  Crawford J;
PI   Bais AJ,  Kochetkova M;
XX
DR   WPI; 2002-619250/66.
XX
PT   New gene (BNO1) mapping to chromosome 16q24.3, useful in gene therapy,
PT   e.g. for diagnosing or treating cancers (e.g. lymphoma),
PT   immune/inflammatory diseases (e.g. AIDS) or neurological disorders (e.g.
PT   Parkinson's disease).
XX
PS   Example 8; Page 63; 85pp; English.
XX
CC   The invention relates to the human and murine BNO1 proteins and nucleic
CC   acids encoding them. The BNO1 protein is a member of the FBXO class of F-
CC   box proteins, containing an F-box motif but no other known protein-
CC   interaction domains. Proteins which contain F-boxes are the substrate
CC   recognition components of SCF ubiquitin-E3 ligases, which are responsible
CC   for ubiquitinating proteins, thereby targeting them for degradation in
CC   the proteasome. In addition, BNO1 is able to interact with Skp1, an
CC   essential component of SCF ubiquitin-E3 ligases, suggesting that it plays
CC   a role in the ubiquitin-proteasome degradation system that is involved in
CC   the regulation of many proteins, particularly those involved in important
CC   cellular processes such as cell cycle regulation. The human BNO1 gene
CC   maps to chromosome 16q24.3, and is expressed as two different isoforms.
CC   Isoform 1 consists of 539 amino acids and is encoded by an open reading
CC   frame (ORF) of 1617 bp, while the longer isoform 2 consists of 568 amino
CC   acids encoded by an ORF of 1704 bp. The mRNAs encoding the 2 human BNO1
CC   isoforms are the product of differential splicing: both comprise exons 1-
CC   9, but the isoform 2 mRNA additionally comprises exon 2.5. Loss of
CC   heterozygosity (LOH) of the long arm of chromosome 16, in which the human
CC   BNO1 gene is situated, is implicated in breast and prostate cancer, and
CC   BNO1 expression is also downregulated in these cancers. BNO1 nucleic
CC   acids, proteins and compounds which modulate BNO1 activity or expression
CC   may be used for treating disorders associated with altered BNO1 activity
CC   or expression. Such disorders include cancers (e.g., breast, prostate,
CC   liver and ovarian cancers), immune/inflammatory diseases (e.g., AIDS
CC   (acquired immunodeficiency syndrome), asthma, Crohn's disease or multiple
CC   sclerosis) or neurological disorders (e.g., Parkinson's disease or
CC   Alzheimer's disease). BNO1 nucleic acids, proteins and antibodies may
CC   also be used to diagnose or prognose disorders associated with BNO1
CC   dysfunction, or a predisposition to these disorders. Additionally, BNO1
CC   nucleic acids and proteins, and transgenic animals comprising human BNO1
CC   nucleic acid sequences or in which BNO1 gene function has been knocked
CC   out are useful in screening potential drugs for treating BNO1-associated
CC   disorders, and the human BNO1 protein isoforms are particularly useful
CC   for identifying BNO1-specific protein substrates that are targeted for
CC   degradation by ubiquitination. Sequences ABQ94326-ABQ94349 represent
CC   human BNO1 gene-specific PCR primers used in SSCP (single-strand
CC   conformation polymorphism) analysis of tumours and cell lines for BNO1
CC   mutations in an exemplification of the invention
XX
SQ   Sequence 20 BP; 6 A; 1 C; 10 G; 3 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 15.8;  DB 1;  Length 20;
  Best Local Similarity   89.5%;  Pred. No. 1.8e+02;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        991 AGGAGCTGAGGGACTGATT 1009
              ||||| |||||||||||  |
Db          1 AGGAGGTGAGGGACTGAAT 19


RESULT 51
AAL61838
ID   AAL61838 standard; DNA; 20 BP.
XX
AC   AAL61838;
XX
DT   22-SEP-2003  (first entry)
XX
DE   Human ETBR-LP-2 antisense oligonucleotide ISIS #204264.
XX
KW   Human; G protein-coupled receptor; hyperproliferative disorder; GPR37L1;
KW   endothelin type b receptor-like protein-2; cerebral vascular disease;
KW   antisense; endothelin-binding receptor-like protein-2; atherosclerosis;
KW   cardiovascular disease; ETBR-LP-2; G-protein coupled receptor 37 like 1;
KW   acute proliferative nephropathy; ETBR-like protein 2; cancer; stroke;
KW   angiogenesis; hypertension; phosphorothioate; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate backbone; All cytidine residues
FT                   are 5-methylcytidines"
FT   modified_base   1. .5
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN   WO2003050244-A2.
XX
```

PD 19-JUN-2003.
XX
PF 04-DEC-2002; 2002WO-US038520.
XX
PR 06-DEC-2001; 2001US-00003126.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Monia BP, Freier SM;
XX
DR WPI; 2003-558997/52.
XX
PT New oligonucleotides which bind the nucleic acid encoding the G protein
PT coupled receptor ETBR-LP-2 (endothelin type b receptor-like protein-2
PT receptor), useful for treating e.g. cancer and cardiovascular diseases.
XX
PS Claim 3; Page 79; 106pp; English.
XX
CC The invention relates to antisense compounds targetted to the nucleic
CC acid encoding the G protein-coupled receptor ETBR-LP-2 (endothelin type b
CC receptor-like protein-2) to inhibit its expression. ETBR-LP-2 is also
CC known as endothelin-binding receptor-like protein-2, ETBR-like protein 2
CC and G-protein coupled receptor 37 like 1 (GPR37L1). Antisense compounds
CC of the invention are useful for treating hyperproliferative disorders
CC (especially cancer) and cardiovascular diseases especially angiogenesis,
CC atherosclerosis, hypertension, cerebral vascular disease, stroke and
CC acute proliferative nephropathy. The present sequence is an antisense
CC oligonucleotide targetted to human ETBR-LP-2 DNA
XX
SQ Sequence 20 BP; 2 A; 9 C; 3 G; 6 T; 0 U; 0 Other;

Query Match 0.9%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1.8e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 808 ACTCTCCCTTCCTCCCTGG 826
||||| ||||||||||||
Db 2 ACTCTGACTTCCTCCCTGG 20

RESULT 52
ABZ91337
ID ABZ91337 standard; DNA; 20 BP.
XX
AC ABZ91337;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-229219/22.
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 6579; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 3 A; 10 C; 4 G; 3 T; 0 U; 0 Other;

Query Match 0.9%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1.8e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 716 CCCCAGCCTGGTGCCCACC 734
| |||||||||||||||| |
Db 1 CACCAGCCTGGTGCCCATC 19

RESULT 53
ABZ88193
ID ABZ88193 standard; DNA; 20 BP.
XX
AC ABZ88193;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-229219/22.

XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 3435; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 6 A; 6 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 0.9%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1.8e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 378 TGCGAGTCCCTGGACAGCA 396
||||||| |||| ||||||
Db 1 TGCGAGTACCTGCACAGCA 19

RESULT 54
ABZ99156
ID ABZ99156 standard; DNA; 20 BP.
XX
AC ABZ99156;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human PDE4C oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-229219/22.

XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 14398; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 3 A; 8 C; 6 G; 3 T; 0 U; 0 Other;

Query Match 0.9%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1.8e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 712 TCGACCCCAGCCTGGTGCC 730
| |||||||||| ||||||
Db 1 TGGACCCCAGCCAGGTGCC 19

RESULT 55
ABD32187
ID ABD32187 standard; DNA; 20 BP.
XX
AC ABD32187;
XX
DT 29-JUL-2004 (first entry)
XX
DE Human PDE4C-derived oligonucleotide SEQ ID 14398.
XX
KW Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
KW surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
KW pulmonary transplantation rejection; ss; primer.
XX
OS Homo sapiens.
XX
PN WO200285309-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013143.
XX
PR 24-APR-2001; 2001US-0286036P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;

```
XX
DR   WPI; 2003-093058/08.
XX
PT   Pharmaceutical composition for treating asthma, has antisense
PT   oligonucleotide containing less percentage of adenosine, targeted to
PT   nucleic acids associated with lung airway or lung dysfunction, and
PT   bronchodilating agent.
XX
PS   Claim 15; SEQ ID NO 14398; 763pp; English.
XX
CC   This invention describes a novel composition (a) a first active agent,
CC   comprising oligonucleotides, effective for alleviating
CC   bronchoconstriction, respiratory tract inflammation, allergies and
CC   reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
CC   surfactant depletion or hyposecretion, when administered to a mammal. The
CC   oligonucleotides are derived from a gene encoding or regulating
CC   expression of a target polypeptide associated with lung airway or lung
CC   dysfunction or cancer and can be anti-sense to the corresponding mRNA.
CC   The invention also describes a kit, that comprises: (a) a delivery
CC   device, in separate containers, (b) the oligonucleotides, (c)
CC   instructions for adding a carrier and for use of the kit. The composition
CC   of the invention has antiallergic, antiinflammatory, antiasthmatic,
CC   analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
CC   beta-adrenergic agonist. The composition is useful for preventing or
CC   treating a respiratory, lung or malignant disease. The administered
CC   composition comprises oligo and is administered to reduce the production
CC   or availability, or to increase the degradation of the target mRNA or to
CC   reduce the amount of target polypeptide present in the lungs. The
CC   pulmonary obstruction, and/or bronchoconstriction and/or lung
CC   inflammation, allergies and/or surfactant hypoproduction are associated
CC   with a disease or condition such as pulmonary vasoconstriction,
CC   inflammation, allergies, asthma, impeded respiration, respiratory
CC   distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
CC   hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
CC   transplantation rejection, pulmonary infections, bronchitis or cancer.
CC   The reduced adenosine content of the anti-sense oligos corresponding to
CC   thymidines present in the target RNA serves to prevent the breakdown of
CC   the oligonucleotides into products that free adenosine into the system
CC   e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
CC   prevent any unwanted effects due to it
XX
SQ   Sequence 20 BP; 3 A; 8 C; 6 G; 3 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 15.8;  DB 1;  Length 20;
  Best Local Similarity   89.5%;  Pred. No. 1.8e+02;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        712 TCGACCCCAGCCTGGTGCC 730
              | ||||||||||| ||||||
Db          1 TGGACCCCAGCCAGGTGCC 19


RESULT 56
ABD24423
ID   ABD24423 standard; DNA; 20 BP.
XX
AC   ABD24423;
XX
DT   29-JUL-2004  (first entry)
XX
DE   AI652901-derived oligonucleotide SEQ ID 3435.
XX
KW   Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
KW   respiratory tract inflammation; adenosine sensitivity; lung; cancer;
KW   surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
KW   analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
KW   beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
KW   respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
KW   emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
KW   pulmonary transplantation rejection; ss; primer.
XX
OS   Homo sapiens.
XX
PN   WO200285309-A2.
XX
PD   31-OCT-2002.
XX
PF   23-APR-2002; 2002WO-US013143.
XX
PR   24-APR-2001; 2001US-0286036P.
XX
PA   (EPIG-) EPIGENESIS PHARM INC.
XX
PI   Nyce JW,  Li Y,  Sandrasagra A,  Katz E,  Pabalan J,  Aguilar D;
PI   Miller S,  Tang L,  Shahabuddin S;
XX
DR   WPI; 2003-093058/08.
XX
PT   Pharmaceutical composition for treating asthma, has antisense
PT   oligonucleotide containing less percentage of adenosine, targeted to
PT   nucleic acids associated with lung airway or lung dysfunction, and
PT   bronchodilating agent.
XX
PS   Claim 15; SEQ ID NO 3435; 763pp; English.
XX
CC   This invention describes a novel composition (a) a first active agent,
CC   comprising oligonucleotides, effective for alleviating
CC   bronchoconstriction, respiratory tract inflammation, allergies and
CC   reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
CC   surfactant depletion or hyposecretion, when administered to a mammal. The
CC   oligonucleotides are derived from a gene encoding or regulating
CC   expression of a target polypeptide associated with lung airway or lung
CC   dysfunction or cancer and can be anti-sense to the corresponding mRNA.
CC   The invention also describes a kit, that comprises: (a) a delivery
CC   device, in separate containers, (b) the oligonucleotides, (c)
CC   instructions for adding a carrier and for use of the kit. The composition
CC   of the invention has antiallergic, antiinflammatory, antiasthmatic,
CC   analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
CC   beta-adrenergic agonist. The composition is useful for preventing or
CC   treating a respiratory, lung or malignant disease. The administered
CC   composition comprises oligo and is administered to reduce the production
CC   or availability, or to increase the degradation of the target mRNA or to
CC   reduce the amount of target polypeptide present in the lungs. The
CC   pulmonary obstruction, and/or bronchoconstriction and/or lung
CC   inflammation, allergies and/or surfactant hypoproduction are associated
CC   with a disease or condition such as pulmonary vasoconstriction,
CC   inflammation, allergies, asthma, impeded respiration, respiratory
CC   distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
CC   hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
CC   transplantation rejection, pulmonary infections, bronchitis or cancer.
CC   The reduced adenosine content of the anti-sense oligos corresponding to
CC   thymidines present in the target RNA serves to prevent the breakdown of
CC   the oligonucleotides into products that free adenosine into the system
CC   e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
CC   prevent any unwanted effects due to it
XX
SQ   Sequence 20 BP; 6 A; 6 C; 5 G; 3 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 15.8;  DB 1;  Length 20;
  Best Local Similarity   89.5%;  Pred. No. 1.8e+02;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        378 TGCGAGTCCCTGGACAGCA 396
              ||||||| |||| ||||||
Db          1 TGCGAGTACCTGCACAGCA 19


RESULT 57
ABD27567
ID   ABD27567 standard; DNA; 20 BP.
XX
AC   ABD27567;
XX
DT   29-JUL-2004  (first entry)
XX
DE   AA504431-derived oligonucleotide SEQ ID 6579.
```

XX
KW Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
KW surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
KW pulmonary transplantation rejection; ss; primer.
XX
OS Homo sapiens.
XX
PN WO200285309-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013143.
XX
PR 24-APR-2001; 2001US-0286036P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-093058/08.
XX
PT Pharmaceutical composition for treating asthma, has antisense
PT oligonucleotide containing less percentage of adenosine, targeted to
PT nucleic acids associated with lung airway or lung dysfunction, and
PT bronchodilating agent.
XX
PS Claim 15; SEQ ID NO 6579; 763pp; English.
XX
CC This invention describes a novel composition (a) a first active agent,
CC comprising oligonucleotides, effective for alleviating
CC bronchoconstriction, respiratory tract inflammation, allergies and
CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
CC surfactant depletion or hyposecretion, when administered to a mammal. The
CC oligonucleotides are derived from a gene encoding or regulating
CC expression of a target polypeptide associated with lung airway or lung
CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
CC The invention also describes a kit, that comprises: (a) a delivery
CC device, in separate containers, (b) the oligonucleotides, (c)
CC instructions for adding a carrier and for use of the kit. The composition
CC of the invention has antiallergic, antiinflammatory, antiasthmatic,
CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
CC beta-adrenergic agonist. The composition is useful for preventing or
CC treating a respiratory, lung or malignant disease. The administered
CC composition comprises oligo and is administered to reduce the production
CC or availability, or to increase the degradation of the target mRNA or to
CC reduce the amount of target polypeptide present in the lungs. The
CC pulmonary obstruction, and/or bronchoconstriction and/or lung
CC inflammation, allergies and/or surfactant hypoproduction are associated
CC with a disease or condition such as pulmonary vasoconstriction,
CC inflammation, allergies, asthma, impeded respiration, respiratory
CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
CC transplantation rejection, pulmonary infections, bronchitis or cancer.
CC The reduced adenosine content of the anti-sense oligos corresponding to
CC thymidines present in the target RNA serves to prevent the breakdown of
CC the oligonucleotides into products that free adenosine into the system
CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
CC prevent any unwanted effects due to it
XX
SQ Sequence 20 BP; 3 A; 10 C; 4 G; 3 T; 0 U; 0 Other;

Query Match 0.9%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1.8e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 716 CCCCAGCCTGGTGCCCACC 734
| |||||||||||||||| |
Db 1 CACCAGCCTGGTGCCCATC 19

RESULT 58
ADH18776
ID ADH18776 standard; DNA; 20 BP.
XX
AC ADH18776;
XX
DT 11-MAR-2004 (first entry)
XX
DE Human apolipoprotein B antisense inhibition target DNA - SEQ ID 765.
XX
KW apolipoprotein B; ApoB; antiarteriosclerotic; cardiant; antidiabetic;
KW anorectic; lipid; cholesterol metabolism; atherosclerosis;
KW diabetes Type 2; obesity; hyperlipidaemia; cardiovascular; gene therapy;
KW antisense inhibition target; human; ds.
XX
OS Homo sapiens.
XX
PN WO2003097662-A1.
XX
PD 27-NOV-2003.
XX
PF 15-MAY-2003; 2003WO-US015493.
XX
PR 15-MAY-2002; 2002US-00147196.
PR 13-NOV-2002; 2002US-0426324P.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Crooke RM, Graham MJ;
XX
DR WPI; 2004-022840/02.
XX
PT New antisense compound, useful for preparing a composition for treating
PT abnormal lipid or cholesterol metabolism, atherosclerosis, diabetes Type
PT 2, obesity, hyperlipidemia or cardiovascular disease.
XX
PS Claim 1; SEQ ID NO 765; 405pp; English.
XX
CC The invention relates to a novel antisense compound targeted to a nucleic
CC acid molecule encoding human apolipoprotein B (ApoB) which specifically
CC hybridises with and inhibits the expression of human apolipoprotein B.
CC The compound of the invention demonstrates antiarteriosclerotic,
CC cardiant, antidiabetic and anorectic activities and may be useful for
CC preparing a composition for treating abnormal lipid or cholesterol
CC metabolism, atherosclerosis, diabetes Type 2, obesity, hyperlipidaemia or
CC cardiovascular disease. Furthermore, the compound has gene therapy
CC applications. The current sequence is that of the human ApoB antisense
CC inhibition target DNA of the invention.
XX
SQ Sequence 20 BP; 6 A; 4 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 0.9%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1.8e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 574 TGCCTAGCCAGTTGGTAAG 592
|||||||||||| | |||
Db 1 TGCCTAGCCAGTTTGAAAG 19

RESULT 59
ADH18453/c
ID ADH18453 standard; DNA; 20 BP.
XX
AC ADH18453;
XX
DT 11-MAR-2004 (first entry)
XX
DE 2'-MOE gapmer antisense oligo targeted to human ApoB DNA 3 - SEQ ID 442.
XX

KW apolipoprotein B; ApoB; antiarteriosclerotic; cardiant; antidiabetic;
KW anorectic; lipid; cholesterol metabolism; atherosclerosis;
KW diabetes Type 2; obesity; hyperlipidaemia; cardiovascular; gene therapy;
KW antisense; 2'-O-methoxyethyl gapmer; phosphorothioate backbone; 2'-MOE;
KW human; ss.
XX
OS Homo sapiens.
XX
PN WO2003097662-A1.
XX
PD 27-NOV-2003.
XX
PF 15-MAY-2003; 2003WO-US015493.
XX
PR 15-MAY-2002; 2002US-00147196.
PR 13-NOV-2002; 2002US-0426324P.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Crooke RM, Graham MJ;
XX
DR WPI; 2004-022840/02.
XX
PT New antisense compound, useful for preparing a composition for treating
PT abnormal lipid or cholesterol metabolism, atherosclerosis, diabetes Type
PT 2, obesity, hyperlipidemia or cardiovascular disease.
XX
PS Claim 1; SEQ ID NO 442; 405pp; English.
XX
CC The invention relates to a novel antisense compound targeted to a nucleic
CC acid molecule encoding human apolipoprotein B (ApoB) which specifically
CC hybridises with and inhibits the expression of human apolipoprotein B.
CC The compound of the invention demonstrates antiarteriosclerotic,
CC cardiant, antidiabetic and anorectic activities and may be useful for
CC preparing a composition for treating abnormal lipid or cholesterol
CC metabolism, atherosclerosis, diabetes Type 2, obesity, hyperlipidaemia or
CC cardiovascular disease. Furthermore, the compound has gene therapy
CC applications. The current sequence is that of the 2'-O-methoxyethyl (2'-
CC MOE) gapmer antisense oligo of the invention which has 2'-MOE 'wings', a
CC phosphorothioate backbone throughout and in which all cytidine residues
CC are 5-methylcytidines.
XX
SQ Sequence 20 BP; 5 A; 5 C; 4 G; 6 T; 0 U; 0 Other;

Query Match 0.9%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1.8e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 574 TGCCTAGCCAGTTGGTAAG 592
||||||||||||| | |||
Db 20 TGCCTAGCCAGTTTGAAAG 2

RESULT 60
ADJ61041
ID ADJ61041 standard; DNA; 20 BP.
XX
AC ADJ61041;
XX
DT 06-MAY-2004 (first entry)
XX
DE Oligonucleotide associated to PDE4C #107.
XX
KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
KW airway inflammation; allergy; asthma; impeded respiration;
KW cystic fibrosis; acute respiratory distress syndrome;
KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
KW ss.
XX
OS Homo sapiens.
XX
PN WO2004011613-A2.
XX
PD 05-FEB-2004.
XX
PF 25-JUL-2003; 2003WO-US023509.
XX
PR 29-JUL-2002; 2002US-0399076P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
PI Shahabuddin S, Lu H, Cong H;
XX
DR WPI; 2004-203534/19.
XX
PT Novel single or multiple target oligonucleotide anti-sense to e.g.
PT initiation codons and introns of respiratory disease-relevant genes e.g.,
PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
PT disease e.g., asthma.
XX
PS Claim 2; SEQ ID NO 1897; 85pp; English.
XX
CC The present invention relates to an oligonucleotide anti-sense to e.g.,
CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
CC end of nucleic acid target comprising gene(s) chosen from e.g.
CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
CC oligonucleotide and optionally surfactant operatively linked to the
CC oligonucleotide. The method is useful for preventing or treating a
CC respiratory or lung disease, which involves administering to the airways
CC of a subject an effective amount of an inhibitor. The oligonucleotide is
CC useful for production of a medicament for the prevention and/or treatment
CC of a respiratory or lung disease. The respiratory or lung disease is
CC chosen from airway inflammation, allergy(ies), asthma, impeded
CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
CC obstruction. The present sequence represents an oligonucleotide of the
CC invention.
XX
SQ Sequence 20 BP; 3 A; 8 C; 6 G; 3 T; 0 U; 0 Other;

Query Match 0.9%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1.8e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 712 TCGACCCCAGCCTGGTGCC 730
| |||||||||| ||||||
Db 1 TGGACCCCAGCCAGGTGCC 19

RESULT 61
ADO33317
ID ADO33317 standard; DNA; 20 BP.
XX
AC ADO33317;
XX
DT 12-AUG-2004 (first entry)
XX
DE Human apolipoprotein B (ApoB) antisense therapy target DNA - SEQ 765.
XX
KW apolipoprotein B; ApoB; cardiovascular; antiarteriosclerotic;
KW antilipaemic; antidiabetic; anorectic; cardiant; vasotropic; hypotensive;
KW anabolic; eating disorder; cytostatic; endocrine; vasotropic;
KW neuroprotective; nootropic; lipid; cholesterol metabolism;
KW hyperlipoproteinaemia; hyperlipidaemia; hypercholesterolaemia;
KW Von Gierke's disease; lipodystrophy; Cushing's syndrome;
KW sexual ateliotic dwarfism; hyperthyroidism; hypertension;
KW anorexia nervosa; Werner's syndrome; hepatoma; multiple myeloma; uraemia;
KW impotence; obstructive liver disease; Alzheimer's; dementia; diabetes;
KW obesity; atherosclerosis; human; chromosome 2p23-2p24; ds;
KW antisense target.
XX
OS Homo sapiens.
XX
PN WO2004044181-A2.

```
XX
PD   27-MAY-2004.
XX
PF   13-NOV-2003; 2003WO-US036411.
XX
PR   13-NOV-2002; 2002US-0426234P.
PR   15-MAY-2003; 2003WO-US015493.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Crooke R,  Graham M,  Lemonidis-Tarbet K,  Dobie KW;
XX
DR   WPI; 2004-420321/39.
XX
PT   Antisense oligonucleotide compound that inhibits expression of mRNA
PT   encoding human apolipoprotein B, useful for treating hyperlipidemia,
PT   diabetes, obesity, von Gierke's disease, lipodystrophies, Cushing's
PT   syndrome.
XX
PS   Example 36; SEQ ID NO 765; 483pp; English.
XX
CC   The invention relates to a novel antisense compound where the compound
CC   hybridises to and inhibits expression of mRNA encoding human
CC   apolipoprotein B (ApoB) after 16-24 hours by at least 30% in 80%
CC   confluent HepG2 cells in culture at a concentration of 150 nM. The
CC   compound of the invention demonstrates cardiovascular,
CC   antiarteriosclerotic, antilipaemic, antidiabetic, anorectic, cardiant,
CC   vasotropic, hypotensive, anabolic, eating disorder-related, cytostatic,
CC   endocrine, vasotropic, neuroprotective and nootropic activities and may
CC   be useful for inhibiting the expression of apolipoprotein B in cells or
CC   tissues in vivo in order to address a condition associated with abnormal
CC   lipid or cholesterol metabolism. The compound may be useful for
CC   decreasing circulating lipoprotein levels, triglyceride levels,
CC   cholesterol levels, lipid levels, fatty acid levels, acute phase
CC   reactants and chylomicrons and thus may be utilised during treatment of
CC   hyperlipoproteinaemia, hyperlipidaemia, hypercholesterolaemia,
CC   cardiovascular disorders, Von Gierke's disease, lipodystrophy, Cushing's
CC   syndrome, sexual ateliotic dwarfism, hyperthyroidism, hypertension,
CC   anorexia nervosa, Werner's syndrome, hepatoma, multiple myeloma, uraemia,
CC   impotence, obstructive liver disease, Alzheimer's disease, dementia,
CC   diabetes, obesity and atherosclerosis. The current sequence is that of a
CC   human apolipoprotein B (ApoB) antisense therapy target DNA of the
CC   invention. The human ApoB gene is located at chromosome 2p23-2p24.
XX
SQ   Sequence 20 BP; 6 A; 4 C; 5 G; 5 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 15.8;  DB 1;  Length 20;
  Best Local Similarity   89.5%;  Pred. No. 1.8e+02;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        574 TGCCTAGCCAGTTGGTAAG 592
              ||||||||||||| | |||
Db          1 TGCCTAGCCAGTTTGAAAG 19


RESULT 62
ADO32994/c
ID   ADO32994 standard; DNA; 20 BP.
XX
AC   ADO32994;
XX
DT   12-AUG-2004  (first entry)
XX
DE   Antisense 2'-MOE gapmer oligo targeted to human ApoB RNA - SEQ 442.
XX
KW   apolipoprotein B; ApoB; cardiovascular; antiarteriosclerotic;
KW   antilipaemic; antidiabetic; anorectic; cardiant; vasotropic; hypotensive;
KW   anabolic; eating disorder; cytostatic; endocrine; vasotropic;
KW   neuroprotective; nootropic; lipid; cholesterol metabolism;
KW   hyperlipoproteinaemia; hyperlipidaemia; hypercholesterolaemia;
KW   Von Gierke's disease; lipodystrophy; Cushing's syndrome;
KW   sexual ateliotic dwarfism; hyperthyroidism; hypertension;
KW   anorexia nervosa; Werner's syndrome; hepatoma; multiple myeloma; uraemia;
KW   impotence; obstructive liver disease; Alzheimer's; dementia; diabetes;
KW   obesity; atherosclerosis; antisense; 2'-MOE gapmer; 2'-methoxyethyl wing;
KW   phosphorothioate backbone; human; chromosome 2p23-2p24; ss.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "OTHER = Phosphorothioate backbone, bases 1-5 and
FT                   16-20 2'-MOE wing bases, all cytidine residues are 5-
FT                   methylcytidines"
XX
PN   WO2004044181-A2.
XX
PD   27-MAY-2004.
XX
PF   13-NOV-2003; 2003WO-US036411.
XX
PR   13-NOV-2002; 2002US-0426234P.
PR   15-MAY-2003; 2003WO-US015493.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Crooke R,  Graham M,  Lemonidis-Tarbet K,  Dobie KW;
XX
DR   WPI; 2004-420321/39.
XX
PT   Antisense oligonucleotide compound that inhibits expression of mRNA
PT   encoding human apolipoprotein B, useful for treating hyperlipidemia,
PT   diabetes, obesity, von Gierke's disease, lipodystrophies, Cushing's
PT   syndrome.
XX
PS   Example 33; SEQ ID NO 442; 483pp; English.
XX
CC   The invention relates to a novel antisense compound where the compound
CC   hybridises to and inhibits expression of mRNA encoding human
CC   apolipoprotein B (ApoB) after 16-24 hours by at least 30% in 80%
CC   confluent HepG2 cells in culture at a concentration of 150 nM. The
CC   compound of the invention demonstrates cardiovascular,
CC   antiarteriosclerotic, antilipaemic, antidiabetic, anorectic, cardiant,
CC   vasotropic, hypotensive, anabolic, eating disorder-related, cytostatic,
CC   endocrine, vasotropic, neuroprotective and nootropic activities and may
CC   be useful for inhibiting the expression of apolipoprotein B in cells or
CC   tissues in vivo in order to address a condition associated with abnormal
CC   lipid or cholesterol metabolism. The compound may be useful for
CC   decreasing circulating lipoprotein levels, triglyceride levels,
CC   cholesterol levels, lipid levels, fatty acid levels, acute phase
CC   reactants and chylomicrons and thus may be utilised during treatment of
CC   hyperlipoproteinaemia, hyperlipidaemia, hypercholesterolaemia,
CC   cardiovascular disorders, Von Gierke's disease, lipodystrophy, Cushing's
CC   syndrome, sexual ateliotic dwarfism, hyperthyroidism, hypertension,
CC   anorexia nervosa, Werner's syndrome, hepatoma, multiple myeloma, uraemia,
CC   impotence, obstructive liver disease, Alzheimer's disease, dementia,
CC   diabetes, obesity and atherosclerosis. The current sequence is that of an
CC   antisense 2'-MOE (2'-methoxyethyl) gapmer oligo of the invention which is
CC   targeted to human ApoB RNA.
XX
SQ   Sequence 20 BP; 5 A; 5 C; 4 G; 6 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 15.8;  DB 1;  Length 20;
  Best Local Similarity   89.5%;  Pred. No. 1.8e+02;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        574 TGCCTAGCCAGTTGGTAAG 592
              ||||||||||||| | |||
Db         20 TGCCTAGCCAGTTTGAAAG 2


RESULT 63
AAT41783/c
ID   AAT41783 standard; DNA; 21 BP.
```

```
XX
AC   AAT41783;
XX
DT   18-FEB-1997  (first entry)
XX
DE   Lacto-N-biosidase gene primer LNB-SRV.
XX
KW   Lacto-N-biosidase; glycosylation; sugar chain; Streptomyces;
KW   polymerase chain reaction; PCR; primer; ss.
XX
OS   Synthetic.
XX
PN   EP739983-A2.
XX
PD   30-OCT-1996.
XX
PF   25-APR-1996;   96EP-00106569.
XX
PR   27-APR-1995;   95JP-00129731.
XX
PA   (TAKI ) TAKARA SHUZO CO LTD.
XX
PI   Mitta M,  Sano M,  Kato I;
XX
DR   WPI; 1996-478747/48.
XX
PT   Streptomyces lacto-N-biosidase DNA - for prodn. of recombinant lacto-N-
PT   biosidase for determination of sugar chain structure and function.
XX
PS   Example 2; Page 25; 27pp; English.
XX
CC   PCR primer LNBP-M (AAT41782) has a HindIII site and an NcoI site upstream
CC   of 24 nucleotides corresponding to positions 106-129 of Streptomyces sp.
CC   142 lacto-N-biosidase DNA (see also AAT41776). Primer LNB-SRV (AAT41783)
CC   is complementary to bases 301-321 of the sequence. The primers were used
CC   to amplify lacto-N-biosidase DNA in pULNBP2-17MluE. Expression plasmid
CC   pLNBM was constructed that allows prodn. of Streptomyces sp. lacto-N-
CC   biosidase (AAW00366) in Escherichia coli transformants
XX
SQ   Sequence 21 BP; 3 A; 7 C; 7 G; 4 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 15.8;  DB 1;  Length 21;
  Best Local Similarity   89.5%;  Pred. No. 1.8e+02;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        746 CCTCGTGCTGCGCCTGGAC 764
              | ||||||||||||| ||||
Db         19 CATCGTGCTGCGCCAGGAC 1


RESULT 64
AAX32869/c
ID   AAX32869 standard; DNA; 21 BP.
XX
AC   AAX32869;
XX
DT   27-AUG-2003  (revised)
DT   20-MAR-2003  (revised)
DT   28-JUN-1999  (first entry)
XX
DE   HBV DR region binding TFO B12.
XX
KW   Triplex-forming oligonucleotide; TFO; promoter region; pre-S gene;
KW   inhibition; hepatitis B virus; HBV adr subtype; DR region; ss.
XX
OS   Synthetic.
OS   Hepatitis B virus.
XX
FH   Key             Location/Qualifiers
FT   misc_feature    21
FT                   /*tag=  a
FT                   /note= "optional monophosphorylation (claim 2)"
XX
PN   WO9920641-A1.
XX
PD   29-APR-1999.
XX
PF   19-OCT-1998;   98WO-CN000248.
XX
PR   21-OCT-1997;   97CN-00106667.
XX
PA   (SHAN-) SHANGHAI INST BIOCHEMISTRY CHINESE ACAD.
XX
PI   Lu C;
XX
DR   WPI; 1999-288270/27.
XX
PT   Triplex-forming oligonucleotides, useful for, e.g. inhibition of
PT   hepatitis B virus (HBV).
XX
PS   Claim 1, 2; Page 22; 39pp; Chinese.
XX
CC   The invention provides triplex-forming oligonucleotides (TFO) and their
CC   modified derivatives. TFO B1-B5 (AAX32862-866) can bind with the promoter
CC   region of pre-S gene in inhibition of hepatitis B virus (HBV) adr subtype
CC   and TFO B11, B12 and B15 (AAX32868-870) can bind with DR region of HBV.
CC   The oligonucleotides are useful for inhibition of HBV and as drug in
CC   treatment of hepatitis B. Since the length of the oligonucleotides can be
CC   suitably increased, the stability and specificity of the formed triplex
CC   DNA with 2 similar homopoly purine/homopoly pyrimidine fragments are
CC   higher. Triplex formation is specifically targeting on the HBV gene
CC   expression, DNA replication and reproduction, or to produce (DNA)2:RNA
CC   hybrid triplex with target sequence of RNA in stopping RNA reverse
CC   transcription, so there is little effect on the human cells. Such
CC   olgionucleotides are chemically modified by 3'-terminal
CC   monophosphorylation, leading to more significant inhibition due to their
CC   higher stability, and the degradation products of the modified
CC   oligonucleotides are not toxic to the body. (Updated on 20-MAR-2003 to
CC   correct DR field.) (Updated on 27-AUG-2003 to correct OS field.)
XX
SQ   Sequence 21 BP; 7 A; 0 C; 14 G; 0 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 15.8;  DB 1;  Length 21;
  Best Local Similarity   89.5%;  Pred. No. 1.8e+02;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        256 CCTCCTCTTCGCCCTCGTC 274
              |||||||||| ||||| ||
Db         20 CCTCCTCTTCCCCCTCCTC 2


RESULT 65
AAF97567
ID   AAF97567 standard; DNA; 21 BP.
XX
AC   AAF97567;
XX
DT   06-JUN-2001  (first entry)
XX
DE   Human gene single nucleotide polymorphism #2328.
XX
KW   Human; variant thrombospondin 1; variant thrombospondin 4; SNP;
KW   polymorphism; vascular disease; coronary artery disease; forensics;
KW   myocardial infarction; atherosclerosis; stroke; venous thromboembolism;
KW   pulmonary embolism; paternity test; ds.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   Variation       replace(11,G)
FT                   /*tag=  a
FT                   /standard_name= "single nucleotide polymorphism"
XX
PN   WO200118250-A2.
XX
PD   15-MAR-2001.
```

```
XX
PF   07-SEP-2000; 2000WO-US024503.
XX
PR   10-SEP-1999;   99US-0153357P.
PR   26-JUL-2000; 2000US-0220947P.
PR   16-AUG-2000; 2000US-0225724P.
XX
PA   (WHED ) WHITEHEAD INST BIOMEDICAL RES.
PA   (MILL-) MILLENNIUM PHARM INC.
XX
PI   Lander ES,  Gargill M,  Ireland JS,  Bolk S,  Daley GQ,  Mccarthy JJ;
XX
DR   WPI; 2001-226749/23.
XX
PT   Nucleic acids comprising single nucleotide polymorphisms, useful in
PT   applications such as forensics, paternity testing, medicine, genetic
PT   analysis and phenotype correlations to diseases such as diabetes and
PT   atherosclerosis.
XX
PS   Example; Page 207; 242pp; English.
XX
CC   The present invention provides a method of diagnosing a vascular disease
CC   in an individual, involving determining the sequence at various
CC   polymorphic sites within the human thrombospondin 1 and thrombospondin 4
CC   genes. The sequences at a number of polymorphic sites are also provided
CC   in the specification. In particular, the method can be used in the
CC   diagnosis of atherosclerosis, myocardial infarction, coronary heart
CC   disease, stroke, peripheral vascular diseases, venous thromboembolism and
CC   pulmonary embolism. Single nucleotide polymorphisms (SNPs) are also
CC   useful in forensics, paternity testing, genetic analysis and phenotype
CC   correlations to diseases. The present sequence is an example of one of
CC   the human gene SNPS shown in the specification
XX
SQ   Sequence 21 BP; 5 A; 11 C; 4 G; 1 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 15.8;  DB 1;  Length 21;
  Best Local Similarity   89.5%;  Pred. No. 1.8e+02;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        701 CCAGCTGGCACTCGACCCC 719
              ||||| | ||||||||||||
Db          2 CCAGCGGACACTCGACCCC 20


RESULT 66
AAN70281
ID   AAN70281 standard; DNA; 27 BP.
XX
AC   AAN70281;
XX
DT   03-OCT-2002  (revised)
DT   26-MAY-1991  (first entry)
XX
DE   Sequence of scissile link probe MRC071 (HL).
XX
KW   Hybridisation; probe; ss.
XX
OS   Synthetic.
XX
PN   EP227976-A.
XX
PD   08-JUL-1987.
XX
PF   04-DEC-1986;   86EP-00116906.
XX
PR   05-DEC-1985;   85US-00805279.
XX
PA   (MEIO-) MEIOGENICS INC.
XX
PI   Duck P,  Bender R,  Crosby W,  Robertson JG;
XX
DR   WPI; 1987-186567/27.
XX
PT   Synthetic nucleic acid probes - comprising two nucleic acid sequences
PT   linked by a scissile linkage.
XX
PS   Example; p29; 46pp; English.
XX
CC   The patent claims a new molecule of formula (NA1----S----NA2)n. NA1 and
CC   NA2 are noncomplementary nucleic acid sequences; ---S--- = a scissile
CC   linkage; n= 1 or 1,000, which is used for the detection of specific DNA
CC   or RNA sequences in a test soln. The scissile link probes may be PL
CC   (Permanent Linkage to Solid Support) or HL (Hydrolysable Linkage to Solid
CC   Support). The differential liability of DNA and RNA may be exploited in a
CC   heterogenous system when the scissile linkage is an RNA molecule. In the
CC   examples, counter probe molecules 9 through 16 were used to determine
CC   suitable hybridisation conditions. (Updated on 03-OCT-2002 to add missing
CC   OS field.)
XX
SQ   Sequence 27 BP; 0 A; 0 C; 0 G; 25 T; 2 U; 0 Other;

  Query Match             0.9%;  Score 15.8;  DB 1;  Length 27;
  Best Local Similarity   70.4%;  Pred. No. 1.8e+02;
  Matches   19;  Conservative    1;  Mismatches    7;  Indels    0;  Gaps    0;

Qy       1382 TTTGTTGTTTGTTTTGTATCTTGTTTT 1408
              ||| || ||| |||| : | || ||||
Db          1 TTTTTTTTTTTTTTTUUTTTTTTTTT 27


RESULT 67
AAN70274
ID   AAN70274 standard; DNA; 27 BP.
XX
AC   AAN70274;
XX
DT   03-OCT-2002  (revised)
DT   26-MAY-1991  (first entry)
XX
DE   Sequence of scissile link probe MRC046 (PL).
XX
KW   Hybridisation; probe; ss.
XX
OS   Synthetic.
XX
PN   EP227976-A.
XX
PD   08-JUL-1987.
XX
PF   04-DEC-1986;   86EP-00116906.
XX
PR   05-DEC-1985;   85US-00805279.
XX
PA   (MEIO-) MEIOGENICS INC.
XX
PI   Duck P,  Bender R,  Crosby W,  Robertson JG;
XX
DR   WPI; 1987-186567/27.
XX
PT   Synthetic nucleic acid probes - comprising two nucleic acid sequences
PT   linked by a scissile linkage.
XX
PS   Example; p29; 46pp; English.
XX
CC   The patent claims a new molecule of formula (NA1----S----NA2)n. NA1 and
CC   NA2 are noncomplementary nucleic acid sequences; ---S--- = a scissile
CC   linkage; n= 1 or 1,000, which is used for the detection of specific DNA
CC   or RNA sequences in a test soln. The scissile link probes may be PL
CC   (Permanent Linkage to Solid Support) or HL (Hydrolysable Linkage to Solid
CC   Support). The differential liability of DNA and RNA may be exploited in a
CC   heterogenous system when the scissile linkage is an RNA molecule. In the
CC   examples, counter probe molecules 9 through 16 were used to determine
CC   suitable hybridisation conditions. (Updated on 03-OCT-2002 to add missing
CC   OS field.)
XX
SQ   Sequence 27 BP; 0 A; 0 C; 0 G; 21 T; 6 U; 0 Other;
```

```
  Query Match             0.9%;  Score 15.8;  DB 1;  Length 27;
  Best Local Similarity   59.3%;  Pred. No. 1.8e+02;
  Matches   16;  Conservative    4;  Mismatches    7;  Indels    0;  Gaps    0;

Qy       1382 TTTGTTGTTTGTTTTGTATCTTGTTTT 1408
              ||| || ||| :::: | | || ||||
Db          1 TTTTTTTTTTUUUUUTTTTTTTTTT 27


RESULT 68
AAN92240
ID   AAN92240 standard; DNA; 27 BP.
XX
AC   AAN92240;
XX
DT   25-MAR-2003  (revised)
DT   31-OCT-2002  (revised)
DT   25-APR-1990  (first entry)
XX
DE   SS probe MRCO46.
XX
KW   Probe MRCO46; solid support; ribonuclease.
XX
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   misc_feature    1. .10
FT                   /*tag=  a
FT                   /note= "deoxyribonucleotides."
FT   misc_feature    11. .16
FT                   /*tag=  b
FT                   /note= "ribonucleotides."
FT   misc_feature    17. .27
FT                   /*tag=  c
FT                   /note= "deoxyribonucleotides."
XX
PN   WO8910415-A.
XX
PD   02-NOV-1989.
XX
PF   29-APR-1988;   88US-00187814.
XX
PR   29-APR-1988;   88US-00187814.
XX
PA   (MEIO-) MEIOGENICS INC.
XX
PI   Duck P,  Bender R;
XX
DR   WPI; 1989-339977/46.
XX
PT   Detecting target nucleic acid molecules - using excess complementary
PT   nucleic acid probes and nicking to complete a cycling sequence.
XX
PS   Disclosure; Page 24; 34pp; English.
XX
CC   Probe MRCO46 is bound by a permanent linkage to a solid support at its 3'
CC   end. It is used by reacting excess probe with a target nucleic acid;
CC   nicking hybridised probe at least once within a predetermined sequence to
CC   form 2 or more probe fragments hybridised to the target sequence, which
CC   results in the probe fragments becoming hybridised to another probe; and
CC   identifying probe fragments, so detecting the target sequence. The probe
CC   can react with target sequence to complete a cycling sequence. Using this
CC   system, sensitivity of 10 exp. -19 to 10 exp. -20 molecules of target can
CC   be obtd. The probe is cleavable at the ribonucleotides by a ds RNase, eg
CC   RNase H or ExoIII. (Updated on 31-OCT-2002 to add missing OS field.)
CC   (Updated on 25-MAR-2003 to correct PR field.)
XX
SQ   Sequence 27 BP; 0 A; 0 C; 0 G; 21 T; 6 U; 0 Other;

  Query Match             0.9%;  Score 15.8;  DB 1;  Length 27;
  Best Local Similarity   59.3%;  Pred. No. 1.8e+02;
  Matches   16;  Conservative    4;  Mismatches    7;  Indels    0;  Gaps    0;

Qy       1382 TTTGTTGTTTGTTTTGTATCTTGTTTT 1408
              ||| || ||| :::: | | || ||||
Db          1 TTTTTTTTTTUUUUUTTTTTTTTTT 27


RESULT 69
AAN92247
ID   AAN92247 standard; DNA; 27 BP.
XX
AC   AAN92247;
XX
DT   25-MAR-2003  (revised)
DT   31-OCT-2002  (revised)
DT   25-APR-1990  (first entry)
XX
DE   SS probe MRCO71.
XX
KW   Probe MRCO71; solid support; ribonuclease.
XX
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   misc_feature    1. .15
FT                   /*tag=  a
FT                   /note= "deoxyribonucleotides."
FT   misc_feature    16. .17
FT                   /*tag=  b
FT                   /note= "ribonucleotides."
FT   misc_feature    18. .27
FT                   /*tag=  c
FT                   /note= "deoxyribonucleotides."
XX
PN   WO8910415-A.
XX
PD   02-NOV-1989.
XX
PF   29-APR-1988;   88US-00187814.
XX
PR   29-APR-1988;   88US-00187814.
XX
PA   (MEIO-) MEIOGENICS INC.
XX
PI   Duck P,  Bender R;
XX
DR   WPI; 1989-339977/46.
XX
PT   Detecting target nucleic acid molecules - using excess complementary
PT   nucleic acid probes and nicking to complete a cycling sequence.
XX
PS   Disclosure; Page 24; 34pp; English.
XX
CC   Probe MRCO71 is bound by a hydrolysable linkage to a solid support at its
CC   3' end. It is used by reacting excess probe with a target nucleic acid;
CC   nicking hybridised probe at least once within a predetermined sequence to
CC   form 2 or more probe fragments hybridised to the target sequence, which
CC   results in the probe fragments becoming hybridised to another probe; and
CC   identifying probe fragments, so detecting the target sequence. The probe
CC   can react with target sequence to complete a cycling sequence. Using this
CC   system, sensitivity of 10 exp. -19 to 10 exp. -20 molecules of target can
CC   be obtd. The probe is cleavable at the ribonucleotides by a ds RNase, eg
CC   RNase H or ExoIII. (Updated on 31-OCT-2002 to add missing OS field.)
CC   (Updated on 25-MAR-2003 to correct PR field.)
XX
SQ   Sequence 27 BP; 0 A; 0 C; 0 G; 25 T; 2 U; 0 Other;

  Query Match             0.9%;  Score 15.8;  DB 1;  Length 27;
  Best Local Similarity   70.4%;  Pred. No. 1.8e+02;
  Matches   19;  Conservative    1;  Mismatches    7;  Indels    0;  Gaps    0;

Qy       1382 TTTGTTGTTTGTTTTGTATCTTGTTTT 1408
              ||| || ||| |||| : | || ||||
Db          1 TTTTTTTTTTTTTTTUUTTTTTTTTT 27
```

```
RESULT 70
AAQ40854/c
ID   AAQ40854 standard; DNA; 27 BP.
XX
AC   AAQ40854;
XX
DT   23-SEP-1993  (first entry)
XX
DE   DNA sequence used in DNA replication method.
XX
KW   ss.
XX
OS   Synthetic.
XX
PN   JP05103673-A.
XX
PD   27-APR-1993.
XX
PF   26-AUG-1991;   91JP-00240525.
XX
PR   26-AUG-1991;   91JP-00240525.
XX
PA   (UYAR-) UNIV ARIZONA.
XX
DR   WPI; 1993-171830/21.
XX
PT   Replication of DNA - useful in genetic engineering and medical
PT   applications.
XX
PS   Disclosure; Page 20; 20pp; Japanese.
XX
CC   The sequence is given in the disclosure to illustrate the invention
XX
SQ   Sequence 27 BP; 27 A; 0 C; 0 G; 0 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 15.8;  DB 1;  Length 27;
  Best Local Similarity   74.1%;  Pred. No. 1.8e+02;
  Matches   20;  Conservative    0;  Mismatches    7;  Indels    0;  Gaps    0;

Qy       1382 TTTGTTGTTTGTTTTGTATCTTGTTTT 1408
             ||| || ||| |||| | | || ||||
Db         27 TTTTTTTTTTTTTTTTTTTTTTTTTTT 1


RESULT 71
AAF99706
ID   AAF99706 standard; DNA; 27 BP.
XX
AC   AAF99706;
XX
DT   12-JUN-2001  (first entry)
XX
DE   Immunostimulatory nucleic acid #822.
XX
KW   Vaccine; cytostatic; virucidal; bactericidal; fungicidal; anti-parasitic;
KW   immunostimulatory; tumour; viral infection; bacterial infection;
KW   fungal infection; parasitic infection; cancer; asthma;
KW   infectious disease; allergy; immune deficiency; phosphorothioate; ss.
XX
OS   Synthetic.
XX
PN   WO200122972-A2.
XX
PD   05-APR-2001.
XX
PF   25-SEP-2000; 2000WO-US026383.
XX
PR   25-SEP-1999;   99US-0156113P.
PR   27-SEP-1999;   99US-0156135P.
PR   23-AUG-2000; 2000US-0227436P.
XX
PA   (IOWA ) UNIV IOWA RES FOUND.
PA   (COLE-) COLEY PHARM GMBH.
XX
PI   Krieg AM,  Schetter C,  Vollmer J;
XX
DR   WPI; 2001-273485/28.
XX
PT   Vaccinating against tumors, infectious diseases, allergies and asthma
PT   using immunostimulatory Py-rich and TG nucleic acids.
XX
PS   Claim 101; Page 56; 338pp; English.
XX
CC   The present invention relates to a method for stimulating an immune
CC   response. The method comprises administering an immunostimulatory nucleic
CC   acid to a non-rodent subject in sufficient quantity to stimulate an
CC   immune response. The present sequence is one such immunostimulatory
CC   nucleic acid. The immunostimulatory nucleic acids can be pyrimidine rich
CC   (py-rich) or thymidine (T) rich. The method is used to vaccinate subjects
CC   against tumour antigens, viral antigens (e.g. herpesviridae, retroviridae
CC   and/or orthomyxoviridae), bacterial antigens (e.g. toxoplasma,
CC   haemophilus, campylobacter, clostridium, Escherichia coli and/or
CC   staphylococcus), fungal antigens and/or parasitic antigens. The method is
CC   also useful for preventing cancer, asthma, infectious disease, allergy or
CC   immune deficiency. The present sequence can also be used to redirect a
CC   Th2 to a Th1 immune response and to activate immune cells. Note: the
CC   present sequence may have a phosphorothioate backbone
XX
SQ   Sequence 27 BP; 0 A; 0 C; 0 G; 27 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 15.8;  DB 1;  Length 27;
  Best Local Similarity   74.1%;  Pred. No. 1.8e+02;
  Matches   20;  Conservative    0;  Mismatches    7;  Indels    0;  Gaps    0;

Qy       1382 TTTGTTGTTTGTTTTGTATCTTGTTTT 1408
             ||| || ||| |||| | | || ||||
Db          1 TTTTTTTTTTTTTTTTTTTTTTTTTTT 27


RESULT 72
ABS78427
ID   ABS78427 standard; DNA; 27 BP.
XX
AC   ABS78427;
XX
DT   13-DEC-2002  (first entry)
XX
DE   Angiogenesis inhibitory oligonucleotide #911.
XX
KW   Angiogenesis inhibitor; ss; angiogenesis; solid tumour growth;
KW   tumour metastasis; precancerous lesion; rheumatoid arthritis; psoriasis;
KW   diabetic retinopathy; retinopathy of prematurity; macular degeneration;
KW   corneal graft rejection; neovascular glaucoma; retrolental fibroplasia;
KW   rubeosis; Osler-Webber Syndrome; myocardial angiogenesis;
KW   plaque neovascularisation; telangiectasia; haemophiliac joint;
KW   angiofibroma; wound granulation; intestinal adhesion; atherosclerosis;
KW   scleroderma; hypertrophic scar.
XX
OS   Synthetic.
XX
PN   WO200253141-A2.
XX
PD   11-JUL-2002.
XX
PF   14-DEC-2001; 2001WO-US048458.
XX
PR   14-DEC-2000; 2000US-0255534P.
XX
PA   (COLE-) COLEY PHARM GROUP INC.
XX
PI   Bratzler RL;
XX
DR   WPI; 2002-566690/60.
XX
```

```
PT   Inhibiting angiogenesis in a subject, involves administering at least one
PT   antiangiogenic nucleic acid molecule to the subject.
XX
PS   Claim 2; Page 35; 276pp; English.
XX
CC   The invention relates to inhibiting angiogenesis in a subject, comprising
CC   administering at least one antiangiogenic nucleic acid molecule. Also
CC   included is a kit comprising a first container housing the antiangiogenic
CC   nucleic acids, and instructions for administering them to a subject
CC   having a condition characterised by unwanted angiogenesis. The method is
CC   useful for inhibiting angiogenesis associated with solid tumour growth,
CC   tumour metastasis, precancerous lesion, rheumatoid arthritis, psoriasis,
CC   diabetic retinopathy, retinopathy of prematurity, macular degeneration,
CC   corneal graft rejection, neovascular glaucoma, retrolental fibroplasia,
CC   rubeosis, Osler-Webber Syndrome, myocardial angiogenesis, plaque
CC   neovascularisation, telangiectasia, haemophiliac joints, angiofibroma,
CC   wound granulation, intestinal adhesions, atherosclerosis, scleroderma and
CC   hypertrophic scars. The present sequence is an antiangiogenic nucleic
CC   acid of the invention
XX
SQ   Sequence 27 BP; 0 A; 0 C; 0 G; 27 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 15.8;  DB 1;  Length 27;
  Best Local Similarity   74.1%;  Pred. No. 1.8e+02;
  Matches   20;  Conservative    0;  Mismatches    7;  Indels    0;  Gaps    0;

Qy       1382 TTTGTTGTTTGTTTTGTATCTTGTTTT 1408
              ||| || ||| |||| | | || ||||
Db          1 TTTTTTTTTTTTTTTTTTTTTTTTTTT 27


RESULT 73
ABL39406
ID   ABL39406 standard; DNA; 27 BP.
XX
AC   ABL39406;
XX
DT   16-APR-2002  (first entry)
XX
DE   Immunostimulatory nucleic acid SEQ ID NO: 842.
XX
KW   Antibody-induced cell lysis; cancer; immunostimulatory; CD20;
KW   angiogenesis; metastasis; cytostatic; phosphorothioate backbone; ss.
XX
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base    1. .27
FT                    /*tag=  a
FT                    /mod_base= OTHER
FT                    /note= "phosphorothioate backbone"
XX
PN   WO200197843-A2.
XX
PD   27-DEC-2001.
XX
PF   22-JUN-2001; 2001WO-US020154.
XX
PR   22-JUN-2000; 2000US-0213346P.
XX
PA   (IOWA ) UNIV IOWA RES FOUND.
XX
PI   Weiner G,  Hartmann G;
XX
DR   WPI; 2002-154611/20.
XX
PT   Treating or preventing cancer, such as basal cell carcinoma, comprises
PT   administering immunostimulatory nucleic acids that induce expression of
PT   cell surface antigens and antibodies to a subject having or at risk of
PT   developing cancer.
XX
PS   Disclosure; Page 310; 312pp; English.
XX
CC   The present invention relates to methods for treating or preventing
CC   cancer, involving administering to a subject having or at risk of
CC   developing cancer immunostimulatory nucleic acids that induce expression
CC   of cell surface antigens and antibodies. The methods are useful for
CC   treating or preventing cancer such as basal cell carcinoma, bladder
CC   cancer, bone cancer, brain and central nervous system (CNS) cancer,
CC   breast cancer, cervical cancer, colon and rectum cancer, connective
CC   tissue cancer, oesophageal cancer, eye cancer, kidney cancer, larynx
CC   cancer, leukaemia, liver cancer, lung cancer, Hodgkin's lymphoma, non-
CC   Hodgkin's lymphoma, melanoma, myeloma, oral cavity cancer, ovarian
CC   cancer, pancreatic cancer, prostate cancer, rhabdomyosarcoma, skin
CC   cancer, stomach cancer, testicular cancer, and uterine cancer. The
CC   present sequence is an immunostimulatory oligonucleotide described in the
CC   exemplification of the invention
XX
SQ   Sequence 27 BP; 0 A; 0 C; 0 G; 27 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 15.8;  DB 1;  Length 27;
  Best Local Similarity   74.1%;  Pred. No. 1.8e+02;
  Matches   20;  Conservative    0;  Mismatches    7;  Indels    0;  Gaps    0;

Qy       1382 TTTGTTGTTTGTTTTGTATCTTGTTTT 1408
              ||| || ||| |||| | | || ||||
Db          1 TTTTTTTTTTTTTTTTTTTTTTTTTTT 27


RESULT 74
ACH03245
ID   ACH03245 standard; DNA; 27 BP.
XX
AC   ACH03245;
XX
DT   25-SEP-2003  (first entry)
XX
DE   Immunostimulatory nucleic acid #880.
XX
KW   Immunostimulatory; antiinflammatory; dermatological; antipsoriatic;
KW   antiulcer; gene therapy; vaccine; non-allergic inflammatory disease;
KW   psoriasis; eczema; allergic contact dermatitis; latex dermatitis;
KW   inflammatory bowel disease; ulcerative colitis; Crohn's disease; ss.
XX
OS   Synthetic.
XX
PN   US2003050268-A1.
XX
PD   13-MAR-2003.
XX
PF   29-MAR-2002; 2002US-00112653.
XX
PR   29-MAR-2001; 2001US-0279642P.
XX
PA   (KRIE/) KRIEG A M.
PA   (BERG/) BERG D J.
XX
PI   Krieg AM,  Berg DJ;
XX
DR   WPI; 2003-521815/49.
XX
PT   Treating non-allergic inflammatory diseases, such as psoriasis, eczema,
PT   allergic contact dermatitis, latex dermatitis or inflammatory bowel
PT   disease by administering an immunostimulatory nucleic acid.
XX
PS   Disclosure; Page 32; 229pp; English.
XX
CC   The invention describes a method of treating non-allergic inflammatory
CC   disease comprising administering to a subject having or at risk of
CC   developing a non-allergic inflammatory disease an immunostimulatory
CC   nucleic acid for prevention or treatment of the disease. The method is
CC   useful for treating non-allergic inflammatory diseases, such as
CC   psoriasis, eczema, allergic contact dermatitis, latex dermatitis or
CC   inflammatory bowel disease e.g., ulcerative colitis or Crohn's disease.
CC   This sequence represents an immunostimulatory nucleic acid
XX
```

```
SQ   Sequence 27 BP; 0 A; 0 C; 0 G; 27 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 15.8;  DB 1;  Length 27;
  Best Local Similarity   74.1%;  Pred. No. 1.8e+02;
  Matches   20;  Conservative    0;  Mismatches    7;  Indels    0;  Gaps    0;

Qy       1382 TTTGTTGTTTGTTTTGTATCTTGTTTT 1408
             ||| || ||| |||| | | || ||||
Db          1 TTTTTTTTTTTTTTTTTTTTTTTTTTT 27


RESULT 75
ADB37208
ID   ADB37208 standard; DNA; 27 BP.
XX
AC   ADB37208;
XX
DT   04-DEC-2003  (first entry)
XX
DE   Immunostimulatory nucleic acid #822.
XX
KW   ds; allergy; asthma; poly-G nucleic acid; aerosol formulation;
KW   hypo-responsive subject; immunostimulatory.
XX
OS   Synthetic.
XX
PN   US2003087848-A1.
XX
PD   08-MAY-2003.
XX
PF   02-FEB-2001; 2001US-00776479.
XX
PR   03-FEB-2000; 2000US-0179991P.
XX
PA   (BRAT/) BRATZLER R L.
PA   (PETE/) PETERSEN D M.
PA   (FOUR/) FOURON Y.
XX
PI   Bratzler RL,  Petersen DM,  Fouron Y;
XX
DR   WPI; 2003-657977/62.
XX
PT   Treating and/or preventing allergy or asthma using an immunostimulatory
PT   nucleic acid alone or in combination with an asthma/allergy medicament.
XX
PS   Disclosure; Page 17; 221pp; English.
XX
CC   The invention relates to a method of treating or preventing allergy or
CC   asthma which comprises administering to a subject a poly-G nucleic acid
CC   in an aerosol formulation. The methods and compositions of the present
CC   invention are useful for diagnosing and/or treating asthma and allergy
CC   especially in a hypo-responsive subject. The present sequence represents
CC   an immunostimulatory nucleic acid of the invention.
XX
SQ   Sequence 27 BP; 0 A; 0 C; 0 G; 27 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 15.8;  DB 1;  Length 27;
  Best Local Similarity   74.1%;  Pred. No. 1.8e+02;
  Matches   20;  Conservative    0;  Mismatches    7;  Indels    0;  Gaps    0;

Qy       1382 TTTGTTGTTTGTTTTGTATCTTGTTTT 1408
             ||| || ||| |||| | | || ||||
Db          1 TTTTTTTTTTTTTTTTTTTTTTTTTTT 27


RESULT 76
AAA40358
ID   AAA40358 standard; DNA; 28 BP.
XX
AC   AAA40358;
XX
DT   10-NOV-2000  (first entry)
XX
DE   pBluescriptSK+ phagemid primer SEQ ID NO: 8.
XX
KW   Primer; cloning; ligation; ss.
XX
OS   Synthetic.
XX
PN   WO200036088-A1.
XX
PD   22-JUN-2000.
XX
PF   17-DEC-1999;   99WO-US030277.
XX
PR   17-DEC-1998;   98US-00213834.
XX
PA   (ROMA/) ROMANTCHIKOV Y.
XX
PI   Romantchikov Y;
XX
DR   WPI; 2000-442381/38.
XX
PT   Inserting a nucleic acid into a circular vector comprising joining their
PT   ends, melting, and reannealing ends at two different concentrations,
PT   useful for cloning small amounts of nucleic acids and forming genomic
PT   libraries.
XX
PS   Example 3; Page 67; 71pp; English.
XX
CC   This invention describes a novel method (M1) for inserting a nucleic acid
CC   (N1) into a circular vector (V1) comprising joining ends of N1 and V1
CC   under a first nucleic acid concentration, melting hybridized cohesive
CC   circularization ends, and reannealing the ends at a second concentration.
CC   The methods are useful for the cloning small amounts of nucleic acids and
CC   forming genomic libraries of complex populations of DNA or cDNA. The
CC   methods allow the cloning of minute amounts of nucleic acids efficiently
CC   and avoids the size selection problems of prior art systems. Larger
CC   nucleic acid fragments are just as easily cloned, allowing highly
CC   representative libraries to be made. Vector to vector ligation is avoided
CC   using the methods. AAA40351-A40366 represents primers used to illustrate
CC   the method of the invention
XX
SQ   Sequence 28 BP; 1 A; 1 C; 1 G; 25 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 15.8;  DB 1;  Length 28;
  Best Local Similarity   74.1%;  Pred. No. 1.8e+02;
  Matches   20;  Conservative    0;  Mismatches    7;  Indels    0;  Gaps    0;

Qy       1383 TTGTTGTTTGTTTTGTATCTTGTTTTT 1409
              | ||| ||| |||| | | || |||||
Db          2 TAGTTTTTTTTTTTTTTTTTTTTTTTT 28


RESULT 77
AAT66995
ID   AAT66995 standard; DNA; 17 BP.
XX
AC   AAT66995;
XX
DT   05-AUG-1997  (first entry)
XX
DE   Vector-specific primer SK-Zap.
XX
KW   Mch3; cysteine protease; apoptosis; AIDS; ischaemia;
KW   neurodegenerative disease; gene therapy; diagnosis; PCR;
KW   polymerase chain reaction; primer; ss.
XX
OS   Synthetic.
XX
PN   WO9718313-A1.
XX
PD   22-MAY-1997.
XX
PF   12-NOV-1996;   96WO-US018118.
XX
```

PR 13-NOV-1995; 95US-00556627.
XX
PA (IDUN-) IDUN PHARM INC.
PA (UYJE-) UNIV JEFFERSON THOMAS.
XX
PI Alnemri ES, Fernandes-Alnemri T, Litwack G, Armstrong R;
PI Tomaselli K;
XX
DR WPI; 1997-289289/26.
XX
PT New gene encoding Mch3, a cysteine protease that regulates apoptosis -
PT for treating human diseases associated with apoptosis, and screening for
PT antagonists and agonists of Mch3.
XX
PS Example 1; Page 26; 52pp; English.
XX
CC Vector-specific primer SK-Zap (T66995) was used with primer T50-pr1
CC (T66994), based on a GenBank sequence expressed sequence tag, to amplify
CC cDNA from a human Jarkat library. A Ced3-interleukin-1- beta converting
CC enzyme (ICE)-like partial cDNA clone was identified. This was used to
CC rescreen the library, leading to the isolation of cDNA clones (T66992-93)
CC for novel apoptotic cysteine protease Mch3-alpha (W15262) and Mch3-beta
CC (W15263)
XX
SQ Sequence 17 BP; 5 A; 4 C; 6 G; 2 T; 0 U; 0 Other;

Query Match 0.9%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.1e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 16 CAAGAATTCGGCACGAG 32
|| ||||||||||||||
Db 1 CAGGAATTCGGCACGAG 17

RESULT 78
AAT90091
ID AAT90091 standard; DNA; 17 BP.
XX
AC AAT90091;
XX
DT 25-MAR-2003 (revised)
DT 09-APR-1998 (first entry)
XX
DE Primer SK-Zap for Mch4 and Mch5 coding sequences.
XX
KW Mch4; Mch5; aspartic acid specific Cys protease; cell apoptosis; stroke;
KW increased cell survival; hormone dependent tumour; autoimmune disease;
KW immunoglobulin mediated glomerulonephritis; degenerative disease;
KW therapy; PCR primer; amplify; ss.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN WO9735020-A1.
XX
PD 25-SEP-1997.
XX
PF 19-MAR-1997; 97WO-US004330.
XX
PR 19-MAR-1996; 96US-00618408.
PR 14-JUN-1996; 96US-00665220.
XX
PA (IDUN-) IDUN PHARM INC.
PA (UYJE-) UNIV JEFFERSON THOMAS.
XX
PI Alnemri ES, Fernandesalnemri T, Litwack G, Armstrong R;
PI Tomaselli K;
XX
DR WPI; 1997-480225/44.
XX
PT Aspartic acid specific cysteine protease(s) Mch4 and Mch5 - which are
PT involved in cell apoptosis, useful to diagnose and treat, e.g. cancer,
PT autoimmune, Alzheimer's or Parkinson's disease.
XX
PS Example 1; Page 30; 76pp; English.
XX
CC This sequence represents a primer for the Mch4 and Mch5 genes of the
CC invention. Mch4 (see AAW23790) and Mch5 (see AAW27391) are members of the
CC Aspartic acid specific Cys protease family involved in cell apoptosis.
CC The genes and proteins can be to diagnose, treat or reduce the severity
CC of diseases resulting from increased cell survival, e.g. hormone
CC dependent tumours such as breast, prostate or ovarian cancers, or
CC autoimmune diseases, such as systemic lupus erythematosus or
CC immunoglobulin mediated glomerulonephritis, diseases resulting from
CC decreased cell survival, e.g. degenerative diseases such as Alzheimer's
CC or Parkinson's disease, or amyotrophic lateral sclerosis or other
CC diseases associated with increased apoptosis such as aplastic anaemia,
CC stroke, ischaemic injury following myocardial infarction or reperfusion
CC injury. (Updated on 25-MAR-2003 to correct PI field.)
XX
SQ Sequence 17 BP; 5 A; 4 C; 6 G; 2 T; 0 U; 0 Other;

Query Match 0.9%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.1e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 16 CAAGAATTCGGCACGAG 32
|| ||||||||||||||
Db 1 CAGGAATTCGGCACGAG 17

RESULT 79
AAX75071
ID AAX75071 standard; RNA; 17 BP.
XX
AC AAX75071;
XX
DT 28-JUL-1999 (first entry)
XX
DE Mouse flt-1 VEGF receptor hammerhead ribozyme substrate #599.
XX
KW Vascular endothelial growth factor receptor; VEGF receptor; flt-1; flk-1;
KW KDR; hammerhead ribozyme; hairpin ribozyme; cleavage;
KW tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;
KW fms-like tyrosine kinase 1; kinase insert domain containing receptor;
KW foetal liver kinase 1; ss.
XX
OS Mus sp.
XX
PN WO9715662-A2.
XX
PD 01-MAY-1997.
XX
PF 25-OCT-1996; 96WO-US017480.
XX
PR 26-OCT-1995; 95US-0005974P.
PR 11-JAN-1996; 96US-00584040.
XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (CHIR) CHIRON CORP.
XX
PI Pavco P, Mcswiggen J, Stinchcomb D, Escobedo J;
XX
DR WPI; 1997-259017/23.
XX
PT Nucleic acid molecule modulating VEGF receptor(s) gene expression or mRNA
PT stability - useful for treating e.g. tumour angiogenesis, psoriasis,
PT rheumatoid arthritis, etc., in a human patient.
XX
PS Claim 4; Page 173; 218pp; English.
XX
CC The present invention describes nucleic acid molecules which modulate the
CC synthesis, expression and/or stability of a mRNA encoding 1 or more
CC receptors of vascular endothelial growth factor (VEGF). A patient
CC (preferably human) having a condition associated with the level of the

```
CC   fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing
CC   receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour
CC   angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can be
CC   treated by administering the nucleic acid molecule or the expression
CC   vector to the patient. AAX67275 to AAX75752 represent specific examples
CC   of nucleic acid molecules from the present invention
XX
SQ   Sequence 17 BP; 0 A; 0 C; 3 G; 0 T; 14 U; 0 Other;

  Query Match             0.9%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   17.6%;  Pred. No. 2.1e+02;
  Matches    3;  Conservative   13;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1382 TTTGTTGTTTGTTTTGT 1398
              :::|:: :::|::::|:
Db          1 UUUGUUUUUUGUUUUGU 17


RESULT 80
AAH77930
ID   AAH77930 standard; DNA; 17 BP.
XX
AC   AAH77930;
XX
DT   13-NOV-2001  (first entry)
XX
DE   PCR primer used to amplify cDNA encoding human Mch6 polypeptide.
XX
KW   Mch6; ced-3 homologue; ICE; interleukin-1-beta converting enzyme;
KW   aspartate-specific cysteine protease; ASCP; apoptotic cell death;
KW   Alzheimer's disease; Parkinson's disease; amyotropic lateral sclerosis;
KW   retinitis pigmentosa; cerebellar degeneration; myelodysplastic syndrome;
KW   aplastic anemia; ischemic injury; myocardial infarction; stroke; cancer;
KW   reperfusion injury; autoimmune disease; systemic lupus erythematosus;
KW   immune-mediated glomerulonephritis; viral infection; cell death;
KW   PCR primer; ss.
XX
OS   Homo sapiens.
XX
PN   US6274318-B1.
XX
PD   14-AUG-2001.
XX
PF   13-MAY-1999;   99US-00311760.
XX
PR   29-MAY-1997;   97US-00865579.
XX
PA   (UYJE-) UNIV JEFFERSON THOMAS.
XX
PI   Alnemri ES,  Fernandes-Alnemri T,  Litwack G;
XX
DR   WPI; 2001-540372/60.
XX
PT   Identifying mammalian homolog ced-3 homolog (Mch)6 activity modulators,
PT   useful for treating lymphomas, carcinomas and hormone dependent tumors,
PT   Alzheimer's disease, Parkinson's disease, comprises using Mch6
PT   polypeptide.
XX
PS   Example 1; Col 12; 36pp; English.
XX
CC   The present PCR primer was used to amplify Mch6 cDNA. Mch6 is a ced-3
CC   homologue, and is a member of the ICE (interleukin-1-beta converting
CC   enzyme) family of aspartate-specific cysteine proteases (ASCPs). The
CC   specification describes a method for identifying mammalian Mch6 activity
CC   modulators (inhibitors or enhancers). The compounds identified by the
CC   method are useful as pharmaceuticals for treating or preventing diseases
CC   characterized by increased apoptotic cell death such as Alzheimer's
CC   disease, Parkinson's disease, amyotropic lateral sclerosis, retinitis
CC   pigmentosa, or cerebellar degeneration, myelodysplastic syndromes such as
CC   aplastic anemia, ischemic injury including myocardial infarction, stroke
CC   and reperfusion injury. The compounds are also useful for treating
CC   diseases characterized by loss of apoptotic cell death such as cancers,
CC   e.g. lymphomas, carcinomas and hormone dependent tumours such as breast,
CC   prostate and ovarian cancer. Increased cell survival or apoptosis
CC   inhibition also results in autoimmune diseases such as systemic lupus
CC   erythematosus and immune-mediated glomerulonephritis as well as viral
CC   infections such as herpes virus, pox virus and adenovirus and the novel
CC   identified compounds are useful for treating these conditions. The Mch6
CC   inhibitors are used to treat or to reduce severity of diseases
CC   characterized by increased programmed cell death
XX
SQ   Sequence 17 BP; 5 A; 4 C; 6 G; 2 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   94.1%;  Pred. No. 2.1e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         16 CAAGAATTCGGCACGAG 32
              || ||||||||||||||
Db          1 CAGGAATTCGGCACGAG 17


RESULT 81
AAS12632
ID   AAS12632 standard; DNA; 17 BP.
XX
AC   AAS12632;
XX
DT   04-DEC-2001  (first entry)
XX
DE   T3 PCR primer for MCH6 cDNA isolation.
XX
KW   Aspartate-specific cysteine protease; MCH6; ss; nootropic;
KW   neuroprotective; anti-Parkinsonian; antianaemic; vasotropic; cardiant;
KW   cerebroprotective; mammalian ced-3 homologue 6; gene therapy; apoptosis;
KW   Alzheimer's disease; Parkinson's disease; retinitis pigmentosa;
KW   cerebellar degeneration; myelodysplastic syndrome; aplastic anaemia;
KW   ischaemic injury; myocardial infarction; stroke; reperfusion injury;
KW   amyotrophic lateral sclerosis; PCR primer; T3.
XX
OS   Synthetic.
XX
PN   US2001016345-A1.
XX
PD   23-AUG-2001.
XX
PF   22-DEC-2000; 2000US-00746731.
XX
PR   29-MAY-1997;   97US-00865579.
PR   25-FEB-1999;   99US-00257218.
XX
PA   (ALNE/) ALNEMRI E S.
PA   (FERN/) FERNANDES-ALNEMRI T.
PA   (LITW/) LITWACK G.
XX
PI   Alnemri ES,  Fernandes-Alnemri T,  Litwack G;
XX
DR   WPI; 2001-535542/59.
XX
PT   New Mch6 polypeptides and genes encoding the polypeptides useful for
PT   diagnosing, treating or reducing the severity of cell death-mediated
PT   diseases such as neurodegenerative diseases e.g. Alzheimer's disease,
PT   Parkinson's disease.
XX
PS   Example 1; Page 7; 15pp; English.
XX
CC   The invention relates to an isolated gene encoding MCH6 (mammalian ced-3
CC   homologue 6) an aspartate-specific cysteine protease and the MCH6
CC   polypeptide. The MCH6-encoding nucleic acids and polypeptides can be used
CC   to diagnose, treat (e.g. by gene therapy) or reduce the severity of cell
CC   death-mediated diseases (i.e. apoptotic) such as neurodegenerative
CC   diseases e.g. Alzheimer's disease, Parkinson's disease, amyotrophic
CC   lateral sclerosis, retinitis pigmentosa and cerebellar degeneration, and
CC   myelodysplastic syndromes, e.g. aplastic anaemia, ischaemic injury,
CC   myocardial infarction, stroke and reperfusion injury. The MCH6-encoding
CC   nucleic acids and polypeptides can also be used to diagnose or generate
```

```
CC   reagents to diagnose diseases mediated or characterised by programmed
CC   cell death. A purified recombinant MCH6 protein can be used to measure
CC   hydrolysis rates for various substrates such as DEVD-AMC and YVAD-AMC in
CC   a continuous fluorometric assay. The present sequence is a PCR primer
CC   used to isolate the cDNA encoding human MCH6
XX
SQ   Sequence 17 BP; 5 A; 4 C; 6 G; 2 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   94.1%;  Pred. No. 2.1e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         16 CAAGAATTCGGCACGAG 32
              || ||||||||||||||
Db          1 CAGGAATTCGGCACGAG 17


RESULT 82
AAD15659
ID   AAD15659 standard; DNA; 17 BP.
XX
AC   AAD15659;
XX
DT   15-NOV-2001  (first entry)
XX
DE   Mch6 cloning primer, T3.
XX
KW   Apoptic protease; mammalian ced-3 homologue 6; Mch6; cancer;
KW   aspartate-specific cysteine protease; ASCP; apoptosis; therapy;
KW   autoimmune disease; cerebellar degeneration; Alzheimer's disease;
KW   cytostatic; Parkinson's disease; immunomodulator; antimicrobial;
KW   viral infection; cell death-mediated disease; neuroprotective; primer;
KW   ss.
XX
OS   Unidentified.
XX
PN   US6271361-B1.
XX
PD   07-AUG-2001.
XX
PF   25-FEB-1999;   99US-00257218.
XX
PR   29-MAY-1997;   97US-00865579.
XX
PA   (UYJE-) UNIV JEFFERSON THOMAS.
XX
PI   Alnemri ES,  Fernandes-Alnemri T,  Litwack G;
XX
DR   WPI; 2001-528686/58.
XX
PT   New apoptotic genes and their apoptotic protease products, useful for
PT   modulating apoptosis for the therapeutic treatment of human diseases,
PT   e.g. cancers, autoimmune disease, Alzheimer's disease or Parkinson's
PT   disease.
XX
PS   Example 1; Col 12; 36pp; English.
XX
CC   The invention relates to an isolated gene encoding apoptic protease,
CC   mammalian ced-3 homologue 6 (Mch6). Mch6 is a member of the aspartate-
CC   specific cysteine protease (ASCP) family. Mch6 DNA and protein sequences
CC   are useful for modulating apoptosis for the therapeutic treatment of
CC   human diseases. Mch6 sequences are useful for upregulating apoptosis
CC   (e.g. for treating cancers, autoimmune disease or viral infections) or
CC   downregulating apoptosis (e.g. for treating Alzheimer's disease,
CC   Parkinson's disease or cerebellar degeneration). The Mch6 sequence is
CC   useful for diagnosing, treating or reducing the severity of cell death-
CC   mediated diseases, as well as other diseases mediated by either increased
CC   or decreased programmed cell death. The present sequence is a primer,
CC   used for cloning and characterisation of Mch6
XX
SQ   Sequence 17 BP; 5 A; 4 C; 6 G; 2 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   94.1%;  Pred. No. 2.1e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         16 CAAGAATTCGGCACGAG 32
              || ||||||||||||||
Db          1 CAGGAATTCGGCACGAG 17


RESULT 83
AAH25194
ID   AAH25194 standard; DNA; 17 BP.
XX
AC   AAH25194;
XX
DT   22-AUG-2001  (first entry)
XX
DE   Primer for DNA encoding aspartate-specific cysteine protease Mch6.
XX
KW   Human; apoptotic protease; Mch6; aspartate-specific cysteine protease;
KW   cell death; cancer; autoimmune disease; systemic lupus erythematosus;
KW   viral infection; degenerative disorder; Alzheimer's disease;
KW   Parkinson's disease; myelodysplastic syndrome; myocardial infarction;
KW   stroke; PCR primer; ss.
XX
OS   Homo sapiens.
XX
PN   US2001006779-A1.
XX
PD   05-JUL-2001.
XX
PF   29-MAY-1997;   97US-00865579.
XX
PR   29-MAY-1997;   97US-00865579.
XX
PA   (ALNE/) ALNEMRI E S.
PA   (FERN/) FERNANDES-ALNEMRI T.
PA   (LITW/) LITWACK G.
XX
PI   Alnemri ES,  Fernandes-Alnemri T,  Litwack G;
XX
DR   WPI; 2001-389294/41.
XX
PT   Isolated gene encoding a human apoptotic protease known as Mch6, useful
PT   in the diagnosis or treatment of cell death-mediated conditions, e.g.
PT   cancers and autoimmune diseases such as systemic lupus erythematosus.
XX
PS   Example 1; Page 7; 15pp; English.
XX
CC   The present PCR primer was used to amplify DNA encoding an apoptotic
CC   protease, designated Mch6. Mch6 is an aspartate-specific cysteine
CC   protease. Mch6 polypeptides and polynucleotides can be used to diagnose,
CC   treat or reduce the severity of cell death-mediated conditions, e.g.
CC   cancers, autoimmune diseases such as systemic lupus erythematosus, viral
CC   infections such as herpesvirus, degenerative disorders such as
CC   Alzheimer's disease and Parkinson's disease, myelodysplastic syndromes
CC   such as myocardial infarction and stroke. They can also be used to screen
CC   for compounds that inhibit or promote Mch6 mediated apoptosis
XX
SQ   Sequence 17 BP; 5 A; 4 C; 6 G; 2 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   94.1%;  Pred. No. 2.1e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         16 CAAGAATTCGGCACGAG 32
              || ||||||||||||||
Db          1 CAGGAATTCGGCACGAG 17


RESULT 84
ACC63780/c
ID   ACC63780 standard; DNA; 17 BP.
XX
```

```
AC   ACC63780;
XX
DT   01-JUL-2003  (first entry)
XX
DE   Murine oligonucleotide associated with tumour supression, SEQ ID 1027.
XX
KW   Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; murine;
KW   tumour suppression; tumour reversion; apoptosis; virus resistance;
KW   viral disease; tumour; cell degeneration; cancer; Alzheimer's disease;
KW   schizophrenia; ss.
XX
OS   Mus musculus.
XX
PN   WO2003025176-A2.
XX
PD   27-MAR-2003.
XX
PF   17-SEP-2002; 2002WO-IB004210.
XX
PR   17-SEP-2001; 2001FR-00011979.
XX
PA   (MOLE-) MOLECULAR ENGINES LAB.
XX
PI   Telerman A,  Amson R,  Tuijnder M;
XX
DR   WPI; 2003-333167/31.
XX
PT   New isolated nucleic acid, useful for treating viral diseases associated
PT   with tumors and cell degeneration, also related polypeptides, antibodies
PT   and transfected cells.
XX
PS   Disclosure; Page 151; 738pp; French.
XX
CC   The present invention relates to murine oligonucleotides (ACC62754-
CC   ACC68806), which are associated with tumour suppression, tumour
CC   reversion, apoptosis and virus resistance. The oligonucleotides are
CC   useful as (1) as probes and primers for detecting, identifying,
CC   quantifying and/or amplifying nucleic acid, e.g. as one component of a
CC   gene chip; in vitro as (anti)sense reagents; and (2) for production of
CC   recombinant polypeptides. The oligonucleotides are useful for preparation
CC   of pharmaceuticals for prevention and/or treatment of viral diseases that
CC   are characterised by development of tumours or cell degeneration,
CC   specifically cancer but also Alzheimer's disease and schizophrenia
XX
SQ   Sequence 17 BP; 4 A; 8 C; 2 G; 3 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   94.1%;  Pred. No. 2.1e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1482 GGTGGGTGTCAGGGATC 1498
              ||||||| |||||||||
Db         17 GGTGGGTATCAGGGATC 1


RESULT 85
ADE52023
ID   ADE52023 standard; DNA; 17 BP.
XX
AC   ADE52023;
XX
DT   29-JAN-2004  (first entry)
XX
DE   Mammalian ced-3 homologue 6 related primer seq id 5.
XX
KW   cytostatic; virucide; nootropic; neuroprotective; antiparkinsonian;
KW   cardiant; apoptosis modulator; aspartate-specific cysteine protease;
KW   gene therapy; aspartate-specific cysteine protease agonist;
KW   aspartate-specific cysteine protease antagonist; Mch6;
KW   mammalian ced-3 homologue 6; apoptosis; cancer; viral infection;
KW   degenerative disorder; Alzheimers disease; Parkinsons disease;
KW   myocardial infarction; human; mammalian ced-3 homologue 6; Mch6; PCR;
KW   primer; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   US2002183504-A1.
XX
PD   05-DEC-2002.
XX
PF   29-JAN-2002; 2002US-00059749.
XX
PR   29-MAY-1997;   97US-00865579.
PR   25-FEB-1999;   99US-00257218.
PR   22-DEC-2000; 2000US-00746731.
XX
PA   (UYJE-) UNIV JEFFERSON THOMAS.
XX
PI   Alnemri ES,  Fernandes-Alnemri T,  Litwack G;
XX
DR   WPI; 2004-040943/04.
XX
PT   New isolated gene encoding a mammalian ced-3 homolog 6, for modulating
PT   apoptosis for the therapeutic treatment of human diseases, such as
PT   cancers and degenerative disorders.
XX
PS   Example 1; SEQ ID NO 5; 15pp; English.
XX
CC   The invention describes an isolated gene (I) encoding Mch6 (mammalian ced
CC   -3 homologue 6), or a functional fragment of it. (I) And the polypeptide
CC   encoded by (I) is used to modulate apoptosis for the therapeutic
CC   treatment of human diseases. (I) Is used to prepared a recombinant
CC   aspartate-specific cysteine protease, that it encodes. The recombinant
CC   protease can be used to screen for Mch6 inhibitors. Disorders involving
CC   apoptosis that can be diagnosed or treated by (I) or the polypeptide it
CC   encodes, including cancers, viral infections, degenerative disorders,
CC   such as Alzheimers and Parkinsons disease, and myocardial infarction.
CC   This sequence represents a primer used in the isolation of human
CC   mammalian ced-3 homologue 6 (Mch6), a member of the aspartate-specific
CC   cysteine protease (ASCP) family of proteases.
XX
SQ   Sequence 17 BP; 5 A; 4 C; 6 G; 2 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   94.1%;  Pred. No. 2.1e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         16 CAAGAATTCGGCACGAG 32
              || |||||||||||||||
Db          1 CAGGAATTCGGCACGAG 17


RESULT 86
AAQ46560
ID   AAQ46560 standard; DNA; 18 BP.
XX
AC   AAQ46560;
XX
DT   25-MAR-2003  (revised)
DT   13-SEP-1993  (first entry)
XX
DE   Monomer DRB5706 for typing of HLA DR beta.
XX
KW   Reverse dot blot hybridisation; tandam; head to tail monomers; probe;
KW   staggared complementary primers; HLA molecular typing; ds.
XX
OS   Synthetic.
XX
PN   WO9309245-A1.
XX
PD   13-MAY-1993.
XX
PF   22-OCT-1992;   92WO-US009113.
XX
PR   31-OCT-1991;   91US-00786228.
```

XX
PA (UYPI-) UNIV PITTSBURGH.
XX
PI Rudert WA, Trucco M;
XX
DR WPI; 1993-167708/20.
XX
PT Detecting presence or absence of nucleic acid sequence - by reverse dot
PT blot hybridisation using tandem head-to-tail monomers contg. probes
PT synthesised by staggered complementary primers.
XX
PS Example 2; Fig 11; 59pp; English.
XX
CC Five amplifications are necessary to fully type DR beta, bringing to 11
CC the number of independent amplifications to be completed: 2 for DQ alpha
CC and beta, 2 for DP alpha and beta, 1 for DR alpha, 1 for DR beta all
CC segments, and 5 for DR beta allele specific segments. While this number
CC is not prohibitive, it can be reduced by performing co-amplifications
CC that reduce the no. of independent reactions necessary to generate all
CC the segments specifically representing DR, DQ and DP alpha and beta chain
CC gene hypervariable regions. The sequence shown is that of a monomer which
CC must be transformed in repetitive polymers to test all the DRB sequences,
CC via the novel, reverse dot blot method of the invention. . See also
CC AAQ41355-78, AAQ41388-414 and AAQ46555-78. (Updated on 25-MAR-2003 to
CC correct PN field.)
XX
SQ Sequence 18 BP; 3 A; 5 C; 6 G; 4 T; 0 U; 0 Other;

Query Match 0.9%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 2.1e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 839 CCTGACGCTGAGCACTG 855
||||||||||||| ||||
Db 2 CCTGACGCTGAGTACTG 18

RESULT 87
ABL31588/c
ID ABL31588 standard; DNA; 18 BP.
XX
AC ABL31588;
XX
DT 21-MAR-2002 (first entry)
XX
DE Human HLA genotyping oligonucleotide SEQ ID NO 1077.
XX
KW Human; human leukocyte antigen; HLA; genotype; polymorphism;
KW immunogenetic; transplantation; genetic disease; ss.
XX
OS Homo sapiens.
XX
PN WO200192572-A1.
XX
PD 06-DEC-2001.
XX
PF 01-JUN-2001; 2001WO-JP004662.
XX
PR 01-JUN-2000; 2000JP-00164798.
XX
PA (NISN) NISSHINBO IND INC.
PA (SYST-) SYSTEM RES INC.
XX
PI Inoko H, Kagiya T, Ichihara T, Matsumura Y, Moriya S, Nishida M;
XX
DR WPI; 2002-122074/16.
XX
PT Human leukocyte antigen (HLA) typing, useful for judging HLA genotypes of
PT individuals e.g. by determining immunogenetic differences when
PT transplanting between them.
XX
PS Disclosure; Page 297; 345pp; Japanese.
XX
CC The invention relates to a typing kit for judging human leukocyte antigen
CC (HLA) genotype of a sample by hybridising a substrate on which 10-24 base
CC oligonucleotides (ABL30512-ABL31809) originating in the sequences of
CC genes e.g. belonging to HLA class I antigens on human genome and
CC containing gene polymorphisms as alloantigens have been immobilised as
CC primers for amplification of cleaved nucleic acids relating to gene
CC polymorphisms. The method is useful for judging HLA genotypes of
CC individuals by determining immunogenetic differences before transplanting
CC between them, providing genetic information to decide compatibility of
CC organ and tissue for transplantation e.g. of bone marrow, kidney, liver,
CC pancreas, Langerhans islet in pancreas and cornea, susceptibility
CC diagnosis of genetic diseases and identifying individuals
XX
SQ Sequence 18 BP; 1 A; 6 C; 8 G; 3 T; 0 U; 0 Other;

Query Match 0.9%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 2.1e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 522 GAGAGCCTGGCCCAGGC 538
|||| |||||||||||||
Db 18 GAGACCCTGGCCCAGGC 2

RESULT 88
AAX33800
ID AAX33800 standard; DNA; 19 BP.
XX
AC AAX33800;
XX
DT 25-JUN-1999 (first entry)
XX
DE S. aureus coding sequence PCR primer SEQ ID NO. 31.
XX
KW S. aureus infection; diagnosis; therapy; central nervous system disorder;
KW upper respiratory tract infection; otitis media; bacterial tracheitis;
KW acute epiglottitis; thyroiditis; empyema; lung abscess; splenic abscess;
KW cardiac infection; infective endocarditis; secretory diarrhoea; ulcer;
KW retroperitoneal abscess; cerebral abscess; blepharitis; conjunctivitis;
KW keratitis; endophthalmitis; preseptal cellulitis; orbital cellulitis;
KW darcryocystitis; epididymitis; intrarenal abscess; perinephric abscess;
KW toxic shock syndrome; impetigo; folliculitis; cutaneous abscess;
KW cellulitis; wound infection; bacterial myositis; septic arthritis;
KW osteomyelitis; Helicobacter pylori infection; stomach cancer; gastritis;
KW PCR primer; ss.
XX
OS Synthetic.
OS Staphylococcus aureus.
XX
PN WO9912557-A1.
XX
PD 18-MAR-1999.
XX
PF 14-SEP-1998; 98WO-US018987.
XX
PR 12-SEP-1997; 97US-0058710P.
XX
PA (SMIK) SMITHKLINE BEECHAM CORP.
XX
PI Burnham MKR, Lonetto MA, Warren PV;
XX
DR WPI; 1999-229138/19.
XX
PT New isolated Staphylococcus aureus polynucleotides.
XX
PS Disclosure; Page 83; 102pp; English.
XX
CC This sequence represents a PCR primer for a S. aureus polynucleotide of
CC the invention. The invention also relates to the polypeptides encoded by
CC the S. aureus polynucleotides. The polypeptides can be used for the
CC treatment or prevention of disease. The polypeptide or polynucleotide can
CC also be used to diagnose diseases related to their expression. The
CC polypeptides and vectors containing them can also be used in immunisation

```
CC   methods. The products can be used for treating infection, e.g. infections
CC   of the upper respiratory tract, (e.g. otitis media, bacterial tracheitis,
CC   acute epiglottitis, thyroiditis), respiratory (e.g. empyema, lung
CC   abscess), cardiac (e.g. infective endocarditis), gastrointestinal (e.g.
CC   secretory diarrhoea, splenic abscess, retroperitoneal abscess), central
CC   nervous system (CNS) (e.g. cerebral abscess), eye (e.g. blepharitis,
CC   conjunctivitis, keratitis, endophthalmitis, preseptal and orbital
CC   cellulitis, darcryocystitis), kidney and urinary tract (e.g.
CC   epididymitis, intrarenal and perinephric abscess, toxic shock syndrome),
CC   skin (e.g. impetigo, folliculitis, cutaneous abscesses, cellulitis, wound
CC   infection, bacterial myositis), bone and joint (e.g. septic arthritis,
CC   osteomyelitis), or Helicobacter pylori infections, (e.g. causing stomach
CC   cancer, ulcers and gastritis). The products can also be used for treating
CC   in-dwelling devices and wounds
XX
SQ   Sequence 19 BP; 4 A; 5 C; 8 G; 2 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 2.1e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         19 GAATTCGGCACGAGGGG 35
              ||||||||||||||| ||
Db          2 GAATTCGGCACGAGCGG 18


RESULT 89
AAA83614
ID   AAA83614 standard; DNA; 19 BP.
XX
AC   AAA83614;
XX
DT   04-DEC-2000  (first entry)
XX
DE   cdk-we-hu ribozyme binding site #89.
XX
KW   Ribozyme; hairpin; hammerhead; gene therapy; vasotropic; restenosis; ss.
XX
OS   Mammalia.
XX
PN   WO200032765-A2.
XX
PD   08-JUN-2000.
XX
PF   06-DEC-1999;   99WO-US028772.
XX
PR   04-DEC-1998;   98US-0110954P.
XX
PA   (IMMU-) IMMUSOL INC.
XX
PI   Tritz R,  Welch PJ,  Barber JR,  Robbins JM;
XX
DR   WPI; 2000-412314/35.
XX
PT   New hairpin and hammerhead ribozyme for inhibiting restenosis, cleaves
PT   RNA encoding a cyclin or cell-cycle dependent kinase other than CDK1,
PT   PCNA and Cyclin B1.
XX
PS   Disclosure; Page 64; 109pp; English.
XX
CC   The present invention relates to a hairpin or hammerhead ribozyme,
CC   designed to cleave RNA encoding a cyclin or cell-cycle dependent kinase
CC   other than cell-cycle dependent kinases CDK1, PCNA and Cyclin B1.
CC   Representative examples of ribozyme recognition sites are given in
CC   AAA82415 to AAA86787. The ribozyme of the invention is useful for
CC   inhibiting restenosis by introduction of the ribozyme into cells. The
CC   ribozyme is resistant to endonuclease activity and hence is efficient in
CC   restenosis treatment
XX
SQ   Sequence 19 BP; 4 A; 2 C; 7 G; 6 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 2.1e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1001 GGACTGATTCCTGTGGT 1017
              ||| |||||||||||||
Db          1 GGAATGATTCCTGTGGT 17


RESULT 90
AAA83613
ID   AAA83613 standard; DNA; 19 BP.
XX
AC   AAA83613;
XX
DT   04-DEC-2000  (first entry)
XX
DE   cdk-we-hu ribozyme binding site #88.
XX
KW   Ribozyme; hairpin; hammerhead; gene therapy; vasotropic; restenosis; ss.
XX
OS   Mammalia.
XX
PN   WO200032765-A2.
XX
PD   08-JUN-2000.
XX
PF   06-DEC-1999;   99WO-US028772.
XX
PR   04-DEC-1998;   98US-0110954P.
XX
PA   (IMMU-) IMMUSOL INC.
XX
PI   Tritz R,  Welch PJ,  Barber JR,  Robbins JM;
XX
DR   WPI; 2000-412314/35.
XX
PT   New hairpin and hammerhead ribozyme for inhibiting restenosis, cleaves
PT   RNA encoding a cyclin or cell-cycle dependent kinase other than CDK1,
PT   PCNA and Cyclin B1.
XX
PS   Disclosure; Page 64; 109pp; English.
XX
CC   The present invention relates to a hairpin or hammerhead ribozyme,
CC   designed to cleave RNA encoding a cyclin or cell-cycle dependent kinase
CC   other than cell-cycle dependent kinases CDK1, PCNA and Cyclin B1.
CC   Representative examples of ribozyme recognition sites are given in
CC   AAA82415 to AAA86787. The ribozyme of the invention is useful for
CC   inhibiting restenosis by introduction of the ribozyme into cells. The
CC   ribozyme is resistant to endonuclease activity and hence is efficient in
CC   restenosis treatment
XX
SQ   Sequence 19 BP; 3 A; 2 C; 7 G; 7 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 2.1e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1001 GGACTGATTCCTGTGGT 1017
              ||| |||||||||||||
Db          2 GGAATGATTCCTGTGGT 18


RESULT 91
AAH58775
ID   AAH58775 standard; DNA; 19 BP.
XX
AC   AAH58775;
XX
DT   10-SEP-2001  (first entry)
XX
DE   Cdk-we-hu ribozyme binding site SEQ ID NO:1199.
XX
KW   Human; ribozyme therapy; hairpin ribozyme; hammerhead ribozyme;
KW   recognition site; target; ribozyme binding site; eye disease; vulnerary;
```

```
KW   proliferative disease; skin disease; psoriasis; diabetic retinopathy;
KW   cytokine; inflammation; cell-cycle dependent kinase; cyclin; MMP;
KW   matrix metalloproteinase; growth factor; reductase; scarring; cytostatic;
KW   antipsoriatic; dermatological; antiseborrheic; antidiabetic; virucide;
KW   antisickling; ophthalmological; keratolytic; gene therapy; viral wart;
KW   atopic dermatitis; actinic keratosis; squamous cell carcinoma;
KW   basal cell carcinoma; seborrheic wart; vitreoretinopathy; scar;
KW   sickle cell retinopathy; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO200130362-A2.
XX
PD   03-MAY-2001.
XX
PF   26-OCT-2000; 2000WO-US029500.
XX
PR   26-OCT-1999;   99US-0161532P.
XX
PA   (IMMU-) IMMUSOL INC.
XX
PI   Robbins JM,  Tritz R;
XX
DR   WPI; 2001-300427/31.
XX
PT   Treating proliferative skin or eye diseases and scarring, using ribozymes
PT   that cleave RNA encoding cytokines involved in inflammation, matrix
PT   metalloproteinases, growth factors and cell-cycle dependent kinases.
XX
PS   Example 1; Page 159; 408pp; English.
XX
CC   The present invention describes a method for treating a proliferative
CC   skin or eye disease and scarring. The method involves administering a
CC   ribozyme (I) which cleaves RNA encoding a cytokine involved in
CC   inflammation, matrix metalloproteinase (MMP), cyclin, cell-cycle
CC   dependent kinase, growth factor or a reductase, or administering a
CC   nucleic acid molecule (II) comprising a promoter operably linked to a
CC   nucleic acid segment encoding (I). (I) can have antipsoriatic,
CC   dermatological, cytostatic, antiseborrheic, antidiabetic, antisickling,
CC   ophthalmological, vulnerary, keratolytic and virucide activities, and
CC   cleaves RNA encoding cytokine involved in inflammation. (I) can be used
CC   in gene therapy. (I) and (II) are useful for treating proliferative skin
CC   diseases such as psoriasis, atopic dermatitis, actinic keratosis,
CC   squamous or basal cell carcinoma and viral or seborrheic wart. They can
CC   also be used for treating proliferative eye diseases such as diabetic
CC   retinopathy, vitreoretinopathy, sickle cell retinopathy, retinopathy of
CC   prematurity and retinal detachment, and for treating and preventing
CC   scarring such as keloid, adhesion and hypertrophic or hypertrophic burn
CC   scar. AAH57577 to AAH62099 represent sequences used in the
CC   exemplification of the present invention
XX
SQ   Sequence 19 BP; 3 A; 2 C; 7 G; 7 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 2.1e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1001 GGACTGATTCCTGTGGT 1017
              ||| ||||||||||||
Db          2 GGAATGATTCCTGTGGT 18


RESULT 92
AAH58776
ID   AAH58776 standard; DNA; 19 BP.
XX
AC   AAH58776;
XX
DT   10-SEP-2001  (first entry)
XX
DE   Cdk-we-hu ribozyme binding site SEQ ID NO:1200.
XX
KW   Human; ribozyme therapy; hairpin ribozyme; hammerhead ribozyme;
KW   recognition site; target; ribozyme binding site; eye disease; vulnerary;
KW   proliferative disease; skin disease; psoriasis; diabetic retinopathy;
KW   cytokine; inflammation; cell-cycle dependent kinase; cyclin; MMP;
KW   matrix metalloproteinase; growth factor; reductase; scarring; cytostatic;
KW   antipsoriatic; dermatological; antiseborrheic; antidiabetic; virucide;
KW   antisickling; ophthalmological; keratolytic; gene therapy; viral wart;
KW   atopic dermatitis; actinic keratosis; squamous cell carcinoma;
KW   basal cell carcinoma; seborrheic wart; vitreoretinopathy; scar;
KW   sickle cell retinopathy; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO200130362-A2.
XX
PD   03-MAY-2001.
XX
PF   26-OCT-2000; 2000WO-US029500.
XX
PR   26-OCT-1999;   99US-0161532P.
XX
PA   (IMMU-) IMMUSOL INC.
XX
PI   Robbins JM,  Tritz R;
XX
DR   WPI; 2001-300427/31.
XX
PT   Treating proliferative skin or eye diseases and scarring, using ribozymes
PT   that cleave RNA encoding cytokines involved in inflammation, matrix
PT   metalloproteinases, growth factors and cell-cycle dependent kinases.
XX
PS   Example 1; Page 159; 408pp; English.
XX
CC   The present invention describes a method for treating a proliferative
CC   skin or eye disease and scarring. The method involves administering a
CC   ribozyme (I) which cleaves RNA encoding a cytokine involved in
CC   inflammation, matrix metalloproteinase (MMP), cyclin, cell-cycle
CC   dependent kinase, growth factor or a reductase, or administering a
CC   nucleic acid molecule (II) comprising a promoter operably linked to a
CC   nucleic acid segment encoding (I). (I) can have antipsoriatic,
CC   dermatological, cytostatic, antiseborrheic, antidiabetic, antisickling,
CC   ophthalmological, vulnerary, keratolytic and virucide activities, and
CC   cleaves RNA encoding cytokine involved in inflammation. (I) can be used
CC   in gene therapy. (I) and (II) are useful for treating proliferative skin
CC   diseases such as psoriasis, atopic dermatitis, actinic keratosis,
CC   squamous or basal cell carcinoma and viral or seborrheic wart. They can
CC   also be used for treating proliferative eye diseases such as diabetic
CC   retinopathy, vitreoretinopathy, sickle cell retinopathy, retinopathy of
CC   prematurity and retinal detachment, and for treating and preventing
CC   scarring such as keloid, adhesion and hypertrophic or hypertrophic burn
CC   scar. AAH57577 to AAH62099 represent sequences used in the
CC   exemplification of the present invention
XX
SQ   Sequence 19 BP; 4 A; 2 C; 7 G; 6 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 2.1e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1001 GGACTGATTCCTGTGGT 1017
              ||| ||||||||||||
Db          1 GGAATGATTCCTGTGGT 17


RESULT 93
ABL88937/c
ID   ABL88937 standard; DNA; 19 BP.
XX
AC   ABL88937;
XX
DT   22-MAY-2002  (first entry)
XX
```

```
DE   HIV-1 related binding molecule oligonucleotide sequence SEQ ID NO:159.
XX
KW   Binding molecule; HIV-1; human immunodeficiency virus type 1;
KW   reverse transcriptase; binding group; ss.
XX
OS   Human immunodeficiency virus 1.
OS   Synthetic.
XX
PN   EP1174518-A1.
XX
PD   23-JAN-2002.
XX
PF   20-JUL-2000; 2000EP-00202611.
XX
PR   20-JUL-2000; 2000EP-00202611.
XX
PA   (AMST-) AMSTERDAM SUPPORT DIAGNOSTICS BV.
XX
PI   Loukachov VV,  Van Gemen B,  Goudsmit J;
XX
DR   WPI; 2002-156696/21.
XX
PT   Collection of binding groups for determining or typing samples,
PT   especially clinical samples, has groups capable to identify essentially
PT   all members of the family of nucleic acids of relatively high
PT   significance.
XX
PS   Disclosure; Page 45; 166pp; English.
XX
CC   The present invention describes a collection of binding groups for a
CC   family of nucleic acids comprising members of relative high and relative
CC   low significance, where the binding groups are selected to be capable to
CC   identify, alone or in combination, essentially all members of the family
CC   of nucleic acids of relatively high significance. The collection of
CC   binding groups is useful for typing of nucleic acid in a clinical sample,
CC   by contacting the nucleic acid with the collection and determining
CC   whether one or more binding groups bound to the nucleic acid of the
CC   sample. This method is useful for determining whether the sample
CC   comprises at least a part of a member of relatively high significance of
CC   a family of nucleic acids. The collection of binding groups is useful for
CC   diagnosing the severity of a disease caused by a pathogen containing a
CC   member of a family of nucleic acids. ABL88779 to ABL89321 represent
CC   oligonucleotide sequences used in the exemplification of the present
CC   invention
XX
SQ   Sequence 19 BP; 9 A; 2 C; 5 G; 3 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 2.1e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1646 TCCATCTAGAACTGTTT 1662
              ||||||||| |||||||
Db         18 TCCATCTAGTACTGTTT 2


RESULT 94
ADF49398
ID   ADF49398 standard; RNA; 19 BP.
XX
AC   ADF49398;
XX
DT   12-FEB-2004  (first entry)
XX
DE   Human BCL2 siNA lower sequence SEQ ID NO:126.
XX
KW   ss; siNA; human; BCL2; short interfering nucleic acid; RNA interference;
KW   cytostatic; immunosuppressive; virucide; anti-HIV; cancer;
KW   autoimmune disease; viral infection; HIV.
XX
OS   Homo sapiens.
XX
PN   WO2003070969-A2.
XX
PD   28-AUG-2003.
XX
PF   18-FEB-2003; 2003WO-US004908.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   06-JUN-2002; 2002US-0386782P.
PR   18-JUL-2002; 2002US-0396905P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J,  Beigelman L;
XX
DR   WPI; 2003-712622/67.
XX
PT   New short interfering nucleic acid, useful e.g. for treatment and
PT   diagnosis of cancer or autoimmune disease, downregulates expression of
PT   the BCL2 gene.
XX
PS   Example 3; SEQ ID NO 126; 148pp; English.
XX
CC   The invention relates to a novel short interfering nucleic acid (siNA)
CC   that downregulates expression of the BCL2 gene by RNA interference. A
CC   siNA of the invention has cytostatic, immunosuppressive, virucide, and
CC   anti-HIV activity. The siNA are useful for modulation (inhibition) of
CC   expression or activity of BCL2 by RNA interference. siNA are used to
CC   modulate expression of BCL2 genes, in cells, tissue explants or
CC   organisms, e.g. for treating cancer, autoimmune diseases and viral
CC   infections (including by HIV) but also for drug screening, diagnosis,
CC   target identification and validation, genetic engineering,
CC   pharmacogenomics, studying gene function and gene mapping (e.g. of single
CC   -nucleotide polymorphisms). The sequences shown in ADF49273-ADF50143
CC   represent siNA of the invention.
XX
SQ   Sequence 19 BP; 8 A; 4 C; 3 G; 0 T; 4 U; 0 Other;

  Query Match             0.9%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   76.5%;  Pred. No. 2.1e+02;
  Matches   13;  Conservative    3;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1129 TGTAGCATGAAACAAAG 1145
              :|:| ||:|||||||||
Db          1 UGUACCAUGAAACAAAG 17


RESULT 95
ADF49812/c
ID   ADF49812 standard; RNA; 19 BP.
XX
AC   ADF49812;
XX
DT   12-FEB-2004  (first entry)
XX
DE   Human BCL2 siNA lower sequence SEQ ID NO:540.
XX
KW   ss; siNA; human; BCL2; short interfering nucleic acid; RNA interference;
KW   cytostatic; immunosuppressive; virucide; anti-HIV; cancer;
KW   autoimmune disease; viral infection; HIV.
XX
OS   Homo sapiens.
XX
PN   WO2003070969-A2.
XX
PD   28-AUG-2003.
XX
PF   18-FEB-2003; 2003WO-US004908.
XX
PR   20-FEB-2002; 2002US-0358580P.
```

```
PR   11-MAR-2002; 2002US-0363124P.
PR   06-JUN-2002; 2002US-0386782P.
PR   18-JUL-2002; 2002US-0396905P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J,  Beigelman L;
XX
DR   WPI; 2003-712622/67.
XX
PT   New short interfering nucleic acid, useful e.g. for treatment and
PT   diagnosis of cancer or autoimmune disease, downregulates expression of
PT . the BCL2 gene.
XX
PS   Example 3; SEQ ID NO 540; 148pp; English.
XX
CC   The invention relates to a novel short interfering nucleic acid (siNA)
CC   that downregulates expression of the BCL2 gene by RNA interference. A
CC   siNA of the invention has cytostatic, immunosuppressive, virucide, and
CC   anti-HIV activity. The siNA are useful for modulation (inhibition) of
CC   expression or activity of BCL2 by RNA interference. siNA are used to
CC   modulate expression of BCL2 genes, in cells, tissue explants or
CC   organisms, e.g. for treating cancer, autoimmune diseases and viral
CC   infections (including by HIV) but also for drug screening, diagnosis,
CC   target identification and validation, genetic engineering,
CC   pharmacogenomics, studying gene function and gene mapping (e.g. of single
CC   -nucleotide polymorphisms). The sequences shown in ADF49273-ADF50143
CC   represent siNA of the invention.
XX
SQ   Sequence 19 BP; 4 A; 3 C; 4 G; 0 T; 8 U; 0 Other;

  Query Match             0.9%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 2.1e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1129 TGTAGCATGAAACAAAG 1145
              |||| ||||||||||||
Db         19 TGTACCATGAAACAAAG 3


RESULT 96
AAA13146/c
ID   AAA13146 standard; DNA; 20 BP.
XX
AC   AAA13146;
XX
DT   17-JUL-2000  (first entry)
XX
DE   PI3K antisense inhibitor oligonucleotide ISIS# 32120.
XX
KW   Phosphatidyl inositol 3 kinase; PI3K; antisense oligonucleotide; p110;
KW   catalytic subunit; treatment; rheumatoid arthritis; asthma; research;
KW   diagnostic; infection; inflammation; tumour formation; inhibitor; ss.
XX
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   misc_feature     1. .20
FT                    /*tag=  a
FT                    /note= "Phosphorothioate internucleoside linkage"
FT   modified_base    1. .5
FT                    /*tag=  b
FT                    /mod_base= OTHER
FT                    /note= "Optionally 2'-methoxyethyl (2'-MOE) nucleotides"
FT   modified_base    16. .20
FT                    /*tag=  c
FT                    /mod_base= OTHER
FT                    /note= "Optionally 2'-methoxyethyl (2'-MOE) nucleotides"
FT
XX
PN   US6046049-A.
XX
PD   04-APR-2000.
XX
PF   19-JUL-1999;   99US-00357070.
XX
PR   19-JUL-1999;   99US-00357070.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP,  Cowsert LM;
XX
DR   WPI; 2000-282691/24.
XX
PT   New antisense compounds targeting nucleic acids encoding human PI3 kinase
PT   p110 delta useful for treating a disease or condition associated with PI3
PT   kinase p110 delta expression, e.g. rheumatoid arthritis, asthma.
XX
PS   Example 15; Col 40; 35pp; English.
XX
CC   This sequence represents a phosphatidyl inositol 3 kinase (PI3K)
CC   targeting antisense oligonucleotide. Phosphatidyl inositol 3 kinases act
CC   as downstream effectors of hormone and growth factor receptors, and have
CC   been implicated in growth factor mediated cell transformation,
CC   mitogenesis, protein trafficking, cell survival and proliferation, and
CC   many other cellular activities. PI3K is a heterodimer, consisting of a
CC   110kD catalytic subunit (p110), and an 85kD regulatory subunit (p85). The
CC   invention relates to antisense oligonucleotides which target the p110
CC   delta mRNA of PI3K. The antisense oligonucleotides specifically hybridise
CC   with various regions of the PI3K mRNA sequence, and inhibit the
CC   expression of PI3K. The antisense oligonucleotides may be used to treat
CC   an animal, particularly human, suspected of having or being prone to a
CC   disease or condition associated with the expression of PI3K, e.g.
CC   rheumatoid arthritis or asthma. The treatment works through the
CC   modulation (preferably inhibition) of the expression of PI3K. The
CC   antisense oligonucleotides may also be used for research and diagnostics,
CC   in pharmaceutical compositions and formulations, in the preparation of
CC   kits for detecting the level of PI3K in a sample, and as prophylaxis,
CC   e.g. to prevent or delay infection, inflammation or tumour formation.
CC   Antisense oligonucleotides, which are able to inhibit gene expression
CC   specifically, are used to elucidate the function of particular genes, and
CC   to distinguish between functions of various members of a biological
CC   pathway
XX
SQ   Sequence 20 BP; 2 A; 8 C; 6 G; 4 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 15.4;  DB 1;  Length 20;
  Best Local Similarity   94.1%;  Pred. No. 2.1e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         19 GAATTCGGCACGAGGGG 35
              |||||||||||||| ||
Db         20 GAATTCGGCACGAGCGG 4


RESULT 97
ABA09745/c
ID   ABA09745 standard; DNA; 20 BP.
XX
AC   ABA09745;
XX
DT   26-FEB-2002  (first entry)
XX
DE   PCR primer GPI2 used in gene sorting method.
XX
KW   Gene sorting; PCR primer; disease diagnosis; disease analysis;
KW   cell differentiation; gene therapy; ss.
XX
OS   Synthetic.
XX
PN   WO200175180-A2.
XX
PD   11-OCT-2001.
```

XX
PF 23-MAR-2001; 2001WO-US009392.
XX
PR 30-MAR-2000; 2000US-00538709.
XX
PA (QBIQ-) QBI ENTERPRISES LTD.
XX
PI Ulanovsky L, Mugasimangalam R, Einat P, Zezin-Sonkin D, Shlomit G;
XX
DR WPI; 2001-626451/72.
XX
PT Sorting genes into non-redundant groups, useful e.g. for gene isolation,
PT diagnosis and in gene therapy, by amplifying cDNA fragments attached to
PT selective adaptors.
XX
PS Example 1; Page 22; 67pp; English.
XX
CC The present invention relates to a method for sorting genes. The method
CC comprises producing first double stranded (ds) cDNA from mRNA by reverse
CC transcription using a poly-T primer. The ds cDNA is then digested with a
CC restriction enzyme that generates cohesive ends with overhanging single
CC stranded sequence containing a constant number of nucleotides, and the
CC digestion products are ligated to a set of ds DNA oligonucleotide
CC adaptors. Each adaptor has at one end, a sequence complementary to a
CC possible overhang and the other end a primer-template sequence specific
CC for the adaptor complementary sequence, and between these two ends the
CC same sequence is present for all adaptors. The ligated cDNA molecules are
CC amplified in separate PCR assays, using for each a primer that anneals to
CC polyT and a second primer, from a set that anneals to the cDNA specific
CC primer-template sequences. Amplicons are finally sorted into non-
CC redundant groups defined by the specific primer that annealed to the
CC primer-template sequence and thus primed PCR. The method is useful for
CC producing a collection of non-redundant cDNA groups, especially where
CC every expressed-gene transcript in the original sample is represented by
CC its own subgroup. The method is also useful for isolation, identification
CC or analysis of genes, analysis and diagnosis of diseases, for studying
CC cell differentiation and in gene therapy. The present sequence was used
CC to illustrate the method of the present invention
XX
SQ Sequence 20 BP; 5 A; 4 C; 6 G; 5 T; 0 U; 0 Other;

Query Match 0.9%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 2.1e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1115 ATACCCCTCAGTACTGT 1131
||||| |||||||||||
Db 18 ATACCACTCAGTACTGT 2

RESULT 98
ABN89953
ID ABN89953 standard; DNA; 20 BP.
XX
AC ABN89953;
XX
DT 16-AUG-2002 (first entry)
XX
DE Real-time validation forward primer for mouse clone IMX3_29.
XX
KW Mouse; antiinflammatory; gene therapy; ileitis; DST; ss; primer;
KW real-time validation.
XX
OS Mus musculus.
XX
PN WO200231114-A2.
XX
PD 18-APR-2002.
XX
PF 11-OCT-2001; 2001WO-US032091.
XX
PR 11-OCT-2000; 2000US-0239483P.
XX
PA (DIGI-) DIGITAL GENE TECHNOLOGIES INC.
XX
PI Viney JL, Sims JE, Dubose RF, Baum PR, Hasel KW, Hilbush BS;
XX
DR WPI; 2002-426279/45.
XX
PT New isolated nucleic acid molecules that are associated with ileitis, for
PT preventing, treating, modulating and diagnosing ileitis in a mammalian
PT subject.
XX
PS Disclosure; Page 219; 273pp; English.
XX
CC The invention relates to a novel isolated nucleic acid molecule
CC comprising a polynucleotide having one of 90 polynucleotide sequences,
CC given in the specification. The polynucleotides of the invention have
CC antiinflammatory activity, and may have a use in gene therapy. The
CC polynucleotide or a polypeptide encoded by it is used for preventing,
CC treating, modulating or ameliorating a medical condition such as ileitis.
CC The polypeptide or polynucleotide is also useful for manufacturing a
CC medicament for treating ileitis. The sequence represents a real-time
CC validation primer for the DNA sequence obtained from one of the mouse
CC clones of the invention
XX
SQ Sequence 20 BP; 4 A; 1 C; 12 G; 3 T; 0 U; 0 Other;

Query Match 0.9%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 2.1e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1598 GAGGGTGGGGGCTGGAA 1614
||| |||||||||||||
Db 2 GAGTGTGGGGGCTGGAA 18

RESULT 99
ABZ30368
ID ABZ30368 standard; DNA; 20 BP.
XX
AC ABZ30368;
XX
DT 30-JAN-2003 (first entry)
XX
DE Candida albicans GRACE strain PCR primer SEQ ID NO 4519.
XX
KW Fungus; yeast; tetracyclin; promoter; GRACE strain; biosynthesis;
KW signal transduction; DNA replication; cell division; growth;
KW proliferation; Candida albicans; fungicide; antifungal; PCR; primer; ss.
XX
OS Candida albicans.
XX
PN WO200253728-A2.
XX
PD 11-JUL-2002.
XX
PF 26-DEC-2001; 2001WO-US049486.
XX
PR 29-DEC-2000; 2000US-0259128P.
PR 20-FEB-2001; 2001US-00792024.
PR 22-AUG-2001; 2001US-0314050P.
XX
PA (ELIT-) ELITRA PHARM INC.
XX
PI Roemer T, Jiang B, Boone C, Bussey H, Ohlsen KL;
XX
DR WPI; 2002-566694/60.
XX
PT Constructing strains for identifying gene products as effective targets
PT for therapeutic intervention, by inactivating in the strain one allele of
PT a gene and placing other allele of the gene under conditional expression.
XX
PS Claim 36; SEQ ID NO 4519; 167pp + Sequence Listing; English.
XX
CC The invention relates to constructing (M1) a strain of diploid fungal

CC cells in which both alleles of a gene are modified, comprising modifying
CC one allele by insertion or replacement by a cassette having an
CC expressible selectable marker and modifying other allele by
CC recombination, of a promoter replacement fragment with a heterologous
CC promoter, so that expression of the second allele is regulated by the
CC promoter. (M1) is useful for constructing a strain of diploid fungal
CC cells in which both alleles of a gene are modified. The diploid fungal
CC cells having both alleles modified are useful for identifying a gene that
CC is essential to the survival or growth of a fungus, a gene that
CC contributes to the virulence and/or pathogenicity of a fungus, a gene
CC that contributes to the resistance of a diploid fungus to an antifungal
CC agent, an antifungal agent that inhibits the growth of a diploid fungus
CC and for identifying a therapeutic agent for treatment of a mammalian
CC disease. (M1) is useful for identifying a compound which modulates the
CC activity of a gene product, preferably enzymatic activity, carbon
CC compound catabolism, biosynthetic, transporter, transcriptional,
CC translational, signal transduction, DNA replication and cell division
CC activity. The method is useful for identifying a compound having the
CC ability to inhibit growth or proliferation of C. albicans cells and for
CC treating infection by C. albicans. The present sequence is that of a PCR
CC primer used in the method of the invention. Note: The sequence data for
CC this patent is not represented in the printed specification but is based
CC on sequence information supplied to Derwent by the European Patent Office
XX
SQ Sequence 20 BP; 3 A; 1 C; 12 G; 4 T; 0 U; 0 Other;

Query Match 0.9%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 2.1e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1044 TGGAGGTGGGGGAATAG 1060
||||||||||||| |||
Db 1 TGGAGGTGGGGGAGTAG 17

RESULT 100
ABZ99386/c
ID ABZ99386 standard; DNA; 20 BP.
XX
AC ABZ99386;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human PDE4C oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-229219/22.
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 14628; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 2 A; 9 C; 4 G; 5 T; 0 U; 0 Other;

Query Match 0.9%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 2.1e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 314 AGCCTGGGGGTCGGCGA 330
| |||||||||||||||
Db 18 AACCTGGGGGTCGGCGA 2

RESULT 101
ABZ93334
ID ABZ93334 standard; DNA; 20 BP.
XX
AC ABZ93334;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-229219/22.
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.

```
XX
PS   Disclosure; SEQ ID NO 8576; 872pp; English.
XX
CC   The invention relates to a novel pharmaceutical composition, which has a
CC   first active agent comprising an oligonucleotide antisense to the
CC   initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC   5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC   junctions of genes encoding a polypeptide associated with lung and/or
CC   nasal airway dysfunction and a second active agent comprising an
CC   antiinflammatory steroid and ubiquinone. A composition of the invention
CC   has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC   immunosuppressive, and cytostatic activity. The composition may have a
CC   use in antisense gene therapy. The composition is useful for treating or
CC   preventing a respiratory, lung or malignant disease or condition, also
CC   for enhancing the prophylactic or therapeutic respiratory effect of an
CC   antiinflammatory steroid in a subject, for reducing or depleting levels
CC   of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC   receptor, producing bronchodilation, increasing levels of ubiquinone or
CC   lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC   lung inflammation, lung allergies, or a respiratory disease or condition.
CC   Note: The sequence data for this patent is not represented in the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 20 BP; 5 A; 7 C; 5 G; 3 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 15.4;  DB 1;  Length 20;
  Best Local Similarity   94.1%;  Pred. No. 2.1e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        385 CCCTGGACAGCAGCAAC 401
              || |||||||||||||||
Db          2 CCTTGGACAGCAGCAAC 18


RESULT 102
ABZ77075
ID   ABZ77075 standard; DNA; 20 BP.
XX
AC   ABZ77075;
XX
DT   07-MAY-2003  (first entry)
XX
DE   Human stearoyl-CoA desaturase phosphorothioate oligonucleotide SEQ:30.
XX
KW   Human; stearoyl-CoA desaturase; phosphorothioate; 2'-O-methoxyethyl;
KW   2'-MOE; cardiovascular; antiarteriosclerotic; antilipaemic; cytostatic;
KW   antiinflammatory; antisense therapy; antisense oligonucleotide; tumour;
KW   abnormal lipid metabolism; abnormal cholesterol metabolism; infection;
KW   atherosclerosis; cardiovascular disease; inflammation; inhibition; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base    1. .20
FT                    /*tag=  a
FT                    /mod_base= OTHER
FT                    /note= "phosphorothioate linkages"
FT   modified_base    1. .5
FT                    /*tag=  b
FT                    /mod_base= OTHER
FT                    /note= "2'-O-methoxyethyl (2'-MOE) gapmer"
FT   modified_base    16. .20
FT                    /*tag=  c
FT                    /mod_base= OTHER
FT                    /note= "2'-O-methoxyethyl (2'-MOE) gapmer"
XX
PN   WO2003012031-A2.
XX
PD   13-FEB-2003.
XX
PF   16-JUL-2002; 2002WO-US022676.
XX
PR   30-JUL-2001; 2001US-00918187.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Crooke RM,  Graham MJ;
XX
DR   WPI; 2003-248160/24.
XX
PT   New antisense oligonucleotides targeted to nucleic acids encoding human
PT   stearoyl-CoA desaturase, useful for treating diseases associated with the
PT   desaturase, e.g. atherosclerosis, and in diagnostic and research
PT   applications.
XX
PS   Claim 3; Page 94; 117pp; English.
XX
CC   The present invention describes a compound (I) that is 8-50 nucleobases
CC   in length targeted to a nucleic acid molecule encoding human stearoyl-CoA
CC   desaturase, and which specifically hybridises with and inhibits the
CC   expression of human stearoyl-CoA desaturase, or which specifically
CC   hybridises with at least an 8-nucleobase portion of an active site on a
CC   nucleic acid molecule encoding human stearoyl-CoA desaturase. Human
CC   stearoyl-CoA desaturase is mapped to chromosome 10. (I) has antilipaemic,
CC   cardiovascular, antiarteriosclerotic, cytostatic and antiinflammatory
CC   activities, and can be used in antisense therapy. The antisense compounds
CC   (I) can be used for modulating the expression of human stearoyl-CoA
CC   desaturase and for treating diseases or conditions associated with
CC   expression of human stearoyl-CoA desaturase, e.g. abnormal lipid or
CC   cholesterol metabolism, atherosclerosis, or cardiovascular diseases. The
CC   antisense compounds (I) can also be used for diagnostics, therapeutics
CC   and prophylaxis, e.g. to prevent or delay infection, inflammation or
CC   tumour formation, as research reagents and kits, and in distinguishing
CC   between functions of various members of a biological pathway. The present
CC   sequence represents a human stearoyl-CoA desaturase inhibiting chimeric
CC   phosphorothioate antisense oligonucleotide, which is given in an example
CC   from the present invention
XX
SQ   Sequence 20 BP; 4 A; 6 C; 4 G; 6 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 15.4;  DB 1;  Length 20;
  Best Local Similarity   94.1%;  Pred. No. 2.1e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        469 TCAGTGACCCTGAGGAT 485
              ||||||||||||||| ||
Db          1 TCAGTGACCCTGAGCAT 17


RESULT 103
ABD29564
ID   ABD29564 standard; DNA; 20 BP.
XX
AC   ABD29564;
XX
DT   29-JUL-2004  (first entry)
XX
DE   AA664176-derived oligonucleotide SEQ ID 8576.
XX
KW   Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
KW   respiratory tract inflammation; adenosine sensitivity; lung; cancer;
KW   surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
KW   analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
KW   beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
KW   respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
KW   emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
KW   pulmonary transplantation rejection; ss; primer.
XX
OS   Homo sapiens.
XX
PN   WO200285309-A2.
XX
PD   31-OCT-2002.
XX
```

```
PF   23-APR-2002; 2002WO-US013143.
XX
PR   24-APR-2001; 2001US-0286036P.
XX
PA   (EPIG-) EPIGENESIS PHARM INC.
XX
PI   Nyce JW,  Li Y,  Sandrasagra A,  Katz E,  Pabalan J,  Aguilar D;
PI   Miller S,  Tang L,  Shahabuddin S;
XX
DR   WPI; 2003-093058/08.
XX
PT   Pharmaceutical composition for treating asthma, has antisense
PT   oligonucleotide containing less percentage of adenosine, targeted to
PT   nucleic acids associated with lung airway or lung dysfunction, and
PT   bronchodilating agent.
XX
PS   Claim 15; SEQ ID NO 8576; 763pp; English.
XX
CC   This invention describes a novel composition (a) a first active agent,
CC   comprising oligonucleotides, effective for alleviating
CC   bronchoconstriction, respiratory tract inflammation, allergies and
CC   reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
CC   surfactant depletion or hyposecretion, when administered to a mammal. The
CC   oligonucleotides are derived from a gene encoding or regulating
CC   expression of a target polypeptide associated with lung airway or lung
CC   dysfunction or cancer and can be anti-sense to the corresponding mRNA.
CC   The invention also describes a kit, that comprises: (a) a delivery
CC   device, in separate containers, (b) the oligonucleotides, (c)
CC   instructions for adding a carrier and for use of the kit. The composition
CC   of the invention has antiallergic, antiinflammatory, antiasthmatic,
CC   analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
CC   beta-adrenergic agonist. The composition is useful for preventing or
CC   treating a respiratory, lung or malignant disease. The administered
CC   composition comprises oligo and is administered to reduce the production
CC   or availability, or to increase the degradation of the target mRNA or to
CC   reduce the amount of target polypeptide present in the lungs. The
CC   pulmonary obstruction, and/or bronchoconstriction and/or lung
CC   inflammation, allergies and/or surfactant hypoproduction are associated
CC   with a disease or condition such as pulmonary vasoconstriction,
CC   inflammation, allergies, asthma, impeded respiration, respiratory
CC   distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
CC   hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
CC   transplantation rejection, pulmonary infections, bronchitis or cancer.
CC   The reduced adenosine content of the anti-sense oligos corresponding to
CC   thymidines present in the target RNA serves to prevent the breakdown of
CC   the oligonucleotides into products that free adenosine into the system
CC   e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
CC   prevent any unwanted effects due to it
XX
SQ   Sequence 20 BP; 5 A; 7 C; 5 G; 3 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 15.4;  DB 1;  Length 20;
  Best Local Similarity   94.1%;  Pred. No. 2.1e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        385 CCCTGGACAGCAGCAAC 401
              || ||||||||||||||
Db          2 CCTTGGACAGCAGCAAC 18


RESULT 104
ABD32417/c
ID   ABD32417 standard; DNA; 20 BP.
XX
AC   ABD32417;
XX
DT   29-JUL-2004  (first entry)
XX
DE   Human PDE4C-derived oligonucleotide SEQ ID 14628.
XX
KW   Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
KW   respiratory tract inflammation; adenosine sensitivity; lung; cancer;
KW   surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
KW   analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
KW   beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
KW   respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
KW   emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
KW   pulmonary transplantation rejection; ss; primer.
XX
OS   Homo sapiens.
XX
PN   WO200285309-A2.
XX
PD   31-OCT-2002.
XX
PF   23-APR-2002; 2002WO-US013143.
XX
PR   24-APR-2001; 2001US-0286036P.
XX
PA   (EPIG-) EPIGENESIS PHARM INC.
XX
PI   Nyce JW,  Li Y,  Sandrasagra A,  Katz E,  Pabalan J,  Aguilar D;
PI   Miller S,  Tang L,  Shahabuddin S;
XX
DR   WPI; 2003-093058/08.
XX
PT   Pharmaceutical composition for treating asthma, has antisense
PT   oligonucleotide containing less percentage of adenosine, targeted to
PT   nucleic acids associated with lung airway or lung dysfunction, and
PT   bronchodilating agent.
XX
PS   Claim 15; SEQ ID NO 14628; 763pp; English.
XX
CC   This invention describes a novel composition (a) a first active agent,
CC   comprising oligonucleotides, effective for alleviating
CC   bronchoconstriction, respiratory tract inflammation, allergies and
CC   reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
CC   surfactant depletion or hyposecretion, when administered to a mammal. The
CC   oligonucleotides are derived from a gene encoding or regulating
CC   expression of a target polypeptide associated with lung airway or lung
CC   dysfunction or cancer and can be anti-sense to the corresponding mRNA.
CC   The invention also describes a kit, that comprises: (a) a delivery
CC   device, in separate containers, (b) the oligonucleotides, (c)
CC   instructions for adding a carrier and for use of the kit. The composition
CC   of the invention has antiallergic, antiinflammatory, antiasthmatic,
CC   analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
CC   beta-adrenergic agonist. The composition is useful for preventing or
CC   treating a respiratory, lung or malignant disease. The administered
CC   composition comprises oligo and is administered to reduce the production
CC   or availability, or to increase the degradation of the target mRNA or to
CC   reduce the amount of target polypeptide present in the lungs. The
CC   pulmonary obstruction, and/or bronchoconstriction and/or lung
CC   inflammation, allergies and/or surfactant hypoproduction are associated
CC   with a disease or condition such as pulmonary vasoconstriction,
CC   inflammation, allergies, asthma, impeded respiration, respiratory
CC   distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
CC   hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
CC   transplantation rejection, pulmonary infections, bronchitis or cancer.
CC   The reduced adenosine content of the anti-sense oligos corresponding to
CC   thymidines present in the target RNA serves to prevent the breakdown of
CC   the oligonucleotides into products that free adenosine into the system
CC   e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
CC   prevent any unwanted effects due to it
XX
SQ   Sequence 20 BP; 2 A; 9 C; 4 G; 5 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 15.4;  DB 1;  Length 20;
  Best Local Similarity   94.1%;  Pred. No. 2.1e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        314 AGCCTGGGGGTCGGCGA 330
              | ||||||||||||||||
Db         18 AACCTGGGGGTCGGCGA 2


RESULT 105
```

```
ADJ61271/c
ID   ADJ61271 standard; DNA; 20 BP.
XX
AC   ADJ61271;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Oligonucleotide associated to PDE4C #337.
XX
KW   interleukin; IL-4 receptor; IL-5 receptor; lung disease;
KW   airway inflammation; allergy; asthma; impeded respiration;
KW   cystic fibrosis; acute respiratory distress syndrome;
KW   pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
KW   ss.
XX
OS   Homo sapiens.
XX
PN   WO2004011613-A2.
XX
PD   05-FEB-2004.
XX
PF   25-JUL-2003; 2003WO-US023509.
XX
PR   29-JUL-2002; 2002US-0399076P.
XX
PA   (EPIG-) EPIGENESIS PHARM INC.
XX
PI   Nyce JW,  Tang L,  Sandrasagra A,  Aguilar D,  Miller S;
PI   Shahabuddin S,  Lu H,  Cong H;
XX
DR   WPI; 2004-203534/19.
XX
PT   Novel single or multiple target oligonucleotide anti-sense to e.g.
PT   initiation codons and introns of respiratory disease-relevant genes e.g.,
PT   CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
PT   disease e.g., asthma.
XX
PS   Claim 2; SEQ ID NO 2127; 85pp; English.
XX
CC   The present invention relates to an oligonucleotide anti-sense to e.g.,
CC   initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
CC   end of nucleic acid target comprising gene(s) chosen from e.g.
CC   interleukin (IL)-4 receptor, IL-5 receptor or salts of the
CC   oligonucleotide and optionally surfactant operatively linked to the
CC   oligonucleotide. The method is useful for preventing or treating a
CC   respiratory or lung disease, which involves administering to the airways
CC   of a subject an effective amount of an inhibitor. The oligonucleotide is
CC   useful for production of a medicament for the prevention and/or treatment
CC   of a respiratory or lung disease. The respiratory or lung disease is
CC   chosen from airway inflammation, allergy(ies), asthma, impeded
CC   respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
CC   (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
CC   (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
CC   obstruction. The present sequence represents an oligonucleotide of the
CC   invention.
XX
SQ   Sequence 20 BP; 2 A; 9 C; 4 G; 5 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 15.4;  DB 1;  Length 20;
  Best Local Similarity   94.1%;  Pred. No. 2.1e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        314 AGCCTGGGGGTCGGCGA 330
              | ||||||||||||||||
Db         18 AACCTGGGGGTCGGCGA 2


RESULT 106
ADO46661/c
ID   ADO46661 standard; DNA; 20 BP.
XX
AC   ADO46661;
XX
DT   15-JUL-2004  (first entry)
XX
DE   Human oligonucleotide #2027.
XX
KW   Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
KW   CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
KW   tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
KW   lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
KW   asthma; lung allergy; inflammation; inflammatory disease;
KW   airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
KW   chronic obstructive pulmonary disease; COPD; allergic rhinitis;
KW   acute respiratory distress syndrome; pulmonary hypertension;
KW   lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
XX
OS   Homo sapiens.
XX
PN   US2004049022-A1.
XX
PD   11-MAR-2004.
XX
PF   25-JUL-2003; 2003US-00627930.
XX
PR   23-APR-2002; 2002WO-US013135.
PR   23-APR-2002; 2002WO-US013143.
XX
PA   (NYCE/) NYCE J W.
PA   (SAND/) SANDRASAGRA A.
PA   (TANG/) TANG L.
PA   (AGUI/) AGUILAR D.
PA   (MILL/) MILLER S.
PA   (SHAH/) SHAHABUDDIN S.
PA   (LUHH/) LU H.
PA   (CONG/) CONG H.
XX
PI   Nyce JW,  Sandrasagra A,  Tang L,  Aguilar D,  Miller S;
PI   Shahabuddin S,  Lu H,  Cong H;
XX
DR   WPI; 2004-293804/27.
XX
PT   Novel single or multiple target oligonucleotide anti-sense to e.g.
PT   initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
PT   RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
PT   asthma.
XX
PS   Claim 2; SEQ ID NO 2127; 174pp; English.
XX
CC   The invention relates to oligonucleotides anti-sense to an initiation
CC   codon, coding region, 5' or 3' intron-exon junction, intron or region
CC   with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
CC   chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
CC   -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
CC   tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
CC   also relates to a method of screening a candidate compound that binds to
CC   one or more nucleic acid target(s) or expressed product(s), for the
CC   prevention and/or treatment of a respiratory or lung disease. The
CC   oligonucleotides are useful for reducing or inhibiting expression of a
CC   gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
CC   CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
CC   tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
CC   useful for preventing or treating a respiratory or lung disease. The
CC   respiratory or lung disease is associated with hyper-responsiveness to
CC   and/or increased levels of, adenosine and/or levels of adenosine A
CC   receptor(s), and/or asthma and/or lung allergies associated with
CC   inflammation or an inflammatory disease. The respiratory or lung disease
CC   is chosen from airway inflammation, allergy, asthma, impeded respiration,
CC   cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
CC   allergic rhinitis, acute respiratory distress syndrome, pulmonary
CC   hypertension, lung inflammation, bronchitis, airway obstruction or
CC   bronchoconstriction. This sequence represents an oligonucleotide of the
CC   invention.
XX
SQ   Sequence 20 BP; 2 A; 9 C; 4 G; 5 T; 0 U; 0 Other;
```

```
  Query Match             0.9%;  Score 15.4;  DB 1;  Length 20;
  Best Local Similarity   94.1%;  Pred. No. 2.1e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        314 AGCCTGGGGGTCGGCGA 330
              | ||||||||||||||||
Db         18 AACCTGGGGGTCGGCGA 2


RESULT 107
ADP11812/c
ID   ADP11812 standard; DNA; 20 BP.
XX
AC   ADP11812;
XX
DT   12-AUG-2004  (first entry)
XX
DE   Set 2 left PCR primer for marker probe #164.
XX
KW   transplant rejection; immune system; rheumatoid arthritis; lupus;
KW   inflammatory bowel disease; multiple sclerosis; HIV; AIDS; ss; primer.
XX
OS   Homo sapiens.
XX
PN   WO2004042346-A2.
XX
PD   21-MAY-2004.
XX
PF   24-APR-2003; 2003WO-US012946.
XX
PR   24-APR-2002; 2002US-00131831.
PR   20-DEC-2002; 2002US-00325899.
XX
PA   (EXPR-) EXPRESSION DIAGNOSTICS INC.
XX
PI   Wohlgemuth J,  Fry K,  Woodward R,  Ly N,  Prentice J,  Morris M;
PI   Rosenberg S;
XX
DR   WPI; 2004-400724/37.
XX
PT   Diagnosing or monitoring transplant rejection, e.g. heart, kidney, liver,
PT   pancreas, pancreatic islet, lung, bone marrow or stem cell transplant
PT   rejection, in an individual, comprises detecting the expression level of
PT   the genes.
XX
PS   Claim 58; SEQ ID NO 1821; 1762pp; English.
XX
CC   The present invention relates to diagnosing or monitoring transplant
CC   rejection, e.g. cardiac or kidney transplant rejection, in an individual
CC   comprises detecting the expression level of one or more genes. The
CC   methods, system and kits are useful in diagnosing or monitoring
CC   transplant rejection, e.g. heart, kidney, liver, pancreas, pancreatic
CC   islet, lung, bone marrow or stem cell transplant rejection,
CC   xenotransplant rejection or mechanical organ replacement rejection, in an
CC   individual. The method is also useful in assessing the immune status of
CC   an individual. The methods are also useful in diagnosing and monitoring
CC   diseases that involve the immune system, e.g. rheumatoid arthritis,
CC   lupus, inflammatory bowel diseases, multiple sclerosis, HIV/AIDS or
CC   viral, bacterial or fungal infection. The present sequence represents a
CC   primer for a 50 mer oligonucleotide marker for diagnosis and monitoring
CC   of allograft rejection and other disorders.
XX
SQ   Sequence 20 BP; 3 A; 7 C; 4 G; 6 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 15.4;  DB 1;  Length 20;
  Best Local Similarity   94.1%;  Pred. No. 2.1e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        486 GAACACTTGTGTGCCAA 502
              ||||||| |||||||||
Db         17 GAACACTGGTGTGCCAA 1


RESULT 108
ADO50692
ID   ADO50692 standard; DNA; 20 BP.
XX
AC   ADO50692;
XX
DT   12-AUG-2004  (first entry)
XX
DE   Human STAT2 antisense target region #13.
XX
KW   Human; ds; antisense; STAT2;
KW   signal transducer and activator of transcription-2;
KW   inflammatory response; viral infection; viral hepatitis;
KW   autoimmune disease; autoimmune encephalitis; cancer.
XX
OS   Homo sapiens.
XX
PN   US2004101853-A1.
XX
PD   27-MAY-2004.
XX
PF   23-NOV-2002; 2002US-00304103.
XX
PR   23-NOV-2002; 2002US-00304103.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Bennett CF,  Dobie KW;
XX
DR   WPI; 2004-399681/37.
XX
PT   New antisense oligonucleotides for modulating STAT2 expression, useful
PT   for diagnosing, preventing or treating diseases or conditions resulting
PT   in activation of an inflammatory response.
XX
PS   Example 15; SEQ ID NO 57; 45pp; English.
XX
CC   The invention relates to a compound 8-80 nucleobases in length targeted
CC   to the Human signal transducer and activator of transcription-2, STAT2,
CC   gene. The compound (an antisense oligonucleotide) specifically hybridises
CC   with the nucleic acid molecule encoding STAT2 (appearing as ADO50639) and
CC   inhibits the expression of STAT2. Also included are a method of
CC   inhibiting the expression of STAT2 in cells or tissues (comprising
CC   contacting the cells or tissues with the new compound so that the
CC   expression of STAT2 is inhibited), a method of screening for a modulator
CC   of STAT2 (comprising contacting a preferred target segment of the nucleic
CC   acid encoding STAT2 with one or more candidate modulators of STAT2, and
CC   identifying one or more modulators that modulate the expression of
CC   STAT2), a diagnostic method for identifying a disease state (comprising
CC   identifying the presence of STAT2 in a sample using at least one of the
CC   primers appearing asADO50640 or ADO50641, or the probe appearing as
CC   ADO50642), a kit or assay device comprising the above compound and a
CC   method of treating an animal having a disease or condition associated
CC   with STAT2 (comprising administering to the animal a therapeutic or
CC   prophylactic amount of the compound so that expression of STAT2 is
CC   inhibited). The antisense oligonucleotide is useful for inhibiting the
CC   expression of STAT2 in cells or tissues to prevent or treat diseases
CC   associated with their expression, such as diseases or conditions
CC   resulting in activation of an inflammatory response e.g. viral infection,
CC   viral hepatitis, autoimmune disease (e.g. autoimmune encephalitis) and
CC   cancer. In addition, the compound is used for diagnostics, prophylaxis,
CC   or as research reagents or kits. The present sequence is a target region
CC   for the antisense oligonucleotides from the human STAT2 gene.
XX
SQ   Sequence 20 BP; 3 A; 6 C; 6 G; 5 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 15.4;  DB 1;  Length 20;
  Best Local Similarity   94.1%;  Pred. No. 2.1e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        502 ACCTGATGCAGCTGCTG 518
              |||||| ||||||||||
Db          4 ACCTGAGGCAGCTGCTG 20
```

```
RESULT 109
ADO50659/c
ID   ADO50659 standard; DNA; 20 BP.
XX
AC   ADO50659;
XX
DT   12-AUG-2004  (first entry)
XX
DE   Human STAT2 antisense oligonucleotide ISIS182971.
XX
KW   Human; ss; antisense; STAT2;
KW   signal transducer and activator of transcription-2;
KW   inflammatory response; viral infection; viral hepatitis;
KW   autoimmune disease; autoimmune encephalitis; cancer.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate backbone and all cytidines are 5
FT                   -methylcytidines"
FT   modified_base   1. .5
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl residue"
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl residue"
XX
PN   US2004101853-A1.
XX
PD   27-MAY-2004.
XX
PF   23-NOV-2002; 2002US-00304103.
XX
PR   23-NOV-2002; 2002US-00304103.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Bennett CF,  Dobie KW;
XX
DR   WPI; 2004-399681/37.
XX
PT   New antisense oligonucleotides for modulating STAT2 expression, useful
PT   for diagnosing, preventing or treating diseases or conditions resulting
PT   in activation of an inflammatory response.
XX
PS   Example 15; SEQ ID NO 24; 45pp; English.
XX
CC   The invention relates to a compound 8-80 nucleobases in length targeted
CC   to the Human signal transducer and activator of transcription-2, STAT2,
CC   gene. The compound (an antisense oligonucleotide) specifically hybridises
CC   with the nucleic acid molecule encoding STAT2 (appearing as ADO50639) and
CC   inhibits the expression of STAT2. Also included are a method of
CC   inhibiting the expression of STAT2 in cells or tissues (comprising
CC   contacting the cells or tissues with the new compound so that the
CC   expression of STAT2 is inhibited), a method of screening for a modulator
CC   of STAT2 (comprising contacting a preferred target segment of the nucleic
CC   acid encoding STAT2 with one or more candidate modulators of STAT2, and
CC   identifying one or more modulators that modulate the expression of
CC   STAT2), a diagnostic method for identifying a disease state (comprising
CC   identifying the presence of STAT2 in a sample using at least one of the
CC   primers appearing asADO50640 or ADO50641, or the probe appearing as
CC   ADO50642), a kit or assay device comprising the above compound and a
CC   method of treating an animal having a disease or condition associated
CC   with STAT2 (comprising administering to the animal a therapeutic or
CC   prophylactic amount of the compound so that expression of STAT2 is
CC   inhibited). The antisense oligonucleotide is useful for inhibiting the
CC   expression of STAT2 in cells or tissues to prevent or treat diseases
CC   associated with their expression, such as diseases or conditions
CC   resulting in activation of an inflammatory response e.g. viral infection,
CC   viral hepatitis, autoimmune disease (e.g. autoimmune encephalitis) and
CC   cancer. In addition, the compound is used for diagnostics, prophylaxis,
CC   or as research reagents or kits. The present sequence is an antisense
CC   oligonucleotide targeting STAT2.
XX
SQ   Sequence 20 BP; 5 A; 6 C; 6 G; 3 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 15.4;  DB 1;  Length 20;
  Best Local Similarity   94.1%;  Pred. No. 2.1e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        502 ACCTGATGCAGCTGCTG 518
              ||||||  ||||||||||
Db         17 ACCTGAGGCAGCTGCTG 1


RESULT 110
AAX84260
ID   AAX84260 standard; DNA; 25 BP.
XX
AC   AAX84260;
XX
DT   08-SEP-1999  (first entry)
XX
DE   PCR primer for human Nck associated protein 1 coding sequence.
XX
KW   Nck associated protein 1; Nap1; human; apoptosis; Alzheimer's disease;
KW   therapy; PCR primer; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO9931239-A1.
XX
PD   24-JUN-1999.
XX
PF   14-DEC-1998;   98WO-JP005646.
XX
PR   15-DEC-1997;   97JP-00363183.
XX
PA   (KYOW ) KYOWA HAKKO KOGYO KK.
PA   (SAKA/) SAKAKI Y.
XX
PI   Sakaki Y;
XX
DR   WPI; 1999-395181/33.
XX
PT   Protein inhibiting apoptosis, useful in the diagnosis and treatment of
PT   Alzheimer's disease.
XX
PS   Disclosure; Page 77; 90pp; Japanese.
XX
CC   This sequence represents a PCR primer used to isolate DNA encoding the
CC   human Nck associated protein 1 (Nap1) of the invention. Nap1 inhibits
CC   apoptosis. The protein can be used in the investigation, diagnosis and
CC   treatment (e.g. by gene therapy) of Alzheimer's disease
XX
SQ   Sequence 25 BP; 0 A; 1 C; 0 G; 24 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 15.4;  DB 1;  Length 25;
  Best Local Similarity   76.0%;  Pred. No. 2.1e+02;
  Matches   19;  Conservative    0;  Mismatches    6;  Indels    0;  Gaps    0;

Qy       1386 TTGTTTGTTTTGTATCTTGTTTTTC 1410
              || ||| |||| | | || ||||||
Db          1 TTTTTTTTTTTTTTTTTTTTTTTTC 25


RESULT 111
AAI73048
```

ID AAI73048 standard; DNA; 26 BP.
XX
AC AAI73048;
XX
DT 24-OCT-2002 (first entry)
XX
DE Scaffold oligonucleotide.
XX
KW Molecular scaffold; fluorophore; fluorescence; energy transfer;
KW emission wavelength; excitation wavelength; multiple; single nucleotide;
KW polymorphism; ss.
XX
OS Synthetic.
XX
PN WO200222883-A1.
XX
PD 21-MAR-2002.
XX
PF 11-SEP-2001; 2001WO-US028967.
XX
PR 11-SEP-2000; 2000US-00658077.
PR 31-JUL-2001; 2001US-0309156P.
XX
PA (UYCO) UNIV COLUMBIA NEW YORK.
XX
PI Ju J, Li Z, Tong A, Russo JJ;
XX
DR WPI; 2002-575158/61.
XX
PT Composition of matter useful for multi-component analyses, comprises
PT multiple fluorophores bound to molecular scaffold at preset positions to
PT permit fluorescence energy transfer between two fluorophores.
XX
PS Disclosure; Page 43; 113pp; English.
XX
CC This sequence represents a molecular scaffold which may be used in a
CC composition of matter comprising multiple fluorophores. The fluorophores
CC are bound to the molecular scaffold at separate predetermined positions,
CC to permit fluorescence energy transfer between two fluorophores. The
CC fluorophores are characterized by maximum emission wavelength of one
CC being greater than the minimum excitation wavelength of the other. The
CC composition is useful for determining whether a preselected nucleotide
CC residue is present at a predetermined position within a nucleic acid. It
CC is also useful in multicomponent analysis including multiplex biological
CC analysis, and identifying multiple single nucleotide polymorphisms. The
CC presence of a number of given nucleotide residues is determined
CC simultaneously by the composition of the invention
XX
SQ Sequence 26 BP; 0 A; 1 C; 0 G; 25 T; 0 U; 0 Other;

Query Match 0.9%; Score 15.4; DB 1; Length 26;
Best Local Similarity 76.0%; Pred. No. 2.1e+02;
Matches 19; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

```
Qy       1386 TTGTTTGTTTTGTATCTTGTTTTTC 1410
                || ||| |||| | | || ||||||
Db          2 TTTTTTTTTTTTTTTTTTTTTTTTC 26
```

RESULT 112
AAS20672
ID AAS20672 standard; DNA; 26 BP.
XX
AC AAS20672;
XX
DT 09-APR-2002 (first entry)
XX
DE Human zalpha11 Ligand sequencing primer ZC7764b.
XX
KW Cytokine; zalpha11 Ligand; zalpha11 receptor; NK cell progenitor;
KW natural killer cell proliferation; T-cell proliferation;
KW B-cell proliferation; anti-tumour response; immune system;
KW immunostimulant; cytostatic; human; sequencing primer; ss.
XX
OS Homo sapiens.
XX
PN US6307024-B1.
XX
PD 23-OCT-2001.
XX
PF 09-MAR-2000; 2000US-00522217.
XX
PR 09-MAR-1999; 99US-0123547P.
PR 11-MAR-1999; 99US-0123904P.
PR 01-JUL-1999; 99US-0142013P.
XX
PA (ZYMO) ZYMOGENETICS INC.
XX
PI Novak JE, Presnell SR, Sprecher CA, Foster DC, Holly RD;
PI Gross JA, Johnston JV, Nelson AJ, Dillon SR, Hammond AK;
XX
DR WPI; 2002-040208/05.
XX
PT New zalpha11 ligand polypeptides and polynucleotides, useful for
PT stimulating proliferation, activation, differentiation and/or induction
PT of inhibition of specialized cell function, or for stimulating an
PT antigenic response.
XX
PS Example 7; Col 139; 105pp; English.
XX
CC The present invention relates to the isolation of a novel cytokine,
CC zalpha11 Ligand and the polynucleotide encoding it. The invention also
CC gives the sequence for the zalpha11 receptor and the polynucleotide
CC encoding it. The zalpha11 Ligand polypeptide stimulates proliferation of
CC natural killer (NK) cells or NK cell progenitors, the activation of NK
CC cells, proliferation of T-cells, proliferation of B-cells stimulated with
CC anti-CD40 antibodies, stimulates an antigenic response in a mammal, and
CC reduces proliferation of B-cells stimulated with anti-IgM antibodies. The
CC zalpha11 Ligand polypeptide is also useful in preparing antibodies that
CC bind to zalpha11 Ligand epitopes. The zalpha11 Ligand polynucleotides can
CC be used as probes or primers to clone regions of a zalpha11 Ligand gene,
CC and in gene therapy. Zalpha11 Ligand may also be used to identify
CC inhibitors of its activity, to enhance the generation of anti-tumour
CC responses with or without the infusion of donor lymphocytes, and to
CC activate or stimulate the immune system. The present sequence represents
CC a sequencing primer used to sequence cDNA clones in the isolation of
CC human zalpha11 Ligand
XX
SQ Sequence 26 BP; 0 A; 1 C; 0 G; 25 T; 0 U; 0 Other;

Query Match 0.9%; Score 15.4; DB 1; Length 26;
Best Local Similarity 76.0%; Pred. No. 2.1e+02;
Matches 19; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

```
Qy       1386 TTGTTTGTTTTGTATCTTGTTTTTC 1410
                || ||| |||| | | || ||||||
Db          2 TTTTTTTTTTTTTTTTTTTTTTTTC 26
```

RESULT 113
ABX93461
ID ABX93461 standard; DNA; 26 BP.
XX
AC ABX93461;
XX
DT 27-MAY-2003 (first entry)
XX
DE LS147-specific polynucleotide sequencing related universal primer #1.
XX
KW LS147; cancer; lung cancer; gene therapy; cytostatic; ss; sequencing;
KW primer; EST clone; expressed sequence tag clone.
XX
OS Synthetic.
XX
PN US2002188114-A1.
XX

PD 12-DEC-2002.
XX
PF 05-JUN-1998; 98US-00092296.
XX
PR 05-JUN-1997; 97US-0048810P.
XX
PA (BILL/) BILLINGEL P.
PA (COHE/) COHEN M.
PA (COLP/) COLPITTS T L.
PA (FRIE/) FRIEDMAN P N.
PA (KLAS/) KLASS M R.
PA (RUSS/) RUSSELL J C.
PA (STRO/) STROUPE S.
XX
PI Billingel P, Cohen M, Colpitts TL, Friedman PN, Klass MR;
PI Russell JC, Stroupe S;
XX
DR WPI; 2003-341045/32.
XX
PT New LS147 polypeptide, useful for preparing a composition for treating
PT e.g., lung cancer.
XX
PS Example 2; Page 39; 47pp; English.
XX
CC The invention describes a purified polypeptide or its fragment derived
CC from the LS147 gene capable of selectively hybridising to the nucleic
CC acid of the gene and has at least 50% identity with the polynucleotide.
CC The LS147 polypeptide is useful for preparing a composition for treating
CC cancer, e.g. lung cancer using gene therapy. This sequence represents a
CC universal primer used to sequence LS147 expressed sequence tag (EST)-
CC clones
XX
SQ Sequence 26 BP; 0 A; 1 C; 0 G; 25 T; 0 U; 0 Other;

Query Match 0.9%; Score 15.4; DB 1; Length 26;
Best Local Similarity 76.0%; Pred. No. 2.1e+02;
Matches 19; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

```
Qy       1386 TTGTTTGTTTTGTATCTTGTTTTTC 1410
                || ||| |||| | | || ||||||
Db          2 TTTTTTTTTTTTTTTTTTTTTTTTC 26
```

RESULT 114
ADH44609
ID ADH44609 standard; DNA; 26 BP.
XX
AC ADH44609;
XX
DT 25-MAR-2004 (first entry)
XX
DE Human cDNA encoding Zalpha11 sequencing primer #3.
XX
KW Human; ss; Zalpha11 ligand; Zalpha11 receptor; immune response;
KW tumour progression; metastasis; tumour stasis; haematopoietic tumour;
KW lymphoma; B cell tumour; systemic lupus erythematosus;
KW rheumatoid arthritis; myasthenia gravis; diabetes; infectious disease;
KW immunocompromised patient; HIV infection; vaccine; primer.
XX
OS Homo sapiens.
XX
PN US6605272-B2.
XX
PD 12-AUG-2003.
XX
PF 03-AUG-2001; 2001US-00923246.
XX
PR 09-MAR-1999; 99US-0123547P.
PR 11-MAR-1999; 99US-0123904P.
PR 01-JUL-1999; 99US-0142013P.
PR 09-MAR-2000; 2000US-00522217.
XX
PA (ZYMO) ZYMOGENETICS INC.
XX
PI Novak JE, Presnell SR, Sprecher CA, Foster DC, Holly RD;
PI Gross JA, Johnston JV, Nelson AJ, Dillon SR, Hammond AK;
XX
DR WPI; 2003-895283/82.
XX
PT Stimulating an immune response in a mammal exposed to an antigen or
PT pathogen, useful for enhancing anti-tumor activity resulting in reduced
PT tumor progression or metastasis, comprises administering zalpha11 ligand
PT polypeptide.
XX
PS Example 7; SEQ ID NO 39; 103pp; English.
XX
CC The invention relates to stimulating an immune response in a mammal
CC exposed to an antigen or pathogen comprises administering a composition
CC comprising mature zalpha11 ligand polypeptide comprising residues 32-162
CC of ADH44572 in a pharmaceutical vehicle. Also included are stimulating an
CC immune response in a mammal exposed to an antigen or pathogen
CC (comprising: (a) determining (in)directly the level of antigen or
CC pathogen present in the mammal; (b) administering a composition
CC comprising zalpha11 ligand polypeptide in a pharmaceutical vehicle; (c)
CC determining (in)directly the level of antigen or pathogen in the mammal;
CC and (d) comparing the antigen or pathogen level in (a) with (b), where a
CC change in the level indicates stimulation of immune response), and
CC stimulating an immune response in a mammal exposed to an antigen or
CC pathogen (comprising: (a) determining a level of antigen- or pathogen-
CC specific antibody; (b) administering a composition comprising zalpha11
CC ligand polypeptide in a pharmaceutical vehicle; (c) determining a post
CC administration level of the antigen- or pathogen-specific antibody; and
CC (d) comparing the level of the antibody in (a) with (b), where an
CC increase in the antibody level indicates stimulation of immune response).
CC The method is useful for stimulating an immune response in a mammal
CC exposed to an antigen or pathogen, and for enhancing anti-tumour activity
CC resulting in a reduction in tumour progression, decrease in metastasis,
CC or tumour stasis. The tumour may be a haematopoietic tumour, a lymphoma
CC or a B cell tumour. The zalpha11 ligand is useful for treating a wide
CC range of diseases arising from defects in the immune system, e.g.
CC systemic lupus erythematosus, rheumatoid arthritis, myasthenia gravis, or
CC diabetes, for boosting immunity to infectious diseases, treating
CC immunocompromised patients, such as HIV+ patients and in improving
CC vaccines. The present sequence is a sequencing primer used in the
CC exemplification of the invention.
XX
SQ Sequence 26 BP; 0 A; 1 C; 0 G; 25 T; 0 U; 0 Other;

Query Match 0.9%; Score 15.4; DB 1; Length 26;
Best Local Similarity 76.0%; Pred. No. 2.1e+02;
Matches 19; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

```
Qy       1386 TTGTTTGTTTTGTATCTTGTTTTTC 1410
                || ||| |||| | | || ||||||
Db          2 TTTTTTTTTTTTTTTTTTTTTTTTC 26
```

RESULT 115
ADI00945
ID ADI00945 standard; DNA; 26 BP.
XX
AC ADI00945;
XX
DT 22-APR-2004 (first entry)
XX
DE Sequencing primer SEQ 39 used to analyse human zalpha11 ligand clone DNA.
XX
KW zalpha11 ligand; immunity; infectious disease; immunocompromised patient;
KW HIV; vaccine; human; ss; PCR; primer.
XX
OS Homo sapiens.
XX
PN US2003125524-A1.
XX
PD 03-JUL-2003.
XX

```
PF   15-NOV-2002; 2002US-00295723.
XX
PR   09-MAR-2000; 2000US-00522217.
XX
PA   (ZYMO ) ZYMOGENETICS INC.
XX
PI   Novak JE,  Presnell SR,  Sprecher CA,  Foster DC,  Holly RD;
PI   Gross JA,  Johnston JV,  Nelson AJ,  Dillon SR,  Hammond AK;
XX
DR   WPI; 2003-811003/76.
XX
PT   New zalpha11 ligand polypeptides, useful for boosting immunity to
PT   infectious diseases, and treating immunocompromised patients, such as
PT   human immunodeficiency virus (HIV) patients, or in improving vaccines.
XX
PS   Example 7; SEQ ID NO 39; 113pp; English.
XX
CC   The invention relates to a novel isolated zalpha11 ligand polypeptide.
CC   The polypeptide of the invention may be useful for boosting immunity to
CC   infectious diseases and treating immunocompromised patients, such as HIV
CC   patients, as well as in improving vaccines. The current sequence is that
CC   of the PCR primer which was used in the exemplification of the invention.
XX
SQ   Sequence 26 BP; 0 A; 1 C; 0 G; 25 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 15.4;  DB 1;  Length 26;
  Best Local Similarity   76.0%;  Pred. No. 2.1e+02;
  Matches   19;  Conservative    0;  Mismatches    6;  Indels    0;  Gaps    0;

Qy       1386 TTGTTTGTTTTGTATCTTGTTTTTC 1410
              || ||| |||| | | || ||||||
Db          2 TTTTTTTTTTTTTTTTTTTTTTTTC 26


RESULT 116
ADP19768
ID   ADP19768 standard; DNA; 26 BP.
XX
AC   ADP19768;
XX
DT   26-AUG-2004  (first entry)
XX
DE   Human zalpha11 ligand PCR primer seqid 39.
XX
KW   cytostatic; zalpha11 ligand; pharmaceutical; cancer; immune response;
KW   melanoma; tumour; solid tumour; haematopoietic tumour; lymphoma; human;
KW   PCR; primer; ss.
XX
OS   Homo sapiens.
XX
PN   US2004110932-A1.
XX
PD   10-JUN-2004.
XX
PF   10-SEP-2003; 2003US-00659684.
XX
PR   09-MAR-1999;   99US-0123547P.
PR   11-MAR-1999;   99US-0123904P.
PR   01-JUL-1999;   99US-0142013P.
PR   09-MAR-2000; 2000US-00522217.
XX
PA   (ZYMO ) ZYMOGENETICS INC.
XX
PI   Novak JE,  Presnell SR,  Sprecher CA,  Foster DC,  Holly RD;
PI   Gross JA,  Johnston JV,  Nelson AJ,  Dillon SR,  Hammond AK;
XX
DR   WPI; 2004-440401/41.
XX
PT   New zalpha11 ligand polynucleotide and polypeptide molecules, useful for
PT   treating cancer, e.g. melanoma, solid tumor, hematopoietic tumor, or
PT   lymphoma.
XX
PS   Example 7; SEQ ID NO 39; 111pp; English.
XX
CC   The invention describes an isolated polypeptide comprising a sequence of
CC   amino acid residues that is at least 90 or 95% identical to residues 41
CC   (Gln) to 148 (Ile), or 32 (Gln) to 148 (Ile) of a sequence of 162 amino
CC   acids (SEQ ID NO:2, human zalpha11 ligand), fully defined in the
CC   specification. Also described are: a pharmaceutical composition
CC   comprising the polypeptide, and a vehicle; a method of treating cancer in
CC   a mammal; a method of stimulating an immune response in a mammal with
CC   melanoma; a method of stimulating an immune response in a mammal bearing
CC   a tumour; an isolated polynucleotide comprising a sequence of nucleotides
CC   that encode amino acid residues cited above, where the polynucleotide
CC   encodes a polypeptide that binds a receptor comprising 538 amino acids,
CC   fully defined in the specification; a pharmaceutical composition
CC   comprising the polynucleotide encoding, in a pharmaceutically acceptable
CC   vehicle; an expression vector comprising the following operably linked
CC   elements a control element; and a DNA segment comprising the
CC   polynucleotide; and an isolated polynucleotide molecule comprising at
CC   least 10 nucleotides of the polynucleotide sequence of 642 bp, fully
CC   defined in the specification. The molecules, compositions and methods are
CC   useful for treating cancer, e.g. melanoma, solid tumour, haematopoietic
CC   tumour, or lymphoma. This sequence represents a primer used in the
CC   expression cloning of human cytokine zalpha11 ligand.
XX
SQ   Sequence 26 BP; 0 A; 1 C; 0 G; 25 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 15.4;  DB 1;  Length 26;
  Best Local Similarity   76.0%;  Pred. No. 2.1e+02;
  Matches   19;  Conservative    0;  Mismatches    6;  Indels    0;  Gaps    0;

Qy       1386 TTGTTTGTTTTGTATCTTGTTTTTC 1410
              || ||| |||| | | || ||||||
Db          2 TTTTTTTTTTTTTTTTTTTTTTTTC 26


RESULT 117
AAX09677
ID   AAX09677 standard; DNA; 20 BP.
XX
AC   AAX09677;
XX
DT   24-MAR-1999  (first entry)
XX
DE   Human biallelic polymorphic marker upstream primer #557.
XX
KW   Polymorphism; biallelic; human; forensic; paternity testing; disease;
KW   detection; phenotypic typing; characteristic; infection; hereditary;
KW   autoimmune disease; cancer; inflammation; drug; therapy; medicament;
KW   treatment; marker; primer; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO9820165-A2.
XX
PD   14-MAY-1998.
XX
PF   05-NOV-1997;   97WO-US020313.
XX
PR   06-NOV-1996;   96US-0030455P.
XX
PA   (WHED ) WHITEHEAD INST BIOMEDICAL RES.
XX
PI   Lander ES,  Wang D,  Hudson T;
XX
DR   WPI; 1998-286974/25.
XX
PT   New isolated nucleic acid segments from the human genome - used for
PT   determining polymorphic forms for use in e.g. forensics, paternity
PT   testing or phenotypic typing for disease.
XX
PS   Claim 15; Page 219; 310pp; English.
XX
CC   AAX09121-X10268 are allele-specific oligonucleotide primers used in the
```

```
CC   isolation of various biallelic polymorphic markers found in the human
CC   genome (represented in AAX10269-X12937). These primers can be used in a
CC   method for determining polymorphic forms in an individual for use in e.g.
CC   forensics, paternity testing or for phenotypic typing for diseases such
CC   as agammaglobulinemia, diabetes insipidus, Lesch-Nyhan syndrome, muscular
CC   dystrophy, Wiskott-Aldrich syndrome, Fabry's disease, familial
CC   hypercholesterolemia, polycystic kidney disease, hereditary
CC   spherocytosis, von Willebrand's disease, tuberous sclerosis, hereditary
CC   haemorrhagic telangiectasia, familial colonic polyposis, Ehlers-Danlos
CC   syndrome, osteogenesis imperfecta, acute intermittent porphyria,
CC   autoimmune diseases, inflammation, cancer, diseases of the nervous
CC   system, infection by pathogenic microorganisms, and characteristics such
CC   as longevity, appearance (e.g. baldness, obesity), strength, speed,
CC   endurance, fertility, and susceptibility or receptivity to particular
CC   drugs or therapeutic treatments. The isolated polymorphic nucleic acid
CC   segments can also be used to produce medicaments for the treatment or
CC   prophylaxis of such diseases
XX
SQ   Sequence 20 BP; 3 A; 2 C; 9 G; 6 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 15.2;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 2.3e+02;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1163 GCTTCCAGCTGGATGTGTGT 1182
              | || |||||||| ||||||
Db          1 GGTTACAGCTGGAGGTGTGT 20


RESULT 118
AAV49804
ID   AAV49804 standard; DNA; 20 BP.
XX
AC   AAV49804;
XX
DT   02-NOV-1998  (first entry)
XX
DE   Mouse haematopoietic marker PCR primer Gli-1 (3').
XX
KW   Mesoderm cell; haematopoiesis; vascular growth; embryo development;
KW   treatment; erythroid cell; blood; infection; myocardial ischaemia;
KW   hypervascularisation; hedgehog compound; modulator; gene therapy;
KW   PCR primer; ss.
XX
OS   Synthetic.
OS   Mus sp.
XX
PN   WO9835020-A2.
XX
PD   13-AUG-1998.
XX
PF   10-FEB-1998;   98WO-US002633.
XX
PR   10-FEB-1997;   97US-0037513P.
PR   16-JUN-1997;   97US-0049763P.
XX
PA   (HARD ) HARVARD COLLEGE.
XX
PI   Baron MH,  Farrington SM,  Belaoussoff M;
XX
DR   WPI; 1998-447218/38.
XX
PT   Stimulating differentiation of mesodermal cells to haematopoietic or
PT   vascular cells - by exposure to an equivalent, specifically hedgehog
PT   protein, of product of extra-embryonic tissue, for treating developmental
PT   abnormalities in utero, e.g. ischaemia, excessive vascular growth.
XX
PS   Example 5; Page 48; 76pp; English.
XX
CC   AAV49781-V49806 are PCR primers used in a method of stimulating a
CC   population of undifferentiated mesodermally derived cells to undergo
CC   haematopoiesis and/or vascular growth by providing them with a compound
CC   that is functionally equivalent to a gene product expressed in extra-
CC   embryonic tissue. This method has applications in the treatment of
CC   developmental errors (in vascular growth or haematopoiesis), in an embryo
CC   in utero. The method can also be used in the treatment of conditions
CC   involving an abnormal number of erythroid cells e.g. anaemia,
CC   inflammation, cancer, organ failure, thrombocytopaenia, polycythaemia
CC   vera, erythroleukaemia and also other blood abnormalities such as the
CC   effects of radiation treatment, infection with human immune deficiency
CC   virus. This compound can also be used in the treatment of myocardial
CC   ischaemia, and hypervascularisation of genetic or degenerative origin
CC   (e.g. ocular neovascularisation of diabetes, breast cancer etc.), to
CC   promote revascularisation for healing wounds such as duodenal ulcers, in
CC   the treatment of excessive vascular growth by treating with a hedgehog
CC   compound that inhibits activity of the compound and in vitro or in vivo
CC   assays for determining activity of compounds that modulate haematopoiesis
CC   and vascular growth e.g. for screening libraries, to test growth factors,
CC   cytokines etc., to examine haematopoietic potential of other embryonic
CC   tissues, to monitor development of primary embryonic cells and vascular
CC   structures, to determine effects of targeted mutations and to study
CC   effects of gene therapy
XX
SQ   Sequence 20 BP; 5 A; 5 C; 6 G; 4 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 15.2;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 2.3e+02;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        502 ACCTGATGCAGCTGCTGCAG 521
              | |||||||||||| | |||
Db          1 AGCTGATGCAGCTGATCCAG 20


RESULT 119
AAX55902/c
ID   AAX55902 standard; DNA; 20 BP.
XX
AC   AAX55902;
XX
DT   08-JUL-1999  (first entry)
XX
DE   Hepatitis B virus classification probe SEQ ID NO:22.
XX
KW   Hepatitis B virus; HBV; classification; probe; S gene; infection;
KW   genotyping; gdw1; gdw2; ss.
XX
OS   Synthetic.
OS   Hepatitis B virus.
XX
PN   JP11103898-A.
XX
PD   20-APR-1999.
XX
PF   30-SEP-1997;   97JP-00282784.
XX
PR   30-SEP-1997;   97JP-00282784.
XX
PA   (SRLS-) SRL KK.
XX
DR   WPI; 1999-305861/26.
XX
PT   New primer and probes - useful for classification of the type of
PT   hepatitis B virus.
XX
PS   Claim 29; Page 13; 17pp; Japanese.
XX
CC   The present invention describes classification of the type of hepatitis B
CC   virus (HBV) involving checking if the 22nd nucleotide (22nt) in the S
CC   gene is cytosine, to distinguish the gdw2 type of HBV from other types.
CC   Also described are: (1) a method as above for distinguishing the gdw2
CC   type gene, involving checking if the 166nt, 169nt, 176nt and 390nt are
CC   adenine, thymine, guanine or cytosine respectively; (2) a method as above
CC   for distinguishing the gdw1 type gene, involving checking if the 392nt is
CC   adenine; (3) a method as above for distinguishing the gyw type gene
CC   involving checking if the 401nt is adenine; and (4) a method as above for
```

```
CC   distinguishing the gdr type gene involving checking if the 328nt is
CC   cytosine and if the 337nt is adenine. The method can classify HBV easily
CC   to match with clinical symptoms. The present sequence represents a probe
CC   for use in the method of the invention
XX
SQ   Sequence 20 BP; 5 A; 8 C; 3 G; 4 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 15.2;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 2.3e+02;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        363 CTGGAGAGCTCGGACTGCGA 382
              ||||||| | |||||||||
Db         20 CTGGAGATTTGGGACTGCGA 1


RESULT 120
AAZ40560/c
ID   AAZ40560 standard; DNA; 20 BP.
XX
AC   AAZ40560;
XX
DT   18-FEB-2000  (first entry)
XX
DE   Human PAK5 primer #2.
XX
KW   Antirheumatic; antiathritic; antiinflammatory; antiallergic; osteopathic;
KW   antipsoriatic; antiarteriosclerotic; antiasthmatic; immunosupressive;
KW   neuroprotective; cardiant; cerebroprotective; cytostatic; antidiabetic;
KW   vulnery; STE20; protein kinase; STLK2; STLK3; STLK4; STLK5; STLK6; STLK7;
KW   ZC1; ZC2; ZC3; ZC4; KHS2; SULU1; SULU3; GEK2; PAK4; PAK5; antagonist;
KW   antibody; gene therapy; rheumatoid arthritis; artherosclerosis; asthma;
KW   inflammatory bowel disease; Crohn's disease; osteoarthritis; psoriasis;
KW   rhinitis; autoimmunity; organ transplantation; multiple sclerosis;
KW   myocardial infarction; cardiovascular disease; stroke; renal failure;
KW   oxidative stress-related neurodegenerative disorder; Parkinson's disease;
KW   amylotrophic lateral sclerosis; Leigh syndrome; cancer; cardiomyopathy;
KW   ischemic disorder; inflammation; diabetes mellitus; fibrosis; mitosis;
KW   mesangial disorder; growth regulation; wound healing; T cell activation;
KW   immunosuppressant; primer; PCR; amplification; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO9953036-A2.
XX
PD   21-OCT-1999.
XX
PF   13-APR-1999;   99WO-US008150.
XX
PR   14-APR-1998;   98US-0081784P.
XX
PA   (SUGE-) SUGEN INC.
XX
PI   Plowman G,  Martinez R,  Whyte D;
XX
DR   WPI; 1999-611301/52.
XX
PT   Novel kinase-related polypeptides used for the diagnosis and treatment of
PT   kinase-related diseases and disorders.
XX
PS   Disclosure; Page 386; 387pp; English.
XX
CC   This sequence represents a PCR primer used to amplify the coding sequence
CC   for a novel STE20-related protein kinase. The invention relates to
CC   nucleic acid molecule encoding a kinase polypeptide selected from STLK2,
CC   STLK3, STLK4, STLK5, STLK6, STLK7, ZC1, ZC2, ZC3, ZC4, KHS2, SULU1,
CC   SULU3, GEK2, PAK4 and PAK5. The proteins are used to identify agonists
CC   and antagonists, and to raise antibodies. The polynucleotides are useful
CC   in gene therapy protocols. The polynucleotides, polypeptides, antibodies,
CC   antagonists and agonists may be used to treat diseases such as immune-
CC   related disorders and diseases (e.g. rheumatoid arthritis,
CC   artherosclerosis, chronic inflammatory bowel disease (e.g. Crohn's
CC   disease), asthma, osteoarthritis, psoriasis, atherosclerosis, rhinitis,
CC   autoimmunity, and organ transplantation, chronic inflammatory pelvic
CC   disease, multiple sclerosis, organ transplantation, myocardial
CC   infarction, cardiovascular disease, stroke, renal failure, oxidative
CC   stress-related neurodegenerative disorders (e.g. amylotrophic lateral
CC   sclerosis, Parkinson's disease and Leigh syndrome), cancer,
CC   cardiomyopathies, ischemic disorders, inflammatory disorders, diabetes
CC   mellitus, fibrotic and mesangial disorders. The proteins may also be
CC   useful for cell growth regulation (e.g. in wound healing), T cell
CC   activation, mitosis control, and as immunosuppressants
XX
SQ   Sequence 20 BP; 4 A; 4 C; 6 G; 6 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 15.2;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 2.3e+02;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        601 GCAAAGAACTACTGCGCCTG 620
              |||||  |||||||| ||||
Db         20 GCAAATGACTACTGCACCTG 1


RESULT 121
AAV69725/c
ID   AAV69725 standard; DNA; 20 BP.
XX
AC   AAV69725;
XX
DT   01-MAR-1999  (first entry)
XX
DE   MAGE-C2 specific PCR primer SL118.
XX
KW   MAGE-C2; human; tumour rejection antigen precursor; TRAP; therapy;
KW   diagnosis; PCR; primer; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO9849184-A1.
XX
PD   05-NOV-1998.
XX
PF   24-APR-1998;   98WO-US008493.
XX
PR   25-APR-1997;   97US-00845528.
XX
PA   (LUDW-) LUDWIG INST CANCER RES.
XX
PI   Lucas S,  De Smet C,  Boon-Falleur T;
XX
DR   WPI; 1999-024041/02.
XX
PT   Tumour rejection antigen precursors - used for determining presence of
PT   cytolytic T cells specific for complexes of a human leukocyte antigen.
XX
PS   Example 11; Page 29; 84pp; English.
XX
CC   This is the nucleotide sequence of primer SL118, which is complementary
CC   to a sequence of the first intron of the human MACE-C2 gene (see
CC   AAV69727). It was used in experiments to determine the chromosomal
CC   location (Xq26-Xq27) of the MACE-C2 gene. MACE-C2 (see AAW81547) is a
CC   novel tumour rejection antigen precursor (TRAP) that is expressed in a
CC   variety of tumours and in normal testis cells, but not by other normal
CC   cells. The invention provides MAGE-C1 and MAGE-C2 nucleic acids and
CC   polypeptides useful e.g. for determining the presence of cytotoxic T
CC   cells specific for complexes of a human leukocyte antigen
XX
SQ   Sequence 20 BP; 3 A; 5 C; 7 G; 5 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 15.2;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 2.3e+02;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;
```

```
Qy        495 TGTGCCAACCTGATGCAGCT 514
              |||||||||| || ||||||
Db         20 TCTGCCAACCAGAGGCAGCT 1


RESULT 122
AAX96441/c
ID   AAX96441 standard; DNA; 20 BP.
XX
AC   AAX96441;
XX
DT   13-SEP-1999  (first entry)
XX
DE   PCR primer used to amplify an ORF of Chlamydia pneumoniae.
XX
KW   Respiratory disease; pneumonia; bronchitis; heart disease; sarcoidosis;
KW   sinusitis; purulent otitis media; erythema nodosum; pharyngitis; vaccine;
KW   neutralising epitope; PCR primer; ss.
XX
OS   Synthetic.
OS   Chlamydophila pneumoniae.
XX
PN   WO9927105-A2.
XX
PD   03-JUN-1999.
XX
PF   20-NOV-1998;   98WO-IB001890.
XX
PR   21-NOV-1997;   97FR-00014673.
PR   04-NOV-1998;   98US-0107078P.
XX
PA   (GEST ) GENSET.
XX
PI   Griffais R;
XX
DR   WPI; 1999-357842/30.
XX
PT   Genome sequence of Chlamydia pneumoniae.
XX
PS   Page 1826; Disclosure; 1912pp; English.
XX
CC   AAX91991-X97517 represent PCR primers used to amplify open reading frames
CC   and other nucleic acid sequences from the genome of Chlamydia pneumoniae
CC   (see AAX91990). C. pneumoniae causes respiratory disease such as
CC   pneumonia and bronchitis and is thought to be a contributing factor in
CC   heart disease, sarcoidosis, sinusitis, purulent otitis media, erythema
CC   nodosum or pharyngitis. The polypeptides encoded by the open reading
CC   frames of the C. pneumoniae genome (see AAY34584- AAY35879) can be used
CC   in immunogenic compositions as vaccines. Vectors containing C. pneumoniae
CC   nucleotides sequences can also be used as immunogenic compositions,
CC   especially where the vector directs the expression of a neutralising
CC   epitope of C. pneumoniae
XX
SQ   Sequence 20 BP; 4 A; 7 C; 6 G; 3 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 15.2;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 2.3e+02;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1617 CCTCCCCGGGAGGAGTGCCA 1636
              | ||||| ||||||||| ||
Db         20 CTTCCCCTGGAGGAGTGGCA 1


RESULT 123
AAX93270/c
ID   AAX93270 standard; DNA; 20 BP.
XX
AC   AAX93270;
XX
DT   13-SEP-1999  (first entry)
XX
DE   PCR primer used to amplify an ORF of Chlamydia pneumoniae.
XX
KW   Respiratory disease; pneumonia; bronchitis; heart disease; sarcoidosis;
KW   sinusitis; purulent otitis media; erythema nodosum; pharyngitis; vaccine;
KW   neutralising epitope; PCR primer; ss.
XX
OS   Synthetic.
OS   Chlamydophila pneumoniae.
XX
PN   WO9927105-A2.
XX
PD   03-JUN-1999.
XX
PF   20-NOV-1998;   98WO-IB001890.
XX
PR   21-NOV-1997;   97FR-00014673.
PR   04-NOV-1998;   98US-0107078P.
XX
PA   (GEST ) GENSET.
XX
PI   Griffais R;
XX
DR   WPI; 1999-357842/30.
XX
PT   Genome sequence of Chlamydia pneumoniae.
XX
PS   Page 1576; Disclosure; 1912pp; English.
XX
CC   AAX91991-X97517 represent PCR primers used to amplify open reading frames
CC   and other nucleic acid sequences from the genome of Chlamydia pneumoniae
CC   (see AAX91990). C. pneumoniae causes respiratory disease such as
CC   pneumonia and bronchitis and is thought to be a contributing factor in
CC   heart disease, sarcoidosis, sinusitis, purulent otitis media, erythema
CC   nodosum or pharyngitis. The polypeptides encoded by the open reading
CC   frames of the C. pneumoniae genome (see AAY34584- AAY35879) can be used
CC   in immunogenic compositions as vaccines. Vectors containing C. pneumoniae
CC   nucleotides sequences can also be used as immunogenic compositions,
CC   especially where the vector directs the expression of a neutralising
CC   epitope of C. pneumoniae
XX
SQ   Sequence 20 BP; 7 A; 7 C; 3 G; 3 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 15.2;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 2.3e+02;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        996 CTGAGGGACTGATTCCTGTG 1015
              ||| |||| |||||||||| |
Db         20 CTGTGGGATTGATTCCTGAG 1


RESULT 124
AAZ50781
ID   AAZ50781 standard; DNA; 20 BP.
XX
AC   AAZ50781;
XX
DT   31-MAY-2000  (first entry)
XX
DE   PCR primer HG03.37R to obtain full length HG03 cDNA.
XX
KW   HG03; G protein-coupled receptor; GPCR; screen; agonist; antagonist;
KW   pharmaceutical; gene therapy; PCR primer; human; ss.
XX
OS   Homo sapiens.
XX
PN   WO200008133-A1.
XX
PD   17-FEB-2000.
XX
PF   02-AUG-1999;   99WO-US017388.
XX
PR   06-AUG-1998;   98US-0095571P.
XX
```

```
PA   (MERI ) MERCK & CO INC.
XX
PI   Liu Q,  Mcdonald TP,  Wang R;
XX
DR   WPI; 2000-205701/18.
XX
PT   Novel G-protein coupled receptor cDNA molecule encoding HG03 polypeptide
PT   useful for identifying its agonists and antagonists which are useful in
PT   pharmaceuticals.
XX
PS   Example 1; Page 18; 36pp; English.
XX
CC   The present sequence is the PCR primer HG03.37R, used to obtain complete
CC   HG03 cDNA sequence by primer walking. Human HG03, which is a G protein-
CC   coupled receptor (GPCR) is expressed at high levels in prostate, placenta
CC   and trachea and at low levels in thymus and testis. HG03 expression
CC   vectors can be used to transform host cells, which may be used in
CC   screening for agonists or antagonists that are potential pharmaceuticals.
CC   It can be used in gene therapy for treatment of diseases associated with
CC   low HG03 activity
XX
SQ   Sequence 20 BP; 5 A; 4 C; 7 G; 4 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 15.2;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 2.3e+02;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1485 GGGTGTCAGGGATCACTTGG 1504
              | |||||||| | |||||||
Db          1 GCGTGTCAGGAAACACTTGG 20


RESULT 125
AAA52987/c
ID   AAA52987 standard; DNA; 20 BP.
XX
AC   AAA52987;
XX
DT   03-JAN-2001  (first entry)
XX
DE   Candida albicans growth gene vector PCR primer #3.
XX
KW   Growth inhibition; survival; pathogen; fungal infection; vulvovaginitis;
KW   PCR primer; ss.
XX
OS   Synthetic.
XX
PN   WO200034481-A2.
XX
PD   15-JUN-2000.
XX
PF   06-DEC-1999;   99WO-EP009833.
XX
PR   04-DEC-1998;   98EP-00204122.
XX
PA   (JANC ) JANSSEN PHARM NV.
XX
PI   Contreras RH,  Nelissen B,  De Backer MD,  Luyten WHML,  Viaene JE;
PI   Logghe MG,  Vialard JE;
XX
DR   WPI; 2000-431302/37.
XX
PT   Novel nucleic acid molecule and polypeptides essential for survival and
PT   growth of yeast candida albicans useful for treating candida albicans
PT   associated diseases and for identifying antifungal compounds.
XX
PS   Example 1; Page 23; 112pp; English.
XX
CC   The present sequence is a PCR primer used during the construction of a
CC   vector for the genes encoding proteins which are essential for the
CC   survival and growth of Candida albicans. This fungus causes infection,
CC   such as vulvovaginitis, in humans, particularly in those who are
CC   immunocompromised. The growth genes and proteins can be used to diagnose
CC   infection, and they can be used as targets for inhibiting the
CC   proliferation of the fungus
XX
SQ   Sequence 20 BP; 2 A; 8 C; 7 G; 3 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 15.2;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 2.3e+02;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        452 GCCCGACTTCGAGCTGCTCA 471
              || ||||  ||||||||||
Db         20 GCGCGACGGCGAGCTGCTCA 1


RESULT 126
AAA26732/c
ID   AAA26732 standard; DNA; 20 BP.
XX
AC   AAA26732;
XX
DT   23-JUN-2000  (first entry)
XX
DE   PCR primer used in Candida albicans polynucleotide identification.
XX
KW   Candida albicans infection; growth; survival; medicament; AIDS;
KW   vulvovaginitis; immunocompromised patient; treat; PCR primer; ss.
XX
OS   Candida albicans.
XX
PN   EP982401-A2.
XX
PD   01-MAR-2000.
XX
PF   23-DEC-1998;   98EP-00310694.
XX
PR   14-AUG-1998;   98GB-00017796.
XX
PA   (JANC ) JANSSEN PHARM NV.
XX
PI   Contreras RH,  Nelissen B,  De Backer MD,  Luyten WHML,  Viaene JE;
PI   Logghe MG;
XX
DR   WPI; 2000-258614/23.
XX
PT   Essential polypeptides isolated from Candida albicans, useful in the
PT   treatment of diseases caused by C.albicans, especially in
PT   immunocompromized subjects, e.g., AIDS patients.
XX
PS   Disclosure; Page 8; 133pp; English.
XX
CC   This sequence represents a PCR primer used in the identification of
CC   polynucleotide sequences encoding polypeptides that are critical for the
CC   survival and growth of Candida albicans. The C. albicans nucleic acid
CC   molecules of the invention may be used as probes and primers for
CC   detecting homologous nucleic acid molecule sequences. The polypeptides
CC   and nucleic acid molecules and compounds identified as selectively
CC   modulating the expression of the polypeptides, may be used as medicaments
CC   or for the preparation of a medicament to treat C.albicans associated
CC   diseases, especially in AIDS patients and to treat vulvovaginitis in
CC   otherwise healthy females. The use of the polypeptides and polynucleotide
CC   sequences to treat C.albicans associated diseases has fewer side effects
CC   and less toxicity than previously used methods such as the use of
CC   amphotericin. This method is therefore especially suitable for
CC   immunocompromised patients, such as AIDS patients
XX
SQ   Sequence 20 BP; 2 A; 8 C; 7 G; 3 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 15.2;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 2.3e+02;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        452 GCCCGACTTCGAGCTGCTCA 471
              || ||||  ||||||||||
```

```
Db         20 GCGCGACGGCGAGCTGCTCA 1


RESULT 127
AAA11324/c
ID   AAA11324 standard; DNA; 20 BP.
XX
AC   AAA11324;
XX
DT   08-NOV-2000  (first entry)
XX
DE   Human TRPC7 gene intron 20/exon 21 junction.
XX
KW   Transmembrane protein; TRPC7; brain; transient receptor potential; TRP;
KW   calcium channel function; human; gene therapy; periodic psychosis;
KW   mutation; ss.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   intron          1. .10
FT                   /*tag=  a
FT                   /number= 20
FT   exon            11. .20
FT                   /*tag=  b
FT                   /number= 21
XX
PN   WO200029571-A1.
XX
PD   25-MAY-2000.
XX
PF   11-NOV-1999;   99WO-JP006289.
XX
PR   12-NOV-1998;   98JP-00321200.
XX
PA   (EIKE ) EIKEN KAGAKU KK.
XX
PI   Shimizu N,  Nagamine K;
XX
DR   WPI; 2000-387784/33.
XX
PT   Nucleic acids encoding transmembrane protein TRPC7 expressed in brain and
PT   homologous to transient receptor potential protein useful in the of
PT   treatment of associated diseases such as periodic psychosis.
XX
PS   Example 7; Page 39; 77pp; Japanese.
XX
CC   The invention relates to the isolation of a nucleic acid (AAA11284)
CC   coding for a transmembrane protein TRPC7 (AAY92944) which is expressed in
CC   brain and is homologous to transient receptor potential (TRP) protein.
CC   This suggests that the TRPC7 protein may have a calcium channel function.
CC   The genomic sequence has been shown to contain 31 introns. This sequence
CC   represents an exon/intron junction from the genomic TRPC7 sequence. The
CC   DNA and protein can be used in the diagnosis and treatment of disorders
CC   associated with TRPC7, especially the screening, monitoring and treatment
CC   (by gene therapy) of periodic psychosis, which appears to be associated
CC   with mutations in the TRPC7 gene
XX
SQ   Sequence 20 BP; 4 A; 9 C; 2 G; 5 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 15.2;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 2.3e+02;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1477 GAAGGGGTGGGTGTCAGGGA 1496
              ||||| || | |||||||||
Db         20 GAAGGTGTAGCTGTCAGGGA 1


RESULT 128
AAC62074
ID   AAC62074 standard; DNA; 20 BP.
XX
AC   AAC62074;
XX
DT   06-MAR-2001  (first entry)
XX
DE   Reverse primer used to amplify a human pancreatic elastase III cDNA.
XX
KW   Human; elastase I; chromosome 12q13; mutant; serine protease; eczema;
KW   hyperproliferative skin condition; psoriasis; lupus erythmatosis;
KW   erythema; cancer; elastase II; PCR primer; ss.
XX
OS   Homo sapiens.
XX
PN   WO200061728-A2.
XX
PD   19-OCT-2000.
XX
PF   12-APR-2000; 2000WO-GB001389.
XX
PR   13-APR-1999;   99GB-00008458.
XX
PA   (QUEE-) QUEEN MARY & WESTFIELD COLLEGE.
XX
PI   Gerst-Talas U,  Dunlop J,  Kelsell DP;
XX
DR   WPI; 2000-679482/66.
XX
PT   Recombinant polynucleotide encoding human elastase I mutant useful for
PT   determining the predisposition of a subject to cancer or
PT   hyperproliferative skin condition such as psoriasis, eczema,
PT   erythematosis.
XX
PS   Disclosure; Page 18; 35pp; English.
XX
CC   PCR primers AAC62073-74 were used to amplify a human elastase II
CC   transcript. The specification describes elastase I, whose gene maps to
CC   chromosome 12q13. Elastase is a serine protease, and is localised in the
CC   basal layer of the mammalian skin. The specification describes a mutant
CC   elastase I, with a frame shift mutation in any one of the codons 207-225.
CC   The mutation results in the disruption of the carboxy terminal of the
CC   protein, and possibly affects substrate binding. An allele encoding a
CC   mutant elastase I can be detected to determine the predisposition of a
CC   subject to a hyperproliferative skin condition (e.g. psoriasis, eczema,
CC   lupus erythmatosis and erythema) or cancer
XX
SQ   Sequence 20 BP; 5 A; 4 C; 10 G; 1 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 15.2;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 2.3e+02;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1304 AGCAGCCGGAGGGAGGGGGG 1323
              | ||||||||||||||| | ||
Db          1 ACCAGCCGGAGGGAGTGAGG 20


RESULT 129
AAH23216/c
ID   AAH23216 standard; DNA; 20 BP.
XX
AC   AAH23216;
XX
DT   17-SEP-2001  (first entry)
XX
DE   Human MMIF mRNA inhibiting antisense oligo ISIS #112369.
XX
KW   Macrophage migration inhibitory factor; MMIF; antisense; neurological;
KW   hyperproliferation; nootropic; antihormonal; immunosuppresive; human;
KW   antiinflammatory; cytostatic; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO200153317-A1.
```

```
XX
PD   26-JUL-2001.
XX
PF   16-JAN-2001; 2001WO-US001475.
XX
PR   20-JAN-2000; 2000US-00489869.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Murray SF,  Cowsert LM,  Wyatt JR;
XX
DR   WPI; 2001-451899/48.
XX
PT   New antisense compound(s) are useful to inhibit a nucleic acid molecule
PT   encoding macrophage migration inhibitory factor.
XX
PS   Claim 3; Page 83; 105pp; English.
XX
CC   The invention relates to antisense oligonucleotides 8-30 nucleotides in
CC   length targeted to a nucleic acid molecule encoding macrophage migration
CC   inhibitory factor (MMIF), where the antisense compound specifically
CC   hybridizes with and inhibits the expression of MMIF. The antisense
CC   nucleotides are useful for the treatment of a disease or condition
CC   associated with MMIF such as neurological, hormonal, immune, inflammatory
CC   or hyperproliferative disorder. Sequences AAH23191-268 represent chimeric
CC   antisense phosphorothioate oligonucleotides used for inhibition of human
CC   MMIF mRNA expression
XX
SQ   Sequence 20 BP; 3 A; 7 C; 8 G; 2 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 15.2;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 2.3e+02;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        624 TACAGCGAGCCGTGCGGCCT 643
              | ||||||||||||||  ||
Db         20 TCCAGCGAGCCGTGCGCGCT 1


RESULT 130
AAD15581/c
ID   AAD15581 standard; DNA; 20 BP.
XX
AC   AAD15581;
XX
DT   15-NOV-2001  (first entry)
XX
DE   Human carbonic anhydrase (CA12) protein target DNA #7.
XX
KW   Human; carbonic anhydrase; CA12; genetic disease; antisense target;
KW   therapeutic; ss.
XX
OS   Homo sapiens.
XX
PN   WO200161030-A2.
XX
PD   23-AUG-2001.
XX
PF   14-FEB-2001; 2001WO-US004732.
XX
PR   14-FEB-2000; 2000US-00504653.
XX
PA   (BOLL/) BOLLON A P.
PA   (GRAY/) GRAY D M.
PA   (JUSE/) JU-SEOG L.
XX
PI   Bollon AP,  Gray DM,  Ju-Seog L;
XX
DR   WPI; 2001-529916/58.
XX
PT   Selecting optimal subsequence antisense targets for inhibition of mRNA
PT   expression of target mRNA for the therapeutic treatment of genetic
PT   disease.
XX
PS   Example 4; Page 23; 87pp; English.
XX
CC   The invention relates to a method for selecting optimal subsequence
CC   antisense targets. The method involves preparing an antisense
CC   oligonucleotide capable of inhibiting mRNA expression of target mRNA
CC   sequences, as well as antisense oligonucleotides capable of binding DNA.
CC   The antisense and antigene libraries are useful for preparing therapeutic
CC   agents for the treatment of genetic disease. The present DNA sequence is
CC   human carbonic anhydrase (CA12) protein target DNA related to the
CC   invention. Note: The present sequence is shown as DNA in the
CC   specification; however, in vivo, this target sequence would be mRNA
XX
SQ   Sequence 20 BP; 2 A; 9 C; 8 G; 1 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 15.2;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 2.3e+02;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        300 CGGCCGCCGCGCTCAGCCTG 319
              |||||||||||  ||| |||
Db         20 CGGCCGCCGCGTGCAGGCTG 1


RESULT 131
AAF62920
ID   AAF62920 standard; DNA; 20 BP.
XX
AC   AAF62920;
XX
DT   08-MAY-2001  (first entry)
XX
DE   Human PEPCK-cytosolic antisense oligonucleotide ISIS 108090.
XX
KW   Human; antiinflammatory; cytostatic; antisense gene therapy;
KW   phosphoenol pyruvate carboxykinase-cytosolic; PEPCK-cytosolic; infection;
KW   inflammation; tumour formation; phosphorothioate; ss.
XX
OS   Homo sapiens.
XX
PN   US6187545-B1.
XX
PD   13-FEB-2001.
XX
PF   21-JAN-2000; 2000US-00488671.
XX
PR   21-JAN-2000; 2000US-00488671.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Mckay R,  Butler MM,  Wyatt J,  Cowsert LM;
XX
DR   WPI; 2001-190979/19.
XX
PT   Antisense compound capable of modulating the expression of phosphoenol
PT   pyruvate carboxykinase-cytosolic, useful for preventing or delaying
PT   infection, inflammation or tumor formation.
XX
PS   Claim 1; Col 43; 64pp; English.
XX
CC   The present sequence is one of a number of antisense compounds of up to
CC   30 nucleobases in length that are capable of inhibiting the expression of
CC   phosphoenol pyruvate carboxykinase-cytosolic (PEPCK-cytosolic). The
CC   antisense compounds are useful for inhibiting the expression of PEPCK-
CC   cytosolic in cells or tissues. They are commonly used as research
CC   reagents and in diagnostics, e.g. to elucidate the function of particular
CC   genes. They are also useful for distinguishing between functions of
CC   various members of a biological pathway and for research use. The
CC   antisense compounds are also useful prophylactically, e.g. to prevent or
CC   delay infection, inflammation or tumour formation. The present sequence
CC   is a chimeric phosphorothioate oligonucleotide with 2'-MOE wings and a
CC   deoxy gap
XX
```

```
SQ   Sequence 20 BP; 2 A; 9 C; 2 G; 7 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 15.2;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 2.3e+02;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        241 TCTCGTCGTCGTCCACCTCC 260
              |||||  ||| |||||||||
Db          1 TCTCGATGTCTTCCACCTCC 20


RESULT 132
AAC91651
ID   AAC91651 standard; DNA; 20 BP.
XX
AC   AAC91651;
XX
DT   16-MAR-2001  (first entry)
XX
DE   Human angiotensinogen gene exon 3 PCR primer, SEQ ID NO:53.
XX
KW   Human angiotensinogen gene; AGT; insulin-dependent diabetes mellitus;
KW   type 1 diabetes; chromosome 1q42-43; single nucleotide polymorphism;
KW   IDDM; SNP; diagnosis; susceptibility; transgenic animal; drug screening;
KW   antidiabetic; gene therapy; exon 3; PCR primer; ss.
XX
OS   Homo sapiens.
XX
PN   WO200071751-A1.
XX
PD   30-NOV-2000.
XX
PF   16-MAY-2000; 2000WO-US013327.
XX
PR   21-MAY-1999;   99US-0135423P.
PR   06-JAN-2000; 2000US-0174700P.
XX
PA   (MYRI-) MYRIAD GENETICS INC.
XX
PI   Mcgrail M,  Russell DL,  Shattuck DM;
XX
DR   WPI; 2001-025172/03.
XX
PT   Novel angiotensinogen gene, mutant alleles of which causes susceptibility
PT   to insulin-dependent diabetes mellitus useful for diagnosis of
PT   predisposition to diabetes.
XX
PS   Example 2; Page 33; 83pp; English.
XX
CC   The invention relates to the human angiotensinogen (AGT) gene, some
CC   mutant alleles of which cause a susceptibility to insulin-dependent
CC   diabetes mellitus (IDDM, type 1 diabetes). The AGT gene is located on
CC   chromosome 1q42-43, a region linked to IDDM. The invention discloses
CC   genomic sequences comprising exons 1-5 of the human AGT gene (AAC91600-
CC   C91604) and a genomic sequence comprising an alternative AGT gene exon 1
CC   (AAC91606). The invention also encompasses the specifically claimed human
CC   AGT mutant nucleic acid sequences AAC91667-C91684, and the mutant
CC   angiotensinogen proteins AAB48945-B48949. The invention also relates to
CC   detecting mutant AGT alleles or gene products thereof which are related
CC   to IDDM; determining whether a person has, or is at risk of developing
CC   diabetes via detection of a polymorphism in the AGT gene; and methods of
CC   screening for drug candidates which may be useful in the treatment of
CC   diabetes resulting from an AGT mutation. Methods of preventing or
CC   treating diabetes are claimed which comprise the administration of a
CC   compound which agonises or antagonises wild-type or mutant AGT, which
CC   agonises or antagonises an AGT receptor, which inhibits AGT gene
CC   expression, or which cleaves AGT proteins. In addition, the invention
CC   encompasses a transgenic non-human animal, or cell line derived
CC   therefrom, comprising a mutant human AGT allele. The polymorphisms
CC   identified in the AGT gene are useful for determining if a person has, or
CC   is at risk from developing insulin-dependent diabetes mellitus. AGT
CC   modulators can be used to treat or prevent diabetes. Mutant AGT proteins
CC   or fragments thereof are useful for screening compounds which bind to AGT
CC   polypeptides. The present sequence represents a human AGT gene exon 3 PCR
CC   primer used in an exemplification of the invention
XX
SQ   Sequence 20 BP; 6 A; 5 C; 6 G; 3 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 15.2;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 2.3e+02;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1219 AACAGTGGTGTGACATCCAG 1238
              | || ||| ||||||||||
Db          1 AGCACTGGAGTGACATCCAG 20


RESULT 133
AAC91840/c
ID   AAC91840 standard; DNA; 20 BP.
XX
AC   AAC91840;
XX
DT   21-MAR-2001  (first entry)
XX
DE   P53 consensus binding sequence mutated probe.
XX
KW   P53; apoptosis; neurodegenerative disease; Alzheimer's disease;
KW   diffuse Lewy body disease; Pick's disease; Parkinson's disease;
KW   progressive supranuclear palsy; multiple system atrophy;
KW   amyotrophic lateral sclerosis; probe; ss.
XX
OS   Unidentified.
XX
PN   WO200074726-A1.
XX
PD   14-DEC-2000.
XX
PF   07-JUN-2000; 2000WO-US015709.
XX
PR   07-JUN-1999;   99US-0138157P.
XX
PA   (GLAD-) GLADSTONE INST J DAVID.
XX
PI   Xu X,  Mucke L;
XX
DR   WPI; 2001-061660/07.
XX
PT   Preventing or treating condition associated especially with neuronal
PT   apoptosis, e.g. Alzheimer's disease by administering an agent having hAPP
PT   anti-p53 apoptotic activity.
XX
PS   Disclosure; Page 15; 29pp; English.
XX
CC   The present invention provides a novel method of preventing a cell from
CC   undergoing apoptosis by administering to the cell an agent having hAPP
CC   anti-p53 apoptotic activity. This method can be used in the treatment of
CC   neurodegenerative diseases such as Alzheimer's disease, Parkinson's
CC   disease, diffuse Lewy body disease, progressive supranuclear palsy,
CC   Pick's disease, multiple system atrophy and amyotrophic lateral sclerosis
XX
SQ   Sequence 20 BP; 6 A; 6 C; 4 G; 4 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 15.2;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 2.3e+02;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1492 AGGGATCACTTGGGATCTTT 1511
              ||||||| || ||||||| |
Db         20 AGGGATCTCTAGGGATCTCT 1


RESULT 134
AAF69698
ID   AAF69698 standard; DNA; 20 BP.
XX
```

AC AAF69698;
XX
DT 18-APR-2001 (first entry)
XX
DE Human IL4Ralpha gene PCR primer #34.
XX
KW Polymorphism; human; interleukin 4 receptor-alpha; IL4R-alpha;
KW allergic disease; PCR primer; ss.
XX
OS Homo sapiens.
XX
PN WO200104270-A1.
XX
PD 18-JAN-2001.
XX
PF 13-JUL-2000; 2000WO-US019094.
XX
PR 13-JUL-1999; 99US-0143435P.
XX
PA (GENA-) GENAISSANCE PHARM INC.
XX
PI Chew A, Denton RR, Duda A, Nandabalan K, Stephens JC;
PI Windemuth AK;
XX
DR WPI; 2001-103078/11.
XX
PT New isolated polynucleotide useful for the identification of therapeutics
PT in allergic diseases is new.
XX
PS Example 1; Page 60; 188pp; English.
XX
CC The present invention relates to polymorphisms of the human interleukin 4
CC receptor-alpha gene (IL4R-alpha; see AAF57718 for the reference
CC sequence). Polynucleotides comprising polymorphic gene variants are
CC useful for therapeutic purposes. For example, where a patient may benefit
CC from expression of a particular IL4Ralpha protein isoform, an expression
CC vector encoding the isoform may be administered to the patient. It may
CC desirable to decrease or block expression of a particular IL4Ralpha
CC isogene, which may be done by turning off by transforming a targeted
CC organ, tissue or cell population with an expression vector that expresses
CC high levels of untranslatable mRNA for the isogene. Specific therapeutics
CC identified by these methods may be useful for allergic diseases. The
CC present sequence is a PCR primer for human IL4R-alpha
XX
SQ Sequence 20 BP; 6 A; 4 C; 8 G; 2 T; 0 U; 0 Other;

Query Match 0.9%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.3e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 579 AGCCAGTTGGTAAGCCAGGT 598
|||||| || |||||||||
Db 1 AGCCAGGTGAGAAGCCAGGT 20

RESULT 135
AAS16424
ID AAS16424 standard; DNA; 20 BP.
XX
AC AAS16424;
XX
DT 05-JUN-2002 (first entry)
XX
DE Mouse Gli-1 transcription factor, 3' primer.
XX
KW Gli-1; transcription factor; mesodermal precursor cell; vasotropic;
KW sonic hedgehog; desert hedgehog; indian hedgehog; moonrat hedgehog;
KW tiggy winkle hedgehog; haemostatic; cytostatic; anaemia; leukopenia;
KW chronic inflammatory disease; cancer; organ failure; thrombocytopenia;
KW ischaemia; tumour; diabetes; aging; hypervascularisation; trauma;
KW infection; neovascularisation; AIDS; acquired immunodeficiency virus;
KW leukaemia; arthritis; polycythaemia vera; erythroleukaemia;
KW transgenic mouse; haematopoiesis; PCR primer; ss.
XX
OS Mus sp.
XX
PN US2001041668-A1.
XX
PD 15-NOV-2001.
XX
PF 10-FEB-1998; 98US-00021660.
XX
PR 10-FEB-1998; 98US-00021660.
XX
PA (HARD) HARVARD COLLEGE.
XX
PI Baron MH, Farrington SM, Belaussoff M;
XX
DR WPI; 2002-017219/02.
XX
PT Stimulating differentiation of mesodermal cells, useful e.g. for treating
PT anemia or ischemia, comprises treatment with functional equivalent of
PT protein expressed in embryonic tissue.
XX
PS Example 5; Page 18; 41pp; English.
XX
CC The invention describes a novel method of stimulating a population of
CC undifferentiated mesodermally derived cells to undergo haematopoiesis
CC and/or vascular growth. This involves treating cells with a compound that
CC is functionally equivalent to a gene product expressed in an embryo's
CC extraembryonic tissue e.g the hedgehog family including sonic, desert,
CC indian, moonrat and tiggy winkle, to modulate differentiation and
CC proliferation of mesodermal precursor cells. The method is used to treat
CC developmental errors in vascular growth and haematopoiesis in utero, to
CC modulate disorders associated with an abnormal number of erythroid cells
CC e.g. polycythaemia vera, erythroleukaemia and anaemia (including
CC idiopathic, constitutional or secondary aplastic,or myelodysplastic
CC forms, where induced by virus, chronic inflammatory disease, cancer,
CC organ failure or drugs, or thrombocytopenia) but also leukopenia (caused
CC by radiation, chemotherapy or infections) e.g. leukaemia, AIDS, to treat
CC tissue ischaemia (specifically myocardial) and hypervascularisation
CC associated with genetic or inherited diseases, trauma, infections and
CC aging, or neovascularisation, e.g. in tumours, diabetes, arthritis etc.
CC This sequence is the mouse Gli-1 transcription factor 3' primer used with
CC the 5' primer (AAS16423) to demonstrate that Gli-1 is a target of the
CC hedgehog signalling pathway in the yolk sac mesoderm, described in the
CC method of the invention
XX
SQ Sequence 20 BP; 5 A; 5 C; 6 G; 4 T; 0 U; 0 Other;

Query Match 0.9%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.3e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 502 ACCTGATGCAGCTGCTGCAG 521
| ||||||||||||| | |||
Db 1 AGCTGATGCAGCTGATCCAG 20

RESULT 136
AAS97838/c
ID AAS97838 standard; DNA; 20 BP.
XX
AC AAS97838;
XX
DT 12-MAR-2002 (first entry)
XX
DE Murine SAC1 gene-specific oligonucleotide PCR primer #405.
XX
KW Human; mouse; SAC1; carbohydrate; sweetener; ethanol; alcoholism; ss;
KW obesity; diabetes; transgenic embryo; body tissue; body fluid; pancreas;
KW blood; tongue; PCR primer; anorectic; antidiabetic; gene therapy;
KW protein replacement therapy.
XX
OS Mus sp.
XX

```
PN   WO200183749-A2.
XX
PD   08-NOV-2001.
XX
PF   25-APR-2001; 2001WO-US013387.
XX
PR   28-APR-2000; 2000US-0200794P.
PR   28-JUL-2000; 2000US-0221419P.
PR   10-NOV-2000; 2000US-0247443P.
XX
PA   (WARN ) WARNER LAMBERT CO.
PA   (MONE-) MONELL CHEM SENSES CENT.
XX
PI   Bachmanov AA,  Beauchamp GK,  Chatterjee A,  De Jong PJ,  Li S,  Li X;
PI   Ohmen JD,  Reed DR,  Ross D,  Tordoff MG;
XX
DR   WPI; 2002-075162/10.
XX
PT   Novel isolated polypeptide comprising variant form of mouse or human SAC1
PT   polypeptide, and is associated with altered preference for carbohydrates
PT   or other sweeteners, useful for preventing obesity, diabetes, alcoholism.
XX
PS   Claim 14; Page 89; 239pp; English.
XX
CC   The invention relates to an isolated polypeptide, comprising a variant
CC   form of mouse or human SAC1 polypeptide. The variant form is associated
CC   with altered preference for carbohydrates, other sweeteners or ethanol.
CC   The polypeptide and its associated DNA sequence can be produced by
CC   recombinant techniques and is useful for preventing obesity, diabetes or
CC   alcoholism associated with SAC1 expression. The sequences are useful in
CC   screening for drugs and sweeteners. Recombinant cell lines and transgenic
CC   embryos may be used in screening for and identifying agents that induce
CC   or repress function of SAC1. Predisposition to diabetes, obesity or
CC   alcoholism can be ascertained by testing any fluid or tissue of a human
CC   (such as blood, pancreas or tongue) for sequence variations of the SAC1
CC   gene. A sequence variation of the SAC1 locus may indicate a
CC   predisposition to diabetes, obesity and/or alcoholism and may provide a
CC   diagnostic mark. The polynucleotide can be detected in a biological
CC   sample by contacting the DNA with a probe to form a hybridisation complex
CC   which is then detected. The sequences represent cDNA encoding human and
CC   mouse SAC1 polypeptides and PCR primers specific for the SCA1 genes
XX
SQ   Sequence 20 BP; 2 A; 9 C; 3 G; 6 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 15.2;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 2.3e+02;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        979 GAGACTAGAGGCAGGAGCTG 998
              ||||| ||||| ||| ||||
Db         20 GAGACCAGAGGAAGGTGCTG 1


RESULT 137
AAD44828/c
ID   AAD44828 standard; DNA; 20 BP.
XX
AC   AAD44828;
XX
DT   13-DEC-2002  (first entry)
XX
DE   Human raf kinase related antisense oligonucleotide #7.
XX
KW   Raf kinase; hyperproliferation; neovascularisation; ocular angiogenesis;
KW   therapy; cancer; cytostatic; anti-angiogenic; vascular; ophthalmological;
KW   antisense; ss.
XX
OS   Unidentified.
XX
PN   US6410518-B1.
XX
PD   25-JUN-2002.
XX
PF   18-FEB-2000; 2000US-00506073.
XX
PR   31-MAY-1994;   94US-00250856.
PR   31-MAY-1995;   95WO-US007111.
PR   26-NOV-1996;   96US-00756806.
PR   07-JUL-1997;   97US-00888982.
PR   06-JUL-1998;   98WO-US013961.
PR   28-AUG-1998;   98US-00143214.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP;
XX
DR   WPI; 2002-597918/64.
XX
PT   Treating cancer, angiogenesis or neovascularization by administering
PT   antisense oligonucleotides targeted to human raf sequences.
XX
PS   Disclosure; Col 57; 41pp; English.
XX
CC   The present invention relates to novel antisense oligonucleotides which
CC   are targetted to nucleic acids encoding human raf proteins and capable of
CC   inhibiting raf expression. The invention also relates to methods of
CC   inhibiting hyperproliferation of cells which involves contacting the
CC   hyperproliferating cells with a therapeutically effective amount of an
CC   oligonucleotide of the invention. The method is useful for treating
CC   cancer, angiogenesis or neovascularisation, especially ocular
CC   angiogenesis or neovascularisation. The present DNA sequence is human raf
CC   kinase related antisense oligonucleotide
XX
SQ   Sequence 20 BP; 2 A; 9 C; 4 G; 5 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 15.2;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 2.3e+02;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1267 CCGGCCCAGGGTGAAGGAAG 1286
              | ||||| ||| ||||||||
Db         20 CTGGCCCTGGGAGAAGGAAG 1


RESULT 138
ABX95003/c
ID   ABX95003 standard; DNA; 20 BP.
XX
AC   ABX95003;
XX
DT   05-JUN-2003  (first entry)
XX
DE   MAGE-C2 specific primer SL118 used to determine chromosomal location.
XX
KW   TRAP; ss; tumour rejection antigen precursor; cytolytic T-cell; CTL;
KW   tumour; seminoma; bladder transitional-cell carcinoma; NSCLC; adaptor;
KW   head-and-neck squamous-cell carcinoma; breast carcinoma; sarcoma;
KW   cutaneous melanoma; nonsmall cell lung cancer; PCR; primer; MAGE-C2;
KW   human.
XX
OS   Homo sapiens.
XX
PN   US2002176865-A1.
XX
PD   28-NOV-2002.
XX
PF   01-MAR-2002; 2002US-00085108.
XX
PR   25-APR-1997;   97US-00845528.
PR   24-APR-1998;   98US-00066281.
PR   17-DEC-1999;   99US-00468433.
PR   09-FEB-2000; 2000US-00501104.
XX
PA   (LUCA/) LUCAS S.
PA   (BOON/) BOON-FALLEUR T.
XX
```

```
PI   Lucas S,  Boon-Falleur T;
XX
DR   WPI; 2003-328468/31.
XX
PT   Novel isolated nucleic acid encoding tumor rejection antigen precursor
PT   MAGE-C3, MAGE-B5, or MAGE-B6, useful as diagnostic probes to determine
PT   presence of abnormal e.g., tumor cells expressing MAGE-C1, MAGE-B5 or
PT   MAGE-B6.
XX
PS   Example 11; Page 12; 59pp; English.
XX
CC   The invention relates to an isolated nucleic acid molecule which encodes
CC   a tumour rejection antigen precursor (TRAP) having an amino acid sequence
CC   of a TRAP encoded by a fully defined MAGE-C3, MAGE-B5, or MAGE-B6
CC   polynucleotide sequence. Also disclosed is a method which is useful for
CC   determining presence of cytolytic T-cells specific for complexes of human
CC   leukocyte antigen (HLA) and a peptide derived from the nucleic acid in a
CC   cytotoxic T-lymphocyte (CTL)-containing sample. The nucleic acid is
CC   useful as a diagnostic probe to determine the presence of abnormal
CC   (tumour) cells such as seminoma, bladder transitional-cell carcinoma,
CC   head-and-neck squamous-cell carcinoma, breast carcinoma, sarcoma,
CC   cutaneous melanoma or nonsmall cell lung cancer (NSCLC) which express
CC   MAGE-C1, MAGE-B5 or MAGE-B6. The nucleic acid is useful for diagnosing a
CC   disorder characterised by expression of MAGE-C1, MAGE-B5 or MAGE-B6 TRAPs
CC   or tumour rejection antigens (TRAs). The present sequence represents the
CC   human MAGE-C2 specific primer SL118 used to determine the chromosomal
CC   location of MAGE-C2
XX
SQ   Sequence 20 BP; 3 A; 5 C; 7 G; 5 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 15.2;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 2.3e+02;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        495 TGTGCCAACCTGATGCAGCT 514
              | ||||||||| || ||||||
Db         20 TCTGCCAACCAGAGGCAGCT 1


RESULT 139
ADB89920/c
ID   ADB89920 standard; DNA; 20 BP.
XX
AC   ADB89920;
XX
DT   04-DEC-2003  (first entry)
XX
DE   Antinsense oligonucleotide targeting human C3 component, ISIS140022.
XX
KW   Human; ss; antisense; complement component C3; inflammation;
KW   septic shock; multiple organ failure; hyperacute organ failure;
KW   autoimmune disorder; CNS inflammation; multiple sclerosis;
KW   atherosclerosis; tumour.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate backbone and all cytosines are 5
FT                   -methyl cytosines"
FT   modified_base   1. .5
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl nucleotides"
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl nucleotides"
XX
PN   US2003096775-A1.
XX
PD   22-MAY-2003.
XX
PF   23-OCT-2001; 2001US-00001076.
XX
PR   23-OCT-2001; 2001US-00001076.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Graham MJ,  Watt AT;
XX
DR   WPI; 2003-606441/57.
XX
PT   New antisense oligonucleotides targeted to a nucleic acid molecule
PT   encoding complement component C3, useful for treating a disease or
PT   condition associated with complement component C3, e.g. autoimmune
PT   disorder or infection.
XX
PS   Example 15; Page 26; 72pp; English.
XX
CC   The invention relates to a compound 8-50 nucleobases in length targeted
CC   to a nucleic acid molecule encoding complement component C3. The compound
CC   specifically hybridises with the nucleic acid molecule encoding
CC   complement component C3 and inhibits the expression of complement
CC   component C3, or specifically hybridises with at least an 8-nucleobase
CC   portion of an active site on a nucleic acid molecule encoding complement
CC   component C3. Also included are a composition comprising the compound and
CC   a pharmaceutical carrier or diluent, inhibiting the expression of
CC   complement component C3 in cells or tissues (comprising contacting the
CC   cells or tissues with the compound cited above) and treating an animal
CC   having a disease or condition associated with complement component C3
CC   comprising administering to the animal the compound cited above so that
CC   expression of complement component C3 is inhibited. The antisense
CC   compounds are useful for inhibiting the expression of complement
CC   component C3 in cells or tissues, or for treating an animal having a
CC   disease or condition associated with complement component C3 such as an
CC   autoimmune disorder (e.g. multiple sclerosis), an infection, or
CC   atherosclerosis, inflammation, septic shock, multiple organ failure,
CC   hyperacute organ failure and CNS inflammation. The compounds are also
CC   useful as research reagents and diagnostics, in distinguishing functions
CC   of various members of a biological pathway, or for preventing or delaying
CC   infection, inflammation or tumour formation. The present sequence is an
CC   antisense oligonucleotide targeting human C3.
XX
SQ   Sequence 20 BP; 1 A; 8 C; 5 G; 6 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 15.2;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 2.3e+02;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        667 GCGTGGAGCAGGGCAAGAGC 686
              ||| |||||||| ||| |||
Db         20 GCGAGGAGCAGGTCAACAGC 1


RESULT 140
ADG18034/c
ID   ADG18034 standard; DNA; 20 BP.
XX
AC   ADG18034;
XX
DT   26-FEB-2004  (first entry)
XX
DE   MAGE-C2 gene PCR primer #4.
XX
KW   MAGE-C2; MAGE-related tumour rejection antigen precursor; TRAP;
KW   tumour immunotherapy; vaccine; PCR; ss; primer.
XX
OS   Unidentified.
XX
PN   US6475783-B1.
XX
PD   05-NOV-2002.
XX
```

PF 24-APR-1998; 98US-00066281.
XX
PR 25-APR-1997; 97US-00845528.
XX
PA (LUDW-) LUDWIG INST CANCER RES.
XX
PI Lucas S, De Smet C, Boon-Falleur T;
XX
DR WPI; 2003-208836/20.
XX
PT Novel MAGE-C2 nucleic acid encoding MAGE-related tumor rejection antigen
PT precursors, useful in diagnostic and therapeutic applications.
XX
PS Example 11; SEQ ID NO 17; 42pp; English.
XX
CC The invention comprises a nucleic acid (designated as MAGE-C2) encoding
CC an MAGE-related tumour rejection antigen precursor (TRAP). The MAGE-C2
CC nucleic acid of the invention is useful for producing MAGE-related tumour
CC rejection precursors (TRAPs), which can be used in tumour immunotherapy
CC and as vaccines. The MAGE-C2 nucleic acid is also useful in diagnostic
CC and therapeutic applications, especially in diagnosing disorders
CC characterised by MAGE-C1 or C2 RNAs or TRAPs. The present DNA sequence
CC represents a PCR primer that was used in an example of the invention.
XX
SQ Sequence 20 BP; 3 A; 5 C; 7 G; 5 T; 0 U; 0 Other;

Query Match 0.9%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.3e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 495 TGTGCCAACCTGATGCAGCT 514
|| |||||||| || ||||||
Db 20 TCTGCCAACCAGAGGCAGCT 1

RESULT 141
ADG92990/c
ID ADG92990 standard; DNA; 20 BP.
XX
AC ADG92990;
XX
DT 11-MAR-2004 (first entry)
XX
DE Human FT-beta subunit phosphorothioate oligonucleotide #18.
XX
KW Human; farnesyl transferase beta subunit; ss; FT-beta subunit;
KW antisense oligonucleotide; phosphorothioate linkage;
KW 2'-O-methoxyethyl sugar moiety; 5-methylcytosine;
KW hyperproliferative disorder; cancer; ovarian carcinoma; adenocarcinoma;
KW colorectal cancer; pancreatic cancer; prostate cancer;
KW inflammatory condition; tumour formation; cytostatic; antiinflammatory;
KW antimicrobial; phosphorothioate oligonucleotide.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN US2003212017-A1.
XX
PD 13-NOV-2003.
XX
PF 10-MAY-2002; 2002US-00144488.
XX
PR 10-MAY-2002; 2002US-00144488.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Monia BP, Freier SM;
XX
DR WPI; 2003-901641/82.
XX
PT New compounds that hybridizes with nucleic acid molecules encoding
PT farnesyl transferase beta subunit and inhibits the expression of farnesyl
PT transferase beta subunit, useful for treating e.g. cancer or inflammatory
PT disease.
XX
PS Example 15; SEQ ID NO 25; 44pp; English.
XX
CC The invention relates to a compound targeted to a nucleic acid molecule
CC encoding the human farnesyl transferase beta (FT-beta) subunit and
CC inhibits the expression of the (FT-beta) subunit, or specifically
CC hybridises with at least an 8-nucleobase portion of an active site on a
CC nucleic acid molecule encoding the FT-beta subunit. The invention also
CC relates to a method of inhibiting the expression of the FT-beta subunit
CC in cells or tissues and a method of treating an animal having a disease
CC or condition associated with the FT-beta subunit. The compound is an
CC antisense oligonucleotide, preferably a chimeric oligonucleotide, which
CC comprises at least one modified internucleoside linkage which is a
CC phosphorothioate linkage, at least one modified sugar moiety which is a
CC 2'-O-methoxyethyl sugar moiety or at least one modified nucleobase which
CC a 5-methylcytosine. The compound is useful in inhibiting the expression
CC of the FT-beta subunit in cells or tissues. It can also be used for
CC treating cells or conditions associated with the FT-beta subunit, such as
CC hyperproliferative disorders, including cancer (such as ovarian
CC carcinoma, adenocarcinoma, colorectal cancer, pancreatic cancer or
CC prostate cancer) and inflammatory conditions. The antisense compounds can
CC also be used as research agents, in diagnostics or for preventing or
CC delaying infection, inflammation or tumour formation. This sequence
CC represents a human farnesyl transferase beta subunit phosphorothioate
CC oligonucleotide of the invention.
XX
SQ Sequence 20 BP; 5 A; 5 C; 6 G; 4 T; 0 U; 0 Other;

Query Match 0.9%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.3e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 879 CTGTACAGCTCGGAACAGCT 898
||| |||||| ||||| |||
Db 20 CTGCACAGCTTGGAACTGCT 1

RESULT 142
ADH94264/c
ID ADH94264 standard; DNA; 20 BP.
XX
AC ADH94264;
XX
DT 22-APR-2004 (first entry)
XX
DE Human gene PCR primer #1109.
XX
KW human; gene sequence; single nucleotide polymorphism; SNP;
KW disease diagnosis; ss; PCR; primer.
XX
OS Homo sapiens.
XX
PN JP2003174883-A.
XX
PD 24-JUN-2003.
XX
PF 11-DEC-2001; 2001JP-00377637.
XX
PR 11-DEC-2001; 2001JP-00377637.
XX
PA (KAGA-) KAGAKU GIJUTSU SHINKO JIGYODAN.
XX
DR WPI; 2003-819215/77.
XX
PT Polynucleotide for detecting single nucleotide polymorphisms existing in
PT human gene, contains isolated human gene having specified sequence.
XX
PS Claim 2; SEQ ID NO 2101; 529pp; Japanese.
XX
CC The invention comprises isolated human gene sequences and PCR primer
CC sequences which can be used to detect single nucleotide polymorphisms
CC (SNPs). The DNA sequences of the invention are useful for detecting SNPs

CC existing in human genes and for the diagnosis of human disease. The
CC present DNA sequence represents a human gene PCR primer of the invention.
XX
SQ Sequence 20 BP; 4 A; 3 C; 8 G; 5 T; 0 U; 0 Other;

Query Match 0.9%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.3e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 176 CACTCTGAGTTCATCAGCAA 195
||||||| | || |||||||
Db 20 CACTCTGCGATCCTCAGCAA 1

RESULT 143
ABZ87187
ID ABZ87187 standard; DNA; 20 BP.
XX
AC ABZ87187;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-229219/22.
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Claim 15; SEQ ID NO 2429; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 4 A; 5 C; 7 G; 4 T; 0 U; 0 Other;

Query Match 0.9%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.3e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 508 TGCAGCTGCTGCAGGAGAGC 527
||||||| ||||||| |||
Db 1 TGCAGCTTCTGCAGGGAAGC 20

RESULT 144
ABZ88322
ID ABZ88322 standard; DNA; 20 BP.
XX
AC ABZ88322;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-229219/22.
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 3564; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed

```
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 15.2;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 2.3e+02;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        916 GAACTTCAACCTGAGGGGGC 935
              ||||||||  ||| |||||  |
Db          1 GAACTTCACCCTCAGGGGCC 20


RESULT 145
ABZ87743
ID   ABZ87743 standard; DNA; 20 BP.
XX
AC   ABZ87743;
XX
DT   17-OCT-2003  (first entry)
XX
DE   Human oligonucleotide sequence.
XX
KW   Human; antisense; lung dysfunction; nasal airway dysfunction;
KW   antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW   antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW   antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW   adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW   lung inflammation; respiratory disease; ds.
XX
OS   Homo sapiens.
XX
PN   WO200285308-A2.
XX
PD   31-OCT-2002.
XX
PF   23-APR-2002; 2002WO-US013135.
XX
PR   24-APR-2001; 2001US-0286137P.
XX
PA   (EPIG-) EPIGENESIS PHARM INC.
XX
PI   Nyce JW,  Li Y,  Sandrasagra A,  Katz E,  Pabalan J,  Aguilar D;
PI   Miller S,  Tang L,  Shahabuddin S;
XX
DR   WPI; 2003-229219/22.
XX
PT   Pharmaceutical composition for treating ailments associated with impaired
PT   respiration, has oligo(s) antisense to specific gene(s) or its
PT   corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT   ubiquinone.
XX
PS   Disclosure; SEQ ID NO 2985; 872pp; English.
XX
CC   The invention relates to a novel pharmaceutical composition, which has a
CC   first active agent comprising an oligonucleotide antisense to the
CC   initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC   5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC   junctions of genes encoding a polypeptide associated with lung and/or
CC   nasal airway dysfunction and a second active agent comprising an
CC   antiinflammatory steroid and ubiquinone. A composition of the invention
CC   has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC   immunosuppressive, and cytostatic activity. The composition may have a
CC   use in antisense gene therapy. The composition is useful for treating or
CC   preventing a respiratory, lung or malignant disease or condition, also
CC   for enhancing the prophylactic or therapeutic respiratory effect of an
CC   antiinflammatory steroid in a subject, for reducing or depleting levels
CC   of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC   receptor, producing bronchodilation, increasing levels of ubiquinone or
CC   lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC   lung inflammation, lung allergies, or a respiratory disease or condition.
CC   Note: The sequence data for this patent is not represented in the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 20 BP; 9 A; 6 C; 3 G; 2 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 15.2;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 2.3e+02;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        950 AAGACAGAGACGACTGAACT 969
              ||  ||  ||||||||||||
Db          1 AAAACCCAGACGACTGAACT 20


RESULT 146
ACD42144/c
ID   ACD42144 standard; DNA; 20 BP.
XX
AC   ACD42144;
XX
DT   05-SEP-2003  (first entry)
XX
DE   Human raf-associated antisense oligonucleotide #6.
XX
KW   Antisense; c-raf; a-raf; b-raf; protein kinase; cancer; ss;
KW   signal transduction; cell proliferation; lung carcinoma; cytostatic;
KW   antisense gene therapy; chemotherapeutic agent; angiogenesis;
KW   hyperproliferative condition; neovascularisation; ocular angiogenesis.
XX
OS   Unidentified.
XX
PN   US2003032607-A1.
XX
PD   13-FEB-2003.
XX
PF   25-JAN-2002; 2002US-00057550.
XX
PR   31-MAY-1994;   94US-00250856.
PR   31-MAY-1995;   95WO-US007111.
PR   26-NOV-1996;   96US-00756806.
PR   07-JUL-1997;   97US-00888982.
PR   06-JUL-1998;   98WO-US013961.
PR   28-AUG-1998;   98US-00143214.
PR   18-FEB-2000; 2000US-00506073.
XX
PA   (MONI/) MONIA B P.
XX
PI   Monia BP;
XX
DR   WPI; 2003-503332/47.
XX
PT   Novel antisense oligonucleotide which is targeted to mRNA encoding human
PT   raf and which is capable of inhibiting raf expression, useful for
PT   treating or preventing hyperproliferative conditions such as cancer.
XX
PS   Disclosure; Page 30; 42pp; English.
XX
CC   The invention relates to an oligonucleotide 8-50 nucleotides in length
CC   which is targeted to mRNA encoding human c-raf, a-raf or b-raf (raf is a
CC   protein kinase playing a regulatory role in signal transduction,
CC   regulating cell proliferation and has been implicated in lung carcinoma),
CC   and which is capable of inhibiting raf expression. Also included is a
CC   composition comprising the oligonucleotide and a pharmaceutically
CC   acceptable carrier. The antisense oligonucleotide is useful for
CC   inhibiting the expression of human raf in human cells or tissues, by
CC   contacting the human cells or tissues with the oligo. The oligo. is also
CC   is useful for treating or preventing a disease or condition associated
CC   with the expression of raf by administering it in combination with a
CC   chemotherapeutic agent to a human or cells of the human, where the
CC   expression of raf is abnormal expression, and the condition is a
CC   hyperproliferative condition such as cancer, angiogenesis or
CC   neovascularisation (preferably ocular angiogenesis or
CC   neovascularisation). The oligo. is also useful for inhibiting
```

```
CC   hyperproliferation of cells. The oligos. are also useful as tools, for
CC   example for detecting and determining the role of raf expression in
CC   various cell functions and physiological processes and conditions and for
CC   diagnosing conditions associated with raf expression and for research
CC   purposes. The present sequence is an antisense oligonucleotide included
CC   in the sequence listing but not mentioned elsewhere in the specification
XX
SQ   Sequence 20 BP; 2 A; 9 C; 4 G; 5 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 15.2;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 2.3e+02;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1267 CCGGCCCAGGGTGAAGGAAG 1286
              | ||||| ||| ||||||||
Db         20 CTGGCCCTGGGAGAAGGAAG 1


RESULT 147
ADM33117/c
ID   ADM33117 standard; DNA; 20 BP.
XX
AC   ADM33117;
XX
DT   03-JUN-2004  (first entry)
XX
DE   Human MAGE-C2 PCR primer #3.
XX
KW   gene therapy; tumour rejection antigen precursor; TRAP;
KW   testicular tumour; ss; PCR; primer.
XX
OS   Homo sapiens.
XX
PN   US2003170256-A1.
XX
PD   11-SEP-2003.
XX
PF   04-JUN-2002; 2002US-00160237.
XX
PR   25-APR-1997;   97US-00845528.
PR   24-APR-1998;   98US-00066281.
XX
PA   (LUCA/) LUCAS S.
PA   (DSME/) DE SMET C.
PA   (BOON/) BOON-FALLEUR T.
XX
PI   Lucas S,  De Smet C,  Boon-Falleur T;
XX
DR   WPI; 2003-898238/82.
XX
PT   New isolated tumor rejection antigen precursor (TRAP) nucleic acid,
PT   useful for diagnosing and treating conditions associated with TRAP
PT   activity or expression, such as testicular tumors.
XX
PS   Example 11; SEQ ID NO 17; 44pp; English.
XX
CC   The invention relates to an isolated nucleic acid molecule which encodes
CC   a tumour rejection antigen precursor (TRAP). The methods and compositions
CC   of the present invention are useful for diagnosing and treating
CC   conditions associated with TRAP activity or expression, such as
CC   testicular tumours. The present sequence represents a human MAGE-C2
CC   primer.
XX
SQ   Sequence 20 BP; 3 A; 5 C; 7 G; 5 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 15.2;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 2.3e+02;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        495 TGTGCCAACCTGATGCAGCT 514
              | |||||||| || ||||||
Db         20 TCTGCCAACCAGAGGCAGCT 1


RESULT 148
ABD23973
ID   ABD23973 standard; DNA; 20 BP.
XX
AC   ABD23973;
XX
DT   29-JUL-2004  (first entry)
XX
DE   Human calmodulin 2-derived oligonucleotide SEQ ID 2985.
XX
KW   Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
KW   respiratory tract inflammation; adenosine sensitivity; lung; cancer;
KW   surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
KW   analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
KW   beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
KW   respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
KW   emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
KW   pulmonary transplantation rejection; ss; primer.
XX
OS   Homo sapiens.
XX
PN   WO200285309-A2.
XX
PD   31-OCT-2002.
XX
PF   23-APR-2002; 2002WO-US013143.
XX
PR   24-APR-2001; 2001US-0286036P.
XX
PA   (EPIG-) EPIGENESIS PHARM INC.
XX
PI   Nyce JW,  Li Y,  Sandrasagra A,  Katz E,  Pabalan J,  Aguilar D;
PI   Miller S,  Tang L,  Shahabuddin S;
XX
DR   WPI; 2003-093058/08.
XX
PT   Pharmaceutical composition for treating asthma, has antisense
PT   oligonucleotide containing less percentage of adenosine, targeted to
PT   nucleic acids associated with lung airway or lung dysfunction, and
PT   bronchodilating agent.
XX
PS   Claim 15; SEQ ID NO 2985; 763pp; English.
XX
CC   This invention describes a novel composition (a) a first active agent,
CC   comprising oligonucleotides, effective for alleviating
CC   bronchoconstriction, respiratory tract inflammation, allergies and
CC   reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
CC   surfactant depletion or hyposecretion, when administered to a mammal. The
CC   oligonucleotides are derived from a gene encoding or regulating
CC   expression of a target polypeptide associated with lung airway or lung
CC   dysfunction or cancer and can be anti-sense to the corresponding mRNA.
CC   The invention also describes a kit, that comprises: (a) a delivery
CC   device, in separate containers, (b) the oligonucleotides, (c)
CC   instructions for adding a carrier and for use of the kit. The composition
CC   of the invention has antiallergic, antiinflammatory, antiasthmatic,
CC   analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
CC   beta-adrenergic agonist. The composition is useful for preventing or
CC   treating a respiratory, lung or malignant disease. The administered
CC   composition comprises oligo and is administered to reduce the production
CC   or availability, or to increase the degradation of the target mRNA or to
CC   reduce the amount of target polypeptide present in the lungs. The
CC   pulmonary obstruction, and/or bronchoconstriction and/or lung
CC   inflammation, allergies and/or surfactant hypoproduction are associated
CC   with a disease or condition such as pulmonary vasoconstriction,
CC   inflammation, allergies, asthma, impeded respiration, respiratory
CC   distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
CC   hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
CC   transplantation rejection, pulmonary infections, bronchitis or cancer.
CC   The reduced adenosine content of the anti-sense oligos corresponding to
CC   thymidines present in the target RNA serves to prevent the breakdown of
CC   the oligonucleotides into products that free adenosine into the system
CC   e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
```

```
CC   prevent any unwanted effects due to it
XX
SQ   Sequence 20 BP; 9 A; 6 C; 3 G; 2 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 15.2;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 2.3e+02;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        950 AAGACAGAGACGACTGAACT 969
              || ||  ||||||||||||||
Db          1 AAAACCCAGACGACTGAACT 20


RESULT 149
ABD23417
ID   ABD23417 standard; DNA; 20 BP.
XX
AC   ABD23417;
XX
DT   29-JUL-2004  (first entry)
XX
DE   Human myosin X-derived oligonucleotide SEQ ID 2429.
XX
KW   Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
KW   respiratory tract inflammation; adenosine sensitivity; lung; cancer;
KW   surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
KW   analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
KW   beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
KW   respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
KW   emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
KW   pulmonary transplantation rejection; ss; primer.
XX
OS   Homo sapiens.
XX
PN   WO200285309-A2.
XX
PD   31-OCT-2002.
XX
PF   23-APR-2002; 2002WO-US013143.
XX
PR   24-APR-2001; 2001US-0286036P.
XX
PA   (EPIG-) EPIGENESIS PHARM INC.
XX
PI   Nyce JW,  Li Y,  Sandrasagra A,  Katz E,  Pabalan J,  Aguilar D;
PI   Miller S,  Tang L,  Shahabuddin S;
XX
DR   WPI; 2003-093058/08.
XX
PT   Pharmaceutical composition for treating asthma, has antisense
PT   oligonucleotide containing less percentage of adenosine, targeted to
PT   nucleic acids associated with lung airway or lung dysfunction, and
PT   bronchodilating agent.
XX
PS   Claim 15; SEQ ID NO 2429; 763pp; English.
XX
CC   This invention describes a novel composition (a) a first active agent,
CC   comprising oligonucleotides, effective for alleviating
CC   bronchoconstriction, respiratory tract inflammation, allergies and
CC   reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
CC   surfactant depletion or hyposecretion, when administered to a mammal. The
CC   oligonucleotides are derived from a gene encoding or regulating
CC   expression of a target polypeptide associated with lung airway or lung
CC   dysfunction or cancer and can be anti-sense to the corresponding mRNA.
CC   The invention also describes a kit, that comprises: (a) a delivery
CC   device, in separate containers, (b) the oligonucleotides, (c)
CC   instructions for adding a carrier and for use of the kit. The composition
CC   of the invention has antiallergic, antiinflammatory, antiasthmatic,
CC   analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
CC   beta-adrenergic agonist. The composition is useful for preventing or
CC   treating a respiratory, lung or malignant disease. The administered
CC   composition comprises oligo and is administered to reduce the production
CC   or availability, or to increase the degradation of the target mRNA or to
CC   reduce the amount of target polypeptide present in the lungs. The
CC   pulmonary obstruction, and/or bronchoconstriction and/or lung
CC   inflammation, allergies and/or surfactant hypoproduction are associated
CC   with a disease or condition such as pulmonary vasoconstriction,
CC   inflammation, allergies, asthma, impeded respiration, respiratory
CC   distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
CC   hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
CC   transplantation rejection, pulmonary infections, bronchitis or cancer.
CC   The reduced adenosine content of the anti-sense oligos corresponding to
CC   thymidines present in the target RNA serves to prevent the breakdown of
CC   the oligonucleotides into products that free adenosine into the system
CC   e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
CC   prevent any unwanted effects due to it
XX
SQ   Sequence 20 BP; 4 A; 5 C; 7 G; 4 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 15.2;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 2.3e+02;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        508 TGCAGCTGCTGCAGGAGAGC 527
              |||||||  |||||||  |||
Db          1 TGCAGCTTCTGCAGGGAAGC 20


RESULT 150
ABD24552
ID   ABD24552 standard; DNA; 20 BP.
XX
AC   ABD24552;
XX
DT   29-JUL-2004  (first entry)
XX
DE   AI652764-derived oligonucleotide SEQ ID 3564.
XX
KW   Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
KW   respiratory tract inflammation; adenosine sensitivity; lung; cancer;
KW   surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
KW   analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
KW   beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
KW   respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
KW   emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
KW   pulmonary transplantation rejection; ss; primer.
XX
OS   Homo sapiens.
XX
PN   WO200285309-A2.
XX
PD   31-OCT-2002.
XX
PF   23-APR-2002; 2002WO-US013143.
XX
PR   24-APR-2001; 2001US-0286036P.
XX
PA   (EPIG-) EPIGENESIS PHARM INC.
XX
PI   Nyce JW,  Li Y,  Sandrasagra A,  Katz E,  Pabalan J,  Aguilar D;
PI   Miller S,  Tang L,  Shahabuddin S;
XX
DR   WPI; 2003-093058/08.
XX
PT   Pharmaceutical composition for treating asthma, has antisense
PT   oligonucleotide containing less percentage of adenosine, targeted to
PT   nucleic acids associated with lung airway or lung dysfunction, and
PT   bronchodilating agent.
XX
PS   Claim 15; SEQ ID NO 3564; 763pp; English.
XX
CC   This invention describes a novel composition (a) a first active agent,
CC   comprising oligonucleotides, effective for alleviating
CC   bronchoconstriction, respiratory tract inflammation, allergies and
CC   reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
CC   surfactant depletion or hyposecretion, when administered to a mammal. The
```

```
CC   oligonucleotides are derived from a gene encoding or regulating
CC   expression of a target polypeptide associated with lung airway or lung
CC   dysfunction or cancer and can be anti-sense to the corresponding mRNA.
CC   The invention also describes a kit, that comprises: (a) a delivery
CC   device, in separate containers, (b) the oligonucleotides, (c)
CC   instructions for adding a carrier and for use of the kit. The composition
CC   of the invention has antiallergic, antiinflammatory, antiasthmatic,
CC   analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
CC   beta-adrenergic agonist. The composition is useful for preventing or
CC   treating a respiratory, lung or malignant disease. The administered
CC   composition comprises oligo and is administered to reduce the production
CC   or availability, or to increase the degradation of the target mRNA or to
CC   reduce the amount of target polypeptide present in the lungs. The
CC   pulmonary obstruction, and/or bronchoconstriction and/or lung
CC   inflammation, allergies and/or surfactant hypoproduction are associated
CC   with a disease or condition such as pulmonary vasoconstriction,
CC   inflammation, allergies, asthma, impeded respiration, respiratory
CC   distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
CC   hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
CC   transplantation rejection, pulmonary infections, bronchitis or cancer.
CC   The reduced adenosine content of the anti-sense oligos corresponding to
CC   thymidines present in the target RNA serves to prevent the breakdown of
CC   the oligonucleotides into products that free adenosine into the system
CC   e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
CC   prevent any unwanted effects due to it
XX
SQ   Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 15.2;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 2.3e+02;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        916 GAACTTCAACCTGAGGGGGC 935
              ||||||||  ||| |||||  |
Db          1 GAACTTCACCCTCAGGGGCC 20


RESULT 151
ADH67851
ID   ADH67851 standard; DNA; 20 BP.
XX
AC   ADH67851;
XX
DT   25-MAR-2004  (first entry)
XX
DE   Human glucocorticoid receptor-specific antisense oligonucleotide #4685.
XX
KW   antisense oligonucleotide; glucocorticoid receptor; infection;
KW   inflammation; tumour formation; diabetes; obesity;
KW   cardiovascular disorder; hyperlipidaemia; Cushing's syndrome; human; ss;
KW   phosphorothioate backbone; 2'-methoxyethyl; 2'-MOE.
XX
OS   Homo sapiens.
XX
PN   WO2003099215-A2.
XX
PD   04-DEC-2003.
XX
PF   20-MAY-2003; 2003WO-US016084.
XX
PR   20-MAY-2002; 2002US-0381857P.
XX
PA   (PHAA ) PHARMACIA CORP.
XX
PI   Crosby SD,  Nalseth AE;
XX
DR   WPI; 2004-035034/03.
XX
PT   New antisense compound targeted to a nucleic acid molecule encoding
PT   mammalian glucocorticoid receptor, useful for treating diabetes, obesity,
PT   cardiovascular disorder, hyperlipidemia or Cushing's syndrome.
XX
PS   Claim 4; SEQ ID NO 4685; 985pp; English.
XX
CC   The invention comprises an antisense oligonucleotides that are targeted
CC   to nucleic acids encoding a mammalian glucocorticoid receptor. The
CC   antisense oligonucleotides of the invention are useful for preventing or
CC   delaying infection, inflammation or tumour formation. The antisense
CC   oligonucleotides are also useful for treating diabetes, obesity,
CC   cardiovascular disorders, hyperlipidaemia or Cushing's syndrome. The
CC   present DNA sequence represents an antisense oligonucleotide that targets
CC   the human glucocorticoid receptor gene. NOTE: The present sequence
CC   contains 2'-methoxyethyl (2'-MOE) wings and a phosphorothioate backbone.
XX
SQ   Sequence 20 BP; 6 A; 1 C; 0 G; 13 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 15.2;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 2.3e+02;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1726 AATATTTTTTACTTTTCTAA 1745
              |||||  ||||  ||||||||
Db          1 AATATATTTTTTTTTTCTAA 20


RESULT 152
ADI79409/c
ID   ADI79409 standard; DNA; 20 BP.
XX
AC   ADI79409;
XX
DT   22-APR-2004  (first entry)
XX
DE   Human MAGE-C2 PCR primer SL118.
XX
KW   Human; ss; MAGE; chromosome Xq26-q27; cancer; cytostatic; TRAP;
KW   tumour rejection antigen precursor; PCR; primer.
XX
OS   Homo sapiens.
XX
PN   US6680191-B1.
XX
PD   20-JAN-2004.
XX
PF   17-DEC-1999;   99US-00468433.
XX
PR   25-APR-1997;   97US-00845528.
PR   24-APR-1998;   98US-00066281.
XX
PA   (LUDW-) LUDWIG INST CANCER RES.
XX
PI   Lucas S,  Boon-Falleur T;
XX
DR   WPI; 2004-088565/09.
XX
PT   New nucleic acid molecules coding for tumor rejection antigen precursors
PT   of the MAGE-C and MAGE-B families, useful for diagnosing, preventing or
PT   treating cancer.
XX
PS   Example 11; SEQ ID NO 17; 56pp; English.
XX
CC   The invention relates to an isolated nucleic acid molecule comprising the
CC   open reading frame of human MAGE-C3 (not defined) appearing as ADI79413,
CC   or its complete complement. Also included are an expression vector
CC   comprising the new nucleic acid molecule operatively linked to a
CC   promoter, an isolated cell line or cell strain transfected or transformed
CC   with the expression vector and a kit useful in a polymerase chain
CC   reaction (PCR) based assay, comprising an oligonucleotide fragment of
CC   ADI79413 comprising nucleotides 175-195 or 711-731. MAGE-C and MAGE-B
CC   family members are tumour rejection antigen precursors (TRAP). The
CC   composition and methods are useful for diagnosing, preventing or treating
CC   cancer. Also disclosed as new are the DNAs and proteins for MAGE-C1, MAGE
CC   -C2, MAGE-B5 and MAGE-B6. The genes for MAGe-C1, C2 and C3 are located on
CC   chromosome Xq26-27. The present sequence is a PCR primer used in the
CC   isolation or analysis of the MAGE genes of the invention.
XX
```

```
SQ   Sequence 20 BP; 3 A; 5 C; 7 G; 5 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 15.2;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 2.3e+02;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        495 TGTGCCAACCTGATGCAGCT 514
              | |||||||| || ||||||
Db         20 TCTGCCAACCAGAGGCAGCT 1


RESULT 153
ADI28308
ID   ADI28308 standard; cDNA; 20 BP.
XX
AC   ADI28308;
XX
DT   22-APR-2004  (first entry)
XX
DE   Human PRL3 antisense target region #52.
XX
KW   Human; antisense gene therapy; ss; PRL3;
KW   protein tyrosine phosphatase type IVA member  3; colorectal cancer;
KW   diabetes; glucose tolerance; insulin resistance; obesity;
KW   hyperproliferative disorder; cytostatic.
XX
OS   Homo sapiens.
XX
PN   US2003235911-A1.
XX
PD   25-DEC-2003.
XX
PF   20-JUN-2002; 2002US-00177554.
XX
PR   20-JUN-2002; 2002US-00177554.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Dobie KW,  Zhang H;
XX
DR   WPI; 2004-070585/07.
XX
PT   New antisense oligonucleotide, comprising a sequence targeted to a
PT   nucleic acid encoding protein tyrosine phosphatase type IVA member 3 (PRL
PT   -3), useful for preparing a composition for treating hyperproliferative
PT   disorders, e.g., cancer.
XX
PS   Example 16; SEQ ID NO 215; 77pp; English.
XX
CC   The invention relates to a compound comprising a sequence comprising 8-80
CC   base pairs (bp) targeted to a nucleic acid encoding protein tyrosine
CC   phosphatase type IVA member 3 (PRL-3), that specifically hybridises with
CC   the nucleic acid encoding PRL-3 and inhibits expression of PRL-3, i.e. is
CC   an antisense oligonucleotide (AO). Also included are a composition
CC   comprising the compound and a carrier or diluent, inhibiting the
CC   expression of PRL-3 in cells or tissues, treating an animal having or
CC   suspected of having a disease or condition associated with PRL-3 and
CC   screening for an antisense compound. The antisense oligonucleotide is
CC   useful for preparing a composition for treating hyperproliferative
CC   disorder, particularly cancer ((e.g. colorectal cancer), diabetes,
CC   reduced glucose tolerance, insulin resistance and obesity. The present
CC   sequence is a Human PRL3 cDNA AO target region.
XX
SQ   Sequence 20 BP; 2 A; 8 C; 4 G; 6 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 15.2;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 2.3e+02;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1428 CTGACCTGTTGTAGGCAGCT 1447
              |||||||||| | |||| ||
Db          1 CTGACCTGTTCTCGGCACCT 20


RESULT 154
ADI28178/c
ID   ADI28178 standard; DNA; 20 BP.
XX
AC   ADI28178;
XX
DT   22-APR-2004  (first entry)
XX
DE   Antisense oligonucleotide targeting human PRL3 ISIS 217516.
XX
KW   Human; antisense gene therapy; ss; PRL3;
KW   protein tyrosine phosphatase type IVA member  3; colorectal cancer;
KW   diabetes; glucose tolerance; insulin resistance; obesity;
KW   hyperproliferative disorder; cytostatic.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate backbone and all cytidines are 5
FT                   -methyl cytidines"
FT   modified_base   1. .5
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl residues"
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl residues"
XX
PN   US2003235911-A1.
XX
PD   25-DEC-2003.
XX
PF   20-JUN-2002; 2002US-00177554.
XX
PR   20-JUN-2002; 2002US-00177554.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Dobie KW,  Zhang H;
XX
DR   WPI; 2004-070585/07.
XX
PT   New antisense oligonucleotide, comprising a sequence targeted to a
PT   nucleic acid encoding protein tyrosine phosphatase type IVA member 3 (PRL
PT   -3), useful for preparing a composition for treating hyperproliferative
PT   disorders, e.g., cancer.
XX
PS   Example 15; SEQ ID NO 85; 77pp; English.
XX
CC   The invention relates to a compound comprising a sequence comprising 8-80
CC   base pairs (bp) targeted to a nucleic acid encoding protein tyrosine
CC   phosphatase type IVA member 3 (PRL-3), that specifically hybridises with
CC   the nucleic acid encoding PRL-3 and inhibits expression of PRL-3, i.e. is
CC   an antisense oligonucleotide (AO). Also included are a composition
CC   comprising the compound and a carrier or diluent, inhibiting the
CC   expression of PRL-3 in cells or tissues, treating an animal having or
CC   suspected of having a disease or condition associated with PRL-3 and
CC   screening for an antisense compound. The antisense oligonucleotide is
CC   useful for preparing a composition for treating hyperproliferative
CC   disorder, particularly cancer ((e.g. colorectal cancer), diabetes,
CC   reduced glucose tolerance, insulin resistance and obesity. The present
CC   sequence is an antisense oligonucleotide targeting human PRL3.
XX
SQ   Sequence 20 BP; 6 A; 4 C; 8 G; 2 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 15.2;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 2.3e+02;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;
```

```
Qy       1428 CTGACCTGTTGTAGGCAGCT 1447
              |||||||||| | |||| ||
Db         20 CTGACCTGTTCTCGGCACCT 1
```

```
RESULT 155
ADI29122
ID   ADI29122 standard; DNA; 20 BP.
XX
AC   ADI29122;
XX
DT   22-APR-2004  (first entry)
XX
DE   Antisense oligonucleotide targeting human MARK3 ISIS 151491.
XX
KW   Human; antisense gene therapy; ss; MARK3;
KW   MAP/microtubule affinity-regulating kinase 3; cancer;
KW   Alzheimer's disease; neurodegenerative disorde;
KW   hyperproliferative disorder; cytostatic.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate backbone and all cytidines are 5
FT                   -methyl cytidines"
FT   modified_base   1. .5
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl residues"
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl residues"
XX
PN   US2003232771-A1.
XX
PD   18-DEC-2003.
XX
PF   17-JUN-2002; 2002US-00174319.
XX
PR   17-JUN-2002; 2002US-00174319.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Ward DT,  Freier SM,  Dobie KW;
XX
DR   WPI; 2004-052188/05.
XX
PT   New antisense compound targeted to a nucleic acid molecule encoding
PT   microtubule-affinity-regulating kinases (MARK3), useful for modulating
PT   expression of MARK3 or for treating cancer or Alzheimer's disease.
XX
PS   Example 15; SEQ ID NO 42; 233pp; English.
XX
CC   The invention relates to a compound comprising a sequence comprising 8-80
CC   base pairs (bp) targeted to a nucleic acid encoding MARK3
CC   (MAP/microtubule affinity-regulating kinase 3), that specifically
CC   hybridises with the nucleic acid encoding MARK3 and inhibits expression
CC   of MARK3, i.e. is an antisense oligonucleotide (AO). Also included are a
CC   composition comprising the compound and a carrier or diluent, inhibiting
CC   the expression of MARK3 in cells or tissues, treating an animal having or
CC   suspected of having a disease or condition associated with MARK3 and
CC   screening for an antisense compound. The antisense oligonucleotide is
CC   useful for preparing a composition for treating hyperproliferative
CC   disorder, particularly cancer and neurodegenerative diseases e.g.
CC   Alzheimer's disease. The present sequence is an antisense oligonucleotide
CC   targeting MARK3.
XX
SQ   Sequence 20 BP; 7 A; 4 C; 4 G; 5 T; 0 U; 0 Other;
```

```
  Query Match             0.9%;  Score 15.2;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 2.3e+02;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1681 CACTGTTCATGAATACACTT 1700
              || |||||| ||| ||||||
Db          1 CAGTGTTCAGGAAAACACTT 20
```

```
RESULT 156
ADK97015
ID   ADK97015 standard; DNA; 20 BP.
XX
AC   ADK97015;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Primer of the invention #2735.
XX
KW   human; single nucleotide polymorphism; SNP; ss; primer.
XX
OS   Synthetic.
XX
PN   JP2003259875-A.
XX
PD   16-SEP-2003.
XX
PF   08-MAR-2002; 2002JP-00064373.
XX
PR   08-MAR-2002; 2002JP-00064373.
XX
PA   (KAGA-) KAGAKU GIJUTSU SHINKO JIGYODAN.
XX
DR   WPI; 2004-093977/10.
XX
PT   Novel polynucleotide useful for PCR amplification along with two DNA
PT   fragment from another set of sequences, or for detecting single
PT   nucleotide polymorphism in human gene.
XX
PS   Claim 2; SEQ ID NO 6044; 2627pp; Japanese.
XX
CC   The present invention relates to a polynucleotide isolated from a human
CC   gene and is useful for detecting a single nucleotide polymorphism in a
CC   human gene or for diagnosing of disease. The invention enables the
CC   detection of a single nucleotide polymorphism in a human gene. The
CC   present sequence represents a primer of the invention.
XX
SQ   Sequence 20 BP; 0 A; 11 C; 1 G; 8 T; 0 U; 0 Other;
```

```
  Query Match             0.9%;  Score 15.2;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 2.3e+02;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        249 TCGTCCACCTCCTCTTCGCC 268
              || ||| |||||||||||| |
Db          1 TCCTCCTCCTCCTCTTCGTC 20
```

```
RESULT 157
ADK95532/c
ID   ADK95532 standard; DNA; 20 BP.
XX
AC   ADK95532;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Primer of the invention #1252.
XX
KW   human; single nucleotide polymorphism; SNP; ss; primer.
XX
OS   Synthetic.
XX
```

```
PN   JP2003259875-A.
XX
PD   16-SEP-2003.
XX
PF   08-MAR-2002; 2002JP-00064373.
XX
PR   08-MAR-2002; 2002JP-00064373.
XX
PA   (KAGA-) KAGAKU GIJUTSU SHINKO JIGYODAN.
XX
DR   WPI; 2004-093977/10.
XX
PT   Novel polynucleotide useful for PCR amplification along with two DNA
PT   fragment from another set of sequences, or for detecting single
PT   nucleotide polymorphism in human gene.
XX
PS   Claim 2; SEQ ID NO 4561; 2627pp; Japanese.
XX
CC   The present invention relates to a polynucleotide isolated from a human
CC   gene and is useful for detecting a single nucleotide polymorphism in a
CC   human gene or for diagnosing of disease. The invention enables the
CC   detection of a single nucleotide polymorphism in a human gene. The
CC   present sequence represents a primer of the invention.
XX
SQ   Sequence 20 BP; 4 A; 6 C; 6 G; 4 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 15.2;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 2.3e+02;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1019 GGAAAACTGAGGCAGCCACC 1038
              ||| ||||| ||||||| ||
Db         20 GGATAACTGTGGCAGCCTCC 1


RESULT 158
ADK97463/c
ID   ADK97463 standard; DNA; 20 BP.
XX
AC   ADK97463;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Primer of the invention #3183.
XX
KW   human; single nucleotide polymorphism; SNP; ss; primer.
XX
OS   Synthetic.
XX
PN   JP2003259875-A.
XX
PD   16-SEP-2003.
XX
PF   08-MAR-2002; 2002JP-00064373.
XX
PR   08-MAR-2002; 2002JP-00064373.
XX
PA   (KAGA-) KAGAKU GIJUTSU SHINKO JIGYODAN.
XX
DR   WPI; 2004-093977/10.
XX
PT   Novel polynucleotide useful for PCR amplification along with two DNA
PT   fragment from another set of sequences, or for detecting single
PT   nucleotide polymorphism in human gene.
XX
PS   Claim 2; SEQ ID NO 6492; 2627pp; Japanese.
XX
CC   The present invention relates to a polynucleotide isolated from a human
CC   gene and is useful for detecting a single nucleotide polymorphism in a
CC   human gene or for diagnosing of disease. The invention enables the
CC   detection of a single nucleotide polymorphism in a human gene. The
CC   present sequence represents a primer of the invention.
XX
SQ   Sequence 20 BP; 5 A; 4 C; 7 G; 4 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 15.2;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 2.3e+02;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        169 GCTCCGGCACTCTGAGTTCA 188
              ||||| ||| |||||| |||
Db         20 GCTCCTGCAATCTGAGCTCA 1


RESULT 159
ADK95099
ID   ADK95099 standard; DNA; 20 BP.
XX
AC   ADK95099;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Primer of the invention #819.
XX
KW   human; single nucleotide polymorphism; SNP; ss; primer.
XX
OS   Synthetic.
XX
PN   JP2003259875-A.
XX
PD   16-SEP-2003.
XX
PF   08-MAR-2002; 2002JP-00064373.
XX
PR   08-MAR-2002; 2002JP-00064373.
XX
PA   (KAGA-) KAGAKU GIJUTSU SHINKO JIGYODAN.
XX
DR   WPI; 2004-093977/10.
XX
PT   Novel polynucleotide useful for PCR amplification along with two DNA
PT   fragment from another set of sequences, or for detecting single
PT   nucleotide polymorphism in human gene.
XX
PS   Claim 2; SEQ ID NO 4128; 2627pp; Japanese.
XX
CC   The present invention relates to a polynucleotide isolated from a human
CC   gene and is useful for detecting a single nucleotide polymorphism in a
CC   human gene or for diagnosing of disease. The invention enables the
CC   detection of a single nucleotide polymorphism in a human gene. The
CC   present sequence represents a primer of the invention.
XX
SQ   Sequence 20 BP; 5 A; 9 C; 3 G; 3 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 15.2;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 2.3e+02;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1284 AAGAGGCACGTGCTCCTCAG 1303
              ||||| ||| | ||||||||
Db          1 AAGAGCCACCTCCTCCTCAG 20


RESULT 160
ADK12219/c
ID   ADK12219 standard; DNA; 20 BP.
XX
AC   ADK12219;
XX
DT   20-MAY-2004  (first entry)
XX
DE   Human complement component C3 DNA, antisense oligonucleotide #59.
XX
KW   Antisense therapy; human; complement component C3; autoimmune disorder;
KW   multiple sclerosis; infection; atherosclerosis; neuroprotective;
KW   antiarteriosclerotic; antimicrobial; antiinflammatory; cytostatic;
```

```
KW   phosphorothioate; ss.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "This oligonucleotide has a phosphorothioate
FT                   backbone and 2'-methyoxyethyl (2'-MOE) wings at the 5'
FT                   and 3' ends, which are 5 nucleotides in length at each
FT                   end. All cytidine residues are 5-methylcytidines"
XX
PN   US2004043956-A1.
XX
PD   04-MAR-2004.
XX
PF   18-AUG-2003; 2003US-00642802.
XX
PR   23-OCT-2001; 2001US-00001076.
XX
PA   (GRAH/) GRAHAM M J.
PA   (WATT/) WATT A T.
XX
PI   Graham MJ,  Watt AT;
XX
DR   WPI; 2004-225730/21.
XX
PT   New antisense compound targeted to a nucleic acid molecule encoding
PT   complement component C3, useful for treating multiple sclerosis, an
PT   infection or atherosclerosis.
XX
PS   Example 15; SEQ ID NO 77; 74pp; English.
XX
CC   The present invention relates to antisense compounds targeted to a
CC   nucleic acids encoding human and mouse complement component C3. The
CC   antisense compound comprises an antisense oligonucleotide that
CC   specifically hybridises with the nucleic acid and inhibits the expression
CC   of complement component C3 in cells. The antisense oligonucleotide is a
CC   chimeric oligonucleotide. The antisense oligonucleotide comprises at
CC   least one modified internucleoside linkage, preferably a phosphorothioate
CC   linkage. It also comprises at least one modified sugar moiety, preferably
CC   a 2'-O-methoxyethyl (2'-MOE) sugar moiety. The antisense oligonucleotide
CC   further comprises at least one modified nucleobase, preferably a 5-
CC   methylcytosine. The antisense oligonucleotides are useful for the
CC   treatment of diseases such as autoimmune disorders e.g. multiple
CC   sclerosis, infections, and atherosclerosis. The present sequence
CC   represents an antisense oligonucleotide used in the examples of the
CC   present invention.
XX
SQ   Sequence 20 BP; 1 A; 8 C; 5 G; 6 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 15.2;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 2.3e+02;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        667 GCGTGGAGCAGGGCAAGAGC 686
              ||| |||||||| ||| |||
Db         20 GCGAGGAGCAGGTCAACAGC 1


RESULT 161
ADJ25457/c
ID   ADJ25457 standard; DNA; 20 BP.
XX
AC   ADJ25457;
XX
DT   20-MAY-2004  (first entry)
XX
DE   Human endothelial lipase antisense oligonucleotide, SEQ ID 3855.
XX
KW   Antilipaemic; Cardiovascular; Analgesic; Antianginal; Antisense therapy;
KW   Human; Endothelial Lipase; dyslipidaemia; high density lipoprotein; HDL;
KW   cardiovascular disorder; metabolic syndrome X; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "This oligonucleotide has a phosphorothioate
FT                   backbone and 2-'methyoxyethyl (2'-MOE) wings at the 5'
FT                   and 3' ends, which are 4 nucleotides in length. Also all
FT                   cytidine residues are 5-methylcytidines"
XX
PN   WO2004009541-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022410.
XX
PR   19-JUL-2002; 2002US-0397106P.
XX
PA   (PHAA ) PHARMACIA CORP.
XX
PI   Bhat BG;
XX
DR   WPI; 2004-132912/13.
XX
PT   New antisense oligonucleotide for modulating endothelial lipase
PT   expression, for diagnosing, preventing or treating e.g. dyslipidemia, low
PT   high density lipoprotein or cardiovascular disorders.
XX
PS   Claim 3; SEQ ID NO 3855; 1007pp; English.
XX
CC   The present invention relates to antisense oligonucleotides (ADJ21603-
CC   ADJ25510) targeted to human Endothelial Lipase (EL) coding sequence
CC   (ADJ25517), where the antisense oligonucleotide specifically hybridises
CC   with and inhibits the expression of EL. The antisense oligonucleotides
CC   are useful for modulating the expression of endothelial lipase in cells
CC   or tissues to treat diseases associated with EL expression, such as
CC   dyslipidaemia, low high density lipoprotein (HDL), cardiovascular
CC   disorder or metabolic syndrome X. In addition, the oligonucleotides are
CC   used for diagnostics, prophylaxis, or as research reagents or kits.
XX
SQ   Sequence 20 BP; 12 A; 6 C; 0 G; 2 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 15.2;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 2.3e+02;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1339 GAGGTGGTTTGTGTATCTTA 1358
              |||||||||| ||| | |||
Db         20 GAGGTGGTTTTTGTTTTTTA 1


RESULT 162
ADK78855/c
ID   ADK78855 standard; DNA; 20 BP.
XX
AC   ADK78855;
XX
DT   20-MAY-2004  (first entry)
XX
DE   Chimeric phosphorothioate oligonucleotide to target Nav1.3 #6189.
XX
KW   Nav1.3; Analgesic; Nootropic; Neuroprotective; post-herpetic neuralgia;
KW   diabetic neuropathy; arthritic pain; migraine headache;
KW   infantile epilepsy; ataxia; ss.
XX
OS   Synthetic.
XX
PN   WO2004016754-A2.
XX
```

PD 26-FEB-2004.
XX
PF 14-AUG-2003; 2003WO-US025465.
XX
PR 14-AUG-2002; 2002US-0403416P.
XX
PA (PHAA) PHARMACIA CORP.
XX
PI Roberds SL;
XX
DR WPI; 2004-203785/19.
XX
PT New antisense compound targeted to a nucleic acid molecule encoding
PT Nav1.3, useful for useful for treating a disease or condition associated
PT with Nav1.3, e.g. pain, seizure disorder such as childhood seizure
PT disorder, or ataxia.
XX
PS Claim 4; SEQ ID NO 6189; 417pp; English.
XX
CC The present invention relates to an antisense compound targeted to a
CC nucleic acid molecule encoding Nav1.3, where the antisense compound
CC specifically hybridizes with and inhibits the expression of Nav1.3. The
CC compound and composition are useful for treating a disease or condition
CC associated with Nav1.3, e.g. pain including but not limited to
CC neuropathic pain, post-herpetic neuralgia, chronic pain, lower back pain,
CC diabetic neuropathy, trigeminal neuropathy, arthritic pain, acute pain,
CC pain from burns, migraine headache, cluster headache, mild-to-moderate
CC headache; seizure disorder such as childhood seizure disorder, including
CC but not limited to neonatal or infantile epilepsy; or ataxia. The present
CC sequence represents a chimeric phosphorothioate oligonucleotide with
CC 2'MOE wings and a deoxy gap. Used during the antisense inhibition of
CC human Nav1.3 expression, the oligonucleotides are designed to target
CC different regions of the human Nav1.3 RNA.
XX
SQ Sequence 20 BP; 10 A; 3 C; 4 G; 3 T; 0 U; 0 Other;

Query Match 0.9%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.3e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```
Qy       1185 AGCATGTACCTTATTATTTT 1204
              | ||||| ||||||| ||||
Db         20 ACCATGTGCCTTATTGTTTT 1
```

RESULT 163
ADL00781
ID ADL00781 standard; DNA; 20 BP.
XX
AC ADL00781;
XX
DT 20-MAY-2004 (first entry)
XX
DE Human VEGF co-regulated chemokine-1 DNA antisense oligonucleotide #314.
XX
KW Human; VEGF co-regulated chemokine-1; VCC-1;
KW vascular endothelial growth factor; ss; antisense compound;
KW phosphorothioate linkage; 2'-O-methoxyethyl sugar moiety;
KW 5-methylcytosine; antisense oligonucleotide; diabetes;
KW immunological disorder; cardiovascular disorder; neurological disorder;
KW ischaemia; reperfusion injury; cancer; angiogenic disorder; haemangioma;
KW tumour angiogenesis; rheumatoid arthritis; atherosclerosis; psoriasis;
KW fibrosis; myocardial infarction; wound healing; bone fracture;
KW cartilage damage; tissue regeneration; organ regeneration;
KW periodontal disease; gut regeneration; atrial fibrillation.
XX
OS Homo sapiens.
XX
PN WO2004016224-A2.
XX
PD 26-FEB-2004.
XX
PF 19-AUG-2003; 2003WO-US025891.
XX
PR 19-AUG-2002; 2002US-0404484P.
XX
PA (PHAA) PHARMACIA CORP.
XX
PI Weinstein EJ;
XX
DR WPI; 2004-192065/18.
XX
PT New antisense compounds targeted to a nucleic acid molecule encoding
PT vascular endothelial growth factor co-regulated chemokine-1 (VCC-1),
PT useful for treating VCC-1-associated disorders, e.g. diabetes or a
PT neurologic disorder.
XX
PS Claim 4; SEQ ID NO 314; 336pp; English.
XX
CC The invention relates to an antisense compound targeted to a nucleic acid
CC molecule encoding human vascular endothelial growth factor (VEGF) co-
CC regulated chemokine-1 (VCC-1), and which specifically hybridises with and
CC inhibits the expression of VCC-1. The invention also relates to a
CC composition comprising the antisense compound, a method of inhibiting the
CC expression of VCC-1 in cells or tissues comprising contacting the cells
CC or tissues with the antisense compound and a method of treating a human
CC having a disease or condition associated with VCC-1 comprising
CC administering the antisense compound to an animal to inhibit expression
CC of VCC-1. The antisense oligonucleotide comprises at least one modified
CC internucleoside linkage, preferably a phosphorothioate linkage. It also
CC comprises at least one modified sugar moiety, preferably a 2'-O-
CC methoxyethyl sugar moiety, and at least one modified nucleobase,
CC specifically a 5-methylcytosine. The antisense oligonucleotide preferably
CC is a chimeric oligonucleotide. The antisense compound is useful for
CC treating a disease or condition associated with VCC-1, such as diabetes,
CC an immunological disorder, a cardiovascular disorder, a neurological
CC disorder, ischaemia, reperfusion injury, cancer or an angiogenic
CC disorder, e.g. haemangioma, tumour angiogenesis, rheumatoid arthritis,
CC atherosclerosis, psoriasis or fibrosis after myocardial infarction. VCC-1
CC antisense oligonucleotides may also be used for wound healing, for
CC healing of bone fractures and cartilage damage, for regeneration of
CC tissues or organs, for treating periodontal diseases, for gut protection
CC or regeneration, for treatment of lung or liver fibrosis or for
CC management of atrial fibrillation. This sequence represents an antisense
CC oligonucleotide targeted to DNA encoding the human VCC-1 polypeptide of
CC the invention.
XX
SQ Sequence 20 BP; 5 A; 4 C; 6 G; 5 T; 0 U; 0 Other;

Query Match 0.9%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.3e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```
Qy        388 TGGACAGCAGCAACAGTGGC 407
              |||||| |||||  ||||||
Db          1 TGGACATCAGCATTAGTGGC 20
```

RESULT 164
ADN48788/c
ID ADN48788 standard; DNA; 20 BP.
XX
AC ADN48788;
XX
DT 15-JUL-2004 (first entry)
XX
DE Human Notch (Drosophila) homologue 4 antisense oligo ISIS 141629.
XX
KW Notch (Drosophila) homologue 4; hyperproliferative disorder; cancer;
KW rheumatoid arthritis; diabetes; prophylactic; infection; inflammation;
KW tumour formation; antisense therapy; human; antisense;
KW phosphorothioate backbone; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX

```
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate backbone where all cytidines are
FT                   5-methyl cytidines"
FT   modified_base   1. .5
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "2' -methoxyethyl (2' -MOE) nucleotide"
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "2' -methoxyethyl (2' -MOE) nucleotide"
XX
PN   US2004077569-A1.
XX
PD   22-APR-2004.
XX
PF   16-OCT-2002; 2002US-00273070.
XX
PR   16-OCT-2002; 2002US-00273070.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Watt AT;
XX
DR   WPI; 2004-340034/31.
XX
PT   New compound of 8-50 nucleobases in length which specifically hybridizes
PT   with and inhibits the expression of Notch (Drosophila) homolog 4, useful
PT   for treating cancer, rheumatoid arthritis or diabetes.
XX
PS   Example 15; SEQ ID NO 41; 66pp; English.
XX
CC   The present invention provides antisense okigonucleotides which are
CC   targeted to nucleic acid encoding human Notch (Drosophila) homologue 4
CC   and which modulate the expression Notch (Drosophila) homologue 4. The
CC   invention is useful for inhibiting the expression of Notch (Drosophila )
CC   homologue 4 in cells or tissues, in treating a disease or condition
CC   associated with Notch (Drosophila) homologue 4 which includes
CC   hyperproliferative disorder such as cancer, rheumatoid arthritis and
CC   diabetes and useful prophylactically to prevent or delay infection,
CC   inflammation and tumour formation. The invention is also useful in
CC   antisense therapy. The present sequence is human Notch (Drosophila)
CC   homologue 4 antisense oligonucleotide. This sequence is used in the
CC   exemplification of the invention.
XX
SQ   Sequence 20 BP; 3 A; 2 C; 9 G; 6 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 15.2;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 2.3e+02;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        608 ACTACTGCGCCTGGCCTACA 627
              || ||||| |||| ||||||
Db         20 ACAACTGCACCTGCCCTACA 1


RESULT 165
ADM16178/c
ID   ADM16178 standard; DNA; 20 BP.
XX
AC   ADM16178;
XX
DT   15-JUL-2004  (first entry)
XX
DE   Murine SAC1 DNA PCR primer #405.
XX
KW   Mouse; SAC1; PCR; ss; carbohydrate; sweetener; ethanol; obesity;
KW   diabetes; alcoholism; antidiabetic; alcohol; anorectic; antialcoholic;
KW   primer.
XX
OS   Mus musculus.
XX
PN   US2004081964-A1.
XX
PD   29-APR-2004.
XX
PF   25-OCT-2002; 2002US-00280183.
XX
PR   25-OCT-2002; 2002US-00280183.
XX
PA   (BACH/) BACHMANOV A A.
PA   (BEAU/) BEAUCHAMP G K.
PA   (LISS/) LI S.
PA   (LIXX/) LI X.
PA   (REED/) REED D R.
PA   (TORD/) TORDOFF M G.
PA   (ROSS/) ROSS D A.
PA   (OHMA/) OHMAN J D.
PA   (CHAT/) CHATTERJEE A.
PA   (DJON/) DE JONG P J.
XX
PI   Bachmanov AA,  Beauchamp GK,  Li S,  Li X,  Reed DR,  Tordoff MG;
PI   Ross DA,  Ohman JD,  Chatterjee A,  De Jong PJ;
XX
DR   WPI; 2004-340133/31.
XX
PT   New isolated polynucleotides for sensing carbohydrates, other sweeteners,
PT   or ethanol, useful for screening drugs for inhibition or restoration of
PT   gene function as antidiabetic, antiobesity or antialcohol consumption
PT   therapies.
XX
PS   Example 12; SEQ ID NO 448; 148pp; English.
XX
CC   The invention relates to SAC1 polypeptides and the polynucleotides
CC   encoding them. The polynucleotides contain a variation associated with
CC   sensing carbohydrates, other sweeteners or ethanol. The invention also
CC   relates to a method for analysing a biomolecule in a biological sample,
CC   comprising altering SAC1 activity in the sample and measuring the
CC   activity, a method for analysing a polynucleotide in a biological sample,
CC   comprising contacting a polynucleotide in a biological sample with a
CC   probe where the probe hybridises to a SAC1 polynucleotide to form a
CC   hybridisation complex and detecting the hybridisation complex, a method
CC   of identifying susceptibility to obesity or diabetes comprising comparing
CC   the nucleotide sequence of the suspected SAC1 allele with a wild type
CC   nucleotide sequence, where the difference between the suspected allele
CC   and the wild-type sequence identifies a sequence variation of the SAC1
CC   nucleotide sequence, and a method of treating or preventing obesity,
CC   diabetes or alcoholism associated with expression of SAC1, comprising
CC   administering to a subject a pharmaceutical composition and a transgenic
CC   animal that carries an altered SAC1 allele. The methods and compositions
CC   of the invention are useful for screening drugs for inhibition or
CC   restoration of gene function as antidiabetic, antiobesity or antialcohol
CC   consumption therapies and for identifying sweeteners and alcohols. This
CC   sequence represents a PCR primer used to amplify murine SAC1 DNA of the
CC   invention.
XX
SQ   Sequence 20 BP; 2 A; 9 C; 3 G; 6 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 15.2;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 2.3e+02;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        979 GAGACTAGAGGCAGGAGCTG 998
              ||||| ||||| ||| ||||
Db         20 GAGACCAGAGGAAGGTGCTG 1


RESULT 166
ADN58843
ID   ADN58843 standard; DNA; 20 BP.
XX
AC   ADN58843;
XX
```

```
DT   12-AUG-2004  (first entry)
XX
DE   Human B7H antisense oligonucleotide ISIS 205954.
XX
KW   B7H; autoimmune disease; ss; antisense; human.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   US2004102398-A1.
XX
PD   27-MAY-2004.
XX
PF   23-NOV-2002; 2002US-00303420.
XX
PR   23-NOV-2002; 2002US-00303420.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP,  Dobie KW;
XX
DR   WPI; 2004-399728/37.
XX
PT   New compound targeted to a nucleic acid molecule encoding B7H and
PT   inhibits expression of B7H, useful for modulating the expression of B7H
PT   or for diagnosing or treating, e.g. autoimmune disease.
XX
PS   Example 15; SEQ ID NO 94; 97pp; English.
XX
CC   The invention relates to a compound targeted to a nucleic acid molecule
CC   encoding B7H, where the compound specifically hybridises with the nucleic
CC   acid molecule encoding B7H and inhibits the expression of B7H. The
CC   compound is useful for modulating the expression of B7H. It is also
CC   useful for diagnosing or treating diseases associated with expression of
CC   B7H, e.g. an autoimmune disease. The present sequence represents a human
CC   B7H antisense oligonucleotide.
XX
SQ   Sequence 20 BP; 5 A; 9 C; 3 G; 3 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 15.2;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 2.3e+02;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1116 TACCCCTCAGTACTGTAGCA 1135
                ||||||||||  |||| | ||
Db          1 TACCCCTCAGCACTGGACCA 20


RESULT 167
ADP48323/c
ID   ADP48323 standard; DNA; 20 BP.
XX
AC   ADP48323;
XX
DT   09-SEP-2004  (first entry)
XX
DE   Human Lck DNA antisense oligonucleotide #16.
XX
KW   Human; lymphocyte specific tyrosine kinase; Lck; ss;
KW   antisense oligonucleotide; phosphorothioate linkage;
KW   2'-O-methoxyethyl sugar moiety; 5-methylcytosine;
KW   hyperproliferative disorder; cancer; cytostatic.
XX
OS   Homo sapiens.
XX
PN   US2004116365-A1.
XX
PD   17-JUN-2004.
XX
PF   10-DEC-2002; 2002US-00316515.
XX
PR   10-DEC-2002; 2002US-00316515.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Borchers AH,  Freier SM;
XX
DR   WPI; 2004-498280/47.
XX
PT   New antisense oligonucleotide compounds, useful for diagnosing,
PT   preventing and/or treating diseases or conditions associated with
PT   aberrant expression or activity of Lck, such as hyperproliferative
PT   disorders.
XX
PS   Example 15; SEQ ID NO 26; 40pp; English.
XX
CC   The invention relates to a compound targeted to a nucleic acid molecule
CC   encoding the human lymphocyte specific tyrosine kinase (Lck) polypeptide.
CC   The compound is an antisense oligonucleotide that specifically hybridises
CC   with the nucleic acid and inhibits expression of the polypeptide. The
CC   antisense oligonucleotide comprises at least one modified internucleoside
CC   linkage i.e. a phosphorothioate linkage, at least one modified sugar
CC   moiety, preferably a 2'-O-methoxyethyl sugar moiety, or at least one
CC   modified nucleobase comprising a 5-methylcytosine. The antisense
CC   compounds are useful for modulating the expression of the human Lck
CC   polypeptide and in preparation of a composition for treating
CC   hyperproliferative disorders, e.g. cancer. This sequence represents an
CC   antisense oligonucleotide targeted to DNA encoding a human Lck
CC   polypeptide of the invention.
XX
SQ   Sequence 20 BP; 3 A; 4 C; 6 G; 7 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 15.2;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 2.3e+02;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        501 AACCTGATGCAGCTGCTGCA 520
                |||||  |||  |||  ||||||
Db         20 AACCTCATGAAGCAGCTGCA 1


RESULT 168
ADQ80769
ID   ADQ80769 standard; DNA; 20 BP.
XX
AC   ADQ80769;
XX
DT   23-SEP-2004  (first entry)
XX
DE   Porcine IGF2 exon 5 UP-primer.
XX
KW   Anorectic; Antidiabetic; Muscular; Gene Therapy; CpG island;
KW   IGF2 gene intron 3; muscle mass; fat deposition; teat number; obesity;
KW   muscle deficiency; diabetes; PCR; primer; ss; pig.
XX
OS   Sus scrofa.
XX
PN   EP1437418-A1.
XX
PD   14-JUL-2004.
XX
PF   10-JAN-2003; 2003EP-00075091.
XX
PR   10-JAN-2003; 2003EP-00075091.
XX
PA   (UYLI-) UNIV LIEGE.
PA   (MELI-) MELICA HB.
PA   (GENT-) GENTEC BV.
XX
PI   Andersson L,  Andersson G,  Georges M,  Buys N;
XX
DR   WPI; 2004-501307/48.
XX
PT   Selecting an animal for desired genotypic or potential phenotypic
PT   properties such as muscle mass and/or fat deposition, comprises testing
PT   for a single nucleotide polymorphism in intron 3 of the IGF2 gene.
```

```
XX
PS   Example 1; Page 21; 38pp; English.
XX
CC   The present invention relates to a method (M1) for selecting an animal
CC   for having desired genotypic or potential phenotypic properties. (M1)
CC   comprises testing the animal for the presence of a nucleic acid
CC   modification affecting: the activity of an evolutionary conserved CpG
CC   island located in intron 3 of an IGF2 gene; and/or binding of a nuclear
CC   factor to an IGF2 gene. The nuclear factor is capable of binding to a
CC   stretch of nucleotides which in the wild type pig, mouse or human IGF2
CC   gene is part of an evolutionary conserved CpG island, located in intron 3
CC   of the IGF2 gene. The stretch is functionally equivalent to (ADQ80709).
CC   The nucleic acid modification in ADQ80709 comprises a G to A transition
CC   at IGF2-intron3-nt3072. (M1) is useful for selecting an animal with
CC   properties related to muscle mass, fat deposition, and/or teat number.
CC   Also claimed is a method (M2) for modulating mRNA transcription of an
CC   IGF2 gene by modulating the activity of an evolutionarily conserved CpG
CC   island located in intron 3 of an IGF2 gene and/or modulating binding of a
CC   nuclear factor to an IGF2 gene. Also claimed is a method (M3) for
CC   identifying a compound capable of modulating mRNA transcription of an
CC   IGF2 gene and a method (M4) for identifying a compound capable of
CC   modulating binding of a nuclear factor to an IGF2 gene. (M2) is useful
CC   for modulating mRNA transcription of an IGF2 gene in a cell or organism.
CC   (M3) and (M4) are useful for identifying compounds capable of modulating
CC   mRNA transcription of an IGF2 gene and/or modulating binding of a nuclear
CC   factor to an IGF2 gene. Compounds identified are potentially useful for
CC   treating obesity, muscle deficiencies and diabetes. The present sequence
CC   is a primer which was used to produce porcine sequence tagged sites (STS)
CC   in an example from the invention.
XX
SQ   Sequence 20 BP; 2 A; 12 C; 1 G; 5 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 15.2;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 2.3e+02;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        275 CTTGCCCCGAACTCCCACCC 294
              |||||| | ||||||| |||
Db          1 CTTGCCTCCAACTCCCTCCC 20


RESULT 169
AAF03309
ID   AAF03309 standard; DNA; 17 BP.
XX
AC   AAF03309;
XX
DT   16-FEB-2001  (first entry)
XX
DE   Hammerhead ribozyme substrate #1604.
XX
KW   Ribozyme; erythropoietin; granulocyte colony stimulating factor;
KW   interferon alpha; ss.
XX
OS   Homo sapiens.
XX
PN   WO200061729-A2.
XX
PD   19-OCT-2000.
XX
PF   11-APR-2000; 2000WO-US009721.
XX
PR   12-APR-1999;   99US-0129390P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Blatt L,  Zwick M,  Pavco P,  Mcswiggen J;
XX
DR   WPI; 2000-647423/62.
XX
PT   Enzymatic and antisense nucleic acid inhibition of repressor genes,
PT   useful for producing e.g. granulocyte colony stimulating factor protein,
PT   interferon alpha and erythropoietin.
XX
PS   Claim 37; Page 92; 164pp; English.
XX
CC   The present invention relates to enzymatic and antisense nucleic acid
CC   molecules that act as inhibitors of the expression of repressor genes
CC   encoding the TR2 Orphan receptor, EAR3/COUP-TF-1, the GATA transcription
CC   factor gene, IRF-2 and/or the CAATT Displacement Protein (CDP).
CC   Inhibition of the repressors removes prevents inhibition (and
CC   consequently increases expression of) genes involved in the production of
CC   erythropoietin, granulocyte colony stimulating factor protein and
CC   interferon alpha
XX
SQ   Sequence 17 BP; 4 A; 2 C; 7 G; 4 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 15;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 2.5e+02;
  Matches   15;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1099 TGTGCATTGGGGACA 1113
              |||||||||||||||
Db          2 TGTGCATTGGGGACA 16


RESULT 170
ADI38744/c
ID   ADI38744 standard; DNA; 20 BP.
XX
AC   ADI38744;
XX
DT   22-APR-2004  (first entry)
XX
DE   Human LIM domain kinase 1 antisense oligonucleotide #28.
XX
KW   neuroprotective; LIM domain kinase 1; developmental disorder;
KW   neurological disorder; diagnostic; prophylaxis; human; ss.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "OTHER= Phosphorothioate backbone. All cytidines
FT                   are 5-methylcytidines"
FT   modified_base   1. .5
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"
FT   modified_base   15. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"
XX
PN   US2004014047-A1.
XX
PD   22-JAN-2004.
XX
PF   18-JUL-2002; 2002US-00199199.
XX
PR   18-JUL-2002; 2002US-00199199.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Cowsert LM,  Dobie KW;
XX
DR   WPI; 2004-121553/12.
XX
PT   New antisense oligonucleotides for modulating LIM domain kinase 1
PT   expression, useful for diagnosing, preventing or treating conditions
PT   associated with the kinase, e.g. neurological or developmental disorders.
XX
PS   Example 15; SEQ ID NO 43; 81pp; English.
XX
```

```
CC   The invention describes a compound 8-80 nucleobases in length targeted to
CC   a nucleic acid molecule encoding LIM domain kinase 1. The compound
CC   specifically hybridises with the nucleic acid molecule encoding LIM
CC   domain kinase 1 and inhibits the expression of LIM domain kinase 1. It
CC   specifically hybridises with at least an 8-nucleobase portion of a
CC   preferred target region on the nucleic acid molecule encoding LIM domain
CC   kinase 1. The antisense oligonucleotide is useful for modulating the
CC   expression of LIM domain kinase 1 in cells or tissues to treat diseases
CC   associated with their expression, such as a developmental disorder or a
CC   neurological disorder. In addition, the compound is used for diagnostics,
CC   prophylaxis, or as research reagents or kits. This sequence represents a
CC   human LIM domain kinase 1 antisense oligonucleotide.
XX
SQ   Sequence 20 BP; 4 A; 4 C; 9 G; 3 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 15;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.5e+02;
  Matches   15;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        736 TCCAGCTGACCCTCG 750
              |||||||||||||||
Db         16 TCCAGCTGACCCTCG 2


RESULT 171
ADI38817
ID   ADI38817 standard; DNA; 20 BP.
XX
AC   ADI38817;
XX
DT   22-APR-2004  (first entry)
XX
DE   Human LIM domain kinase 1 antisense oligonucleotide #101.
XX
KW   neuroprotective; LIM domain kinase 1; developmental disorder;
KW   neurological disorder; diagnostic; prophylaxis; human; ss.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   modified_base    1. .20
FT                    /*tag=  b
FT                    /mod_base= OTHER
FT                    /note= "OTHER= Phosphorothioate backbone. All cytidines
FT                    are 5-methylcytidines"
FT   modified_base    1. .5
FT                    /*tag=  a
FT                    /mod_base= OTHER
FT                    /note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"
FT   modified_base    15. .20
FT                    /*tag=  c
FT                    /mod_base= OTHER
FT                    /note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"
XX
PN   US2004014047-A1.
XX
PD   22-JAN-2004.
XX
PF   18-JUL-2002; 2002US-00199199.
XX
PR   18-JUL-2002; 2002US-00199199.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Cowsert LM,  Dobie KW;
XX
DR   WPI; 2004-121553/12.
XX
PT   New antisense oligonucleotides for modulating LIM domain kinase 1
PT   expression, useful for diagnosing, preventing or treating conditions
PT   associated with the kinase, e.g. neurological or developmental disorders.
XX
PS   Example 15; SEQ ID NO 116; 81pp; English.
XX
CC   The invention describes a compound 8-80 nucleobases in length targeted to
CC   a nucleic acid molecule encoding LIM domain kinase 1. The compound
CC   specifically hybridises with the nucleic acid molecule encoding LIM
CC   domain kinase 1 and inhibits the expression of LIM domain kinase 1. It
CC   specifically hybridises with at least an 8-nucleobase portion of a
CC   preferred target region on the nucleic acid molecule encoding LIM domain
CC   kinase 1. The antisense oligonucleotide is useful for modulating the
CC   expression of LIM domain kinase 1 in cells or tissues to treat diseases
CC   associated with their expression, such as a developmental disorder or a
CC   neurological disorder. In addition, the compound is used for diagnostics,
CC   prophylaxis, or as research reagents or kits. This sequence represents a
CC   human LIM domain kinase 1 antisense oligonucleotide.
XX
SQ   Sequence 20 BP; 3 A; 9 C; 4 G; 4 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 15;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.5e+02;
  Matches   15;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        736 TCCAGCTGACCCTCG 750
              |||||||||||||||
Db          5 TCCAGCTGACCCTCG 19


RESULT 172
ADG16131
ID   ADG16131 standard; DNA; 24 BP.
XX
AC   ADG16131;
XX
DT   26-FEB-2004  (first entry)
XX
DE   Compound activity characterisation-related oligonucleotide SeqID6.
XX
KW   compound activity characterisation; cellular activity;
KW   phenotypic attribute; candidate medicine; candidate treatment;
KW   multiple biological descriptor; cell marker; ss.
XX
OS   Unidentified.
XX
PN   WO200181895-A2.
XX
PD   01-NOV-2001.
XX
PF   24-APR-2001; 2001WO-US013248.
XX
PR   26-APR-2000; 2000US-0199778P.
PR   20-FEB-2001; 2001US-00790214.
XX
PA   (CYTO-) CYTOKINETICS INC.
XX
PI   Oestreicher DR,  Sabry JH,  Adams CL,  Vaisberg EA,  Crompton AM;
XX
DR   WPI; 2002-041423/05.
XX
PT   Characterizing cellular activity of compound, by receiving images of
PT   cells with known activity and images of cells treated with compound,
PT   characterizing phenotypic attributes of images and comparing the
PT   phenotypes.
XX
PS   Disclosure; Fig 18; 139pp; English.
XX
CC   This invention relates to a novel method for the characterisation of the
CC   activity of a compound on cell. The method involves receiving images of
CC   cells with a cellular activity and images of other cells treated with the
CC   compound, quantitatively characterising phenotypic attributes of the
CC   image of cells with a cellular activity to produce a target phenotype for
CC   the cellular activity and that of the image of other cells to produce a
CC   second phenotype for the compound, and comparing the two phenotypes to
CC   determine whether the compound possesses cellular activity. The invention
CC   may be useful for characterising cellular activity of a compound, for
CC   determining information about properties of substances based upon the
```

```
CC   information about structure of living or non-living cells exposed to
CC   substances. The invention is also useful for identifying promising
CC   candidates in a search for new and better medicines and treatments using
CC   multiple biological descriptors from a single cell markers or components.
XX
SQ   Sequence 24 BP; 0 A; 1 C; 1 G; 22 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 15;  DB 1;  Length 24;
  Best Local Similarity   78.3%;  Pred. No. 2.4e+02;
  Matches   18;  Conservative    0;  Mismatches    5;  Indels    0;  Gaps    0;

Qy       1387 TGTTTGTTTTGTATCTTGTTTTT 1409
             | ||| |||| | | ||||||||
Db          2 TTTTTTTTTTTTTTTTGTTTTT 24


RESULT 173
ADO81152/c
ID   ADO81152 standard; DNA; 24 BP.
XX
AC   ADO81152;
XX
DT   29-JUL-2004  (first entry)
XX
DE   Prion protein polymorphic microsatellite marker consensus sequence #30.
XX
KW   gene typing; polymorphic microsatellite loci; PML;
KW   disease predisposition; microsatellite marker; prion disease;
KW   cystic fibrosis; malignant hyperthermia syndrome; metabolic disease;
KW   milk protein; hormone; transcription factor; pT7-blue-vector; sheep;
KW   microsatellite; ds.
XX
OS   Synthetic.
XX
PN   DE10236711-A1.
XX
PD   26-FEB-2004.
XX
PF   09-AUG-2002; 2002DE-01036711.
XX
PR   09-AUG-2002; 2002DE-01036711.
XX
PA   (UYHO-) UNIV HOHENHEIM.
XX
PI   Geldermann H,  Preuss S,  Han Y;
XX
DR   WPI; 2004-215730/21.
XX
PT   Typing genes that contain polymorphic microsatellite loci, useful for
PT   identifying predisposition to disease, by amplification and determining
PT   length of amplicons.
XX
PS   Claim 9; Page 50; 64pp; German.
XX
CC   The invention describes a method of typing (M1) a gene (I) that has one
CC   or more polymorphic microsatellite loci (PML). The method comprises: PCR
CC   amplification of at least one DNA region of (I) that includes PML, using
CC   as template a DNA sample containing at least one segment of (I); and
CC   determining the length of the resulting amplicon(s). Also described are:
CC   a method of determining (M2) microsatellite markers (MM) for
CC   predisposition to a disease, associated with a gene that includes one or
CC   more PML; and prediagnosis (M3) of diseases associated with gene that
CC   include PML. The method is used to identify microsatellite markers, in a
CC   disease-related gene, that are associated with a predisposition to
CC   diseases and for prediagnosis of such diseases, especially prion diseases
CC   but also cystic fibrosis, malignant hyperthermia syndrome in pigs and
CC   metabolic diseases; also to type genes that encode milk proteins,
CC   hormones or transcription factors. The method is simpler, quicker and
CC   particularly less expensive than known methods based on sequencing. This
CC   sequence represents a prion protein polymorphic microsatellite marker
CC   consensus sequence.
XX
SQ   Sequence 24 BP; 20 A; 4 C; 0 G; 0 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 15;  DB 1;  Length 24;
  Best Local Similarity   78.3%;  Pred. No. 2.4e+02;
  Matches   18;  Conservative    0;  Mismatches    5;  Indels    0;  Gaps    0;

Qy       1378 TGTGTTTGTTGTTTGTTTTGTAT 1400
             ||| |||||| ||  |||||| |
Db         24 TGTTTTTGTTTTTGTTTTTGTTT 2


RESULT 174
ACF79235
ID   ACF79235 standard; DNA; 25 BP.
XX
AC   ACF79235;
XX
DT   04-DEC-2003  (first entry)
XX
DE   Calix(a)arene-oligonucleotide hybrid.
XX
KW   Calix(4)arene; triplex; gene therapy; DNA sensor; ss.
XX
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   stem_loop       1. .25
FT                   /*tag=  a
FT   modified_base   13
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "OTHER= calix(4)arene nucleoside"
XX
PN   WO2003059925-A1.
XX
PD   24-JUL-2003.
XX
PF   19-JUN-2002; 2002WO-KR001160.
XX
PR   15-JAN-2002; 2002KR-00002316.
XX
PA   (POST-) POSTECH FOUND.
XX
PI   Kim BH,  Kim SJ;
XX
DR   WPI; 2003-627375/59.
XX
PT   New calix(4)arene-nucleoside hybrid useful in gene therapy has at least
PT   one nucleoside attached to a calix(4)arene group through amide bonding,
PT   and is derived from a calix(4)arene having amino groups.
XX
PS   Claim 7; Page 20; 16pp; English.
XX
CC   The present sequence is that of a calix(4)arene-oligonucleotide hybrid of
CC   the invention, which includes a calix(4)arene-nucleoside (preferably
CC   thymidine) derivative. The calix(4)arene-oligonucleotide hybrid functions
CC   as a DNA hairpin structure mimic. It effectively recognises DNA or RNA
CC   through triplex formation by bonding between the calix(4)arene-containing
CC   cavity and a biologically active substance. The hybrid has a certain
CC   level of both rigidity and flexibility, is stable in vivo, has high cell
CC   permeability and can be mass-produced. It can be used as a DNA sensor or
CC   for gene therapy
XX
SQ   Sequence 25 BP; 0 A; 0 C; 0 G; 24 T; 0 U; 1 Other;

  Query Match             0.9%;  Score 15;  DB 1;  Length 25;
  Best Local Similarity   75.0%;  Pred. No. 2.4e+02;
  Matches   18;  Conservative    0;  Mismatches    6;  Indels    0;  Gaps    0;

Qy       1386 TTGTTTGTTTTGTATCTTGTTTTT 1409
             || ||| |||| | | || ||||||
Db          2 TTTTTTTTTTTNTTTTTTTTTTT 25
```

```
RESULT 175
ABX12469
ID   ABX12469 standard; DNA; 27 BP.
XX
AC   ABX12469;
XX
DT   10-MAY-2003  (first entry)
XX
DE   Coxsackie B virus 4 (CBV-4) strain VD2921, PCR primer dT26V.
XX
KW   Coxsackie virus strain VD2921; diabetogenic coxsackie B virus-4; CBV-4;
KW   strain VD2921; VP1; VP2; VP3; VP4; P2A; P2B; P2C; P3A; P3B; P3C; P3D;
KW   diabetes; diabetogenic enterovirus; beta cell loss; blindness;
KW   renal failure; leg amputation; PCR; primer; ss.
XX
OS   Coxsackievirus.
XX
PN   WO2002103060-A2.
XX
PD   27-DEC-2002.
XX
PF   19-JUN-2002; 2002WO-IB003278.
XX
PR   20-JUN-2001; 2001SE-00002198.
XX
PA   (INNO-) INNOVENTUS PROJECT AB.
XX
PI   Tuvemo HT,  Frisk GE,  Yin H;
XX
DR   WPI; 2003-278229/27.
XX
PT   Polymerase chain reaction and primers for detecting nucleic acids from
PT   the diabetogenic coxsackie B virus-4 strain VD2921.
XX
PS   Example 5; Page 44; 79pp; English.
XX
CC   The invention describes a polymerase chain reaction (PCR) and primers for
CC   detecting nucleic acids from the diabetogenic coxsackie B virus-4 (CBV-4)
CC   strain VD2921, (particularly VP1, VP2, VP3, VP4, P2A, P2B, P2C, P3A, P3B,
CC   P3C and P3D nucleic acids). The methods and primers are used for the
CC   detection of CBV-4 strain VD2921 which is associated with diabetes
CC   (diabetogenic enterovirus). Early detection of the diabetes e.g.
CC   detection of diabetogenic enteroviral RNA in peripheral mononuclear
CC   cells, can improve prognosis by allowing treatment e.g. with antiviral
CC   drugs, to prevent further loss of beta cells and severe long term
CC   consequences of diabetes including blindness, renal failure and leg
CC   amputations. This sequence represents a primer used to determine the
CC   genomic structure of diabetogenic coxsackie B virus 4 (CBV-4) strain
CC   VD2921
XX
SQ   Sequence 27 BP; 0 A; 0 C; 0 G; 26 T; 0 U; 1 Other;

  Query Match             0.9%;  Score 15;  DB 1;  Length 27;
  Best Local Similarity   70.4%;  Pred. No. 2.4e+02;
  Matches   19;  Conservative    1;  Mismatches    7;  Indels    0;  Gaps    0;

Qy       1384 TGTTGTTTGTTTTGTATCTTGTTTTTC 1410
                | || ||| |||| | | || |||||:
Db          1 TTTTTTTTTTTTTTTTTTTTTTTTTTV 27


RESULT 176
AAX67192
ID   AAX67192 standard; RNA; 18 BP.
XX
AC   AAX67192;
XX
DT   20-JUL-1999  (first entry)
XX
DE   Human CD40 hairpin ribozyme target SEQ ID NO:3824.
XX
KW   Arthritic condition; graft tolerance; immune response; target; cleavage;
KW   hammerhead ribozyme; hairpin ribozyme; human; rabbit; mouse; collagenase;
KW   stromelysin; synovial membrane; joint; arthritis; osteoarthritis;
KW   rheumatoid arthritis; autoimmune disease; allergy; inflammation;
KW   diagnosis; ss.
XX
OS   Homo sapiens.
XX
PN   WO9618736-A2.
XX
PD   20-JUN-1996.
XX
PF   22-NOV-1995;   95WO-US015516.
XX
PR   13-DEC-1994;   94US-00354920.
PR   23-DEC-1994;   94US-00363253.
PR   23-DEC-1994;   94US-00363254.
PR   17-FEB-1995;   95US-00390850.
PR   20-APR-1995;   95US-00426124.
PR   02-MAY-1995;   95US-00432874.
PR   04-MAY-1995;   95US-00434509.
PR   07-JUL-1995;   95US-0000951P.
PR   07-JUL-1995;   95US-0000974P.
PR   07-AUG-1995;   95US-00512861.
PR   05-OCT-1995;   95US-00541365.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Beigelman L,  Stinchcomb DT,  Jarvis T,  Draper K,  Pavco P;
PI   Mcswiggen J,  Gustofson J,  Usman N,  Wincott F,  Matulic-Adamic J;
PI   Karpeisky A,  Thompson JD,  Modak A,  Burgin A;
XX
DR   WPI; 1996-300653/30.
XX
PT   Enzymatic nucleic acid molecules having a hammer-head motif - used for
PT   the treatment of arthritis, induction of graft tolerance or treatment of
PT   auto-immune diseases.
XX
PS   Claim 10; Page 218; 307pp; English.
XX
CC   The present invention describes a novel enzymatic nucleic acid (ENA)
CC   having a hammerhead motif (HM) comprising: (i) at least 5 ribose residues
CC   ; (ii) a 2'-C-allyl modification at position 4 of the ENA; (iii) at least
CC   ten 2'-O-methyl modifications; and (iv) a 3'-end modification. The ENA's
CC   can inhibit collagenase and stromelysin production in the synovial
CC   membrane of joints for the treatment or prevention of arthritis,
CC   particularly osteoarthritis or rheumatoid arthritis. The ENA's can also
CC   be used to treat antigen presenting cells of a donor to induce tolerance
CC   in a recipient to an alloantigen of a donor. They can also be used for
CC   enhancing graft tolerance or for treating autoimmune disease, and for
CC   treating allergies and other inflammatory conditions. The ENA's can also
CC   be used in diagnosis. Ribozyme therapy impacts on the expression of
CC   stromelysin without introducing the non-specific effects upon gene
CC   expression which accompany treatment with retinoids and dexamethasone.
CC   The concentration of ribozyme required to affect a therapeutic treatment
CC   is lower than that required of antisense molecules, and is highly
CC   specific. The present sequence is used in the exemplification of the
CC   present invention
XX
SQ   Sequence 18 BP; 1 A; 4 C; 8 G; 0 T; 5 U; 0 Other;

  Query Match             0.8%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   66.7%;  Pred. No. 2.7e+02;
  Matches   12;  Conservative    4;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        505 TGATGCAGCTGCTGCAGG 522
                :| :|| ||:||:|||||
Db          1 UGGUGCUGCUGCUGCAGG 18


RESULT 177
AAT76222
ID   AAT76222 standard; DNA; 18 BP.
XX
AC   AAT76222;
```

XX
DT 12-SEP-1997 (first entry)
XX
DE Human IL5 antisense oligonucleotide HUMIL5AS3.
XX
KW Asthma; airway epithelium; adenosine free; cystic fibrosis;
KW chronic obstructive pulmonary disease; bronchitis; interleukin; ss.
XX
OS Synthetic.
XX
PN WO9640162-A1.
XX
PD 19-DEC-1996.
XX
PF 06-JUN-1996; 96WO-US009306.
XX
PR 07-JUN-1995; 95US-00474497.
XX
PA (UYEC-) UNIV EAST CAROLINA.
XX
PI Nyce JW, Metzger WJ;
XX
DR WPI; 1997-051871/05.
XX
PT Treatment of airway diseases such as asthma - by topically applying
PT adenosine-free antisense oligo:nucleotide to airway epithelium of
PT subject.
XX
PS Claim 5; Page 31; 71pp; English.
XX
CC A method for treating airway disease in a subject has been produced,
CC which involves the topical administration of an essentially adenosine
CC free antisense oligonucleotide (ON) to the airway epithelium of the
CC subject. The present sequence is an antisense oligonucleotide HUMIL5AS3
CC specific for the human IL5. The method can be used to treat airway
CC diseases such as cystic fibrosis, asthma, chronic obstructive pulmonary
CC disease, bronchitis and other airway diseases characterised by an
CC inflammatory response. By eliminating adenosine from the antisense ON,
CC its liberation upon antisense degradation is prevented, thereby
CC preventing adenosine-induced bronchoconstriction in patients with hyper-
CC reactive airways
XX
SQ Sequence 18 BP; 0 A; 1 C; 3 G; 14 T; 0 U; 0 Other;

Query Match 0.8%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 2.7e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1381 GTTTGTTGTTTGTTTTGT 1398
|||| |||||||||| |
Db 1 GTTTTTTGTTTGTTTTCT 18

RESULT 178
AAX54018
ID AAX54018 standard; DNA; 18 BP.
XX
AC AAX54018;
XX
DT 05-JUL-1999 (first entry)
XX
DE Human IL-5 antisense oligonucleotide fragment.
XX
KW Antisense oligonucleotide; multiple target; antisense treatment;
KW impaired respiration; inflammation; lung disease;
KW pulmonary vasoconstriction; inflammation; allergic rhinitis;
KW acute asthma; allergy; asthma; impeded respiration;
KW respiratory distress syndrome; pain; cystic fibrosis;
KW pulmonary hypertension; pulmonary vasoconstriction; emphysema;
KW chronic obstructive pulmonary disease; leukemia; lymphoma; carcinoma;
KW colon cancer; breast cancer; lung cancer; pancreatic cancer;
KW hepatocellular carcinoma; kidney cancer; melanoma; hepatic metastasis;
KW prostate cancer; ss.
XX
OS Synthetic.
XX
PN WO9913886-A1.
XX
PD 25-MAR-1999.
XX
PF 17-SEP-1998; 98WO-US019419.
XX
PR 17-SEP-1997; 97US-0059160P.
PR 09-JUN-1998; 98US-00093972.
XX
PA (UYEC-) UNIV EAST CAROLINA.
XX
PI Nyce JW;
XX
DR WPI; 1999-229400/19.
XX
PT New antisense oligonucleotides used in treatment of, e.g. pulmonary
PT vasoconstriction.
XX
PS Disclosure; Page 49; 120pp; English.
XX
CC The specification describes antisense oligonucleotides (AAX52869-X55271)
CC directed against at least 2 mRNAs selected from target genes, coding and
CC non-coding regions of RNAs corresponding to target genes, gene initiation
CC codons, genomic flanking regions, intron-exon borders, the 5'-end, the 3'
CC -end and the juxta-section between coding and non-coding regions and all
CC segments of RNAs encoding proteins associated with one or more diseases,
CC conditions or mixtures. The antisense oligonucleotides may be derived
CC from sequences AAX55272-74. These multiple target oligonucleotides
CC (specifically AAX55180-271) can be used for the antisense treatment of
CC diseases and conditions. Typical diseases and conditions are those
CC associated with impaired respiration and inflammation, including lung
CC diseases, pulmonary vasoconstriction, inflammation, allergic rhinitis,
CC acute asthma, allergies, asthma, impeded respiration, respiratory
CC distress syndrome, pain, cystic fibrosis, pulmonary hypertension,
CC pulmonary vasoconstriction, emphysema, chronic obstructive pulmonary
CC disease (COPD), and cancers such as leukemias, lymphomas, carcinomas e.g.
CC colon cancer, breast cancer, lung cancer, pancreatic cancer,
CC hepatocellular carcinoma, kidney cancer, melanoma, hepatic metastases, as
CC well as all types of cancers which may metastasize or have metastasized
CC to the lungs, including breast and prostate cancer
XX
SQ Sequence 18 BP; 0 A; 1 C; 3 G; 14 T; 0 U; 0 Other;

Query Match 0.8%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 2.7e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1381 GTTTGTTGTTTGTTTTGT 1398
|||| |||||||||| |
Db 1 GTTTTTTGTTTGTTTTCT 18

RESULT 179
AAA33462
ID AAA33462 standard; DNA; 18 BP.
XX
AC AAA33462;
XX
DT 28-JUL-2000 (first entry)
XX
DE Low adenosine antisense oligonucleotide SEQ ID NO:1151.
XX
KW Human; adenosine receptor; low adenosine antisense oligonucleotide;
KW phosphorothioate; impaired respiration; inflammation; allergy;
KW allergic disease; bronchoconstriction; inhibitor; antiinflammatory;
KW antiallergic; antiasthmatic; cytostatic; analgesic; impaired airway;
KW lung disease; ischaemic condition; pulmonary vasoconstriction; asthma;
KW respiratory distress syndrome; pain; cystic fibrosis; emphysema;
KW pulmonary hypertension; chronic obstructive pulmonary disease; COPD;
KW cancer; leukaemia; lymphoma; carcinoma; metastasis; ss.

XX
OS Homo sapiens.
XX
PN WO200009525-A2.
XX
PD 24-FEB-2000.
XX
PF 03-AUG-1999; 99WO-US017712.
XX
PR 03-AUG-1998; 98US-0095212P.
XX
PA (UYEC-) UNIV EAST CAROLINA.
XX
PI Nyce JW;
XX
DR WPI; 2000-205971/18.
XX
PT New antisense oligonucleotides useful for treating e.g. pulmonary
PT vasoconstruction, inflammation, allergies, asthma, hypertension,
PT bronchitis, emphysema, respiratory distress syndrome, ischemia or
PT cancers.
XX
PS Claim 18; Page 409; 1343pp; English.
XX
CC The present invention describes a new composition comprising an antisense
CC oligonucleotide (ON) with low adenosine (up to 15%), which targets
CC nucleic acids involved in bronchoconstriction, allergies, and/or
CC inflammation. The ON can have antiinflammatory, antiallergic,
CC antiasthmatic, cytostatic and analgesic activities. The compositions are
CC useful for the treatment of diseases associated with inflammation,
CC impaired airways, including lung disease and diseases whose secondary
CC effects afflict the lungs of a subject. They can be used for treating
CC e.g. ischaemic conditions, pulmonary vasoconstriction, allergies, asthma,
CC impeded respiration, respiratory distress syndrome, pain, cystic
CC fibrosis, pulmonary hypertension, emphysema, chronic obstructive
CC pulmonary disease (COPD), and cancers such as leukaemias, lymphomas,
CC carcinomas, and cancers which may metastasise to the lungs, including
CC breast and prostate cancer. The reduction of the adenosine content of the
CC ONs reduces side effects. The A-containing ONs break down with the
CC release of deoxyadenosine which activates adenosine receptors causing
CC bronchoconstriction and inflammation. AAA32313 to AAA35312 represent the
CC nucleotide sequences given in the sequence listing from the present
CC invention, which correspond to SEQ ID NO:1 to 2815, and then the last 185
CC sequences are also called SEQ ID NO:1 to 185, but the sequences differ
CC from the previously named sequences. SEQ ID NO:11 to 1680 (AAA32323 to
CC AAA33992) are specifically claimed ONs from the present invention. N.B.
CC Sequences given in the disclosure of the present invention do not match
CC up with their corresponding SEQ ID NO: sequences given in the sequence
CC listing
XX
SQ Sequence 18 BP; 0 A; 1 C; 3 G; 14 T; 0 U; 0 Other;

Query Match 0.8%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 2.7e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1381 GTTTGTTGTTTGTTTTGT 1398
|||| |||||||||| |
Db 1 GTTTTTTGTTTGTTTTCT 18

RESULT 180
AAF19584
ID AAF19584 standard; DNA; 18 BP.
XX
AC AAF19584;
XX
DT 14-MAR-2001 (first entry)
XX
DE Human IL5 polynucleotide fragment #1151.
XX
KW Low adenosine antisense oligonucleotide; phosphorothioate; allergy;
KW human; airway disorder; bronchoconstriction; lung inflammation;
KW surfactant depletion; respiratory; bronchodilator; antiinflammatory;
KW immunosuppressive; antiasthmatic; analgesic; hypotensive; cytostatic;
KW respiratory obstruction; pulmonary obstruction; impeded respiration;
KW surfactant hypoproduction; pulmonary vasoconstriction; asthma; RDS;
KW respiratory distress syndrome; pain; cystic fibrosis; allergic rhinitis;
KW pulmonary hypertension; emphysema; pulmonary transplantation rejection;
KW chronic obstructive pulmonary disease; pulmonary infection; bronchitis;
KW cancer; ss.
XX
OS Homo sapiens.
XX
PN WO200062736-A2.
XX
PD 26-OCT-2000.
XX
PF 24-MAR-2000; 2000WO-US008020.
XX
PR 06-APR-1999; 99US-0127958P.
XX
PA (UYEC-) UNIV EAST CAROLINA.
PA (NYCE/) NYCE J W.
XX
PI Nyce JW;
XX
DR WPI; 2000-679539/66.
XX
PT Low adenosine (A) content antisense oligonucleotides which do not trigger
PT adenosine receptors during metabolism, useful e.g. for treating cancers
PT and respiratory obstructions.
XX
PS Claim 14; Page 208; 1592pp; English.
XX
CC The present invention describes low adenosine (A) content antisense
CC oligonucleotides and compositions (I) comprising them. In the antisense
CC oligonucleotides the A is replaced by a 'Universal' or alternative base.
CC (I) can have respiratory, bronchodilator, antiinflammatory, analgesic,
CC immunosuppressive, antiasthmatic, hypotensive and cytostatic activities.
CC The antisense oligonucleotides and (I) can be used to down-regulate the
CC expression and or activity of target polypeptides associated with
CC lung/respiratory disorders and malignancies, such as stimulating and
CC activating peptide factors and transmitters, transcription factors,
CC immunoglobulins and antibodies, antibody receptors, cytokines and
CC chemokines, endogenously produced specific and non-specific enzymes,
CC binding proteins, adhesion molecules and their receptors, cytokine and
CC chemokine receptors, adenosine receptors, bradykinin receptors, central
CC nervous system (CNS) and peripheral nervous and non-nervous system
CC receptors, CNS and peripheral nervous and non-nervous system peptide
CC transmitters, defensins, growth factors, vasoactive peptides and
CC receptors, binding proteins and malignancy associated proteins. The
CC antisense oligonucleotides may be used in this way to treat disorders
CC including respiratory obstruction (especially pulmonary obstruction
CC and/or bronchoconstriction) and/or lung inflammation, allergy(ies) and/or
CC surfactant hypoproduction which are associated with a disease or
CC condition selected from pulmonary vasoconstriction, inflammation,
CC allergies, asthma, impeded respiration, respiratory distress syndrome
CC (RDS), pain, cystic fibrosis (CF), allergic rhinitis (AR), pulmonary
CC hypertension, emphysema, chronic obstructive pulmonary disease (COPD),
CC pulmonary transplantation rejection, pulmonary infections, bronchitis,
CC and/or cancer. AAF18434 to AAF21543 represent human polynucleotide
CC fragments and antisense oligonucleotides used in the exemplification of
CC the present invention
XX
SQ Sequence 18 BP; 0 A; 1 C; 3 G; 14 T; 0 U; 0 Other;

Query Match 0.8%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 2.7e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1381 GTTTGTTGTTTGTTTTGT 1398
|||| |||||||||| |
Db 1 GTTTTTTGTTTGTTTTCT 18

RESULT 181
ABZ95278
ID ABZ95278 standard; DNA; 18 BP.
XX
AC ABZ95278;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human IL-5 antisense fragment no.1142.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-229219/22.
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 10520; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 18 BP; 0 A; 1 C; 3 G; 14 T; 0 U; 0 Other;

Query Match 0.8%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 2.7e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1381 GTTTGTTGTTTGTTTTGT 1398
||||.|||||||||||.|
Db 1 GTTTTTTGTTTGTTTCT 18

RESULT 182
ABZ97335/c
ID ABZ97335 standard; DNA; 18 BP.
XX
AC ABZ97335;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human IL4-R oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-229219/22.
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 12577; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 18 BP; 2 A; 6 C; 7 G; 3 T; 0 U; 0 Other;

Query Match 0.8%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 2.7e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 713 CGACCCCAGCCTGGTGCC 730
||| ||||||||||||||
Db 18 CGAGACCAGCCTGGTGCC 1

RESULT 183
ABD19252
ID ABD19252 standard; DNA; 18 BP.
XX
AC ABD19252;
XX
DT 29-JUL-2004 (first entry)
XX
DE Human IL5 DNA fragment 1142.
XX
KW Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
KW surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
KW pulmonary transplantation rejection; ds.
XX
OS Homo sapiens.
XX
PN WO200285309-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013143.
XX
PR 24-APR-2001; 2001US-0286036P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-093058/08.
XX
PT Pharmaceutical composition for treating asthma, has antisense
PT oligonucleotide containing less percentage of adenosine, targeted to
PT nucleic acids associated with lung airway or lung dysfunction, and
PT bronchodilating agent.
XX
PS Claim 15; SEQ ID NO 10520; 763pp; English.
XX
CC This invention describes a novel composition (a) a first active agent,
CC comprising oligonucleotides, effective for alleviating
CC bronchoconstriction, respiratory tract inflammation, allergies and
CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
CC surfactant depletion or hyposecretion, when administered to a mammal. The
CC oligonucleotides are derived from a gene encoding or regulating
CC expression of a target polypeptide associated with lung airway or lung
CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
CC The invention also describes a kit, that comprises: (a) a delivery
CC device, in separate containers, (b) the oligonucleotides, (c)
CC instructions for adding a carrier and for use of the kit. The composition
CC of the invention has antiallergic, antiinflammatory, antiasthmatic,
CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
CC beta-adrenergic agonist. The composition is useful for preventing or
CC treating a respiratory, lung or malignant disease. The administered
CC composition comprises oligo and is administered to reduce the production
CC or availability, or to increase the degradation of the target mRNA or to
CC reduce the amount of target polypeptide present in the lungs. The
CC pulmonary obstruction, and/or bronchoconstriction and/or lung
CC inflammation, allergies and/or surfactant hypoproduction are associated
CC with a disease or condition such as pulmonary vasoconstriction,
CC inflammation, allergies, asthma, impeded respiration, respiratory
CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
CC transplantation rejection, pulmonary infections, bronchitis or cancer.
CC The reduced adenosine content of the anti-sense oligos corresponding to
CC thymidines present in the target RNA serves to prevent the breakdown of
CC the oligonucleotides into products that free adenosine into the system
CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
CC prevent any unwanted effects due to it
XX
SQ Sequence 18 BP; 0 A; 1 C; 3 G; 14 T; 0 U; 0 Other;

Query Match 0.8%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 2.7e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1381 GTTTGTTGTTTGTTTTGT 1398
||||.||||||||||.|
Db 1 GTTTTTTGTTTGTTTTCT 18

RESULT 184
ABD30366/c
ID ABD30366 standard; DNA; 18 BP.
XX
AC ABD30366;
XX
DT 29-JUL-2004 (first entry)
XX
DE Human IL4-R derived oligonucleotide SEQ ID 12577.
XX
KW Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
KW surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
KW pulmonary transplantation rejection; ss; primer.
XX
OS Homo sapiens.
XX
PN WO200285309-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013143.
XX
PR 24-APR-2001; 2001US-0286036P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-093058/08.
XX
PT Pharmaceutical composition for treating asthma, has antisense
PT oligonucleotide containing less percentage of adenosine, targeted to
PT nucleic acids associated with lung airway or lung dysfunction, and
PT bronchodilating agent.
XX
PS Claim 15; SEQ ID NO 12577; 763pp; English.
XX
CC This invention describes a novel composition (a) a first active agent,
CC comprising oligonucleotides, effective for alleviating
CC bronchoconstriction, respiratory tract inflammation, allergies and
CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
CC surfactant depletion or hyposecretion, when administered to a mammal. The
CC oligonucleotides are derived from a gene encoding or regulating
CC expression of a target polypeptide associated with lung airway or lung
CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
CC The invention also describes a kit, that comprises: (a) a delivery
CC device, in separate containers, (b) the oligonucleotides, (c)
CC instructions for adding a carrier and for use of the kit. The composition
CC of the invention has antiallergic, antiinflammatory, antiasthmatic,
CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
CC beta-adrenergic agonist. The composition is useful for preventing or
CC treating a respiratory, lung or malignant disease. The administered
CC composition comprises oligo and is administered to reduce the production
CC or availability, or to increase the degradation of the target mRNA or to
CC reduce the amount of target polypeptide present in the lungs. The

```
CC   pulmonary obstruction, and/or bronchoconstriction and/or lung
CC   inflammation, allergies and/or surfactant hypoproduction are associated
CC   with a disease or condition such as pulmonary vasoconstriction,
CC   inflammation, allergies, asthma, impeded respiration, respiratory
CC   distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
CC   hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
CC   transplantation rejection, pulmonary infections, bronchitis or cancer.
CC   The reduced adenosine content of the anti-sense oligos corresponding to
CC   thymidines present in the target RNA serves to prevent the breakdown of
CC   the oligonucleotides into products that free adenosine into the system
CC   e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
CC   prevent any unwanted effects due to it
XX
SQ   Sequence 18 BP; 2 A; 6 C; 7 G; 3 T; 0 U; 0 Other;

  Query Match             0.8%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 2.7e+02;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        713 CGACCCCAGCCTGGTGCC 730
              |||  ||||||||||||||
Db         18 CGAGACCAGCCTGGTGCC 1


RESULT 185
ADJ59154/c
ID   ADJ59154 standard; DNA; 18 BP.
XX
AC   ADJ59154;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Oligonucleotide associated to IL 4R #9.
XX
KW   interleukin; IL-4 receptor; IL-5 receptor; lung disease;
KW   airway inflammation; allergy; asthma; impeded respiration;
KW   cystic fibrosis; acute respiratory distress syndrome;
KW   pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
KW   ss.
XX
OS   Homo sapiens.
XX
PN   WO2004011613-A2.
XX
PD   05-FEB-2004.
XX
PF   25-JUL-2003; 2003WO-US023509.
XX
PR   29-JUL-2002; 2002US-0399076P.
XX
PA   (EPIG-) EPIGENESIS PHARM INC.
XX
PI   Nyce JW,  Tang L,  Sandrasagra A,  Aguilar D,  Miller S;
PI   Shahabuddin S,  Lu H,  Cong H;
XX
DR   WPI; 2004-203534/19.
XX
PT   Novel single or multiple target oligonucleotide anti-sense to e.g.
PT   initiation codons and introns of respiratory disease-relevant genes e.g.,
PT   CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
PT   disease e.g., asthma.
XX
PS   Claim 2; SEQ ID NO 10; 85pp; English.
XX
CC   The present invention relates to an oligonucleotide anti-sense to e.g.,
CC   initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
CC   end of nucleic acid target comprising gene(s) chosen from e.g.
CC   interleukin (IL)-4 receptor, IL-5 receptor or salts of the
CC   oligonucleotide and optionally surfactant operatively linked to the
CC   oligonucleotide. The method is useful for preventing or treating a
CC   respiratory or lung disease, which involves administering to the airways
CC   of a subject an effective amount of an inhibitor. The oligonucleotide is
CC   useful for production of a medicament for the prevention and/or treatment
CC   of a respiratory or lung disease. The respiratory or lung disease is
CC   chosen from airway inflammation, allergy(ies), asthma, impeded
CC   respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
CC   (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
CC   (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
CC   obstruction. The present sequence represents an oligonucleotide of the
CC   invention.
XX
SQ   Sequence 18 BP; 2 A; 6 C; 7 G; 3 T; 0 U; 0 Other;

  Query Match             0.8%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 2.7e+02;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        713 CGACCCCAGCCTGGTGCC 730
              |||  ||||||||||||||
Db         18 CGAGACCAGCCTGGTGCC 1


RESULT 186
ADO44644/c
ID   ADO44644 standard; DNA; 18 BP.
XX
AC   ADO44644;
XX
DT   15-JUL-2004  (first entry)
XX
DE   Human oligonucleotide #10.
XX
KW   Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
KW   CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
KW   tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
KW   lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
KW   asthma; lung allergy; inflammation; inflammatory disease;
KW   airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
KW   chronic obstructive pulmonary disease; COPD; allergic rhinitis;
KW   acute respiratory distress syndrome; pulmonary hypertension;
KW   lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
XX
OS   Homo sapiens.
XX
PN   US2004049022-A1.
XX
PD   11-MAR-2004.
XX
PF   25-JUL-2003; 2003US-00627930.
XX
PR   23-APR-2002; 2002WO-US013135.
PR   23-APR-2002; 2002WO-US013143.
XX
PA   (NYCE/) NYCE J W.
PA   (SAND/) SANDRASAGRA A.
PA   (TANG/) TANG L.
PA   (AGUI/) AGUILAR D.
PA   (MILL/) MILLER S.
PA   (SHAH/) SHAHABUDDIN S.
PA   (LUHH/) LU H.
PA   (CONG/) CONG H.
XX
PI   Nyce JW,  Sandrasagra A,  Tang L,  Aguilar D,  Miller S;
PI   Shahabuddin S,  Lu H,  Cong H;
XX
DR   WPI; 2004-293804/27.
XX
PT   Novel single or multiple target oligonucleotide anti-sense to e.g.
PT   initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
PT   RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
PT   asthma.
XX
PS   Claim 2; SEQ ID NO 10; 174pp; English.
XX
CC   The invention relates to oligonucleotides anti-sense to an initiation
CC   codon, coding region, 5' or 3' intron-exon junction, intron or region
```

CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
CC also relates to a method of screening a candidate compound that binds to
CC one or more nucleic acid target(s) or expressed product(s), for the
CC prevention and/or treatment of a respiratory or lung disease. The
CC oligonucleotides are useful for reducing or inhibiting expression of a
CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
CC useful for preventing or treating a respiratory or lung disease. The
CC respiratory or lung disease is associated with hyper-responsiveness to
CC and/or increased levels of, adenosine and/or levels of adenosine A
CC receptor(s), and/or asthma and/or lung allergies associated with
CC inflammation or an inflammatory disease. The respiratory or lung disease
CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
CC hypertension, lung inflammation, bronchitis, airway obstruction or
CC bronchoconstriction. This sequence represents an oligonucleotide of the
CC invention.
XX
SQ Sequence 18 BP; 2 A; 6 C; 7 G; 3 T; 0 U; 0 Other;

Query Match 0.8%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 2.7e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 713 CGACCCCAGCCTGGTGCC 730
||| |||||||||||||
Db 18 CGAGACCAGCCTGGTGCC 1

RESULT 187
ADQ26950/c
ID ADQ26950 standard; DNA; 18 BP.
XX
AC ADQ26950;
XX
DT 09-SEP-2004 (first entry)
XX
DE Human myosin heavy chain MYH14 exon 1 PCR primer M1b-F.
XX
KW ss; human; non-muscle myosin-family heavy chain protein; MYH14;
KW chromosome 19q13.3; Charcot-Marie-Tooth syndrome; brain;
KW peripheral nerve; ovary; intestine; primer; PCR.
XX
OS Homo sapiens.
XX
PN DE10260633-A1.
XX
PD 24-JUN-2004.
XX
PF 16-DEC-2002; 2002DE-01060633.
XX
PR 16-DEC-2002; 2002DE-01060633.
XX
PA (RAUT/) RAUTENSTRAUSS B.
XX
PI Rautenstrauss B, Reis A, Leal A;
XX
DR WPI; 2004-469573/45.
XX
PT New isolated nucleic acid encoding the human myosin heavy chain protein
PT MYH14, useful for identifying mutations or alterations in nucleic acid,
PT derived from chromosome 19q 13.3.
XX
PS Disclosure; Page 4; 21pp; German.
XX
CC This invention describes a novel non-muscle, human myosin-family heavy
CC chain protein, designated MYH14 which maps to chromosome 19q13.3, a
CC region associated with Charcot-Marie-Tooth syndrome. MYH14 is associated
CC with brain, peripheral nerves, ovary and intestines and has closest
CC homology with the myosin family proteins MYH0, MYH10 and MHC11. The
CC product of the invention is used to identify mutations and alteration in
CC nucleic acids, by hybridisation. Computer-based comparison of the human
CC chromosomal 19q region with the rat sequence AF139055 (encoding a non-
CC muscle myosin heavy chain B) indicated a potential human homologue. A set
CC of exonic primers was designed and used to amplify cDNA derived from mRNA
CC isolated from the sciatic nerve. The 13 amplicons were sequenced and
CC assembled to form an approximately 6kb sequence that included an open
CC reading frame for MYH14, but lacked the polyadenylation signal. The
CC corresponding gene contains 40 exons (about 100 kb), entirely present
CC within the bacterial artificial chromosomes AC020906, AC010515 and
CC AC008655. The MYH14 protein corresponds to the hypothetical protein FLJ
CC 13881. This sequence represents a PCR primer used to amplify the human
CC MYH14 gene.
XX
SQ Sequence 18 BP; 6 A; 2 C; 10 G; 0 T; 0 U; 0 Other;

Query Match 0.8%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 2.7e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 257 CTCCTCTTCGCCCTCGTC 274
|||||| ||||| |||||
Db 18 CTCCTCCTCGCCTTCGTC 1

RESULT 188
AAZ22783
ID AAZ22783 standard; DNA; 19 BP.
XX
AC AAZ22783;
XX
DT 06-DEC-1999 (first entry)
XX
DE Rabbit alpha-actin 5' PCR primer.
XX
KW Asthma; immunoglobulin E; IgE; ligand; reverse transcriptase; PCR;
KW primer; Fc receptor; ss.
XX
OS Synthetic.
OS Oryctolagus cuniculus.
XX
PN WO9945777-A1.
XX
PD 16-SEP-1999.
XX
PF 03-MAR-1999; 99WO-US004571.
XX
PR 10-MAR-1998; 98US-0077398P.
XX
PA (CHIL-) CHILDRENS HOSPITAL PHILADELPHIA.
XX
PI Grunstein MM, Hakonarson H;
XX
DR WPI; 1999-571674/48.
XX
PT Treating asthma in humans by administering an Fc-epsilon-RII receptor
PT protein ligand.
XX
PS Example 1; Page 35; 84pp; English.
XX
CC THis sequence represents a rabbit alpha-actin 5' PCR primer, used with a
CC 3' primer (AAZ22784) in a control experiment to determine general
CC transcription levels in rabbit airway smooth muscle (ASM) cells. The
CC level of Fc receptor subtype mRNA expression in ASM cells was being
CC assessed, the ASM cells having previously been sensitised by exposure to
CC human serum containing immunoglobulin E (IgE) obtained from asthmatic
CC patients. The Fc receptor protein, which binds immunoglobulins and is
CC expressed on airway smooth muscle cells, plays a significant role in the
CC development of the asthmatic state in an individual having an asthma
CC attack. There are several subtypes of this receptor: Fc-gamma-RI; Fc-
CC gamma-RIIa, b, c; Fc-gamma-RIII; and Fc-epsilon-RII. Fc-epsilon-RII is an

```
CC   inducible, low affinity IgE receptor which was found to be upregulated in
CC   rabbit ASM cells on exposure to IgE. Antibodies directed against Fc-
CC   epsilon-RII can block the induction of the pro-inflammatory allergic
CC   pulmonary response. This could provide a method for the prevention or
CC   treatment of asthma by administering an anti-Fc-epsilon-RII receptor
CC   protein ligand (such as an antibody), and also for the identification and
CC   characterisation of such ligands
XX
SQ   Sequence 19 BP; 7 A; 4 C; 6 G; 2 T; 0 U; 0 Other;

  Query Match             0.8%;  Score 14.8;  DB 1;  Length 19;
  Best Local Similarity   88.9%;  Pred. No. 2.7e+02;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        864 GTCATCAAGAAGAAGCTG 881
              | ||||||| ||||||||
Db          2 GACATCAAGGAGAAGCTG 19


RESULT 189
AAA13267
ID   AAA13267 standard; cDNA; 19 BP.
XX
AC   AAA13267;
XX
DT   25-JUL-2000  (first entry)
XX
DE   PCR primer #2 used in GnRH-I and GnRH-II expression determination.
XX
KW   Gonadotrophin-releasing hormone; GnRH; differentiation modulator;
KW   osteoporosis; bone metabolism; bone repair; osteogenesis imperfecta;
KW   osteomalacia; bone loss; fracture healing; PCR primer; ss.
XX
OS   Synthetic.
XX
PN   GB2343182-A.
XX
PD   03-MAY-2000.
XX
PF   27-OCT-1998;   98GB-00023515.
XX
PR   27-OCT-1998;   98GB-00023515.
XX
PA   (FERR ) FERRING BV.
XX
PI   Akinsanya K,  Hayward A,  Qi S;
XX
DR   WPI; 2000-331495/29.
XX
PT   Composition containing gonadotropin-releasing hormone II peptide, useful
PT   e.g. for treating osteoporosis and for accelerating bone repair.
XX
PS   Example 4; Page 12; 16pp; English.
XX
CC   This sequence represents a PCR primer used in the expression
CC   determination of gonadotrophin-releasing hormone (GnRH) I and II. GnRH is
CC   released by the hypothalamus and acts on the pituitary to stimulate the
CC   release of lutenizing hormone and follicle stimulating hormone. GnRH is
CC   capable of modulating the differentiation of bone precursor cells, and
CC   inducing the expansion of osteoblast populations. The invention relates
CC   to GnRH-II peptide analogues that can be used in compositions for
CC   treating osteoporosis (and other diseases of bone metabolism) and for the
CC   acceleration of bone repair. The compositions have osteogenic activity.
CC   The compositions are used to treat or prevent osteoporosis, other
CC   disorders of bone metabolism (e.g. osteogenesis imperfecta, osteomalacia
CC   or bone loss resulting from prolonged periods of immobility), and to
CC   accelerate bone growth and repair (e.g. for healing fractures)
XX
SQ   Sequence 19 BP; 0 A; 5 C; 12 G; 2 T; 0 U; 0 Other;

  Query Match             0.8%;  Score 14.8;  DB 1;  Length 19;
  Best Local Similarity   88.9%;  Pred. No. 2.7e+02;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        536 GGCGCGGCTGGGCTCTCG 553
              |||| ||| |||||||||
Db          2 GGCGGGGCGGGGCTCTCG 19


RESULT 190
AAA84391
ID   AAA84391 standard; DNA; 19 BP.
XX
AC   AAA84391;
XX
DT   04-DEC-2000  (first entry)
XX
DE   Cyclin D3 ribozyme binding site #3.
XX
KW   Ribozyme; hairpin; hammerhead; gene therapy; vasotropic; restenosis; ss.
XX
OS   Mammalia.
XX
PN   WO200032765-A2.
XX
PD   08-JUN-2000.
XX
PF   06-DEC-1999;   99WO-US028772.
XX
PR   04-DEC-1998;   98US-0110954P.
XX
PA   (IMMU-) IMMUSOL INC.
XX
PI   Tritz R,  Welch PJ,  Barber JR,  Robbins JM;
XX
DR   WPI; 2000-412314/35.
XX
PT   New hairpin and hammerhead ribozyme for inhibiting restenosis, cleaves
PT   RNA encoding a cyclin or cell-cycle dependent kinase other than CDK1,
PT   PCNA and Cyclin B1.
XX
PS   Disclosure; Page 76; 109pp; English.
XX
CC   The present invention relates to a hairpin or hammerhead ribozyme,
CC   designed to cleave RNA encoding a cyclin or cell-cycle dependent kinase
CC   other than cell-cycle dependent kinases CDK1, PCNA and Cyclin B1.
CC   Representative examples of ribozyme recognition sites are given in
CC   AAA82415 to AAA86787. The ribozyme of the invention is useful for
CC   inhibiting restenosis by introduction of the ribozyme into cells. The
CC   ribozyme is resistant to endonuclease activity and hence is efficient in
CC   restenosis treatment
XX
SQ   Sequence 19 BP; 3 A; 7 C; 6 G; 3 T; 0 U; 0 Other;

  Query Match             0.8%;  Score 14.8;  DB 1;  Length 19;
  Best Local Similarity   88.9%;  Pred. No. 2.7e+02;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1556 CCATCGTGTACTGCAGAG 1573
              ||| ||||| ||||||||
Db          1 CCAGCGTGTCCTGCAGAG 18


RESULT 191
AAA85488
ID   AAA85488 standard; DNA; 19 BP.
XX
AC   AAA85488;
XX
DT   04-DEC-2000  (first entry)
XX
DE   Cyclin A1 ribozyme binding site #110.
XX
KW   Ribozyme; hairpin; hammerhead; gene therapy; vasotropic; restenosis; ss.
XX
OS   Mammalia.
```

XX
PN WO200032765-A2.
XX
PD 08-JUN-2000.
XX
PF 06-DEC-1999; 99WO-US028772.
XX
PR 04-DEC-1998; 98US-0110954P.
XX
PA (IMMU-) IMMUSOL INC.
XX
PI Tritz R, Welch PJ, Barber JR, Robbins JM;
XX
DR WPI; 2000-412314/35.
XX
PT New hairpin and hammerhead ribozyme for inhibiting restenosis, cleaves
PT RNA encoding a cyclin or cell-cycle dependent kinase other than CDK1,
PT PCNA and Cyclin B1.
XX
PS Disclosure; Page 93; 109pp; English.
XX
CC The present invention relates to a hairpin or hammerhead ribozyme,
CC designed to cleave RNA encoding a cyclin or cell-cycle dependent kinase
CC other than cell-cycle dependent kinases CDK1, PCNA and Cyclin B1.
CC Representative examples of ribozyme recognition sites are given in
CC AAA82415 to AAA86787. The ribozyme of the invention is useful for
CC inhibiting restenosis by introduction of the ribozyme into cells. The
CC ribozyme is resistant to endonuclease activity and hence is efficient in
CC restenosis treatment
XX
SQ Sequence 19 BP; 5 A; 0 C; 11 G; 3 T; 0 U; 0 Other;

Query Match 0.8%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 2.7e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1042 GGTGGAGGTGGGGGAATA 1059
||||||||| |||||| |
Db 1 GGTGGAGGTTGGGGAAGA 18

RESULT 192
AAA84248
ID AAA84248 standard; DNA; 19 BP.
XX
AC AAA84248;
XX
DT 04-DEC-2000 (first entry)
XX
DE Cyclin D1 ribozyme binding site #15.
XX
KW Ribozyme; hairpin; hammerhead; gene therapy; vasotropic; restenosis; ss.
XX
OS Mammalia.
XX
PN WO200032765-A2.
XX
PD 08-JUN-2000.
XX
PF 06-DEC-1999; 99WO-US028772.
XX
PR 04-DEC-1998; 98US-0110954P.
XX
PA (IMMU-) IMMUSOL INC.
XX
PI Tritz R, Welch PJ, Barber JR, Robbins JM;
XX
DR WPI; 2000-412314/35.
XX
PT New hairpin and hammerhead ribozyme for inhibiting restenosis, cleaves
PT RNA encoding a cyclin or cell-cycle dependent kinase other than CDK1,
PT PCNA and Cyclin B1.
XX
PS Disclosure; Page 74; 109pp; English.
XX
CC The present invention relates to a hairpin or hammerhead ribozyme,
CC designed to cleave RNA encoding a cyclin or cell-cycle dependent kinase
CC other than cell-cycle dependent kinases CDK1, PCNA and Cyclin B1.
CC Representative examples of ribozyme recognition sites are given in
CC AAA82415 to AAA86787. The ribozyme of the invention is useful for
CC inhibiting restenosis by introduction of the ribozyme into cells. The
CC ribozyme is resistant to endonuclease activity and hence is efficient in
CC restenosis treatment
XX
SQ Sequence 19 BP; 4 A; 3 C; 9 G; 3 T; 0 U; 0 Other;

Query Match 0.8%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 2.7e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 656 GCTGGACGTCTGCGTGGA 673
|||||| ||||||| |||
Db 1 GCTGGAGGTCTGCGAGGA 18

RESULT 193
AAH27311/c
ID AAH27311 standard; DNA; 19 BP.
XX
AC AAH27311;
XX
DT 08-AUG-2001 (first entry)
XX
DE Human TSG16 PCR primer #11.
XX
KW Tumour suppressor gene 16; TSG16; human; immune response modulator;
KW inflammatory response modulator; signal transduction activator;
KW cytokine inhibitor; gene therapy; anticancer; anti-inflammatory;
KW autoimmune disorder; infection; chromosome 16q24.3;
KW cellular proliferation suppressor; PCR primer; ss.
XX
OS Homo sapiens.
XX
PN WO200132861-A1.
XX
PD 10-MAY-2001.
XX
PF 30-OCT-2000; 2000WO-AU001329.
XX
PR 29-OCT-1999; 99AU-00003771.
XX
PA (WOME-) WOMEN'S & CHILDREN'S HOSPITAL.
XX
PI Callen DF, Whitmore SA, Kremmidiotis G, Kochetkova M, Crawford J;
XX
DR WPI; 2001-316439/33.
XX
PT New nucleic acid representing the human tumor suppressor gene TSG16,
PT useful e.g. for diagnosis and treatment of tumors, inflammatory and
PT immunological disorders.
XX
PS Claim 84; Page 184; 215pp; English.
XX
CC The present invention relates to human tumour suppressor gene 16 (TSG16;
CC see AAH23688). TSG16 was isolated from chromosome 16q24.3. TSG16
CC suppresses cellular proliferation. TSG16 is useful for treating disorders
CC associated with decreased expression or activity of TSG16, e.g. cancers,
CC (auto)immune disorders, inflammation, complications of wound healing and
CC infections (by viruses, bacteria, fungi, parasites, protozoa or
CC helminths). The present sequence is a PCR primer, which was used in the
CC present invention
XX
SQ Sequence 19 BP; 5 A; 4 C; 7 G; 3 T; 0 U; 0 Other;

Query Match 0.8%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 2.7e+02;

```
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        818 CCTCCCTGGCTTCAGCCA 835
              |||| |||||||||||| |
Db         19 CCTCACTGGCTTCAGCGA 2


RESULT 194
AAH59553
ID   AAH59553 standard; DNA; 19 BP.
XX
AC   AAH59553;
XX
DT   10-SEP-2001  (first entry)
XX
DE   Cyclin D3 ribozyme binding site SEQ ID NO:1977.
XX
KW   Human; ribozyme therapy; hairpin ribozyme; hammerhead ribozyme;
KW   recognition site; target; ribozyme binding site; eye disease; vulnerary;
KW   proliferative disease; skin disease; psoriasis; diabetic retinopathy;
KW   cytokine; inflammation; cell-cycle dependent kinase; cyclin; MMP;
KW   matrix metalloproteinase; growth factor; reductase; scarring; cytostatic;
KW   antipsoriatic; dermatological; antiseborrheic; antidiabetic; virucide;
KW   antisickling; ophthalmological; keratolytic; gene therapy; viral wart;
KW   atopic dermatitis; actinic keratosis; squamous cell carcinoma;
KW   basal cell carcinoma; seborrheic wart; vitreoretinopathy; scar;
KW   sickle cell retinopathy; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO200130362-A2.
XX
PD   03-MAY-2001.
XX
PF   26-OCT-2000; 2000WO-US029500.
XX
PR   26-OCT-1999;   99US-0161532P.
XX
PA   (IMMU-) IMMUSOL INC.
XX
PI   Robbins JM,  Tritz R;
XX
DR   WPI; 2001-300427/31.
XX
PT   Treating proliferative skin or eye diseases and scarring, using ribozymes
PT   that cleave RNA encoding cytokines involved in inflammation, matrix
PT   metalloproteinases, growth factors and cell-cycle dependent kinases.
XX
PS   Example 1; Page 215; 408pp; English.
XX
CC   The present invention describes a method for treating a proliferative
CC   skin or eye disease and scarring. The method involves administering a
CC   ribozyme (I) which cleaves RNA encoding a cytokine involved in
CC   inflammation, matrix metalloproteinase (MMP), cyclin, cell-cycle
CC   dependent kinase, growth factor or a reductase, or administering a
CC   nucleic acid molecule (II) comprising a promoter operably linked to a
CC   nucleic acid segment encoding (I). (I) can have antipsoriatic,
CC   dermatological, cytostatic, antiseborrheic, antidiabetic, antisickling,
CC   ophthalmological, vulnerary, keratolytic and virucide activities, and
CC   cleaves RNA encoding cytokine involved in inflammation. (I) can be used
CC   in gene therapy. (I) and (II) are useful for treating proliferative skin
CC   diseases such as psoriasis, atopic dermatitis, actinic keratosis,
CC   squamous or basal cell carcinoma and viral or seborrheic wart. They can
CC   also be used for treating proliferative eye diseases such as diabetic
CC   retinopathy, vitreoretinopathy, sickle cell retinopathy, retinopathy of
CC   prematurity and retinal detachment, and for treating and preventing
CC   scarring such as keloid, adhesion and hypertrophic or hypertrophic burn
CC   scar. AAH57577 to AAH62099 represent sequences used in the
CC   exemplification of the present invention
XX
SQ   Sequence 19 BP; 3 A; 7 C; 6 G; 3 T; 0 U; 0 Other;

  Query Match             0.8%;  Score 14.8;  DB 1;  Length 19;
  Best Local Similarity   88.9%;  Pred. No. 2.7e+02;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1556 CCATCGTGTACTGCAGAG 1573
              ||| ||||| ||||||||
Db          1 CCAGCGTGTCCTGCAGAG 18


RESULT 195
AAH60650
ID   AAH60650 standard; DNA; 19 BP.
XX
AC   AAH60650;
XX
DT   10-SEP-2001  (first entry)
XX
DE   Cyclin A1 ribozyme binding site SEQ ID NO:3074.
XX
KW   Human; ribozyme therapy; hairpin ribozyme; hammerhead ribozyme;
KW   recognition site; target; ribozyme binding site; eye disease; vulnerary;
KW   proliferative disease; skin disease; psoriasis; diabetic retinopathy;
KW   cytokine; inflammation; cell-cycle dependent kinase; cyclin; MMP;
KW   matrix metalloproteinase; growth factor; reductase; scarring; cytostatic;
KW   antipsoriatic; dermatological; antiseborrheic; antidiabetic; virucide;
KW   antisickling; ophthalmological; keratolytic; gene therapy; viral wart;
KW   atopic dermatitis; actinic keratosis; squamous cell carcinoma;
KW   basal cell carcinoma; seborrheic wart; vitreoretinopathy; scar;
KW   sickle cell retinopathy; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO200130362-A2.
XX
PD   03-MAY-2001.
XX
PF   26-OCT-2000; 2000WO-US029500.
XX
PR   26-OCT-1999;   99US-0161532P.
XX
PA   (IMMU-) IMMUSOL INC.
XX
PI   Robbins JM,  Tritz R;
XX
DR   WPI; 2001-300427/31.
XX
PT   Treating proliferative skin or eye diseases and scarring, using ribozymes
PT   that cleave RNA encoding cytokines involved in inflammation, matrix
PT   metalloproteinases, growth factors and cell-cycle dependent kinases.
XX
PS   Example 1; Page 295; 408pp; English.
XX
CC   The present invention describes a method for treating a proliferative
CC   skin or eye disease and scarring. The method involves administering a
CC   ribozyme (I) which cleaves RNA encoding a cytokine involved in
CC   inflammation, matrix metalloproteinase (MMP), cyclin, cell-cycle
CC   dependent kinase, growth factor or a reductase, or administering a
CC   nucleic acid molecule (II) comprising a promoter operably linked to a
CC   nucleic acid segment encoding (I). (I) can have antipsoriatic,
CC   dermatological, cytostatic, antiseborrheic, antidiabetic, antisickling,
CC   ophthalmological, vulnerary, keratolytic and virucide activities, and
CC   cleaves RNA encoding cytokine involved in inflammation. (I) can be used
CC   in gene therapy. (I) and (II) are useful for treating proliferative skin
CC   diseases such as psoriasis, atopic dermatitis, actinic keratosis,
CC   squamous or basal cell carcinoma and viral or seborrheic wart. They can
CC   also be used for treating proliferative eye diseases such as diabetic
CC   retinopathy, vitreoretinopathy, sickle cell retinopathy, retinopathy of
CC   prematurity and retinal detachment, and for treating and preventing
CC   scarring such as keloid, adhesion and hypertrophic or hypertrophic burn
CC   scar. AAH57577 to AAH62099 represent sequences used in the
CC   exemplification of the present invention
XX
```

```
SQ   Sequence 19 BP; 5 A; 0 C; 11 G; 3 T; 0 U; 0 Other;

  Query Match             0.8%;  Score 14.8;  DB 1;  Length 19;
  Best Local Similarity   88.9%;  Pred. No. 2.7e+02;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1042 GGTGGAGGTGGGGGAATA 1059
              ||||||||| |||||| |
Db          1 GGTGGAGGTTGGGGAAGA 18


RESULT 196
AAH59410
ID   AAH59410 standard; DNA; 19 BP.
XX
AC   AAH59410;
XX
DT   10-SEP-2001  (first entry)
XX
DE   Cyclin D1 ribozyme binding site SEQ ID NO:1834.
XX
KW   Human; ribozyme therapy; hairpin ribozyme; hammerhead ribozyme;
KW   recognition site; target; ribozyme binding site; eye disease; vulnerary;
KW   proliferative disease; skin disease; psoriasis; diabetic retinopathy;
KW   cytokine; inflammation; cell-cycle dependent kinase; cyclin; MMP;
KW   matrix metalloproteinase; growth factor; reductase; scarring; cytostatic;
KW   antipsoriatic; dermatological; antiseborrheic; antidiabetic; virucide;
KW   antisickling; ophthalmological; keratolytic; gene therapy; viral wart;
KW   atopic dermatitis; actinic keratosis; squamous cell carcinoma;
KW   basal cell carcinoma; seborrheic wart; vitreoretinopathy; scar;
KW   sickle cell retinopathy; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO200130362-A2.
XX
PD   03-MAY-2001.
XX
PF   26-OCT-2000; 2000WO-US029500.
XX
PR   26-OCT-1999;   99US-0161532P.
XX
PA   (IMMU-) IMMUSOL INC.
XX
PI   Robbins JM,  Tritz R;
XX
DR   WPI; 2001-300427/31.
XX
PT   Treating proliferative skin or eye diseases and scarring, using ribozymes
PT   that cleave RNA encoding cytokines involved in inflammation, matrix
PT   metalloproteinases, growth factors and cell-cycle dependent kinases.
XX
PS   Example 1; Page 205; 408pp; English.
XX
CC   The present invention describes a method for treating a proliferative
CC   skin or eye disease and scarring. The method involves administering a
CC   ribozyme (I) which cleaves RNA encoding a cytokine involved in
CC   inflammation, matrix metalloproteinase (MMP), cyclin, cell-cycle
CC   dependent kinase, growth factor or a reductase, or administering a
CC   nucleic acid molecule (II) comprising a promoter operably linked to a
CC   nucleic acid segment encoding (I). (I) can have antipsoriatic,
CC   dermatological, cytostatic, antiseborrheic, antidiabetic, antisickling,
CC   ophthalmological, vulnerary, keratolytic and virucide activities, and
CC   cleaves RNA encoding cytokine involved in inflammation. (I) can be used
CC   in gene therapy. (I) and (II) are useful for treating proliferative skin
CC   diseases such as psoriasis, atopic dermatitis, actinic keratosis,
CC   squamous or basal cell carcinoma and viral or seborrheic wart. They can
CC   also be used for treating proliferative eye diseases such as diabetic
CC   retinopathy, vitreoretinopathy, sickle cell retinopathy, retinopathy of
CC   prematurity and retinal detachment, and for treating and preventing
CC   scarring such as keloid, adhesion and hypertrophic or hypertrophic burn
CC   scar. AAH57577 to AAH62099 represent sequences used in the
CC   exemplification of the present invention
XX
SQ   Sequence 19 BP; 4 A; 3 C; 9 G; 3 T; 0 U; 0 Other;

  Query Match             0.8%;  Score 14.8;  DB 1;  Length 19;
  Best Local Similarity   88.9%;  Pred. No. 2.7e+02;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        656 GCTGGACGTCTGCGTGGA 673
              |||||| ||||||| |||
Db          1 GCTGGAGGTCTGCGAGGA 18


RESULT 197
ABK10370/c
ID   ABK10370 standard; DNA; 19 BP.
XX
AC   ABK10370;
XX
DT   21-MAY-2002  (first entry)
XX
DE   Rat Collagen I RT-PCR probe.
XX
KW   Vascular inflammation; cardiac tissue damage; inflammatory response;
KW   inflammation-related disorder; trauma induced inflammation;
KW   surgically induced inflammation; bacterial induced inflammation;
KW   viral induced inflammation; cardiovascular disorder; atherosclerosis;
KW   coronary artery disease; aneurysm; arteriosclerosis; angina;
KW   myocardial infarction; embolism; stroke; thrombosis; Kawasaki disease;
KW   vascular plaque inflammation; vascular plaque rupture; calcification;
KW   vascular calcification; valvar calcification; PCR; probe; ss;
KW   aldosterone blocker.
XX
OS   Rattus sp.
XX
PN   WO200209683-A2.
XX
PD   07-FEB-2002.
XX
PF   26-JUL-2001; 2001WO-US023520.
XX
PR   27-JUL-2000; 2000US-0221358P.
PR   12-JAN-2001; 2001US-0261352P.
XX
PA   (PHAA ) PHARMACIA CORP.
XX
PI   Rocha R,  Zack MD,  Mcmahon EG;
XX
DR   WPI; 2002-195909/25.
XX
PT   Treating or preventing an inflammation-related disorder e.g. coronary
PT   artery disease, aneurysm, arteriosclerosis and myocardial infarction,
PT   comprises treatment with an aldosterone blocker.
XX
PS   Example 18; Page 111; 210pp; English.
XX
CC   The invention relates to treating or preventing an inflammation-related
CC   disorder comprises treatment with an aldosterone blocker or its salts.
CC   Rats were treated with aldosterone in the presence of salt to induce
CC   vascular inflammation and cardiac tissue damage. The damage induced by
CC   the treatment was preceded by an inflammatory response characterised by
CC   upregulation of proinflammatory molecules. Administration of eplerenone
CC   markedly attenuated this initial vascular inflammatory response and
CC   subsequent myocardial infarction. The aldosterone blocker is used for
CC   treating or preventing inflammation-related disorders (occurring in
CC   tissue or organs), such as trauma induced inflammation, surgically
CC   induced inflammation, bacterial induced inflammation or viral induced
CC   inflammation, e.g. cardiovascular disorders (e.g. coronary artery
CC   disease, aneurysm, arteriosclerosis, atherosclerosis, myocardial
CC   infarction, embolism, stroke, thrombosis, angina, vascular plaque
CC   inflammation, vascular plaque rupture, Kawasaki disease, calcification
CC   (e.g. vascular calcification and valvar calcification) and inflammation)
CC   or cardiovascular disorder which occurs in whole or in part in the
```

```
CC   kidney, brain or heart. The present sequence is an RT-PCR (reverse
CC   transcriptase PCR) probe for a rat gene encoding a molecule involved in
CC   regulation of inflammation whose expression may be altered by
CC   administration of an aldosterone blocker. The probes are labelled at
CC   their 5' end with 6-carboxyfluorescein (6FAM) and 6-carboxy-N,N,N',N'-
CC   tetramethylrhodamine (TAMRA) at the 3' end
XX
SQ   Sequence 19 BP; 5 A; 3 C; 8 G; 3 T; 0 U; 0 Other;

  Query Match             0.8%;  Score 14.8;  DB 1;  Length 19;
  Best Local Similarity   88.9%;  Pred. No. 2.7e+02;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        736 TCCAGCTGACCCTCGTGC 753
              ||||||||||| || |||
Db         18 TCCAGCTGACCTTCCTGC 1


RESULT 198
AAI67970/c
ID   AAI67970 standard; DNA; 19 BP.
XX
AC   AAI67970;
XX
DT   13-MAR-2002  (first entry)
XX
DE   VEGF gene specific reverse primer.
XX
KW   VEGF; chromatin; cytostatic; vasotropic; antidiabetic; ophthalmological;
KW   antirheumatic; antiarthritic; antipsoriatic; anti-HIV; antisickling;
KW   neuroprotective; nootropic; cerebroprotective; antibacterial; fungicide;
KW   virucide; gene therapy; Veg 1; zinc finger; PCR primer; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO200183793-A2.
XX
PD   08-NOV-2001.
XX
PF   27-APR-2001; 2001WO-US040616.
XX
PR   28-APR-2000; 2000US-0200590P.
PR   28-AUG-2000; 2000US-0228523P.
XX
PA   (SANG-) SANGAMO BIOSCIENCES INC.
XX
PI   Wolffe AP,  Collingwood T;
XX
DR   WPI; 2002-075165/10.
XX
PT   Modification of chromatin structure for facilitating transcription,
PT   replication and repair, comprises contacting chromatin with fusion
PT   molecule comprising DNA binding domain and component of a chromatin
PT   remodeling complex.
XX
PS   Example 7; Page 77; 99pp; English.
XX
CC   The invention provides a method of modifying a region of interest in
CC   cellular chromatin that involves contacting the cellular chromatin with a
CC   fusion molecule that binds to a binding site in the region of interest,
CC   where the fusion molecule comprises a DNA binding domain and a component
CC   of a chromatin remodeling complex or its functional fragment, which
CC   modifies the region of interest. The method is useful for modifying a
CC   region of interest, in particular a gene encoding a product such as
CC   vascular endothelial growth factor, erythropoietin, androgen receptor,
CC   peroxisome proliferator-activated receptor (PPAR-gamma2), p16, p53, pRb,
CC   dystrophin and e-cadherin in cellular chromatin present in a plant,
CC   animal or human cell. The chromatin modification facilitates detection of
CC   sequence of interest comprising a single nucleotide polymorphism,
CC   activation or repression of a gene of interest or recombination between
CC   an exogenous nucleic acid and cellular chromatin. It also results in
CC   generation of an accessible region in the cellular chromatin which
CC   facilitates binding of an exogenous molecule such as polypeptides,
CC   nucleic acids, small molecule therapeutics, minor groove binders, major
CC   groove binders and intercalators (see ABB07125 for further uses of the
CC   fusion molecule and encoding polynucleotides). The present sequence
CC   represents a PCR primer specific for the VEGF gene
XX
SQ   Sequence 19 BP; 4 A; 9 C; 4 G; 2 T; 0 U; 0 Other;

  Query Match             0.8%;  Score 14.8;  DB 1;  Length 19;
  Best Local Similarity   88.9%;  Pred. No. 2.7e+02;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1322 GGAGGTCGGAGGTCGTGG 1339
              | || ||||||||||||||
Db         19 GTAGCTCGGAGGTCGTGG 2


RESULT 199
AAI72105/c
ID   AAI72105 standard; DNA; 19 BP.
XX
AC   AAI72105;
XX
DT   25-MAR-2002  (first entry)
XX
DE   VEGF reverse primer.
XX
KW   Target site; transcriptional effector protein; zinc finger domain; human;
KW   vascular endothelial growth factor; VEGF; cellular chromatin;
KW   gene expression; sequence-specific; DNA binding protein; phenotype;
KW   copy number; p53; cancer; gene function; primer; probe; ss.
XX
OS   Synthetic.
XX
PN   WO200183751-A2.
XX
PD   08-NOV-2001.
XX
PF   27-APR-2001; 2001WO-US013631.
XX
PR   28-APR-2000; 2000US-0200590P.
XX
PA   (SANG-) SANGAMO BIOSCIENCES INC.
XX
PI   Raschke E,  Wolffe AP,  Case CC;
XX
DR   WPI; 2002-066534/09.
XX
PT   Binding an exogenous molecule (EM) to a binding site located within a
PT   region of interest in chromatin, useful for modulating gene expression,
PT   by identifying an EM target site within an accessible region and
PT   introducing the EM into the cell.
XX
PS   Example 11; Page 30; 50pp; English.
XX
CC   The sequences given in AAI72104-11 are primers and probes which were used
CC   to analyse chromatin immunoprecipitates by hydrolyzable probe analysis,
CC   whereby the chromatin is immunoprecipitated after identification using
CC   the method of the invention. The method of the invention is for binding
CC   an exogenous molecule (EM) to a binding site (BS), where the BS is
CC   located within a region of interest in cellular chromatin. The method
CC   comprises identifying an accessible region within the region of interest,
CC   identifying a target site for the EM within the accessible region, and
CC   introducing the EM into the cell, where the EM binds to the BS. The
CC   method is useful for modulating gene expression by administering an
CC   exogenous molecule. The binding of an exogenous molecule to a binding
CC   site in cellular chromatin can be used for detection of a particular
CC   sequence, for example, an exogenous molecule, such as a sequence-specific
CC   DNA binding protein, can be used to detect variant alleles associated
CC   with a disease or with a particular phenotype in patient samples and to
CC   detect the presence of pathological microorganisms in clinical samples.
CC   Exogenous molecules can also be used to quantify copy number of a gene in
CC   a sample. For example, detection of the loss of one copy of a p53 gene in
```

```
CC   a clinical sample is an indicator of susceptibility to cancer. The
CC   methods can also be used in assays to determine gene function and to
CC   determine changes in phenotype resulting from specific modulation of gene
CC   expression
XX
SQ   Sequence 19 BP; 4 A; 9 C; 4 G; 2 T; 0 U; 0 Other;

  Query Match             0.8%;  Score 14.8;  DB 1;  Length 19;
  Best Local Similarity   88.9%;  Pred. No. 2.7e+02;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1322 GGAGGTCGGAGGTCGTGG 1339
              | || ||||||||||||||
Db         19 GTAGCTCGGAGGTCGTGG 2


RESULT 200
ABA95113/c
ID   ABA95113 standard; DNA; 19 BP.
XX
AC   ABA95113;
XX
DT   20-MAY-2002  (first entry)
XX
DE   Collagen I gene specific reverse primer.
XX
KW   Aldosterone; cyclooxygenase-2; cardiovascular; eplerenone; cardiant;
KW   vasotropic; antiarteriosclerotic; cerebroprotective; thrombolytic; rat;
KW   antianginal; antiinflammatory; vulnerary; antibacterial; virucide; ss;
KW   nephrotropic; collagen I; PCR primer.
XX
OS   Rattus sp.
XX
PN   WO200209759-A2.
XX
PD   07-FEB-2002.
XX
PF   26-JUL-2001; 2001WO-US023601.
XX
PR   27-JUL-2000; 2000US-0221364P.
PR   12-JAN-2001; 2001US-0261497P.
XX
PA   (PHAA ) PHARMACIA CORP.
XX
PI   Rocha R,  Zack MD,  Mcmahon EG;
XX
DR   WPI; 2002-227077/28.
XX
PT   Method for treating or preventing inflammation-related cardiovascular
PT   disorders comprises administration of an aldosterone antagonist and
PT   cyclooxygenase-2 inhibitor combination.
XX
PS   Example 18; Page 160; 273pp; English.
XX
CC   The invention provides a method for treating or preventing an
CC   inflammation-related cardiovascular disorder. The method involves
CC   administration of an aldosterone antagonist and cyclooxygenase-2
CC   inhibitor combination or their salts. The method is used to treat or
CC   prevent inflammation-related cardiovascular disorders in the heart,
CC   kidney and/or brain, e.g. coronary artery disease, aneurysm, embolism,
CC   arteriosclerosis, atherosclerosis, myocardial infarction, thrombosis,
CC   stroke, angina, vascular plaque inflammation, vascular plaque rupture,
CC   Kawasaki disease, vascular or valvar calcification, trauma-, surgically-,
CC   bacterial- or viral-induced inflammation. The use of eplerenone in
CC   conjunction with the aldosterone receptor antagonist markedly attenuates
CC   the initial vascular inflammatory response and subsequent myocardial
CC   injury. Sequences ABA95106-138 represent TaqMan primers and probes
CC   designed from known sequences of rat genes such as transforming growth
CC   factor beta 1 (TGFbeta1), atrial natriuretic factor (ANP), collagen I and
CC   III, cyclooxegenase-2 (COX-2), osteopontin, monocyte chemoattractant
CC   protein-1 (MCP-1), intercellular adhesion molecule-1 (ICAM-1), vascular
CC   adhesion molecule-1 (VCAM-1) and a reference cyclophilin, used in the
CC   course of the invention
XX
SQ   Sequence 19 BP; 5 A; 3 C; 8 G; 3 T; 0 U; 0 Other;

  Query Match             0.8%;  Score 14.8;  DB 1;  Length 19;
  Best Local Similarity   88.9%;  Pred. No. 2.7e+02;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        736 TCCAGCTGACCCTCGTGC 753
              ||||||||||| || |||
Db         18 TCCAGCTGACCTTCCTGC 1


RESULT 201
ADC18709/c
ID   ADC18709 standard; DNA; 19 BP.
XX
AC   ADC18709;
XX
DT   18-DEC-2003  (first entry)
XX
DE   Rat RT-PCR primer 11 used for amplification of Collagen I gene.
XX
KW   aldosterone receptor antagonist; non-steroidal anti-inflammatory drug;
KW   NSAID; cardiovascular disorder; inflammation; prostaglandin production;
KW   anti-inflammatory drug; ulcer;
KW   human arachidonic acid/prostaglandin pathway; cyclooxygenase; COX; COX-2;
KW   prostaglandin G/H synthase II; combination therapy; cardiovascular-gen;
KW   hypotensive; cardiant; antiarteriosclerotic; thrombolytic;
KW   cerebroprotective; antianginal; vasotropic; antiinflammatory;
KW   immunomodulator; dermatological; hypertension; heart failure;
KW   coronary artery disease; aneurysm; arteriosclerosis; atherosclerosis;
KW   myocardial infarction; embolism; stroke; thrombosis; angina;
KW   vascular plaque inflammation; vascular plaque rupture; Kawasaki disease;
KW   calcification; inflammation-related disorder; ss; rat; Collagen I;
KW   RT-PCR; reverse transcription PCR; PCR; primer.
XX
OS   Rattus sp.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "OTHER= Labelled with FAM (6-carboxyfluoroscein)"
FT   modified_base   19
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "OTHER= Labelled with TAMRA (6-carboxy-N,N,N',N'-
FT                   tetramethylrhodamine) quencher dye"
XX
PN   WO2003063908-A1.
XX
PD   07-AUG-2003.
XX
PF   30-JAN-2003; 2003WO-US002923.
XX
PR   30-JAN-2002; 2002US-0353008P.
XX
PA   (PHAA ) PHARMACIA CORP.
XX
PI   Mcmahon EG,  Rocha R;
XX
DR   WPI; 2003-697387/66.
XX
PT   Combination used for treating cardiovascular disorder e.g. hypertension
PT   comprises aldosterone receptor antagonist and non-steroidal
PT   antiinflammatory drug.
XX
PS   Disclosure; Page 75; 79pp; English.
XX
CC   This invention relates to an aldosterone receptor antagonist and a non-
CC   steroidal anti-inflammatory drug (NSAID) for use in the treatment of
CC   cardiovascular disorders. Prostaglandins play a major role in the
CC   inflammation process and the inhibition of prostaglandin production and
```

```
CC   have been the target of anti-inflammatory drug discovery. Common NSAIDs,
CC   however, are also active in other prostaglandin-regulated processes and
CC   can produce severe side-effects such as life-threatening ulcers. NSAIDS
CC   prevent prostaglandin production by inhibiting enzymes in the human
CC   arachidonic acid/prostaglandin pathway including cyclooxygenase (COX). A
CC   novel inducible enzyme associated with inflammation has been described,
CC   termed COX-2 or prostaglandin G/H synthase II, which is a novel target
CC   for drug therapy. It has been suggested that inflammation plays a role in
CC   cardiovascular disease. The present invention therefore proposes an
CC   aldosterone receptor antagonist and NSAID for the combination therapy
CC   treatment for cardiovascular disease. The invention may have
CC   cardiovascular-gen, hypotensive, cardiant, antiarteriosclerotic,
CC   thrombolytic, cerebroprotective, antianginal, vasotropic,
CC   antiinflammatory, immunomodulator or dermatological activities. The
CC   invention may be useful for the treatment of a cardiovascular disorder
CC   (for example hypertension, heart failure, coronary artery disease,
CC   aneurysm, arteriosclerosis, atherosclerosis, myocardial infarction,
CC   embolism, stroke, thrombosis, angina, vascular plaque inflammation,
CC   vascular plaque rupture, Kawasaki disease, calcification and
CC   inflammation) and inflammation-related disorders occurring in tissues or
CC   organs, for example heart, brain and kidney. The synergistic combination
CC   of aldosterone receptor antagonist and NSAID is effective and well
CC   tolerated during therapy. The present sequence is that of an RT-PCR
CC   primer which was used for amplification of the rat Collagen I gene during
CC   the exemplification of the invention.
XX
SQ   Sequence 19 BP; 5 A; 3 C; 8 G; 3 T; 0 U; 0 Other;

  Query Match             0.8%;  Score 14.8;  DB 1;  Length 19;
  Best Local Similarity   88.9%;  Pred. No. 2.7e+02;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        736 TCCAGCTGACCCTCGTGC 753
              |||||||||||  || |||
Db         18 TCCAGCTGACCTTCCTGC 1


RESULT 202
ADF71326
ID   ADF71326 standard; RNA; 19 BP.
XX
AC   ADF71326;
XX
DT   12-FEB-2004  (first entry)
XX
DE   Protein tyrosine phosphatase type IV (PRL3) gene siNA, SEQ ID No 111.
XX
KW   short interfering nucleic acid; siNA;
KW   protein tyrosine phosphatase type IV; PRL3; RNA interference; cytostatic;
KW   cancer; ss.
XX
OS   Homo sapiens.
XX
PN   WO2003070886-A2.
XX
PD   28-AUG-2003.
XX
PF   11-FEB-2003; 2003WO-US004347.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   06-JUN-2002; 2002US-0386782P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J,  Beigelman L,  Usman N;
XX
DR   WPI; 2003-697606/66.
XX
PT   New short interfering nucleic acid, useful e.g. for treatment and
PT   diagnosis of cancer , downregulates expression of a protein tyrosine
PT   phosphatase type IVa gene.
XX
PS   Example 3; SEQ ID NO 111; 131pp; English.
XX
CC   The invention relates to a novel short interfering nucleic acid (siNA)
CC   that downregulates expression of a protein tyrosine phosphatase type IV
CC   (PRL3) gene by RNA interference. The invention further relates to
CC   modulating the expression of PRL3 genes in cells, tissue explants or
CC   organisms by the introduction of an siNA; kits for in vitro or in vivo
CC   delivery of an siNA; conjugates and/or complexes of siNA; and vectors
CC   that express siNA. The novel siNA's of the invention have cytostatic
CC   activity. siNA's are used to modulate expression of PRL3 genes, in cells,
CC   tissue explants or organisms, e.g. for treating cancer but also for drug
CC   screening; diagnosis; target identification and validation; genetic
CC   engineering; pharmacogenomics; studying gene function and gene mapping
CC   (e.g. of single-nucleotide polymorphisms). This polynucleotide sequence
CC   represents a short interfering nucleic acid for downregulating the
CC   expression of a protein tyrosine phosphatase type IV (PRL3) gene of the
CC   invention.
XX
SQ   Sequence 19 BP; 2 A; 9 C; 8 G; 0 T; 0 U; 0 Other;

  Query Match             0.8%;  Score 14.8;  DB 1;  Length 19;
  Best Local Similarity   88.9%;  Pred. No. 2.7e+02;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        524 GAGCCTGGCCCAGGCGCG 541
              |||||  |||||||||  ||
Db          2 GAGCCCGGCCCAGGCCCG 19


RESULT 203
ADF71252/c
ID   ADF71252 standard; RNA; 19 BP.
XX
AC   ADF71252;
XX
DT   12-FEB-2004  (first entry)
XX
DE   Protein tyrosine phosphatase type IV (PRL3) gene siNA, SEQ ID No 37.
XX
KW   short interfering nucleic acid; siNA;
KW   protein tyrosine phosphatase type IV; PRL3; RNA interference; cytostatic;
KW   cancer; ss.
XX
OS   Homo sapiens.
XX
PN   WO2003070886-A2.
XX
PD   28-AUG-2003.
XX
PF   11-FEB-2003; 2003WO-US004347.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   06-JUN-2002; 2002US-0386782P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J,  Beigelman L,  Usman N;
XX
DR   WPI; 2003-697606/66.
XX
PT   New short interfering nucleic acid, useful e.g. for treatment and
PT   diagnosis of cancer , downregulates expression of a protein tyrosine
PT   phosphatase type IVa gene.
XX
```

```
PS   Example 3; SEQ ID NO 37; 131pp; English.
XX
CC   The invention relates to a novel short interfering nucleic acid (siNA)
CC   that downregulates expression of a protein tyrosine phosphatase type IV
CC   (PRL3) gene by RNA interference. The invention further relates to
CC   modulating the expression of PRL3 genes in cells, tissue explants or
CC   organisms by the introduction of an siNA; kits for in vitro or in vivo
CC   delivery of an siNA; conjugates and/or complexes of siNA; and vectors
CC   that express siNA. The novel siNA's of the invention have cytostatic
CC   activity. siNA's are used to modulate expression of PRL3 genes, in cells,
CC   tissue explants or organisms, e.g. for treating cancer but also for drug
CC   screening; diagnosis; target identification and validation; genetic
CC   engineering; pharmacogenomics; studying gene function and gene mapping
CC   (e.g. of single-nucleotide polymorphisms). This polynucleotide sequence
CC   represents a short interfering nucleic acid for downregulating the
CC   expression of a protein tyrosine phosphatase type IV (PRL3) gene of the
CC   invention.
XX
SQ   Sequence 19 BP; 0 A; 8 C; 9 G; 0 T; 2 U; 0 Other;

  Query Match             0.8%;  Score 14.8;  DB 1;  Length 19;
  Best Local Similarity   88.9%;  Pred. No. 2.7e+02;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        524 GAGCCTGGCCCAGGCGCG 541
              ||||| |||||||||| ||
Db         18 GAGCCCGGCCCAGGCCCG 1


RESULT 204
ADF75525
ID   ADF75525 standard; RNA; 19 BP.
XX
AC   ADF75525;
XX
DT   26-FEB-2004  (first entry)
XX
DE   Sense siNA that down regulates human PTP-1B expression (SeqID 66).
XX
KW   human; ss; siRNA; short interfering nucleic acid; siNA;
KW   protein tyrosine phosphatase-1B; PTP-1B; RNA interference; RNAi;
KW   micro-RNA; miRNA; short hairpin RNA; shRNA; gene silencing; antisense;
KW   obesity; insulin resistance; diabetes; anorectic; antidiabetic.
XX
OS   Homo sapiens.
XX
PN   WO2003070881-A2.
XX
PD   28-AUG-2003.
XX
PF   11-FEB-2003; 2003WO-US004123.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   06-JUN-2002; 2002US-0386782P.
PR   26-JUL-2002; 2002US-00206705.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J,  Beigelman L,  Usman N;
XX
DR   WPI; 2003-697604/66.
XX
PT   New short interfering nucleic acid, useful e.g. for treatment and
PT   diagnosis of obesity, downregulates expression of a protein tyrosine
PT   phosphatase-1B gene.
XX
PS   Example 3; SEQ ID NO 66; 140pp; English.
XX
CC   This invention relates to novel short interfering nucleic acid (siNA)
CC   molecules that downregulate expression of a protein tyrosine phosphatase-
CC   1B (PTP-1B) gene by RNA interference (RNAi). Specifically, the siNAs can
CC   be short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA
CC   (miRNA) or short hairpin RNA (shRNA), all of which can mediate inhibition
CC   of PTP-1B. The present invention describes sequence-specific post-
CC   trancriptional gene silencing in animals using siNA molecules and
CC   antisense oligonucleotides to modulate PTP-1B gene expression or
CC   activity. Furthermore, these siNA molecules provide useful reagents for a
CC   variety of therapeutic and diagnostic purposes, and as such can be used
CC   for treating obesity, insulin resistance or diabetes (types I and II), as
CC   well as for drug screening, target identification and validation, genetic
CC   engineering, pharmacogenomics and for studying gene function and gene
CC   mapping (for example of single-nucleotide polymorphisms). Accordingly,
CC   these molecules exhibit anorectic and antidiabetic activities. This
CC   oligonucleotide sequence is a sense siNA molecule that targets human PTP-
CC   1B RNA of the invention.
XX
SQ   Sequence 19 BP; 6 A; 3 C; 8 G; 0 T; 2 U; 0 Other;

  Query Match             0.8%;  Score 14.8;  DB 1;  Length 19;
  Best Local Similarity   83.3%;  Pred. No. 2.7e+02;
  Matches   15;  Conservative    1;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1275 GGGTGAAGGAAGAGGCAC 1292
              |||:|||||||||| | |
Db          2 GGGUGAAGGAAGAGACCC 19


RESULT 205
ADF75710/c
ID   ADF75710 standard; RNA; 19 BP.
XX
AC   ADF75710;
XX
DT   26-FEB-2004  (first entry)
XX
DE   Antisense siNA that down regulates human PTP-1B expression (SeqID 251).
XX
KW   human; ss; siRNA; short interfering nucleic acid; siNA;
KW   protein tyrosine phosphatase-1B; PTP-1B; RNA interference; RNAi;
KW   micro-RNA; miRNA; short hairpin RNA; shRNA; gene silencing; antisense;
KW   obesity; insulin resistance; diabetes; anorectic; antidiabetic;
KW   antisense.
XX
OS   Homo sapiens.
XX
PN   WO2003070881-A2.
XX
PD   28-AUG-2003.
XX
PF   11-FEB-2003; 2003WO-US004123.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   06-JUN-2002; 2002US-0386782P.
PR   26-JUL-2002; 2002US-00206705.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J,  Beigelman L,  Usman N;
XX
DR   WPI; 2003-697604/66.
XX
PT   New short interfering nucleic acid, useful e.g. for treatment and
PT   diagnosis of obesity, downregulates expression of a protein tyrosine
PT   phosphatase-1B gene.
XX
PS   Example 3; SEQ ID NO 251; 140pp; English.
```

```
XX
CC   This invention relates to novel short interfering nucleic acid (siNA)
CC   molecules that downregulate expression of a protein tyrosine phosphatase-
CC   1B (PTP-1B) gene by RNA interference (RNAi). Specifically, the siNAs can
CC   be short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA
CC   (miRNA) or short hairpin RNA (shRNA), all of which can mediate inhibition
CC   of PTP-1B. The present invention describes sequence-specific post-
CC   trancriptional gene silencing in animals using siNA molecules and
CC   antisense oligonucleotides to modulate PTP-1B gene expression or
CC   activity. Furthermore, these siNA molecules provide useful reagents for a
CC   variety of therapeutic and diagnostic purposes, and as such can be used
CC   for treating obesity, insulin resistance or diabetes (types I and II), as
CC   well as for drug screening, target identification and validation, genetic
CC   engineering, pharmacogenomics and for studying gene function and gene
CC   mapping (for example of single-nucleotide polymorphisms). Accordingly,
CC   these molecules exhibit anorectic and antidiabetic activities. This
CC   oligonucleotide sequence is an antisense siNA molecule that targets human
CC   PTP-1B RNA of the invention.
XX
SQ   Sequence 19 BP; 2 A; 8 C; 3 G; 0 T; 6 U; 0 Other;

  Query Match              0.8%;  Score 14.8;  DB 1;  Length 19;
  Best Local Similarity   88.9%;  Pred. No. 2.7e+02;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1275 GGGTGAAGGAAGAGGCAC 1292
              ||||||||||||||| | |
Db         18 GGGTGAAGGAAGAGACCC 1


RESULT 206
ADF84165/c
ID   ADF84165 standard; RNA; 19 BP.
XX
AC   ADF84165;
XX
DT   26-FEB-2004  (first entry)
XX
DE   Human breakpoint cluster region-targeted siRNA - SEQ ID 459.
XX
KW   short interfering nucleic acid; siNA; breakpoint cluster region;
KW   v-abl Abelson murine leukaemia viral oncogene homologue 1; BCR-ABL;
KW   cytostatic; leukaemia; lymphoma; human; BCR; ss; siRNA.
XX
OS   Homo sapiens.
XX
PN   WO2003070972-A2.
XX
PD   28-AUG-2003.
XX
PF   20-FEB-2003; 2003WO-US005234.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   06-JUN-2002; 2002US-0386782P.
PR   15-AUG-2002; 2002US-0404039P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   14-JAN-2003; 2003US-0439922P.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J,  Beigelman L,  Chowrira B;
XX
DR   WPI; 2003-679889/64.
XX
PT   New double-stranded interfering nucleic acid, useful e.g. for treatment
PT   and diagnosis of leukemia and lymphoma, downregulates the breakpoint
PT   cluster region-Abelson (BCR-ABL) gene.
XX
PS   Example 7; SEQ ID NO 459; 197pp; English.
XX
CC   The invention relates to a novel double-stranded short interfering
CC   nucleic acid (siNA) that downregulates expression of the breakpoint
CC   cluster region-v-abl Abelson murine leukaemia viral oncogene homologue 1
CC   (BCR-ABL) gene. The siRNA of the invention demonstrates cytostatic
CC   activity and may be useful for modulating expression of the BCR-ABL gene,
CC   as well as for treating leukaemia or lymphoma and in diagnosis, drug
CC   screening, target identification and validation, genetic engineering,
CC   gene function studies and gene mapping. The current sequence is that of
CC   the human BCR-targeted siRNA of the invention.
XX
SQ   Sequence 19 BP; 2 A; 6 C; 6 G; 0 T; 5 U; 0 Other;

  Query Match              0.8%;  Score 14.8;  DB 1;  Length 19;
  Best Local Similarity   88.9%;  Pred. No. 2.7e+02;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        943 GCCCTCCAAGACAGAGAC 960
              ||||| || |||||||||
Db         19 GCCCTGCAGGACAGAGAC 2


RESULT 207
ADF83902
ID   ADF83902 standard; RNA; 19 BP.
XX
AC   ADF83902;
XX
DT   26-FEB-2004  (first entry)
XX
DE   Human breakpoint cluster region-targeted siRNA - SEQ ID 196.
XX
KW   short interfering nucleic acid; siNA; breakpoint cluster region;
KW   v-abl Abelson murine leukaemia viral oncogene homologue 1; BCR-ABL;
KW   cytostatic; leukaemia; lymphoma; human; BCR; ss; siRNA.
XX
OS   Homo sapiens.
XX
PN   WO2003070972-A2.
XX
PD   28-AUG-2003.
XX
PF   20-FEB-2003; 2003WO-US005234.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   06-JUN-2002; 2002US-0386782P.
PR   15-AUG-2002; 2002US-0404039P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   14-JAN-2003; 2003US-0439922P.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J,  Beigelman L,  Chowrira B;
XX
DR   WPI; 2003-679889/64.
XX
PT   New double-stranded interfering nucleic acid, useful e.g. for treatment
PT   and diagnosis of leukemia and lymphoma, downregulates the breakpoint
PT   cluster region-Abelson (BCR-ABL) gene.
XX
PS   Example 7; SEQ ID NO 196; 197pp; English.
XX
CC   The invention relates to a novel double-stranded short interfering
CC   nucleic acid (siNA) that downregulates expression of the breakpoint
CC   cluster region-v-abl Abelson murine leukaemia viral oncogene homologue 1
CC   (BCR-ABL) gene. The siRNA of the invention demonstrates cytostatic
CC   activity and may be useful for modulating expression of the BCR-ABL gene,
CC   as well as for treating leukaemia or lymphoma and in diagnosis, drug
CC   screening, target identification and validation, genetic engineering,
```

```
CC   gene function studies and gene mapping. The current sequence is that of
CC   the human BCR-targeted siRNA of the invention.
XX
SQ   Sequence 19 BP; 5 A; 6 C; 6 G; 0 T; 2 U; 0 Other;

  Query Match             0.8%;  Score 14.8;  DB 1;  Length 19;
  Best Local Similarity   83.3%;  Pred. No. 2.7e+02;
  Matches   15;  Conservative    1;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        943 GCCCTCCAAGACAGAGAC 960
              ||||: || |||||||||
Db          1 GCCCUGCAGGACAGAGAC 18


RESULT 208
ADH16211
ID   ADH16211 standard; RNA; 19 BP.
XX
AC   ADH16211;
XX
DT   11-MAR-2004  (first entry)
XX
DE   Human BACE transcript target sequence/siNA upper strand, SEQ ID NO:1.
XX
KW   RNA interference; short interfering nucleic acid; siNA;
KW   short interfering RNA; siRNA; double-stranded RNA; micro-RNA; miRNA;
KW   short hairpin RNA; shRNA; expression modulation; gene therapy;
KW   drug screening; diagnosis; therapeutic target identification;
KW   pharmacogenomics; gene function analysis; gene mapping;
KW   Alzheimer's disease; dementia; stroke; cardiovascular accident;
KW   beta-secretase; BACE; human; target sequence; ss.
XX
OS   Homo sapiens.
XX
PN   WO2003070895-A2.
XX
PD   28-AUG-2003.
XX
PF   18-FEB-2003; 2003WO-US004710.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   06-JUN-2002; 2002US-0386782P.
PR   25-JUL-2002; 2002US-00205309.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J,  Beigelman L;
XX
DR   WPI; 2003-697608/66.
XX
PT   New short interfering nucleic acids, useful e.g. for treatment and
PT   diagnosis of Alzheimer's disease, which down regulates expression of the
PT   beta-secretase gene.
XX
PS   Example 3; SEQ ID NO 1; 144pp; English.
XX
CC   The invention relates to short interfering nucleic acids (siNA) which
CC   downregulate expression of the human beta-secretase (BACE) gene by RNA
CC   interference. The siNAs may or may not comprise ribonucleotides and may
CC   be double or single stranded. They further comprise sense and antisense
CC   regions, or alternatively are assembled from a sense oligonucleotide and
CC   an antisense oligonucleotide. Specifically, the siNAs include short
CC   interfering RNA (siRNA), double-stranded RNA, micro-RNA (miRNA) and short
CC   hairpin RNA (shRNA). The siNAs can be unmodified or chemically modified,
CC   can contain deoxyribonucleotides, and can be chemically synthesised,
CC   expressed from a vector or enzymatically synthesised. The invention also
CC   relates to kits for the in vitro or in vivo delivery of siNA; conjugates
CC   and/or complexes of siNA; and vectors that express siNA. The siNAs are
CC   used to modulate expression of the BACE gene in cells, tissue explants or
CC   organisms (e.g., by ex vivo gene therapy), or in grafts and transplants
CC   for the treatment of a variety of conditions. They may be used for
CC   treating Alzheimer's disease or other degenerative conditions such as
CC   dementia and stroke/cardiovascular accident. The siNAs are also useful
CC   for drug screening, diagnosis, therapeutic target identification and
CC   validation, genetic engineering, pharmacogenomics, studying gene
CC   function, and gene mapping (e.g., of single nucleotide polymorphisms).
CC   The present sequence represents the upper strand of a human BACE-targeted
CC   double-stranded siNA, which is identical to the BACE transcript target
CC   sequence.
XX
SQ   Sequence 19 BP; 2 A; 11 C; 4 G; 0 T; 2 U; 0 Other;

  Query Match             0.8%;  Score 14.8;  DB 1;  Length 19;
  Best Local Similarity   83.3%;  Pred. No. 2.7e+02;
  Matches   15;  Conservative    1;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        708 GCACTCGACCCCAGCCTG 725
              ||||:|| |||||||| |
Db          2 GCACUCGUCCCCAGCCCG 19


RESULT 209
ADH16536/c
ID   ADH16536 standard; RNA; 19 BP.
XX
AC   ADH16536;
XX
DT   11-MAR-2004  (first entry)
XX
DE   Human BACE siNA lower strand, SEQ ID NO:326.
XX
KW   RNA interference; short interfering nucleic acid; siNA;
KW   short interfering RNA; siRNA; double-stranded RNA; micro-RNA; miRNA;
KW   short hairpin RNA; shRNA; expression modulation; gene therapy;
KW   drug screening; diagnosis; therapeutic target identification;
KW   pharmacogenomics; gene function analysis; gene mapping;
KW   Alzheimer's disease; dementia; stroke; cardiovascular accident;
KW   beta-secretase; BACE; human; ss.
XX
OS   Homo sapiens.
XX
PN   WO2003070895-A2.
XX
PD   28-AUG-2003.
XX
PF   18-FEB-2003; 2003WO-US004710.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   06-JUN-2002; 2002US-0386782P.
PR   25-JUL-2002; 2002US-00205309.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J,  Beigelman L;
XX
DR   WPI; 2003-697608/66.
XX
PT   New short interfering nucleic acids, useful e.g. for treatment and
PT   diagnosis of Alzheimer's disease, which down regulates expression of the
PT   beta-secretase gene.
XX
PS   Example 3; SEQ ID NO 326; 144pp; English.
XX
CC   The invention relates to short interfering nucleic acids (siNA) which
CC   downregulate expression of the human beta-secretase (BACE) gene by RNA
CC   interference. The siNAs may or may not comprise ribonucleotides and may
```

CC be double or single stranded. They further comprise sense and antisense
CC regions, or alternatively are assembled from a sense oligonucleotide and
CC an antisense oligonucleotide. Specifically, the siNAs include short
CC interfering RNA (siRNA), double-stranded RNA, micro-RNA (miRNA) and short
CC hairpin RNA (shRNA). The siNAs can be unmodified or chemically modified,
CC can contain deoxyribonucleotides, and can be chemically synthesised,
CC expressed from a vector or enzymatically synthesised. The invention also
CC relates to kits for the in vitro or in vivo delivery of siNA; conjugates
CC and/or complexes of siNA; and vectors that express siNA. The siNAs are
CC used to modulate expression of the BACE gene in cells, tissue explants or
CC organisms (e.g., by ex vivo gene therapy), or in grafts and transplants
CC for the treatment of a variety of conditions. They may be used for
CC treating Alzheimer's disease or other degenerative conditions such as
CC dementia and stroke/cardiovascular accident. The siNAs are also useful
CC for drug screening, diagnosis, therapeutic target identification and
CC validation, genetic engineering, pharmacogenomics, studying gene
CC function, and gene mapping (e.g., of single nucleotide polymorphisms).
CC The present sequence represents the lower strand of a human BACE-targeted
CC double-stranded siNA.
XX
SQ Sequence 19 BP; 2 A; 4 C; 11 G; 0 T; 2 U; 0 Other;

Query Match 0.8%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 2.7e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy        708 GCACTCGACCCCAGCCTG 725
              ||||||| |||||||| |
Db         18 GCACTCGTCCCCAGCCCG 1
```

RESULT 210
ADH16224/c
ID ADH16224 standard; RNA; 19 BP.
XX
AC ADH16224;
XX
DT 11-MAR-2004 (first entry)
XX
DE Human BACE transcript target sequence/siNA upper strand, SEQ ID NO:14.
XX
KW RNA interference; short interfering nucleic acid; siNA;
KW short interfering RNA; siRNA; double-stranded RNA; micro-RNA; miRNA;
KW short hairpin RNA; shRNA; expression modulation; gene therapy;
KW drug screening; diagnosis; therapeutic target identification;
KW pharmacogenomics; gene function analysis; gene mapping;
KW Alzheimer's disease; dementia; stroke; cardiovascular accident;
KW beta-secretase; BACE; human; target sequence; ss.
XX
OS Homo sapiens.
XX
PN WO2003070895-A2.
XX
PD 28-AUG-2003.
XX
PF 18-FEB-2003; 2003WO-US004710.
XX
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 06-JUN-2002; 2002US-0386782P.
PR 25-JUL-2002; 2002US-00205309.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Mcswiggen J, Beigelman L;
XX
DR WPI; 2003-697608/66.
XX
PT New short interfering nucleic acids, useful e.g. for treatment and
PT diagnosis of Alzheimer's disease, which down regulates expression of the
PT beta-secretase gene.
XX
PS Example 3; SEQ ID NO 14; 144pp; English.
XX
CC The invention relates to short interfering nucleic acids (siNA) which
CC downregulate expression of the human beta-secretase (BACE) gene by RNA
CC interference. The siNAs may or may not comprise ribonucleotides and may
CC be double or single stranded. They further comprise sense and antisense
CC regions, or alternatively are assembled from a sense oligonucleotide and
CC an antisense oligonucleotide. Specifically, the siNAs include short
CC interfering RNA (siRNA), double-stranded RNA, micro-RNA (miRNA) and short
CC hairpin RNA (shRNA). The siNAs can be unmodified or chemically modified,
CC can contain deoxyribonucleotides, and can be chemically synthesised,
CC expressed from a vector or enzymatically synthesised. The invention also
CC relates to kits for the in vitro or in vivo delivery of siNA; conjugates
CC and/or complexes of siNA; and vectors that express siNA. The siNAs are
CC used to modulate expression of the BACE gene in cells, tissue explants or
CC organisms (e.g., by ex vivo gene therapy), or in grafts and transplants
CC for the treatment of a variety of conditions. They may be used for
CC treating Alzheimer's disease or other degenerative conditions such as
CC dementia and stroke/cardiovascular accident. The siNAs are also useful
CC for drug screening, diagnosis, therapeutic target identification and
CC validation, genetic engineering, pharmacogenomics, studying gene
CC function, and gene mapping (e.g., of single nucleotide polymorphisms).
CC The present sequence represents the upper strand of a human BACE-targeted
CC double-stranded siNA, which is identical to the BACE transcript target
CC sequence.
XX
SQ Sequence 19 BP; 1 A; 11 C; 2 G; 0 T; 5 U; 0 Other;

Query Match 0.8%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 2.7e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy       1582 GCAGGGGAGGGGCTGAGA 1599
              ||||||||| ||||| ||
Db         18 GCAGGGGAGAGGCTGGGA 1
```

RESULT 211
ADH16549
ID ADH16549 standard; RNA; 19 BP.
XX
AC ADH16549;
XX
DT 11-MAR-2004 (first entry)
XX
DE Human BACE siNA lower strand, SEQ ID NO:339.
XX
KW RNA interference; short interfering nucleic acid; siNA;
KW short interfering RNA; siRNA; double-stranded RNA; micro-RNA; miRNA;
KW short hairpin RNA; shRNA; expression modulation; gene therapy;
KW drug screening; diagnosis; therapeutic target identification;
KW pharmacogenomics; gene function analysis; gene mapping;
KW Alzheimer's disease; dementia; stroke; cardiovascular accident;
KW beta-secretase; BACE; human; ss.
XX
OS Homo sapiens.
XX
PN WO2003070895-A2.
XX
PD 28-AUG-2003.
XX
PF 18-FEB-2003; 2003WO-US004710.
XX
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 06-JUN-2002; 2002US-0386782P.
PR 25-JUL-2002; 2002US-00205309.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.

```
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J,  Beigelman L;
XX
DR   WPI; 2003-697608/66.
XX
PT   New short interfering nucleic acids, useful e.g. for treatment and
PT   diagnosis of Alzheimer's disease, which down regulates expression of the
PT   beta-secretase gene.
XX
PS   Example 3; SEQ ID NO 339; 144pp; English.
XX
CC   The invention relates to short interfering nucleic acids (siNA) which
CC   downregulate expression of the human beta-secretase (BACE) gene by RNA
CC   interference. The siNAs may or may not comprise ribonucleotides and may
CC   be double or single stranded. They further comprise sense and antisense
CC   regions, or alternatively are assembled from a sense oligonucleotide and
CC   an antisense oligonucleotide. Specifically, the siNAs include short
CC   interfering RNA (siRNA), double-stranded RNA, micro-RNA (miRNA) and short
CC   hairpin RNA (shRNA). The siNAs can be unmodified or chemically modified,
CC   can contain deoxyribonucleotides, and can be chemically synthesised,
CC   expressed from a vector or enzymatically synthesised. The invention also
CC   relates to kits for the in vitro or in vivo delivery of siNA; conjugates
CC   and/or complexes of siNA; and vectors that express siNA. The siNAs are
CC   used to modulate expression of the BACE gene in cells, tissue explants or
CC   organisms (e.g., by ex vivo gene therapy), or in grafts and transplants
CC   for the treatment of a variety of conditions. They may be used for
CC   treating Alzheimer's disease or other degenerative conditions such as
CC   dementia and stroke/cardiovascular accident. The siNAs are also useful
CC   for drug screening, diagnosis, therapeutic target identification and
CC   validation, genetic engineering, pharmacogenomics, studying gene
CC   function, and gene mapping (e.g., of single nucleotide polymorphisms).
CC   The present sequence represents the lower strand of a human BACE-targeted
CC   double-stranded siNA.
XX
SQ   Sequence 19 BP; 5 A; 2 C; 11 G; 0 T; 1 U; 0 Other;

  Query Match             0.8%;  Score 14.8;  DB 1;  Length 19;
  Best Local Similarity   83.3%;  Pred. No. 2.7e+02;
  Matches   15;  Conservative    1;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1582 GCAGGGGAGGGGCTGAGA 1599
              |||||||||  |||:| ||
Db          2 GCAGGGGAGAGGCUGGGA 19


RESULT 212
ADL79131/c
ID   ADL79131 standard; RNA; 19 BP.
XX
AC   ADL79131;
XX
DT   20-MAY-2004  (first entry)
XX
DE   Human HER2 (EGFR2) siNA lower strand, SEQ ID NO:296.
XX
KW   RNA interference; short interfering nucleic acid; siNA;
KW   short interfering RNA; siRNA; double-stranded RNA; micro-RNA; miRNA;
KW   short hairpin RNA; shRNA; expression modulation; gene therapy;
KW   drug screening; diagnosis; therapeutic target identification;
KW   pharmacogenomics; gene function analysis; gene mapping; cancer;
KW   cytostatic; human; oncogene; epidermal growth factor receptor; EGFR;
KW   HER2; EGFR2; neu; erbB2; c-erb-B-2; ss.
XX
OS   Homo sapiens.
XX
PN   WO2003070912-A2.
XX
PD   28-AUG-2003.
XX
PF   20-FEB-2003; 2003WO-US005045.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   29-MAY-2002; 2002WO-US016840.
PR   06-JUN-2002; 2002US-00163552.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393924P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   19-SEP-2002; 2002US-00251117.
PR   21-OCT-2002; 2002US-00277494.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J,  Pavco P,  Beigelman L,  Fosnaugh K,  Jamison S;
XX
DR   WPI; 2003-697612/66.
XX
PT   New short interfering nucleic acid, useful e.g. for treatment and
PT   diagnosis of cancer, downregulates expression of the epidermal growth
PT   factor receptor gene.
XX
PS   Example 3; SEQ ID NO 296; 171pp; English.
XX
CC   The invention relates to short interfering nucleic acids (siNA) which
CC   downregulate expression of one or more human epidermal growth factor
CC   receptor (EGFR) genes (including HER1, HER2 HER3 and HER4) by RNA
CC   interference. The siNAs may or may not comprise ribonucleotides and may
CC   be double or single stranded. They further comprise sense and antisense
CC   regions, or alternatively are assembled from a sense oligonucleotide and
CC   an antisense oligonucleotide. Specifically, the siNAs include short
CC   interfering RNA (siRNA), double-stranded RNA, micro-RNA (miRNA) and short
CC   hairpin RNA (shRNA). The siNAs can be unmodified or chemically modified,
CC   can contain deoxyribonucleotides, and can be chemically synthesised,
CC   expressed from a vector or enzymatically synthesised. The invention also
CC   relates to kits for the in vitro or in vivo delivery of siNA; conjugates
CC   and/or complexes of siNA; and vectors that express siNA. The siNAs are
CC   used to modulate expression of EGFR genes in cells, tissue explants or
CC   organisms (e.g., by ex vivo gene therapy), or in grafts and transplants
CC   for the treatment of a variety of conditions. They may be used for
CC   treating a wide range of cancers such as breast and ovarian cancer. The
CC   siNAs are also useful for drug screening, diagnosis, therapeutic target
CC   identification and validation, genetic engineering, pharmacogenomics,
CC   studying gene function, and gene mapping (e.g., of single nucleotide
CC   polymorphisms). The present sequence represents the lower strand of a
CC   HER2 (EGFR2)-targeted double-stranded siNA.
XX
SQ   Sequence 19 BP; 6 A; 9 C; 4 G; 0 T; 0 U; 0 Other;

  Query Match             0.8%;  Score 14.8;  DB 1;  Length 19;
  Best Local Similarity   88.9%;  Pred. No. 2.7e+02;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1085 TGTGTGCGGGTGGCTGTG 1102
              | ||||| ||||||||||
Db         18 TCTGTGCCGGTGGCTGTG 1


RESULT 213
ADL78920/c
ID   ADL78920 standard; RNA; 19 BP.
XX
AC   ADL78920;
XX
DT   20-MAY-2004  (first entry)
XX
DE   Human HER2 (EGFR2) transcript target sequence/siNA upper strand, SEQ:85.
XX
KW   RNA interference; short interfering nucleic acid; siNA;
KW   short interfering RNA; siRNA; double-stranded RNA; micro-RNA; miRNA;
KW   short hairpin RNA; shRNA; expression modulation; gene therapy;
```

KW drug screening; diagnosis; therapeutic target identification;
KW pharmacogenomics; gene function analysis; gene mapping; cancer;
KW cytostatic; human; oncogene; epidermal growth factor receptor; EGFR;
KW HER2; EGFR2; neu; erbB2; c-erb-B-2; target sequence; ss.
XX
OS Homo sapiens.
XX
PN WO2003070912-A2.
XX
PD 28-AUG-2003.
XX
PF 20-FEB-2003; 2003WO-US005045.
XX
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 29-MAY-2002; 2002WO-US016840.
PR 06-JUN-2002; 2002US-00163552.
PR 06-JUN-2002; 2002US-0386782P.
PR 03-JUL-2002; 2002US-0393924P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 19-SEP-2002; 2002US-00251117.
PR 21-OCT-2002; 2002US-00277494.
PR 15-JAN-2003; 2003US-0440129P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Mcswiggen J, Pavco P, Beigelman L, Fosnaugh K, Jamison S;
XX
DR WPI; 2003-697612/66.
XX
PT New short interfering nucleic acid, useful e.g. for treatment and
PT diagnosis of cancer, downregulates expression of the epidermal growth
PT factor receptor gene.
XX
PS Example 3; SEQ ID NO 85; 171pp; English.
XX
CC The invention relates to short interfering nucleic acids (siNA) which
CC downregulate expression of one or more human epidermal growth factor
CC receptor (EGFR) genes (including HER1, HER2 HER3 and HER4) by RNA
CC interference. The siNAs may or may not comprise ribonucleotides and may
CC be double or single stranded. They further comprise sense and antisense
CC regions, or alternatively are assembled from a sense oligonucleotide and
CC an antisense oligonucleotide. Specifically, the siNAs include short
CC interfering RNA (siRNA), double-stranded RNA, micro-RNA (miRNA) and short
CC hairpin RNA (shRNA). The siNAs can be unmodified or chemically modified,
CC can contain deoxyribonucleotides, and can be chemically synthesised,
CC expressed from a vector or enzymatically synthesised. The invention also
CC relates to kits for the in vitro or in vivo delivery of siNA; conjugates
CC and/or complexes of siNA; and vectors that express siNA. The siNAs are
CC used to modulate expression of EGFR genes in cells, tissue explants or
CC organisms (e.g., by ex vivo gene therapy), or in grafts and transplants
CC for the treatment of a variety of conditions. They may be used for
CC treating a wide range of cancers such as breast and ovarian cancer. The
CC siNAs are also useful for drug screening, diagnosis, therapeutic target
CC identification and validation, genetic engineering, pharmacogenomics,
CC studying gene function, and gene mapping (e.g., of single nucleotide
CC polymorphisms). The present sequence represents the upper strand of a
CC human HER2 (EGFR2)-targeted double-stranded siNA, which is identical to
CC the HER2 transcript target sequence.
XX
SQ Sequence 19 BP; 2 A; 5 C; 9 G; 0 T; 3 U; 0 Other;

Query Match 0.8%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 2.7e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 565 GCCTGCTGATGCCTAGCC 582
||| ||||||||| ||||
Db 19 GCCAGCTGATGCCCAGCC 2

RESULT 214
ADL78882
ID ADL78882 standard; RNA; 19 BP.
XX
AC ADL78882;
XX
DT 20-MAY-2004 (first entry)
XX
DE Human HER2 (EGFR2) transcript target sequence/siNA upper strand, SEQ:47.
XX
KW RNA interference; short interfering nucleic acid; siNA;
KW short interfering RNA; siRNA; double-stranded RNA; micro-RNA; miRNA;
KW short hairpin RNA; shRNA; expression modulation; gene therapy;
KW drug screening; diagnosis; therapeutic target identification;
KW pharmacogenomics; gene function analysis; gene mapping; cancer;
KW cytostatic; human; oncogene; epidermal growth factor receptor; EGFR;
KW HER2; EGFR2; neu; erbB2; c-erb-B-2; target sequence; ss.
XX
OS Homo sapiens.
XX
PN WO2003070912-A2.
XX
PD 28-AUG-2003.
XX
PF 20-FEB-2003; 2003WO-US005045.
XX
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 29-MAY-2002; 2002WO-US016840.
PR 06-JUN-2002; 2002US-00163552.
PR 06-JUN-2002; 2002US-0386782P.
PR 03-JUL-2002; 2002US-0393924P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 19-SEP-2002; 2002US-00251117.
PR 21-OCT-2002; 2002US-00277494.
PR 15-JAN-2003; 2003US-0440129P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Mcswiggen J, Pavco P, Beigelman L, Fosnaugh K, Jamison S;
XX
DR WPI; 2003-697612/66.
XX
PT New short interfering nucleic acid, useful e.g. for treatment and
PT diagnosis of cancer, downregulates expression of the epidermal growth
PT factor receptor gene.
XX
PS Example 3; SEQ ID NO 47; 171pp; English.
XX
CC The invention relates to short interfering nucleic acids (siNA) which
CC downregulate expression of one or more human epidermal growth factor
CC receptor (EGFR) genes (including HER1, HER2 HER3 and HER4) by RNA
CC interference. The siNAs may or may not comprise ribonucleotides and may
CC be double or single stranded. They further comprise sense and antisense
CC regions, or alternatively are assembled from a sense oligonucleotide and
CC an antisense oligonucleotide. Specifically, the siNAs include short
CC interfering RNA (siRNA), double-stranded RNA, micro-RNA (miRNA) and short
CC hairpin RNA (shRNA). The siNAs can be unmodified or chemically modified,
CC can contain deoxyribonucleotides, and can be chemically synthesised,
CC expressed from a vector or enzymatically synthesised. The invention also
CC relates to kits for the in vitro or in vivo delivery of siNA; conjugates
CC and/or complexes of siNA; and vectors that express siNA. The siNAs are
CC used to modulate expression of EGFR genes in cells, tissue explants or
CC organisms (e.g., by ex vivo gene therapy), or in grafts and transplants
CC for the treatment of a variety of conditions. They may be used for
CC treating a wide range of cancers such as breast and ovarian cancer. The
CC siNAs are also useful for drug screening, diagnosis, therapeutic target
CC identification and validation, genetic engineering, pharmacogenomics,
CC studying gene function, and gene mapping (e.g., of single nucleotide
CC polymorphisms). The present sequence represents the upper strand of a
CC human HER2 (EGFR2)-targeted double-stranded siNA, which is identical to

```
CC   the HER2 transcript target sequence.
XX
SQ   Sequence 19 BP; 0 A; 4 C; 9 G; 0 T; 6 U; 0 Other;

  Query Match             0.8%;  Score 14.8;  DB 1;  Length 19;
  Best Local Similarity   55.6%;  Pred. No. 2.7e+02;
  Matches   10;  Conservative    6;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1085 TGTGTGCGGGTGGCTGTG 1102
              : :|:|| ||:|||:|:|
Db          2 UCUGUGCCGGUGGCUGUG 19


RESULT 215
ADL79169
ID   ADL79169 standard; RNA; 19 BP.
XX
AC   ADL79169;
XX
DT   20-MAY-2004  (first entry)
XX
DE   Human HER2 (EGFR2) siNA lower strand, SEQ ID NO:334.
XX
KW   RNA interference; short interfering nucleic acid; siNA;
KW   short interfering RNA; siRNA; double-stranded RNA; micro-RNA; miRNA;
KW   short hairpin RNA; shRNA; expression modulation; gene therapy;
KW   drug screening; diagnosis; therapeutic target identification;
KW   pharmacogenomics; gene function analysis; gene mapping; cancer;
KW   cytostatic; human; oncogene; epidermal growth factor receptor; EGFR;
KW   HER2; EGFR2; neu; erbB2; c-erb-B-2; ss.
XX
OS   Homo sapiens.
XX
PN   WO2003070912-A2.
XX
PD   28-AUG-2003.
XX
PF   20-FEB-2003; 2003WO-US005045.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   29-MAY-2002; 2002WO-US016840.
PR   06-JUN-2002; 2002US-00163552.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393924P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   19-SEP-2002; 2002US-00251117.
PR   21-OCT-2002; 2002US-00277494.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J,  Pavco P,  Beigelman L,  Fosnaugh K,  Jamison S;
XX
DR   WPI; 2003-697612/66.
XX
PT   New short interfering nucleic acid, useful e.g. for treatment and
PT   diagnosis of cancer, downregulates expression of the epidermal growth
PT   factor receptor gene.
XX
PS   Example 3; SEQ ID NO 334; 171pp; English.
XX
CC   The invention relates to short interfering nucleic acids (siNA) which
CC   downregulate expression of one or more human epidermal growth factor
CC   receptor (EGFR) genes (including HER1, HER2 HER3 and HER4) by RNA
CC   interference. The siNAs may or may not comprise ribonucleotides and may
CC   be double or single stranded. They further comprise sense and antisense
CC   regions, or alternatively are assembled from a sense oligonucleotide and
CC   an antisense oligonucleotide. Specifically, the siNAs include short
CC   interfering RNA (siRNA), double-stranded RNA, micro-RNA (miRNA) and short
CC   hairpin RNA (shRNA). The siNAs can be unmodified or chemically modified,
CC   can contain deoxyribonucleotides, and can be chemically synthesised,
CC   expressed from a vector or enzymatically synthesised. The invention also
CC   relates to kits for the in vitro or in vivo delivery of siNA; conjugates
CC   and/or complexes of siNA; and vectors that express siNA. The siNAs are
CC   used to modulate expression of EGFR genes in cells, tissue explants or
CC   organisms (e.g., by ex vivo gene therapy), or in grafts and transplants
CC   for the treatment of a variety of conditions. They may be used for
CC   treating a wide range of cancers such as breast and ovarian cancer. The
CC   siNAs are also useful for drug screening, diagnosis, therapeutic target
CC   identification and validation, genetic engineering, pharmacogenomics,
CC   studying gene function, and gene mapping (e.g., of single nucleotide
CC   polymorphisms). The present sequence represents the lower strand of a
CC   HER2 (EGFR2)-targeted double-stranded siNA.
XX
SQ   Sequence 19 BP; 3 A; 9 C; 5 G; 0 T; 2 U; 0 Other;

  Query Match             0.8%;  Score 14.8;  DB 1;  Length 19;
  Best Local Similarity   77.8%;  Pred. No. 2.7e+02;
  Matches   14;  Conservative    2;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        565 GCCTGCTGATGCCTAGCC 582
              ||| ||:||:||| ||||
Db          1 GCCAGCUGAUGCCCAGCC 18


RESULT 216
ADN34242/c
ID   ADN34242 standard; RNA; 19 BP.
XX
AC   ADN34242;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Lower strand of cyclin D1 targeted double stranded siNA #23.
XX
KW   short interfering nucleic acid; siNA; cyclin; Cytostatic; Vasotropic;
KW   cancer; cell-proliferation disorder; restenosis; drug screening;
KW   genetic engineering; pharmacogenomics; gene mapping;
KW   single nucleotide polymorphisms; ss.
XX
OS   Homo sapiens.
XX
PN   WO2003072705-A2.
XX
PD   04-SEP-2003.
XX
PF   06-FEB-2003; 2003WO-US003662.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   06-JUN-2002; 2002US-0386782P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   17-SEP-2002; 2002US-0411275P.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Thompson J,  Mcswiggen J,  Beigelman L;
XX
DR   WPI; 2003-689983/65.
XX
PT   New short interfering nucleic acid, useful e.g. for treatment and
PT   diagnosis of cancer and restenosis, down regulates expression of at least
PT   one cyclin gene.
XX
PS   Example 3; SEQ ID NO 262; 144pp; English.
XX
CC   The present invention relates to a short interfering nucleic acid (siNA)
CC   that down regulates expression of at least one cyclin gene by RNA
CC   interference. siNA are used to modulate expression of cyclin genes, in
CC   cells, tissue explants or organisms, e.g. for treating a wide range of
```

```
CC   cancers and other cell-proliferation disorders such as restenosis, but
CC   also for drug screening, diagnosis, target identification and validation;
CC   genetic engineering, pharmacogenomics, studying gene function and gene
CC   mapping (e.g. of single-nucleotide polymorphisms). The present sequence
CC   represents the lower strand of cyclin D1 targeted double stranded siNA.
XX
SQ   Sequence 19 BP; 4 A; 9 C; 3 G; 0 T; 3 U; 0 Other;

  Query Match             0.8%;  Score 14.8;  DB 1;  Length 19;
  Best Local Similarity   88.9%;  Pred. No. 2.7e+02;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        655 TGCTGGACGTCTGCGTGG 672
              ||||||| ||||||| ||
Db         18 TGCTGGAGGTCTGCGAGG 1


RESULT 217
ADN34003
ID   ADN34003 standard; RNA; 19 BP.
XX
AC   ADN34003;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Upper strand of cyclin D1 targeted double stranded siNA #23.
XX
KW   short interfering nucleic acid; siNA; cyclin; Cytostatic; Vasotropic;
KW   cancer; cell-proliferation disorder; restenosis; drug screening;
KW   genetic engineering; pharmacogenomics; gene mapping;
KW   single nucleotide polymorphisms; ss.
XX
OS   Homo sapiens.
XX
PN   WO2003072705-A2.
XX
PD   04-SEP-2003.
XX
PF   06-FEB-2003; 2003WO-US003662.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   06-JUN-2002; 2002US-0386782P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   17-SEP-2002; 2002US-0411275P.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Thompson J,  Mcswiggen J,  Beigelman L;
XX
DR   WPI; 2003-689983/65.
XX
PT   New short interfering nucleic acid, useful e.g. for treatment and
PT   diagnosis of cancer and restenosis, down regulates expression of at least
PT   one cyclin gene.
XX
PS   Example 3; SEQ ID NO 23; 144pp; English.
XX
CC   The present invention relates to a short interfering nucleic acid (siNA)
CC   that down regulates expression of at least one cyclin gene by RNA
CC   interference. siNA are used to modulate expression of cyclin genes, in
CC   cells, tissue explants or organisms, e.g. for treating a wide range of
CC   cancers and other cell-proliferation disorders such as restenosis, but
CC   also for drug screening, diagnosis, target identification and validation;
CC   genetic engineering, pharmacogenomics, studying gene function and gene
CC   mapping (e.g. of single-nucleotide polymorphisms). The present sequence
CC   represents the upper strand of cyclin D1 targeted double stranded siNA
CC   which is identical to the cyclin D1 transcript target sequence.
XX
SQ   Sequence 19 BP; 3 A; 3 C; 9 G; 0 T; 4 U; 0 Other;

  Query Match             0.8%;  Score 14.8;  DB 1;  Length 19;
  Best Local Similarity   66.7%;  Pred. No. 2.7e+02;
  Matches   12;  Conservative    4;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        655 TGCTGGACGTCTGCGTGG 672
              :||:||| |:|:||| ||
Db          2 UGCUGGAGGUCUGCGAGG 19


RESULT 218
ADO14572/c
ID   ADO14572 standard; RNA; 19 BP.
XX
AC   ADO14572;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human PDGFr-targeted siNA upper strand SEQ ID NO:3.
XX
KW   cytostatic; vasotropic; nephrotropic; cerebroprotective;
KW   treating leukaemia; solid tumors; restenosis; polycystic kidney disease;
KW   bronchiolitis; glomerulonephritis; stroke; RNA interference;
KW   short interfering nucleic acid; siNA; short interfering RNA; siRNA;
KW   double-stranded RNA; micro-RNA; miRNA; short hairpin RNA; shRNA;
KW   expression modulation; gene therapy; drug screening; diagnosis;
KW   therapeutic target identification; pharmacogenomics;
KW   gene function analysis; gene mapping; human;
KW   platelet derived growth factor receptor; PDGFr; ss.
XX
OS   Homo sapiens.
XX
PN   WO2003072704-A2.
XX
PD   04-SEP-2003.
XX
PF   05-FEB-2003; 2003WO-US003473.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   06-JUN-2002; 2002US-0386782P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J,  Beigelman L,  Chowrira B;
XX
DR   WPI; 2003-731605/69.
XX
PT   New short interfering nucleic acid, useful e.g. for treatment and
PT   diagnosis of tumors, downregulates expression of the platelet-derived
PT   growth factor receptor gene.
XX
PS   Example 3; SEQ ID NO 3; 148pp; English.
XX
CC   The invention relates to short interfering nucleic acids (siNA) which
CC   downregulate expression of the human platelet-derived growth factor
CC   receptor (PDGFr) gene by RNA interference. The siNAs may or may not
CC   comprise ribonucleotides and may be double or single stranded. They
CC   further comprise sense and antisense regions, or alternatively are
CC   assembled from a sense oligonucleotide and an antisense oligonucleotide.
CC   Specifically, the siNAs include short interfering RNA (siRNA, double-
CC   stranded RNA, micro-RNA (miRNA) and short hairpin RNA (shRNA). The siNAs
CC   can be unmodified or chemically modified, can contain
CC   deoxyribonucleotides, and can be chemically synthesised, expressed from a
CC   vector or enzymatically synthesised. The invention also relates to kits
CC   for the in vitro or in vivo delivery of siRNA; conjugates and/or
CC   complexes of siRNA; and vectors that express siNA. The siNAs are used to
CC   modulate expression of the PDGFr gene in cells, tissue explants or
CC   organisms (e.g., by ex vivo gene therapy), or in grafts and transplants
```

CC for the treatment of a variety of conditions. They may be used for
CC treating leukaemia and solid tumours, restenosis, polycystic kidney
CC disease, bronchiolitis, glomerulonephritis and stroke. The siNAs are also
CC useful for drug screening, diagnosis, therapeutic target identification
CC and validation, genetic engineering, pharmacogenomics, studying gene
CC function, and gene mapping (e.g., of single nucleotide polymorphisms).
CC The present sequence represents the upper strand of a human PDGFr-
CC targeted double-stranded siNA, which is identical to the PDGFr transcript
CC target sequence.
XX
SQ Sequence 19 BP; 5 A; 9 C; 4 G; 0 T; 1 U; 0 Other;

Query Match 0.8%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 2.7e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 663 GTCTGCGTGGAGCAGGGC 680
||||||||.|.|||||||
Db 18 GTCTGCGTTGGGCAGGGC 1

RESULT 219
ADO14883
ID ADO14883 standard; RNA; 19 BP.
XX
AC ADO14883;
XX
DT 01-JUL-2004 (first entry)
XX
DE Human PDGFr-targeted siNA lower strand SEQ ID NO:314.
XX
KW cytostatic; vasotropic; nephrotropic; cerebroprotective;
KW treating leukaemia; solid tumors; restenosis; polycystic kidney disease;
KW bronchiolitis; glomerulonephritis; stroke; RNA interference;
KW short interfering nucleic acid; siNA; short interfering RNA; siRNA;
KW double-stranded RNA; micro-RNA; miRNA; short hairpin RNA; shRNA;
KW expression modulation; gene therapy; drug screening; diagnosis;
KW therapeutic target identification; pharmacogenomics;
KW gene function analysis; gene mapping; human;
KW platelet derived growth factor receptor; PDGFr; ss.
XX
OS Homo sapiens.
XX
PN WO2003072704-A2.
XX
PD 04-SEP-2003.
XX
PF 05-FEB-2003; 2003WO-US003473.
XX
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Mcswiggen J, Beigelman L, Chowrira B;
XX
DR WPI; 2003-731605/69.
XX
PT New short interfering nucleic acid, useful e.g. for treatment and
PT diagnosis of tumors, downregulates expression of the platelet-derived
PT growth factor receptor gene.
XX
PS Example 3; SEQ ID NO 314; 148pp; English.
XX
CC The invention relates to short interfering nucleic acids (siNA) which
CC downregulate expression of the human platelet-derived growth factor
CC receptor (PDGFr) gene by RNA interference. The siNAs may or may not
CC comprise ribonucleotides and may be double or single stranded. They
CC further comprise sense and antisense regions, or alternatively are
CC assembled from a sense oligonucleotide and an antisense oligonucleotide.
CC Specifically, the siNAs include short interfering RNA (siRNA, double-
CC stranded RNA, micro-RNA (miRNA) and short hairpin RNA (shRNA). The siNAs
CC can be unmodified or chemically modified, can contain
CC deoxyribonucleotides, and can be chemically synthesised, expressed from a
CC vector or enzymatically synthesised. The invention also relates to kits
CC for the in vitro or in vivo delivery of siRNA; conjugates and/or
CC complexes of siRNA; and vectors that express siNA. The siNAs are used to
CC modulate expression of the PDGFr gene in cells, tissue explants or
CC organisms (e.g., by ex vivo gene therapy), or in grafts and transplants
CC for the treatment of a variety of conditions. They may be used for
CC treating leukaemia and solid tumours, restenosis, polycystic kidney
CC disease, bronchiolitis, glomerulonephritis and stroke. The siNAs are also
CC useful for drug screening, diagnosis, therapeutic target identification
CC and validation, genetic engineering, pharmacogenomics, studying gene
CC function, and gene mapping (e.g., of single nucleotide polymorphisms).
CC The present sequence represents the lower strand of a human PDGFr-
CC targeted double-stranded siNA, which is identical to the PDGFr transcript
CC target sequence.
XX
SQ Sequence 19 BP; 1 A; 4 C; 9 G; 0 T; 5 U; 0 Other;

Query Match 0.8%; Score 14.8; DB 1; Length 19;
Best Local Similarity 72.2%; Pred. No. 2.7e+02;
Matches 13; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

Qy 663 GTCTGCGTGGAGCAGGGC 680
|:|:|||:|.|||||||
Db 2 GUCUGCGUUGGGCAGGGC 19

RESULT 220
ADF92112/c
ID ADF92112 standard; DNA; 19 BP.
XX
AC ADF92112;
XX
DT 26-FEB-2004 (first entry)
XX
DE Human cytokeratin 18-related R3 PCR primer - SEQ ID 200.
XX
KW human; cytokeratin; CK; LAMP; loop mediated isothermal amplification;
KW tumour metastasis; prostate cancer; lymphoma; human; CK18; ss; primer;
KW PCR; R3.
XX
OS Homo sapiens.
XX
PN WO2003097878-A1.
XX
PD 27-NOV-2003.
XX
PF 20-MAY-2003; 2003WO-JP006256.
XX
PR 21-MAY-2002; 2002JP-00145689.
PR 17-JUN-2002; 2002JP-00175271.
PR 09-JUL-2002; 2002JP-00199759.
XX
PA (SYSM-) SYSMEX CORP.
XX
PI Tada S, Akai Y, Imura Y, Abe S, Minekawa H;
XX
DR WPI; 2004-012543/01.
XX
PT LAMP nucleic acid amplification primers for detection of cytokeratin
PT expression as indicator in diagnosis of tumour metastasis.
XX
PS Claim 3; SEQ ID NO 200; 266pp; Japanese.
XX
CC The invention relates to novel nucleic acid amplification primers for the
CC detection of human cytokeratin (CK) 18, 19 or 20 expression by the LAMP
CC (loop mediated isothermal amplification) method. The primers of the
CC invention may be useful for the detecting cytokeratin 18-20 expression as

CC an indicator for the diagnosis of tumour metastasis, particularly
CC prostate cancer and lymphoma. The amplification using the primers is
CC highly efficient and allows very sensitive detection of tumour
CC metastasis. The current sequence is that of the human CK18-related PCR
CC primer of the invention.
XX
SQ Sequence 19 BP; 1 A; 9 C; 3 G; 6 T; 0 U; 0 Other;

Query Match 0.8%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 2.7e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1302 AGAGCAGCCGGAGGGAGG 1319
||| ||||| ||||||||
Db 18 AGAACAGCCTGAGGGAGG 1

RESULT 221
ADH01576/c
ID ADH01576 standard; RNA; 19 BP.
XX
AC ADH01576;
XX
DT 11-MAR-2004 (first entry)
XX
DE Protein tyrosine phosphatase siRNA sequence, SEQ ID No 188.
XX
KW small interfering RNA; siRNA; protein tyrosine phosphatase; PTP; PTP1B;
KW insulin receptor protein phosphorylation; Jak2; antidiabetic; anorectic;
KW antiinflammatory; neuroprotective; cytostatic; immunosuppressive;
KW antimicrobial; gene therapy; ss; siRNA.
XX
OS Unidentified.
XX
PN WO2003099227-A2.
XX
PD 04-DEC-2003.
XX
PF 23-MAY-2003; 2003WO-US016651.
XX
PR 23-MAY-2002; 2002US-0383249P.
PR 14-APR-2003; 2003US-0462942P.
XX
PA (CEPT-) CEPTYR INC.
XX
PI Lewis SP, Klinghoffer R, Wilson LK;
XX
DR WPI; 2004-035036/03.
XX
PT New small interfering polynucleotide that modulates protein tyrosine
PT phosphatase (PTP)1B polypeptide signal transduction, useful for treating
PT disorders associated with altered PTP1B signal transduction, e.g.
PT diabetes or cancer.
XX
PS Example 3; SEQ ID NO 188; 234pp; English.
XX
CC The invention relates to a novel isolated small interfering RNA (siRNA)
CC polynucleotide, comprising at least one nucleotide sequence from any of
CC the 20 fully defined sequences given in the specification. The invention
CC further relates to: a pharmaceutical composition comprising a new siRNA
CC polynucleotide and a physiological carrier; a recombinant nucleic acid
CC construct, comprising a polynucleotide that is capable of directing
CC transcription of an siRNA; a host cell transformed or transfected with
CC the above recombinant nucleic acid construct; a method for interfering
CC with expression of a protein tyrosine phosphatase (PTP)1B polypeptide, or
CC its variant; a method for identifying a component of a PTP1B signal
CC transduction pathway; a method for modulating an insulin receptor protein
CC phosphorylation state in a cell; a method for altering a Jak2 protein
CC phosphorylation state in a cell; and a method for treating a Jak2-
CC associated disorder. The siRNA has the following activities:
CC antidiabetic, anorectic, antiinflammatory, neuroprotective, cytostatic,
CC immunosuppressive, and antimicrobial. The novel siRNA polynucleotides can
CC be used in gene therapy to treat disorders. The composition and methods
CC are useful in treating disorders associated with PTP1B-mediated signal
CC transduction, such as diabetes, obesity, hyperglycaemia-induced
CC apoptosis, inflammation, neurodegenerative disorders, cancer, autoimmune
CC diseases or infection. This polynucleotide sequence represents an siRNA
CC used for modulating the signal transduction of a protein tyrosine
CC phosphatase of the invention.
XX
SQ Sequence 19 BP; 5 A; 6 C; 4 G; 0 T; 4 U; 0 Other;

Query Match 0.8%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 2.7e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1033 GCCACCTAAGGTGGAGGT 1050
||||| ||| ||||||||
Db 19 GCCACTTAATGTGGAGGT 2

RESULT 222
ADK95769/c
ID ADK95769 standard; DNA; 19 BP.
XX
AC ADK95769;
XX
DT 06-MAY-2004 (first entry)
XX
DE Primer of the invention #1489.
XX
KW human; single nucleotide polymorphism; SNP; ss; primer.
XX
OS Synthetic.
XX
PN JP2003259875-A.
XX
PD 16-SEP-2003.
XX
PF 08-MAR-2002; 2002JP-00064373.
XX
PR 08-MAR-2002; 2002JP-00064373.
XX
PA (KAGA-) KAGAKU GIJUTSU SHINKO JIGYODAN.
XX
DR WPI; 2004-093977/10.
XX
PT Novel polynucleotide useful for PCR amplification along with two DNA
PT fragment from another set of sequences, or for detecting single
PT nucleotide polymorphism in human gene.
XX
PS Claim 2; SEQ ID NO 4798; 2627pp; Japanese.
XX
CC The present invention relates to a polynucleotide isolated from a human
CC gene and is useful for detecting a single nucleotide polymorphism in a
CC human gene or for diagnosing of disease. The invention enables the
CC detection of a single nucleotide polymorphism in a human gene. The
CC present sequence represents a primer of the invention.
XX
SQ Sequence 19 BP; 6 A; 3 C; 7 G; 3 T; 0 U; 0 Other;

Query Match 0.8%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 2.7e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 213 CTCACCATGCCTAGCCTT 230
|||| ||||||| |||||
Db 18 CTCAACATGCCTTGCCTT 1

RESULT 223
ADO52027/c
ID ADO52027 standard; DNA; 19 BP.
XX
AC ADO52027;
XX

DT 15-JUL-2004 (first entry)
XX
DE Rat collagen I gene specific reverse RT-PCR primer.
XX
KW Inflammation-related disorder; aldosterone blocker; inflammation;
KW cardiac remodeling; myocarditis; cardiomyopathy; vasculitis;
KW Behcet's disease; PCR; primer; rat; collagen I; ss.
XX
OS Rattus sp.
XX
PN US2004037806-A1.
XX
PD 26-FEB-2004.
XX
PF 24-JAN-2003; 2003US-00350964.
XX
PR 25-JAN-2002; 2002US-0351851P.
XX
PA (PHAA) PHARMACIA CORP.
XX
PI Rocha R, Zack MD;
XX
DR WPI; 2004-280243/26.
XX
PT Preventing or treating an inflammation-related disorder such as
PT cardiomyopathy, comprises using an aldosterone blocker to alter
PT expression products, e.g., IL-8, involved in the regulation of
PT inflammation or cardiac remodeling.
XX
PS Example 18; Page 36; 109pp; English.
XX
CC The invention relates to a method for preventing or treating an
CC inflammation-related disorder which involves administering a
CC therapeutically-effective amount of an aldosterone blocker to alter the
CC expression of one or more expression products involved, directly or
CC indirectly, in the regulation of inflammation or cardiac remodeling in
CC the subject. The method is useful to treat an inflammation-related
CC disorder such as myocarditis, cardiomyopathy, vasculitis and Behcet's
CC disease. The present sequence is a TaqMan RT-PCR primer specific for rat
CC collagen I gene. This sequence is used to illustrate the method of the
CC invention.
XX
SQ Sequence 19 BP; 5 A; 3 C; 8 G; 3 T; 0 U; 0 Other;

Query Match 0.8%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 2.7e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 736 TCCAGCTGACCCTCGTGC 753
||||||||||| || |||
Db 18 TCCAGCTGACCTTCCTGC 1

Search completed: December 13, 2004, 08:32:59
Job time : 37 secs

GenCore version 5.1.6

OM nucleic - nucleic search, using sw model

Run on: December 13, 2004, 08:40:35 ; Search time 21 Seconds
(without alignments)
3.679 Million cell updates/sec

Title: US-10-091-333-2
Perfect score: 1764
Sequence: 1 tttggccctcgaggccaaga.....ataaacatgtttgttaaaac 1764

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 0.5

Searched: 1121 seqs, 21900 residues

Total number of hits satisfying chosen parameters: 2242

Minimum DB seq length: 8
Maximum DB seq length: 50

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 1 summaries

Database : rst2.seq:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query Match	Length	DB	ID	Description
1	19	1.1	19	1	CO578459	ACCESSION:CO578459

ALIGNMENTS

RESULT 1
CO578459
LOCUS CO578459 19 bp mRNA linear EST 20-JUL-2004
DEFINITION TvEST093E02 Tv30236_PT cDNA Library Trichomonas vaginalis cDNA 5', mRNA sequence.
ACCESSION CO578459
VERSION CO578459.1 GI:50409027
KEYWORDS EST.
SOURCE Trichomonas vaginalis
ORGANISM Trichomonas vaginalis
Eukaryota; Parabasalidea; Trichomonada; Trichomonadida; Trichomonadidae; Trichomonadinae; Trichomonas.
REFERENCE 1 (bases 1 to 19)
AUTHORS Zhou,Y., Shu,W.M., Huang,S.C.C., Huang,K.Y. and Tang,P.
TITLE Analysis of Gene Expression Profile in Trichomonas vaginalis by EST Sequencing
JOURNAL Unpublished (2003)
COMMENT Contact: Tang, P.
Molecular Regulation and Bioinformatics Laboratory, College of Medicine
Chang Gung University
259 Wenhwa 1st. Road, Kweishan, Taoyuan 333, Taiwan
Tel: +886 3 3283016 EXT5136
Fax: +886 3 3283031
Email: petang@mail.cgu.edu.tw
PCR PRimers
FORWARD: T7
BACKWARD: T3
Seq primer: T3.
FEATURES Location/Qualifiers
source 1. .19
/organism="Trichomonas vaginalis"
/mol_type="mRNA"
/db_xref="taxon:5722"
/cell_line="ATCC30236"
/dev_stage="Trophozoites at mid-log phase"
/lab_host="XL1 Blue-MRF'"
/clone_lib="Tv30236_PT cDNA Library"
/note="Vector: Lambda ZAP-Express (Stratagene); Site_1: EcoRI; Site_2: XhoI"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 21;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy         18 AGAATTCGGCACGAGGGGG 36
              |||||||||||||||||||
Db          1 AGAATTCGGCACGAGGGGG 19
```

Search completed: December 13, 2004, 08:40:56
Job time : 21 secs